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Abstract 
 i 
ABSTRACT 
Esophageal adenocarcinoma has one of the poorest outcomes of all solid 
tumors, attributable, at least in part, to lack of an early stage diagnostic test. 
Aberrant methylation is an early and frequent event in carcinogenesis 
providing an opportunity for early cancer detection. The overall aim of this 
thesis is to identify and validate regions of aberrant methylation as a 
biomarker for early detection of esophageal adenocarcinoma and the 
dysplastic stages of its precursor disease, Barrett’s esophagus. By using 
well-classified patient data and stringent, quality controlled biospecimen 
selection for training and validation cohorts, I found regions of disease-
associated aberrant methylation that are novel for esophageal 
carcinogenesis. With comprehensive technical and independent validation by 
targeted amplicon sequencing and whole genome methylation profiling of a 
large external validation cohort, I demonstrated potential utility of these target 
regions for identification of intervention requiring disease. For subsequent 
blood investigation, all target regions are unmethylated in peripheral blood 
from healthy patients and amplification assays for targeted sequencing are 
suitable for degraded, shorter fragments of cell-free circulating DNA in blood. 
I proposed a panel of three methylation biomarkers (TUBA3FP, VANGL2, 
ARL10) for identification of intervention requiring disease, reporting 100% 
sensitivity and 84.6% specificity and demonstrated biomarker application for 
prediction of disease progression as well as utility for monitoring disease 
status with treatment. I was also able to show utility for predicting the 
necessity of treatment for low-grade dysplasia, which is controversial in 
guidelines worldwide. By performing genome-wide methylation and 
expression profiling, as well as cancer-associated mutation screening on 
single tissue biopsies from all stages of the metaplasia-dysplasia-
adenocarcinoma sequence, I was able to gain a more complete 
understanding of the genetic and epigenetic changes occurring in 
esophageal adenocarcinogenesis. The research presented in this thesis 
demonstrates that I have been able to propose potentially clinically valuable 
methylation biomarkers for the detection of intervention-requiring disease, 
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with potential application for non-invasive, high-risk population screening for 
identification of esophageal adenocarcinoma at an early, treatable stage. 
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CHAPTER 1:   INTRODUCTION 
1.1  Introduction 
Cancer is no longer thought of as purely a genetic disease, with epigenetic 
alterations proving ubiquitous across nearly all human cancers1. In some 
cases, such as retinoblastoma and rhabdoid tumor, epigenetic change has 
even been identified as the principal driver of carcinogenesis2, 3. Altered DNA 
methylation occurs early and frequently in cancer development with some 
changes already present in precursor lesions4, making it an attractive choice 
for a diagnostic biomarker.  
 
Esophageal adenocarcinoma (EAC) is the sixth leading cause of cancer 
death in the western world5. Furthermore, EAC incidence rates have risen 
faster than that of any other cancer in western countries over the past 
several decades; thus research into improved early detection, treatment and 
prevention is of high priority. Effective intervention for EAC is possible and 
often curative with diagnosis at an early stage6, 7, but most patients are 
diagnosed at a late, incurable stage, contributing to the poor prognosis and 
high case fatality ratio. One of the major challenges associated with EAC is 
early disease identification. DNA methylation biomarkers have been shown 
to have clinical application for early detection in cancers such as colorectal 
and lung1, and have similar potential for EAC. 
 
This introductory chapter aims to provide a summary of research in the field 
of epigenetic aberrations in EAC development, focusing on how these 
changes could be used as biomarkers for early disease detection. 
1.2  Epigenetics and cancer 
Epigenetics refers to heritable changes that do not alter the underlying DNA 
sequence, including key processes such as DNA methylation, chromatin 
modifications and nucleosome positioning. Mammalian DNA methylation 
involves the addition of a methyl group (CH3) to the 5th carbon position on a 
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cytosine base of a CpG dinucleotide (cytosine followed directly by guanine) 
in the DNA sequence. Eighty to ninety percent of CpG sites in human DNA 
are methylated, however promoter regions of mammalian genes are often 
GC-rich (known as CpG islands) and entirely unmethylated, correlating with 
increased transcriptional activity8. The presence of methylation in promoter 
regions is transcriptionally repressive, whereas a lack of methylation allows 
for active transcription of the associated gene9. DNA methylation is widely 
regarded as the most stable and informative epigenetic mark for 
understanding gene expression and cell differentiation10.  
 
Chromatin is a complex of DNA and protein (histone) that dictates DNA 
structure in eukaryotic cell nuclei. Histones act as a spool around which DNA 
can wind and when modified, can influence chromatin arrangement and 
ultimately, gene transcription (Figure 1-1). Condensed chromatin 
(heterochromatin) is typically not transcribed, whereas the less compact form 
of chromatin (euchromatin) is active and the associated DNA can be 
transcribed.  
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Figure 1-1: Gene expression is influenced by epigenetic mechanisms such 
as DNA methylation and histone modification. Figure courtesy of the National 
Institutes of Health (http://commonfund.nih.gov/epigenomics/figure.aspx) 
 
Aberrant DNA methylation plays an important role in carcinogenesis by either 
inactivation of usually active tumour suppressor genes (disease-associated 
hypermethylation), or activation of normally inactive oncogenes 
(demethylation, or disease-associated hypomethylation). Gene silencing 
associated with promoter CpG island DNA hypermethylation has been 
identified not only in many cancers, but also precursor lesions (Figure 1-2). 
Early stage aberrant DNA methylation may indicate potential disease 
progression and subsequent carcinogenesis and thus may be useful as a 
biomarker for early cancer detection11.  
 
 
Figure 1-2: Aberrant DNA methylation in cancer. Tumor cells show increased 
methylation in promoter regions of specific loci, but a global decrease in DNA 
methylation at non genic regions, for example in repeated sequences. White 
lollipop: unmethylated CpG site, red lollipop: methylated CpG site. 
 
The field of epigenetics is one of the most promising and rapidly expanding 
areas in biomarker research, with mechanisms such as DNA methylation and 
histone modification likely to be some of the earliest events in 
carcinogenesis12. Importantly, epigenetic disruption has been found to 
precede genetic change, further supporting the use of epigenetic 
mechanisms such as DNA methylation as early detection biomarkers.  
Recent advances in technology have lead to a deeper understanding of 
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epigenetic processes occurring during carcinogenesis and a resultant focus 
on epigenetic alterations (in particular, aberrant DNA methylation) as 
biomarkers for early cancer detection, prognosis and disease monitoring 8, 12.   
1.2.1  Methylation biomarkers for early cancer detection 
One of the biggest challenges in oncology is early disease detection. Major 
efforts are underway to identify biomarkers that enable detection of early-
stage, treatable, and potentially curable carcinogenic change rather than 
advanced, often incurable cancer. Epigenetic alterations are now well 
recognized as a key step in carcinogenesis, with promoter hypermethylation 
of tumour suppressor genes showing promise as early-stage biomarkers in a 
number of different cancer types13, 14.  
 
Aberrant methylation is specific, stable and detectable in peripheral blood, 
making it an attractive cancer biomarker. Despite its suitability as a cancer 
detection aid, being detectable in blood, stool, urine and solid biopsy15-23, and 
despite the plethora of potential DNA methylation biomarkers proposed for a 
wide variety of cancer types, only minimal DNA methylation biomarkers have 
been clinically implemented. Commercial tests are currently available for just 
a handful of DNA methylation biomarkers for both diagnostic purpose and 
cancer therapy treatment decisions1.  
 
MDxHealth’s PredictMDxTM for Glioblastoma tests for methylation of the DNA 
repair gene, O-6-methylguanine-DNA methyltransferase (MGMT) in 
glioblastoma (the most common and aggressive malignant primary brain 
tumour in humans) tissue, and uses results to identify patients most likely to 
respond to alkylating agent treatment. MGMT methylation was also shown to 
have prognostic value in glioblastoma, predicting significant increase in both 
overall and progression-free survival24. Epigenomics’ Epi proLung® BL assay 
detects methylated Short Stature Homeobox 2 (SHOX2) in bronchial 
washings from patients with suspected lung carcinoma, introduced into 
clinical practice as a routine diagnostic aid in a German hospital in 2012. 
Very recently, SHOX2 methylation has been investigated in blood, with 
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promising results for not only diagnostic purposes but also therapy 
monitoring25, 26. 
 
The most advances in commercially available methylation biomarkers are in 
the field of colorectal cancer. Exact Sciences CologardTM measures 
methylated BMP3 and NDRG4 (as well as point mutations in KRAS, 
haemoglobin and β-actin (as a reference)) in stool as a non-invasive 
screening test, intended as an adjunct to colonoscopy, reporting 92% 
sensitivity for detection of colorectal cancer, 42% for advanced precancerous 
lesion and 87% specificity27. Further studies have extended these findings, 
reporting 85-100% detection of colorectal cancer and 53-83% for high-grade 
dysplasia and adenoma28-31. Commercial blood tests for the early detection 
of colorectal cancer have been launched by Epigenomics (Epi proColon®), 
Quest Diagnostics (ColoVantage®) and Abbott Molecular (RealTime mS9); 
all measuring the methylation status of Septin 9 (SEPT9). In Australia, Quest 
Diagnostics have teamed with Clinical Genomics who have recently 
launched regional pilot ColoVantage Plasma testing, which examines 
methylated BCAT1 and IKZF1 in patient plasma for early colorectal cancer 
diagnosis. Methylation in these two targets has also shown utility for disease 
recurrence, with supporting data presented at the American Society of 
Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium in San 
Francisco on 23 January 2016. 
 
Over the past two decades, the use of DNA methylation biomarkers for 
cancer diagnosis has been assessed, with many alterations identified as 
potential biomarkers but only few translated to clinical use32. One of the 
major obstacles limiting clinical implementation appears to be variability in 
reported accuracy in subsequent studies. The use of comprehensive 
validation, large independent cohorts, and standardization of methylation 
assessment may help reduce this variability. Another key issue for clinical 
uptake is standardization of quantitative methodology, ensuring multi-
laboratory reproducibility1. 
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1.3  Barrett’s esophagus and esophageal adenocarcinoma 
Barrett’s esophagus (BE) is the replacement of normal squamous epithelium 
with columnar, goblet-cell containing epithelium in the distal esophagus, in 
response to long-standing gastro-esophageal reflux disease (GERD)33. It is a 
relatively common disorder, with an estimated incidence of 1-2% of the adult 
population34, but often or even usually, remains undiagnosed. Barrett’s 
esophagus arises in the distal esophagus, extending proximally from the 
gastroesophageal junction (GEJ) and is measured using Prague Criteria 
(Figure 1-3).  
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Figure 1-3: Barrett’s esophagus extent is quantified using Prague Criteria. 
Prague Criteria specifies a circumferential extent and maximal extent, 
measured in centimeters from the defined GEJ. For example, BE (C3 M7) is 
Barrett’s mucosa extending circumferentially for 3cm, with maximal tongues 
as far as 7cm from the GEJ. Figure courtesy of the International Working 
Group for the Classification of Reflux Oesophagitis (IWGCO), 
http://www.iwgco.net. The criteria and their validation is outlined by Sharma 
et al, 200635. 
 
The chief significance of BE lies in its role as precursor disease to 
esophageal adenocarcinoma (EAC)36, which arises following a multistage 
metaplasia-dysplasia-adenocarcinoma progression (as outlined in 
 
Figure 1-4). The presence of BE has been reported to increase risk of EAC 
30- to 125-fold37, 38. However, only a small proportion of BE sufferers 
(estimated as less than 0.5% per year39) will progress from non-dysplastic 
disease, highlighting the need for stratification of BE patients to identify those 
at risk of dysplastic progression. 
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Figure 1-4: The multistage development of esophageal adenocarcinoma: 
from normal healthy squamous epithelium through metaplasia, to dysplasia 
and finally adenocarcinoma. Image courtesy of John Hopkins Pathology 
(http://pathology2.jhu.edu/beweb/cancer.cfm). 
 
Of all solid tumors, EAC has one of the poorest outcomes, with 5-year 
survival rates as low as 14%40, 41, however a three times higher survival rate 
has been reported when associated with early diagnosis as opposed to 
metastatic disease at diagnosis42.   
1.3.1  The need for an alternative to histology-based diagnosis 
Current clinical methods for BE diagnosis require endoscopic identification of 
columnar esophageal mucosa and histological confirmation of the presence 
of intestinal metaplasia with mucin-containing goblet cells. This combined 
endoscopic and histology-based method, also used for EAC diagnosis, 
presents a number of challenges in the detection of early stage disease. First 
and foremost, these methods are invasive and not viable for even high-risk 
population screening (such as Caucasian males aged over 40 with 
longstanding reflux) due to significant expense to the health care system and 
limited availability of specialist time and facilities. Thus with endoscopy-
histology based diagnosis, disease is often detected at a late-stage, 
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contributing to the extremely poor prognosis associated with esophageal 
adenocarcinoma.  
 
Secondly, large numbers of biopsies must be taken to reduce sampling error 
and ensure that the ‘worst case’ diagnosis isn’t missed. Even with these 
precautions, low-grade dysplasia (LGD) is frequently not detected or missed 
in diagnosis. Poor diagnostic reproducibility is common for patients 
diagnosed with LGD, with subsequent endoscopy often reporting the 
presence of non-dysplastic Barrett’s mucosa only, despite no treatment being 
received for LGD. 
 
Current histology-guided clinical care for BE/EAC is problematic, not only 
due to endoscopic sampling error but also histological misclassification, due 
to poor sample preparation, biological heterogeneity or other artefacts43. 
Furthermore, pathology-based dysplasia assessment has been shown to be 
highly variable, with substantial inter- and intra-observer variation reported. 
Late stage detection and poor prognosis of EAC (5-year survival rates are 
typically <15%44) are potentially partly attributable to ineffective 
endoscopic/histologic diagnosis methods and may be overcome by 
identification of accurate, robust biomarkers occurring early in the 
development of EAC. 
1.3.2  Epigenetic regulation of genes in EAC carcinogenesis 
It is well established that promoter hypermethylation is a frequent mechanism 
of transcriptional inactivation and gene silencing of tumor suppressor 
genes45, 46 and there is significant evidence that these epigenetic alterations 
play an important role in EAC carcinogenesis38, 47.  Genome-wide analysis 
reveals that global hypomethylation is the dominant change in BE 
development, followed by a much smaller wave of selective promoter 
hypermethylation in the progression to adenocarcinoma48, 49. 
 
In a comprehensive review of epigenetic alterations in BE pathogenesis to 
EAC by Argawal et al in 2012, 35 genes were reported to be aberrantly 
methylated in BE and EAC, all originating from single-locus studies48. Genes 
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observed to be aberrantly methylated in EAC tissues include AKAP12, APC, 
CDH13, DAPK1, GPX3, MGMT, p16/CDKN2A, RUNX3, SFRP1, TERT, 
TIMP3 and WIF-148. To date the only studies which have addressed 
identification of dysplastic BE progression are not convincing in their 
specificity. For example, APC, TIMP3 and TERT promoters were 
hypermethylated in 90-100% of Barrett’s mucosa from patients who had 
progressed to EAC but specificity was poor, ranging from 15 to 35%50. 
 
In the only genome-wide EAC methylation study to date, Krause et al 
(2016)49 reported on the lack of separation between BE and EAC cohorts in 
unsupervised clustering, indicating that aberrant methylation is an early event 
in metaplasia-dysplasia-neoplasia progression (Figure 1-5). Only mentioned 
in passing and not the focus of this study, just 2024 CpG sites were identified 
as differentially methylated between EAC and BE (in comparison to the 
52,590 CpG sites differentially methylated in EAC compared to normal 
epithelium). This smaller subset is the focus of my thesis; the differentially 
methylated regions with clinical utility for early detection EAC screening. 
 
 
Figure 1-5: Aberrant methylation occurs early in EAC carcinogenesis as 
evidenced by differentially methylated probe and gene counts in EAC and BE 
(compared to normal esophageal mucosa) identified by Krause et al49 in the 
first genome-wide EAC methylation study to date. FDR < 0.01 and beta value 
difference ≥ 0.20. 
1.3.3  Proposed diagnostic biomarkers 
Lack of early diagnostic screening for Barrett’s esophagus and esophageal 
adenocarcinoma is not due to lack of research, with numerous studies 
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investigating alternatives to current combined endoscopic/histologic 
methods. Despite the plethora of studies performed, none have replaced or 
been universally implemented as a supplement to current clinical practice.  
1.3.3.1  Barrett’s esophagus diagnostic biomarkers 
Since 2013, I have been a member of Cancer Council Australia’s Barrett’s 
Esophagus and Early Esophageal Adenocarcinoma Working Party, 
responsible for evaluating current literature and collating evidence into an 
online Wiki: Clinical practice guidelines for the diagnosis and management of 
Barrett’s esophagus and early esophageal adenocarcinoma51. More 
specifically, I was responsible for review and evaluation of literature (23 
articles) to answer the question ‘Are there biomarkers for the diagnosis 
(presence) of Barrett’s esophagus?’ (http://wiki.cancer.org.au/australia/ 
Clinical_question:Are_there_biomarkers_for_the_diagnosis_(presence)_of_B
O%3F). Overall findings were summarized in a publication in the Journal of 
Gastroenterology and Hepatology in May 201552; a full copy of this paper is 
included in the final section of this thesis: Reprints of publications arising 
during my thesis candidature. 
 
In brief, I found that numerous biomarkers had been proposed to aid in the 
diagnosis of Barrett’s esophagus, including tissue and serum markers as well 
as evaluation of a non-endoscopic capsule sponge device paired with 
immunohistochemistry for Trefoil factor 3 (TFF3). None of the studies 
provided sufficient evidence for recommendation as a supplement to replace 
current clinical practice due to high risk of bias in study design, wide variation 
in accuracy estimates across studies and no evidence of comparison with 
current standard practice. 
1.3.3.2  Esophageal adenocarcinoma diagnostic biomarkers 
In 2009, a panel of eight DNA-methylation biomarkers for predicting the risk 
of progression from BE to esophageal adenocarcinoma (p16, RUNX3, HPP1, 
NELL1, TAC1, SST, AKAP12 and CDH13) was trialed in a multi-center, 
retrospective, double-blinded validation study38, reporting 50% sensitivity 
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(predicting half the HGD and EAC incidence) when specificity was set to 0.9 
(10% of non-progressors falsely predicted as progressors). Three of these 
biomarkers originated from a real-time quantitative methylation specific PCR 
(MSP) study in 200553, based on previous studies from as early as 1997-
2002 47, 54-58). Interestingly, APC and TIMP3 were also tested by Schulmann 
in this study and not selected as possible predictive methylation markers for 
increased risk of EAC; but later proposed (alongside TERT) as a possible 
panel for this purpose by Clement et al in 200650. The further five biomarkers 
comprising the eight gene panel were selected based on MSP interrogation 
by Jin et al. in 2007-200859-63. Interestingly, all eight biomarkers were 
originally selected based on their status as common methylation-inactivated 
tumor suppressor genes in other forms of human neoplasia, rather than a 
targeted screening approach specific for EAC and its precursor disease BE.  
 
This panel of eight DNA methylation biomarkers to predict the risk of 
progression proposed by Stephen Meltzer and his team at John Hopkins 
University38 has been launched commercially in 2013. A significant limitation 
of the Meltzer laboratory test is its reliance on endoscopic tissue biopsies.  
 
In a 2013 study by Alvi et al64, a new four gene DNA methylation panel 
(SLC22A18, PIGR, GJA and RIN2) was put forward as an adjunct to 
histopathology to enable stratification of patients into three risk groups based 
on the number of genes methylated. However this work is still in research 
phase and requires further validation before it can be considered for clinical 
application. HumanMethylation27 BeadChip® (HM27) microarrays were used 
for discovery (22 BE, 2 duodenum and 24 EAC samples), with selected 
genes validated using pyrosequencing40, 64. In the field of esophageal cancer, 
more comprehensive Infinium HumanMethylation 450K (HM450) arrays have 
been used to investigate potential biomarkers for the early diagnosis of 
esophageal squamous cell carcinoma (SCC)65, however the same cannot be 
said for EAC and its precursor disease BE. Searching GEO datasets platform 
GPL13534 (publicly available HM450 data) AND esophagus returns only 
GSE72874 (released 1st April 2016, by Krause et al49; these data were used 
as an external validation data set for this thesis). However this single HM450 
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data set for EAC does not include any dysplastic (low or high-grade) 
samples. Thus, my study is novel in its analysis of the full metaplasia-
dysplasia-adenocarcinoma progression sequence (including both low and 
high grade dysplastic mucosa) using HM450 technology. 
 
Significant epigenetic changes occur during EAC carcinogenesis, however 
much of the focus of biomarker research to date has been directed towards 
aberrant methylation observed in EAC when compared to normal mucosa. 
For many cancers this ‘tumor v normal’ approach will work, but for EAC the 
situation is more complicated. Much of the aberrant hypermethylation in EAC 
is already present in its precursor disease, Barrett’s esophagus49. However, 
just 0.5% of BE sufferers will ever progress, and BE itself is otherwise 
asymptomatic and benign. Thus, for a clinically viable early-EAC biomarker, 
it is important to focus on aberrant methylation present in dysplastic BE and 
adenocarcinoma that is NOT present in benign BE. This may be a significant 
contributing factor to the lack of transfer from research to clinical use that 
EAC biomarkers have experienced to date. Further confounding the 
situation, there has always been significant difficulty surrounding the 
diagnosis and treatment of low-grade dysplasia and thus it has generally 
been excluded from research studies. This is unfortunate as identification at 
this early treatable stage is key to reducing current poor prognosis of EAC. 
My thesis aims to address this by inclusion of low- (and high-) grade 
dysplastic mucosa and a focus on hypermethylation biomarkers present in 
dysplasia and EAC, using methylation in both BE and normal healthy 
mucosa as baseline. 
1.3.4  The future: blood-based biomarkers 
Blood is one of the most accessible biological fluids; it comes into close 
contact with all tissues and can carry disease specific biomarkers.  From a 
practical perspective, blood analysis is already a well-established clinical 
routine; the infrastructure is already in place, therefore minimal effort is 
required to integrate validated blood biomarkers into clinical practice.  
Furthermore, blood-based biomarkers have the capacity to be easily 
reassessed over time, essential for monitoring disease progression and to 
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detect emerging recurrence. Blood tests are ideal to meet the current 
deficiencies surrounding EAC diagnosis: reproducible, easily integrated into 
healthcare management systems and a cost-effective method for screening 
high-risk populations66. Development of blood-based biomarkers has been 
shown to potentially improve detection rates in cancers such as ovarian, 
prostate, colorectal and gastric67-70 and would stand to do the same for EAC.  
 
Cell-free circulating DNA (cfc-DNA), present in human blood plasma is 
known to contain DNA methylation patterns characteristic of disease 
occurring elsewhere in the body11. The origins of cfc-DNA remain unclear; 
both passive release during cell death and active secretion from proliferating 
cells have been postulated. Importantly, disease diagnosis and monitoring 
has been shown to be possible using cfc-DNA from blood plasma as it 
contains mutations and DNA methylation patterns characteristic of disease11, 
71, 72. 
 
The challenge in using cfc-DNA from blood plasma for biomarker discovery is 
its low concentration (present in ng/mL range); only a few genes can be 
interrogated.  One solution to this problem is to start with well-characterised 
tumour tissue for biomarker discovery then transition to blood once potential 
biomarkers have been uncovered. Traditionally, the vast majority of attempts 
to develop diagnostic biomarkers have been developed this way. For 
example, Epigenomics Inc. have developed a cfc-DNA-based biomarker, 
SEPT9, for colorectal cancer using this approach23. However, the transition 
from tissue-identified putative biomarkers to blood plasma is not straight-
forward11. For example, methylated DNA analysis in ovarian adenocarcinoma 
in tumour tissue and in cfc-DNA from plasma resulted in methylation patterns 
that were similar but not identical73.  It has also been shown that 
independently confirmed tumour tissue-derived biomarkers (in hepatocelluar 
carcinoma) did not perform equally as well in plasma74. 
 
With regards to EAC, there is some evidence of tissue-identified markers 
showing value as blood biomarkers. Tachykinin-1 (TAC1) promoter 
hypermethylation was examined in subjects with matched tissue and plasma 
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samples at various stages of neoplastic evolution by Jin et al60.  Some level 
of tissue-blood correlation was observed with approximately 44% matched 
TAC1 methylation status observed between tissue and plasma. However, 
approximately 44% of patients were observed to have TAC1 
hypermethylation in tissue but not in plasma and approximately12% were 
observed to have TAC1 hypermethylation in plasma but not in tissue60. 
Potential methylation blood biomarkers DAPK (death-associated protein 
kinase) and APC (adenomatous polyposis coli gene) have been examined in 
EAC with variable results. Methylated DAPK and methylated APC were 
detected in the plasma of 61% of EAC patients by Hoffmann et al in 200975. 
However, Kawakami et al showed that hypermethylated APC was detectable 
in not only 92% of EAC patients but also 40% of BE patients76, an 
observation with significant impact on clinical utility of the biomarker. 
 
BE with high-grade dysplasia (HGD) and EAC are the later stages of the 
Barrett’s metaplasia-dysplasia-adenocarcinoma sequence at which 
intervention by either endoscopic or operative treatment is mandated in 
patients who are fit for such intervention52. The discovery of a biomarker 
panel for intervention-requiring disease with potential blood test application 
would provide an easily implemented, and potentially cost-effective test for 
high-risk population screening, enabling detection of in-situ and invasive 
malignancy at an early, curable stage, which would ultimately lead to 
improved prognosis and lower incidence of incurable disease77.  
1.4  Conclusions 
This chapter has presented a summary of research in the field of epigenetic 
aberrations in the development of esophageal adenocarcinoma and how 
these changes could be used as biomarkers for early disease detection, 
addressing the need for an alternative to current endoscopy-histology 
methods. 
 
Epigenetic mechanisms, such as DNA methylation and histone modification, 
are some of the earliest events in carcinogenesis and thus lend themselves 
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to clinical application as diagnostic biomarkers for early cancer detection. 
This has been shown by clinically implemented methylation biomarker tests 
such as Epi proLung® (lung carcinoma diagnostic), PredictMDxTM 
(glioblastoma treatment), CologardTM (colorectal cancer diagnostic, adjunct to 
colonoscopy) as well as Epi proColon®, RealTime mS9 and ColoVantage® 
(colorectal cancer diagnostic blood testing). 
 
Current clinical methods for BE and EAC diagnosis require histopathologic 
examination of tissue biopsies taken during endoscopic examination, which 
is challenging on a number of levels and a strain on the health care system 
due to limited availability of specialist time and facilities. Significant 
epigenetic changes occur during EAC carcinogenesis, however no 
biomarkers have been implemented in clinical use to date. This may be due 
in part to the complicated nature of the disease (precursor BE is benign, with 
a progression rate of just 0.5%), and the tumor-normal focus of much 
research to date, rather than using a BE baseline and including challenging 
low-grade dysplastic samples to ensure true early detection biomarkers are 
identified. 
 
There is an urgent need to introduce a non-invasive, diagnostic test for early 
identification of intervention-requiring disease to significantly alter clinical 
outcomes for this highly fatal disease. This study aims to take the first steps, 
by using well-classified patient data and stringent, quality controlled 
biospecimens to perform genome-wide methylation and expression profiling 
on tissue samples over the full metaplasia-dysplasia-adenocarcinoma 
sequence of EAC development. With comprehensive technical and 
independent validation by targeted amplicon sequencing and whole genome 
methylation profiling of a large external validation cohort, I aim to ensure 
robustness and the highest chance of success in moving research to clinical 
implementation. Importantly, for anticipated subsequent blood investigation, 
all target regions will be selected to be unmethylated in peripheral blood from 
healthy patients and amplification assays for targeted sequencing will be 
suitable for the degraded, shorter fragments of cell-free circulating DNA in 
blood.  
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1.5  Hypotheses, aims and study design 
1.5.1  Hypotheses underpinning study design 
Several hypotheses were made underlying the study design for this thesis. 
Firstly, that aberrant methylation in human esophageal tissue biopsies can 
be used to discover disease-specific methylation changes in the 
development of esophageal adenocarcinoma, possibly novel discoveries if 
samples from all phases of the metaplasia-dysplasia-adenocarcinoma 
sequence are examined. Secondly, that altered methylation status in 
diseased tissue is reflected and measurable in cell-free circulating DNA (cfc-
DNA) in blood. With these hypotheses, this thesis aims to identify clinically 
valuable, potential biomarkers for the early identification of esophageal 
adenocarcinoma, with a view to future blood test application. 
1.5.2  Aims of this thesis 
The overall aim of this thesis is to identify aberrant methylation in EAC 
carcinogenesis with potential blood biomarker application for the early 
identification of intervention requiring disease. 
 
Specific aims are: 
 
Aim 1: To use well-classified patient data and stringent, quality-controlled 
biospecimen selection for training and validation cohort assembly; performing 
global genome-wide methylation and expression profiling at all stages of the 
metaplasia-dysplasia-adenocarcinoma sequence to uncover novel disease-
associated aberrant methylation with potential clinical application.  
 
Aim 2: To comprehensively validate and characterize disease-associated 
differentially methylated target regions indicative of early esophageal 
adenocarcinoma, concurrently initiating assay development with direct 
transferability to blood biomarker investigation.  
 
Chapter 1:  Introduction 
 18 
Aim 3: To evaluate methylation biomarker performance with regard to 
diagnostic utility and application for disease progression prediction and 
disease monitoring during treatment. 
 
Aim 4: To examine cancer-associated mutational load at all phases of 
disease progression, and use this information to gain a more complete 
understanding of genetic and epigenetic changes occurring in the 
development of esophageal adenocarcinoma. 
 
From these findings, I hope to propose potentially clinically valuable 
methylation biomarkers for the early detection of esophageal 
adenocarcinoma. 
1.5.3  Study Design 
The study is based on well-defined patient cohorts and comprehensively 
classified samples and can be broken down into four phases that reflect the 
four aims of the thesis (Figure 1-6). It follows the well-established discovery 
and validation model proposed by Pepe et al78 for biomarker development for 
the early detection of cancer, aiming to identify leads for potentially clinically 
applicable biomarkers and prioritizing these identified leads.  
 
Chapter 1:  Introduction 
 19 
 
Figure 1-6: Study design schematic. This thesis aims to identify aberrant 
methylation in EAC carcinogenesis for the early identification of intervention 
requiring disease using a genome-wide epigenetic and genetic approach to 
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gain a complete understanding of changes occurring throughout the 
metaplasia-dysplasia-adenocarcinoma progression.  
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CHAPTER 2:   MATERIALS AND GENERAL METHODS 
2.1  Materials 
2.1.1  Reagents and chemicals 
Reagents and chemicals used for this study are summarized in Table 2-1. 
 
Table 2-1: List of reagents and chemicals 
Reagent/Chemical Name Supplier Supplier Location 
2-Mercaptoethanol (HSCH2CH2OH) Sigma-Aldrich St Louis, MO, USA 
2-Propanol ((CH3)2CHOH) Sigma-Aldrich St Louis, MO, USA 
4’,5’-Dibromo-2’,7’-dinitroflourescein 
disodium salt (Eosin B), (C20H6N2O9Br2Na2) 
Agilent Technologies Santa Clara, CA, USA 
Agarose UltraPureTM 1000 Life Technologies Carlsbad, CA, USA 
Boric acid (H3BO3) Sigma-Aldrich St Louis, MO, USA 
Chloroform-isoamyl alcohol mixture 24:1, 
≥99.5% for molecular biology 
Sigma-Aldrich St Louis, MO, USA 
CpGenome Universally Methylated DNA Merck Millipore Billerica, MA, USA 
Custom DNA oligonucleotides, lyophilized, 
25nmole  
Integrated DNA 
Technologies, Inc. 
Coralville, IA, USA 
Dimethyl sulfoxide (DMSO), ((CH3)2SO) Sigma-Aldrich St Louis, MO, USA 
Ethanol, 200 proof (absolute) for molecular 
biology (CH3CH2OH) 
Sigma-Aldrich St Louis, MO, USA 
Ethylenediaminetetraacetic acid 
((HO2CCH2)2NCH2CH2N(CH2CO2H)2) 
Sigma-Aldrich St Louis, MO, USA 
Formalin solution, neutral buffered, 10% Sigma-Aldrich St Louis, MO, USA 
Hematoxylin (C16H14O6.xH2O) Agilent Technologies Santa Clara, CA, USA 
Human Genomic DNA from blood, in 10mM 
Tris HCl, 1mM EDTA, pH 8.0 
Roche Diagnostics Mannheim, GER 
Magnesium chloride (MgCl2) Life Technologies Carlsbad, CA, USA 
NaOH, molecular biology grade, 1.0N Sigma-Aldrich St Louis, MO, USA 
Nuclease-free water (H2O) Qiagen Hilden, GER 
PhiX Control v3, 10nM Illumina, Inc. San Diego, CA, USA 
Polysorbate 20, aka Tween 20 (C58H114O26) Sigma-Aldrich St Louis, MO, USA 
Proteinase K, 20mg/mL Qiagen Hilden, GER 
RNAlater® RNA stabilization reagent Life Technologies Carlsbad, CA, USA 
Sodium Dodecyl Sulfate (NaC12H25SO4) Applied Biosystems Foster City, CA, USA 
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Reagent/Chemical Name Supplier Supplier Location 
SYBR® Safe DNA Gel Stain Life Technologies Carlsbad, CA, USA 
SYTO® 9 Green Fluorescent Nucleic Acid 
Stain 
Life Technologies Carlsbad, CA, USA 
Tris base: 2-Amino-2-(hydroxymethyl)-1,3-
propanediol (NH2C(CH2OH)3) 
Sigma-Aldrich St Louis, MO, USA 
Tris hydrochloride (NH2C(CH2OH)3) HCl Sigma-Aldrich St Louis, MO, USA 
UltraPureTM DEPC Treated Water Life Technologies Carlsbad, CA, USA 
Yeast tRNA, 10mg/mL Applied Biosystems Foster City, CA, USA 
 
2.1.2  Commercial kits 
Commercial kits used throughout this study are summarized in Table 2-2. 
Optimization and alteration to commercial kit protocol is given in the methods 
section of the associated chapter. 
 
Table 2-2: List of commercial kits 
Commercial Kit Name Supplier Supplier Location 
Bioanalyzer RNA 6000 Nano Kit Agilent 
Technologies 
Santa Clara, CA, USA 
dNTP Set, 100nM, PCR Grade Life Technologies Carlsbad, CA, USA 
EZ DNA MethylationTM Gold Kit Zymo Research Irvine, CA, USA 
GeneChip® WT PLUS Reagent Kit Affymetrix, Inc. Santa Clara, CA, USA 
Human HCT116 DKO Methylated and Non-
methylated DNA Set 
Zymo Research Irvine, CA, USA 
Infinium HumanMethylation450 BeadChip Kit Illumina, Inc. San Diego, CA, USA 
KAPA Biosystems Library Quantification 
Complete Kit, optimized for Roche LC480 
GeneWorks Pty Ltd Thebarton, SA, AUS 
MinElute PCR Purification Kit Qiagen Hilden, GER 
MiSeq Reagent Kit v2, 300 cycles Illumina, Inc. San Diego, CA, USA 
NEBNext® UltraTM Library Preparation Kit New England 
BioLabs Inc. 
Beverly, MA, USA 
PCR Low Ladder Marker Set Sigma-Aldrich St Louis, MO, USA 
Platinum® Taq DNA Polymerase, 10x buffer 
and MgCl2 
Life Technologies Carlsbad, CA, USA 
Qubit® dsDNA BR Assay Kit Life Technologies Carlsbad, CA, USA 
Qubit® dsDNA HS Assay Kit Life Technologies Carlsbad, CA, USA 
RNase-free DNase set Qiagen Hilden, GER 
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Commercial Kit Name Supplier Supplier Location 
RNeasy Mini Kit Qiagen Hilden, GER 
TruSeq DNA PCR-free LT Sample 
Preparation Kit, Set A 
Illumina, Inc. San Diego, CA, USA 
TruSeq DNA PCR-free LT Sample 
Preparation Kit, Set B 
Illumina, Inc. San Diego, CA, USA 
UltraClean® Tissue & Cells DNA Isolation Kit GeneWorks Pty Ltd Thebarton, SA, AUS 
Wizard® SV Gel & PCR Clean Up System Promega Madison, WI, USA 
 
2.1.3  Products and equipment 
Products and equipment used for this study are summarized in Table 2-3. 
 
Table 2-3: List of products and equipment 
Product/Equipment Name Supplier Supplier Location 
2100 Bioanalyzer Agilent Technologies Santa Clara, CA, USA 
BioSpec-nano Spectrophotometer Shimadzu Kyoto, JAP 
BX51 research system microscope  Olympus Tokyo, JA 
ChemiDocTM XRS Imaging System Bio-Rad Hercules, CA, USA 
Illumina HiSeq 2500 Illumina, Inc. San Diego, CA, USA 
LightCycler® 480 Instrument II Real-
Time PCR System 
Roche Diagnostics Mannheim, GER 
Magnetic stand-96 Life Technologies Carlsbad, CA, USA 
NanoDrop Spectrophotometer ThermoFisher Scientific Waltham, MA, USA 
Polytron PT3100 rotor stator 
homogenizer 
Kinematica Lucerne, Switzerland 
PowerPacTM Basic Power Supply Bio-Rad Hercules, CA, USA 
Vacutainer® 10mL K2EDTA tube Becton, Dickinson and 
Company (BD) 
Franklin Lakes, NJ, 
USA 
Vacutainer® system Becton, Dickinson and 
Company (BD) 
Franklin Lakes, NJ, 
USA 
Veriti 96-well ThermalCycler Applied Biosystems Foster City, CA, USA 
Wide Mini-Sub Cell GT electrophoresis 
cell 
Bio-Rad Hercules, CA, USA 
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2.1.4  Software, genome browsers and online tools 
The software, genome browsers and online tools used for this study are 
summarized in Table 2-4. Website links are included as Appendix 1. 
 
Table 2-4: List of software, genome browsers and online tools 
Software/Genome Browser/Tool Supplier/Source Supplier Location 
Affymetrix® Expression ConsoleTM Affymetrix, Inc. Santa Clara, CA, USA 
Bioconductor minfi package 3.2 Bioconductor Seattle, WA, USA 
Database for Annotation, Visualization 
and Integrated Discovery (DAVID) 
v6.7 
National Institutes of 
Health 
Berthesda, MD, USA 
GenomeStudio v2011.1 with 
Methylation module 1.9.0 
Illumina, Inc. San Diego, CA, USA 
HaplotypeCaller (Genome Analysis 
Toolkit (GATK) variant discovery tools) 
Broad Institute Cambridge, MA, USA 
Illumina Experiment Manager (IEM) 
v1.9 
Illumina, Inc. San Diego, CA, USA 
Integrative Genomics Viewer (IGV) Broad Institute Cambridge, MA, USA 
KAPA Library Quantification Data 
Analysis Template 
GeneWorks Pty Ltd Thebarton, SA, AUS 
Linear Models for Microarray Analysis 
(LIMMA) package 
Bioconductor Seattle, WA, USA 
MethPrimer: designing primer pairs for 
methylation PCRs 
The Li Lab, Peking Union 
Medical College Hospital 
Peking, China 
Multiple Primer Analyzer ThermoFisher Scientific Waltham, MA, USA 
Transcriptome Analysis Console 
(TAC) software 
Affymetrix, Inc. Santa Clara, CA, USA 
UCSC Genome Browser on Human 
Feb. 2009 (GRCh37/hg19) assembly 
University of California, 
Santa Cruz 
Santa Cruz, USA 
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2.2  General methods 
2.2.1  Nucleic acid isolation from esophageal and control tissues 
2.2.1.1  DNA isolation 
DNA was isolated from esophageal and control tissues using MO BIO’s 
UltraClean® Tissue & Cells DNA Isolation Kit (Cat #12334-50), as per 
manufacturers instructions with the exception of eluting in nuclease-free 
water. The suggested second 50µL elution was implemented for increased 
yield. Briefly, 700µL of TD1 solution (thoroughly shaken) was added to each 
tube of dry beads. A section of thawed tissue biopsy was added directly to 
the beads/TD1, followed by 15µL of 20mg/mL Proteinase K. Tubes were 
taped horizontally to a vortex and shaken at 2800 rpm for 10 minutes, then 
incubated at 60°C for 30 minutes. The liquid sample was transferred to a spin 
filter and centrifuged at 10,000 xg for 1 minute. 400µL of TD2 was added to 
each column then centrifuged at 10,000 xg for 30 seconds. The column was 
dried by centrifugation at 10,000 xg for 1 minute. DNA was eluted in 50µL 
nuclease-free water, after 2 minutes incubation at room temperature by 
centrifugation at 10,000 xg for 30 seconds. A second elution was performed 
using a further 50µL nuclease-free water, incubating at room temperature 2 
minutes, then centrifuging at 10,000 xg for 30 seconds. All centrifugation 
steps were performed at room temperature. Isolated DNA was quantified 
(refer to Section 2.2.1.3  Estimation of nucleic acid concentration) then stored 
at -80°C. 
2.2.1.2  RNA isolation 
RNA was isolated from fresh frozen tissue samples following Polytron 
PT3100 rotor stator homogenization, using the RNeasy Mini Kit (Qiagen, Cat 
#74104) according to the manufacturers protocol with the exception of 
reapplication of 30µL nuclease water for elution (following 3min incubation at 
room temperature). On-column DNA digestion was performed using the 
RNase-Free DNase Set (Qiagen, Cat #79254).  
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Briefly, 10µL 2-Mercaptoethanol was added per 1mL RLT buffer. Thawed 
sections of tissue biopsies were weighed and placed in 600µL prepared RLT 
buffer. Tissue was homogenized on ice using the Polytron PT3100 rotor 
stator homogenizer for 30 seconds at 13,000 rpm, then centrifuged at 14,000 
rpm for 3 minutes. The lysate supernatant was added to an equal volume of 
70% ethanol and bound to an RNeasy spin column by centrifugation at 
10,000rpm for 15 seconds. RNA was washed using 350µL Buffer RW1 by 
centrifugation at 10,000 rpm for 15 seconds. On-column DNase digestion 
was performed using Qiagen’s RNase-Free DNase Set by adding 10µL of 
prepared DNase I enzyme to 70µL RDD buffer per sample, adding to the 
column and incubating at room temperature for 15 minutes. RNA was 
washed after DNase treatment using 350µL Buffer RW1 by centrifugation at 
10,000 rpm for 15 seconds. Two further wash steps using 500µL RPE buffer 
were performed by centrifugation at 10,000 rpm for 15 seconds (first wash) 
and 2 minutes (second wash). The column was dried by centrifugation at 
10,000 rpm for 1 minute. RNA was eluted in 30µL nuclease-free water, after 
3 minutes incubation at room temperature by centrifugation at 10,000 rpm for 
1 minute. A second elution was performed by reapplying the eluate, 
incubating at room temperature 3 minutes, then centrifugation at 10,000 rpm 
for 1 minute. All centrifugation steps were performed at room temperature. 
Isolated RNA was quantified (refer to Section 2.2.1.3  Estimation of nucleic 
acid concentration) then stored at -80°C. 
2.2.1.3  Estimation of nucleic acid concentration 
Genomic DNA yield and estimated purity (based on absorbance ratios 
260nm/280nm and 260nm/230nm), was determined using the BioSpec-Nano 
Spectrophotometer, using 2µL DNA, setting the instrument to double-
stranded DNA (dsDNA) and pathlength to 0.7mm. Blanking was performed 
on nuclease-free water.  
 
Total RNA yield, estimated purity and integrity were determined using the 
BioSpec-Nano Spectrophotometer and Agilent 2100 Bioanalyzer, with the 
Bioanalyzer RNA 6000 Nano Kit (Agilent, Cat #5067-1511). Total RNA yield 
and purity was estimated with the BioSpec-nano Spectrophotometer, using 
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2µL of RNA, setting the instrument to RNA and pathlength to 0.7mm. 
Blanking was performed on nuclease-free water. RNA integrity and yield 
were determined using the Agilent 2100 Bioanalyzer, as outlined in Section 
2.2.1.4  Determination of RNA integrity. 
2.2.1.4  Determination of RNA integrity 
Bioanalyzer RIN (0 – 10) was used to estimate the integrity of total RNA 
using electrophoretic trace and takes into account the presence or absence 
of degradation products. The integrity of RNA extracted from esophageal and 
control tissues was determined using the Agilent 2100 Bioanalyzer and 
Bioanalyzer RNA 6000 Nano Kit (Agilent, Cat #5067-1511) according to the 
manufacturer’s instructions.  
 
Briefly, all reagents were allowed to equilibrate to room temperature for 
30min, protecting the dye concentrate from light. The RNA 6000 Nano dye 
concentrate was vortexed for 10 seconds and centrifuged briefly. 65µL of 
pre-filtered gel matrix was combined with 1µL of dye concentrate, vortexed 
thoroughly and centrifuged at 14,000 rpm for 10 minutes at room 
temperature. The gel-dye mix was protected from light and allowed to 
equilibrate to room temperature for 30 minutes prior to use. 9µL of gel-dye 
mix was loaded into the appropriate well of a RNA Nano chip and 
pressurized for 30 seconds to distribute the gel. A further 9µL of gel-dye mix 
was loaded into 2 additional gel-dye wells. 5µL of RNA 6000 Nano marker 
was added to the ladder well and each of the 12 sample wells. 1µL of thawed 
RNA ladder (previously heat denatured for 2 minutes at 70°C, aliquoted and 
stored at -80°C) was added to the ladder well. Samples were heat denatured 
at 70°C for 2 minutes to minimize secondary structure formation, then stored 
on ice. 1µL of each sample was added to each of the 12 sample wells. The 
chip was vortexed for 60 seconds at 2400 rpm in an IKA vortex mixer and 
analyzed in the Agilent 2100 Bioanalyzer within 5 minutes. Successful RNA 
isolation results in 2 ribosomal peaks (18S and 28S, at ~2400 and 4000nt). A 
marker peak at 25nt will be present for all samples. 
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(A) 
 
(B) 
 
Figure 2-1: RNA integrity of 10 esophageal tissue samples analyzed using 
the Agilent Bioanalyzer RNA 6000 Nano Kit. Total RNA was found to be 
intact with minimal degradation, evidenced by RIN of 8.90 – 10. Two 
ribosomal peaks, 18S and 28S (visualized at approximately 2400 and 4000nt 
respectively), as well as the marker peak are evident for all esophageal 
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samples. (A) Electrophoretic traces. Sample blanks contain the marker peak 
only. (B) Gel separation. Esophageal samples show clean 18S and 28S 
bands. 
2.2.2  Agarose gel electrophoresis 
Agarose gels were used to resolve DNA samples such as PCR products and 
prepared libraries for amplicon sequencing. Briefly, gels were 2.5% agarose 
(in 1x Tris/Borate/EDTA (TBE) buffer), using SYBR® Safe DNA Gel Stain for 
visualization in 30 lanes/gel format. Amount of DNA loaded per lane varied 
according to expected fragment size. DNA samples were diluted in nuclease-
free water and a final concentration of 1x loading buffer (Sigma Aldrich, PCR 
Low Ladder Marker Set, Cat #D7808). The molecular weight marker included 
a 20bp and 100bp ladder, loading 8µL/lane at a final concentration of 1x 
loading buffer, 0.4µg/µL 20bp ladder, 0.08µg/µL 100bp ladder (Sigma 
Aldrich, PCR Low Ladder Marker Set, Cat #D7808). The resultant ladder 
contained dsDNA fragments from 20 to 1000bp in 20bp increments. Gels 
were run at 100V (constant) for 90 minutes.  Visualization was by ultraviolet 
transillumination performed using the Bio-Rad ChemiDocTM XRS Imaging 
System. 
2.2.3  DNA recovery 
2.2.3.1  Wizard® SV Gel and PCR Clean Up System 
Promega’s Wizard® SV Gel and PCR Clean Up system (Cat #A9282), is a 
membrane-based purification system (binding up to 40µg DNA) for direct 
clean up of PCR products (100bp – 10kb). This system was used for clean 
up of BSP amplified target regions prior to library preparation when all pooled 
amplicons were > 100bp.  
 
Briefly, an equal volume of membrane binding solution was added to the 
PCR amplification product, mixed, then placed onto an SV mini-column and 
incubated at room temperature for 1 minute then centrifuged at 16,000 xg for 
1 minute. The column was washed using 700µL of membrane wash solution, 
centrifuged at 16,000 xg for 1minute, then repeated using a further 500µL of 
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membrane wash solution and increasing centrifugation time to 5 minutes. 
The column was re-centrifuged for 1 minute with the lid off to allow for 
complete evaporation of residual ethanol. Elution was performed using 50µL 
of nuclease-free water, incubating 1 minute at room temperature, then 
centrifuging at 16,000 xg for 1 minute. All centrifugation steps were 
performed at room temperature. Purified DNA was quantified (Section 2.2.4  
Qubit® fluorometric double-stranded DNA quantification) then stored at -
20°C. 
2.2.3.2  Qiagen Min Elute PCR Purification Kit 
Qiagen’s Min Elute PCR Purification Kit (Cat #28004) is a column-based 
purification system (5µg maximum binding capacity) for direct clean up of 
PCR products (70bp – 4kb), used for clean up of BSP amplified target 
regions prior to library preparation when pooled amplicons include targets < 
100bp. Protocol was performed as per the manufacturers instructions, with 
the exception of pH indicator addition, omitted due to interference with 
downstream sequencing; and alterations to elution procedure for increased 
yield.  
 
Briefly, 5 volumes of Buffer PB were added to 1 volume of PCR reaction and 
passed over the column by centrifugation at 13,000 rpm for 1 minute. DNA 
was washed using 750µL Buffer PE by centrifugation at 13,000 rpm for 1 
minute, then dried by an additional 1 minute centrifugation at maximum 
speed. Samples were air-dried a further 1min at room temperature with the 
lid open to ensure complete evaporation of all residual ethanol. DNA was 
eluted in 10µL nuclease-free water, incubating 1 minute at room temperature, 
then centrifuging 1 minute at 13,000rpm. Elution was repeated with a further 
10µL nuclease-free water. Finally, 10µL of eluate was reapplied, incubated 
and centrifuged as before to result in ~18-19µL purified DNA. All 
centrifugation steps were performed at room temperature. Purified DNA was 
quantified (Section 2.2.4  Qubit® fluorometric double-stranded DNA 
quantification) then stored at -20°C. 
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2.2.3.3  Solid Phase Reversible Immobilization (SPRI) beads 
SPRI beads are paramagnetic beads that reversibly bind DNA in the 
presence of polyethylene glycol (PEG) and salt. The volumetric ratio of 
beads to DNA can be altered to allow for size-selection manipulation. 
Illumina SPRI beads (Sample Purification Beads (SPB)) were used for MiSeq 
library preparation, more specifically for clean up of very small fragments and 
DNA concentration after end-repair, prior to A-tailing and again for clean up 
of the adapter ligated library, removing adapter dimers and other small 
fragments. Results from investigation of column-based versus bead-based 
clean up for library preparation optimization (amplicon sizes 70 – 200 bp) is 
covered in Section 5.3.2.1  Column versus bead-based clean up. 
2.2.4  Qubit® fluorometric double-stranded DNA quantification 
Qubit® fluorometric assays are highly selective for quantification of double 
stranded DNA (dsDNA). The Qubit® dsDNA BR Assay Kit (Life 
Technologies, Cat #Q32850) is a broad range kit, accurate for initial sample 
concentrations 100pg/µL – 1000ng/µL and was used for quantification of 
amplified regions of interest prior to pooling and pooled amplicons prior to 
library preparation. The Qubit® dsDNA HS Assay Kit (Life Technologies, Cat 
#Q32851) is a high sensitivity kit, accurate for initial sample concentrations 
10pg/µL – 100ng/µL and was used for quantification of library adapter-ligated 
DNA. The single pooled library was accurately quantified for PCR-competent 
sequencing templates using KAPA quantification (Section 5.2.4.3  
Quantification of PCR-competent sequencing template). 
 
Qubit® assays (broad range and high sensitivity) were carried out according 
to the manufacturer’s instruction. Briefly, all reagents were equilibrated to 
room temperature for 30 minutes, protected from light. A working solution 
was created by mixing reagent to buffer in a 1:200 ratio. Two standards were 
prepared, mixing 10µL of each supplied standard with 190µL of working 
solution. Samples were prepared by mixing 1-2µL of DNA with working 
solution to 200µL (based on expected sample concentration). All samples 
and standards were vortexed 2-3 seconds and read using the Qubit® 
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Fluorometer, running a new standard curve each time. Resultant reads were 
adjusted to account for initial dilution. 
2.2.5  DNA methylation studies 
2.2.5.1  DNA lysis 
DNA was lysed to ensure all protein was cleaved prior to bis-conversion, 
aiding in achieving maximal conversion efficiency. Genomic DNA (500ng) 
was incubated in 1x DNA lysis buffer (2ng/µL tRNA, 280ng/µL Proteinase-K, 
1% SDS), in a final volume of 20µL, for 1 hour at 37°C.  
2.2.5.2  Bisulfite conversion of DNA 
Bisulfite conversion of DNA was performed using Zymo’s EZ DNA 
Methylation Gold Kit (Cat #D5005) as per the manufacturer’s instructions, 
with the exception of alterations to the elution protocol. Briefly, 130µL of 
prepared CT-conversion reagent was added to 500ng lysed genomic DNA (in 
20µL final volume), and heat denatured at 98°C for 10 minutes, incubated at 
64°C for 2½ hours, then cooled to 4°C. 600µL of M-binding buffer was added 
to a Zymo spin column, followed by the converted DNA and mixed by 
inversion. Converted DNA was bound to the column by centrifugation at 
14,000 rpm for 30 seconds, then washed using 100µL M-wash buffer and 
centrifuging at 14,000 rpm for 30 seconds. Desulfonation was performed by 
incubation with 200µL M-desulfonation buffer for 15 minutes at room 
temperature, and centrifuging at 14,000 rpm for 30 seconds. After 
desulfonation, DNA was washed twice using 200µL M-wash buffer and 
centrifuging at 14,000 rpm for 30 seconds. The column was air-dried for 2 
minutes with the lid open to allow for complete evaporation of residual 
ethanol. Bis-DNA was eluted following a 2 minute incubation in 10µL M-
elution buffer and centrifuging at 14,000 rpm for 30 seconds. The eluate was 
re-applied to the column to increase yield, incubated 2 minutes and 
centrifuged at 14,000 rpm for 30 seconds. Following this, a further 10uL 
nuclease-free water (Qiagen nuclease-free water, Cat #129114) was added 
to the column, incubated for 2 minutes, then eluted by centrifugation for 30 
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seconds at 14,000 rpm  (total eluate volume ~18-19uL). All centrifugation 
steps were performed at room temperature. 
2.2.5.3  Quantification of bisulfite converted DNA 
The concentration of bis-converted DNA can be quickly estimated using a 
spectrophotometer. Bisulfite-converted DNA is single stranded with limited 
non-specific base pairing at room temperature, thus its absorption coefficient 
at 260nm resembles that of RNA. Therefore, the concentration of bisulfite-
converted DNA can be estimated using the Shimadzu BioSpec Nano 
Spectrophotometer, setting the instrument to RNA and pathlength to 0.7mm 
(using a value of 40ug/mL for Ab260 = 1.0).  
2.2.5.4  Bisulfite-specific PCR (BSP) 
Bisulfite-specific PCR was used to amplify bis-converted regions of interest 
for targeted amplicon sequencing. Oligonucleotide primers, specific to the 
bisulfite-modified sequence were designed to facilitate this analysis. Assays 
were optimized to ensure unbiased amplification of methylated and 
unmethylated DNA input. Sections 5.2.3.1  and 5.3.1.2  outline the primer 
design process and resultant BSP assays. 
 
Duplicate (optimization) or triplicate (technical and independent validation 
cohorts) PCR amplification was performed for each region of interest using 
primers as described in Table 5-6. Amplicon genomic location is summarized 
in Table 5-5. BSP assays were performed in a final volume of 10µL, 
containing 5-10ng bisulfite-converted DNA template, 200µM dNTPs, 200nM 
each primer, 1x buffer without MgCl2, 1.0 – 1.5mM MgCl2 and 0.033U/µL 
Platinum® Taq DNA polymerase. SYTO® 9 was used for optimization of 
BSP assays (1:20 dilution) but not included for amplification prior to targeted 
sequencing due to possible interference. SYTO® 9 (excitation maximum: 
483nm, florescence emission maximum: 503nm) is less inhibitory to PCR 
than the traditionally used SYBR Green I and results in highly reproducible, 
robust melt curves79.  
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Amplification was performed using the Roche LightCycler ® 480 Instrument II 
Real-Time PCR system, in 96-well plate format (Roche LightCycler ® 480 
Multiwell Plate 96, Cat #04 729 692 001) under the following conditions: 
95°C, 2 min x 1 cycle; 95°C, 40 sec / χ°C, 90 sec / 72°C, 2 min x 5 cycles; 
95°C, 40 sec / χ°C, 1 min / 72°C, 90 sec x 35-40 cycles; 72°C, 5 min x 1 
cycle, cool to 40°C, hold 10 sec; where χ represents the optimized annealing 
temperature for the specific BSP assay. For melting curve analysis (BSP 
optimization only) the following melt program was added prior to cooling: 
95°C, 15 sec x 1 cycle; 65°C, 1 min x 1 cycle, continuous acquisition (5 
acquisitions/°C) to 97°C. Ramp speeds were set to maximum (4.4°C/s for 
heating, 2.2°C/s for cooling). Table 5-7 outlines the optimal assay conditions 
for each primer set. 
2.2.5.5  DNA methylation detection 
Heat dissociation melt curve analysis was used to determine bias in 
amplification for BSP assay optimization (Section 2.2.5.4  outlines SYTO® 9 
addition and melt curve cycling). Melt curve analysis (Tm calling) was 
performed using the Roche LightCycler ® 480 Instrument II Real-Time PCR 
system. Initially, bisulfite-converted Human HCT116 DKO Methylated (M) 
and Non-Methylated (U) DNA as well as Human Genomic DNA from blood 
(B) was used for optimization (Figure 2-2). Later, as Human Genomic DNA 
proved to be entirely unmethylated in all regions of interest, it was adopted 
as the unmethylated control (U) and CpGenome Universally Methylated DNA 
was used as a fully methylated (M) control. BSP assays were optimized to 
ensure a 50:50 mix of bisulfite-converted unmethylated/methylated control 
amplified in proportion to amplification of fully methylated and fully 
unmethylated controls. 
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Figure 2-2: Determination of DNA methylation status using heat dissociation 
melt curve analysis. Bisulphite-specific PCR amplification of 
Chr19:44,455,288-44,455,448, 160bp, containing 11 CpG sites. Fully 
methylated DNA dissociates at 82.2+/-0.2°C, fully unmethylated DNA 
dissociates at 78.6+/-0.2°C. Duplicate inputs of fully methylated bisulphite-
converted DNA (M), fully unmethylated bisulphite converted DNA (U), 
bisulphite converted commercially available human genomic DNA from blood 
(B), 50:50 mix of U and M, both pre- and post-bisulphite conversion, wild-
type control (non-bisulphite converted 50:50 mix of U and M) and no 
template control (NTC) were run. The 50:50 mixture of methylated and 
unmethylated DNA input (both pre- and post-bisulphite conversion) show 
unbiased amplification, in proportion to U and M controls, using 2mM MgCl2 
and 58°C annealing. For this target region, human genomic DNA from 
normal blood (B) is entirely unmethylated, important for a disease-associated 
hypermethylation blood biomarker. 
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CHAPTER 3:   PATIENT COHORT AND SAMPLE SELECTION 
3.1  Introduction 
Despite detection and reproducibility problems, histopathological evaluation 
of esophageal tissue biopsies is still the clinical ‘gold standard’ for the 
surveillance and treatment of Barrett’s esophagus and its dysplastic 
progression80. As outlined in Chapter 1, this combined endoscopic and 
histologic diagnosis method has a number of pitfalls, leading to problematic 
patient classification. During endoscopy, abnormality must be correctly 
identified and then accurately sampled. The Seattle Protocol, recommended 
by guidelines worldwide52, 81, is based on the premise that systematic, high-
count sampling will minimize the possibility of missing ‘worst case’ diagnosis. 
Further confounding accurate diagnoses are technical issues with 
preparation of H&E tissue sections and inherent biological heterogeneity of 
tissue biopsy, further increasing the possibility of misclassification43.  
 
Intra-observer and even inter-observer variability in dysplasia diagnosis, in 
particular low-grade dysplasia, is a problem recognized almost 30 years 
ago82, that still exists today, even among highly experienced specialist  
gastrointestinal pathologists52, 83, 84.This may be due in part to inadequate 
tissue sections (poor preparation as well as biopsy sampling error) or atypia 
related to inflammation or ulceration. However, even with perfect sampling 
and technical preparation of H&E sections, dysplasia assessment remains 
highly variable. The risk of progression from non-dysplastic BE to EAC is 
relatively low, with a rate of ~0.2-0.4% per year85, however progression from 
low to high-grade dysplasia or EAC may be as high as 85% at 9 years86. 
Thus, detection of LGD is really the most important stage for identification of 
treatable, early stage disease; but clinically is the most difficult and often 
eludes detection. The low-grade dysplasia conundrum: the need for accurate 
detection, yet the most problematic identification, has important implications 
for research studies that rely on correct classification of sample and patient. 
Misclassification will impact downstream analysis and quality of result. 
Numerous diagnostic biomarkers have been proposed for BE and EAC52, 87, 
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many of which provide contradictory evidence for clinical utility, perhaps due 
in part to this conundrum. 
 
When selecting patient cohorts and samples for biomarker development 
studies, attention must be paid to variation in attributes such as patient 
demographic, treatment stage and history, as well as source of non-tumor 
specimen and selection of appropriate controls. Matching attributes such as 
age, sex, race and life-style characteristics such as smoking habits between 
disease and control groups is important for the reliable identification of 
potentially relevant biomarkers78. 
3.1.1  Ethical considerations 
This study falls under ethics approval already obtained for the Australian-
wide research group “Progression of Barrett’s Esophagus to Cancer 
Network” (PROBE-NET). PROBE-NET encompasses a large number of 
studies Australia-wide, supporting research into understanding biological 
mechanisms for the progression of BE to EAC, identification and testing of 
biomarkers, developing strategies to prevent or delay disease progression 
and developing better treatments and novel therapies.  
 
More specifically, this study comes under the umbrella of biomarker 
identification and testing, as outlined on p27 of the PROBE-NET NEAF: “Our 
primary aim is to identify those factors associated with progression 
from normal esophageal mucosa to reflux esophagitis to BE to EAC 
across the full range of potential modifiers, including biomarkers (such as 
levels of RNA or protein expression, or methylation), phenotype 
(including BMI), medical conditions (such as gastroesophageal reflux, type II 
diabetes), environmental factors (smoking, alcohol) and pharmacologic 
factors (in particular, anti−acid medications, aspirin and non-steroidal 
anti−inflammatory drugs [NSAIDs]).” 
 
Ethical and scientific approval from the Human Research Ethics Committee 
(HREC) and site-specific approval (SSA) for this project was renewed in 
early 2014. HREC reference HREC/13/SVH/344, granted 14th January 2014, 
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approves human tissue and blood collection at St Vincent’s Hospital, 
Reginald V N Lord’s private rooms (St Vincent’s Clinic, Suite 606, Level 6), 
Westmead hospital and Nepean hospital. Site specific approval for St 
Vincent’s Hospital required renewal during the project, and was approved on 
the 19th February 2014 (valid until 14th January 2019), SSA reference 
SSA/14/SVH/46. Copies of the confirmation letters (HREC/13/SVH/344, 
SSA/14/SVH/46) are included as Appendix 2. 
3.1.2  Chapter 3 aims 
To apply stringent criteria to classify and select suitable samples for 
methylation and expression profiling, targeted amplicon sequencing and pan-
cancer mutation screening. 
3.2  Methods 
3.2.1  Biospecimen collection and processing  
Human esophageal, duodenal and proximal stomach tissue biopsies and 
peripheral blood were obtained from consenting patients undergoing 
standard endoscopy or esophagectomy, prior to sedation. 
3.2.1.1  Tissue biopsy collection and processing 
Tissue samples were placed directly into RNAlater® RNA Stabilization 
Reagent (Life Technologies, Cat #AM7020) to stabilize and protect RNA, 
eliminating the need for immediate processing or freezing. In brief, 
endoscopic biopsies ≤ 4mm were placed into 400µL RNAlater® RNA 
Stabilization Reagent, whilst larger surgical samples (> 5mm) were cut into 
smaller pieces and placed into 1mL of RNAlater®. Samples were stored at 
4°C for a minimum of 24 hours to allow full permeation of the preservative 
solution into the sample.  
 
A central section was taken of each biopsy, formalin-fixed, embedded in 
paraffin, and stained with hematoxylin and eosin (H&E). For surgical samples 
with multiple tissue fragments, a section was taken for each fragment, placed 
in a separate tube with sample number maintained and suffixed with a 
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unique identifier, for example: N1427142(2). Each section was evaluated by 
a minimum of two independent pathologists, blinded to patient details and 
hospital diagnosis. Tissue samples were stored at -20°C for 1 month, then 
residual RNAlater removed and moved to permanent -80°C storage. 
Standard ‘non-research’ routine biopsies were taken as part of all endoscopic 
procedures and analyzed independently by hospital pathologists to 
determine patient diagnosis. 
3.2.1.2  Blood collection and processing 
Blood was drawn from consenting patients, prior to sedation, via cannula into 
BD Vacutainer® 10mL K2EDTA tubes (Cat #367525), up to 40mL per patient. 
Immediately after collection, each tube was mixed by inversion and 
transported to the laboratory at room temperature for processing. Whenever 
possible, blood processing was completed within 8hrs from time of collection, 
avoiding possible contamination of cell-free circulating DNA (cfc-DNA) with 
DNA released from leukocytes lysed during longer pre-processing times88. A 
double-spin protocol was utilized, comprising initial 10 minute centrifugation 
at 3000rpm, separating plasma (transferred to RCF 30,000 xg rated tubes), 
from buffy coat and red blood cell layers (discarded). A subsequent 10 
minute centrifugation of the isolated plasma was performed at 16,000 xg to 
enrich for cell-free, or exosome-associated DNA (fragments of nucleic acid 
not associated with cells or cell fragments will remain in suspension at this 
speed, whereas cellular-associated DNA is pelleted out and discarded). 
Plasma supernatant containing cfc-DNA was transferred to cryogenic vials 
(Sigma-Aldrich, Nunc® CryoTubes® 1.8mL internal thread, Cat #V7634-
500EA), without disturbing the pellet (visible for >1mL of plasma), and stored 
at -80°C. All centrifugation steps were performed at 4°C.  
3.2.2  Data collection and storage 
Patient and sample data were recorded on standardized forms at each visit 
from a consenting patient. On consent, a patient ID was assigned and 
remained unchanged for return visits. Patient ID stickers were affixed to 
every page of the sample and patient data forms.  
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Patient and sample data were collated into password-protected, searchable 
databases, recording fields outlined in Table 3-1. Hardcopy originals of 
patient and data collection forms were scanned and stored in pdf format.  
 
Table 3-1: Database fields recorded for patient and biospecimen tracking. 
General data were recorded (patient and sample) at the time of collection, 
and associated biospecimen nucleic acid extraction data updated as 
performed. §: calculated automatically. 
 Patient-specific fields Tissue-specific fields Blood-specific fields 
General 
data  
Patient ID, Surname, 
First name, Sex, DOB, 
Visit #, Endoscopic 
diagnosis, Pathology-
confirmed diagnosis, 
Reflux, Reflux surgery, 
Prague criteria, 
Procedure comments, 
Hospital pathology.  
Tissue sample ID, Date 
collected, Age at 
collection§, Pathologist 
sample evaluation, 
Distance (cm), Site, 
Appearance, Tissue 
storage location, 
Comments.  
Blood sample ID, Date 
collected, Age at 
collection§, EDTA tube 
count, Collection time, 
Time processing 
complete, Processing 
time§, Plasma volume 
(mL), Storage location, 
Comments. 
DNA 
isolation 
N/A Tissue DNA code, 
Extraction date, Protocol 
used, Lysis time, DNA 
concentration (ng/µL), 
260/280, 260/230, DNA 
volume (µL), Total DNA 
(µg), Storage location. 
Plasma DNA code, 
Extraction date, Protocol 
used, Extraction format, 
Volume plasma used 
(mL), Volume plasma 
remaining§, Thaw time 
(min), Thaw until lysis 
time (min), Lysis 
temperature (°C), Time 
through column (min), 
DNA concentration 
(ng/µL), DNA volume 
(µL), Total DNA (ng), 
Storage location, 
Extraction notes. 
RNA 
isolation 
N/A Tissue RNA code, 
Extraction date, Protocol 
used, Tissue weight 
(mg), RNA 
N/A 
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 Patient-specific fields Tissue-specific fields Blood-specific fields 
concentration (ng/µL), 
260/280, 260/230, RIN, 
RNA volume (µL), Total 
RNA (µg), Storage 
location. 
 
3.2.3  Patient data collection 
As part of patient consent, additional data (in the form of a health 
questionnaire) were collected (enrollment only; not return visits). The health 
questionnaire records the following items: 
• Frequency of reflux 
• Frequency of heartburn 
• Medications (previous and current) 
• Previous operations 
• Family history (reflux, heartburn, Barrett’s esophagus, esophageal 
cancer) 
• Current weight (kg), height (cm) and waist circumference (cm); as well 
as most ever weighed (kg) 
• Smoking history 
• Alcohol consumption history 
• Previous medical conditions (diabetes (and how it was treated), high 
blood pressure, stomach cancer, esophageal cancer, other cancers) 
 
The patient explicitly consents (or can choose to disallow) researchers to 
access their medical, oncology and pathology records.  
3.2.4  Sample data collection 
Sample data were recorded on standardized forms at the time of collection. 
Duplicate sample number stickers (one for the tissue or blood tube, the other 
for the sample collection form) ensure the possibility of error was minimized.  
 
The sample collection form consists of a: 
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• General data sheet 
• Tracking log form 
• Clinical classification form 
• Tissue biopsy report and blood collection form 
• Histology classification form 
3.2.4.1  General data sheet 
The general data sheet recorded patient ID, visit number, patient name, 
address, telephone number and email, GP name, Medicare number and two 
contact person details. The invitation date (date the patient was invited to the 
study) was also recorded; generally via post (letter and information pack 
sent) in the weeks prior to their procedure, or on the day (for return visits). An 
endoscopy clinic or hospital patient sticker was affixed to this page. 
 
Procedure information (procedure date, endoscopist, hospital, doctor and 
confirmation that written consent was obtained) was also recorded on the 
general data sheet. 
3.2.4.2  Tracking log form 
A log form was used for biospecimen tracking and to ensure all 
documentation was complete. Dates were recorded (date issued/requested, 
date received/completed, and date to Queensland Institute of Medical 
Research (QIMR, centralized database for all biospecimen collection under 
the ProbeNet umbrella)), for each of the eight documentation components: 
1. Information brochure 
2. Consent form 
3. Health questionnaire 
4. Endoscopy report 
5. Clinical classification form 
6. Pathology report 
7. Biopsy report form 
8. Histology classification form 
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For biospecimen collection, the log form recorded the date collected, number 
of sample tubes, storage location and date stored for tissue and blood 
samples. 
3.2.4.3  Clinical classification form 
A clinical classification form was completed during the procedure and 
included sections for recording: 
• Primary indication for the procedure (reflux, dyspepsia, BE 
surveillance, treatments, pre- / post-surgical, etc…) 
• Distance to the gastroesophageal junction (GOJ) aboral (cm) 
• Clinical diagnosis for the patient (no abnormality detected, reflux 
esophagitis, BE, EAC, adenocarcinoma of the cardia, squamous cell 
carcinoma (SCC), etc…) 
 
The recorded clinical classification was signed and dated by the endoscopist 
or doctor performing the procedure. 
3.2.4.4  Tissue biopsy report and blood collection form 
The procedure date, site and doctor were recorded on this form. An 
endoscopy clinic or hospital patient sticker was affixed to this page. 
 
Collected biospecimen data included: 
• Tissue biopsy data: 
o Tissue sample number (sticker affixed to form, duplicate sticker 
affixed to sample tube). A unique sample number was used for 
each biopsy. 
o Distance from the GOJ (cm) 
o Biopsy site (esophageal, upper stomach, duodenal, other) 
o Biopsy appearance (columnar, squamous, tumor, etc…) 
o Any comments 
• Blood data: 
o Blood sample number (sticker affixed to form, duplicate sticker 
affixed to blood tube). The same sample number was applied to 
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ALL tubes collected of a specific type (EDTA tubes for plasma). 
If serum was also collected (for other studies), a new sample 
number was applied to ALL serum tubes. 
o Time of collection 
o Type of blood collection tube (EDTA, serum, etc…) 
o Any comments  
3.2.4.5  Histology classification form 
The histology classification form was completed based on hospital patient 
classification (worst diagnosis detected in routine ‘non-research’ biopsies, 
analyzed independently by hospital pathologists to determine patient 
diagnosis). Classification was signed and dated by the endoscopist or doctor 
responsible for the patient. 
3.2.5  Patient and sample classification 
Patient classification was based on hospital biopsy sampling and pathology 
(as recorded on the histology classification form (Section 3.2.4.5)). Research 
sample classification was based on blinded, independent evaluation of 
H&E stained slides from a representative section of sample tissue, performed 
by a minimum of two pathologists (as outlined in Section 3.2.1.1). For 
identification of Barrett’s esophagus (BE), the presence of goblet cell 
containing columnar mucosa was required. 
3.2.6  Patient selection for study inclusion 
In all cohorts, patients were age and gender matched (see Table 3-2: Patient 
cohort summary, p51), with patients free from any other forms of cancer 
(both presently and previously).  
3.2.7  Sample selection for study inclusion 
Stringent quality requirements were imposed on extracted nucleic acid to 
ensure successful downstream methylation and expression profiling, targeted 
amplicon sequencing and pan-cancer mutation screening. Yields of greater 
than 500ng and 1.5µg were required for tissue RNA and DNA respectively. 
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Absorbance ratios for 260nm/280nm were required to fall in the range 1.70 – 
2.00 and 260nm/230nm: 1.70 – 2.30. RNA integrity number (RIN; RNA only) 
was required to be ≥ 7.50 to proceed with expression profiling.  
 
Tissue samples for the study were classified as normal squamous (N), BE 
without dysplasia (BE), BE with low-grade dysplasia (LGD), BE with high-
grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). Samples 
classified as “indefinite for dysplasia” were excluded. Uniformity in clinical 
treatment regimes and pathological definition allowed for grouping of HGD 
and EAC classifications for data analysis purposes. Minimum 60% 
homogeneity was required for inclusion of individual tissue biopsies in the 
study, however, in practice, the majority of biopsies selected (with the 
exception of LGD) were pathology-confirmed 80-100% homogeneity (Table 
3-3). 
3.2.8  Nucleic acid isolation from esophageal and control tissues 
DNA and RNA were isolated as per Section 2.2.1  from each selected tissue 
biopsy that met inclusion criteria described in Section 3.2.7  Sample selection 
for study inclusion. A number of extraction kits were trialed and optimized to 
ensure optimal yield and quality of nucleic acid for downstream applications 
(results outlined in Section 3.3.4  Optimization of nucleic acid isolation from 
esophageal tissue). 
3.3  Results 
3.3.1  Patient and biospecimen collections 
Over the course of the study (February 2013 – February 2016), 3058 tissue 
and 566 blood samples were collected from 319 unique patients (127 normal, 
70 non-dysplastic BE, 1 BE-ID (indefinite for dysplasia), 17 LGD, 22 HGD, 27 
EAC and 55 ‘Other’). ‘Other’ includes classifications such as esophagitis, 
cardiac mucosa, and squamous cell carcinoma. Repeat visits comprised 
43.64% of all visits (247 in 566), breakdown as outlined in Figure 3-1. 
Patients consenting to medical record access enabled full previous histories 
(prior to enrolment in the study) to be extracted.  
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Figure 3-1: Patient return visits over the duration of the study. 319 unique 
patients enrolled in the study over 3 years with patients returning up to 10 
times for follow-up and treatment. 
 
Nucleic acid was extracted from 437 esophageal and control tissue samples 
(245 DNA and 185 RNA) for downstream applications such as genome-wide 
methylation and expression profiling, targeted sequencing and pan-cancer 
mutation screening (not including samples for protocol optimization, Figure 
3-2). Of the 245 tissue DNA extractions, associated classification breakdown 
is as follows: 9 Duodenal, 9 Proximal stomach, 123 N, 43 non-dysplastic BE, 
3 BE-ID, 16 LGD, 19 HGD, 16 EAC and 7 ‘Other’, including esophagitis and 
cardiac mucosa samples. Of the 192 tissue RNA extractions, associated 
classification breakdown is as follows: 9 Duodenal, 9 Proximal stomach, 99 
N, 26 non-dysplastic BE, 3 BE-ID, 9 LGD, 17 HGD, 13 EAC and 7 ‘Other’, 
including esophagitis and cardiac mucosa samples. Note here that 
classification refers to sample classification, not patient diagnosis (matched 
normal proximal samples from diseased patients were extracted and 
analyzed).  
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Figure 3-2: Nucleic acid extraction from esophageal and control tissues by 
sample classification. Tissue samples were selected for nucleic acid 
extraction based on pathologist evaluation of the associated H&E stained 
section (≥ 60% homogeneity). Resultant nucleic acid yield and purity, along 
with sample homogeneity and patient characteristics were aspects for 
consideration when selecting samples for downstream applications. 
 
Cell-free circulating DNA was extracted from 210 plasma samples and stored 
at -80°C for anticipated blood biomarker investigative studies. Of these 210 
plasma samples, the associated classification breakdown is as follows: 71 N, 
43 non-dysplastic BE, 3 BE-ID, 10 LGD, 22 HGD, 15 EAC and 46 ‘Other’; 
where ‘Other’ refers to patients suffering from squamous cell carcinoma, 
esophagitis, cardiac mucosa and esophageal inflammation. Note here that 
classification of blood samples is synonymous with patient diagnosis. 
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3.3.2  Patient cohorts 
This study used five patient cohorts (summarized in Table 3-2): a training 
cohort, technical validation cohort, independent validation cohort, the Cancer 
Genome Atlas cohort and an external validation cohort.  
 
Genome-wide methylation (HM450) and expression (HTA2.0) profiling was 
performed on a training cohort (n=48 samples from 27 patients). A subset of 
this (technical validation cohort, n=24 samples from 18 patients) underwent 
targeted amplicon sequencing (10 target regions) to validate observed 
disease-associated differential methylation. An independent validation cohort 
(n=24 samples from 15 patients) independently confirmed these results, 
examining the previous ten, plus an additional eight (total 18) regions of 
interest. A large EAC-focused external validation cohort from collaborators in 
Queensland49 was also used to validate differential methylation findings.  
3.3.2.1  Training cohort 
Genome-wide methylation and expression profiling was performed on a 
training cohort of 48 samples from 27 patients, divided into two subsets. The 
first subset consisted of DNA and RNA extracted from 24 esophageal tissue 
samples taken from 12 patients (3 patients from each of the four 
classifications: normal esophagus (N), Barrett’s esophagus (BE), Barrett’s 
esophagus with low-grade dysplasia (LGD) and combined Barrett’s 
esophagus with high grade dysplasia and esophageal adenocarcinoma 
(HGD/EAC)). A proximal (25cm, matched normal) and distal sample 
(reflecting disease classification, or in the case of a normal patient, normal 
distal esophagus tissue) was included for each selected patient.  
 
The second subset of the training cohort consisted of 24 samples from 15 
patients (5 patients each from the three classifications: BE, LGD, HGD/EAC). 
A distal sample was taken from each of the 15 patients (reflecting disease 
classification), with a matched normal, duodenal and proximal stomach 
sample taken from a representative case from each of the disease 
classifications.  
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The first subset confirmed no difference in molecular signature from matched 
normal samples (taken proximally from diseased patients) to that from 
normal healthy patients, irrespectively of whether taken proximally or distally 
(results Section 4.3.2.1  Normal squamous tissue methylation) and tight 
sample clustering, indicative of minimal patient-to-patient difference. The 
second subset was profiled subsequently to analysis of the first and thus 
more focused on diseased samples, where molecular signature was found to 
be more variable.  
3.3.2.2  Technical validation cohort 
The technical validation cohort consisted of a subset of the training cohort, 
used to validate selected target regions differentially methylated in genome-
wide profiling. Targeted amplicon sequencing was used for validation. The 
cohort comprised 24 samples from 18 patients, selected primarily on tissue 
homogeneity.  
3.3.2.3  Independent validation cohort 
The independent validation cohort was used to independently validate 
selected target regions differentially methylated in genome-wide profiling 
using targeted amplicon sequencing. This cohort consisted of 24 samples 
from 15 patients. Two control samples, CpGenome universally methylated 
DNA (Millipore, Cat #S7821) and fully unmethylated DNA (Human genomic 
DNA from blood, Roche, Cat #11 691 112 001) were included in this cohort. 
The cohort also contained a time-series of multiple samples from a single 
patient to examine methylation changes with disease treatment. 
3.3.2.4  External validation cohort 
An external validation cohort, consisting of genome-wide methylation profiling 
data (Illumina Infinium HumanMethylation450 BeadChip®) from a total of 250 
samples from 154 patients was obtained with the kind permission of A/Prof. 
Andrew Barbour from the University of Queensland, Translational Research 
Institute at the Princess Alexandra Hospital. This data formed a part of a 
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comprehensive characterization of methylation in esophageal 
adenocarcinoma, identifying a CIMP subtype and was published in February 
201649. The external validation cohort was comprised of 125 EAC, 19 BE (11 
adjacent BE from EAC patients, 8 BE samples from BE patients), 85 non-
tumor squamous esophagus (10 GERD, 75 normal squamous) and 21 
normal stomach samples. No intermediate stages of dysplasia were 
analyzed. 
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Table 3-2: Patient cohort summary. Four cohorts were used, a Training cohort, Technical validation cohort, Independent validation cohort 
and External validation cohort. The external validation cohort also consisted of 10 samples (disease-affected distal esophagus) taken 
from control patients suffering from GERD, average age 55.7 ± 10.8 years, 60.0% male, 40.0% female (data not shown). Average 
Prague Criteria rounded to the nearest whole integer.  
 
 
Total (n) Duodenal 
Proximal 
Stomach 
N BE LGD HGD EAC 
         
Training Cohort         
  Patients (n) 27 N/A N/A 15 9    7    3    5  
  Samples (n) 48 3 3 18 9 7 3 5 
    Average age ± Standard deviation (yrs)  68.0 ± 15.0 68.0 ± 15.0 68.2 ± 10.8 63.2 ± 11.2 66.9 ± 6.9 69.0 ± 12.1 70.4 ± 8.6 
    Gender: Male (%)  66.7 66.7 83.3 77.8 71.4 100 80.0 
                  Female (%)  33.3 33.3 16.7 22.2 28.6 0 20.0 
    Average Prague Criteria (Cx Mx)  N/A N/A N/A C1 M3 C3 M6 C2 M4 C2 M2 
 
Technical Validation Cohort 
        
  Patients (n) 18 N/A N/A 3 6 3 2 4 
  Samples (n) 24 0 0 9 6 3 2 4 
    Average age ± Standard deviation (yrs)  N/A N/A 69.0 ± 12.4 62.0 ± 10.0 65.0 ± 9.0 73.0 ± 14.8 71.0 ± 9.9 
    Gender: Male (%)  N/A N/A 88.9 83.3 100.0 100.0 75.0 
                  Female (%)  N/A N/A 11.1 16.7 0.0 0.0 25.0 
    Average Prague Criteria (Cx Mx)  N/A N/A N/A C1 M3 C4 M8 C2 M4 C3 M3 
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Total (n) Duodenal 
Proximal 
Stomach 
N BE LGD HGD EAC 
Independent Validation Cohort 
  Patients (n)1 15 N/A N/A 0 6 4 3 4 
  Samples (n)2 24 0 0 5 6 4 3 4 
    Average age ± Standard deviation (yrs)  N/A N/A 62.0 ± 9.5 59.0 ± 11.1 667.0 ± 13.0 62.0 ± 14.0 59.0 ± 7.0 
    Gender: Male (%)  N/A N/A 100.0 83.3 100.0 66.7 100.0 
                  Female (%)  N/A N/A 0.0 16.7 0.0 33.3 0.0 
    Average Prague Criteria (Cx Mx)  N/A N/A N/A C3 M5 C9 M10 C7 M8 C5 M8 
 
External Validation Cohort 
        
  Patients (n) 154 0 N/A 11 8    0 0 125 
  Samples (n) 250 0 21 75 19 0 0 125 
    Average age ± Standard deviation (yrs)  N/A 63.6 ± 11.8 61.5 ± 12.3 66.6 ± 10.2 N/A N/A 62.6 ± 10.5 
    Gender: Male (%)  N/A 90.5 87.5 86.7 N/A N/A 92.5 
                  Female (%)  N/A 9.5 12.5 13.3 N/A N/A 7.5 
  
                                            
1 This cohort contained a patient with consecutive follow up samples to examine methylation changes with disease treatment (HGD, LGD and BE sample taken as patient classification improved) 
2 Two control samples (fully methylated and fully unmethylated standard material) were included in the independent cohort (details not shown) 
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3.3.3  Sample cohorts 
Nucleic acid yield and purity, sample homogeneity and patient characteristics 
were aspects for consideration when selecting samples for downstream 
applications. Sample quality characteristics of each cohort are summarized in 
Table 3-3. Typically, higher nucleic acid yield was obtained from samples at 
more advanced stages of disease; however the highest yields were recorded 
for control duodenal and proximal stomach samples.  
 
Absorbance ratios A260/280 and A260/230 reflect sample purity, with pure 
DNA resulting in A260/280 of approximately 1.8; RNA ~2.0. Pure nucleic acid 
will have A260/230 ~2.0 – 2.2. Ratios are affected by nucleotide mix as well 
as pH and ionic strength of nucleic acid eluate; therefore were used as a 
guide only. Overall, DNA cohorts showed reproducible A260/280 ~1.90; RNA 
~2.10-2.15; concordant with contaminant-free nucleic acid. A260/230 was 
much more variable: DNA ~ 1.85-2.30; RNA 1.70-2.20. 
 
A minimum of 60% homogeneity was required for inclusion of individual 
tissue biopsies in the study, however, in practice, the majority of biopsies 
selected (with the exception of LGD) were pathology-confirmed 80-100% 
homogeneity (Table 3-3). 
 
Table 3-3: Sample quality within each patient cohort. All characteristics are 
mean ± standard deviation. Homogeneity averages performed over all 
available pathologist evaluation. Technical and independent validation 
cohorts used for targeted DNA sequencing only. Sample quality control data 
not available for the External Validation cohort. NA: nucleic acid, RIN: RNA 
integrity number. 
 
Total NA (µg) RIN A260/280 A260/230 
Homogeneity 
(%) 
DNA cohorts 
Training Cohort 
Duodenal 16.39 ± 3.17 - 1.91 ± 0.01 2.19 ± 0.06 100.0 ± 0.0 
Proximal stomach 9.51 ± 3.62 - 1.92 ± 0.01 2.16 ± 0.08 100.0 ± 0.0 
Normal 4.37 ± 1.65 - 1.90 ± 0.06 1.89 ± 0.24 100.0 ± 0.0 
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Total NA (µg) RIN A260/280 A260/230 
Homogeneity 
(%) 
Non-dysplastic BE 3.14 ± 1.58 - 1.91 ± 0.11 1.97 ± 0.20 91.6 ± 13.6 
LGD 7.53 ± 6.61 - 1.89 ± 0.05 1.97 ± 0.18 66.3 ± 14.8 
HGD-EAC 9.84 ± 6.90 - 1.90 ± 0.03 2.12 ± 0.14 81.9 ± 33.5 
 
Technical Validation Cohort  
Normal 4.08 ± 1.86 - 1.88 ± 0.08 1.98 ± 0.30 100.0 ± 0.0 
Non-dysplastic BE 3.50 ± 1.96 - 1.87 ± 0.08 1.99 ± 0.17 95.6 ± 7.2 
LGD 10.89 ± 10.77 - 1.86 ± 0.02 1.87 ± 0.14 78.1 ± 3.9 
HGD-EAC 11.98 ± 6.67 - 1.88 ± 0.01 2.12 ± 0.17 96.7 ± 6.1 
 
Independent Validation Cohort 
Normal 3.83 ± 1.10 - 1.87 ± 0.10 2.14 ± 0.44 100.0 ± 0.0 
Non-dysplastic BE 5.94 ± 2.12 - 1.89 ± 0.08 2.33 ± 0.13 98.9 ± 3.0 
LGD 7.29 ± 2.48 - 1.87 ± 0.06 2.28 ± 0.35 63.8 ± 4.0 
HGD-EAC 8.60 ± 3.12 - 1.89 ± 0.06 2.19 ± 0.36 92.5 ± 9.0 
      
RNA cohorts 
Training Cohort 
Duodenal 5.78 ± 1.53 8.27 ± 0.75 2.15 ± 0.05 2.21 ± 0.07 100.0 ± 0.0 
Proximal stomach 10.38 ± 5.77 8.23 ± 0.81 2.14 ± 0.02 2.19 ± 0.02 100.0 ± 0.0 
Normal 1.46 ± 1.08 9.08 ± 0.53 2.16 ± 0.07 1.71 ± 0.19 100.0 ± 0.0 
Non-dysplastic BE 3.44 ± 1.36 9.11 ± 0.60 2.10 ± 0.02 1.82 ± 0.18 91.6 ± 13.6 
LGD 4.72 ± 5.00 9.10 ± 0.63 2.12 ± 0.02 1.88 ± 0.27 66.3 ± 14.8 
HGD-EAC 3.97 ± 2.86 8.93 ± 0.80 2.13 ± 0.01 1.86 ± 0.26 81.9 ± 33.5 
 
3.3.4  Optimization of nucleic acid isolation from esophageal tissue 
A number of extraction kits were trialed and optimized to ensure optimal yield 
and quality of nucleic acid for downstream applications. 
3.3.4.1  DNA isolation 
Five alternative kits for DNA isolation were trialed and optimized (Table 3-4), 
with the best yield and purity attained using Mo Bio’s UltraClean® Tissue & 
Cells DNA Isolation Kit (Figure 3-3). The most significant problems 
encountered were with low 260nm/230nm absorbance ratios, indicative of 
phenol, guanidine or other organic contamination. We hypothesized this was 
due to high salt concentration from the RNAlater, which fully penetrates the 
tissue and thus was not alleviated with additional wash steps. 
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Table 3-4: Optimization of DNA isolation from fresh frozen esophageal tissue 
samples, preserved in RNAlater.  Five kits were trialed using protocol 
variation to optimize yield and purity. Due to small biopsy size, different 
tissue biopsies were used for the comparison, however they were all of the 
same tissue type (normal squamous tissue) and equivalent input amounts 
used. 
Supplier Kit Protocol Variation 
Samples 
tested 
Qiagen DNeasy Blood & Tissue Kit Reapply eluate 10 
  2x AW2 wash 10 
  2x AW2 wash, 2x EtOH wash, 56°C 10min dry 2 
  
2x AW2 wash, 56°C 10min dry, AE successive 
elution 
1 
  
2x AW2 wash, 56°C 10min dry, H2O 
successive elution 
1 
  2x AW2 wash, 56°C 5min dry, variable elution 6 
  Tissue wash, 2x AW2 wash, 56°C 5min dry 10 
Qiagen QIAamp DNA Mini Kit Variable elution (reapply v successive) 6 
Qiagen Gentra Puregene Tissue Overnight rehydration 6 
Thermo 
Fisher 
GeneJET Genomic DNA 
Purification 
2 x 50µL elution 3 
MO BIO 
UltraClean® Tissue & Cells 
DNA Isolation 
Elution in H2O rather than TD3 4 
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Figure 3-3: Yield and purity of DNA isolation kit optimization. (A) & (B) The 
best yields were obtained from Mo Bio’s UltraClean® Tissue & Cells DNA 
Isolation Kit, averaging 9.24 ± 5.09µg total DNA yield at a concentration of 
100.4 ± 55.34ng/µL. (C) A260/280 ratios were acceptable for the majority of 
samples across all kits and protocols tested. Pure DNA will have A260/280 
~1.8; the UltraClean® kit averaged 260/280 1.838 ± 0.029. (D) A260/230 
ratios were poor for the majority of samples. Best results were obtained for 
Mo Bio’s UltraClean® (average 1.783 ± 0.268) and Thermo Fisher 
Scientific’s GeneJET kits (all samples 260/230>1.45). Pure DNA will have 
A260/230 range: ~2.0-2.2.   
 
There is some evidence of correlation between DNA yield (total DNA (µg)) 
and purity (260/230) (Figure 3-4). The poorest 260/230 ratios (<1.0) occur 
when total DNA yield is less than 5µg. This supports the observation that the 
best choice of kit is the one returning the highest yields (Mo Bio’s 
UltraClean® kit).  
 
 
Figure 3-4: Correlation between DNA yield (µg) and purity (A260/230). Linear 
regression line of best fit is plotted with 95% confidence band. Pearson 
correlation coefficient r2 = 0.1804 (assumes Gaussian distribution). 
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As a result of kit testing and optimization, DNA for this study was isolated 
from esophageal and control tissues using Mo Bio’s UltraClean® Tissue & 
Cells DNA Isolation Kit (Cat #12334-50), as per the manufacturers instruction 
with the exception of eluting in nuclease-free water. The suggested second 
50µL elution was implemented for increased yield.  
3.3.4.2  RNA isolation 
Four alternative kits for RNA isolation were trialed and optimized, with the 
best yield and purity attained using Qiagen’s RNeasy Mini Kit. Yield, purity, 
correlation and biases in RNA isolation from esophageal tissue were 
examined following extraction from 154 tissue samples (Appendix 3: Yield, 
purity, correlation and bias in RNA isolation from esophageal tissue). Data 
includes trial kit extractions (Mo Bio’s UltraClean® Tissue & Cells RNA 
Isolation Kit, Bioline’s Isolate II RNA Mini Kit and Zymo’s Quick-RNATM 
MiniPrep kit) as well as the selected RNeasy Mini Kit (Qiagen); chosen on 
the basis of superior absorbance ratios and RNA integrity number (RIN). As 
observed for DNA isolation, the most significant problem encountered was 
low A260/230 absorbance ratio, indicative of phenol, guanidine or other 
organic contamination. Again, we hypothesized this was due to high salt 
concentration from RNAlater, which fully penetrates the tissue and thus is not 
alleviated with additional wash steps. 
 
As a result of kit testing and optimization, RNA for this study was isolated 
from frozen tissue samples performing Polytron PT3100 rotor stator 
homogenization and using the RNeasy Mini Kit (Qiagen, Cat #74104) 
according to the manufacturers protocol with the exception of reapplication of 
30uL nuclease water for elution (following 3min incubation at room 
temperature). On-column DNA digestion was performed using the RNase-
Free DNase Set (Qiagen, Cat #79254).  
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3.4  Discussion 
Despite the abundance of biomarker discovery studies for Barrett’s 
esophagus and esophageal adenocarcinoma, none have been implemented 
for clinical use to date40. This study aims to use only exceptionally well-
classified samples for genome-wide profiling as well as targeted sequencing, 
using publicly available and external cohorts (containing much larger sample 
numbers) for further validation. The study falls under the umbrella of the 
nation-wide collaborative research group PROBE-NET, and thus patient 
consent, as well as patient data and sample collection protocol was already 
established. For the most part, this was adopted without change, however 
some alterations were made, such as blood processing protocols to enrich 
for cancer-associated cfc-DNA. 
 
Interestingly, on the basis of research sample pathology, a number of 
patients were brought in for repeat endoscopy. For example, low-grade 
dysplasia was detected in a particular research sample by a single 
pathologist and independently classified as ‘indefinite for dysplasia’ by 
another. Hospital biopsies reported non-dysplastic Barrett’s only for this 
patient. Based on our observations, the patient was invited for repeat 
endoscopy and with thorough sampling, LGD classification was confirmed by 
hospital pathology. This highlights the problematic aspect of endoscopic 
sampling for patient diagnosis and the need for alternative methods.  
 
Initial analysis of genome-wide methylation data was performed using the 
first subset of the training cohort (24 samples from 12 patients), prior to 
sample selection for the second subset. The purpose of this was primarily 
analyses of methylation signature of normal esophagus, however 
comparison of differential methylation in BE versus (LGD/HGD/EAC) was 
also performed to determine if our analyses had the potential to identify 
clinically useful methylation biomarkers. This preliminary dataset identified a 
number of disease-associated hyper-methylated regions. Top hits of 
DCBLD2, HS3ST3B1, ZNF878, ZNF844 were identified using cut-off criteria 
of baseline (BE) methylation < 0.10 and delta methylation (LGD and HGD 
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and EAC) > 0.25; and imposing criteria: N tissue and normal peripheral blood 
methylation < 0.10. These targets looked promising. Promoter 
hypermethylation inducing epigenetic down-regulation of discoidin, CUB and 
LCCL domain containing 2 (DCBLD2) had been previously observed in 
gastric cancer cell proliferation and invasion13, but was novel for dysplastic 
BE and EAC. Notable in our analyses was the abundance of aberrantly 
methylated zinc finger loci. Hypermethylation of zinc finger protein genes has 
long been associated with carcinogenesis in various forms of human cancer, 
such as ZNF382 in acute myeloid leukemia89, however identified loci, 
encoding zinc finger protein 878 and 844, had not previously been 
associated with EAC development.  
 
However, using the second subset (24 samples from 15 patients) as 
validation for the first revealed an intriguing observation. The top 32 genes 
identified as differentially methylated in LGD, HGD and EAC, compared to N 
and BE in the first subset, showed a trend of hypermethylation in BE, LGD, 
HGD and EAC (with only minimal methylation detected in normal and control 
tissues and normal peripheral blood). How did this change in methylation 
status of non-dysplastic BE arise? Aspects such as gender bias, differences 
in patient age, Prague criteria, biopsy distance from GOJ, time between 
biopsy sampling and nucleic acid extraction, DNA concentration/purity and 
time from nucleic acid extraction until genome-wide profiling were analyzed: 
all showed no significant difference between the two subsets (data not 
shown). Thus it was hypothesized sample homogeneity could be responsible 
for this phenomenon. In view of this, a further two expert pathologists were 
invited to classify each of the samples involved, scoring each sample and 
providing an estimate composition of the representative section. In addition 
to this, the original two pathologists repeated their analyses of the same 
samples (in a blinded manner, unaware they had previously analyzed these 
sections). Estimated sample homogeneity between the first and second 
subset using the now more comprehensive sample homogeneity evaluation 
was analyzed and found to significantly different (Unpaired t-test, assuming 
Gaussian distribution, p = 0.0093). The problem stemmed from inclusion of 
LGD patients in the comparative analysis. These samples had lower 
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homogeneity (a 60% minimum was required for inclusion; the remainder of 
these biopsies tended to be non-dysplastic BE), thus skewing the results 
(Figure 3-5). Overall, sample composition reanalysis showed strong inter- 
and intra-observer agreement for classification of N, non-dysplastic BE, HGD 
and EAC samples, however significant variability was reported surrounding 
samples containing LGD.   
 
Sample classification in the first subset had been based on patient confirmed 
diagnosis (thereby including LGD samples with 25%, 14% and 65% LGD 
(and the remainder generally non-dysplastic BE) in the LGD classification. In 
contrast, sample classification in the second subset was based on sample 
confirmed diagnosis, and included significantly fewer of these controversial 
‘mixed classification’ samples. The lead candidates selected in subset 1, 
based on BE (unmethylated) vs LGD-HGD-EAC (hypermethylated) actually 
had some percentage of non-dysplastic BE tissue contributing to the 
hypermethylated LGD/HGD/EAC profile. Hence these targets, when re-
examined using subset 2 data, actually showed hypermethylation in some 
non-dysplastic BE samples (Figure 3-5 (C)). This preliminary analysis 
triggered (i) the recruitment of two further pathologists (four in total) for 
evaluation of all difficult samples (variable reports of sample homogeneity) 
for all sample cohorts included in this study, (ii) the strict homogeneity 
requirement cut-offs implemented for the study, (iii) use of sample confirmed 
diagnosis, rather than patient diagnosis for classification and (iv) exclusion of 
controversial, difficult to diagnose LGD samples from analyses for the BE vs 
HGD-EAC comparison (results for LGD still examined and included). 
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(C) (i) DCBLD2 Subset 1 
 
(ii) DCBLD2 Subset 2 
 
Figure 3-5: Variation in sample classification from multiple pathologists. (A) 
H&E stained section (200x magnification) of an esophageal tissue sample 
(34cm distally) taken from an 83 year old male (B) Percentage composition 
classification from four independent, blinded pathologists. Pathologist C and 
D unknowingly evaluated the same sample a second time, a minimum of 5 
weeks later (sample not recognized). NS: normal squamous, CM: cardiac 
mucosa, BE: Barrett’s esophagus, ID: indefinite for dysplasia, LGD: low-
grade dysplasia, HGD: high-grade dysplasia, EAC: esophageal 
adenocarcinoma. (C) Impact of incorrect classification: (i) discoidin, CUB and 
LCCL domain containing 2 (DCBLD2), selected as a candidate for 
discrimination of dysplasia/EAC from non-dysplastic BE in subset 1 was 
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based on LGD samples which included a proportion of non-dysplastic BE 
tissue. (ii) This resulted in the apparent hypermethylation of this target region 
in non-dysplastic BE in subsequent subset 2 analyses. 
 
The typical approach for cancer biomarker development studies is to use the 
current clinical ‘gold standard’ diagnosis method to determine sample/patient 
classification and evaluate potential biomarker performance with respect to 
this40, 78. As reported in literature80, my study confirmed the classification of 
non-dysplastic BE, HGD and EAC to be generally undisputed, however LGD 
was frequently not detected or missed and showed poor reproducibility when 
it was detected. Many studies to date have completely avoided the inclusion 
of LGD samples and patients due to their inherent difficulty. However, these 
samples are highly valuable for identification of early-phase, treatable 
disease. I considered a ‘reverse’ approach for sample classification, using 
resultant molecular signature from genome-wide analyses to group similar 
samples post-analysis. However, with complexities such as high rates of 
chromothripsis90, and a stem cell/inflammation origin rather than mutation-
driven like many other cancers (Section 4.3.7  Methylation of tumor 
suppressor p63); this approach unnecessarily complicated sample 
classification and could possibly introduce further bias when deciding 
grouping for comparative analysis, so was discarded. My approach was to 
exclude LGD from all comparative groups (therefore these patients and 
samples did not play a role in determining disease-specific differential 
methylation or expression targets), but include LGD samples in all cohorts to 
determine if identified disease-specific changes are detectable at this early 
stage of carcinogenesis.  
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CHAPTER 4:   GENOME-WIDE METHYLATION AND 
EXPRESSION PROFILING 
4.1  Introduction 
4.1.1  Current field of play 
Despite the plethora of studies investigating specific methylation or 
expression changes in esophageal adenocarcinoma, very few studies have 
combined genome-wide methylation and expression profiling to characterize 
the role of methylation in EAC development. Krause et al49 were the first to 
do this comprehensively, using Illumina’s Infinium HumanMethylation450 
BeadChip® (HM450) technology for methylation profiling (n=250; 125 EAC, 
19 BE, 85 N, 21 Stomach) and Illumina Human HT12 (v4) for expression 
profiling (n=70; 48 EAC, 4 BE, 18 N), publishing their results in 2016. The 
group kindly shared their HM450 data for validation purposes for this study 
(GSE72874), prior to making the data publicly available in April 2016. 
 
The absence of dysplastic or any intermediate development phase samples 
is a notable omission from the Krause et al study. Low and high-grade 
dysplasia are important phases in the metaplasia-dysplasia-adenocarcinoma 
development sequence and cannot be ignored if a full understanding of the 
role of methylation in EAC carcinogenesis is to be elucidated. This study is, 
to date, novel in its analysis of the full metaplasia-dysplasia-adenocarcinoma 
progression sequence (including both low and high grade dysplastic mucosa) 
using comprehensive, genome-wide methylation and expression profiling 
techniques. Inclusion of intermediate phases of disease development allows 
for elucidation of methylation and expression differences observed not only 
between tumor and normal (as is the case for most studies), but also 
between non-dysplastic precursor disease and early-phase EAC 
development, important for identification of potential early stage biomarkers. 
We anticipate differential methylation and expression for each of the 
comparison groups to be informative about biological changes occurring 
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during disease progression and possibly uncover novel changes occurring 
during early carcinogenesis.  
4.1.2  Epigenetic involvement in EAC carcinogenesis 
Genes frequently reported as hyper-methylated in BE and EAC include (but 
are not limited to) AKAP12, APC, CDH13, DAPK1, GPX and GST, HPP1, 
MGMT, NELL1, p16/CDKN2A, Reprimo (RPRM), PRDM2, RUNX3, SFRP, 
SOCS, SST, TAC1, TERT, TIMP3, WIF138, 47, 48, 50, 53, 56-63, 76, 91-93. 
 
Epigenetic involvement in carcinogenesis is still not yet fully understood and 
recent publications have highlighted that DNA methylation at promoter 
regions of tumor suppressor genes causing transcriptional silencing / loss of 
methylation at oncogene promoters resulting in increased expression may 
only be a small part of the story. Interestingly, genome-wide methylation 
analysis has revealed that global hypomethylation (and not 
hypermethylation) is the dominant change in development of Barrett’s 
metaplasia, but progression from BE to EAC is characterised by a smaller 
wave of selective promoter hypermethylation48. Hypermethylation sites in BE 
and EAC are mainly CpG-rich promoters, with the most hyper-methylated 
tumors showing the worst patient survival49. 
4.1.3  Methylation and expression: The bigger picture 
In a genome-wide methylation and transcriptomic profiling study of normal, 
BE and EAC samples, Krause et al (2016)49 reported 63% of detected 
differential methylation showing significant correlation with mRNA expression 
levels. This raises the question: what is happening with the other 
approximately 40%? 
 
In a recent (2015) article examining changes in correlation between promoter 
methylation and gene expression in cancer, Moarii et al94 challenged the 
simplistic model of direct inhibition of gene expression by promoter 
methylation in cancer development. They performed a large scale meta-
analysis of methylation profiles of normal and cancer tissues and the 
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variations in expression of associated target genes and found the interplay 
between promoter methylation and gene expression in cancer is not simple. 
They found that cancer-specific methylation does not always repress gene 
expression but instead targets genes that are lowly expressed in normal 
tissues. Their findings suggest that epigenetic reprogramming may contribute 
to carcinogenesis in part by modifying gene expression susceptibility to 
changes in DNA methylation rather than a direct influence. This recent study 
highlights that interdependence of genetic and epigenetic alterations is poorly 
understood and not a simple association.  
4.1.4  Pathways in EAC tumorigenesis 
In the development of EAC, both genetic and epigenetic mechanisms 
contribute to alteration of signaling pathways that are believed to drive 
tumorigenesis39. Pathways associated with aberrant promoter methylation in 
BE and EAC include enrichment of known cancer signaling pathways: cell 
adhesion, regulation of epithelial-to-mesenchymal transition (EMT) and 
transforming growth factor (TGF) and WNT signaling49. The WNT gene 
family encode for secreted signaling proteins, and are involved in several 
developmental processes regulating cell fate as well as being implicated in 
carcinogenesis. Vascular endothelial growth factors (VEGFs) are involved in 
angiogenesis, the formation of new blood vessels, needed for tumor growth 
and metastatic spread of tumors. There is evidence that VEGF pathways 
may be important in neoplastic progression of BE to EAC95-97. 
4.1.5  The origin of BE and tumor suppressor p63 methylation 
The origin of Barrett’s esophagus has been a subject of considerable 
controversy without achieving consensus in the field86. Many of the common 
cancers show early genetic and epigenetic changes that result in cancer 
development; however for a subset of inflammation-induced cancers, the 
story is more interesting. The appearance of Barrett’s esophagus and 
progression to EAC is similar to that of gastric IM and the progression to 
gastric adenocarcinoma in many ways. Both progress via a metaplasia-
dysplasia-adenocarcinoma sequence with IM triggered by chronic 
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inflammation due to gastroesophageal reflux disease in the case of BE, and 
Helicobactor pylori infection in the case of gastric IM98.  
 
Initially, Barrett’s esophagus was thought to originate from gastric cardia 
epithelium, in a migratory process to repair reflux-damaged esophageal 
epithelium, however the dominant concept is now centered around 
esophageal squamous stem cells, which when damaged by acid reflux are 
induced to switch their fate to the generation of columnar epithelium with 
intestinal characteristics99. The prevailing concept currently accepted in the 
field for the origin of BE is that of a discrete population of residual embryonic 
cells (RECs) that exist at the gastroesophageal junction (GEJ) in normal 
individuals. These RECs expand and colonize regions of the esophagus 
affected by chronic reflux, forming intestinal metaplasia (IM) within days of 
esophageal injury86. There is more evidence of inflammation-induced stem 
cell oncogenesis than mutation-driven oncogenesis for EAC; with 25% of 
putative Barrett’s stem cells showing no cancer-related genomic aberration in 
a 2015 study by Yamamoto et al100.  
 
In 2008, Ben-Porath et al established an embryonic stem (ES) cell gene-set 
enrichment signature, consisting of four groups (ES expressed, NOS targets, 
polycomb targets, Myc targets) of 13 partially overlapping gene sets that 
were associated with human ES cell identity. They examined a number of 
aggressive human tumors and found that poorly differentiated breast, 
glioblastoma, bladder carcinomas display an ES-like signature, with striking 
correlation between tumor grade and presence of the signature, however 
were unable to determine whether this signature is inherited from a stem-cell-
of-origin or is re-activated during tumor progression101. 
 
Tumor suppressor p63 is a member of the p53 transcription factor family, 
involved in the self-renewal of epithelial stem cells. Interestingly, it is almost 
never mutated in cancer, yet alterations in p63 expression are associated 
with tumorigenesis and chemoresistance in a number of different cancers102. 
The reduced expression of p63 in bladder carcinoma has been shown to 
correlate with tumor stage and grade (p63 was easily detectable in normal 
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bladder tissue)103. Park et al. also showed that abnormal expression of two 
major isoforms of p63 (TAp63 and ΔNp63) were observed on treatment of 
human bladder carcinoma cell lines with 5-Aza-2’-deoxycytidine, suggesting 
aberrant promoter methylation of both these isoforms in bladder 
carcinogenesis103. The residual embryonic stem cell theory for the origin of 
Barrett’s esophagus is supported by p63 null mouse models, which quickly 
develop Barrett’s-like tissue. On analysis, this tissue is a near-exact match 
with human Barrett’s at the gene expression level104. The potential 
therapeutic opportunities are immense: therapies targeting RECs (which 
have different gene expression signatures to normal tissues) could provide 
an avenue for permanent eradication of BE before it progresses to cancer. 
4.1.6  Chapter 4 aims 
First, to use genome-wide methylation and transcriptomic profiling to define 
global methylation and expression change occurring at all stages of 
esophageal adenocarcinoma development; including novel intermediate 
stages of Barrett’s esophagus with low- and high-grade dysplasia.  
Second, to investigate DNA methylation correlation with expression of 
neighbouring transcripts. Subsequent gene set enrichment analysis will be 
used to examine changed pathways in disease development.  
Third, to investigate aberrant tumor suppressor p63 promoter methylation to 
understand its role in the origin and development of Barrett’s esophagus. 
4.2  Methods 
4.2.1  Establishing comparison groups 
Comparison groups were established to interrogate methylation and 
associated expression data more comprehensively. The following groups 
were established: 
• Normal (N) versus Barrett’s esophagus without dysplasia (BE). No 
restrictions on dysplastic disease or EAC. For identification of Barrett’s 
esophagus. 
• Normal (N) versus high-grade dysplasia (HGD) AND esophageal 
adenocarcinoma (EAC). No restrictions on non-dysplastic BE or low-
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grade dysplasia. For identification of intervention-requiring disease. 
Due to lack of restriction surrounding non-dysplastic BE; this is not 
necessarily a clinically valuable comparison: the majority of non-
dysplastic BE patients will not progress to dysplastic disease or EAC39 
and as such, identification will result in costly surveillance programs 
without improvement in EAC prognosis. 
• Normal (N) AND Barrett’s esophagus without dysplasia (BE) versus 
high-grade dysplasia (HGD) AND esophageal adenocarcinoma (EAC). 
No restrictions on LGD. For differentiation of intervention-requiring 
disease from non-intervention requiring disease; this is the most 
clinically relevant comparison. 
 
As a result of identification and classification challenges surrounding low 
grade dysplasia as well as much lower levels of homogeneity within sample 
biopsies; primary training analysis did not include LGD data. However, whole 
genome methylation and expression profiling was performed on these 
samples and weight given to shortlisted training regions hypermethylated in 
LGD. LGD samples were included in cohorts for targeted sequencing 
validation (Chapter 5:  Target Region Validation and Characterization). 
4.2.2  Genome-wide profiling 
Genome-wide methylation and transcriptomic profiling was performed on 
DNA and RNA extracted from single tissue biopsies (n=48) from 27 patients 
comprising the Training cohort (Table 3-2).  
4.2.2.1  Genome-wide methylation profiling 
Clinical samples were profiled for methylation status using Illumina’s Infinium 
HumanMethylation450 BeadChip® (HM450) in two rounds of 24 samples, 
performed as a service by the Australian Genome Research Facility (AGRF, 
Melbourne, Australia). DNA samples were re-checked by Nanodrop 
spectrophotometer (Thermo Fisher Scientific Inc., Waltham, USA) and quality 
confirmed by resolution check on a 0.8% agarose gel (130V for 90min). 1µg 
of DNA was bisulfite converted using Zymo EZ DNA MethylationTM Kit as per 
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the manufacturer’s protocol. Preliminary data analysis was performed using 
Illumina’s GenomeStudio v2011.1 with Methylation module 1.9.0 software, 
using the default Illumina settings. Multiple rounds of array data were 
analysed (i) separately as discovery and validation sets, (ii) as a combined 
data set, strengthening the statistical significance of the assembled list of 
target regions. 
4.2.2.2  Genome-wide transcriptome profiling 
Clinical samples were profiled for comprehensive exploration of the 
transcriptome using Affymetrix GeneChip Human Transcriptome Array 2.0 
(HTA2.0), in two rounds of 24 samples, performed as a service by the 
Ramaciotti Centre for Genomics  (UNSW, Sydney, Australia). RNA samples 
were quality checked at three stages of processing (first cycle cRNA after 
clean up, second-cycle single-stranded cDNA after clean up and fragmented, 
labeled cDNA), checking yield, length and absorbance ratio 260nm/280nm at 
the first two stages and length at the third stage. 100ng total RNA input was 
used, with labeling performed using the Affymetrix GeneChip® WT PLUS 
Reagent Kit (Cat #902281) as per manufacturer’s protocol. 5.2µg of 
fragmented and labeled ssDNA was hybridized to the array. Follow 
troubleshooting for poor hybridization, an additional pre-hybridization step 
was performed (30min), prior to incubation (16hrs at 45°C, rotation @ 60rpm, 
Incubator: Affymetrix 640). Fluidics as per protocol FS450_0001, Instrument: 
Affymetrix 450, Scanner: Affymetrix 3000 7G. Multiple rounds of array data 
were analysed (i) separately as discovery and validation sets, (ii) as a 
combined data set, strengthening the statistical significance of the 
assembled list of differentially expressed regions. Comparison groups 
established for whole-genome methylation profiling (Section 4.2.1  
Establishing comparison groups) were maintained for comprehensive 
transcriptomic interrogation. 
4.2.3  Statistical analysis 
Bioinformatic analysis of genome-wide methylation and transcriptomic 
profiling was kindly performed by Dr Elena Zotenko, a computational analyst 
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with Professor Susan Clark’s Epigenetics Research Program at the Garvan 
Institute of Medical Research.  
4.2.3.1  Differential methylation statistical analyses 
Illumina HumanMethylation450 raw data was pre-processed and background 
normalised with Bioconductor minfi package v3.2 (PMID: 24478339), using 
the preprocessIllumina(…, bg.correct = TRUE, normalise = “controls”, 
reference=1) command. Resultant M-values were used for differential 
methylation statistical analysis105. Differential methylation analysis between 
comparison groups was carried out using the Bioconductor Linear Models for 
Microarray Data (LIMMA) package. Hyper-methylated probes were filtered 
based on false discovery rate (FDR < 0.05) and baseline methylation (avg. 
beta < 0.10), then merged into regions based on distance cut-off of 300bp. 
DMRs must span at least two filtered probes and at least one filtered probe 
with increase in methylation of at least 20%. Data was filtered to remove 
probes located on X and Y chromosomes. Regional filtering ensured 
identified loci are robust. 
4.2.3.2  Differential expression statistical analyses 
Affymetrix HTA2.0 raw data was pre-processed and robust multi-array 
average (RMA) normalised using Affymetrix Expression Console. Differential 
analysis between comparison groups was carried out using Affymetrix 
Transcriptome Analysis Console. Differentially expressed probes were 
selected based on FDR < 0.05 and log-fold change > +0.585 or -0.585 
(equivalent to 1.5 fold change up or down). Data was filtered to remove 
probes located on X and Y chromosomes.  
4.2.4  Integrative analysis: methylation and expression correlation  
Genome-wide data were interrogated to investigate whether particular 
aberrant methylation was responsible for downstream altered RNA 
expression. Integrative analysis of HM450 and HTA2.0 array data was 
performed to identify regions whose hyper-methylation negatively correlated 
with expression of nearby transcripts (20kb cut-off from transcription start 
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site). Pearson correlation between expression and methylation beta-values of 
probes within hyper-methylated regions were computed. Region/transcript 
pairs showing strong negative correlation were given priority for validation by 
targeted amplicon sequencing. 
 
In a separate script, the degree of correlation between expression and 
methylation in Normal, BE and HGD-EAC samples was measured. LGD 
samples were not included in this analysis due to sample heterogeneity and 
inter- as well as intra-observer disagreement in classification and 
composition. Towards this end, each transcript on the HTA2.0 array was 
paired with HM450 probes in the regions containing the transcript itself and 
+/- 20kb flanking regions. The degree of correlation was assessed with 
Spearman rank correlation test. For correlation analysis, we only considered 
pairs between highly variable transcripts and probes, which we define as 75th 
percentile of standard deviation in expression and methylation. 
4.2.5  Gene Set Enrichment Analysis (GSEA) 
Functional enrichment analysis was performed using Gene Set Enrichment 
Analysis (GSEA) against MolSigDB v5.0 database of known pathways, gene 
ontology terms and curated gene lists from the literature106, 107. The DAVID 
(Database for Annotation, Visualisation and Integrated Discovery) gene 
function annotation tool (http://david.ncifcrf.gov) was used to identify enriched 
biological themes and function-related gene groups occurring during disease 
development108, 109. 
4.2.6  Control samples 
4.2.6.1  Control tissues 
Proximal stomach and duodenal (small intestine, immediately beyond the 
stomach) tissues have similar mucosal structure to Barrett’s esophageal 
tissue, enabling filtering of aberrant methylation indicative of tissue type (the 
maintenance of columnar epithelium phenotype) rather than the existence of 
BE. The training cohort for methylation and expression profiling included n=3 
duodenal and n=3 proximal stomach controls; taken from non-dysplastic BE, 
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LGD and HGD patients. The external validation cohort (250 samples from 
154 patients) included 21 gastric samples (from EAC patients) as well as 10 
distal esophageal samples from patients suffering from gastroesophageal 
reflux disease (GERD) as controls. The question of biological similarity of 
matched normal proximal tissue from diseased patients (BE and EAC occur 
distally at the gastroesophageal junction) compared to that of healthy 
patients (proximal and distal esophageal tissue) was addressed by inclusion 
of a number of samples from these sites for methylation and expression 
profiling.  
4.2.6.2  Control blood 
To ensure clinically appropriate target region selection from methylation 
profiling, publicly available data (Gene Expression Omnibus (GEO) 
accession GSE48472)110 were used to filter for methylation evident in normal 
peripheral blood (PT1-PT5). As described by Slieker et al110, DNA was 
isolated from whole blood taken from five healthy volunteers (mean age 28 
years, SD = 6.1) using the Qiagen mini kit according to manufacturer’s 
protocol. 
 
It must be noted that a more appropriate control blood sample would be the 
cell-free circulating DNA (cfc-DNA) fraction isolated from plasma, as this 
fraction is known to contain both mutations and DNA methylation patterns 
characteristic of disease occurring elsewhere in the body11, 71, 72.  However 
due to the very low yields and highly fragmented DNA comprising the cell-
free circulating fraction of plasma, it is not a practical control for genome-
wide methylation profiling using HM450 technology. These considerations 
and the transition from tissue-identified putative biomarkers to blood plasma 
biomarkers are discussed more fully in Section 1.3.4 Blood-based 
biomarkers. 
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4.2.7  Aberrant promoter methylation of tumor suppressor p63  
Loss of tumor suppressor p63 expression has been associated with 
carcinogenesis in a variety of cancer types102. This, and the observation that 
p63 null mouse models quickly develop Barrett’s-like tissue104 led us to 
interrogate p63 promoter methylation in our samples. We examined 
methylation in the two promoter regions of tumor suppressor p63 in the 
external validation cohort (250 samples from 154 patients (Table 3-2): 125 
EAC, 18 BE, 85 non-tumor squamous esophagus and 21 normal stomach 
samples), plotting heat maps and bar charts for average methylation at 
HM450 probes within these regions.  
4.3  Results 
4.3.1  Quality control 
4.3.1.1  Methylation profiling quality control 
Illumina’s Infinium HumanMethylation450 BeadChip® (HM450) was used for 
investigation of DNA methylation status, interrogating over 485 000 (485 512) 
CpG sites in the human methylome, representing ~1.7% total genomic CpG 
sites; a 17-fold improvement over the previous HumanMethylation27 
BeadChip®111, 112. Furthermore, HM450 array data have shown to have 
excellent concordance with those from bisulfite sequencing113, reinforcing it 
as one of the leading options for methylation analyses. Overall, forty-six (of 
48) samples resulted in more than 485 000 detected CpG (p<0.01); at 
p<0.05 these two samples (484,993 and 462,934 at p<0.01) detected 
485,081 and 475,120 CpG sites respectively. All internal sample-
independent (staining, extension, target removal and hybridization) and 
sample-dependent (bisulfite conversion, specificity, non-polymorphic and 
negative) controls were as expected.  
4.3.1.2  Transcriptomic profiling quality control 
Recent advances in whole-transcript expression arrays such as Affymetrix’s 
GeneChip® Human Transcriptome Array 2.0 (HTA 2.0) have significantly 
improved coverage of all transcript isoforms, providing significantly more 
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coverage than previous exon arrays, equivalent to two full lanes of RNA 
sequencing on an Illumina® HiSeqTM 2000 system. Affymetrix GeneChip® 
Human Transcriptome Array 2.0 (HTA 2.0) was used for gene expression 
profiling of all transcript isoforms, covering >285 000 full length transcripts 
(both coding and non-coding) to 44,699 protein coding and 22,829 non-
protein coding genes. All samples were within the defined criteria for quality 
control at three stages of processing: cRNA, single-stranded cDNA and 
fragmented, labeled cDNA. 
4.3.2  Global methylation density 
Diagnostic density plots of beta values were assembled to check overall 
HM450 data quality and visualize global disease-associated methylation. 
Profiles of normal squamous tissue were examined to determine if distance 
aboral or esophageal disease present distally affects global methylation. 
Diagnostic density plots of samples from the metaplasia-dysplasia-
adenocarcinoma sequence were examined globally to check for the 
presence of disease-associated aberrant methylation. 
4.3.2.1  Normal squamous tissue methylation 
Methylation density of normal squamous tissue biopsied proximally in the 
esophagus, typically 25cm aboral, was compared in samples taken from all 
disease classes (disease develops distally). There was no significant 
difference in the methylation profile of this tissue, irrespective of whether it 
was taken from a normal healthy patient, or a patient at any stage in the 
metaplasia-dysplasia-adenocarcinoma development sequence. This profile 
(Figure 4-1) is typical of normal, disease-free genome-wide methylation: the 
majority of regions are either entirely methylated or entirely unmethylated. 
Disease-associated aberrant methylation is associated with increased partial 
methylation, as can be seen in Figure 4-3.  
 
There was also no significant difference in methylation profile of squamous 
esophageal tissue taken proximally or distally in a normal healthy patient. 
Comparison of global methylation beta values attained for proximal and distal 
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biopsies from the same (healthy, normal) individual show strong correlation 
(example Figure 4-2, Pearson correlation: 0.99). Thus, matched normal 
samples (taken proximally from diseased patients) can be used for further 
analyses. 
 
(A) 
 
(B) 
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Figure 4-1: Comparison of methylation beta density in proximal esophageal 
tissue from examples of normal healthy patients versus patients at all stages 
of the metaplasia-dysplasia-adenocarcinoma sequence. Data represented as 
(A) Density and (B) Violin plots. All samples taken at 25cm proximally. 
Patient disease status as per Violin plot, y-axis. No significant difference was 
detected in methylation of proximal normal squamous epithelium, irrespective 
of patient disease status.  
 
 
Figure 4-2: Correlation of global methylation beta values in normal squamous 
esophageal epithelium, taken proximally and distally from a single healthy 
patient. Strong correlation (Pearson correlation 0.99), supports hypotheses of 
uniform squamous epithelium methylation profile throughout the esophagus, 
irrespective of distance aboral.  
4.3.2.2  Disease-associated aberrant methylation 
Methylation density of distal, disease-associated epithelium was compared 
across all disease stages in the development of esophageal 
adenocarcinoma. As disease develops from normal squamous epithelium 
(healthy and diseased patient, biopsied proximally, Figure 4-3, in dark green) 
through the metaplasia-dysplasia-adenocarcinoma sequence, increased 
partial methylation is observed, indicating an increased prevalence of sub-
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populations of cells becoming more highly methylated as disease 
progresses. As expected, methylation density profile of duodenal and 
proximal stomach tissues are similar to that of normal squamous epithelia 
from the esophagus: CpG sites are either universally methylated or entirely 
unmethylated across the entire cell population. 
 
(A) 
 
(B) 
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Figure 4-3: Comparison of methylation beta density in distal esophageal 
tissue from normal healthy patients versus patients at all stages of the 
metaplasia-dysplasia-adenocarcinoma sequence. Data represented as (A) 
Density and (B) Violin plots. Increased densities of intermediate beta-values 
are observed for diseased samples with respect to normal squamous 
esophageal, duodenal and proximal stomach epithelium; showing positive 
correlation with disease severity.  
 
Disease-associated aberrant methylation is apparent between all disease 
classes, including the three comparison classes used for this study: N v BE, 
N v HGD-EAC and BE v HGD-EAC (Figure 4-4 (i), (ii), (iii)). Of clinical 
interest is detectable differential methylation between non-dysplastic BE and 
BE with low-grade dysplasia (Figure 4-4 (iv), Pearson correlation 0.95), a 
problematic distinction by histology.  
(i) (ii)  
(iii) (iv)  
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Figure 4-4: Correlation of global methylation beta values between disease 
classes (i) N v BE, N is matched normal sample taken proximally. Pearson 
correlation 0.87; (ii) N v HGD-EAC, N is matched normal sample taken 
proximally. Pearson correlation 0.88; (iii) BE v HGD-EAC, samples from 
different patients, Pearson correlation 0.90; (iv) Non-dysplastic BE v BE-
LGD, samples from different patients, Pearson correlation 0.95. These plots 
show evidence of differential methylation across all disease comparisons, 
including the clinically significant development of LGD from non-dysplastic 
disease. 
4.3.3  Tissue heterogeneity 
Tissue heterogeneity is problematic for current diagnostic methods, which 
require not only accurate disease identification and biopsy by the 
endoscopist, but rely on representative sectioning (blinded, it is not possible 
to identify disease visually in the biopsy) for histology to identify 
heterogeneous disease. One interesting sample came from a 70-year old 
male, taken distally at 40cm (at the GEJ). The biopsy contained a small area 
of destroyed glands, possibly a focus of adenocarcinoma, evaluated as such 
by 1 of 4 pathologists in independent, blinded evaluation (Figure 4-5). 
Interestingly, on repeat analysis, this same pathologist identified that 
dysplasia was present, but instead recorded a much higher composition of 
low-grade dysplasia. The difficulty faced by pathologists with a sample such 
as this is, despite universal recognition of an area of destroyed glands, there 
is insufficient information to determine whether the area of destroyed glands 
is due to inflammation, adenocarcinoma, or is simply the basal layer of 
squamous epithelium.  
 
Assuming the H&E section to be representative of the entire biopsy, this very 
small section of destroyed glands, despite being swamped by an abundance 
of copies of DNA from surrounding normal (squamous and cardiac mucosa) 
epithelium, was able to be identified as focal adenocarcinoma by methylation 
changes apparent when comparing beta values from this sample with that of 
a matched normal sample taken proximally at the same visit. A proportion of 
the observed aberrant methylation (Figure 4-5(C)) is hypothesized to be 
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attributable to a small focus of adenocarcinoma; supported by slightly 
hypermethylated probes detected for this sample in regions identified as 
aberrantly methylated in the group of HGD-EAC samples profiled. Figure 
4-5(D) shows five regions, hypermethylated in HGD and EAC samples 
(LRRC43, CACNA2D2, ZNF221, ISM2 and TRANK1) also showing 
increased methylation in this sample. It is also plausible that a proportion of 
aberrant methylation may also be due to tissue type differences between 
proximal squamous epithelium and cardiac mucosa at the GEJ, however the 
presence of methylation in regions hypermethylated in dysplastic and 
adenocarcinoma samples supports the hypothesis that much of the aberrant 
methylation in this case is attributable to the presence of focal disease, rather 
than maintenance of columnar-type mucosa. 
 
(A)  
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(B)       
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(D) 
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Figure 4-5: Focal adenocarcinoma, difficult to diagnose by histopathologic 
evaluation, can be detected by aberrant methylation. (A) H&E stained section 
(100x) of an esophageal tissue biopsy (40cm distally at GEJ) taken from a 70 
year old male with moderately differentiated adenocarcinoma at the 
gastroesophageal junction and lymph node and liver metastases. Area of 
destroyed glands (boxed), identified histologically as a possible small focus 
of adenocarcinoma. (B) Percentage composition classification from four 
independent, blinded pathologists. Pathologist C and D unknowingly 
evaluated the same sample a second time, a minimum of 5 weeks later. All 
pathologists agreed the predominant tissue type was a mixture of cardiac 
mucosa and normal squamous epithelium. Only 1 of 4 pathologists identified 
the area of destroyed glands as focal dysplasia/adenocarcinoma. NS: normal 
squamous, CM: cardiac mucosa, BE: Barrett’s esophagus, ID: indefinite for 
dysplasia, LGD: low-grade dysplasia, HGD: high-grade dysplasia, EAC: 
esophageal adenocarcinoma. (C) Correlation of global methylation beta 
values between the heterogeneous distal biopsy (possible focal 
adenocarcinoma, EAC_DISTAL_PN200372) and a matched normal tissue 
biopsy taken proximally at 25cm (EAC_PROXIMAL_PN200372). Pearson 
correlation 0.98 indicates methylation profile is very similar between the two 
samples, however aberrant hypermethylation in the distal sample (beta 
~0.50) is discernable by skew. (D) Low level aberrant disease-associated 
hypermethylation of LRRC43, CACNA2D2, ZNF221, ISM2 and TRANK1 is 
detectable in this particular sample (Possible focal EAC_PN200372, in grey), 
despite the associated heterogeneity problems. Height of bars indicate 
percentage methylation (0.0 – 1.0), colour code N: blue, BE: green, HGD and 
EAC: pink, duodenal and proximal stomach: grey and normal blood: dark red. 
4.3.4  Global methylation and transcriptomic analyses 
4.3.4.1  Genome-wide methylation profiling 
As expected, the largest differential methylation was detected in HGD-EAC 
when compared to N (55,424 hypermethylated (Figure 4-6) and 20,876 
hypomethylated (Figure 4-7) CpG sites; FDR < 0.01 and Δβ ≥ 0.20), followed 
by BE compared to N (44,201 hypermethylated (Figure 4-8) and 26,985 
Chapter 4:  Genome-wide Methylation and Expression Profiling 
 87 
hypomethylated (Figure 4-9) CpG sites; FDR < 0.01 and Δβ ≥ 0.20) and 
finally BE compared to HGD-EAC (1,648 hypermethylated (Figure 4-10) and 
153 hypomethylated (Figure 4-12) CpG sites; FDR<  0.01 and Δβ ≥ 0.20). 
Details of the top 100 hyper- and hypomethylated probes detected for each 
comparison group: N v BE, N v HGD-EAC and BE v HGD-EAC are given in 
Appendix 4: Top differentially methylated sites identified by genome-wide 
methylation profiling. 
 
The most significantly hypermethylated regions in HGD and EAC (with 
respect to normal esophageal epithelium) were, in the most part, also 
significantly hypermethylated in non-dysplastic BE, but unmethylated in 
peripheral blood from normal, healthy patients, as well as normal 
esophageal, duodenal and proximal stomach mucosa (Figure 4-6(A)). 
Interestingly, one of three duodenal tissue samples did not cluster with other 
duodenal, proximal stomach and normal esophageal mucosa, instead 
showing slight hypermethylation in these regions. This sample is shown as 
an outlier in Figure 4-6(B). 
 
(A) N v HGD-EAC Hypermethylation heat map 
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(B) N v HGD-EAC Hypermethylation PCA plot 
 
Figure 4-6: Top 500 hypermethylated CpG sites detected in the N v HGD-
EAC comparison, FDR < 0.01 and Δβ ≥ 0.20 expressed as a (A) Heatmap 
showing patients (and their respective classification), with methylation values 
assigned as eight discrete regions from 0.000 – 1.000 in increments of 0.125 
for better visualization (B) Principal component analysis (PCA) plots, showing 
clustering of samples by classification (PC1 and PC2 only). 
 
The most significantly hypomethylated regions in HGD and EAC (with 
respect to normal esophageal epithelium) were also hypomethylated in non-
dysplastic BE. More than half of the top 500 identified regions were also 
hypomethylated with respect to normal peripheral blood (Section 4.2.6.2  
Control blood), however a significant number of regions displayed little or no 
methylation in normal peripheral blood; and thus unable to be differentiated 
from HGD/EAC (Figure 4-7(A)). For this comparison, normal mucosa 
samples cluster strongly, showing very similar methylation profiles. Duodenal 
samples cluster with non-dysplastic, dysplastic and EAC samples; with more 
variably methylated proximal stomach samples clustering alone (Figure 
4-7(B)). From this, we can hypothesize that much of the hypomethylation 
occurring is attributable to the maintenance of columnar mucosa phenotype 
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rather than disease-associated progression through the metaplasia-
dysplasia-adenocarcinoma sequence. For this reason, no hypomethylation 
targets were carried through to validation and targeted sequencing studies. 
 
(A) N v HGD-EAC Hypomethylation heat map 
 
(B) N v HGD-EAC Hypomethylation PCA plot 
 
Figure 4-7: Top 500 hypomethylated CpG sites detected in the N v HGD-
EAC comparison, FDR < 0.01 and Δβ ≥ 0.20 expressed as a (A) Heatmap 
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showing patients (and their respective classification), with methylation values 
assigned as eight discrete regions from 0.000 – 1.000 in increments of 0.125 
for better visualization (B) Principal component analysis (PCA) plots, showing 
clustering of samples by classification (PC1 and PC2 only). 
 
Observations for hypermethylation in N v BE are very similar to those for 
hypermethylation in N v HGD-EAC. The most significantly hypermethylated 
regions in BE (with respect to normal esophageal epithelium) were, in the 
most part, also significantly hypermethylated in HGD and EAC, but 
unmethylated in peripheral blood from normal, healthy patients, as well as 
normal esophageal, duodenal and proximal stomach mucosa (Figure 4-8(A)). 
As for the N v HGD-EAC comparison, one of three duodenal tissue samples 
did not cluster with other duodenal, proximal stomach and normal 
esophageal mucosa, instead showing slight hypermethylation in these 
regions. This sample is shown as an outlier in Figure 4-8(B). 
 
(A) N v BE Hypermethylation heat map 
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(B) N v BE Hypermethylation PCA plot 
 
Figure 4-8: Top 500 hypermethylated CpG sites detected in the N v BE 
comparison, FDR < 0.01 and Δβ ≥ 0.20 expressed as a (A) Heatmap 
showing patients (and their respective classification), with methylation values 
assigned as eight discrete regions from 0.000 – 1.000 in increments of 0.125 
for better visualization (B) Principal component analysis (PCA) plots, showing 
clustering of samples by classification (PC1 and PC2 only). 
 
Observations for hypomethylation in N v BE are very similar to those for 
hypomethylation in N v HGD-EAC, with the exception that slightly higher 
methylation levels were observed in duodenal, proximal stomach, dysplastic 
disease and EAC samples. Also, there were fewer incidences of regions with 
little or no methylation in normal peripheral blood (Figure 4-9(A)). Clustering 
for this comparison is very similar to that of hypomethylation in N v HGD-
EAC with normal mucosa clustering strongly, indicating very similar inter-
patient methylation profile. Duodenal samples cluster with non-dysplastic, 
dysplastic and EAC samples; with more variably methylated proximal 
stomach samples clustering alone (Figure 4-9(B)). These data further 
support the hypothesis of hypomethylation being attributable to maintenance 
of columnar mucosa rather than disease-associated changes. For this 
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reason, no hypomethylation targets were carried through to validation and 
targeted sequencing studies. 
 
(A) N v BE Hypomethylation heat map 
 
(B) N v BE Hypomethylation PCA plot 
 
Figure 4-9: Top 500 hypomethylated CpG sites detected in the N v BE 
comparison, FDR < 0.01 and Δβ ≥ 0.20 expressed as a (A) Heatmap 
showing patients (and their respective classification), with methylation values 
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assigned as eight discrete regions from 0.000 – 1.000 in increments of 0.125 
for better visualization (B) Principal component analysis (PCA) plots, showing 
clustering of samples by classification (PC1 and PC2 only).  
 
Results for hypermethylation in the BE v HGD-EAC comparison showed 
several variable subsets (Figure 4-10(A)). Of clinical interest is the subset of 
hypermethylated HGD-EAC samples with corresponding absence of 
methylation in non-dysplastic BE, normal esophageal mucosa, control 
tissues and blood (marked by a green box). It is these targets that will be the 
focus of further validation as they are able to differentiate intervention-
requiring disease from the relatively ubiquitous, non-dysplastic, benign, 
Barrett’s esophagus.  
 
Below the green box (Figure 4-10(A)) is a similar subset with the exception of 
high-level methylation in normal peripheral blood. This highlights the 
importance of using normal peripheral blood as a control for biomarkers with 
potential transferability for a screening blood test: regions corresponding to 
these CpG sites are not clinically useful as HGD-EAC is not discernable from 
the methylation occurring in the blood of normal, healthy individuals.  
 
Clustering for this comparison shows distinct clustering into tissue type and 
disease classes (Figure 4-10(B)).  
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(A) BE v HGD-EAC Hypermethylation heat map 
 
 
(B) BE v HGD-EAC Hypermethylation PCA plot 
 
Figure 4-10: Top 500 hypermethylated CpG sites detected in the BE v HGD-
EAC comparison, FDR < 0.01 and Δβ ≥ 0.20 expressed as a (A) Heatmap 
showing patients (and their respective classification), with methylation values 
assigned as eight discrete regions from 0.000 – 1.000 in increments of 0.125 
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for better visualization (B) Principal component analysis (PCA) plots, showing 
clustering of samples by classification (PC1 and PC2 only).  
 
The subset above the green box (Figure 4-10(A)) is interesting in that 
increased methylation is observed across all classifications (HGD-EAC, 
normal esophageal mucosa, control tissues and normal peripheral blood) 
with the exception of lower levels of methylation in non-dysplastic BE (note 
that this is low-level methylation, rather than absence of methylation). 
Regions from this subset were not considered for further validation due to 
inability to differentiate between normal and cancerous tissues, however they 
present an interesting case. What is happening biologically for de-
methylation to occur only during metaplasia, returning strongly to a 
methylated status if progression to EAC occurs? It is interesting to note that 
these regions are also strongly methylated in blood. Many CpG sites from 
this subset correspond to regions not annotated by Gencode v19. However, 
those that do, correspond to protein coding genes such as FOXK1, CANT1, 
GPR37L1. Interestingly, these regions often are quite small, surrounded by 
regions of universal methylation (irrespective of disease status), and 
occurring within the gene body, for example in FOXK1 and CANT1. However 
there are instances, such as in GPR37L1 that this BE-specific reduced 
methylation is occurring in a promoter region. 
 
An example of a protein coding gene, Forkhead box K1 (FOXK1), that 
contains a region of decreased methylation in only non-dysplastic Barrett’s 
mucosa is given Figure 4-11 in below. Average methylation of normal 
esophageal mucosa for this region is 0.969; normal peripheral blood 0.939 
and esophageal adenocarcinoma 0.862 (slightly lower due to a single HGD-
EAC sample with reduced methylation), whereas BE tissues averaged 0.491. 
FOXK1 has been proposed to participate in processes such as cell 
differentiation, regulation of transcription and multicellular organismal 
development. FOXK1 gene ontology (GO) annotations include transcription 
factor activity, sequence-specific DNA binding and RNA polymerase II 
transcription factor activity. Therefore, we can hypothesize that these lower 
levels of methylation in metaplastic tissue may be playing a role in cell 
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differentiation processes specific to Barrett’s esophagus mucosal formation 
and maintenance. 
 
 
Figure 4-11: Forkhead box K1 (FOXK1) contains a region (chr7.4781703) 
highly methylated in all (esophageal adenocarcinoma tissues, normal 
esophageal mucosa and peripheral blood from normal healthy patients), but 
non-dysplastic Barrett’s esophageal tissues (green box). Region with lower 
methylation in BE tissues is surrounded by regions of universally methylation 
across all disease types. Genome browser shows HM450 data for a subset 
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of the training cohort with >90% tissue sample homogeneity. Height of bars 
indicate percentage methylation (0.0 – 1.0), colour code N: blue, BE: green, 
HGD and EAC: pink, duodenal and proximal stomach: grey and normal 
blood: dark red. 
 
Results for hypomethylation in the BE v HGD-EAC comparison show high 
level methylation in normal esophageal mucosa and control tissues as well 
as non-dysplastic BE. The majority of HGD-EAC regions identified as 
hypomethylated still have mid-level methylation present. Methylation levels in 
blood for these targets range from absent, through mid-level and a subset of 
targets that are strongly methylated in blood (Figure 4-12(A)). As for other 
hypomethylation comparisons, these patterns are not suitable for biomarker 
selection and hence, no hypomethylation targets were carried through to 
validation and targeted sequencing studies. Clustering for this comparison 
shows distinct grouping of HGD-EAC and N samples with BE, duodenal and 
proximal stomach all maintaining distinct groups but cluster more closely to 
each other than N or HGD-EAC. (Figure 4-12(B)).  
 
(A) BE v HGD-EAC Hypomethylation heat map 
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(B) BE v HGD-EAC Hypomethylation PCA plot 
 
Figure 4-12: All hypomethylated CpG sites (n=153) detected in the BE v 
HGD-EAC comparison, FDR < 0.01 and Δβ ≥ 0.20 expressed as a (A) 
Heatmap showing patients (and their respective classification), with 
methylation values assigned as eight discrete regions from 0.000 – 1.000 in 
increments of 0.125 for better visualization (B) Principal component analysis 
(PCA) plots, showing clustering of samples by classification (PC1 and PC2 
only).  
4.3.4.2  Genome-wide transcriptomic profiling 
As for genome-wide methylation profiling, the largest differential expression 
differences were detected in HGD-EAC when compared to N (3,799 up-
regulated (Figure 4-13) and 2,998 down-regulated (Figure 4-14) transcript 
clusters; adjusted p-value < 0.05 and logfc > log2(1.5)), followed by BE 
compared to N (2,512 up-regulated (Figure 4-15) and 1,984 down-regulated 
(Figure 4-16) transcript clusters; adjusted p-value < 0.05 and logfc > 
log2(1.5)) and finally BE compared to HGD-EAC (553 up-regulated (Figure 
4-17) and 297 down-regulated (Figure 4-18) transcript clusters; adjusted p-
value < 0.05 and logfc > log2(1.5)). Binning for heat maps was based on 
quantiles of expression values. Details of the top 100 up- and down-
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regulated transcript clusters detected for each comparison group: N v BE, N 
v HGD-EAC and BE v HGD-EAC are given in Appendix 5: Top differentially 
expressed transcript clusters identified by genome-wide expression profiling. 
 
The most significantly up-regulated genes in HGD and EAC (with respect to 
normal esophageal epithelium) were, in the most part, also significantly up-
regulated in non-dysplastic BE, duodenal and proximal stomach mucosa 
(Figure 4-13(A)). This pattern is also reflected in the tight clustering of normal 
esophageal mucosa samples and the general clustering of all other tissue 
types (BE, HGD, EAC, duodenal and proximal stomach) together (Figure 
4-13(B)). 
 
(A) N v HGD-EAC Up-regulated genes heat map 
 
 
 
 
 
 
 
Chapter 4:  Genome-wide Methylation and Expression Profiling 
 100 
(B) N v HGD-EAC Up-regulated genes PCA plot 
 
Figure 4-13: Top 200 up-regulated genes detected in the N v HGD-EAC 
comparison, FDR < 0.01 and FC > 1.5, expressed as a (A) Heatmap showing 
patients (and their respective classification), with expression values assigned 
into eight discrete regions (‘bins’) from 0.80 – 13.00 (B) Principal component 
analysis (PCA) plots, showing clustering of samples by classification (PC1 
and PC2 only).  
 
The most significantly down-regulated genes in HGD and EAC (with respect 
to normal esophageal epithelium) are also down-regulated in non-dysplastic 
BE, as well as duodenal and proximal stomach control tissues (Figure 
4-14(A)). For this comparison, normal esophageal mucosa samples cluster 
strongly, showing very similar global expression patterns with all other tissue 
types (BE, HGD, EAC, duodenal and proximal stomach) clustering together  
(Figure 4-14(B)). 
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(A) N v HGD-EAC Down-regulated genes heat map 
 
(B) N v HGD-EAC Down-regulated genes PCA plot 
 
Figure 4-14: Top 200 down-regulated genes detected in the N v HGD-EAC 
comparison, FDR < 0.01 and FC > 1.5, expressed as a (A) Heatmap showing 
patients (and their respective classification), with expression values assigned 
into eight discrete regions (‘bins’) from 0.80 – 13.00 (B) Principal component 
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analysis (PCA) plots, showing clustering of samples by classification (PC1 
and PC2 only).  
 
From both the up- and down-regulated expression analysis of N v HGD-EAC, 
and the clustering of HGD-EAC with non-dysplastic BE and control tissues; 
we can hypothesize that much of the most significant differential expression 
is attributable to the maintenance of columnar mucosa rather than disease 
progression through the metaplasia-dysplasia-adenocarcinoma sequence. 
Thus we can conclude that tissue type difference (flat squamous cells 
comprising normal healthy esophageal mucosa as opposed to the columnar 
mucosa present in BE, HGD, EAC and control tissues) has a more significant 
impact on global expression profile than disease development. 
 
Observations for up-regulation in N v BE are very similar to those for up-
regulation in N v HGD-EAC. The most significantly up-regulated genes in BE 
(with respect to normal esophageal epithelium) were, in the most part, also 
significantly up-regulated in HGD and EAC, as well as duodenal and 
proximal stomach tissues (Figure 4-15(A)). As for the N v HGD-EAC 
comparison, tight clustering of the normal esophageal mucosa was separate 
from the general clustering of all other tissue types (BE, HGD, EAC, 
duodenal and proximal stomach)(Figure 4-15(B)). 
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(A) N v BE Up-regulated genes heat map 
 
(B) N v BE Up-regulated genes PCA plot 
 
Figure 4-15: Top 200 up-regulated genes detected in the N v BE comparison, 
FDR < 0.01 and FC > 1.5, expressed as a (A) Heatmap showing patients 
(and their respective classification), with expression values assigned into 
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eight discrete regions (‘bins’) from 0.80 – 13.00 (B) Principal component 
analysis (PCA) plots, showing clustering of samples by classification (PC1 
and PC2 only).  
 
Observations for down-regulation in N v BE were very similar to those for 
down-regulation in N v HGD-EAC with the most significantly down-regulated 
genes in BE (with respect to normal esophageal epithelium) also down-
regulated in HGD and EAC, as well as duodenal and proximal stomach 
control tissues (Figure 4-16(A)). For this comparison, as for N v HGD-EAC, 
normal esophageal mucosa samples cluster strongly, showing very similar 
global expression patterns, with other tissue types (BE, HGD, EAC, duodenal 
and proximal stomach) clustering together  (Figure 4-16(B)). 
 
(A) N v BE Down-regulated genes heat map 
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(B) N v BE Down-regulated genes PCA plot 
 
Figure 4-16: Top 200 down-regulated genes detected in the N v BE 
comparison, FDR < 0.01 and FC > 1.5, expressed as a (A) Heatmap showing 
patients (and their respective classification), with expression values assigned 
into eight discrete regions (‘bins’) from 0.80 – 13.00 (B) Principal component 
analysis (PCA) plots, showing clustering of samples by classification (PC1 
and PC2 only).  
 
Thus the clustering and differential expression data from the N v BE 
comparison support our hypothesis that the most significant differential 
expression is attributable to the maintenance of columnar mucosa rather 
than disease progression through the metaplasia-dysplasia-adenocarcinoma 
sequence.  
 
The most significantly up-regulated genes in HGD and EAC (with respect to 
non-dysplastic Barrett’s epithelium) are not up-regulated in any other 
classification groups, meaning that this comparison is able to differentiate 
HGD and EAC not only from non-dysplastic BE, but also normal healthy 
esophageal mucosa, as well as duodenal and proximal stomach tissues 
(Figure 4-17(A)). Of clinical interest may be the subset of up-regulated HGD-
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EAC samples with corresponding absence of, or very low level expression in 
all other classification groups (marked by a green box). Other identified 
differentially expressed genes in this comparison are biologically interesting, 
but not clinically valuable as biomarkers due to their need for defined 
expression level thresholds to differentiate intervention requiring disease 
from surveillance only patients. For this comparison, HGD-EAC samples 
cluster separately from all other tissue types (N, BE, duodenal and proximal 
stomach), however HGD-EAC clustering is not tight, indicating there is 
significant difference in global expression patterns between individuals with 
esophageal adenocarcinoma  (Figure 4-17(B)). This supports increasing 
evidence that esophageal adenocarcinoma is a complex disease with 
different molecular subtypes49, and ultimately, expression biomarkers may 
not be the best choice for a biomarker universally detectable across all these 
variable subtypes.  
 
(A) BE v HGD-EAC Up-regulated genes heat map 
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(B) BE v HGD-EAC Up-regulated genes PCA plot 
 
Figure 4-17: Top 200 up-regulated genes detected in the BE v HGD-EAC 
comparison, FDR < 0.01 and FC > 1.5, expressed as a (A) Heatmap showing 
patients (and their respective classification), with expression values assigned 
into eight discrete regions (‘bins’) from 0.80 – 13.00 (B) Principal component 
analysis (PCA) plots, showing clustering of samples by classification (PC1 
and PC2 only).  
 
The most significantly down-regulated genes in HGD and EAC (with respect 
to non-dysplastic Barrett’s epithelium) are also down-regulated in normal 
esophageal mucosa as well as proximal stomach tissues, but up-regulated in 
duodenal tissues (Figure 4-18(A)). These genes are not clinically useful as 
potential biomarkers due to an inability to differentiate between normal and 
carcinogenic tissues. The duodenum, or proximal small intestine is where 
most chemical digestion takes place and is structurally very similar to 
Barrett’s mucosa. Both are columnar, goblet cell containing mucosae. 
Biologically, the genes identified as down-regulated in BE v HGD-EAC are 
likely not disease-associated (due to concurrent lack of expression in normal, 
healthy esophageal mucosa), but associated with maintenance and/or 
function of columnar mucosa. Interestingly, clustering for down-regulation in 
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BE v HGD-EAC results in separation of all different classification groups in 
just two dimensions (Figure 4-18(B)).  
 
(A) BE v HGD-EAC Down-regulated genes heat map 
 
(B) BE v HGD-EAC Down-regulated genes PCA plot 
 
Figure 4-18: Top 200 down-regulated genes detected in the BE v HGD-EAC 
comparison, FDR < 0.01 and FC > 1.5, expressed as a (A) Heatmap showing 
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patients (and their respective classification), with expression values assigned 
into eight discrete regions (‘bins’) from 0.80 – 13.00 (B) Principal component 
analysis (PCA) plots, showing clustering of samples by classification (PC1 
and PC2 only).  
4.3.5  Integrative analysis: methylation and expression correlation 
It has been generally accepted that cancer-associated promoter 
hypermethylation results in transcriptional silencing of tumor suppressor 
genes, whilst hypomethylation may lead to activation of normally inactive 
oncogenes. However, this overly simplistic methylation-expression 
correlation has recently come into focus as more and more evidence of a 
lack of correlation is reported from studies across various cancer types114.  
 
Correlation analysis of genome-wide methylation and expression profiling 
data did not support a strong relationship, especially for disease-associated, 
significantly differentially methylated regions. Methylation and expression 
correlation is examined in detail for selected disease-associated top 
differentially methylated target regions for biomarker validation in Section 
5.3.8  Differential expression in selected target regions for validation. 
 
Despite the overall lack of strong correlation, there was still evidence of 
individual cases supporting cancer-associated methylation-expression 
correlation. For example, one of the top identified hypo-methylated regions in 
BE v HGD-EAC (refer to Appendix 4, Table 3: Top 100 hyper- and hypo-
methylated probes for differentiating intervention-requiring disease from 
Barrett’s esophagus, 7th hypo-methylated entry (sorted by greatest |Δβ|)) is 
BST2 (also known as tetherin or CS317 antigen). Bone Marrow Stromal Cell 
Antigen 2 (BST2), has been identified as an oncogene in a number of 
cancers, including breast cancer115-118, head and neck cancer119, lung 
cancer120, myelomas121, 122, glioblastoma123, cervical cancer124 and 
endometrial cancer125, 126. BST2 expression in human breast tumours and 
breast cancer cell lines has been reported to be inversely proportional to the 
methylation of CpG sites within, or in close proximity to the promoter 
region115. Epigenetic regulation of BST has also been reported in cervical 
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cancer124, with hypomethylation resulting in activation of oncogene BST2 and 
resultant elevated expression. Here, we noted significant hypo-methylation in 
HGD and EAC samples with respect to non-dysplastic BE (Δβ -0.3643, p-
value 4.01 x10-5) as well as significant up-regulation in expression (2.22 fold 
change, p-value 0.0418).  
 
Despite this widespread up-regulation of BST2 across numerous cancer 
types, there is also evidence of BST2 down-regulation in other solid tumors, 
and an unchanged expression profile in others (as outlined in Table 4-1), as 
outlined by Mahauad-Fernandez et al127 in their 2016 review of the role of 
BST2 in host protection and disease manifestation. 
 
Table 4-1: BST2 expression profile in various cancers. Reproduced from 
Mahauad-Fernandez et al, 2016127. 
 
4.3.6  Gene set enrichment analysis 
From Section 4.3.4  Global methylation and transcriptomic analyses, we 
hypothesized that much of the hypomethylation occurring across each of the 
comparison classes is attributable to change in mucosal structure 
(maintenance of columnar mucosa) rather than disease-associated 
progression through the metaplasia-dysplasia-adenocarcinoma sequence. 
Similarly for expression regulation, for example, the significantly down-
regulated genes in both N vs HGD-EAC and N vs BE comparisons did not 
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differentiate between disease and control (duodenal and proximal stomach) 
tissues, as apparent in Figure 4-14(A) and Figure 4-16(A). Thus for gene set 
enrichment analyses (GSEA), the focus was placed on up-regulation 
occurring in Barrett’s formation and esophageal carcinogenesis.   
 
Analysis of up-regulation using MSigDB hallmark (H) collection (50 gene 
sets: representing specific, well-defined biological states or processes 
without overlap), computational (C4) gene sets (858 gene sets comprising 
427 cancer gene neighborhoods106, 128 and 431 cancer modules129) and 
oncogenic signatures (C6) (cellular pathway signatures often dis-regulated in 
cancer), revealed expected functional association as disease developed as 
well as highlighting the importance of examining molecular change between 
precursor disease and cancer, instead of the universally accepted ‘normal vs 
tumor’. 
 
Table 4-2 below shows hallmark gene sets up-regulated in HGD-EAC 
compared to normal healthy esophageal tissue. One of the greatest fold 
enrichments (approximately 4-fold) occurs in angiogenesis gene sets (see 
Figure 4-19). This is not surprising, as it is well known that solid tumors 
release angiogenic growth factors to stimulate blood vessel growth, providing 
vital nutrients and oxygen. Angiogenic factors have been linked with 
prognosis in esophageal adenocarcinoma patients but as yet there is no 
evidence for benefit from anti-angiogenic therapy130, 131. Other gene sets up-
regulated in N v HGD-EAC include interferon alpha and interferon gamma 
response as well as inflammatory response and p53 pathway gene sets.  
 
Table 4-2: Hallmark gene sets up-regulated in HGD-EAC compared to 
normal healthy esophageal tissue. Filtered p-value ≤ 0.05. List total (up-
regulated N v HGD-EAC genes) = 316. Table sorted by fold enrichment 
(decreasing). pval: p-value, fold enr: fold enrichment, bonf: Bonferroni 
correction, benj: Benjamini false discovery rate adjustment, fdr: false 
discovery rate.  
term	 count	 %	 pval	 genes	 fold	enr	 bonf	 benj	 fdr	
angiogenesis	 10	 3.16%	 1.34E-04	 CXCL6,FSTL1,ITGAV,LUM,NRP1,POSTN,SPP1,STC1,TIMP1,VCAN	 3.91	 6.71E-03	 6.04E-03	 1.34E-03	
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term	 count	 %	 pval	 genes	 fold	enr	 bonf	 benj	 fdr	
kras	signaling	
up	
43	 13.61%	 2.05E-11	
ADAMDEC1,ANO1,ANXA10,BIRC
3,C3AR1,CA2,CCL20,CFB,CLEC4A
,CTSS,CXCR4,DUSP6,ELTD1,ETS1
,FCER1G,GNG11,HKDC1,HSD11B
1,IL1B,IL2RG,IL33,IL7R,INHBA,IR
F8,MMD,MMP10,NRP1,PECAM
1,PIGR,PLAUR,PLEK2,PSMB8,PT
GS2,SCG5,SPP1,SPRY2,TFPI,TLR8
,TPH1,TRIB2,TSPAN1,TSPAN13,
USH1C	
2.98	 1.02E-09	 4.60E-09	 1.02E-09	
interferon	
alpha	
response	
20	 6.33%	 9.70E-06	
BST2,DDX60,EPSTI1,IFI27,IFI30,I
FI44,IFIT3,IFITM1,IFITM2,IFITM3
,NMI,OASL,PARP14,PNPT1,PSM
B8,PSMB9,RIPK2,RSAD2,RTP4,S
ELL	
2.91	 4.85E-04	 5.84E-04	 1.30E-04	
epithelial	
mesenchymal	
transition	
42	 13.29%	 1.14E-10	
ANPEP,CALU,CDH11,COL12A1,C
OL6A3,CXCL1,CXCL6,DAB2,DCN,
FAP,FMOD,FSTL1,HTRA1,IL8,INH
BA,ITGAV,LAMA3,LAMC1,LAMC
2,LGALS1,LUM,MATN2,MEST,M
GP,MMP1,MMP2,MMP3,NT5E,
PLAUR,PMP22,POSTN,SGCB,SPA
RC,SPP1,TFPI2,THBS1,TIMP1,TN
FRSF11B,TPM1,TPM2,VCAM1,V
CAN	
2.88	 5.68E-09	 1.28E-08	 2.84E-09	
coagulation	 25	 7.91%	 1.04E-05	
A2M,ANG,C2,CFB,CFI,CTSE,CTSK
,DPP4,DUSP6,F2RL2,GDA,HMGC
S2,HTRA1,MEP1A,MMP1,MMP1
0,MMP2,MMP3,MMP7,PECAM
1,SERPINA1,SPARC,TFPI2,THBS1
,TIMP1	
2.53	 5.19E-04	 5.84E-04	 1.30E-04	
interferon	
gamma	
response	
29	 9.18%	 1.79E-04	
BST2,CCL2,CFB,DDX60,EPSTI1,F
PR1,HLA-B,HLA-
DMA,IFI27,IFI30,IFI44,IFIT3,IFIT
M2,IFITM3,IRF8,METTL7B,NMI,
OASL,PARP14,PNPT1,PSMB8,PS
MB9,PTGS2,RIPK2,RSAD2,RTP4,
SELP,TNFAIP6,VCAM1	
2.01	 8.94E-03	 6.70E-03	 1.49E-03	
inflammatory	
response	 28	 8.86%	 4.98E-04	
AHR,AQP9,ATP2B1,BST2,C3AR1,
CCL2,CCL20,CXCL6,FPR1,GPR18
3,HAS2,IFITM1,IL1B,IL7R,IL8,INH
BA,LYN,MEP1A,MET,NMI,PLAUR
,RIPK2,RTP4,SELE,SELL,SLC4A4,T
IMP1,TNFAIP6	
1.92	 2.49E-02	 1.60E-02	 3.56E-03	
uv	response	
down	
20	 6.33%	 3.39E-03	
ANXA4,ATP2B1,CDC42BPA,DAB
2,GCNT1,HAS2,ICA1,LAMC1,LTB
P1,MET,NFIB,NRP1,PIK3R3,PLCB
4,PMP22,PPARG,PRKCA,PTPRM,
TFPI,TGFBR2	
1.91	 1.69E-01	 7.62E-02	 1.69E-02	
complement	 23	 7.28%	 1.50E-02	
ANG,C2,C4BPB,CA2,CBLB,CFB,C
TSL1,CTSS,CXCL1,DPP4,DUSP6,F
5,FCER1G,GCA,LYN,MMP12,PLA
2G7,PLAUR,PSMB9,SERPINA1,TF
PI2,TIMP1,ZEB1	
1.60	 7.52E-01	 2.42E-01	 5.37E-02	
il2	stat5	
signaling	 23	 7.28%	 1.78E-02	
AHR,ANXA4,CA2,CDC6,ENPP1,F
2RL2,GALM,GPR65,IFITM3,IL2R
A,IRF8,ITGA6,ITGAV,NRP1,NT5E,
ODC1,P4HA1,SELL,SELP,SLC2A3,
SLC39A8,SPP1,SYT11	
1.58	 8.90E-01	 2.67E-01	 5.93E-02	
g2m	
checkpoint	
22	 6.96%	 3.03E-02	
AURKA,BUB1,CASC5,CCNB2,CDC
6,CDK1,CDK4,CDKN3,CKS1B,CKS
2,HMMR,KIF15,MAD2L1,NEK2,O
DC1,PBK,SLC12A2,SNRPD1,STIL,
TOP2A,TPX2,ZAK	
1.52	 1.00E+00	 4.25E-01	 9.46E-02	
estrogen	
response	late	 22	 6.96%	 3.34E-02	
ABHD2,AGR2,ASS1,CA2,CDC6,D
NAJC12,FARP1,HMGCS2,IL17RB,
LAMC2,MEST,MYB,PDZK1,PLA2
G16,SERPINA1,SLC27A2,STIL,TFF
1,TFPI2,TMPRSS3,TOP2A,TSPAN
13	
1.50	 1.00E+00	 4.42E-01	 9.83E-02	
dna	repair	 5	 1.58%	 4.71E-02	 EIF1B,NPR2,RAD51,RFC3,RFC4	 0.48	 1.00E+00	 5.58E-01	 1.24E-01	
kras	signaling	
down	 6	 1.90%	 9.16E-03	
CAPN9,FAM46C,HTR1D,PTPRJ,R
SAD2,UGT2B17	
0.42	 4.58E-01	 1.59E-01	 3.52E-02	
myc	targets	
v1	 6	 1.90%	 8.72E-03	
CDK4,MAD2L1,ODC1,PSMB3,RF
C4,SNRPD1	
0.42	 4.36E-01	 1.59E-01	 3.52E-02	
myogenesis	 6	 1.90%	 7.51E-03	 COL6A3,FABP3,IGFBP7,NQO1,SPARC,TPM2	 0.41	 3.75E-01	 1.54E-01	 3.41E-02	
p53	pathway	 5	 1.58%	 2.77E-03	 APAF1,DRAM1,GPX2,IFI30,SLC7A11	 0.35	 1.39E-01	 6.93E-02	 1.54E-02	
 
Interestingly, a number of N v HGD-EAC gene sets also showed significant 
up-regulation in N v BE, including KRAS signaling, epithelial-mesenchymal 
transition (EMT) and coagulation gene sets (Figure 4-19). Despite reported 
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low KRAS mutational load in esophageal adenocarcinoma (supported by 
mutational screening performed as part of this study, refer to Section 7.3.2.2  
BRAF and KRAS mutation in the esophagus), increases in KRAS expression 
have been reported in a subset of patients with poor prognosis132. KRAS 
signaling gene sets were significantly enriched in N v HGD-EAC (43 genes, 
2.98 fold enrichment) and also N v BE (24 genes, 2.31 fold enrichment). In a 
recent 2016 paper, Kestens et al reported that inducing BMP4 signaling in 
both BE and EAC cells results in an invasive epithelial-mesenchymal 
transition-like phenotype133. In our data, we found EMT gene sets to be 
significantly enriched in N v HGD-EAC (42 genes, 2.88 fold enrichment) and 
also N v BE (21 genes, 2.00 fold enrichment). These data indicate that 
molecular change is occurring early in the metaplasia-dysplasia-
adenocarcinoma sequence and may indicate a predisposition for malignant 
change in Barrett’s patients. 
 
(A) 
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(B) 
 
Figure 4-19: Selected hallmark gene sets up-regulated in HGD-EAC 
compared to normal healthy esophageal tissue. (A) Gene set fold enrichment 
for all comparison classes when statistically significant (p-value ≤ 0.05) (B) 
Gene count of up-regulated genes identified belonging to the specified gene 
set. The >40 KRAS signaling and epithelial-mesenchymal transition genes 
identified as up-regulated in HGD-EAC compared to normal, healthy 
esophageal epithelium each comprise approximately 13% of the full N v 
HGD-EAC up-regulated gene list (n=316). 
 
Myc target genes are involved in cell growth, apoptosis and metabolism and 
have long been associated with oncogenesis in a variety of cancer types134. 
An interesting phenomenon is observed for the Myc targets gene set. 
Significant up-regulation of this gene set apparent in BE v HGD-EAC (20 
genes, 2.26 fold enrichment), but not N v HGD-EAC (6 genes, 0.42 fold 
enrichment) (Figure 4-19). Furthermore, analysis of up-regulated 
computational gene sets (cancer gene neighborhoods (CGN)) in N v HGD-
EAC reveals that the majority of these gene sets are actually showing a 
much more significant fold enrichment (and gene count hit) when examined 
in the BE v HGD-EAC gene list (Figure 4-20). Refinement of the comparison 
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results in enrichment for carcinogenic change. These observations highlight 
the importance of examining not only the commonly accepted normal vs 
tumor comparison, but investigating precursor disease vs tumor. It is 
especially important in the case of esophageal adenocarcinoma and 
biomarker discovery, as Barrett’s esophagus is a benign and relatively 
common precursor and would create a very large unnecessary load on the 
health system should an early stage biomarker identify non-dysplastic 
precursor disease.  
  
Figure 4-20: Selected cancer gene neighborhoods computational gene sets 
up-regulated in HGD-EAC compared to normal healthy esophageal tissue. 
Gene set fold enrichment for all comparison classes when statistically 
significant (p-value ≤ 0.05) reveals the greater fold enrichment of these 
genes when using BE v HGD-EAC comparison class. Gene count of up-
regulated genes is given as a data label above the each bar.  
4.3.7  Methylation of tumor suppressor p63 in Barrett’s carcinogenesis 
Loss of tumor suppressor p63 expression has been associated with 
carcinogenesis in a variety of cancer types102. This, and the observation that 
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the p63 null mouse models quickly develop Barrett’s-like tissue104 led us to 
interrogate p63 promoter methylation in our samples. There are two promoter 
regions for tumor suppressor p63, which vary in disease-associated 
differential methylation (refer to Figures 4-19 and 4-20). 
 
Promoter 1 shows increased methylation in N and GERD (GastroEsophageal 
Reflux Disease) and a subset of HGD-EAC tissues, with lower methylation 
observed in BE, proximal stomach and a subset of HGD-EAC tissues. 
Normal and GERD tissues become almost entirely methylated in the latter 
half of promoter 1 (Figure 4-21). However the inverse appears to be evident 
in promoter 2 (3 central CpG sites), where BE, HGD-EAC and stomach are 
almost entirely methylated, but only low levels of methylation observed in N 
and GERD tissues. Thus, we can hypothesize that increased methylation of 
tumor suppressor p63 promoter 2 may be a contributing factor to reduced 
p63 expression possibly implicated in development of Barrett’s esophagus 
and/or carcinogenic progression.  
 
(A) 
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(B) 
 
Figure 4-21: Average methylation at seven probes in p63 promoter 1 in the 
external validation cohort (N, BE, HGD-EAC, GERD and stomach tissues), 
expressed as a (A) Barplot (B) Heatmap (N in green, BE in blue, HGD-EAC 
in purple, GERD in light blue and stomach in orange), methylation binning 
into eight discrete regions from 0.000 – 1.000 in increments of 0.125.  
 
 
cg
16
76
47
81
cg
05
12
90
81
cg
12
18
84
16
cg
06
72
07
22
cg
04
48
92
43
cg
04
48
31
01
cg
21
72
34
86
Meth. Values
(0,0.125]
(0.125,0.25]
(0.25,0.375]
(0.375,0.5]
(0.5,0.625]
(0.625,0.75]
(0.75,0.875]
(0.875,1]
Chapter 4:  Genome-wide Methylation and Expression Profiling 
 118 
(A) 
 
(B) 
 
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
0.25
0.50
0.75
1.00
cg
02
12
29
81
cg
13
51
80
31
cg
06
52
04
50
cg
04
86
05
63
cg
02
63
75
93
cg
12
18
48
54
va
lue
sample_type
N
BE
HGD_EAC
GERD
STOM
cg
02
12
29
81
cg
13
51
80
31
cg
06
52
04
50
cg
04
86
05
63
cg
02
63
75
93
cg
12
18
48
54
Meth. Values
(0,0.125]
(0.125,0.25]
(0.25,0.375]
(0.375,0.5]
(0.5,0.625]
(0.625,0.75]
(0.75,0.875]
(0.875,1]
Chapter 4:  Genome-wide Methylation and Expression Profiling 
 119 
Figure 4-22: Average methylation at seven probes in p63 promoter 2 in the 
external validation cohort (N, BE, HGD-EAC, GERD and stomach tissues), 
expressed as a (A) Barplot (B) Heatmap (N in green, BE in blue, HGD-EAC 
in purple, GERD in light blue and stomach in orange), methylation binning 
into eight discrete regions from 0.000 – 1.000 in increments of 0.125. 
4.4  Discussion 
The results presented in this chapter examine global methylation and 
expression change in the multi-phase development of esophageal 
adenocarcinoma. Gene set enrichment and analysis of DNA methylation-
gene expression correlation are used to examine global molecular change at 
each phase of metaplasia-dysplasia-adenocarcinoma development. Finally, 
aberrant methylation of tumor suppressor gene p63 is examined in our data 
to understand its role in the origin and development of Barrett’s esophagus 
and esophageal adenocarcinoma. 
 
There was no significant difference in methylation profile of normal 
squamous epithelia, irrespective of sample biopsy location (distance aboral), 
as well as in proximal samples with any form of esophageal disease distally 
(non-dysplastic BE, dysplasia or esophageal adenocarcinoma). Hence 
matched normal samples (taken proximally from diseased patients) were 
used for further analyses; optimal as matched disease-normal pairs control 
for biological perturbations unique to an individual. 
 
Global methylation analysis revealed significant methylation change between 
benign Barrett’s and developed EAC, however more clinically significant was 
detectable methylation change between non-dysplastic BE and BE with low-
grade dysplasia. Thus we can conclude that detection of aberrant 
methylation is viable for identification of initiation of carcinogenic progression 
at an easily treatable stage. 
 
A downfall of the current endoscopic-histologic diagnosis method is difficult 
interpretation of small regions of destroyed glands. These regions may be 
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due to inflammation, tissue damage during histological preparation or more 
seriously, a focus of dysplastic or carcinogenic tissue. An interesting sample 
contained predominantly normal tissue (a mixture of normal squamous 
epithelia and cardiac mucosa) with a small section (approximately 5%) of 
destroyed glands, identified as focal dysplasia/adenocarcinoma by only 1 of 
4 pathologists. Aberrant methylation was apparent and detectable globally in 
this sample, clinically important for more robust, reliable diagnosis of early 
stage disease in the future. 
 
Differential methylation and expression were examined across three 
comparison classes, normal vs tumor, normal vs Barrett’s and non-dysplastic 
Barrett’s vs tumor. High-grade dysplastic samples were included alongside 
tumor samples. 
 
The most significant hypermethylation detected in normal vs tumor 
comparison also showed significant hypermethylation in BE samples, 
highlighting that methylation change occurs early and is maintained in 
disease development but also highlighting deficiency in the comparison for 
identification of potential biomarkers. This is by no means universal for 
biomarkers across all cancer types, but due to the benign and common 
nature of Barrett’s esophagus, as well as low incidence of carcinogenic 
progression, identification of non-dysplastic BE is undesirable for an effective 
biomarker. Using the Barrett’s vs tumor comparison resulted in a smaller set 
of significant differential methylation, however actually enriches for disease-
associated change. Using this comparison, a subset of regions was identified 
that are methylated in intervention-requiring disease (dysplasia and 
adenocarcinoma) but unmethylated in normal, stomach, intestinal and BE 
tissues, as well as in normal peripheral blood, important for potential 
biomarker development into a non-invasive blood test. 
 
Analysis across all methylation comparisons revealed that much of the 
hypomethylation occurring is attributable to the maintenance of columnar 
mucosa, rather than disease-associated progression through the metaplasia-
dysplasia-adenocarcinoma sequence. For this reason, no hypomethylation 
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targets were carried through to biomarker validation and targeted sequencing 
analysis. 
 
The most significantly up-regulated genes in HGD and EAC (with respect to 
normal esophageal epithelium) were, in the most part, also significantly up-
regulated in non-dysplastic BE, duodenal and proximal stomach mucosa  
 
Genome-wide transcriptomic profiling in normal vs tumor as well as normal 
vs Barrett’s comparisons showed agreement in the most significantly up-
regulated genes. Furthermore, the majority of these genes were also up-
regulated in control tissues, indicating that much of the increased expression 
is due to maintenance of columnar mucosa, rather than disease-associated. 
Similarly, this was found for down-regulation across all comparison classes. 
This analysis highlighted that tissue type difference (flat squamous cells 
comprising normal healthy esophageal mucosa as opposed to columnar 
mucosa present in BE, HGD, EAC and control tissues) has a more significant 
impact on global expression profile than disease development. Using the 
Barrett’s vs tumor comparison enabled identification of a subset of genes 
with increased expression in only dysplasia and adenocarcinoma, however 
this was not a discrete, binary separation as observed for methylation; 
instead there was low level expression observed in normal, control and BE 
tissues. This analysis indicates potential utility of an RNA expression 
biomarker is compromised, as a cut-off must be set. DNA methylation 
appears to be a more ideal biomarker for early esophageal adenocarcinoma 
identification due to the large subset of results with binary ‘on-off’ results. 
 
High quality genome-wide methylation and expression profiling data was 
obtained from the same esophageal tissue biopsies, enabling true 
examination of methylation-expression correlation. Our analysis showed 
evidence of generally accepted relationships: cancer-associated promoter 
methylation results in transcriptional silencing of tumor suppressor genes and 
hypomethylation leads to activation of normally inactive oncogenes. However 
correlation analysis of genome-wide methylation and expression profiling 
data did not support a strong relationship, especially for disease-associated, 
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significantly differentially methylated regions. A recent study by Moarii et al94 
hypothesized that cancer-specific methylation targets genes that are lowly 
expressed in normal tissues and may contribute to carcinogenesis by 
modifying expression susceptibility rather than simplistic direct inhibition. 
This, and evidence of lack of methylation-expression correlation in other 
cancers supports our findings for esophageal adenocarcinoma here135-138. 
 
Furthermore, there are limitations associated with use of microarray 
technology for genome-wide methylation profiling: most CpG sites assayed 
using HM450 are concentrated around promoter regions and gene bodies, 
however approximately 25% are located in intergenic regions111, so not 
accompanied by gene association. Differential methylation in intergenic 
regions may be over transcriptional regulatory elements such as enhancers 
(involved in enhancer-promoter interactions), insulators, locus control regions 
or similar139, and shouldn’t be disregarded in favor of those with explicit gene 
association as potential biomarkers. Enhancer methylation, for example, can 
affect gene expression as far as 1Mb from transcription start site140 and 
therefore correlation studies will not identify this associations. It was originally 
planned to use integrative analysis to prioritize disease-specific methylation 
change as potential biomarkers in the development of EAC. Based on our 
observed lack of strong methylation-expression correlation and recent 
publications challenging direct association94, 135-138, emphasis for biomarker 
selection remained on significant disease-associated hypermethylation, as 
discussed further in Chapter 5.  
 
Gene set enrichment analysis revealed expected functional association as 
disease developed, as well as highlighting the importance of precursor 
disease vs tumor over normal vs tumor comparisons for identification of 
disease-associated change. Enriched gene sets in esophageal 
adenocarcinoma development include those for angiogenesis, inflammatory 
response, cytokine (interferon alpha and interferon gamma) response as well 
as p53 pathways. Gene sets showing early enrichment in precursor disease 
as well as adenocarcinoma include KRAS signaling, epithelial-mesenchymal 
transition and coagulation. Examination of cancer-specific gene sets showed 
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the advantage of using Barrett’s vs tumor comparison: significant fold 
enrichment (and gene count) was observed in these gene sets compared to 
using normal vs tumor gene list. For our purposes, using precursor disease 
vs tumor enriches for intervention-requiring disease-specific change, 
important for an early stage esophageal adenocarcinoma biomarker panel. 
 
p63 is known to be involved in self-renewal of epithelial stem cells. The 
prevailing concept currently accepted for the origin of Barrett’s is 
inflammation-triggered stem cell metaplasia at the gastro-esophageal 
junction. p63 is implicated in this process as null mice quickly develop BE like 
tissue104. Furthermore, p63 is a known tumor suppressor and loss of 
expression is associated with carcinogenesis in a variety of cancer types. 
Our data showed disease-specific methylation occurring in one of two p63 
promoter regions, which may be a contributing factor to reduced p63 
expression and its role in BE development and/or carcinogenic progression. 
 
Overall, analysis of global differential methylation and expression change 
was informative about biological changes occurring with disease progression. 
It became apparent that aberrant hypermethylation has the most utility as a 
potentially clinically viable biomarker and the best comparison class to use to 
enrich for cancer-specific change is a benign precursor disease versus 
dysplastic disease-adenocarcinoma comparison. This was taken forward for 
target region validation and characterization, discussed in Chapter 5.  
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CHAPTER 5:   TARGET REGION VALIDATION AND 
CHARACTERIZATION  
5.1  Introduction 
Complete and comprehensive validation of potential biomarker targets is an 
important phase of biomarker development following large-scale discovery 
studies. To ensure robustness and give biomarkers the best chance of 
successful downstream implementation to clinical use, it is important that 
different technology is utilized for validation and discovery studies. For 
example, a whole-genome microarray approach for discovery and targeted 
sequencing for validation. For discovery studies, a genome-wide approach is 
recommended, examining the entire genome in samples at all stages of 
carcinogenic progression. From here, focus can narrow to selected potential 
targets for validation. Technology such as MiSeq targeted amplicon 
sequencing is appropriate for validation studies as it is able to accurately 
quantitate methylation (or lack of) at each CpG site, at single-base resolution, 
across multiple regions of interest.   
 
Both technical and independent validation is important; technical validation 
uses the same cohort (or a subset of) that used for discovery and ensures 
equivalent biomarker performance despite variations in methodology and 
analysis. An independent cohort ensures robustness of selected targets. 
Large sample cohorts are exceptionally valuable for biomarker validation, 
strengthening support for selected target regions as clinically valuable 
biomarkers before embarking on the next phase of development, usually 
retrospective longitudinal repository studies, as outlined in Pepe’s landmark 
publication ‘Phases of Biomarker Development for Early Detection of 
Cancer’78. 
 
Significant emphasis in the last decade has been placed on the development 
of non-invasive screening tests for early cancer detection, thus highlighting 
the importance of ability to detect biomarkers in biological specimens such as 
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stool, urine, saliva and blood. Cell-free circulating DNA from blood plasma 
has been found to carry methylation biomarkers for cancers occurring 
elsewhere in the body and are detectable at early stages of development 11, 
22, providing the perfect vehicle for a non-invasive, early-stage cancer 
screening test. Thus to increase chances of clinical implementation, 
investigations into detection in blood should be carried out early in biomarker 
development studies.  
 
In recent years, chromatin state annotation using computational 
segmentation models has emerged as a powerful tool for discovering 
regulatory regions and interpreting disease-association studies141. 
ChrommHMM is an automated computational system for learning chromatin 
states and can be used to characterize biological function of specific regions 
within the genome, for example if a region is an active transcription start site 
for a particular gene or a distal regulatory element able to influence 
transcription independently of its distance from a promoter142. Although this 
information does not influence biomarker selection or its likely success as a 
clinically valuable tool, it does provide valuable insight into mechanism by 
which the epigenetic regulation is influencing carcinogenic progression. 
5.1.1  Chapter 5 aims 
To establish, comprehensively validate and characterize disease-associated 
differentially methylated target regions indicative of early esophageal 
adenocarcinoma, concurrently initiating assay development with direct 
transferability to blood biomarker investigation.  
5.2  Methods 
5.2.1  Target region selection 
Region selection for validation by targeted amplicon sequencing was based 
on cut-offs and exclusion criteria applied to genome-wide methylation 
profiling data, as outlined in Table 5-1. Furthermore, differential methylation 
(meeting cut-offs) was required to be present in at least two neighbouring (≤ 
300bp apart) probes for the region to be considered for validation. Only 
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hypermethylated regions were considered for validation.  The priority list was 
created by firstly applying a minimum baseline requirement, dictating 
baseline methylation cut-offs (β ≤ 0.05 (N comparisons) or β ≤ 0.10 (BE v 
HGD-EAC)). Secondly, minimum delta methylation (the change in 
methylation between baseline and disease) cut-offs were applied (Δβ ≥ 0.50 
(N comparisons) or Δβ ≥ 0.20 (BE v HGD-EAC)). Thirdly, a series of 
exclusion criteria was applied to filter DMRs: removing regions with (i) 
methylation β > 0.10 in any normal peripheral blood sample (publicly 
available data set GEO accession GSE48472)110, (ii) methylation β > 0.10 in 
any normal oesophageal tissue sample, (iii) methylation β > 0.10 in any 
control tissue sample (duodenal or proximal stomach tissue). If any probe 
within the region (regions defined as having at least 2 differentially 
methylated probes no further than 300bp apart) did not meet the specified 
criteria, the region was discarded or segmented to only include probes which 
met all selection criteria.  
 
Table 5-1: Criteria and cut-offs for selection of regions for validation by 
targeted amplicon sequencing. Cut-offs apply to average methylation values 
detected for each probe within the defined multiple-probe target region.  
 N v HGD-EAC N v BE BE v HGD-EAC 
Baseline methylation (β) ≤ 0.05 ≤ 0.05 ≤ 0.10 
Methylation change (Δβ) ≥ 0.50 ≥ 0.50 ≥ 0.20 
Normal blood (β) ≤ 0.10 ≤ 0.10 ≤ 0.10 
Normal esophageal tissue (β) ≤ 0.10 ≤ 0.10 ≤ 0.10 
Duodenal tissue (β) ≤ 0.10 ≤ 0.10 ≤ 0.10 
Proximal stomach tissue (β) ≤ 0.10 ≤ 0.10 ≤ 0.10 
 
Exclusion criteria pertaining to proximal stomach and duodenal tissue 
controls ensures selected biomarker target regions are disease-associated 
rather than indicative of columnar mucosa maintenance. Exclusion criteria 
pertaining to human peripheral blood from normal, healthy individuals 
ensures applicability of selected target regions as blood biomarkers for early 
disease identification.  
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A priority ranked DMR list was created for each of the three comparisons, 
based on weighted ranking: 55% Δ methylation, 40% baseline methylation, 
5% number of probes in region (0.55 Δβ + 0.40 baseline β + 0.05 probe 
count). An increased number of differentially methylated probes within the 
target region ensures robustness. Regions were shortlisted for selection with 
the most emphasis placed on validating regions from the clinically relevant 
BE v HGD-EAC comparison, for the identification of intervention requiring 
disease. Target regions from the overlap between N v BE and N v HGD-EAC 
(herein known as ‘N v Any disease’, identifying a subset of target regions that 
are methylated early and maintained in the metaplasia-dysplasia-
adenocarcinoma sequence), were used to prioritize regions for validation 
from these two comparisons. Finally, differentially methylated regions / 
transcript pairs showing strong negative correlation were prioritised for assay 
design and optimisation.  
 
As a result of identification and classification challenges surrounding low 
grade dysplasia as well as much lower levels of homogeneity within sample 
biopsies; primary training analysis did not include LGD data. However, whole 
genome methylation and expression profiling was performed on these 
samples and weight given to shortlisted training regions hypermethylated in 
LGD. LGD samples were included in cohorts for targeted sequencing 
validation. 
5.2.2  Internal targeted amplicon sequencing validation 
Targeted sequencing was used to interrogate the methylation status of 
individual CpG sites of selected regions in mucosa at all stages of EAC 
development, (i) performing technical validation of differentially methylated 
regions identified by genome-wide methylation profiling and (ii) further 
validating these regions in an independent cohort.  
 
To perform targeted amplicon sequencing on selected regions: 
1. Bisulphite-specific PCR (BSP) assays were designed to target regions 
and optimized, enabling unbiased amplification of both methylated and 
unmethylated DNA. 
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2. MiSeq library preparation was optimised for the specific set of target 
regions selected. 
3. Amplification, library preparation and MiSeq analysis of both a 
technical and independent cohort was performed. 
4. Targeted amplicon sequencing results were compared to genome-
wide methylation profiling for validation of selected target regions. 
5.2.3  Unbiased amplification of target regions 
Bisulphite-specific PCR (BSP) assays were designed to selected target 
regions and optimized to enable unbiased amplification of both methylated 
and unmethylated DNA for targeted amplicon sequencing. DNA isolated from 
esophageal tissue biopsies was used for technical and independent 
validation of disease-associated aberrant methylation, however amplification 
assays were developed for easy transition to analysis of cfc-DNA extracted 
from human blood plasma. Primer/BSP assay design and optimization was 
based on protocols described by Clark et al 2006 in Nature Protocols143.  
5.2.3.1  Primer design 
A region of interest was defined, containing the DMR, and up to 500bp either 
side; only if the methylation in the flanking regions reflected the differential 
methylation observed in the DMR. Common SNPs (present in ≥ 1% samples) 
within the region of interest were identified using UCSC Genome Browser on 
Human Feb. 2009 (GRCh37/hg19) Assembly (dbSNP138 and dbSNP141). 
MethPrimer144 was used to interrogate the region of interest sequence using 
the settings outlined in Table 5-2 below, attempting optimal settings, then the 
relaxed settings if this failed. 
 
Table 5-2: General parameters for BSP primer selection using 
MethPrimer144. Optimal settings were used as a starting point, then relaxed if 
no primers were found.  
 Optimal Settings Relaxed settings 
Product CpGs 5 3 
Primer non-CpG C’s 4 3 
Primer poly-X 5 5 
Primer poly-T 8 8 
 Min Optimal Max Min Optimal Max 
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 Optimal Settings Relaxed settings 
Product Size (bp) 50 100 250 50 100 300 
Primer Tm (°C) 55 60 65 50 60 65 
Primer size (bp) 22 28 32 20 28 35 
 
Due to inherent high CpG content (and hence resultant high poly-T following 
bisulfite conversion), MethPrimer was often unable to return any results, 
even when using relaxed settings. Primers were designed manually in this 
case, using the following guidelines: 
• If possible, primers were positioned over non-CpG containing 
sequence (if this was unavoidable, primers were placed over regions 
with one CpG site, for which a degenerate base was used). 
Degenerate bases were positioned as far from the 3’ end as possible 
(Y for C in forward primer, R for G in reverse primer). 
• Primers were positioned so as not to contain common SNPs of any 
type. Non-CpG SNPs were allowed within the amplicon, however CpG 
SNPs were not allowed at all within the defined amplicon. 
• Primer pairs were melt temperature (Tm) matched to within 1.0°C. 
Calculated Tm for primers can vary significantly, depending on the 
calculation method used. Tm was checked with Primer3Plus145 as well 
as ThermoFisher Scientific Multiple Primer Analyzer, which uses a 
modified nearest-neighbor method based on Breslauer et al146. 
• Primers were positioned to have one or more T’s from non-CpG C’s at 
or near 3’ end, ensuring amplification of bis-modified DNA only. 
• Primers were checked for minimal predicted self-dimer and cross 
primer-dimer formation using ThermoFisher Scientific’s Multiple 
Primer Analyzer. 
• Amplicons were designed to be 100-150bp in length; enforcing a 70bp 
minimum (<70bp problematic for library preparation) and a 200bp 
maximum (>200bp not ideal for investigation of fragmented cfc-DNA).  
 
If possible, BSP assays were positioned within or containing the identified 
DMR, otherwise within the flanking region of interest. Up to 5 primer pairs on 
DNA top and opposite strands were designed and the best three ordered 
(judged on predicted self-/cross-primer dimer formation, predicted secondary 
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structure formation, closest match in Tm and most optimal amplicon length 
(100-150bp)).  
 
Primer oligonucleotides were ordered from Integrated DNA Technologies 
(IDT), lyophilized at 25nmole with standard desalting. Nuclease-free water 
was added to create a 100µM stock solution of each oligonucleotide, and a 
1:1 serial dilution performed to obtain 100µL of a 50µM working stock. Both 
the stock and the working solutions were stored at -20°C.  
5.2.3.2  Standard material for amplification optimization 
Universally methylated (Millipore CpGenome Universally Methylated DNA 
(Cat #S7821)) and universally unmethylated (Roche Human Genomic DNA 
from blood (Cat #11 691 112 001) DNA was used as standard material for 
BSP assay optimization. Roche human blood unmethylated standard 
material was implemented following testing (originally enzymatically modified 
DNA Set from Zymo Research (Human HCT116 DKO Methylated and Non-
methylated DNA set (Cat #D5014)); and doubles as an additional control, 
ensuring the regions of interest are unmethylated in normal human blood. 
 
Bisulfite-converted DNA was prepared at a range of compositions: 100% 
unmethylated DNA (100U), 100% methylated DNA (100M), 50% 
unmethylated + 50% methylated DNA (both a pre- (50:50 Pre) and post- 
(50:50 Post) bisulfite conversion mixture. A ‘wild-type’ control (WT, 50:50 
mixture of non-bisulfite converted methylated:unmethylated DNA), was 
prepared as a control to ensure assays amplify bis-converted DNA only. 
 
DNA standard material was lysed (Section 2.2.5.1  DNA lysis) to assist in 
achieving maximal bisulfite-conversion efficiency and in keeping with later 
treatment of clinical specimens, where protein may still be associated with 
the DNA; then bisulfite converted (as per Section 2.2.5.2  Bisulfite conversion 
of DNA). Following quantification (Section 2.2.5.3  Quantification of bisulfite 
converted DNA), all DNA standard material was diluted to 2ng/µL in 
nuclease-free water (Qiagen Nuclease-free water, Cat #129114) prior to 
storage at -20°C. 
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5.2.3.3  BSP optimization 
BSP assays were optimized to ensure equal, unbiased amplification of both 
methylated and unmethylated DNA input. This was done using duplicate 
inputs of DNA standard material: 100U, 50:50 Pre, 50:50 Post, 100M, WT-
control and NTC (nuclease-free water in lieu of DNA template). BSP assays 
were performed as outlined in Section 2.2.5.4  Bisulfite-specific PCR (BSP). 
Variation in MgCl2 concentration (1.0mM – 2.5mM, in increments of 0.5mM) 
and anneal temperature (1°C increments) was used to adjust bias in 
amplification of methylated and unmethylated DNA, evaluated by heat 
dissociation melt curve analysis (as described in Section 2.2.5.5  DNA 
methylation detection). Additional cycling (up to 5 cycles) was performed 
(target dependent) if required. 
 
For all assays deemed to be optimized by heat dissociation melt curve 
analysis, PCR product (one lane each from amplification of 100U, 50:50 Pre, 
50:50 Post, 100M, WT-control and NTC) was run on a 2.5% agarose gel (as 
per Section 2.2.2  Agarose gel electrophoresis) to confirm amplification of a 
single product of the expected size, free from non-specific product formation. 
5.2.4  MiSeq targeted sequencing 
Protocol for MiSeq targeted amplicon sequencing includes: 
1) Preparation of pooled amplicons  
2) MiSeq library preparation and quality control 
3) Quantification of PCR-competent sequencing template 
4) MiSeq targeted sequencing run 
5.2.4.1  Preparation of pooled amplicons 
DNA extracted from esophageal tissue (technical and independent validation 
cohorts) was adjusted to 27.78ng/µL with nuclease-free water, taking 500ng 
(18µL) for each sample. For the independent validation cohort (amplification 
of 18 targets), each sample was prepared in duplicate.  
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DNA was lysed and bisulfite-converted as per protocol outlined in Section 
2.2.5  DNA methylation studies, then diluted in nuclease free water, based on 
the number of target regions being amplified (quadruplicate 2.5µL input per 
target region required). For technical validation (10 target regions), DNA was 
made up to 120µL (included budgeted excess). For independent validation 
(18 target regions, duplicate sample preparations), pooled eluted DNA was 
made up to 240µL; resulting in DNA input of 7.5-10ng per PCR reaction 
(based on 70-100% bisulfite conversion yield). Diluted DNA was aliquoted 
into 11.8µL fractions prior to storage at -20°C.  
 
PCR amplification of target regions was performed as per protocol in Section 
2.2.5.4  Bisulfite-specific PCR (BSP), excluding SYTO® 9 addition and the 
associated melt curve cycling program. Technical (10 target regions) and 
independent (18 target regions) cohorts consisted of 24 samples each, 
amplified in quadruplicate in a 96-well plate (one full plate per target region). 
Quadruplicates pooled prior to  storage at -20°C. Three example samples per 
amplicon (one representative sample per classification: N, BE, HGD/EAC) 
were quantified using the broad range Qubit® kit, as outlined in Section 2.2.4  
Qubit® fluorometric double-stranded DNA quantification. For each patient 
sample, 150-200ng (where possible) of each amplified target region was 
pooled into a single tube as per Table 5-3.  
 
Table 5-3: Amount of amplified target (ng) intended and actual, pooled per 
patient sample. Input amounts varied to compensate for sample loss due to 
amplicon size. Pooling for independent validation done in two batches (small 
(72-122bp) and large (125-196bp) amplicons). ind: regions analyzed in the 
independent cohort only. All other regions were analyzed in both technical 
and independent cohorts. 
Target Region 
Amplicon 
Size   (bp) 
Technical Validation Independent Validation  
Intended 
amount (ng) 
Actual 
amount (ng) 
Intended 
amount (ng) 
Actual 
amount (ng) 
KLF7ind 72 - - 200 200 
TNFAIP8L3ind 76 - - 200 200 
TEPPind 85 - - 200 150 
LRRC43 86 200 183 200 200 
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Target Region 
Amplicon 
Size   (bp) 
Technical Validation Independent Validation  
Intended 
amount (ng) 
Actual 
amount (ng) 
Intended 
amount (ng) 
Actual 
amount (ng) 
ISM2 90 200 113 200 191 
ZNF570 93 200 171 200 200 
ZNF790 101 200 200 150 150 
CACNA2D2 104 200 124 150 149 
ELOVL5 119 200 45 150 66 
TRANK1 122 200 176 150 150 
ZNF699ind 125 - - 200 200 
TUBA3FP 137 200 200 200 200 
SCOC 148 200 200 200 200 
VANGL2ind 148 - - 200 200 
ZNF221ind 160 - - 150 150 
MGMTind 164 - - 150 150 
ARL10 181 200 200 150 150 
Upstream CA4ind 196 - - 150 150 
 
Following pooling, each patient sample (now consisting of amplified 
methylated and unmethylated target DNA) underwent clean up as per 
Section 2.2.3.2  Qiagen Min Elute PCR Purification Kit, recovering DNA 
down to 70bp in size. A 100 – 200ng aliquot of clean pooled DNA was taken 
per patient and stored at -20°C for later comparison against post-library 
preparation equivalent. Purified DNA was quantified using the broad range 
Qubit® kit, as outlined in Section 2.2.4  Qubit® fluorometric double-stranded 
DNA quantification. DNA was diluted to obtain 50µL at 20ng/µL for library 
preparation and stored at -20°C overnight. 
5.2.4.2  MiSeq library preparation and quality control 
For each patient, 1µg of pooled amplified target was used for MiSeq library 
preparation. Technical and independent validation cohorts were prepared 
separately. For unique indexing of 24 samples (adapter sequences given in 
Appendix 6: Illumina TruSeq Adapter Sequences), Illumina TruSeq DNA 
PCR-Free LT Sample Preparation Kit, Set A and Set B were required (Cat 
#FC-121-3001 and Cat #FC-121-3002 respectively). End-repair, A-tailing and 
adapter ligation as per manufacturer’s protocol. Clean-up steps were altered 
to account for shorter amplicon size. Clean-up after end-repair used a 2:1 
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ratio of undiluted beads:DNA to ensure capture of <100bp fragments, with 
volumes adjusted accordingly. Double clean-up after adapter ligation used a 
1:1 ratio of undiluted beads:DNA to capture adapter-ligated DNA fragments  
>200bp, and remove adapter dimers or incomplete ligation products.  
 
A 60-100ng aliquot was taken from each post-library preparation sample 
(less DNA required due to longer fragment length) for comparison against the 
pre-library preparation equivalent. Pre- and post-library preparation DNA was 
visualized on 2.5% agarose SYBRsafe gel (as per protocol in Section 2.2.2  
Agarose gel electrophoresis), to confirm the approximate 120-130bp 
increase in adapter ligated samples. The resultant adapter-ligated DNA was 
quantified using the Qubit® high sensitivity kit, as outlined in Section 2.2.4  
Qubit® fluorometric double-stranded DNA quantification. Calculations were 
performed to convert ng/µL to nM for each sample, using an average library 
size of 238bp (technical cohort, 10 target regions) and 242bp (independent 
cohort, 18 target regions), using the following equation: 
 
 𝑥 !"!" ×  !"! !"!! × !!"#$!!"!"× !! = 𝑛𝑀  
 
where N = average fragment size (bp) 
 x = Qubit concentration (ng/µL) 
 
30nM and 10nM single pooled samples were prepared using adapter ligated 
individual patient samples, adding the appropriate volume of each sample, 
diluting in Illumina resuspension buffer. 5µL of 30nM and 10nM pooled 
samples were taken for KAPA quantification (Section 5.2.4.3  Quantification 
of PCR-competent sequencing template). Pooled sample concentration was 
re-checked using the Qubit® high sensitivity kit, as outlined in Section 2.2.4  
Qubit® fluorometric double-stranded DNA quantification.  
5.2.4.3  Quantification of PCR-competent sequencing template 
KAPA Biosystems Library Quantification Complete Kit, optimized for Roche 
LC480 (GeneWorks, Cat #KP-KK4854) was used for accurate quantification 
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of PCR-competent sequencing templates, crucial for reliable cluster 
amplification. Quantification was performed on single pooled 10nM and 30nM 
samples (1:100,000, 1:200,000, 1:400,000 and 1:800,000 dilutions), 
measured against a standard curve (20pm – 0.0002pm, 10-fold dilution 
series), as per the manufacturer’s instruction. Reactions were performed in 
triplicate. Background subtracted amplification curves and Ct scores were 
reviewed, ensuring replicate data points differed by ≤ 0.2 cycles and all 
library dilutions fell within the dynamic range of the assay. A standard curve 
was generated, ensuring the following criteria were met: (i) Average ΔCt 
between standards in the range 3.1 – 3.6, (ii) Reaction efficiency 90 – 110%, 
(iii) R2 ≥ 0.99, (iv) NTC Ct detected at least 3 cycles later than average Ct for 
standard 6 (0.0002pm). KAPA Library Quantification Data Analysis Template 
was used to determine working concentration of single pooled 10nM and 
30nM samples, including size adjustment calculations to account for 
difference between average fragment length of the library and KAPA 
standards (452bp). 
5.2.4.4  MiSeq targeted sequencing run 
Illumina MiSeq reagent Kit v2, 300 cycles (Cat #MS-102-2002) was used to 
prepare the library for sequencing with the MiSeq desktop sequencer (up to 
325 cycles of sequencing, sufficient for up to 151-cycle paired-end reads plus 
two eight-cycle index reads). Library was diluted to 2nM working 
concentration (using KAPA quantification calculation) for denaturation with 
NaOH to a final concentration of 10pM DNA in 1mM NaOH. A 10nM PhiX 
(Illumina, PhiX Control v3, Cat #FC-110-3001) was prepared and denatured 
alongside the 10nM library (final concentration 10pM in 1mM NaOH). Illumina 
Experiment Manager (IEM) was used to create sample sheets and all kit 
components were prepared as per the manufacturer’s instruction. A 
maintenance wash was performed on the MiSeq desktop sequencer prior to 
performing the run. Cluster density (K/mm) and cluster passing filter (%) 
results were recorded for each run. 
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5.2.5  MiSeq data analysis 
MiSeq bioinformatic analysis was kindly performed by Dr Phuc Loi Luu at the 
Garvan Institute of Medical Research. Paired-end fastq files were obtained 
for each library and aligned to hg19 using GitHub bwa-meth 
(arXiv:1401.1129). Downstream analysis was performed using the 
‘ampliconAnalysis’ function of the R v3.2.3 package aaRon. Data quality was 
assessed using on-target read counts and bisulfite conversion efficiency for 
all amplicons in all samples. Percent methylation at each CpG site was 
calculated and used in all subsequent analysis.  
5.2.6  External differential methylation validation 
Raw HM450 data and sample annotations were obtained from the University 
of Queensland study, Krause et al49 (GSE72874; to be released 01/04/2016). 
The study included 250 samples from 154 patients, comprised of 125 EAC, 
19 BE (8 from BE patients, 11 adjacent BE from EAC patients), 75 normal 
squamous esophagus and 31 control (10 GERD and 21 normal stomach 
samples); herein referred to as the ‘External validation cohort’ (Table 3-2). 
Raw HM450 data was obtained for peripheral blood samples (Blood_PT1-5) 
from Slieker et al110 (PMID:23919675; GSE48472). Illumina 
HumanMethylation450 (HM450) raw data was pre-processed and 
background normalised with Bioconductor minfi package (PMID: 24478339), 
using the preprocessIllumina(…, bg.correct = TRUE, normalise = “controls”, 
reference=1) command. Resultant M-values were used for differential 
methylation statistical analysis105. Target regions (as defined in Table 5-5) 
were elongated to include flanking regions either side, and were evaluated 
for average methylation status at each probe using the external validation 
cohort. Data was analyzed (i) using only BE samples from BE patients (n=8) 
(ii) using all BE samples (n=19); those from BE patients (n=8) and adjacent 
BE from EAC patients (n=11). 
5.2.7  Chromatin state discovery and characterization 
We used computational segmentation (ChromHMM v1.10141, Core 15-state 
model) of the primary esophagus epigenome into chromatin states to assist 
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in characterization of regions for MiSeq amplicon sequencing. Segmentation 
was obtained from the  Epigenome Roadmap project 
(http://egg2.wustl.edu/roadmap/web_portal/chr_state_learning.html). Briefly, 
ChromHMM segmentation model was trained on 60 high-quality epigenomes 
spanning five chromatin marks H3K4me3, H3K4me1, H3K36me3, 
H3K27me3 and H3K9me3. The model was then applied to produce 
chromatin state assignment in 127 epigenomes including primary esophagus  
(E079; primary esophagus tissue from 34 year old Caucasian male). 
5.2.8  Differential expression in selected target regions for validation 
Differential expression was examined in genes corresponding to target 
regions selected for validation (regions as defined in Table 5-5). Transcript 
cluster ID, log fold change, t-statistic, p-value and transcript ID were 
recorded, with statistically significant differential expression defined as 
p≤0.05. 
5.3  Results 
5.3.1  Bisulfite-specific PCR for target region amplification 
5.3.1.1  Target regions for assay design  
Target regions for BSP assay design were based on biomarker filtering cut-
offs and exclusion criteria applied to genome-wide methylation profiling data, 
as well as weighted priority ranking, based on baseline methylation, Δβ, and 
number of probes in the identified differentially methylated region (Section 
5.2.1  Target region selection). Resultant target regions (identified by their 
RefSeq gene association) for BSP assay design are given in Table 5-4 
below. 
 
Table 5-4: Target regions for BSP assay design, identified by their RefSeq 
gene association. 26 regions associated with 25 genes (§: two distinct 
regions within KLF7) across three comparison classes were included with 
focus on the clinically relevant BE v HGD-EAC comparison for identification 
of intervention requiring disease. 
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BE v HGD-EAC N v HGD-EAC N v Any disease 
ADAM22 TEPP ELOVL5 MGMT 
ARL10 TNFAIP8L3 PRDM2 RUNDC3B 
C1orf51 TRANK1 ZNF790 SCOC 
CACNA2D2 TUBA3FP  ZNF569 
GRASP Upstream CA4  ZNF570 
ISM2 VANGL2   
KLF7§ ZNF221   
LRRC43 ZNF699   
MTERF    
 
MGMT, although not ranked highly in weighted priority lists, was detected in 
differential methylation analysis and was included for targeted amplicon 
sequencing as a result of considerable literature support: promoter 
hypermethylation of MGMT has been reported to have diagnostic and 
prognostic utility not only in esophageal adenocarcinoma and gastrointestinal 
cancers, but also in glioblastoma, lung and cervical cancers91-93, 147-151. 
Notable was the abundance of aberrantly methylated zinc finger loci across 
all comparison groups. Hypermethylation of zinc finger protein genes has 
long been associated with carcinogenesis in various forms of human cancer, 
however these particular loci and their role in esophageal adenocarcinoma 
development have yet to be elucidated.  
5.3.1.2  Successful assays for BSP amplification 
A total of 165 primers (forward and reverse) for assays over 26 target regions 
were designed and tested. Of these assays, a number were unable to be 
successfully optimized due to biased amplification of 
methylated/unmethylated input, non-specific product formation, amplification 
of wild-type (non-bisulfite converted) DNA input, and were discarded. 
Selected disease-associated differentially methylated target regions for BSP 
amplification and sequencing validation (18 of 26 target regions) are outlined 
in Table 5-5.  
 
Table 5-5: Disease-associated, differentially methylated target regions for 
BSP amplification and sequencing validation, identified by RefSeq gene 
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association. Regions in grey were additional targets included for independent 
validation cohort (18 target regions; technical validation cohort evaluated in 
10 target regions only). CpG site count refers to sites for methylation analysis 
only (CpG sites occurring in primer regions not analyzed). 
 Locus Chr Start End 
Amplicon 
length (bp) 
CpG 
sites 
N v HGD-EAC 
ELOVL5 6p12.1 6 53,212,967 53,213,085 119 8 
ZNF790 19q13.11 19 37,329,427 37,329,327 101 6 
N v Any disease 
SCOC 4q31.1 4 141,294,938 141,294,791 148 10 
ZNF570 19q13.11 19 37,960,451 37,960,359 93 5 
MGMT 10q26.3 10 131,265,276 131,265,113 164 17 
BE v HGD-EAC 
ARL10 5q35.2 5 175,792,604 175,792,424 181 19 
CACNA2D2 3p21.31 3 50,541,229 50,541,332 104 8 
ISM2 14q24.3 14 77,965,343 77,965,434 92 6 
LRRC43 12q24.31 12 122,667,942 122,667,857 86 7 
TRANK1 3p22.2 3 36,985,944 36,986,065 122 13 
TUBA3FP 22q11.22 22 21,368,817 21,368,681 137 8 
KLF7 2q33.3 2 208,031,073 208,031,144 72 8 
TNFAIP8L3 15q21.3 15 51,385,011 51,385,936 76 4 
TEPP 16q21 16 58,018,911 58,018,827 85 6 
ZNF699 19p13.2 19 9,420,542 9,420,418 125 10 
VANGL2 1q23.3 1 160,370,041 160,370,188 148 9 
ZNF221 19q13.2 19 44,455,289 44,455,448 160 11 
Upstream CA4 17q23.2 17 58,212,732 58,212,927 196 8 
 
Primers for successfully optimized BSP assays averaged 25 ± 3bp (minimum 
18bp, maximum 33bp), sequences given in Table 5-6.  
 
Table 5-6: Primer sequences for successfully optimized BSP assays for 
target region amplicon sequencing. Sequences as ordered, specific for 
bisulfite converted DNA. Degenerate bases ‘Y’: pyrimidine (thymine or 
cytosine) and ‘R’: purine (adenine or guanine). ‘T’ indicates cytosine origin in 
wild-type DNA (prior to bisulfite conversion); ‘t’ thymine origin in wild-type 
DNA. Equivalently for ‘A’ and ‘a’ in reverse primers. 
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 Forward Primer Reverse Primer 
N v HGD-EAC 
ELOVL5 YgttgtTtggtttTaataaaaaTtg AcctttcctttttAtcctAttctctc 
ZNF790 ggatggggTtTaaatgTagg AaacRAtAcactctAAAaaatAtaAtcc 
N v Any disease 
SCOC ggaggtaTtgaggatgTagTtTtag ActAccRAAAtcaAttAAtccaa 
ZNF570 gTaTYggagtTaTaTagatggTTtg ccaccaAttctAttctAcaAAtc 
MGMT gTYgggTTtgaggTagtTtg caaactaaAAcacaAaAcctcaAA 
BE v HGD-EAC 
ARL10 agYgTTagTaTTaaggggTTTag caAcRAcaAtAcattAtAAAActtAtaAtA 
CACNA2D2 gTagTTYgaatTTtgTTTtaTtggTt aAAaAcRAcaAAAtctAaAAtAtAAAAAc 
ISM2 gTaTTtggaYgtTTTTTaTTTtTTtT A cRAccaAatcaaaAaAaAcc 
LRRC43 gTagatTTTaggTTTTagggaTTagTT ccRAaactctAAAAAcctAAacc 
TRANK1 TYgggaaTTTTtgaggat AtccRAaAAAaccaAAAcac 
TUBA3FP gaaggTagggaggatgTTTaTaagg cccRAcaacccaAtActAtaAAttA 
KLF7 gggTtatataagggggTtgagg acRaccctccctAtcccttA 
TNFAIP8L3 gataTtgagTaaTaggaggaagTTaTTTaTagT AaccRAtAAaAAtAAAcaAaAacc 
TEPP tTTTTaagggTagtTTtgTTtTTagatT AAAccRctAaAatAaaActAtAAcacttA 
ZNF699 gaaagaggaatTagaagtgtgTttTtg AAAcRAAAcaAAAcaAAacaAAaaA 
VANGL2 gtTTaggaagaTagTTTTaggagggaT cctAcRccttcaAatAcccaA 
ZNF221 gggTattTtgggaagtgtTTTaa caActcaaaatatcacaAaataaaAAAtaac 
Upstr. CA4 aaaTaTagaTtggaggagtggtaaataTtaa tAtAccccaAaAaAcactAcaAAcc 
 
5.3.1.3  Optimized BSP assay parameters 
Bisulfite-specific PCR assays were optimized to amplify methylated and 
unmethylated DNA without bias prior to targeted sequencing using the MiSeq 
desktop sequencer. Optimized assay parameters are given in Table 5-7. 
 
Table 5-7: Optimized BSP assay parameters for unbiased amplification of 
methylated and unmethylated DNA. An initial 5 cycles with longer anneal and 
extension times were always performed prior to 35-45 cycles of shorter 
anneal-extension. Tm: average melt temperature (°C) of 100% unmethylated 
(U) or methylated (M) DNA standard material, amplified using the stated 
parameters. 
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BSP         
Assay 
Anneal   
(°C) 
MgCl2  
(mM) 
Amplification 
Cycles 
Tm (°C) 
100U 
Tm (°C) 
100M 
ELOVL5 60 1.0 40 77.6 ± 0.2 81.4 ± 0.2 
ZNF790 57 1.0 40 77.1 ± 0.4 80.1 ± 0.3 
SCOC 57 1.0 40 78.9 ± 0.3 82.0 ± 0.2 
ZNF570 56 1.0 40 72.2 ± 0.8 74.4 ± 0.8 
ARL10 55 1.0 40 80.6 ± 0.4 86.8 ± 0.2 
CACNA2D2 58 1.5 40 76.3 ± 0.3 81.1 ± 0.3 
ISM2 57 1.5 35 76.9 ± 0.4 80.2 ± 0.1 
LRRC43 56 1.0 40 75.1± 0.2 78.2 ± 0.3 
TRANK1 55 1.0 40 82.1 ± 0.3 86.8 ± 0.2 
TUBA3FP 61 1.0 40 77.2 ± 0.3 80.3 ± 0.4 
KLF7 61 1.0 40 81.2 ± 0.4 87.2 ± 0.2 
TNFAIP8L3 58 1.5 40 75.0 ± 0.3 77.4 ± 0.4 
TEPP 60 1.5 40 74.5 ± 0.4 77.3 ± 0.3 
ZNF699 54 1.0 45 74.8 ± 0.2 78.2 ± 0.3 
VANGL2 60 1.0 40 79.2 ± 0.4 82.0 ± 0.2 
ZNF221 61 1.0 40 80.8 ± 0.4 84.3 ± 0.2 
MGMT 57 1.0 40 80.0 ± 0.5 84.6 ± 0.2 
Upstr. CA4 62 1.0 45 77.7± 0.3 79.6 ± 0.3 
 
5.3.1.4  BSP assay quality control 
Optimization of bisulfite-specific PCR conditions results in amplification of a 
single product, of the expected size, without any amplification of non-specific 
products, wild type (non-bisulfite converted) control DNA or no template 
control. Characteristics of a successfully optimized bisulfite-specific PCR 
assay are outlined in Figure 5-1. 
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Figure 5-1: Characteristics of a successfully optimized bisulfite specific PCR 
assay: 181bp region in Chr5: 175,792,604-175,792,424; HIG1 hypoxia 
inducible domain family, member 2A and ADP-ribosylation factor-like 10 
(ARL10). (A) A clean, single product without evidence of non-specific product 
formation is detected for all methylated and unmethylated DNA inputs at the 
predicted molecular weight (MW): 181bp for ARL10. U: 100% unmethylated 
input, M: 100% methylated input, Pre: 50% methylated and 50% 
unmethylated input, mixed prior to bisulfite conversion, Post: 50% methylated 
and 50% unmethylated input, mixed following bisulfite conversion, clean-up 
and quantitation. No product is detected for non-bisulfite converted ‘wild-type’ 
DNA (WT) or no template control (NTC). Gel is 2.5% agarose, run at 100V 
constant for 90min. (B) Amplification of all DNA occurs at the same Ct 
(threshold cycle), ± < 1.0 Ct, irrespective of the methylation status of the DNA 
input. (C) Distinct melt temperatures (Tm) are obtained for methylated and 
unmethylated DNA input (melts in green). This region of ARL10 has 21 CpG 
sites, hence the large ΔTm (~6°C). A 50:50 mixture of methylated and 
unmethylated DNA input (melts in pink) results in dual peaks at the same 
temperatures, and in proportion to those obtained for 100% methylated and 
unmethylated input. Results for (B) and (C) are the mean and standard 
deviation for duplicate reactions at the stated run conditions in Table 5-7. 
5.3.2  MiSeq library preparation 
5.3.2.1  Column versus bead-based clean up 
MiSeq library preparation clean up steps (after end-repair and adapter 
ligation), were optimised to account for shorter amplicon sizes (resulting from 
design enabling direct transfer to analysis of cfc-DNA extracted from human 
blood plasma). Clean up post end-repair was tested using variable solid 
phase reversible immobilization (SPRI) bead ratios (1.6:1, 1.8:1, 2:1 
undiluted beads:DNA, selected based on Figure 5-2) as well as column clean 
up (Qiagen Min Elute PCR Purification Kit, methods as per Section 2.2.3.2  
Qiagen Min Elute PCR Purification Kit). Example amplicons were pooled into 
three samples for evaluation (80-90bp, 90-100bp, 180-190bp) 
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Figure 5-2: Retained DNA fragment sizes in relation to SPRI bead:DNA ratio. 
Image courtesy of CoreGenomics (http://core-genomics.blogspot.com.au/ 
search?q=SPRI+beads).  
 
Resultant DNA losses were calculated based on Qubit® broad range 
quantification (as per protocol Section 2.2.4  Qubit® fluorometric double-
stranded DNA quantification), prior to and after clean-up. Clean-up success 
was evaluated via visualisation on 2.5% agarose (protocol Section 2.2.2  
Agarose gel electrophoresis). Column clean up resulted in similar DNA loss 
across all input sizes (yields of 35.0, 29.9, 34.5% for 80-90bp, 90-100bp and 
180-190bp pools respectively), whereas bead-based clean up yields were 
fragment size dependent, showing significant losses for the very short 80-
90bp pool, irrespective of bead dilution, but very minimal loss for larger 
amplicons (Table 5-8). Agarose gel showed a clean, single band for all 
output (results not shown). Thus, in view of better performance for amplicons 
≥ 90-100bp, bead-based clean up was implemented for MiSeq library 
preparation. A 2:1 ratio was used to minimize DNA loss, accepting that 
primer-dimer or self-dimer remaining at this point may not be removed 
(column based clean up prior to library preparation removes primer-dimer, 
self-dimer and excess primer remaining from amplification).  
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Table 5-8: Percentage yield based on DNA fragment size input and SPRI 
bead:DNA ratio used for clean-up. Insufficient very small fragment (80-90bp) 
DNA existed for testing of all bead ratios as well as column clean up, thus 2:1 
ratio was omitted. 
 
DNA fragment range (bp) SPRI bead:DNA Yield (%) 
80 - 90 
1.6:1 19.35 
1.8:1 24.75 
90-100 
1.6:1 32.90 
1.8:1 37.40 
2:1 44.80 
180-190 
1.6:1 91.50 
1.8:1 91.50 
2:1 102.75 
5.3.2.2  KAPA quantification 
Accurate quantification of PCR-competent sequencing templates is crucial 
for reliable cluster amplification. For this, KAPA Biosystems Library 
Quantification complete kit, optimized for Roche LC480 was used to quantify 
10nM and 30nM libraries for both technical and independent cohorts. Figure 
5-3 shows KAPA quantification results for 10nM and 30nM libraries prepared 
for targeted sequencing of the technical validation cohort.  
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(C) 
  
Figure 5-3: KAPA quantification results for 10nM and 30nM libraries prepared 
for targeted sequencing of the technical validation cohort. (A) All library 
dilutions fell within assay dynamic range, with standard curve replicate data 
points differing by less than the required ≤ 0.2 cycles (average (abs) 0.033 ± 
0.042 cycles) and average ΔCt 3.47 ± 0.09 cycles (within the required 3.1 – 
3.6). (B) Generated standard curve reaction efficiency was 94% (required 90-
110%), R2 = 0.99993 (required R2 ≥ 0.99), NTC detected 3.92 cycles later 
than 0.0002pm standard (required > 3.0 cycles later). (C) Following size 
adjustment calculations for difference between average library fragment 
length and KAPA standards, PCR competent sequencing template was 
determined to be at 18.37nM (2.95ng/µL) and 47.88nM (7.69ng/µL) for 
original 10 and 30nM libraries respectively. 
5.3.2.3  MiSeq library quality control 
Pooled amplified target DNA for each patient sample pre- and post-library 
preparation was visualized on 2.5% agarose gel to confirm the approximate 
120-130bp increase in adapter ligated samples. All gels confirmed the 
expected increase in both technical and independent validation cohorts, 
however clear bands were difficult to visualize for smaller amplicons. 
Minimum on-target reads for all patient samples across all targets (including 
the smallest amplicons) were above the required minimum for robust 
methylation determination (Table 5-9); hence visualization difficulties are 
likely due to gel resolution, rather than yield loss during library preparation. 
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An example quality control gel (technical cohort, 10 target regions, 12 patient 
samples, pre- and post-library preparation) is shown in Figure 5-4 below. 
 
 
Figure 5-4: Agarose gel size verification of pooled amplicons pre- and post-
library preparation. Twelve patient samples (N, BE) from the technical 
validation cohort, analyzing 10 target regions are shown. Pre-library 
preparation DNA ranges from 86 to 181bp (86, 92, 93, 101, 104, 119, 122, 
138, 148, 181bp). Following adapter ligation there will be an approximate 
120-130bp increase in fragment length. Due to size similarity some bands 
are unable to be individually distinguished. 
5.3.3  Robust methylation determination 
Cluster density (K/mm) and cluster passing filter (%) of 592K/mm, 97.4% and 
673K/mm, 96.8% were obtained for technical and independent validation 
respectively. Cluster passing filter should be >90%, ideally ≥ 95% for high 
quality data. Cluster densities of ~800K/mm are expected for libraries with 
pre-adapter ligation lengths > 200bp, however clustering is much less 
efficient for amplicons 100-150bp, as we have here (average pre-adapter 
ligation length 118 ± 30bp and 123 ± 37bp for technical and independent 
validation libraries). An average of 362,081 ± 55,280 total reads per patient 
sample (all target regions) was attained for technical validation; on-target 
reads comprising 61.04 ± 0.85%. A slight improvement in data quality was 
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attained for independent validation, averaging of 425,206 ± 72,985 total 
reads per patient sample; on-target reads comprising 65.75 ± 1.48%.  
 
For robust methylation determination, >300 on-target reads are necessary. 
The number of on-target reads attained for each amplicon within each 
sample is impacted not only by initial amount of amplified target input into 
library preparation (150-200ng/assay maximum, refer to Table 5-3), but also 
by amplicon size (proportionally more loss of smaller amplicons occurs 
during clean up). This is apparent in Figure 5-5, showing on-target reads 
attained for each sample, grouped by amplicon. Pooling for independent 
validation was done in two batches (small (72-122bp) and large (125-196bp) 
amplicons), with input amounts (150/200ng maximum) varied to compensate 
for DNA loss due to amplicon size (Table 5-9). 
 
(A) 
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(B) 
  
 
Figure 5-5: Number of on-target reads attained per patient sample for 
technical (A) and independent (B) validation. Results grouped by amplicon. 
On-target read count is impacted by amplicon length and amount of amplified 
DNA target input into library preparation.  
 
For technical validation (10 target regions), a worst case of 1,732 on-target 
reads (amplification of ISM2 (92bp)), was attained for sample N1324361 
(normal esophagus). Minimum on-target reads averaged 15,639; minimum 
1,732; maximum 63,443 for this cohort. 1,732 on-target reads was well in 
excess of the minimum required for robust methylation determination; hence 
analysis of additional target regions was possible without impacting data 
quality. For this reason, a further 8 target regions were included (total 18) for 
independent validation. A worst case of 312 on-target reads (amplification of 
KLF7 (72bp)), was attained for sample N1425519 (non-dysplastic BE). 
Minimum on-target reads averaged 9,365; minimum 312; maximum 27,099. 
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Despite a significant increase in the number of target regions for analysis in 
the independent validation cohort (total library DNA remains unchanged), 
there were still sufficient on-target reads in every sample, for every target to 
enable robust methylation determination. Table 5-9 gives minimum on-target 
reads attained for both technical (10 target regions) and independent (18 
target regions) validation. 
 
Table 5-9: MiSeq targeted sequencing minimum on-target reads per patient 
sample for technical (10 target regions) and independent (18 target regions) 
validation. Regions in grey for independent validation only. 24 samples each 
cohort. Despite the increased number of target regions analyzed for 
independent validation, minimum on-target reads were still above the 300 
required for robust methylation determination.  
  Technical validation Independent validation 
Target region 
Amplicon 
Size (bp) 
DNA input to 
library prep 
(ng) 
Minimum 
on-target 
reads 
DNA input to 
library prep 
(ng) 
Minimum 
on-target 
reads 
LRRC43 86 183 3,000 200 2,011 
ISM2 92 113 1,732 191 2,111 
ZNF570 93 171 3,859 200 3,097 
ZNF790 101 200 11,840 150 5,677 
CACNA2D2 104 124 6,467 150 2,150 
ELOVL5 119 45 5,537 66 3,980 
TRANK1 122 176 13,453 150 8,265 
TUBA3FP 137 200 21,036 200 11,302 
SCOC 148 200 26,022 200 15,251 
ARL10 181 200 63,443 150 27,099 
KLF7 72   200 312 
TNFAIP8L3 76   200 924 
TEPP 85   150 2,275 
ZNF699 125   200 15,946 
VANGL2 148   200 12,035 
ZNF221 160   150 24,734 
MGMT 164   150 12,597 
Upstream CA4 196   150 18,814 
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5.3.4  Targeted amplicon sequencing validation 
Average methylation at each CpG site within each target region was plotted 
for all patient samples analyzed (Table 5-10). Technical and independent 
validation cohorts were evaluated separately for cross-cohort, as well as 
genome-wide methylation profiling validation.  
 
Table 5-10: Sample classification of technical and independent validation 
cohorts for MiSeq targeted amplicon sequencing. The combined HGD-EAC 
group was separated to determine if target region hypermethylation 
increases further with progression to invasive adenocarcinoma. 
 
Technical 
Validation Cohort 
Independent 
Validation Cohort 
Total 
Normal 9 5 14 
Non-dysplastic BE 6 6 12 
LGD 3 4 7 
HGD 2 3 5 
EAC 4 4 8 
Methylation controls 0 2 2 
    
Totals: 24 24 48 
 
Overall success or failure of the validation is summarized in Table 5-11 
below. The majority of target regions validated were hypermethylated in HGD 
and EAC with respect to BE (BE v HGD-EAC, 13 regions), two regions 
hypermethylated in HGD and EAC with respect to normal esophageal 
mucosa (N v HGD-EAC) and a further three regions hypermethylated in BE, 
HGD and EAC with respect to normal esophageal mucosa (N v Any 
disease). 
 
Table 5-11: Overview of success or failure of technical and/or independent 
validation of target regions examined by targeted sequencing. 18 target 
regions were validated, 10 in the technical validation, 18 in the independent 
validation (8 independent validation only targets in grey). A failed result is 
indicated if any data collected did not support original hypotheses from whole 
genome methylation profiling. 
Chapter 5:  Target Region Validation and Characterization 
 153 
 Result Reason 
N v HGD-EAC 
ELOVL5 Success All validation results supported whole genome methylation profiling 
ZNF790 Success All validation results supported whole genome methylation profiling 
N v Any disease 
SCOC Variable  Amplification bias, methylation above expected baseline in N samples 
ZNF570 Failure Methylation above expected baseline (N samples, independent cohort only) 
MGMT Success All validation results supported whole genome methylation profiling 
BE v HGD-EAC 
ARL10 Success All validation results supported whole genome methylation profiling 
CACNA2D2 Success All validation results supported whole genome methylation profiling 
ISM2 Failure Independent cohort failed to validate technical results 
LRRC43 Success All validation results supported whole genome methylation profiling 
TRANK1 Variable  Amplification bias, methylation above expected baseline in N samples 
TUBA3FP Success All validation results supported whole genome methylation profiling 
KLF7 Success All validation results supported whole genome methylation profiling 
TNFAIP8L3 Variable Amplification bias, methylation above expected baseline in N samples 
TEPP Success All validation results supported whole genome methylation profiling 
ZNF699 Success All validation results supported whole genome methylation profiling 
VANGL2 Success All validation results supported whole genome methylation profiling 
ZNF221 Success All validation results supported whole genome methylation profiling 
Upstream CA4 Success All validation results supported whole genome methylation profiling 
 
Due to large amounts of data collected, example target regions will be 
examined in detail in this and the following sections, as outlined below: 
• Examples of successful internal targeted amplicon sequencing 
validation (ARL10, TUBA3FP) in Section 5.3.4.1 
• A brief discussion regarding failed and variable success validation 
targets (Examples: ISM2, TRANK1, TNFAIP8L3), in Section 5.3.4.2 
• Further in-depth examination, including external validation in large 
cohort (Examples: KLF7, LRRC43, VANGL2), in Section 5.3.5 
• Promoter methylation of MGMT (both internally and externally 
validated) in Section 5.3.5.1 
 
With the exception of MGMT, no further in depth analysis was performed of 
the five targets in the N v HGD-EAC and N v Any disease comparisons, due 
to inability to differentiate non-dysplastic BE from dysplastic disease and 
EAC (not clinically relevant). Promoter methylation of DNA repair gene 
MGMT, due to its prevalence in literature and reported diagnostic and 
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prognostic utility in esophageal adenocarcinoma and other cancers93, 152, 153, 
is discussed further in Section 5.3.5.1. 
5.3.4.1  Successful internal sequencing validation 
This section comprises an examination of targets with successful validation 
by MiSeq targeted amplicon sequencing, using examples ARL10 and 
TUBA3FP (both validated using technical and independent cohorts). 
 
To date, there is not much known about ADP-ribosylation factor-like 10 
(ARL10) and its role in carcinogenesis. In 2004, Louro et al154, examined 
transcript levels of RASL11A and ARL9 (RASL11A and ARL9/ARL10 
subfamily code for small GTPases, highly conserved among eukaryotes) in 
normal and prostate tumor samples; finding RAS11A to be significantly 
down-regulated in prostate tumor compared to normal prostate tissue, but no 
difference in ARL9 expression (in the same tissue samples). No methylation 
analysis was performed. Small guanosine-5’-triphosphate (GTP)-binding 
protein regulators (such as ARL10) act as molecular switches, regulating 
function of other proteins to control signaling pathways155. In view of the 
importance of small GTPases in the cell cycle, their interaction with a range 
of signaling proteins and the apparent adenocarcinoma-associated promoter 
methylation of ARL10; further studies into the functional mechanism of 
ARL10 are warranted.  
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(B) 
   
(C)      
 
 
 ARL10
  Independent Validation
  (BE v HGD/EAC comparison)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Chr5: 175,792,450 - 175,792,586
D
N
A
 M
et
hy
la
tio
n
EAC independent cohort
HGD independent cohort
LGD independent cohort
BE independent cohort
N independent cohort
  ARL10
  Technical (te) and Independent (in) Validation
   (Two-way ANOVA, BE v HGD/EAC comparison)
N
 te
N
 in
B
E 
te
B
E 
in
LG
D
 te
LG
D
 in
H
G
D
 te
H
G
D
 in
EA
C
 te
EA
C
 in
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
D
N
A
 M
et
hy
la
tio
n
****
****
ns
ns
ARL10
95% Confidence Intervals (Dunnet)
Mean methylation difference
-0.3 -0.2 -0.1 0.0 0.1
BE - Normal
BE - LGD
BE - HGD  
BE - EAC  
  SCOC
0.0
0.2
0.4
0.6
0.8
1.0
Chr4: 141,294,816 - 141,294,917
D
N
A
 M
et
hy
la
tio
n EAC
HGD
LGD
BE
Normal
Chapter 5:  Target Region Validation and Characterization 
 156 
(D) 
 
Figure 5-6: Targeted amplicon sequencing of disease-associated differential 
methylation occurring in the promoter region of ADP-ribosylation factor-like 
10 (ARL10). (A) Targeted amplicon sequencing region (nineteen CpG sites, 
Chr5: 175,792,604 – 175,792,424) showing results for technical and 
independent validation cohorts separately. (B) Hypermethylation of a subset 
of dysplastic disease and EAC observed for the technical cohort was 
validated by independent cohort results. The LGD patient (independent 
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cohort) with observed ~60% methylation across all CpG sites within the 
target region had no further visits on clinical follow up, therefore predicted 
disease progression was unable to be confirmed. (C) Mean methylation 
difference (technical and independent sequencing data) from non-dysplastic 
BE was the most significant for EAC. (D) Technical and independent 
sequencing validate the observed aberrant methylation detected using 
genome-wide methylation profiling; genome browser showing HM450 data 
for a subset of the Training Cohort with >90% tissue sample homogeneity; 
ARL10 amplicon shown in red. Height of bars indicate percentage 
methylation (0.0 – 1.0), colour code N: blue, BE: green, HGD and EAC: pink, 
duodenal and proximal stomach: grey and normal blood: dark red. 
 
Aberrant promoter hypermethylation (our target for sequencing validation 
positioned within the flanking active transcription start site, Figure 5.7(D)) of 
Tubulin, alpha 3f, pseudogene (TUBA3FP) in EAC is a novel finding. 
Pseudogenes, although not protein-coding, may still be functional or have a 
regulatory role. There is not much known regarding pathways, gene 
ontology, biological processes or associated disorders in which TUBA3FP is 
involved, however there is some evidence for the use of TUBA3FP for 
determination of cancer tissue origin, scoring genes from exome-based 
analyses for level of mutational burden, presented by Robasky et al at the 
2013 ASHG (American Society of Human Genetics) conference 
(http://www.ashg.org/2013meeting/abstracts/fulltext/f130123239.htm). 
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(B) 
 
(C)      
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(D)  
 
Figure 5-7: Targeted amplicon sequencing of disease-associated differential 
methylation occurring in the promoter region of Tubulin, alpha 3f, 
pseudogene (TUBA3FP). (A) Targeted amplicon sequencing region (eight 
CpG sites, Chr22: 21,368,817 – 21,368,681) showing results for technical 
and independent validation cohorts separately. Methylation level for 
dysplastic and EAC samples were elevated in comparison to non-dysplastic 
BE and N in the independent cohort, but not to the same extent (Δβ) as the 
technical cohort. (B) Hypermethylation of a subset of dysplastic disease and 
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EAC observed for the technical cohort was validated by independent cohort 
results. Hypermethylation of the entire EAC technical cohort was not 
reproducible in the independent cohort. (C) Mean methylation difference 
(technical and independent sequencing data) from non-dysplastic BE was 
the statistically significant for not only EAC, but also any form of dysplastic 
Barrett’s. (D) Technical and independent sequencing validate the observed 
aberrant methylation detected using genome-wide methylation profiling; 
genome browser showing HM450 data for a subset of the Training Cohort 
with >90% tissue sample homogeneity; TUBA3FP amplicon shown in red. 
Height of bars indicate percentage methylation (0.0 – 1.0), colour code N: 
blue, BE: green, HGD and EAC: pink, duodenal and proximal stomach: grey 
and normal blood: dark red. 
5.3.4.2  Failed and variable success validation targets 
This section comprises an examination of targets with failed or variable 
success validation, using examples of ISM2, TRANK1 and TNFAIP8L3 
(excerpt from Table 5-11 below). 
 Result Reason 
ISM2 Failure Independent cohort failed to validate technical results 
TRANK1 Variable  Amplification bias, methylation above expected baseline in N samples 
TNFAIP8L3 Variable Amplification bias, methylation above expected baseline in N samples 
 
Of the 13 target regions (refer to Table 5-11) for identification of intervention 
requiring disease (BE v HGD-EAC), there was one incidence of failure of 
independent cohort to validate technical cohort results (ISM2), hypothesized 
to be attributable to technical issues with target amplification for the 
independent cohort; supported by external validation cohort results for this 
region (Figure 5-8). Technical validation sequencing supported genome-wide 
methylation profiling with average β (all CpG sites in region): 0.013 ± 0.006 
and 0.026 ± 0.029 for N and non-dysplastic BE samples respectively, and 
0.388 ± 0.245 for HGD-EAC (Δβ>0.35). This was further supported by 
HM450 data for the 75 N and 19 BE samples in the external validation cohort  
(average methylation of probes in the selected target region β < 0.05 in 75 of 
75 N and 18 of 19 BE samples), but disparate with independent validation 
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sequencing results (average β (all CpG sites in region): 0.47 ± 0.04 and 0.28 
± 0.08 for N and non-dysplastic BE samples respectively).  
 
Isthmin (ISM) encodes a protein expressed in skin and mucosal tissues, with 
proapoptotic, antiangiogenic and antitumorigenic properties. It has been 
shown to induce apoptosis in endothelial cells, but under different conditions 
may promote adhesion and survival in these same cells156, 157.  In 2008, 
Xiang et al158 examined ISM and its role in tumor growth, finding that its 
expression inhibited endothelial cell capillary network formation and 
significantly suppressed melanoma tumor growth in mice. They found that 
the suppressed tumor growth was due to inhibition of angiogenesis; ISM 
overexpression did not affect tumor cell proliferation. At the time, this was 
ground-breaking as ISM had no known functions. Angiogenesis (the 
formation of new blood vessels from pre-existing ones) is an important factor 
in tumor progression and metastases with limitation of angiogenesis a 
treatment approach emerging across a number of cancer types159-161. ISM1 
has been shown to inhibit glioma growth by inhibition of angiogenesis; with 
Yuan et al identifying isthmin as a novel angiogenesis inhibitor for glioma 
therapy in 2012162. 
 
My initial findings and supporting validation of the presence of aberrant 
promoter ISM2 hypermethylation in EAC leads to the hypothesis that this 
aberrant methylation may lead to downstream silencing of isthmin, allowing 
angiogenesis to go unchecked, promoting tumor progression and metastasis 
by the formation of new blood vessels. Failure of independent validation 
cohort sequencing to support technical cohort sequencing and genome-wide 
sequencing of the large external validation cohort supports conclusions of 
technical issues with target amplification of this region for independent 
sequencing validation.   
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(B) 
 
Figure 5-8: Validation of disease-associated differential methylation occurring 
in the promoter region of Isthmin 2 (ISM2) failed for independent validation 
cohort sequencing. (A) Unexpected high-level DNA methylation was 
observed across all disease classes in targeted sequencing of the 
independent validation cohort. This did not support the EAC associated 
hypermethylation observed in the technical cohort (B) Genome-wide 
methylation profiling data for the external validation cohort (250 samples) 
supports differential methylation observed in the training (HM450) and 
technical validation (sequencing) cohorts; with hypermethylation only 
detected in a subset of EAC samples (normal squamous epithelium, Barrett’s 
mucosa, and inflamed epithelium from GERD patients all entirely 
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unmethylated). Elongated validation region includes 9 probes, Chr14: 
77,964,542 – 77,965,870. Targeted amplicon sequencing region (containing 
six CpG sites, Chr14: 77,965,343 – 77,965,434; indicated by red arrow,) 
contains probe cg11951910. Heatmap methylation values separated into 
eight discrete regions 0.000 – 1.000 in increments of 0.125.  
 
Further to the failed sequencing validation of ISM2, there were two 
incidences (TRANK1, TNFAIP8L3) of methylation above expected baseline 
in normal and non-dysplastic BE in both technical and independent 
sequencing validation when compared back to genome-wide methylation 
profiling (training cohort and external validation cohort, data not shown). 
Methylation controls (50:50 methylated:unmethylated standard DNA) were 
run as part of the independent validation cohort to determine any target 
region amplification bias. TRANK1 and TNFAIP8L3 showed methylation 
amplification bias of 26.3 ± 0.8% and 15.2 ± 0.7% respectively, showing that 
amplification prior to targeted sequencing was responsible for skewed 
methylation results for both these targets. External HM450 data for the 75 
normal squamous esophageal and 19 non-dysplastic BE comprising this 
cohort supported the unmethylated status of this category of samples; 
supporting hypotheses of amplification bias prior to sequencing. Despite 
amplification bias, targeted sequencing results were still able to return 
statistically significant Δβ (BE v EAC, p<0.0001) for both TRANK1 and 
TNFAIP8L3 target regions.  
 
Despite amplification bias of TRANK1 and TNFAIP8L3, both regions are 
interesting targets. In 2015, in a genome-wide approach to link clinical 
outcome with genotype in breast cancer, Pongor et al identified 
Tetratricopeptide Repeat and Ankyrin Repeat Containing 1 (TRANK1) as one 
of the top 10 driver oncogenes, citing 5.3% mutational prevalence163. In the 
case of esophageal adenocarcinoma, an inflammation-induced stem cell 
origin rather than a driver mutation origin is favored; but this is not to say that 
accumulation of mutations during tumorigenesis is not occurring; indeed, 
these mutations may be required for tumor progression and metastasis to 
occur.  
Chapter 5:  Target Region Validation and Characterization 
 165 
 
The Tumor Necrosis Factor, Alpha-Induced Protein 8 (TNFAIP8) family, only 
identified in 2008164, 165 encodes lipid transfer proteins, capturing and 
shuttling phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 
3,4,5-triphosphate across the plasma membrane166. More than half of all 
human cancers have hyperactivation of phosphoinositide signaling and 
marked up-regulation of the TNFAIP8L2 (TIPE2), yet lipid signaling in cancer 
cells is not yet fully understood167-169. In the TNFAIP8 family, most is known 
about TNFAIP8L2 (TIPE2), which regulates both inflammation and 
carcinogenesis170, whereas the role of TNFAIP8L3 (also known as TIPE3) 
has remained largely unknown until very recently167. Fayngerts et al (2014) 
showed that TNFAIP8L3 knockout diminished tumorigenesis and enforced 
expression enhances oncogenesis in lung, bladder and colorectal carcinoma 
cell lines167. The oncogenic role of TNFAIP8L3 has lead to its proposal as a 
therapeutic target for malignant disease treatment; support for this has yet to 
be published. 
5.3.5  External differential methylation validation 
Differential methylation of selected target regions, elongated to include 
flanking regions on either side, were validated using genome-wide 
methylation profiling data from an external validation cohort, consisting of 
250 samples from 154 patients (125 EAC, 19 BE (8 from BE patients, 11 
adjacent BE from EAC patients), 85 non-tumor squamous esophagus and 21 
normal stomach samples (Table 3-2). Average methylation beta-values at 
each probe were determined to produce barplots and heatmaps for all target 
regions. Examples of validation for KLF7, LRRC43 and VANGL2 are given in 
Figure 5-9, Figure 5-10 and Figure 5-11 respectively. External validation 
results support internal genome-wide methylation profiling, as well as internal 
validation by targeted amplicon sequencing.  
 
Kruppel-like factor 7 (KLF7) is a member of the Kruppel-like family of DNA-
binding transcription factors, regulating cell proliferation, differentiation and 
survival. Members in this family contain three C2H2 zinc fingers at the 
extreme carboxyl end, aiding in binding to GC rich sites. Expression of KLF4 
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and KLF7 have been found to be critical for decisions between proliferation 
and cell cycle arrest and differentiation171. The proteins encoded by this 
family of genes have been implicated in type 2 diabetes progression172, as 
well as recently identified as a tumor suppressor genes involved in 
carcinogenesis and metastasis in a variety of cancer types. A flurry of 
publications in 2015 associated various KLF family members with 
carcinogenic progression: KLF4 in myeloid leukemia, breast and esophageal 
squamous cell carcinoma173-175, KLF2 in pancreatic ductal 
adenocarcinoma176, KLF8 in colorectal cancer177 and KLF17 in breast and 
esophageal cancer178, 179. The role of epigenetic silencing of this family of 
DNA-binding transcription factors and regulation of metastasis has been 
examined by Sacheva et al (2015), who published evidence that the 
epigenetic silencing of KLF3 by promoter hypermethylation in primary mouse 
and human metastatic sarcoma increases pro-metastatic miR-182180. My 
findings of aberrant promoter hypermethylation in KLF7 in dysplastic disease 
and esophageal adenocarcinoma are therefore not surprising; however the 
involvement of this particular family member in EAC carcinogenesis is novel 
and further studies to elucidate mechanisms of involvement are warranted. 
 
(A) 
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(D) 
 
Figure 5-9: Validation of disease-associated differential methylation occurring 
in the promoter region of Kruppel-like factor 7 (ubiquitous) (KLF7), identified 
using the clinically relevant BE v HGD-EAC comparison for identification of 
intervention-requiring disease. Elongated validation region examined 
includes 12 probes, Chr2: 208,030,666 – 208,031,996. Targeted amplicon 
sequencing region (eight CpG sites, Chr2: 208,031,073-208,031,144), 
indicated by red arrow, lies between probes cg04396539 and cg21246614. 
Barplot (A) and heatmap (B) show External Validation Cohort results. 
Genome browser (C) shows HM450 data for a subset of the Training Cohort 
with >90% tissue sample homogeneity. DNA methylation evaluation by 
targeted amplicon sequencing (D) shows results for Independent Validation 
Cohort. External validation (A) and (B) supports internal genome-wide 
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methylation profiling of the Training Cohort (C), as well as internal validation 
by targeted amplicon sequencing of the Independent Validation Cohort (D). 
There is evidence of aberrant methylation in a subset of dysplastic disease 
and EAC samples, with external validation supporting our observed bimodal 
methylation of advanced disease samples. Intriguing for this target region 
was increased methylation in occasional BE samples. There was no 
supporting evidence of dysplastic progression of these patients (Training or 
Independent Validation Cohorts) during the course of this study. Follow-up 
clinical data was not available for the External Validation Cohort. (B) 
Heatmap methylation values separated into eight discrete regions 0.000 – 
1.000 in increments of 0.125. Heatmap sample classification color scheme 
as for barplot (A). (C) Height of bars indicate percentage methylation (0.0 – 
1.0), colour code N: blue, BE: green, HGD and EAC: pink, duodenal and 
proximal stomach: grey and normal blood: dark red. 
 
Leucine rich repeat containing 43 (LRRC43) is a member of the leucine-rich 
repeat (LRR) superfamily, involved in a diverse range of cell-cell and cell-
extracellular matrix interactions such as adhesion, target recognition and 
receptor-ligand binding181. The human protein atlas (www.proteinatlas.org) 
shows evidence of LRRC43 expression (high level antibody staining) across 
a number of cancers including colorectal, glioma, melanoma and head and 
neck cancer182, 183. Overexpression of LRR superfamily member, leucine rich 
repeat containing G-protein coupled receptor 5 (LGR5), an intestinal stem 
cell marker, has been observed in hepatocellular carcinoma with β-catenin 
mutation (LGR5 is a downstream target gene of the Wnt signaling 
pathway)184. Furthermore, LGR5 has also been found to have prognostic 
significance in gastric carcinoma (expression associated with poor 
survival)185, but only in gastric cancers with nuclear β-catenin positivity. 
Interestingly, increased LGR expression did NOT have any effect on growth 
or migration of gastric carcinoma cells186. LRRC15 has been found to be 
frequently overexpressed in breast carcinoma 187-189 as well as androgen-
independent prostate cancer190 and is associated with aggressive, high-
grade tumors in both cases. As a result of this association, O’Prey et al 
sought to investigate the role of LRRC15 on adenoviral delivery of tumor 
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suppressor 53; which was found to repress cell death due to adenoviral p53 
by impeding adenoviral infection191. Thus, despite some research into the 
LRR superfamily and its role in carcinogenesis in a number of cancer types; 
functional roles of specific family members are as yet unclear. We can 
hypothesize that LRR family members (such as LRRC43, identified here to 
exhibit EAC-associated aberrant promoter hypermethylation in genome-wide 
methylation profiling studies, validated by targeted sequencing (Figure 
5-10)), may be responsible for mediating nuclear import of oncoprotein (such 
as LRCC59-PP2A interaction in prostate cancer192); however further 
functional studies would be necessary to confirm this hypothesis. 
 
(A) 
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Figure 5-10: Validation of disease-associated differential methylation 
occurring in the promoter region of leucine rich repeat containing 43 
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(LRRC43), identified using the clinically relevant BE v HGD-EAC comparison 
for identification of intervention-requiring disease. Elongated validation region 
examined includes 5 probes, Chr12: 122,667,438 – 122,668,038. Targeted 
amplicon sequencing region (seven CpG sites, Chr12: 122,667,942 – 
122,667,857), indicated by red arrow, lies next to probe cg26953749. Barplot 
(A) and heatmap (B) show External Validation Cohort results. Genome 
browser (C) shows HM450 data for a subset of the Training Cohort with 
>90% tissue sample homogeneity. DNA methylation evaluation by targeted 
amplicon sequencing (D) shows results for both the Technical and 
Independent Validation Cohorts. External validation (A) and (B) support 
internal genome-wide methylation profiling of the Training Cohort (C), as well 
as internal validation by targeted amplicon sequencing of the Technical and 
Independent Validation Cohorts (D). There is evidence of aberrant 
methylation in a subset of dysplastic disease and EAC samples, with external 
validation supporting our observed bimodal methylation of advanced disease 
samples. (B) Heatmap methylation values separated into eight discrete 
regions 0.000 – 1.000 in increments of 0.125. Heatmap sample classification 
color scheme as for barplot (A). (C) Height of bars indicate percentage 
methylation (0.0 – 1.0), colour code N: blue, BE: green, HGD and EAC: pink, 
duodenal and proximal stomach: grey and normal blood: dark red. 
 
Vang-like 2 (VANGL2) is a developmental membrane protein that plays a 
role in regulation of cell polarity, most notable for its involvement in neural 
tube defects occurring during the first trimester of pregnancy193-195. However, 
a developing role for VANGL2 in cancer has recently begun to be elucidated. 
The reactivation of embryonic development pathways to promote aggressive 
cell behaviour is not uncommon in cancer. Initial data mining efforts by 
Hatakeyama et al (2014) suggest that VANGL1 and VANGL2 are 
dysregulated in human cancers, and include the observation that estrogen 
receptor (ER)-positive breast cancer patients with elevated VANGL1 
expression correlate with worse overall survival196. Aberrant promoter 
methylation in a subset of dysplastic disease and EAC suggests that 
VANGL2 may also be involved in esophageal carcinogenesis, a novel finding 
in the EAC field. Reactivation of this embryonic developmental pathway 
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increases invasion and metastasis197, therefore  we could hypothesize that 
the subset of patients with aberrantly methylated VANGL2 may represent 
more aggressive cancers with worse survival. Comprehensive analysis with 
associated long-term survival data would be required to test this hypothesis. 
 
(A) 
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(D) 
 
Figure 5-11: Validation of disease-associated differential methylation 
occurring in the promoter region of vang-like 2 (VANGL2), identified using the 
clinically relevant BE v HGD-EAC comparison for identification of 
intervention-requiring disease. Elongated validation region examined 
includes 12 probes, Chr1: 160,369,972 – 160,370,983. Targeted amplicon 
sequencing region (nine CpG sites, Chr1: 160,370,041 – 160,370,188), 
indicated by red arrow, includes probe cg25388404. Barplot (A) and heatmap 
(B) show External Validation Cohort results. Genome browser (C) shows 
HM450 data for a subset of the Training Cohort with >90% tissue sample 
homogeneity. DNA methylation evaluation by targeted amplicon sequencing 
(D) shows results for the Independent Validation Cohort. External validation 
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(A) and (B) support internal genome-wide methylation profiling of the Training 
Cohort (C), as well as internal validation by targeted amplicon sequencing of 
the Independent Validation Cohort (D). There is evidence of aberrant 
methylation in a subset of dysplastic disease and EAC samples, with external 
validation supporting our observed bimodal methylation of advanced disease 
samples. (B) Heatmap methylation values separated into eight discrete 
regions 0.000 – 1.000 in increments of 0.125. Heatmap sample classification 
color scheme as for barplot (A). (C) Height of bars indicate percentage 
methylation (0.0 – 1.0), colour code N: blue, BE: green, HGD and EAC: pink, 
duodenal and proximal stomach: grey and normal blood: dark red. 
5.3.5.1  Promoter hypermethylation of DNA repair gene MGMT 
O-6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair gene, 
crucial for genome stability. MGMT repairs naturally occurring carcinogenic 
and mutagenic O6-methylguanine back to guanine, preventing mismatch and 
errors during replication and transcription198. The majority of cancers with 
DNA repair deficiency are epigenetically rather than mutationally regulated, 
for example, Halford et al reported just 6 of 113 sequential colorectal cancer 
samples evaluated had missense MGMT mutation; most having reduced 
MGMT expression due to promoter hypermethyation199. Aberrant MGMT 
promoter hypermethylation plays a significant role in the multistep process of 
Barrett’s carcinogenesis, with 71-79% of EAC reported to be deficient in 
MGMT93, 200.  
 
As explained in a recent review by Bernstein et al (2105)153, epigenetic 
silencing of MGMT would likely increase mutation rates; one or more of 
which may provide the cell with selective advantage. Carried on, this 
continued presence of epigenetically repressed MGMT would generate 
further mutations, some of which could produce a tumor. From this, we could 
hypothesize that the subset of non-dysplastic Barrett’s mucosa with 
increased promoter MGMT methylation would be more susceptible to 
malignant change, although it would not be possible to predict which of these 
patients will progress using this information alone. Thus, epigenetic MGMT 
repression, in co-ordination with repression of other DNA repair genes could 
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be one avenue for identification of non-dysplastic Barrett’s mucosa with 
malignant-change potential. To this end, Jiang et al152 evaluated mRNA 
expression of 27 repair genes, in astrocytoma compared to normal brain 
tissue and found 13, including MGMT, to be significantly down-regulated in in 
any grade of astrocytoma, including low-grade lesions. There is some 
evidence of MGMT methylation association with IDH1 mutation, for example 
81.3% of IDH1-mutated glioma has methylated MGMT compared non-IDH1 
mutated tumors (in which 58.3% were reported to be MGMT methylated)201; 
discussed further in Section 7.3.2.1  IDH1/2 and TET2 mutation in the 
esophagus. 
 
Promoter hypermethylation of MGMT, reported to have diagnostic and 
prognostic utility in esophageal adenocarcinoma and other cancers93, 152, 153 
was validated here to be present in not only subsets of EAC and dysplastic 
BE mucosa, but also a subset of non-dysplastic BE mucosa. Methylation 
bimodality (hypermethylation in only a subset of any disease class, with a 
subset entirely unmethylated) is observed, in sequencing results (Figure 
5-12(A)) as well as HM450 external validation (Figure 5-12(C)). MGMT 
promoter methylation in non-dysplastic Barrett’s mucosa as well as dysplasia 
and adenocarcinoma is supported by external validation (Figure 5-12) and to 
some extent, reports in literature. Kuester et al93 reported MGMT 
hypermethylation in 21.4% normal esophageal mucosa (n=28), 88.9% of 
non-dysplastic Barrett’s metaplasia (n=27) and 78.9% of EAC (n=47) using 
methylation specific PCR. For our external validation cohort, MGMT promoter 
hypermethylation (region as defined for sequencing validation, cut-off 
β>0.10) was observed in approximately 3% of normal esophageal mucosa 
(n=75), 78% of Barrett’s mucosa (n=18) and 54% of EAC (n=125).  
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Figure 5-12: Targeted amplicon sequencing of disease-associated differential 
methylation occurring in the promoter region of O-6-methylguanine-DNA 
methyltransferase (MGMT). (A) Targeted amplicon sequencing region 
(seventeen CpG sites, Chr10: 131,265,276 – 131,265,113) showing 
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independent validation sequencing only (this region was not analyzed for 
technical validation). Elevated methylation for any form of disease (BE, 
through dysplastic disease, to EAC) was observed in comparison to the fully 
unmethylated state of normal, healthy esophageal tissue. (B), (C) This was 
supported by external validation HM450 data. Elongated validation region 
examined includes 10 probes, Chr10: 131,265,137 – 131,265,697. Targeted 
amplicon sequencing region (red arrow), lies over three probes: cg14194875, 
cg00618725 and cg12434587. (C) The unmethylated status of normal 
healthy esophageal tissue was also observed for GERD, stomach and 
normal peripheral blood samples. Heatmap methylation values separated 
into eight discrete regions 0.000 – 1.000 in increments of 0.125. (D) Genome 
browser shows HM450 data for a subset of the Training Cohort with >90% 
tissue sample homogeneity; MGMT amplicon shown in red. Height of bars 
indicate percentage methylation (0.0 – 1.0), colour code N: blue, BE: green, 
HGD and EAC: pink, duodenal and proximal stomach: grey and normal 
blood: dark red. 
5.3.6  Bimodal methylation clustering 
Methylation bimodality (hypermethylation of a subset of a particular disease 
class, with another subset entirely unmethylated) was observed for the 
majority of target regions analyzed here and supported by genome-wide 
methylation profiling of a large external validation cohort. Hypermethylated 
samples across target regions did not correlate with disease severity, nor 
other clinicopathological factors, such as patient age, gender or presence of 
Helicobacter pylori gastric infection. Thus, it appears that bimodal clustering 
is target specific and may be due to a variety of reasons. For example, we 
could hypothesize that the subset of patients with aberrantly methylated 
VANGL2 may represent a more aggressive dysplasia or adenocarcinoma 
with worse survival due to reactivation of embryonic development pathways 
associated with invasion. Similarly, the subset of Barrett’s metaplasia, 
dysplasia and adenocarcinoma patients with promoter MGMT 
hypermethylation may represent a subset of tissues with greater malignant-
change potential due to repressed DNA repair pathways. Furthermore, the 
inflammation-triggered stem cell origin of Barrett’s may result in molecularly 
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distinct groups of disease arising, which may contribute to the observed 
bimodal clustering. This is discussed further in Section 4.3.7  Methylation of 
tumor suppressor p63. We could also hypothesize that chromothriptic events, 
reported as being more prevalent in EAC than any other cancer (recently 
reported to be as high as 32%)90, result in massive genomic rearrangement 
that could potentially impact methylation machinery in a subset of EAC 
samples. As a concluding point it is worth noting that this bimodal 
methylation clustering could also be due to possible ‘contamination’ of 
samples with tissue types other than the assigned classification. Despite the 
stringent cut-off criteria for inclusion of samples in the study, it is possible 
that the H&E section was not representative of the entire biopsy and thus the 
molecularly distinct methylomes arising in a sample originate from the 
different tissue types contributing to the section of biopsy used. 
5.3.7  Chromatin state discovery and characterization  
ChromHMM was used to determine chromatin state and resultant biological 
characterization of selected target regions for MiSeq amplicon sequencing 
(Table 5-12). The majority of selected target regions were located over active 
transcription start sites (TSS) or flanking active TSS, including the target 
region ~14Kb upstream of CA4 (Figure 5-13).  
 
Table 5-12: Biological characterization of target regions based on 
ChromHMM chromatin state discovery. Regions in grey were additional 
targets included for independent targeted sequencing validation (18 target 
regions; technical validation cohort evaluated in 10 target regions only). TSS: 
transcription start site. Target region for MGMT, ISM2 and TNFAIP8L3 
across TssA/TssAFlnk boundary. §Target region location for CACNA2D2 only 
29bp from region defined as active TSS.  
 Chr Start End ChromHMM Characterization 
N v HGD-EAC 
ELOVL5 6 53,212,967 53,213,085 Active TSS 
ZNF790 19 37,329,427 37,329,327 Active TSS 
N v Any disease 
SCOC 4 141,294,938 141,294,791 Active TSS 
ZNF570 19 37,960,451 37,960,359 Active TSS 
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 Chr Start End ChromHMM Characterization 
MGMT 10 131,265,276 131,265,113 Active TSS / Flanking active TSS 
BE v HGD-EAC 
ARL10 5 175,792,604 175,792,424 Active TSS 
CACNA2D2 3 50,541,229 50,541,332 Quiescent / Low§ 
ISM2 14 77,965,343 77,965,434 Active TSS / Flanking active TSS 
LRRC43 12 122,667,942 122,667,857 Active TSS 
TRANK1 3 36,985,944 36,986,065 Active TSS 
TUBA3FP 22 21,368,817 21,368,681 Flanking active TSS 
KLF7 2 208,031,073 208,031,144 Active TSS 
TNFAIP8L3 15 51,385,011 51,385,936 Active TSS / Flanking active TSS 
TEPP 16 58,018,911 58,018,827 Flanking active TSS 
ZNF699 19 9,420,542 9,420,418 Active TSS 
VANGL2 1 160,370,041 160,370,188 Active TSS 
ZNF221 19 44,455,289 44,455,448 Active TSS 
Upstream CA4 17 58,212,732 58,212,927 Active TSS 
 
 
Figure 5-13: Despite being 14kb upstream of carbonic anhydrase IV (CA4), 
the target region for amplicon sequencing is located within the defined active 
transcription start site. ChromHMM annotation for normal esophageal 
mucosa; note that chromatin marks may be disrupted in carcinogenesis and 
therefore associated regulatory regions may vary. Targeted amplicon 
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sequencing region Chr17: 58,212,732 – 58,212,927 is marked in red (with 
arrow). Height of bars indicate percentage methylation (0.0 – 1.0), colour 
code N: blue, BE: green, HGD and EAC: pink, duodenal and proximal 
stomach: grey and normal blood: dark red. 
5.3.8  Differential expression in selected target regions for validation 
Firstly, chromatin state discovery was used to determine the biological 
characterization of target regions selected for validation (Table 5-12). All 
regions were across active transcription start sites or flanking active 
transcription start sites with the exception of CACNA2D2, however the 
differentially methylated target region for CACNA2D2 was only 29bp from the 
active transcription start site. Note that ChrommHMM annotation is based on 
normal esophageal mucosa and chromatin marks may be disrupted by 
carcinogenesis. We examined gene expression of these regions to examine 
whether disease-associated differential methylation at, or near the 
transcription start site resulted in altered expression of these genes. Log fold 
change and p-values of differential expression of transcript clusters for target 
region genes are given in Table 5-13 below. 
 
Table 5-13: Differential expression of transcript clusters for target region 
genes. Target regions and calculated log fold change based on comparison 
classes as defined in Table 5-5. LogFC: log fold change. Tstat: t-statistic. IT: 
intronic transcript. AS: anti-sense RNA. Statistically significant differential 
expression (p≤0.05) in grey. 
Transcript	
Gene	
Transcript	Cluster	
ID	 LogFC	 Tstat	 P-value	 Transcript	ID	
	 	 	 	 	 	
ELOVL5	 TC06001813.hg.1	 -0.245145919	 -0.864904524	 0.396979192	 NM_00124828	
ZNF790	 TC19001472.hg.1	 -0.450496532	 -2.767122934	 0.011629737	 NM_206894	
ZNF790-AS1	 TC19000507.hg.1	 -0.099202052	 -1.462030727	 0.158711797	 NR_040027	
	 	 	 	 	 	
SCOC	 TC04000689.hg.1	 -0.41001175	 -1.728479308	 0.098753639	 NM_001153585	
ZNF570	 TC19000516.hg.1	 -0.106415402	 -0.641224589	 0.528395537	 NM_144694	
MGMT	 TC10000927.hg.1	 -0.010392113	 -0.093501137	 0.926402275	 NM_002412	
	 	 	 	 	 	
ARL10	 TC05000997.hg.1	 -0.03767486	 -0.603898245	 0.552456155	 NM_173664	
CACNA2D2	 TC03001433.hg.1	 -0.185665587	 -2.849359038	 0.009675928	 NM_001005505	
ISM2	 TC14001347.hg.1	 -0.029111072	 -0.498198159	 0.623583098	 NM_182509	
LRRC43	 TC12000970.hg.1	 -0.060884717	 -1.099328887	 0.28421468	 NM_001098519	
TRANK1	 TC03001283.hg.1	 -1.402882517	 -4.992270035	 6.31E-05	 NM_014831	
TUBA3FP	 TC22000528.hg.1	 0.051041094	 0.688895904	 0.49851898	 NR_003608	
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Transcript	
Gene	
Transcript	Cluster	
ID	 LogFC	 Tstat	 P-value	 Transcript	ID	
KLF7	 TC02002705.hg.1	 -0.34787389	 -1.337845056	 0.195423858	 NM_003709	
KLF7-IT1	 TC02002707.hg.1	 -0.453495891	 -1.638188279	 0.116456368	 ENST00000428777	
TNFAIP8L3	 TC15001360.hg.1	 -0.06422292	 -0.478649142	 0.637192575	 NM_207381	
TEPP	 TC16000498.hg.1	 -0.006025816	 -0.092379042	 0.927282866	 NM_199046	
ZNF699	 TC19001145.hg.1	 -0.130564682	 -0.674957758	 0.507153486	 BC109268	
VANGL2	 TC01001369.hg.1	 -0.145596905	 -1.759018502	 0.093311761	 NM_020335	
ZNF221	 TC19000612.hg.1	 0.200488844	 1.795277556	 0.087187766	 NM_013359	
Upstream	CA4	 TC17000736.hg.1	 -0.12668215	 -1.930207555	 0.067361484	 NM_000717	
 
The majority of differential expression of transcript clusters for target region 
genes were not significant. The majority of disease-associated 
hypermethylation, including all statistically significant changes, resulted in a 
decrease in expression. Given the recent work by Moarii et al94, these 
findings are not surprising and support the more complicated nature of the 
relationship between promoter methylation and gene expression in cancer 
development. 
5.4  Discussion 
The results presented in this chapter cover internal validation by targeted 
amplicon sequencing, using both technical and independent cohorts, as well 
as external validation by whole genome methylation profiling using a large 
cohort (250 samples from 154 patients) of the first published HM450 data for 
esophageal adenocarcinoma mucosa (GSE72874, released 01/04/2016). 
 
Target regions for validation were carefully selected by applying stringent 
criteria and a series of cut-offs, including minimizing baseline methylation, 
methylation in normal esophageal mucosa, normal peripheral blood and 
control tissues and maximizing methylation change. Control tissues ensure 
selected biomarker targets are disease-associated rather than associated 
with the maintenance of columnar mucosa. Peripheral blood from normal, 
healthy individuals ensures applicability of selected targets as blood 
biomarkers for early disease identification. 
 
Potential esophageal adenocarcinoma methylation biomarkers, as identified 
by current literature (including p16 (CDKN2A), TMEFFF2 (HPP1), RUNX3, 
CDH13, TAC1, NELL1, AKAP12, SST, APC, DAPK, CDH1, MGMT, TIMP3, 
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p57 (CDKN1C), p73, EREG38, 59, 60, 62, 63) were examined in our samples to 
gain more insight into these biomarkers and also evaluate the impact of 
availability of HM450 technology over the older 27k microarrays. The majority 
of literature biomarkers exhibited differential methylation with respect to 
distinguishing ‘any disease’ from normal esophageal mucosa: Barrett’s 
mucosa was not distinguishable from dysplastic or EAC tissues. Exceptions 
were CDH1, EREG and CDKN1C which showed no differential methylation in 
our samples, the possibility of a BE only marker and poor coverage (only 1 
EAC sample differentially methylated) respectively. Overall, the majority of 
these biomarkers were unable to differentiate non-dysplastic BE from 
dysplasia and EAC, thus ultimately lacking real clinical utility owing to the low 
rate of carcinogenic progression and benign nature of Barrett’s esophagus.  
 
Based on these findings, the HM450 training cohort data set was reanalyzed 
using the comparison N vs any disease (BE/LGD/HGD/EAC). Strong 
differential methylation was observed, as expected due to not only disease 
progression, but also change in tissue mucosal structure. The top 15 
differentially methylated regions identified using this comparison all had 
average baseline methylation (N samples) <0.08 and average delta 
methylation of >0.60 (maximum 0.69). None of the current literature markers 
were in the top 15 identified differentially methylated regions. NELL1 was the 
highest of the literature hits, with average baseline methylation 0.06 and 
average delta methylation 0.52. The lack of literature hits in the top 
differentially methylated target regions using this comparison is likely 
indicative of the much greater coverage provided by HM450 technology. 
 
For comprehensive validation, alternative technology (targeted sequencing 
rather than the whole genome methylation microarray approach used for 
discovery) was applied, namely MiSeq amplicon sequencing. The advantage 
of utilizing a MiSeq targeted sequencing approach is its ability to accurately 
quantitate the levels of methylated and unmethylated alleles at each CpG 
site across multiple regions of interest at single-base resolution, thus 
enabling selection of the most clinically appropriate disease-specific 
biomarkers. 
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I used unbiased amplification of methylated and unmethylated DNA by 
bisulfite-specific PCR as a starting point for MiSeq and designed assays to 
be directly applicable for investigations in blood. By designing short 
amplicons (72-196bp) and adjusting MiSeq library preparation protocols to 
suit this, the test is directly applicable for investigating the methylation status 
of the short, degraded fragments of cell-free circulating DNA extracted from 
blood plasma. 
 
The majority of targets (13 of 18, 72%) that underwent validation were 
successfully validated, with technical and independent internal validation as 
well as large cohort external validation supporting original hypotheses from 
discovery data. Among these targets are regions with little known regarding 
function, such as ARL10 and TUBA3FP; and also well-defined regions with 
known carcinogenic roles, such as zinc finger family member KLF7 and 
leucine-rich repeat superfamily member LRRC43. Aberrant promoter 
methylation of many of these regions is novel for EAC carcinogenesis, for 
example targets such as VANGL2, LRRC43 and KLF7. A developing role for 
VANGL2 in carcinogenesis has only recently begun to be elucidated, with a 
role in ER-positive breast cancer uncovered in 2014. LRRC43 has been 
implicated in a number of different cancers such as colorectal, glioma, 
melanoma and head and neck cancer, but is novel for esophageal 
adenocarcinoma. A flurry of publications in 2015 associated various KLF 
family members with carcinogenic progression in various cancers, including 
KLF4 in esophageal squamous cell carcinoma and KLF17 in esophageal 
cancer; however aberrant KLF7 methylation and its role in EAC 
carcinogenesis is novel.  
 
MiSeq targeted amplicon sequencing enabled elucidation of distinct 
methylation populations within disease classifications, trending towards 
either entirely unmethylated or highly methylated. This bimodal methylation 
was observed for the majority of target regions identified as biomarkers for 
intervention requiring disease (BE v HGD-EAC). This observation gives rise 
to hypotheses of specific sub-populations within disease classifications that 
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may represent more aggressive disease (for example, methylated VANGL2 
induces reactivation of embryonic development pathways associated with 
invasion) or disease with greater malignant potential (for example, 
methylated MGMT results in repressed DNA repair pathways). An alternative 
hypothesis for bimodal methylation is the inflammation-triggered stem cell 
origin of BE. Molecularly distinct groups of disease may arise triggered by 
reflux-induced inflammation at the gastroesophageal junction, contributing to 
the observed bimodal methylation clustering observed for BE, dysplastic 
disease and EAC. One final hypothesis for this bimodal methylation is the 
high levels of chromothriptic events, reported as being more prevalent in 
EAC than any other cancer90. This chromothripsis may result in massive 
catastrophic genomic rearrangement that potentially disrupts the methylation 
machinery in a subset of EAC samples to result in the observed methylation 
bimodality. Further studies would be required to determine if any, or a 
combination of these hypotheses, are correct. 
 
Deficient or absent DNA repair is an important underlying cause of cancer153. 
Promoter methylation reducing DNA repair gene expression occurs early in 
progression to GI cancers153. This early hypermethylation is evident in 
elevated MGMT methylation observed in non-dysplastic Barrett’s mucosa 
and maintained through dysplastic development and progression to 
adenocarcinoma. It is possible that this DNA repair gene silencing may 
contribute to the high levels of genomic instability evident in EAC90. A future 
aspect of this work may be in predicting patient response to, and/or suitability 
for, neoadjuvant chemotherapy. Cancer cells deficient in DNA repair are 
more vulnerable to inactivation by DNA damaging agents than normal cells, 
which can be used to clinical advantage. For example, methylation of DNA 
repair gene MGMT could be investigated as a possible biomarker for 
predicting patient suitability for neoadjuvant chemotherapy in surgery-
requiring esophageal adenocarcinoma. There are many DNA repair 
pathways that could be used to create a panel of biomarkers to this effect: in 
2015, Bernstein et al153 reported 18 DNA repair proteins, active across 6 
different DNA repair pathways, that were subject to epigenetic induced down-
regulation in GI cancers.  
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ChromHMM was used for characterization of validated target regions, the 
majority (17 of 18, 94%) of which were over active transcription start sites or 
flanking active transcription start sites. Despite this, very few of these 
differentially methylated target regions were associated with differentially 
expressed transcript clusters (3 of 18, 17% with statistically significant down-
regulation). Given the recent work by Moarii et al94, these findings are not 
surprising and support the more complicated nature of the relationship 
between promoter methylation and gene expression in cancer development. 
 
This comprehensive validation and characterization of disease-associated 
differentially methylated target regions shows biomarker viability for early 
esophageal adenocarcinoma. Through careful consideration of assay design, 
there is direct transferability of this work for investigation of these target 
regions in blood. 
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CHAPTER 6:   METHYLATION BIOMARKERS FOR 
ESOPHAGEAL ADENOCARCINOMA AND PRECURSOR 
DISEASE 
6.1  Introduction 
As outlined in Chapter 1 there is an urgent need for a better way to diagnose 
early stage esophageal adenocarcinoma. Current endoscopic/histologic 
methods are not viable for high-risk population screening, resulting in late 
stage diagnosis, contributing to the poor outcome for this disease.  
 
Carcinogenic progression for esophageal adenocarcinoma is not 
straightforward. High population prevalence of non-dysplastic precursor 
disease, but low progression rates to dysplasia are complicating factors for a 
screening test. Identification of asymptomatic, benign BE is not necessary if 
a reliable, robust method for low and high-grade dysplasia identification 
exists. The most clinically relevant biomarkers would differentiate patients 
with dysplastic Barrett’s (low and high-grade) as well as EAC from those non-
dysplastic Barrett’s or a normal, healthy esophagus. This is the focus of my 
thesis. 
6.1.1  Diagnostic EAC biomarkers 
The current state of play for early diagnostic biomarkers for EAC is nicely 
summarized by Shah et al in a 2013 review202, applying the National Cancer 
Institute’s Early Detection Research Network (EDRN) guidelines for 
biomarker discovery and development (a 5-phase process) to show 
development status of EAC diagnostic biomarkers (Figure 6-1). In brief, 
Phase I includes preclinical exploratory studies (normal versus tumor 
analyses), Phase II: clinical assay development and validation, Phase III: 
retrospective longitudinal repository studies (assay applied to prospectively 
collected stored samples to assess biomarker utility), Phase IV: prospective 
screening and Phase V: cancer control studies (large-scale clinical trials).  
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Using these guidelines, this study falls into Phases I and II of the EDRN 
biomarker development process. The value in reverting essentially ‘back to 
the start’ for this study lies in its focus on inclusion of dysplastic BE samples 
for profiling and changing the current ‘tumor-normal’ focus to the more 
clinically appropriate ‘intervention requiring disease vs non-dysplastic, benign 
BE’ focus. Implementing HM450 profiling of LGD and HGD is novel for early 
EAC detection biomarker studies and may be key to identification of 
biomarkers with true clinical utility that retain robustness and 
sensitivity/specificity as they progress towards clinical implementation. 
 
 
Figure 6-1: Summary of current diagnostic biomarkers for BE and EAC with 
respect to the Early Detection Research Network (EDRN) clinical phases of 
development. Figure courtesy of Shah et al202 (2013) review: ‘Early 
diagnostic biomarkers for esophageal adenocarcinoma – the current state of 
play’. For early diagnostic EAC biomarkers, DNA methylation is one of the 
better performing biomarkers, and has progressed as far as Phase III 
studies.  
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6.1.2  Prediction biomarkers in EAC 
Possibly the most progressed of all EAC biomarkers are those for predicting 
risk of progression from BE to EAC. As outlined in Chapter 1, a panel of eight 
DNA methylation biomarkers to predict the risk of progression from BE to 
EAC, proposed by Stephen Meltzer and his team at John Hopkins 
University38 has been launched commercially in 2013. A significant limitation 
of the Meltzer laboratory test is its reliance on endoscopic tissue biopsies. 
The test is intended be used as a supplement to current 
endoscopic/histology diagnosis and surveillance; and may reduce load on 
heath care systems by increasing surveillance interval of low-risk progression 
patients. However, the impact on outcome for EAC sufferers has not been 
evaluated and may not be significant as the test does not address disease 
detection in a high-risk population, but rather focuses on patients with known 
non-dysplastic disease (who are likely already in surveillance programs and 
would have any progressive disease detected by standard 
endoscopic/histologic surveillance at an early, curable stage). 
 
A more informative prediction biomarker for EAC may be surrounding 
patients diagnosed with LGD. There is disagreement in guidelines worldwide 
regarding treatment of LGD, ranging from a surveillance-only approach to an 
aggressive treatment approach (removal of dysplastic tissue by endoscopic 
mucosal resection (EMR) or radio-frequency ablation (RFA))52, 81. A 
biomarker able to predict the necessity of treatment for LGD, for example if 
LGD would naturally regress to non-dysplastic disease without treatment 
versus LGD likely to progress to HGD and EAC, would be valuable in guiding 
treatment decision and result in better use of specialist time. There is no 
necessity for a biomarker such as this to be blood-based; LGD patients 
would be undergoing endoscopic surveillance and tissue biopsies taken 
routinely, thus a tissue-based biomarker is acceptable in this situation. A 
biomarker for determination of treatment regime for LGD patients would be 
used as an adjunct to current surveillance and used to guide subsequent 
surveillance or treatment to avoid progression to EAC. 
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Furthermore, biomarkers for monitoring disease status during treatment 
would also be clinically valuable in the current EAC climate. A biomarker for 
this purpose may be used to assess whether current treatment regimes are 
effective or if a more aggressive treatment approach is required. A blood-
based biomarker here would be valuable, however EMR and RFA treatment 
require endoscopic examination and thus even a tissue-based biomarker 
may have some level of clinical utility, used as an adjunct to current 
endoscopic/histologic disease surveillance methods. 
 
This chapter aims to not only evaluate methylation biomarker performance 
with regard to diagnostic utility (investigating biomarkers individually and 
multiplexed into panels); but also investigate applications such as those 
described above by performing full clinical follow up on all patients used in 
the study to determine possible application for disease progression prediction 
(non-dysplastic to dysplastic BE as well as LGD progression or natural 
regression) as well as possible application in disease monitoring with 
treatment. 
6.1.3  Chapter 6 aims 
To evaluate DNA methylation biomarker performance with regard to 
diagnostic utility and application for disease progression prediction and 
disease monitoring with treatment. 
6.2  Methods 
6.2.1  Probe level biomarker filtering 
In addition to a global analysis of genome-wide methylation profiling data, 
more specific biomarker-focussed analysis was performed. Biomarker 
filtering cut-offs (hypermethylation) were applied to probes from each 
comparison as outlined in Table 6-1. Baseline methylation (baseline groups: 
N or BE as per comparison group) cut-offs were applied, then differentially 
methylated regions (DMRs) were ranked and filtered to remove those with 
methylation evident in normal peripheral blood (using the publicly available 
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data set GEO accession GSE48472)110, with foresight for a non-invasive 
blood biomarker test. Differentially methylated probes were further filtered to 
remove those with methylation above baseline in control (duodenal and 
proximal stomach) tissues, as well as normal squamous epithelium (for BE v 
HGD-EAC comparison). Integrative Genomics Viewer (IGV, Broad Institute, 
Cambridge, USA) was used to visualise and explore HM450 methylation 
data203. No exclusion criteria regarding differential methylation in 
neighbouring probes was applied (as it was for selection of regions for 
validation by targeted sequencing, Section 5.2.1  Target region selection). 
 
Table 6-1: Cut-off criteria (hypermethylation) applied for determination of 
clinically relevant biomarkers. Cut-offs apply to average methylation values 
detected for each probe within the defined target region.  
 N v HGD-EAC N v BE BE v HGD-EAC 
Baseline methylation (β) ≤ 0.10 ≤ 0.10 ≤ 0.10 
Methylation change (Δβ) ≥ 0.50 ≥ 0.50 ≥ 0.20 
Normal blood (β) ≤ 0.10 ≤ 0.10 ≤ 0.10 
Normal esophageal tissue (β) ≤ 0.10 ≤ 0.10 ≤ 0.10 
Duodenal tissue (β) ≤ 0.10 ≤ 0.10 ≤ 0.10 
Proximal stomach tissue (β) ≤ 0.10 ≤ 0.10 ≤ 0.10 
6.2.2  Determination of biomarker performance 
Sensitivity and specificity for each of the individual target regions was 
calculated based on MiSeq targeted sequencing data for methylation at 
individual CpG sites within each region. Average methylation at each probe 
was compared to a predefined cut-off (Table 6-2) and assigned a true 
negative (TN, Avg β<specified cut-off) or false positive (FP, Avg β>specified 
cut-off) for baseline samples or a true positive (TP, Avg β>specified cut-off) 
or false negative (FN, Avg β<specified cut-off) for disease samples. A 
positive result was recorded when ANY probe within the specified region 
returned an average methylation above the designated cut-off for that region. 
Cut-offs were assigned to achieve maximum sensitivity with minimum impact 
on specificity. The performance of individual target regions was evaluated by 
determining sensitivity (percentage of TP with respect to total disease 
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samples) and specificity (percentage of FP with respect to total baseline 
samples). The performance of various multiplexed target regions was 
evaluated using sensitivity and specificity for individual target regions; 
regions were selected based on attaining maximum sensitivity with minimum 
impact on specificity. Cut-offs, TN, FP, TP and FN counts were as for 
individual target regions.   
6.2.3  Evaluation of biomarkers for prediction of progression and 
disease monitoring 
Clinical follow up was performed on all patients who contributed samples to 
either technical or independent validation cohorts and had associated MiSeq 
targeted sequencing data (technical validation cohort patients also had 
HM450 and HTA2.0 profiling data). Average methylation at each CpG site of 
patients with changed clinical diagnoses were compared to averages of all 
other patients with those particular diagnoses. Unpaired t-tests or ordinary 
one-way ANOVA were performed to evaluate if aberrant methylation was 
statistically significant. 
6.3  Results 
6.3.1  Biomarker determination 
Heat maps were compiled for all disease-associated hypermethylated probes 
meeting specified cut-off criteria (Table 6-1) for each of the comparisons: N v 
HGD-EAC (Figure 6-2, 799 probes), N v BE (Figure 6-3, 235 probes) and BE 
v HGD-EAC (Figure 6-4, 165 probes), based on genome-wide methylation 
profiling data of the training cohort. A Venn diagram (Figure 6-5) shows the 
overlap in identified biomarker probes between each of the comparison 
groups. Details of all hypermethylated biomarker probes meeting cut-off 
criteria for each comparison are given in Appendix 7: Hypermethylation 
biomarker probes for BE and EAC. GENCODE v19 was used for reference 
human genome annoation204.   
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Figure 6-2: Hypermethylated biomarker probes (n=799) for differentiation of 
HGD and EAC from N (Δβ ≥ 0.50). Baseline restrictions applied to normal 
tissue (unmethylated, β ≤ 0.05) as well as control (duodenal and proximal 
stomach) tissues and blood from normal healthy patients (β ≤ 0.10). No 
restriction placed on methylation level in BE patients. Samples shown are a 
subset of the training cohort with >90% tissue sample homogeneity. All 
samples taken proximally are normal, healthy esophageal mucosa. 
Methylation values separated into eight discrete regions 0.000 – 1.000 in 
increments of 0.125. 
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Figure 6-3: Hypermethylated biomarker probes (n=235) for differentiation of 
BE from N (Δβ ≥ 0.50). Baseline restrictions applied to normal tissue 
(unmethylated, β ≤ 0.05) as well as control (duodenal and proximal stomach) 
tissues and blood from normal healthy patients (β ≤ 0.10). No restriction 
placed on methylation level in HGD and EAC patients. Samples shown are a 
subset of the training cohort with >90% tissue sample homogeneity. All 
samples taken proximally are normal, healthy esophageal mucosa. 
Methylation values separated into eight discrete regions 0.000 – 1.000 in 
increments of 0.125.  
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Figure 6-4: Hypermethylated biomarker probes (n=165) for differentiation of 
intervention requiring disease (HGD and EAC) from BE and N (Δβ ≥ 0.20). 
Baseline restrictions applied to non-dysplastic BE tissue (unmethylated, β ≤ 
0.10) as well as control (normal esophageal epithelium, duodenal and 
proximal stomach) tissues and blood from normal healthy patients (β ≤ 0.10). 
Samples shown are a subset of the training cohort with >90% tissue sample 
homogeneity. All samples taken proximally are normal, healthy esophageal 
mucosa. Methylation values separated into eight discrete regions 0.000 – 
1.000 in increments of 0.125.  
 
Considerable overlap (n=168) was present in hypermethylation biomarker 
probes differentiating BE and HGD-EAC from normal healthy esophageal 
tissue (Figure 6-5). 71.49% of hypermethylated probes for BE identification 
also identify HGD and EAC, meaning the majority of disease-associated 
aberrant methylation occurring early in the metaplasia-dysplasia-carcinoma 
sequence is maintained. Conversely, only 21.03% of hypermethylated 
probes for HGD-EAC identification also identify BE, indicating that much of 
the significant aberrant methylation associated with high-grade dysplasia and 
esophageal adenocarcinoma is developed late in the metaplasia-dysplasia-
carcinoma sequence. As can be seen in Figure 6-2, many of the HGD-EAC 
biomarkers show some level of increased methylation in BE, however due to 
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hypermethylation criteria Δβ ≥ 0.50, these biomarkers are not identified as 
being associated with BE. Thus, it appears that methylation becomes more 
prolific in these regions as disease progresses.  
 
The majority of clinically relevant hypermethylation probes for the detection 
of intervention requiring disease (differentiating HGD and EAC from non-
dysplastic BE and normal healthy esophageal tissue) are unique to this 
comparison (91.5%, 151 of 165 unique). Forcing baseline methylation of N 
and non-dysplastic BE to be ≤ 0.10 results in lower average Δβ methylation 
to HGD-EAC samples. An overlap of 14 differentially methylated probes with 
the N v HGD-EAC comparison was observed, indicating higher levels of 
methylation in HGD and EAC for these particular probes (≥ 0.50). Note that 
region selection for validation by targeted amplicon sequencing included 
criteria pertaining to identification of aberrant methylation across groups of 
probes (within 300bp, at least 2 differentially methylated probes required) as 
well as region suitability for BSP assay design. Hence some of the top 
aberrantly hypermethylated individual probes listed in Appendix 7: 
Hypermethylation biomarker probes for BE and EAC were not part of regions 
selected for validation.  
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Figure 6-5: Venn diagram showing overlap in identified hypermethylated 
biomarker probes between each of the comparison groups. Totals: N v BE 
n=235 probes, N v HGD-EAC n=799 probes, BE v HGD-EAC n=165 probes. 
Considerable overlap was present in probes for identification of BE and 
HGD-EAC from N, sharing 168 common regions, whereas the majority of 
clinically relevant probes for differentiating intervention requiring disease 
from normal and non-dysplastic disease were unique to the comparison. 
Venn diagram created using BioVenn205. 
6.3.2  Performance of individual target regions 
Sensitivity and specificity of each individual target region (and the cut-off 
used) are given in Table 6-2. Analysis was performed both with and without 
LGD patients (included with HGD and EAC as intervention requiring disease) 
to determine whether target regions were capable of detecting these difficult 
to classify patient samples. Sensitivity and specificity data for MGMT has 
been determined using the ‘N v Any disease’ comparison due to observed 
elevated methylation of non-dysplastic BE, confirming results reported in 
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literature93, 151. Results for VANGL2 exclude the CpG site at Chr1: 
160,370,070 due to assay positioning restrictions (unable to design assay to 
region of interest due to ubiquitous poly-C repeats, assay moved to 
CpGi1843 shore). 
 
The performance of individual target regions as stand-alone biomarkers for 
detection of HGD-EAC or ‘Any disease’ (non-dysplastic BE through to EAC) 
is relatively high with reported sensitivity and specificity of ≥ 80% for the five 
regions. However the majority of these (with the exception of MGMT, β cut-
off 0.02) rely on arbitrary methylation cut-offs 0.15 – 0.45; meaning that low 
level methylation exists in normal squamous esophageal tissue. MGMT 
methylation is a reliable marker (94.1% sensitivity, 80.0% specificity) for 
evidence of any disease (non-dysplastic as well as dysplastic BE and EAC) 
in tissue biopsies. Methylation beta-value cut-off of 0.02 for this assay 
indicates the region is unmethylated in normal healthy esophagus, but 
become methylated with metaplastic change and maintains methylation 
throughout dysplastic progression and adenocarcinoma development. 
 
The performance of individual target regions as stand-alone biomarkers for 
differentiation of intervention requiring disease from normal and non-
dysplastic disease is more complicated. Reported sensitivities (42.9 – 92.3%) 
reflect the bimodal methylation observed in targeted sequencing results 
(easily visualized in Figure 5-9(D)). These biomarkers have been shown to 
be either highly or un-methylated; a trend seen across all 13 regions and 
discussed in Chapter 5:  Target Region Validation and Characterization. 
However these shortcomings are overcome by multiplexing of target regions, 
with just three biomarkers needed to identify 100% of HGD and EAC in our 
technical and independent validation cohorts (refer to Section 6.3.3  
Performance of multiplexed target regions). 
 
Table 6-2: Sensitivity and specificity of individual target region methylation for 
disease detection. Data pertains to the listed comparison classes only. LGD 
sensitivity / specificity include LGD alongside HGD and EAC for identification 
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of any dysplastic disease and adenocarcinoma. Marked regions (*) have 
results from the independent cohort only; all other regions have data from 
both the technical and independent cohorts. Data sorted by highest 
sensitivity within comparison group. 
 
Cut-
off 
Sens 
(%) 
True 
positive 
count 
Total 
disease 
samples 
Spec 
(%) 
False 
positive 
count 
Total 
baseline 
samples 
 LGD 
Sens 
(%) 
LGD 
Spec 
(%) 
          
N v HGD-EAC          
 ZNF790 0.20 100.0 13 13 85.7 2 14 100.0 85.7 
 ELOVL5 0.15 84.6 11 13 100.0 0 14 75.0 100.0 
          
N v Any disease          
 MGMT* 0.02 94.1 16 17 80.0 1 5   
 SCOC 0.45 90.6 29 32 100.0 0 14   
 ZNF570 0.40 87.5 28 32 85.7 2 14   
          
N-BE v HGD-EAC          
 ISM2 0.10 92.3 12 13 57.7 11 26 85.0 57.7 
 TUBA3FP 0.05 84.6 11 13 84.6 4 26 80.0 84.6 
 LRRC43 0.08 84.6 11 13 80.8 5 26 65.0 80.8 
 VANGL2* 0.02 71.4 5 7 100.0 0 11 63.6 100.0 
 ARL10 0.08 69.2 9 13 100.0 0 26 55.0 100.0 
 CACNA2D2 0.08 61.5 8 13 84.6 4 26 45.0 84.6 
 TRANK1 0.25 61.5 8 13 73.1 7 26 55.0 73.1 
 KLF7* 0.04 57.1 4 7 90.9 1 11 45.5 90.9 
 ZNF699* 0.015 57.1 4 7 81.8 2 11 54.5 81.8 
 ZNF221* 0.03 57.1 4 7 72.7 3 11 63.6 72.7 
 Upstream CA4* 0.07 42.9 3 7 90.9 1 11 36.4 90.9 
 TNFAIP8L3* 0.30 42.9 3 7 90.9 1 11 27.3 90.9 
 TEPP* 0.04 42.9 3 7 72.7 3 11 54.5 72.7 
 
6.3.3  Performance of multiplexed target regions 
Sensitivity and specificity was also considered for a ‘multiplex’ of target 
regions, selecting panels based on attaining maximum sensitivity with 
minimum impact on specificity.  Two panels were selected, one for detection 
of intervention requiring disease (differentiating HGD and EAC from N and 
BE), the other for detection of any dysplastic disease or adenocarcinoma 
(differentiating LGD, HGD and EAC from N and BE), results in Table 6-3. As 
previously, VANGL2 results exclude Chr1: 160,370,070 CpG methylation due 
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to assay positioning restrictions (unable to design assay to region of interest 
due to ubiquitous poly-C repeats, assay moved to CpGi1843 shore). 
 
Multiplexing target regions significantly improves ability to accurately detect 
disease-associated differential methylation, overcoming problematic bimodal 
methylation observed for individual targets. A triplex of hypermethylation in 
any of TUBA3FP, VANGL2 or ARL10 (regions as per Table 5-5) was able to 
accurately identify all HGD and EAC patients with 100% sensitivity (beta 
value cut-offs of 0.05, 0.02 and 0.08 respectively). Test specificity of 84.6% 
was reported (based on methylation detected in patients with a normal 
healthy esophagus, or non-dysplastic Barrett’s). For the detection of any 
dysplastic disease or adenocarcinoma, the panel was adjusted and 
hypermethylation above cut-off in any of TUBA3FP, ARL10 and ZNF699 
(beta-value cut-offs 0.05, 0.08 and 0.015 respectively) was used. This triplex 
was successfully able to identify 95% of all LGD, HGD and EAC patients, 
with 76.9% specificity (as previously, based on methylation detected in 
patients with a normal healthy esophagus or non-dysplastic Barrett’s). A 
single LGD patient (PN200335, variable homogeneity reported, as low as 5-
10% LGD) was not methylated above designated cut-off in any of the target 
regions, therefore 95% sensitivity (19 of 20 samples) is maximal for this 
comparison. 
 
Table 6-3: Sensitivity and specificity of multiplexed target region methylation 
for disease detection. Triplex was required for both comparisons to achieve 
maximum sensitivity. A single LGD patient was not methylated above cut-off 
levels in any of the target regions tested, hence 95% sensitivity is maximal 
for this comparison. Cut-offs, TN, FP, TP and FN counts as designated for 
individual regions (Table 6-2). 
 
Sens 
(%) 
True 
positive 
count 
Total 
disease 
samples 
Spec 
(%) 
False 
positive 
count 
Total 
baseline 
samples 
 
Multiplex for detection of intervention requiring disease (N-BE v HGD-EAC) 
TUBA3FP + VANGL2 + ARL10 100.0 13 13 84.6 4 26 
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Sens 
(%) 
True 
positive 
count 
Total 
disease 
samples 
Spec 
(%) 
False 
positive 
count 
Total 
baseline 
samples 
Multiplex for detection of dysplastic disease and EAC (N-BE v LGD-HGD-EAC) 
TUBA3FP + ZNF699 + ARL10 95.0 19 20 76.9 6 26 
 
6.3.4  Methylation biomarkers for prediction of non-dysplastic to 
dysplastic disease progression 
There is evidence of application of these biomarkers for predicting 
progression of non-dysplastic to dysplastic BE. Clinical follow up on all 
patients that contributed a non-dysplastic BE sample to either the technical 
or independent validation cohorts revealed a single patient who progressed 
to dysplastic BE, approximately 1 year later (Figure 6-6). 
 
The patient, male, aged 60, had no known family history of BE or EAC, did 
not suffer from reflux or heartburn at the time the sample was taken (Nissen 
fundoplication at 38 years of age), and consented to the study for the first 
time at a pre-operative ‘check endoscopy’ prior to sleeve gastrectomy 
(weight loss surgery) at which time his BMI was 55.2kg/m2 (181cm, 181kg), 
explaining the high frequency of subsequent visits. The decision to perform a 
sleeve gastrectomy was difficult as this form of intervention is known 
increase reflux and worsen BE, however due to his BMI, hypertension, Type 
2 diabetes mellitus, obstructive sleep apnea requiring continuous positive 
airway pressure therapy and other indications, weight loss intervention was 
prioritized. At his first consenting visit, BE (C4 M5) with no evidence of 
dysplasia or malignancy was identified.  
 
At visit 2 (endoscopy performed due to vomiting and eating difficulties), the 
procedure was abandoned early due to complications and no research 
biopsies were taken. The patient had lost 20kg and was diagnosed with 
Grade A reflux esophagitis and BE (C3 M3) (endoscopic classification only, 
histological classification not possible (no biopsies taken)). At visit 3, BE (C1 
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M5) was identified and LGD at 40cm was confirmed by hospital 
histopathology (Figure 6-6). 
 
 
 
Figure 6-6: Patient timeline for non-dysplastic to dysplastic disease 
progression. The sample contributing to our study was taken at visit one, 
when the patient was diagnosed with non-dysplastic BE. Patient 
classification at visit 3 based on histopathology from hospital biopsies. 
 
The methylation profile of testis, prostate and placenta expressed (TEPP) 
and target region upstream of carbonic anhydrase IV (Upstream CA4) 
showed significant increase (p<0.0001, both regions) in methylation of non-
dysplastic BE, taken one year before development of low-grade dysplasia 
(compared to all other non-dysplastic BE samples where patients did not 
progress over the course of this study). Progression patient separated and 
labeled ‘BE pro’ in Figure 6-7. 
 
Chapter 6:  Methylation Biomarkers for Esophageal Adenocarcinoma and 
Precursor Disease 
 210 
 
 
 
 
Figure 6-7: Methylation biomarker target regions TEPP and Upstream CA4 
for predicting progression from non-dysplastic to dysplastic disease. Average 
methylation at each CpG site within the target region (TEPP 6 sites, 
upstream CA4 8 sites) plotted for all patients in the independent validation 
cohort (24 samples from 15 patients). Statistical significance was evaluated 
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using an unpaired t-test. BEpro: results from non-dysplastic BE patient with 
dysplastic progression 1 year subsequent to analysis of this sample.  
 
These results provide evidence that aberrant methylation of these target 
regions may indicate predisposition to dysplastic progression, of particular 
clinical significance in a case such as the one described here. This patient 
has been flagged for follow up: DNA has been extracted from a tissue 
sample taken at visit 3 (LGD diagnosis) and sent to collaborators in 
Queensland (A/Prof. Andrew Barbour and colleagues) for HM450 profiling. 
This data has been included on a collaborative NHMRC grant application to 
investigate the potential of these biomarkers for disease prediction. 
6.3.5  Methylation biomarkers for prediction of the necessity of 
treatment for low grade dysplasia 
The ability to predict progression from low to high grade dysplasia is of 
particular clinical importance as it may aid in determining how to treat a 
patient with a LGD classification (still disputed and discussed in guidelines 
for the management of Barrett’s worldwide)52, 81. Similarly, biomarkers for the 
natural regression of LGD to non-dysplastic Barrett’s are of clinical interest 
as these markers, combined with markers for progression from LGD to HGD, 
could be used together to determine treatment and/or surveillance regime for 
patients of this controversial classification. 
6.3.5.1  Low grade to high grade progression 
There is evidence of application of these biomarkers for prediction of 
progression from low to high-grade dysplasia. Clinical follow up on all 
patients who contributed an LGD sample to either the technical or 
independent validation cohorts revealed a single patient who progressed 
from low- to high-grade dysplasia during the course of this study (Figure 6-8). 
 
The patient, male, aged 66, had no known family history of BE or EAC and 
consented to the study for the first time when he was being treated for his 
long-segment LGD (C11 M11). At this, and all three subsequent visits, he 
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was treated by endoscopic mucosal resection. Focal HGD was first identified 
approximately 8 months after his first visit (in one of six samples). This was 
confirmed approximately 3 months later, with focal high grade dysplasia 
observed in one of eight fragments sent for hospital histopathology 
(extensive low-grade dysplasia also still present). 
 
 
 
 
Figure 6-8: Patient timeline for low to high-grade dysplastic progression. The 
sample contributing to our study was taken at visit one, when the patient was 
diagnosed with LGD. Patient classification at subsequent visits based on 
histopathology from hospital biopsies. Focal HGD was identified and treated 
at visit 3, but persisted at visit 4 (where further treatment was also 
performed). EMR: Endoscopic mucosal resection, Tx: treatment. 
 
Increased methylation of target regions in leucine rich repeat containing 43 
(LRRC43) and zinc finger protein 699 (ZNF699) for this LGD patient are 
consistent with the profile of more advanced disease. The patient progressed 
to HGD approximately 8 months later, despite several endoscopic mucosal 
resection treatments for his long segment LGD (Figure 6-9). 
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Figure 6-9: Methylation biomarker target regions LRRC43 and ZNF699 for 
predicting progression from low to high-grade dysplasia. Average methylation 
at each CpG site within the target region (LRRC43 7 sites, ZNF699 10 sites) 
plotted for all patients in the technical (te) and independent (in) validation 
cohorts (LRRC43: total of 48 samples from 33 patients) and the independent 
cohort only (ZNF699: 24 samples from 15 patients). Statistical significance 
evaluated using an ordinary one-way ANOVA test and Dunnett’s multiple 
comparisons test, with a single pooled variance. Grey data points (LRRC43) 
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pertain to a patient that regressed from HGD to LGD to non-dysplastic BE 
with treatment (refer to Section 6.3.6  Methylation biomarkers for disease 
monitoring with treatment), indicating that the global methylation profile of 
this patient has not quite returned to that of non-dysplastic BE, showing 
remnants of previous higher level disease. 
 
These results provide evidence that increased methylation of these target 
regions in LGD patients may indicate predisposition to disease progression, 
thus warranting a more aggressive treatment approach. It is also plausible 
that these samples contain different proportions of cell sub-types with high 
and low methylation at these target sites. A full study over an elongated time 
period with increased numbers of patients with progressive disease is 
needed to confirm this hypothesis. 
6.3.5.2  Natural regression from low grade to non-dysplastic disease 
There is evidence of application of these biomarkers for prediction of natural 
regression from low-grade dysplasia to non-dysplastic disease. Clinical follow 
up on all patients that contributed an LGD sample to either the technical or 
independent validation cohorts revealed a single patient who regressed from 
LGD to non-dysplastic BE (without treatment) during the course of this study 
(Figure 6-10). 
 
The patient, male, aged 56, had no known family history of BE or EAC and 
consented to the study for the first time when he was undergoing surveillance 
for his long-segment LGD (C8 M8). Notable was a small ulcer (biopsied, non-
malignant) and bleeding Barrett’s. At this, and three subsequent visits, his 
LGD was extensively biopsied but not treated. His Barrett’s fluctuated in 
circumferential and maximal extent, with extensive LGD identified (v1: 30-
34cm, v2: 30-43cm, v3: 31-35cm, v4: 32-39cm). At visit 5, no dysplasia was 
observed (biopsies from 32-38cm). The patient has a follow up endoscopy 
scheduled for March 2016. 
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Figure 6-10: Patient timeline for natural regression from low grade to non-
dysplastic Barrett’s. The sample contributing to our study was taken at visit 2; 
the patient was suffering from persistent LGD but was not undergoing any 
form of treatment. Patient classification at preceding and subsequent visits 
based on histopathology from hospital biopsies. Non-dysplastic BE with no 
residual LGD was the diagnosis at visit 5.  
 
The universally unmethylated profile of a number of target regions, such as  
Tubulin, alpha 3f, pseudogene (TUBA3FP) and ADP-ribosylation factor-like 
10 (ARL10) (Figure 6-11) for a patient with persistent LGD (untreated, 
constant surveillance) is consistent with the profile of non-dysplastic BE 
patients. This methylation pattern was evident in a number of other target 
regions including calcium channel, voltage-dependent, alpha 2 / delta subunit 
2 (CACNA2D2), leucine rich repeat containing 43 (LRRC43) and 
tetratricopeptide repeat and ankyrin repeat containing 1 (TRANK1) (data not 
shown). On follow-up, this patient was diagnosed as being without dysplasia 
two years after our LGD biopsy was taken and analyzed. 
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Figure 6-11: Methylation biomarker target regions TUBA3FP and ARL10 for 
predicting the necessity of treatment for low-grade dysplasia. Average 
methylation at each CpG site within the target region (TUBA3FP 8 sites, 
ARL10 19 sites) plotted for all patients in both the technical (te) and 
independent (in) validation cohorts (total of 48 samples from 33 patients). 
Statistical significance was evaluated using an ordinary one-way ANOVA test 
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and Dunnett’s multiple comparisons test, with a single pooled variance. ns = 
not significant. 
 
These results provide evidence that absence of methylation in these target 
regions in LGD patients may indicate predisposition to natural disease 
regression, thus warranting a less aggressive treatment or surveillance 
approach. A full study over an elongated time period with increased numbers 
of patients with is needed to confirm this hypothesis. This patient has been 
flagged for follow up: DNA has been extracted from a tissue sample taken at 
visit 5 (non-dysplastic BE diagnosis) and sent to our collaborators in 
Queensland (Dr Andrew Barbour) for HM450 profiling. This data has been 
included on a collaborative NHMRC grant application to investigate the 
progression of BE to dysplastic disease and adenocarcinoma.  
6.3.6  Methylation biomarkers for disease monitoring with treatment 
There is evidence of application of these biomarkers for monitoring disease 
regression with treatment. Included in the independent validation cohort were 
multiple samples taken from a single patient who was successfully treated. 
The patient was monitored over three visits in the space of 7½ months. A 
baseline methylation profile of matched normal esophageal tissue was taken 
at the first visit (proximally at 25cm), and diseased tissue samples at this 
(HGD) and each subsequent (LGD, then non-dysplastic BE) visit were taken 
prior to treatment.  
 
The methylation profile of tumor necrosis factor, alpha-induced protein 8-like 
3 (TNFAIP8L3) and zinc finger protein 699 (ZNF699) showed significant 
correlation (p=0.0019, p<0.0001 respectively) with disease regression over 
time as the patient was treated. Results are the average methylation 
detected at each CpG in the target region using MiSeq amplicon sequencing 
(Figure 6-12). 
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Figure 6-12: Methylation biomarker target regions TNFAIP8L3 and ZNF699 
for monitoring disease regression with treatment. Statistical significance was 
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evaluated using an ordinary one-way ANVOA test and Dunnett’s multiple 
comparisons test, with single pooled variance. Tx: treatment, v: visit. 
 
Interestingly both markers showed a significant drop in methylation by the 
second visit, despite the patient still being classified as having LGD. 
Following this analysis the patient has had two further visits and was 
diagnosed with non-dysplastic BE on both occasions. Methylation of these 
target regions may be clinically valuable for monitoring disease status and 
with treatment and possibly have application in predicting disease recurrence 
as part of a screening panel. 
6.4  Discussion 
The results presented in this chapter give insight into methylation biomarker 
performance (both individually and as a panel) and possible utility of the 
identified biomarkers for diagnosis, prediction of progression and disease 
monitoring. Irrespective of comparison group, cut-off criteria for biomarker 
selection enforced a minimal methylation, or unmethylated status in normal 
healthy esophageal tissue, duodenal and proximal stomach tissue and 
normal peripheral blood from healthy individuals, with biomarkers showing 
disease-associated hypermethylation within specified target regions. The 
mucosal structure of proximal stomach and duodenal tissue controls, similar 
to that of Barrett’s esophagus, enabled filtering of hypermethylation 
attributable to the maintenance of columnar epithelium, leaving only disease-
associated aberrant methylation.  
 
The N v BE comparison class identified biomarkers hypermethylated in non-
dysplastic Barrett’s epithelium with respect to normal, healthy esophageal 
mucosa. Typically, CpG sites identified by this comparison were very highly 
hypermethylated in Barrett’s epithelium (up to 80%, with average baseline 
methylation of normal epithelium typically 1-2%). The unmethylated status of 
duodenal and proximal stomach control tissues means that these biomarkers 
specifically indicate the presence of Barrett’s esophagus. No restrictions 
were placed on methylation in dysplastic BE or EAC for this comparison, 
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however interestingly, hypermethylation biomarkers for non-dysplastic BE 
remained highly methylated in dysplastic BE and EAC, indicating that 
disease-associated hypermethylation occurring early is maintained 
throughout metaplasia-dysplasia-adenocarcinoma progression. These 
biomarkers may be useful for confirming the presence of BE, however do not 
offer any clinical advantage over current histological identification, thus the 
focus of this thesis remained on the clinically relevant BE v HGD-EAC 
comparison. 
 
The N v HGD-EAC comparison class identified biomarkers hypermethylated 
in intervention requiring disease in comparison to normal, healthy 
esophageal epithelium. In general, these CpG sites were very highly 
methylated in advanced disease, with average hypermethylation of up to 
80% and average baseline methylation typically ~1-2%. No restrictions were 
placed on methylation in non-dysplastic BE and as such, methylation varied, 
but generally showed an intermediate level of hypermethylation at the sites 
that were highly hypermethylated in advanced disease. The clinical utility of 
these biomarkers is debatable. Detection and ongoing surveillance of non-
dysplastic BE, with its high prevalence (estimated incidence of 1-2% of the 
adult population34) and very low progression rate (estimated <0.5% per 
year39), is not economically viable for the healthcare system. Until current 
endoscopic / histologic surveillance programs for BE evolve, the focus for 
early detection needs to remain on identification of dysplastic BE and EAC. 
The observation that >70% of hypermethylation biomarkers for the 
identification of BE overlap with those for HGD-EAC detection supports 
observations by Krause et al49, that aberrant methylation occurring early in 
BE transformation is maintained throughout EAC development.  
 
The BE v HGD-EAC comparison class identified biomarkers hypermethylated 
in intervention requiring disease with respect to non-dysplastic Barrett’s and 
normal, healthy esophageal epithelium. In general, these sites were not as 
highly methylated as those identified in comparisons with normal esophageal 
epithelium only, however did exhibit hypermethylation up to 60% with 
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average baseline methylation typically ~1-2%. This is the most clinically 
valuable comparison class, distinguishing patients that require intervention 
from those that do not. Despite exclusion of the difficult to classify low-grade 
dysplastic tissues from algorithms to identify these biomarkers, a number of 
the selected target regions also showed good sensitivity (up to 85%) for 
disease detection in these samples.  
 
With regards to differentiation of intervention requiring disease from non-
dysplastic Barrett’s epithelium, sensitivity and specificity of validated target 
regions was generally insufficient for consideration as stand-alone 
biomarkers. However, multiplexing target regions into panels for identification 
of early-stage disease results in significant improvement in performance. A 
triplex of three target regions (TUBA3FP, VANGL2 and ARL10) is able to 
successfully differentiate high-grade dysplasia and EAC from normal and BE 
samples with 100% sensitivity and 84.6% specificity (4 false positives in 26 
baseline samples). For the identification of any dysplastic disease, including 
the notoriously difficult to diagnose LGD patients (differentiating LGD, HGD 
and EAC from normal and BE patients), a triplex of TUBA3FP, ARL10 and 
ZNF699 reported 95% sensitivity (a single LGD patient unable to be 
identified) and 76.9% specificity (6 false positives in 26 baseline samples). 
 
By performing comprehensive clinical follow-up on all patients that had 
associated targeted sequencing data, I have demonstrated the possible utility 
of these biomarkers for the prediction of progression from non-dysplastic to 
dysplastic disease. Particularly remarkable was that increased methylation of 
target regions TEPP (testis, prostate and placenta expressed) and upstream 
of CA4 (carbonic anhydrase IV) was observed in a non-dysplastic BE 
sample, one-year prior to dysplastic progression.  
 
Results were also suggestive of biomarker utility for prediction of necessity of 
treatment for LGD, a heavily debated topic in guidelines worldwide52, 81. A 
patient with persistent LGD (untreated, classification confirmed over several 
visits) showed minimal methylation (<0.05; as for non-dysplastic and normal 
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healthy esophagus) in several target regions (including TUBA3FP, ARL10, 
CACNA2D2, LRRC43 and TRANK1), 2 years prior to natural regression 
(without treatment) of disease to non-dysplastic status. Conversely, there is 
also evidence of application of these biomarkers for prediction of low to high-
grade dysplasia. A patient with persistent long-segment LGD showed 
elevated methylation in LRRC43 and ZNF699, eight months prior to 
progression to HGD, despite several endoscopic mucosal resection 
treatments. In particular, hypermethylation of the regulatory region 
associated with leucine rich repeat containing 43 (LRRC43) shows evidence 
of utility for prediction of necessity of treatment for LGD; predicting both a 
natural regression of disease without treatment, as well as disease 
progression despite treatment.  
 
Finally, several biomarkers (in particular, TNFAIP8L3 and ZNF699) also 
showed evidence of application for monitoring disease regression with 
treatment. Elevated methylation levels apparent in HGD samples show return 
to unmethylated status (as for matched normal esophagus) in non-dysplastic 
BE, with successful ablation therapy.  
 
In summary, I have demonstrated the potential of selected hypermethylation 
biomarkers for diagnostic application, prediction of disease progression or 
regression (and hence an aid for determining treatment and/or surveillance 
regimes for LGD patients), and application for disease monitoring with 
treatment.  
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CHAPTER 7:   PAN-CANCER MUTATION PROFILING 
7.1  Introduction 
7.1.1  Pan-cancer mutation panel development 
Researchers at The Kinghorn Cancer Centre (TKCC), Sydney, Australia, are 
developing a novel pan-cancer mutation screening panel (not yet publicly 
available), aiming to provide a wider, all-encompassing analysis across 
disparate cancer types. As currently available panels tend to be specific to 
certain major cancers, this panel focuses on inclusion of genes to identify 
rare or poorly studied cancer types as well as screening for mutations in well-
known cancer-associated genes. I would like to acknowledge Professor 
Marcel Dinger and his team at The Kinghorn Cancer Centre for including me 
in the development of this panel. For the collaboration, I provided his team 
with esophageal tissue DNA to aid in panel development; in return, they 
provided me with sequencing results for interrogation of the training cohort 
with regards to cancer-associated gene mutations. I would also like to 
acknowledge Dr Mark McCabe for his help in library preparation and 
processing of raw data. 
7.1.2  Mutational landscape of esophageal adenocarcinoma 
The molecular basis of events involved in BE progression to EAC are still 
debated with a large number of recurrently mutated genes in EAC also 
evident in non-dysplastic, non-progressive BE206. High mutational frequency 
is observed in EAC, but as yet no direct causality has been confirmed207. 
 
The genomic landscape of somatic alteration in esophageal adenocarcinoma 
has been the subject of much investigation over the past years. In an exome 
and whole-genome sequencing study in 2013, Dulak et al identified 26 
significantly mutated genes from analysis of 149 EAC tumor-normal pairs, of 
which 21 were novel (TP53, CDKN2A, SMAD4, ARID1A and PIK3CA have 
been previously implicated in EAC)208. Investigation of somatic mutation, not 
only in EAC tissues, but also dysplastic and non-dysplastic Barrett’s (EAC 
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precursor) mucosa was investigated by Weaver et al in 2014. Their approach 
involved identification of recurrently mutated genes in EAC followed by 
screening benign, metaplastic, never-dysplastic BE, and high-grade 
dysplasia. Interestingly they found that the majority of recurrently mutated 
genes in EAC were also mutated in non-dysplastic BE, with only TP53 and 
SMAD4 mutations confined to HGD and EAC (Figure 7-1)206. This is an 
interesting observation as it supports the hypothesis that EAC is not a 
mutation driven cancer, given that the majority (99.5%) of non-dysplastic BE 
cases will not progress to dysplasia or EAC. 
 
 
 
Figure 7-1: Percentage of never-dysplastic Barrett’s esophagus (NDBE), high 
grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) with 
mutations in recurrently mutated genes (mutated in ≥4 samples) occurring in 
the EAC discovery and validation cohorts. TP53 and SMAD4 are the only 
genes with mutations specific to HGD and EAC only (p<0.05). Figure from 
Weaver et al 2014206. 
 
Despite mounting evidence that many cases of EAC may not be mutation-
driven, there are still a number of genes identified in literature as significantly 
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mutated in EAC that are analyzed as part of the Kinghorn pan-cancer 
mutation screening panel (Figure 7-2). Of particular interest are TP53 and 
SMAD4, specific to only intervention-requiring disease and not occurring in 
non-dysplastic precursor disease mucosa. The eight significantly mutated 
genes in EAC (ARID1A, ARID2, CDKN2A (P16), KAT6A, PIK3CA, SMAD4, 
SMARCA4, TP53) identified in the literature206, 208 and also in the pan-cancer 
panel will be analyzed in training cohort samples (genome-wide methylation 
and expression profiling data exists for these same samples). Further 
mutations may also be identified. 
 
         
Figure 7-2: Overlap of significantly mutated genes in EAC identified by Dulak 
et al (n=26) and Weaver et al (n=15) with the Kinghorn pan-cancer panel for 
rare and poorly understood cancers (n=312). Seven genes were common 
between the two studies (ARID1A, CDKN2A, CNTNAP5, SMAD4, 
SMARCA4, TLR4, TP53), with eight of the Dulak genes in the Kinghorn 
panel (ARID1A, ARID2, CDKN2A, KAT6A, PIK3CA, SMAD4, SMARCA4, 
TP53) and five from the Weaver study in the Kinghorn panel (ARID1A, 
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CDKN2A, SMAD4, SMARCA4, TP53 (common to all)). Venn diagram 
created using BioVenn205 
7.1.3  Somatic mutation calling 
Somatic mutation calling from matched tumor-normal patient samples has 
become a critical part of cancer genomics, not only for characterization, but 
also clinical applications such as determining treatment regimens209. Tumor 
heterogeneity, copy number alteration and sample degradation present a 
challenge for the detection of somatic mutation, combined with base-calling 
error and read alignment problems to be overcome for robust mutation 
calling accuracy210, 211. Strelka, used here for somatic mutation calling, uses 
a joint probability-based statistical approach for simultaneous matched 
tumor-normal dataset analysis. It has been shown to achieve significantly 
higher sensitivity at the lowest SNV fraction, maintaining low false positive 
rates209. 
7.1.4  Molecular basis of CIMP in human neoplasia 
CpG island methylator phenotype (CIMP), or widespread CpG island 
promoter hypermethylation, was initially identified in colorectal cancer, but 
has since been studied in a number of tumor types, including but not limited 
to breast, bladder, gastric, glioblastoma (gliomas), hepatocellular, lung, 
ovarian, pancreatic, prostate, melanoma and duodenal adenocarcinoma212, 
213. 
 
Interestingly, the molecular basis of CIMP in glioma was shown to be 
established by, and highly dependent on, the mutation of a single gene: 
isocitrate dehydrogenase 1 (IDH1)214. The mutation, most commonly (>95% 
in glioma214) an amino acid substitution at arginine 132 (R132), alters specific 
histone marks, induces extensive DNA hypermethylation. Similarly in acute 
myeloid leukemia (AML), a casual relationship was identified between IDH1 
and IDH2 mutations and global DNA hypermethylation (a specific 
hypermethylation signature). Furthermore, Tet methylcytosine dioxygenase 2 
(TET2) loss-of-function mutations were mutually exclusive with IDH1/2 
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mutations, and also associated with similar epigenetic changes215. The 
prevalence of somatic IDH mutation among cancer types is highly variable, 
with rates varying from >70% in glioma, 15-30% in AML, 10% in melanoma 
and <5% or absent in many other solid tumors, such as gastrointestinal 
stromal tumors (GIST), bladder, breast, colorectal, lung, ovarian, pancreas, 
prostate and thyroid carcinoma212, 216-218, despite CIMP being reported in 
these tumors219-226. 
 
The molecular basis of CIMP in colorectal cancer has been suggested to be 
one of two types: either v-raf murine sarcoma viral oncogene homolog B1 
(BRAF) mutation (known as ‘CIMP high’) or v-Ki-ras2 Kirsten rat sarcoma 
viral oncogene homolog (KRAS) mutation (‘CIMP low’)227, 228. This is 
somewhat surprising considering both KRAS and BRAF are members of the 
ras signal transduction pathway and are typically mutually exclusive229. The 
question of whether BRAF mutation is causal for CIMP development or 
whether CIMP provides a favorable environment for BRAF mutation 
acquisition was investigated by Hinoue et al in colorectal cancer cell lines. 
They did not find any evidence of a causal relationship upon examination of 
100 CIMP-associated CpG sites in eight stably transfected clones over 
multiple passages230.  
 
It is evident that CIMP is not a single phenotype consistent across all cancer 
types. In a review in 2013, Hughes et al suggested a cancer-specific CIMP 
nomenclature be adopted, for example G-CIMP for glioma CIMP, etc...212 
Esophageal adenocarcinoma falls under the umbrella of gastrointestinal (GI: 
esophagus, stomach, small and large intestine, liver, gallbladder and 
pancreas) cancers, for which many epigenetic similarities exist231. For 
example, colorectal CIMP has been reported to be prevalent in a subset of 
hepatocellular carcinoma (HCC)232. However, despite their gastrointestinal 
grouping and mucosal structure similarities, there are also many epigenetic 
disparities between these cancers. There is evidence of E-CIMP (esophageal 
adenocarcinoma CIMP) being similar to CIMP as defined in gastric and 
colorectal cancers49, however the molecular basis of CIMP in EAC is yet to 
be elucidated. 
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7.1.5  Chapter 7 aims 
To ascertain cancer-associated mutational load in the development of 
esophageal adenocarcinoma, and use this information to gain a more 
complete understanding of genetic and epigenetic changes occurring in the 
metaplasia-dysplasia-adenocarcinoma sequence. 
7.2  Methods 
7.2.1  Pan-cancer mutation panel target selection 
A novel custom tumor gene panel designed through Roche/NimbleGen by 
the Hormones and Cancer group at the Kinghorn Centre for Clinical 
Genomics at the Garvan Institute of Medical Research was applied to a 
subset of the training cohort. Dr Mark McCabe kindly performed the library 
preparation as well as processing of the raw sequencing data.   
 
The panel uses capture sequencing to probe a set of >300 pan-cancer genes 
in their entirety (refer to Appendix 8: Pan-cancer targets for mutational 
profiling for a full list of genes examined by the panel); the selected targets 
based on general cancer-associated genes from multiple commercially 
available panels (Illumina’s TruSeq Tumor Panel and TruSeq Amplicon 
Cancer Panel, Oxford Gene Technology’s SureSeq Solid Tumor Panel, 
Foundation Medicine’s FoundationOne panel, Agena Bioscience’s 
OncoCarta volumes 1, 2 and 3 and Aglient’s Haloplex panel). The panel is 
still under development and aims to address carcinogenic changes in rare 
and poorly understood cancers; using blood and tissue derived tumor DNA 
from pituitary, head and neck (salivary gland and skull base), breast 
(phyllodes), pancreas, lung and esophageal adenocarcinoma for 
development. 
7.2.2  Library preparation and sequencing 
100ng of DNA extracted from esophageal tissue (biopsies as for HM450 and 
HTA2.0 profiling) was subject to library preparation using a combination of 
the NEBNext Ultra kit (applicable to Illumina sequencing platforms) and 
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Roche’s SeqCap Library SR Kit according to manufacturer’s instructions. 
Capture sequencing of 24 samples was performed on a single lane on an 
Illumina HiSeq 2500.  
7.2.3  Mutation-screening statistical analyses  
Raw fastq files were uploaded to cloud-based genomic analysis platform 
DNAnexus (www.dnanexus.com). Sequences were genome-aligned to the 
hs37d5 reference genome using Burrows-Wheeler Aligner (BWA-MEM, 
v0.7.10), and then sorted with PCR duplicates marked using novosort 
(v1.03.01)233. Base quality (BQ) scores were generated for each base 
sequenced and used to predict the probability that the called base was the 
true base. Mapping quality (MQ) scores were assigned to each read; when 
MQ=0 (reads mapped to multiple locations within the genome), they were 
discarded. QUAL scores were assigned for each variant as a measure of its 
likelihood of being present in the cohort and finally a Genotype quality (GQ) 
score was obtained; measuring of the probability that the genotype called at 
the given allele in the patient was correct. QUAL and GQ scores incorporate 
BQ and MQ for each base and read that contains the given allele as well as 
the depth of coverage234. Aligned reads were processed according to the 
Genome Analysis Toolkit (GATK v3.3 (best practices guide)). Reads were 
realigned around indels and BQ scores recalibrated to improve the quality of 
alignments235. Single nucleotide variants and small insertions/deletions were 
identified using HaplotypeCaller v3.3 or Strekla (for somatic variant 
detection) and then annotated using Ensembl Variant Effect Predictor (VEP, 
v74)236. Annotation provides (i) chromosomal location of the variant, (ii) type 
of variant, (iii) predicted variant effect (benign or deleterious), (iv) occurrence 
in healthy individuals and (v) conservation of wild type alleles across multiple 
species. Pairwise analysis of each disease-normal pair was performed to 
identify disease-specific mutation. As for previous methylation and 
expression profiling studies, normal samples are esophageal tissue from 
patients with esophageal disease, with the sample taken proximally (at 
approximately 25cm). Analysis of all normal samples was performed to 
establish germline mutational load.  
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Data were filtered for high and medium impact variants. High impact variants 
include non-sense mutations (introduction of a stop codon), loss of a stop 
codon, splice acceptor or donor variant and any frame-shift variant. Most (if 
not all) missense mutation (non-synonymous change) will be classified as 
medium impact, regardless of subsequent amino acid change. Small in-
frame insertions or deletions are classified as medium impact. The remainder 
are low impact, including intronic variants, UTR variants and silent mutations 
(synonymous variants; DNA change but no impact on protein sequence).  
7.3  Results 
7.3.1  Pan-cancer panel profiling 
Sequencing was of consistently high coverage, with >90% of targeted 
regions at >100x, with average depth of coverage ~700x. Analysis of over 
4372 exons in 313 cancer-associated genes enabled detection of germline 
and somatic mutations in esophageal tissue as disease develops and 
progresses. 
7.3.1.1  Mutational load 
Normal samples (n=15) were analyzed to establish germline mutational load. 
Somatic pan-cancer mutation load was calculated for each of 9 disease-
normal pairs throughout the metaplasia-dysplasia-adenocarcinoma sequence 
(BE (n=2), BE-LGD mixed (n=3), LGD (n=2), EAC-HGD (n=2)). Results were 
separated into mutations classified as either high or medium impact (by 
Variant Effect Predictor (VEP)). Mutational load varied, but in general an 
increase in mutational load was detected as disease progressed (Figure 7-3). 
It is interesting to note the detection of cancer-associated mutation in 
Barrett’s mucosa, a non-dysplastic, benign epithelium. The detection of 
mutations with a cancer association at this early pre-cancerous stage 
indicates that genetic aberration is occurring early in EAC carcinogenesis. 
 
An interesting anomaly is the distinct lack of cancer associated somatic 
mutation in one of the EAC samples (labeled HGD-EAC in Figure 7-3 below). 
In comparison to a biopsy containing just a 5% focus of destroyed glands 
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suspected to be adenocarcinoma (refer to Section 4.3.3  Tissue 
heterogeneity), mutational load for this sample is significantly reduced (4.74 
fold decrease in high and medium impact mutations). The sample was taken 
from a 70 year old male with invasive adenocarcinoma, one month before 
undergoing esophagectomy with the biopsy evaluated to be >80% EAC and 
noted as developed tumor by at least one pathologist. This anomaly 
highlights the complexities of EAC and the heterogeneous biological 
signatures within the disease. Detection of such high mutational load in a 
biopsy with only a 5% focus of adenocarcinoma reflects well on method 
sensitivity. We could also hypothesize that there may be some field effect 
where normal tissue surrounding neoplastic tissue becomes similarly 
mutated and thus is at risk of neoplastic transformation.   
 
(A)   
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(B) 
 
 
Figure 7-3: Somatic pan-cancer mutation load (high and medium impact 
mutations) detected in esophageal mucosa during progression through the 
metaplasia-dysplasia-adenocarcinoma sequence. (A) Mutation count in 
diseased samples (B) Expressed as a percentage of all mutations detected 
in esophageal tissue. Percentages are of 897 total SNPs/indels (100 high 
impact, 797 medium impact mutations). Somatic variants called by Strelka, 
variants annotated by Variant Effect Predictor (VEP), filtering performed 
using Gemini.  
7.3.1.2  Disease-normal pairwise analyses 
Pairwise-analysis of somatic mutation in 9 disease-normal pairs (BE (n=2), 
BE-LGD mixed (n=3), LGD (n=2), EAC-HGD (n=2)), classified as either high 
or medium impact (by VEP) uncovered 897 SNPs/indels (classifying 100 as 
high, 797 as medium impact mutations). Somatic variants called by Strelka, 
variants annotated by Variant Effect Predictor (VEP), filtering performed 
using Gemini.  
 
Combined Annotation Dependent Depletion (CADD) is a tool for scoring the 
deleteriousness of SNVs and indels in the human genome, quantitatively 
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prioritizing functional, deleterious and disease causal variants.237. Applying 
minimum scaled CADD scoring of 20 (resulting in the top 1% most 
deleterious mutations) reduces this to identification of a total of 636 
SNPs/indels (97 high and 539 medium impact mutations). Applying CADD 30 
(resulting in the top 0.1% most deleterious mutations) further reduces this to 
identification of a total of 192 SNPs/indels (66 high and 126 medium impact 
mutations), given in Table 7-1.  
 
Table 7-1: Top 0.1% most deleterious pan-cancer somatic mutation from 
pairwise disease-normal analysis of samples at all stages of esophageal 
adenocarcinoma development. Returning SNPs and indels classified as 
either high or medium impact by VEP. Minimum scaled CADD score 30. 
Ordered by impact severity then variant location. 
Variant	 Type	 Gene	 Impact	 Impact	Severity	
chr1:g.16255388G>T	 SNP	 SPEN	 stop_gained	 HIGH	
chr1:g.17349186C>A	 SNP	 SDHB	 stop_gained	 HIGH	
chr1:g.27057682C>T	 SNP	 ARID1A	 stop_gained	 HIGH	
chr1:g.27106373AGGCAATGACTT
TGAGATGTCCAAACACCCAG>A	 Deletion	 ARID1A	 frameshift_variant	 HIGH	
chr1:g.27106861C>T	 SNP	 ARID1A	 stop_gained	 HIGH	
chr1:g.206649604G>T	 SNP	 IKBKE	 stop_gained	 HIGH	
chr11:g.113075226C>T	 SNP	 NCAM1	 stop_gained	 HIGH	
chr12:g.46287298C>A	 SNP	 ARID2	 stop_gained	 HIGH	
chr16:g.3779388G>C	 SNP	 CREBBP	 stop_gained	 HIGH	
chr16:g.3789709C>A	 SNP	 CREBBP	 stop_gained	 HIGH	
chr16:g.3828718C>A	 SNP	 CREBBP	 stop_gained	 HIGH	
chr16:g.23641437C>A	 SNP	 PALB2	 stop_gained	 HIGH	
chr16:g.68772290G>T	 SNP	 CDH1	 stop_gained	 HIGH	
chr16:g.89880936G>C	 SNP	 FANCA	 stop_gained	 HIGH	
chr17:g.7578263G>A	 SNP	 TP53	 stop_gained	 HIGH	
chr17:g.37868607G>T	 SNP	 ERBB2	 stop_gained	 HIGH	
chr17:g.41245042C>A	 SNP	 BRCA1	 stop_gained	 HIGH	
chr17:g.49244258G>T	 SNP	 NME1-NME2	 stop_gained	 HIGH	
chr17:g.59878695G>T	 SNP	 BRIP1	 stop_gained	 HIGH	
chr19:g.10597459C>A	 SNP	 KEAP1	 stop_gained	 HIGH	
chr19:g.10599868C>A	 SNP	 KEAP1	 stop_gained	 HIGH	
chr19:g.11105636G>T	 SNP	 SMARCA4	 stop_gained	 HIGH	
chr19:g.17954641T>TC	 Insertion	 JAK3	 frameshift_variant	 HIGH	
chr2:g.141243069T>TGG	 Insertion	 LRP1B	 frameshift_variant	 HIGH	
chr2:g.191905853C>A	 SNP	 STAT4	 stop_gained	 HIGH	
chr2:g.234676519C>T	 SNP	 UGT1A10	 stop_gained	 HIGH	
chr20:g.54956548C>A	 SNP	 AURKA	 stop_gained	 HIGH	
chr22:g.41536182T>A	 SNP	 EP300	 stop_gained	 HIGH	
chr22:g.41548270A>T	 SNP	 EP300	 stop_gained	 HIGH	
chr3:g.36779163C>A	 SNP	 DCLK3	 stop_gained	 HIGH	
chr3:g.37042446A>T	 SNP	 MLH1	 stop_gained	 HIGH	
chr3:g.52643906C>A	 SNP	 PBRM1	 stop_gained	 HIGH	
chr3:g.138665322G>T	 SNP	 FOXL2	 stop_gained	 HIGH	
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Variant	 Type	 Gene	 Impact	 Impact	Severity	
chr3:g.142280158C>A	 SNP	 ATR	 stop_gained	 HIGH	
chr4:g.1806083G>T	 SNP	 FGFR3	 stop_gained	 HIGH	
chr4:g.66286164C>A	 SNP	 EPHA5	 stop_gained	 HIGH	
chr4:g.104072462C>A	 SNP	 CENPE	 stop_gained	 HIGH	
chr4:g.104081828G>T	 SNP	 CENPE	 stop_gained	 HIGH	
chr4:g.106156095C>A	 SNP	 TET2	 stop_gained	 HIGH	
chr4:g.153271230A>T	 SNP	 FBXW7	 stop_gained	 HIGH	
chr5:g.41929932G>T	 SNP	 FBXO4	 stop_gained	 HIGH	
chr5:g.56178614C>G	 SNP	 MAP3K1	 stop_gained	 HIGH	
chr5:g.64766668G>T	 SNP	 ADAMTS6	 stop_gained	 HIGH	
chr5:g.98236518C>A	 SNP	 CHD1	 stop_gained	 HIGH	
chr5:g.112128218G>T	 SNP	 APC	 stop_gained	 HIGH	
chr5:g.112175525G>T	 SNP	 APC	 stop_gained	 HIGH	
chr5:g.131939047C>T	 SNP	 RAD50	 stop_gained	 HIGH	
chr5:g.149440518C>A	 SNP	 CSF1R	 stop_gained	 HIGH	
chr5:g.180058728C>A	 SNP	 FLT4	 stop_gained	 HIGH	
chr6:g.393348G>T	 SNP	 IRF4	 stop_gained	 HIGH	
chr7:g.55229238C>A	 SNP	 EGFR	 stop_gained	 HIGH	
chr7:g.81335691C>A	 SNP	 HGF	 stop_gained	 HIGH	
chr7:g.140453092C>A	 SNP	 BRAF	 stop_gained	 HIGH	
chr7:g.151835883C>A	 SNP	 KMT2C	 stop_gained	 HIGH	
chr7:g.151845205C>A	 SNP	 KMT2C	 stop_gained	 HIGH	
chr7:g.151874215C>A	 SNP	 KMT2C	 stop_gained	 HIGH	
chr8:g.37698908C>T	 SNP	 GPR124	 stop_gained	 HIGH	
chr9:g.37015184C>A	 SNP	 PAX5	 stop_gained	 HIGH	
chr9:g.98268881C>A	 SNP	 PTCH1	 initiator_codon_variant	 HIGH	
chr9:g.135771912C>A	 SNP	 TSC1	 stop_gained	 HIGH	
chr9:g.139393640GC>G	 Deletion	 NOTCH1	 frameshift_variant	 HIGH	
chr9:g.139413062C>CT	 Insertion	 NOTCH1	 frameshift_variant	 HIGH	
chrX:g.53253957C>A	 SNP	 KDM5C	 stop_gained	 HIGH	
chrX:g.63410150G>T	 SNP	 AMER1	 stop_gained	 HIGH	
chrX:g.76889095C>A	 SNP	 ATRX	 stop_gained	 HIGH	
chrX:g.123200089G>T	 SNP	 STAG2	 stop_gained	 HIGH	
chr1:g.11167547A>T	 SNP	 MTOR	 missense_variant	 MED	
chr1:g.11187790C>A	 SNP	 MTOR	 missense_variant	 MED	
chr1:g.38005813C>A	 SNP	 SNIP1	 missense_variant	 MED	
chr1:g.65313346C>A	 SNP	 JAK1	 missense_variant	 MED	
chr1:g.120464359C>A	 SNP	 NOTCH2	 missense_variant	 MED	
chr1:g.150549919T>A	 SNP	 MCL1	 missense_variant	 MED	
chr1:g.186645981C>A	 SNP	 PTGS2	 missense_variant	 MED	
chr1:g.228111919C>A	 SNP	 WNT9A	 missense_variant	 MED	
chr1:g.243716220C>A	 SNP	 AKT3	 missense_variant	 MED	
chr1:g.243828074C>A	 SNP	 AKT3	 missense_variant	 MED	
chr10:g.123263433G>T	 SNP	 FGFR2	 missense_variant	 MED	
chr11:g.31823123C>A	 SNP	 PAX6	 missense_variant	 MED	
chr11:g.32439161C>T	 SNP	 WT1	 missense_variant	 MED	
chr11:g.76158044G>C	 SNP	 C11orf30	 missense_variant	 MED	
chr11:g.76175054C>A	 SNP	 C11orf30	 missense_variant	 MED	
chr11:g.94180495G>T	 SNP	 MRE11A	 missense_variant	 MED	
chr11:g.94212841C>A	 SNP	 MRE11A	 missense_variant	 MED	
chr11:g.108190782C>A	 SNP	 ATM	 missense_variant	 MED	
chr11:g.118342932G>T	 SNP	 KMT2A	 missense_variant	 MED	
chr11:g.118360543C>A	 SNP	 KMT2A	 missense_variant	 MED	
chr11:g.118361991C>A	 SNP	 KMT2A	 missense_variant	 MED	
chr11:g.118392014A>T	 SNP	 KMT2A	 missense_variant	 MED	
chr11:g.125496668C>A	 SNP	 CHEK1	 missense_variant	 MED	
chr12:g.441056G>A	 SNP	 KDM5A	 missense_variant	 MED	
chr14:g.38061763C>A	 SNP	 FOXA1	 missense_variant	 MED	
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chr14:g.62194244C>A	 SNP	 HIF1A	 missense_variant	 MED	
chr14:g.62199176G>T	 SNP	 HIF1A	 missense_variant	 MED	
chr14:g.62204846T>A	 SNP	 HIF1A	 missense_variant	 MED	
chr14:g.105239678C>A	 SNP	 AKT1	 missense_variant	 MED	
chr15:g.40993283G>A	 SNP	 RAD51	 missense_variant	 MED	
chr15:g.88680635C>A	 SNP	 NTRK3	 missense_variant	 MED	
chr15:g.90630708C>A	 SNP	 IDH2	 missense_variant	 MED	
chr16:g.3827632G>A	 SNP	 CREBBP	 missense_variant	 MED	
chr16:g.9916227C>G	 SNP	 GRIN2A	 missense_variant	 MED	
chr16:g.9934874C>A	 SNP	 GRIN2A	 missense_variant	 MED	
chr16:g.23625399C>G	 SNP	 PALB2	 missense_variant	 MED	
chr16:g.67645870C>A	 SNP	 CTCF	 missense_variant	 MED	
chr16:g.67660599G>T	 SNP	 CTCF	 missense_variant	 MED	
chr16:g.67663314G>T	 SNP	 CTCF	 missense_variant	 MED	
chr17:g.7577105G>A	 SNP	 TP53	 missense_variant	 MED	
chr17:g.7577121G>A	 SNP	 TP53	 missense_variant	 MED	
chr17:g.7578526C>A	 SNP	 TP53	 missense_variant	 MED	
chr17:g.8108544C>A	 SNP	 AURKB	 missense_variant	 MED	
chr17:g.29683562C>A	 SNP	 NF1	 missense_variant	 MED	
chr17:g.37618417AGCAGAG>A	 Deletion	 CDK12	 inframe_deletion	 MED	
chr17:g.37872610G>T	 SNP	 ERBB2	 missense_variant	 MED	
chr17:g.37880201C>A	 SNP	 ERBB2	 missense_variant	 MED	
chr17:g.38548597TA>T	 Deletion	 TOP2A	 splice_region_variant	 MED	
chr17:g.49244270C>T	 SNP	 NME1-NME2	 missense_variant	 MED	
chr17:g.59857626G>A	 SNP	 BRIP1	 missense_variant	 MED	
chr17:g.63010814C>A	 SNP	 GNA13	 missense_variant	 MED	
chr17:g.63052690G>A	 SNP	 GNA13	 missense_variant	 MED	
chr18:g.45374860G>T	 SNP	 SMAD2	 missense_variant	 MED	
chr18:g.48591925G>T	 SNP	 SMAD4	 missense_variant	 MED	
chr19:g.11101922C>T	 SNP	 SMARCA4	 missense_variant	 MED	
chr19:g.11170507G>T	 SNP	 SMARCA4	 missense_variant	 MED	
chr19:g.17942116C>A	 SNP	 JAK3	 missense_variant	 MED	
chr19:g.17942163G>T	 SNP	 JAK3	 missense_variant	 MED	
chr19:g.30311640C>A	 SNP	 CCNE1	 missense_variant	 MED	
chr2:g.29445210C>A	 SNP	 ALK	 missense_variant	 MED	
chr2:g.29456471C>A	 SNP	 ALK	 missense_variant	 MED	
chr2:g.39240649C>A	 SNP	 SOS1	 missense_variant	 MED	
chr2:g.39283916C>A	 SNP	 SOS1	 missense_variant	 MED	
chr2:g.58387256G>T	 SNP	 FANCL	 missense_variant	 MED	
chr2:g.61717804C>A	 SNP	 XPO1	 missense_variant	 MED	
chr2:g.121729577C>T	 SNP	 GLI2	 missense_variant	 MED	
chr2:g.140990850C>A	 SNP	 LRP1B	 missense_variant	 MED	
chr2:g.141291595C>A	 SNP	 LRP1B	 missense_variant	 MED	
chr2:g.141751626C>A	 SNP	 LRP1B	 missense_variant	 MED	
chr2:g.170059434C>A	 SNP	 LRP2	 missense_variant	 MED	
chr2:g.170092360G>T	 SNP	 LRP2	 missense_variant	 MED	
chr2:g.170099933C>A	 SNP	 LRP2	 missense_variant	 MED	
chr2:g.170150660C>A	 SNP	 LRP2	 missense_variant	 MED	
chr2:g.191940984C>A	 SNP	 STAT4	 missense_variant	 MED	
chr2:g.198257857C>A	 SNP	 SF3B1	 missense_variant	 MED	
chr2:g.212543853C>A	 SNP	 ERBB4	 missense_variant	 MED	
chr2:g.212812239C>A	 SNP	 ERBB4	 missense_variant	 MED	
chr20:g.36026228G>T	 SNP	 SRC	 missense_variant	 MED	
chr20:g.36031164C>A	 SNP	 SRC	 missense_variant	 MED	
chr20:g.36031585C>T	 SNP	 SRC	 missense_variant	 MED	
chr20:g.39744957G>T	 SNP	 TOP1	 missense_variant	 MED	
chr20:g.62331856C>A	 SNP	 ARFRP1	 missense_variant	 MED	
chr22:g.30035192C>A	 SNP	 NF2	 missense_variant	 MED	
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chr22:g.42522724G>T	 SNP	 CYP2D6	 missense_variant	 MED	
chr3:g.10084295C>A	 SNP	 FANCD2	 missense_variant	 MED	
chr3:g.12633289C>A	 SNP	 RAF1	 missense_variant	 MED	
chr3:g.37089065G>T	 SNP	 MLH1	 missense_variant	 MED	
chr3:g.47098879C>T	 SNP	 SETD2	 missense_variant	 MED	
chr3:g.87313662C>A	 SNP	 POU1F1	 missense_variant	 MED	
chr3:g.89468478C>A	 SNP	 EPHA3	 missense_variant	 MED	
chr3:g.119631596C>T	 SNP	 GSK3B	 missense_variant	 MED	
chr3:g.134911541C>T	 SNP	 EPHB1	 missense_variant	 MED	
chr3:g.134920478C>A	 SNP	 EPHB1	 missense_variant	 MED	
chr3:g.142184067A>G	 SNP	 ATR	 missense_variant	 MED	
chr3:g.142218513C>A	 SNP	 ATR	 missense_variant	 MED	
chr4:g.55962447C>G	 SNP	 KDR	 missense_variant	 MED	
chr4:g.153245393C>A	 SNP	 FBXW7	 missense_variant	 MED	
chr5:g.38966777C>A	 SNP	 RICTOR	 missense_variant	 MED	
chr5:g.98233011C>A	 SNP	 CHD1	 missense_variant	 MED	
chr5:g.138223183G>T	 SNP	 CTNNA1	 missense_variant	 MED	
chr6:g.106543578C>A	 SNP	 PRDM1	 missense_variant	 MED	
chr6:g.152382133G>A	 SNP	 ESR1	 missense_variant	 MED	
chr6:g.152382257C>A	 SNP	 ESR1	 missense_variant	 MED	
chr7:g.2977548C>A	 SNP	 CARD11	 missense_variant	 MED	
chr7:g.2985588G>A	 SNP	 CARD11	 missense_variant	 MED	
chr7:g.92354975G>A	 SNP	 CDK6	 missense_variant	 MED	
chr7:g.116418839A>T	 SNP	 MET	 missense_variant	 MED	
chr7:g.148516764G>T	 SNP	 EZH2	 missense_variant	 MED	
chr7:g.151836816C>A	 SNP	 KMT2C	 missense_variant	 MED	
chr7:g.151842295G>T	 SNP	 KMT2C	 missense_variant	 MED	
chr7:g.151864233G>T	 SNP	 KMT2C	 missense_variant	 MED	
chr8:g.37690545C>T	 SNP	 GPR124	 missense_variant	 MED	
chr8:g.48811106C>G	 SNP	 PRKDC	 missense_variant	 MED	
chr8:g.61777584C>A	 SNP	 CHD7	 missense_variant	 MED	
chr9:g.5081832C>A	 SNP	 JAK2	 missense_variant	 MED	
chr9:g.5089710C>A	 SNP	 JAK2	 missense_variant	 MED	
chr9:g.87636192G>A	 SNP	 NTRK2	 missense_variant	 MED	
chr9:g.98224263C>A	 SNP	 PTCH1	 missense_variant	 MED	
chr9:g.135797319C>A	 SNP	 TSC1	 missense_variant	 MED	
chrX:g.39916480C>A	 SNP	 BCOR	 missense_variant	 MED	
chrX:g.44918322C>A	 SNP	 KDM6A	 missense_variant	 MED	
chrX:g.47430356G>T	 SNP	 ARAF	 missense_variant	 MED	
chrX:g.63412094C>A	 SNP	 AMER1	 missense_variant	 MED	
chrX:g.76872147C>A	 SNP	 ATRX	 missense_variant	 MED	
chrX:g.100609675C>A	 SNP	 BTK	 missense_variant	 MED	
chrX:g.110385421C>A	 SNP	 PAK3	 missense_variant	 MED	
 
OMIM® (Online Mendelian Inheritance in Man) was used for annotation of 
somatic mutation with human genetic disorders (http://omim.org/ Online 
Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of 
Genetic Medicine, John Hopkins University, Baltimore, MD, USA). Table 7-2 
gives the subset of top 0.1% most deleterious somatic mutations (applying 
CADD scoring of 30) with cancer-associated OMIM disorders (including 
cancer susceptibility). A total of 53 SNPs (20 high and 33 medium impact 
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mutations) meet this criteria. No mutations with esophageal adenocarcinoma 
OMIM disorder were detected in our samples, however it is important to note 
that esophageal mutations had not been specifically targeted during pan 
cancer panel design at this stage and our collaboration was intended to 
investigate utility of this panel across a variety of rare and poorly understood 
cancer types. 
 
Table 7-2: Cancer-associated OMIM disorders from the subset of the top 
0.1% most deleterious pan-cancer somatic mutation from pairwise disease-
normal analysis of samples at all stages of esophageal adenocarcinoma 
development. Includes only somatic mutation with human cancer or cancer 
susceptibility OMIM annotation. Returning SNPs and indels classified as 
either high or medium impact by VEP. Minimum scaled CADD score 20. 
Mutations with gastrointestinal cancer (or susceptibility to) OMIM annotation 
in grey. 
 
Gene	 OMIM	Title	 OMIM	Disorders	
SPEN	 SPEN,	Drosophila,	homolog	of;	One-twenty	two	protein		 613484:None;606077:Megakaryoblastic	leukemia,	acute	(2)	
SDHB	
Succinate	dehydrogenase	
complex,	subunit	B,	iron	
sulfur	(Ip)	
185470:Paragangliomas	4,	115310	(3);Pheochromocytoma,	171300	
(3);Paraganglioma	and	gastric	stromal	sarcoma,	606864	(3);Cowden	
syndrome	2,	612359	(3);Gastrointestinal	stromal	tumor,	606764	(3)	
PALB2	 Partner	and	localizer	of	BRCA2	
610355:Fanconi	anemia,	complementation	group	N,	610832	
(3);{Breast	cancer,	susceptibility	to},	114480	(3);{Pancreatic	cancer,	
susceptibility	to,	3},	613348	(3)	
CDH1	 Cadherin-1	(E-cadherin;	uvomorulin)	
192090:Endometrial	carcinoma,	somatic,	608089	(3);Ovarian	
carcinoma,	somatic,	167000	(3);{Breast	cancer,	lobular},	114480	
(3);Gastric	cancer,	familial	diffuse,	with	or	without	cleft	lip	and/or	
palate,	137215	(3);{Prostate	cancer,	susceptibility	to},	176807	(3)	
TP53	 Tumor	protein	p53	
191170:Colorectal	cancer,	114500	(3);Li-Fraumeni	syndrome,	151623	
(3);Hepatocellular	carcinoma,	114550	(3);Osteosarcoma,	259500	
(3);Choroid	plexus	papilloma,	260500	(3);Nasopharyngeal	carcinoma,	
607107	(3);Pancreatic	cancer,	260350	(3);Adrenal	cortical	carcinoma,	
202300	(3);Breast	cancer,	114480	(3);{Basal	cell	carcinoma	7},	614740	
(3);{Glioma	susceptibility	1},	137800	(3)	
ERBB2	
Avian	erythroblastic	
leukemia	viral	(v-erb-b2)	
oncogene	homolog	2	
164870:Adenocarcinoma	of	lung,	somatic,	211980	(3);Glioblastoma,	
somatic,	137800	(3);Gastric	cancer,	somatic,	613659	(3);Ovarian	
cancer,	somatic,	(3)	
BRCA1	 Breast	cancer-1	gene	 113705:{Breast-ovarian	cancer,	familial,	1},	604370	(3);{Pancreatic	cancer,	susceptibility	to,	4},	614320	(3)	
BRIP1	 BRCA1-associated	C-terminal	helicase	1	
605882:Breast	cancer,	early-onset,	114480	(3);Fanconi	anemia,	
complementation	group	J,	609054	(3)	
SMARCA4	
SWI/SNF-related,	matrix-
associated,	actin-dependent	
regulator	of	
603254:{Rhabdoid	tumor	predisposition	syndrome	2},	613325	
(3);Mental	retardation,	autosomal	dominant	16,	614609	(3)	
AURKA	 Aurora	kinase	A	 603072:{Colon	cancer,	susceptibility	to},	114500	(3)	
EP300	 E1A-binding	protein,	300kD	 602700:Rubinstein-Taybi	syndrome	2,	613684	(3);Colorectal	cancer,	somatic,	114500	(3)	
MLH1	 mutL,	E.	coli,	homolog	of,	1	 120436:Colorectal	cancer,	hereditary	nonpolyposis,	type	2,	609310	(3);Mismatch	repair	cancer	syndrome,	276300	(3);Muir-Torre	
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syndrome,	158320	(3)	
FGFR3	 Fibroblast	growth	factor	receptor-3	
134934:Achondroplasia,	100800	(3);Hypochondroplasia,	146000	
(3);Thanatophoric	dysplasia,	type	I,	187600	(3);Crouzon	syndrome	with	
acanthosis	nigricans,	612247	(3);Muenke	syndrome,	602849	
(3);Bladder	cancer,	somatic,	109800	(3);Colorectal	cancer,	somatic,	
114500	(3);Cervical	cancer,	somatic,	603956	(3);LADD	syndrome,	
149730	(3);CATSHL	syndrome,	610474	(3);Nevus,	epidermal,	somatic,	
162900	(3);Thanatophoric	dysplasia,	type	II,	187601	(3);Spermatocytic	
seminoma,	somatic,	273300	(3)	
APC	 Adenomatous	polyposis	coli	
611731:Adenomatous	polyposis	coli,	175100	(3);Gastric	cancer,	
somatic,	613659	(3);Adenoma,	periampullary,	somatic	
(3);Hepatoblastoma,	somatic,	114550	(3);Desmoid	disease,	hereditary,	
135290	(3);Colorectal	cancer,	somatic,	114500	(3);Brain	tumor-
polyposis	syndrome	2,	175100	(3);Gardner	syndrome,	175100	(3)	
EGFR	 Epidermal	growth	factor	receptor	
131550:Nonsmall	cell	lung	cancer,	response	to	tyrosine	kinase	
inhibitor	in,	211980	(3);Adenocarcinoma	of	lung,	response	to	tyrosine	
kinase	inhibitor	in,	211980	(3);{Nonsmall	cell	lung	cancer,	susceptibility	
to},	211980	(3);?Inflammatory	skin	and	bowel	disease,	neonatal,	2,	
616069	(3)	
BRAF	 Murine	sarcoma	viral	(v-raf)	oncogene	homolog	B1	
164757:Melanoma,	malignant,	somatic	(3);Colorectal	cancer,	somatic	
(3);Adenocarcinoma	of	lung,	somatic,	211980	(3);Nonsmall	cell	lung	
cancer,	somatic	(3);Cardiofaciocutaneous	syndrome,	115150	
(3);Noonan	syndrome	7,	613706	(3);LEOPARD	syndrome	3,	613707	(3)	
PAX5	
Paired	box	homeotic	gene-5	
(B-cell	lineage	specific	
activator	
167414:{Leukemia,	acute	lymphoblastic,	susceptibility	to,	3},	615545	
(3)	
PTCH1	 Patched,	Drosophila,	homolog	of	
601309:Basal	cell	nevus	syndrome,	109400	(3);Basal	cell	carcinoma,	
somatic,	605462	(3);Holoprosencephaly-7,	610828	(3)	
FGFR2	
Fibroblast	growth	factor	
receptor-2	(bacteria-
expressed	kinase)	
176943:Crouzon	syndrome,	123500	(3);Jackson-Weiss	syndrome,	
123150	(3);Beare-Stevenson	cutis	gyrata	syndrome,	123790	(3);Pfeiffer	
syndrome,	101600	(3);Apert	syndrome,	101200	(3);Saethre-Chotzen	
syndrome,	101400	(3);Craniosynostosis,	nonspecific	(3);Gastric	cancer,	
somatic,	613659	(3);Craniofacial-skeletal-dermatologic	dysplasia,	
101600	(3);Antley-Bixler	syndrome	without	genital	anomalies	or	
disordered	steroidogenesis,	207410	(3);Scaphocephaly	and	Axenfeld-
Rieger	anomaly	(3);LADD	syndrome,	149730	(3);Scaphocephaly,	
maxillary	retrusion,	and	mental	retardation,	609579	(3);Bent	bone	
dysplasia	syndrome,	614592	(3)	
WT1	 Wilms	tumor-1	
607102:Wilms	tumor,	type	1,	194070	(3);Denys-Drash	syndrome,	
194080	(3);Nephrotic	syndrome,	type	4,	256370	(3);Frasier	syndrome,	
136680	(3);Meacham	syndrome,	608978	(3);Mesothelioma,	somatic,	
156240	(3)	
ATM	
Ataxia-telangiectasia	
mutated	(includes	
complementation	groups	A,	
C,	
607585:Ataxia-telangiectasia,	208900	(3);Lymphoma,	B-cell	non-
Hodgkin,	somatic	(3);{Breast	cancer,	susceptibility	to},	114480	
(3);Lymphoma,	mantle	cell	(3);T-cell	prolymphocytic	leukemia,	somatic	
(3)	
KMT2A	 Lysine	(K)-specific	methyltransferase	2E	
159555:Wiedemann-Steiner	syndrome,	605130	(3);Leukemia,	
myeloid/lymphoid	or	mixed-lineage	(2)	
AKT1	 Murine	thymoma	viral	(v-akt)	oncogene	homolog-1	
164730:Breast	cancer,	somatic,	114480	(3);Colorectal	cancer,	somatic,	
114500	(3);Ovarian	cancer,	somatic,	167000	(3);{Schizophrenia,	
susceptibility	to},	181500	(2);Proteus	syndrome,	somatic,	176920	
(3);Cowden	syndrome	6,	615109	(3)	
NF1	 Neurofibromin	(neurofibromatosis,	type	I)	
613113:Neurofibromatosis,	type	1,	162200	(3);Leukemia,	juvenile	
myelomonocytic,	607785	(3);Neurofibromatosis,	familial	spinal,	
162210	(3);Neurofibromatosis-Noonan	syndrome,	601321	(3);Watson	
syndrome,	193520	(3)	
SMAD4	
Mothers	against	
decapentaplegic,	
Drosophila,	homolog	of,	4	
600993:Pancreatic	cancer,	somatic,	260350	(3);Juvenile	
polyposis/hereditary	hemorrhagic	telangiectasia	syndrome,	175050	
(3);Myhre	syndrome,	139210	(3);Polyposis,	juvenile	intestinal,	174900	
(3)	
ALK	 Anaplastic	lymphoma	kinase	(Ki-1)	 105590:{Neuroblastoma,	susceptibility	to,	3},	613014	(3)	
SRC	 Protooncogene	SRC,	Rous	sarcoma	 190090:Colon	cancer,	advanced,	somatic	(3)	
Chapter 7:  Pan-Cancer Mutation Profiling 
 239 
Gene	 OMIM	Title	 OMIM	Disorders	
ATR	
Anthrax	toxin	receptor	
1;Ataxia-telangiectasia	and	
Rad3-related	(FRAP-related	
protein-1);Serpin	peptidase	
inhibitor,	clade	A,	member	
2,	pseudogene	
606410:{Hemangioma,	capillary	infantile,	susceptibility	to},	602089	
(3);GAPO	syndrome,	230740	(3);601215:Seckel	syndrome	1,	210600	
(3);Cutaneous	telangiectasia	and	cancer	syndrome,	familial,	614564	
(3);107410:None	
ESR1	 Estrogen	receptor	1	
133430:Estrogen	resistance,	615363	(3);{HDL	response	to	hormone	
replacement,	augmented}	(3);{Migraine,	susceptibility	to},	157300	
(3);{Atherosclerosis,	susceptibility	to}	(3);{Myocardial	infarction,	
susceptibility	to},	608446	(3);{Breast	cancer},	114480	(1)	
MET	
Oncogene	MET;RNA	
guanine-7-
methyltransferase	
164860:Renal	cell	carcinoma,	papillary,	1,	familial	and	somatic,	605074	
(3);Hepatocellular	carcinoma,	childhood	type,	114550	
(3);603514:None	
JAK2	 Janus	kinase	2	(a	protein-tyrosine	kinase)	
147796:Polycythemia	vera,	263300	(3);Thrombocythemia	3,	614521	
(3);Myelofibrosis,	somatic,	254450	(3);{Budd-Chiari	syndrome},	600880	
(3);Leukemia,	acute	myelogenous,	601626	(3);Erythrocytosis,	somatic,	
133100	(3)	
 
7.3.1.3  Known EAC somatic alterations  
Eight significantly mutated genes in EAC identified in the literature206, 208 were 
analyzed as part of the pan-cancer panel, namely ARID1A, ARID2, CDKN2A 
(P16), KAT6A, PIK3CA, SMAD4, SMARCA4 and TP53. Of particular interest 
are TP53 and SMAD4, specific to only intervention-requiring disease (HGD 
and EAC) and not occurring in non-dysplastic BE epithelium. These 
mutations were examined in training cohort samples (for which we also have 
genome-wide methylation and expression profiling data), and summarized in 
Table 7-3 below. 
 
Table 7-3: Known EAC somatic alterations (ARID1A, ARID2, CDKN2A (P16), 
KAT6A, PIK3CA, SMAD4, SMARCA4 and TP53) examined as part of the 
pan-cancer dataset. Samples were nine pairwise disease-normal analysis at 
all stages of esophageal adenocarcinoma development (n=2 non-dysplastic 
BE, n=3 mixed BE-LGD, n=2 LGD, n=2 HGD/EAC; each with matched 
normal squamous esophageal mucosa pairing). Results returned SNPs and 
indels classified as either high or medium impact by VEP (ordered by impact 
severity). No CDKN2A (P16) mutations were returned for these samples at 
the assigned level of impact severity.  
Variant	 Type	 Gene	 Impact	 Impact	severity	
Amino	acid	
change	
chr1:g.27057682C>T	 SNP	 ARID1A	 stop_gained	 HIGH	 Q/*	
chr1:g.27106373AGGC Deletion	 ARID1A	 frameshift_variant	 HIGH	 GNDFEMSKH
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Variant	 Type	 Gene	 Impact	 Impact	severity	
Amino	acid	
change	
AATGACTTTGAGATGTC
CAAACACCCAG>A	
PG/X	
chr1:g.27106861C>T	 SNP	 ARID1A	 stop_gained	 HIGH	 R/*	
chr12:g.46287298C>A	 SNP	 ARID2	 stop_gained	 HIGH	 S/*	
chr17:g.7578263G>A	 SNP	 TP53	 stop_gained	 HIGH	 R/*	
chr19:g.11105636G>T	 SNP	 SMARCA4	 stop_gained	 HIGH	 E/*	
chr12:g.46125065C>A	 SNP	 ARID2	 missense_variant	 MED	 N/K	
chr12:g.46215233A>G	 SNP	 ARID2	 missense_variant	 MED	 E/G	
chr12:g.46230697C>A	 SNP	 ARID2	 missense_variant	 MED	 L/I	
chr12:g.46243873C>A	 SNP	 ARID2	 missense_variant	 MED	 A/D	
chr12:g.46244790C>A	 SNP	 ARID2	 missense_variant	 MED	 L/I	
chr12:g.46244919C>G	 SNP	 ARID2	 missense_variant	 MED	 Q/E	
chr12:g.46244965C>A	 SNP	 ARID2	 missense_variant	 MED	 A/E	
chr12:g.46246024G>C	 SNP	 ARID2	 missense_variant	 MED	 S/T	
chr12:g.46254685G>T	 SNP	 ARID2	 missense_variant	 MED	 M/I	
chr17:g.7577034C>A	 SNP	 TP53	 missense_variant	 MED	 G/W	
chr17:g.7577105G>A	 SNP	 TP53	 missense_variant	 MED	 P/L	
chr17:g.7577121G>A	 SNP	 TP53	 missense_variant	 MED	 R/C	
chr17:g.7577575A>C	 SNP	 TP53	 missense_variant	 MED	 Y/D	
chr17:g.7578475G>C	 SNP	 TP53	 missense_variant	 MED	 P/R	
chr17:g.7578526C>A	 SNP	 TP53	 missense_variant	 MED	 C/F	
chr18:g.48591925G>T	 SNP	 SMAD4	 missense_variant	 MED	 C/F	
chr19:g.11101922C>T	 SNP	 SMARCA4	 missense_variant	 MED	 R/C	
chr19:g.11101935T>C	 SNP	 SMARCA4	 missense_variant	 MED	 I/T	
chr19:g.11144811G>C	 SNP	 SMARCA4	 missense_variant	 MED	 V/L	
chr19:g.11145812C>G	 SNP	 SMARCA4	 splice_region_variant	 MED	 None	
chr19:g.11170507G>T	 SNP	 SMARCA4	 missense_variant	 MED	 G/C	
chr3:g.178917565G>T	 SNP	 PIK3CA	 missense_variant	 MED	 C/F	
chr3:g.178927423C>T	 SNP	 PIK3CA	 missense_variant	 MED	 L/F	
chr3:g.178943747C>A	 SNP	 PIK3CA	 splice_region_variant	 MED	 None	
chr3:g.178952085A>G	 SNP	 PIK3CA	 missense_variant	 MED	 H/R	
chr8:g.41790102G>T	 SNP	 KAT6A	 missense_variant	 MED	 P/Q	
chr8:g.41790234G>T	 SNP	 KAT6A	 missense_variant	 MED	 T/N	
chr8:g.41790661G>T	 SNP	 KAT6A	 missense_variant	 MED	 P/T	
chr8:g.41791355C>A	 SNP	 KAT6A	 missense_variant	 MED	 Q/H	
chr8:g.41795055C>A	 SNP	 KAT6A	 missense_variant	 MED	 R/L	
chr8:g.41832273C>A	 SNP	 KAT6A	 missense_variant	 MED	 M/I	
 
As expected, the majority of (seven of eight) known genes mutated in EAC 
included in the pan-cancer screening panel were detected in our paired 
disease-normal analysis. These were typically single nucleotide 
polymorphisms, with multiple varied point mutations occurring within each of 
the genes examined. Missense and splice region variants (medium impact 
severity) were much more common than stop gain or frameshift variants 
(high impact severity). 
 
The disease-classification distribution of known EAC somatic mutation was 
examined across our dataset (Figure 7-4). SMAD4 and TP53 mutation are 
reported to be specific to intervention-requiring disease whereas the 
remaining six known EAC mutations are also detectable in non-dysplastic 
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BE. Our data supported literature observations, with SMAD4 only detectable 
in HGD/EAC samples and TP53 in dysplastic disease and HGD/EAC, but not 
detected in non-dysplastic disease. Interestingly, in our samples, ARID1A 
was observed to be similar to TP53 in disease classification distribution and 
was also not detected in non-dysplastic BE. However this observation is from 
only a small number of samples and we hypothesize that with increased 
sample size it would also possibly be observed in non-dysplastic BE 
samples. All other genes had mutations that were detectable in non-
dysplastic BE mucosa. 
 
 
 
Figure 7-4: Disease-classification distribution of known EAC somatic 
mutation in training cohort disease-normal pairwise analysis. ARID1A, 
ARID2, KAT6A, PIK3CA, SMAD4, SMARCA4 and TP53 were evaluated for 
mutational count within each disease class (BE, mixed BE-LGD, LGD, HGD-
EAC) in disease-normal pairwise analysis of training cohort samples. Both 
medium and high impact mutations were included. 
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7.3.2  CIMP causal mutation in the esophagus 
CIMP in EAC has been reported as early as 2001, however analysis has 
typically focused on marker genes for colorectal CIMP, where it was first 
identified47, 49, rather than establishing a specific esophageal 
adenocarcinoma CIMP profile (E-CIMP). In 2011, Kaz et al observed 
methylation sub-groups ‘high methylation epigenotype’ (HME) and ‘low 
methylation epigenotype’ (LME) in both BE and EAC, but did not attempt to 
attribute it to a causal genetic mutation or demographic/phenotypic 
feature238. Since then, the molecular basis of CIMP in EAC has still not been 
addressed. Our pan-cancer panel includes sequencing of IDH1, IDH2, TET2, 
KRAS and BRAF mutations, all of which have been previously implicated in 
CIMP formation in other cancers214 215, 229. We examined all dysplastic and 
EAC tissues for evidence of any high or medium impact, disease-associated 
SNP or indels present (Figure 7-5) and found minimal evidence of mutation 
in these genes in the development of EAC. This supports previously reported 
findings that the molecular basis of CIMP in esophageal adenocarcinoma is 
very different to that in glioma or AML; and even varies from that of other 
solid GI tumors such as colorectal cancer. 
 
 
Figure 7-5: CIMP causal gene mutational load in esophageal carcinogenesis. 
Prevalence of cancer-associated somatic mutation in genes implicated in 
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CIMP causality in other cancers (IDH1, IDH2, TET2, BRAF and KRAS) in 
samples at all stages of esophageal adenocarcinoma development. Results 
expressed as percentage prevalence across all samples analyzed. 
7.3.2.1  IDH1/2 and TET2 mutation in the esophagus  
In matched disease-normal pairwise analysis, there was evidence of an IDH1 
SNP (chr2:g.209116240C>G, missense variant, codon change gaG/gaC, 
amino acid change Glu/Asp) in a single LGD patient, notably NOT occurring 
at R132, as found in glioma214. This same patient also showed evidence of 
an IDH2 SNP (chr15:g.90631586C>A, splice region variant, no codon or 
amino acid change). Two TET2 mutations were detected in a single EAC 
patient (both missense variant, chr4:g.106157848C>A, 
chr4:g.106196343C>A, codon change Caa/Aaa, tCt/tAt, amino acid change 
Gln/Lys, Ser/Tyr respectively). There is no evidence for TET2 and IDH1/2 as 
mutually exclusive mutations in our data. These data support previously 
reported findings that the molecular basis of CIMP in solid tumors such as 
esophageal adenocarcinoma is very different to that of glioma or AML212.  
7.3.2.2  BRAF and KRAS mutation in the esophagus 
There was evidence of four different BRAF single nucleotide polymorphisms 
(SNPs) in our pan-cancer genetic screening panel. Two of these mutations 
occurred in a single LGD patient, the other two mutations were evident in two 
further individuals. BRAF mutations are as outlined in Table 7-4. 
 
Table 7-4: BRAF mutation occurring in esophageal tissue matched disease-
normal pairwise analysis 
Variant Impact 
Codon 
change 
Amino acid 
change 
chr7:g.140434499C>A Missense variant ttG/ttT Leu/Phe 
chr7:g.140439677C>A Missense variant Gcc/Tcc Ala/Ser 
chr7:g.140494197C>T Missense variant Gaa/Aaa Glu/Lys 
chr7:g.140501303G>C Missense variant Cag/Gag Gln/Glu 
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We did not detect any KRAS mutations in our training cohort samples. This is 
somewhat surprising as both KRAS and BRAF are members of the ras signal 
transduction pathway and are typically mutually exclusive in colorectal 
cancer229. Lack of detection of KRAS mutation may be due to the low 
numbers of samples analysed (9 disease-normal pairs: BE (n=2), BE-LGD 
mixed (n=3), LGD (n=2), EAC-HGD (n=2)), further confounded by the 
variability in genetic signature commonly observed in EAC tissues207. 
7.4  Discussion 
The pan-cancer mutational profiling panel has continued to develop as 
publications identify possible further targets. An additional 12 targets have 
been flagged for inclusion, namely AhR (aryl hydrocarbon receptor), 
SDHAF2§, TMEM127§, MAX§, EGLN1§, HIF2A§, KIF1B§, EPHB2, ARMC5, 
LTS2, PHD2, GR101. Of particular interest for esophageal adenocarcinoma 
is transmembrane protein 127 (TMEM127), a tumor susceptibility gene. 
Genes from this family (TMEM40 and TMEM109) are included on patent 
PCT/US2011/041659, Method for determining predisposition to esophageal 
and esophageal-related disorders (Esophageal disorders: esophagitis, 
squamous cell carcinoma or esophageal, cardia or gastric adenocarcinoma; 
Esophageal-related disorders: head and neck cancer, throat cancer, gastric 
cancer or mouth cancer). Furthermore, in a 2013 exome and whole-genome 
sequencing study, Dulak et al examined recurrent driver events and 
mutational complexity in esophageal adenocarcinoma, finding TMEM132D to 
be altered in 14 of 146 cases (9.6%), placing it in the top 30 mutated genes 
in EAC208.  
 
Somatic mutation pan-cancer profiling of known EAC alterations in the 
training cohort supports observations reported in literature that the majority of 
alterations occur early in the metaplasia-dysplasia-adenocarcinoma 
sequence. Weaver et al (2014) reported only TP53 and SMAD4 to be 
specific for HGD and EAC, and not present in non-dysplastic BE206. Our 
                                            
§ From Martins and Bugalho. 2014. Int J Endocrinol. Epub 2014 May 12239. 
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findings supported this observation, however interestingly we note that TP53 
mutation is also detected in low-grade dysplastic Barrett’s mucosa. These 
observations (that the majority of known EAC somatic mutation are already 
detectable in non-dysplastic BE mucosa) support the hypothesis that EAC is 
not a mutation-driven cancer. 
 
Aside from known EAC mutations, a large number of alterations across a 
wide-range of genes were present in not only EAC samples, but also low-
grade dysplastic and non-dysplastic Barrett’s mucosa. This is interesting as 
pan-cancer panel development has included genes far removed from those 
expected to be involved in the development of gastrointestinal neoplasia; 
including familial pituitary genes and pituitary development (embryonic) 
genes. We observed a very low rate of universal alteration in our samples. 
Very few genes had the same mutation detected in all diseased samples. 
More commonly, genes would have various point mutations across various 
samples. For example, twelve BRCA2 single nucleotide polymorphisms were 
observed across all but two of our disease-normal pairs (one non-dysplastic 
BE, one mixed BE-LGD), with one EAC sample containing 5 different BRCA2 
mutations, but the majority of other samples each containing a single unique 
BRCA2 SNP.  
 
With regard to somatic pan-cancer mutation load observed in our samples 
(representing the full spectrum of disease progression), we note a general 
trend in increased mutational load as disease progresses through the 
metaplasia-dysplasia-neoplasia sequence, with some anomalies, such as a 
very low mutational load (similar to non-dysplastic BE samples) in an 
advanced invasive EAC sample. This is not too surprising, given the 
evidence that EAC is not considered to be a mutation-driven cancer and the 
highly variable genomic signatures and wide range of mutation rates 
observed in of EAC tumors49, 90, 206, 208. 
 
A CpG island methylator phenotype (CIMP) phenotype has been observed in 
many cancers, however the molecular basis of this phenotype is not 
universal across all cancers. CIMP in glioma is reported to be established by, 
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and highly dependent on, IDH1 mutation, which alters histone marks and 
induces extensive DNA hypermethylation214. Similarly in acute myeloid 
leukemia, IDH1, IDH2 and TET2 mutations were found to induce a global 
hypermethylation signature215. However it has been reported that in many 
solid tumors such as gastrointestinal stromal tumors (GIST), bladder, breast, 
colorectal, lung, ovarian, pancreas, prostate and thyroid carcinoma212, 216-218, 
IDH1 mutation is absent, despite CIMP being reported in these tumors219-226. 
The molecular basis of CIMP in colorectal cancer has been suggested to be 
either BRAF or KRAS mutation driven, however a causal relationship has not 
been established and the inverse, that CIMP may provide a favorable 
environment for mutation to occur, has been proposed230. No esophageal 
adenocarcinoma CIMP profile has been established, and despite variations 
in CIMP causation across cancer types, a colorectal CIMP profile has 
continued to be used to classify EAC-CIMP as recently as this year49. We 
investigated levels of IDH1, IDH2, TET2, KRAS and BRAF mutation in our 
esophageal adenocarcinoma and developmental samples and found low 
mutational load, supporting the hypothesis that alterations in these genes are 
not causal for EAC and more work is needed to define an EAC CIMP profile 
and determine a causal factor for this phenotype. 
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CHAPTER 8:   GENERAL DISCUSSION AND CONCLUDING 
REMARKS 
8.1  Introduction 
In this thesis, I have addressed the problem of poor esophageal 
adenocarcinoma outcome due to lack of an early stage diagnostic test, by 
identification and validation of aberrant methylation, an early and frequent 
event in carcinogenesis, as a biomarker for early detection of esophageal 
adenocarcinoma and dysplastic forms of its precursor disease, Barrett’s 
esophagus. 
 
In this final chapter I will summarize major experimental findings and put 
these into context of the current field of methylation and esophageal 
adenocarcinoma diagnostics. 
8.2  Overview of experimental findings 
The major findings of this thesis are: 
 
1. RNA preservation solutions work effectively at maintaining 
isolated RNA integrity in esophageal tissue, but introduce 
problems associated with high salt concentration. Esophageal 
tissue samples were placed directly into RNAlater, which fully 
penetrates the tissue and preserves RNA for downstream 
applications, but introduces purity problems due to high salt 
concentration. Special care needs to be taken extracting nucleic acids 
to ensure high yield and purity.  
2. Current ‘gold standard’ endoscopic/histologic methods are 
inadequate for robust, consistent diagnosis of low-grade 
dysplasia. Low-grade dysplastic samples are of exceptional 
importance as they represent early stage carcinogenic change, but 
diagnostic difficulties may introduce bias to potential biomarker 
identification. To address this, low-grade dysplastic tissues were 
Chapter 8:  General Discussion and Concluding Remarks 
 248 
included at every stage of the study, but not used for bioinformatic 
analyses to determine potential biomarker candidates, thereby not 
able to introduce error due incorrect diagnosis, but able to be checked 
to determine if selected biomarker candidates were useful in these 
very early stage samples. Sample heterogeneity cut-offs were applied 
to ensure robust, reliable determination of biomarker candidates. 
3. Comprehensive same sample genome-wide methylation and 
expression profiling from samples at every stage of the 
metaplasia-dysplasia-adenocarcinoma sequence is novel for this 
disease. Disease-associated differential methylation exists and is 
detectable between non-dysplastic BE and BE with areas of low-grade 
dysplasia. This is clinically important for early-stage detection 
biomarkers. The use of non-dysplastic BE as baseline compared to 
combined HGD-EAC was informative for methylation changes 
associated with early stage carcinogenic development. 
4. The most significantly hypermethylated regions in HGD and EAC 
(with respect to normal esophageal epithelium) were, in the most 
part, also significantly hypermethylated in non-dysplastic BE, but 
unmethylated in normal peripheral blood as well as normal 
esophageal, duodenal and proximal stomach mucosa. This 
highlights problems associated with simple normal versus cancer 
analyses for esophageal adenocarcinoma biomarker identification, as 
these regions are not specific to early-stage carcinogenesis and 
cancer, but also identify common, benign precursor disease. 
Furthermore, the most significantly hypermethylated regions in BE 
with respect to normal esophageal epithelium are also significantly 
hypermethylated in HGD and EAC, but unmethylated in normal 
peripheral blood as well as normal esophageal, duodenal and 
proximal stomach mucosa. Thus, we can infer that disease-associated 
methylation change occurs early, and is maintained throughout the 
metaplasia-dysplasia-adenocarcinoma progression. 
5. Much of the hypomethylation occurring in the metaplasia-
dysplasia-adenocarcinoma sequence is attributable to 
maintenance of columnar mucosa rather than disease-associated 
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progression through the development sequence. For this reason, 
no hypomethylation targets were carried through to validation and 
targeted sequencing studies. 
6. Much of the significant differential expression (both up- and 
down-regulated) is also attributable to the maintenance of 
columnar mucosa rather than disease progression through the 
metaplasia-dysplasia-adenocarcinoma sequence. Thus we can 
conclude that tissue type difference (squamous cells comprising 
normal, healthy esophageal mucosa, as opposed to columnar mucosa 
present in BE, HGD, EAC and control tissues) has a more significant 
impact on global expression profile than disease development. 
7. Esophageal adenocarcinoma is a complex disease with many 
different molecular subtypes, leading to large variation in global 
expression patterns between individuals. Significantly less intra-
classification variation was observed in global methylation than 
expression, supporting methylation biomarkers as more viable than 
expression biomarkers for universally detectable change irrespective 
of variable esophageal adenocarcinoma subtypes.  
8. Methylation-expression correlation analyses support recent 
literature claiming more complex interactions in cancer 
development than simplistic ‘hypomethylation resulting in 
transcriptional activation and hypermethylation triggering 
transcriptional silencing’. Whilst these associations were observed 
in our data sets, they were by no means the predominant occurrence. 
Disease-associated differential methylation at or near the transcription 
start site resulted in statistically significant (p≤0.05) alteration in 
expression of these genes in just 18% of target regions selected for 
validation.  
9. Gene set enrichment revealed expected functional association as 
disease developed as well as highlighting the importance of 
precursor versus intervention-requiring disease for enrichment 
of disease associated change. Enriched gene sets in esophageal 
adenocarcinoma development include those for angiogenesis, 
inflammatory response, cytokine (interferon alpha and interferon 
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gamma) response as well as p53 pathways. Gene sets showing early 
enrichment in precursor disease as well as adenocarcinoma include 
KRAS signaling, epithelial-mesenchymal transition and coagulation. 
Cancer neighborhood gene sets selected as the most enriched using 
N v HGD-EAC showed significantly increased fold enrichment and 
gene count in the BE v HGD-EAC comparison. 
10. Increased methylation of tumor suppressor p63 promoter region 
may be a contributing factor to reduced p63 expression and 
possibly implicated in BE development and/or carcinogenic 
progression Our data support disease-associated tumor suppressor 
p63 promoter methylation in one of two p63 promoter regions in BE, 
HGD and EAC samples compared to normal and gastro-esophageal 
reflux disease samples. Loss of tumor suppressor p63 expression is 
associated with carcinogenesis in a number of cancer types. Its 
importance in the origin of BE is highlighted in experiments showing 
that a p63 null mouse quickly develops Barrett’s-like tissue. 
11. Adaptation of sequencing protocols was successful for short 
amplicons in tissue samples with direct transferability to blood 
biomarker investigation. Bisulfite-specific PCR for unbiased 
amplification of specific regions of interest combined with targeted 
amplicon sequencing was used to validate potential methylation 
biomarker candidates. Assay design and protocol adaptation were 
performed so that techniques are immediately transferable to the 
short, fragmented circulating DNA extracted from blood.  
12. The use of control (proximal stomach and duodenal) tissues with 
similar mucosal structure to Barrett’s esophageal tissue enable 
effective filtering of aberrant methylation indicative of 
maintenance of columnar epithelium. Control normal peripheral 
blood was used to further filter biomarker candidates to ensure 
suitability for future blood test. The resultant subset of disease-
associated aberrant methylation is clinically applicable for an early 
cancer detection test. 
13. Potential hypermethylation biomarkers include ARL10, a region 
upstream of CA4, CACNA2D2, KLF7, LRRC43, TEPP, TUBA3FP, 
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VANGL2, ZNF221 and ZNF699.  Disease-associated 
hypermethylated target regions indicative of early esophageal 
adenocarcinoma were established using stringent cut-off criteria 
applied to global methylation profiling data (little or no methylation in 
non-dysplastic BE, normal esophageal mucosa and control tissues as 
well as normal peripheral blood) and validated using BSP amplification 
and target amplicon sequencing. Global methylation profiling (n=250 
samples) of an external data set (the only published HM450 data set 
for esophageal adenocarcinoma) were used for further validation. A 
number of these candidates are novel, not only for esophageal 
adenocarcinoma identification, but for their role in carcinogenesis (for 
example ARL10 and TUB3FP); others, such as KLF7 and VANGL2 
have family members associated with carcinogenesis in other cancer 
types, but are novel for EAC carcinogenesis.  
14. Aberrant promoter methylation of DNA repair gene MGMT plays a 
significant role in the multistep process of Barrett’s 
carcinogenesis. Our data do not support literature surrounding the 
reported diagnostic utility of MGMT promoter methylation in 
esophageal adenocarcinoma, due to methylation observed in a subset 
of non-dysplastic BE. However the very low methylation levels 
observed in normal squamous epithelia, GERD and stomach tissues 
do support a disease-associated role. Early epigenetic silencing of 
DNA repair gene MGMT (at the non-dysplastic BE stage) would likely 
increase mutation rates, one or more which may provide the cell with 
selective advantage. Carried on, continued epigenetic repression of 
MGMT would generate further mutations, which may produce tumor. 
We can hypothesize from our data that the subset of non-dysplastic 
BE patients showing promoter MGMT hypermethylation may be more 
susceptible to malignant change. However it would not be possible to 
predict disease progression using this information alone. It is likely 
that epigenetic MGMT repression would need to occur in co-ordination 
with repression of other DNA repair genes or other biological events.  
15. Bimodal methylation clustering (hypermethylation of a subset of 
a particular disease class, with another subset entirely 
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unmethylated) was observed across all stages of Barrett’s 
carcinogenesis. We hypothesize that this may be, in part, due to the 
inflammation-triggered stem cell origin of BE resulting in molecularly 
disparate groups of disease arising, as observed in expression 
profiling of all stages of disease development. Chromothripsis, 
massive genomic rearrangement more prevalent in EAC then any 
other cancer, may also contribute to the bimodality in EAC samples. 
16. Novel potentially clinical useful methylation biomarkers have 
been identified as a result of this study. A triplex of 
hypermethylation in any of TUBA3FP, VANGL2 or ARL10 was able to 
accurately identify all HGD and EAC patients with 100% sensitivity 
(beta value cut-offs 0.05, 0.02 and 0.08 respectively) with 84.6% 
specificity (based on methylation detected in patients with a normal, 
healthy esophagus, or non-dysplastic BE). The triplex was able to 
successfully identify 95% of all LGD, HGD and EAC patients 
(specificity 76.9%). 
17.  There is evidence of application of identified biomarkers for 
predicting dysplastic progression. TEPP and a target region 
upstream of CA4 showed significant hypermethylation in a non-
dysplastic BE sample taken one year before development of low-
grade dysplasia. Aberrant methylation of these target regions may 
indicate predisposition to dysplastic progression. 
18. There is evidence of application of identified biomarkers for 
predicting the necessity of treatment for low-grade dysplasia. 
Treatment of low-grade dysplasia is still disputed and discussed in 
guidelines for the management of Barrett’s worldwide. The ability to 
predict progression from low to high-grade dysplasia may aid in 
determining how aggressively to treat LGD. Methylation of LRRC43 
and ZNF699 in an LGD patient was consistent with a more advanced 
disease profile 8 months prior to HGD progression, despite several 
endoscopic mucosal resection treatments. Similarly, biomarkers for 
the natural regression of LGD to non-dysplastic BE may aid in 
treatment determination and/or surveillance regime for LGD patients. 
For example, a patient with persistent long segment LGD (untreated, 
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constant surveillance) was observed to have complete absence of 
methylation in a number of target regions, including ARL10, 
TUBA3FP, CACNA2D2, LRRC43 and TRANK1. On follow-up, this 
patient was diagnosed as being without dysplasia two years after the 
LGD biopsy was taken and analyzed for this study. 
19. There is evidence of application of identified biomarkers for 
disease monitoring with treatment. A HGD patient was monitored 
and successfully treated over three visits in the space of 7½ months. 
Diagnoses of HGD (visit 1), LGD (visit 2) and non-dysplastic BE, no 
evidence of dysplasia (visit 3) were reflected in the methylation profile 
of TNFAIP8L3 and ZNF699, which showed significant correlation with 
disease regression as the patient was treated. Methylation of these 
target regions may be clinically valuable for monitoring disease status 
with treatment and have possible application in predicting disease 
recurrence as part of a screening panel. 
20. Increased mutational load was detected as disease progressed 
through the metaplasia-dysplasia-adenocarcinoma sequence. 
Interesting was the detection of cancer-associated mutational load in 
non-dysplastic Barrett’s mucosa, a benign epithelium. This is in line 
with observations that disease-associated methylation change occurs 
early, and is maintained throughout the metaplasia-dysplasia-
adenocarcinoma progression. An interesting anomaly was an 
advanced, invasive carcinoma sample showing a distinct lack of 
cancer-associated somatic mutation; again highlighting the variation in 
molecular subtypes of esophageal adenocarcinoma. 
21. Our data supported current literature regarding somatic mutation 
in EAC. Pairwise disease-normal analyses showed TP53, SMAD4 
and ARID1A mutations to be specific to intervention-requiring disease 
and not detectable in non-dysplastic BE epithelium. Mutations in other 
genes such as SMARCA4, PIK3CA, KAT6A and ARID2 were 
observed in non-dysplastic BE as well as more advanced disease. 
22. There is minimal evidence to support esophageal CIMP causal 
mutation in genes implicated in CIMP formation in other cancers. 
IDH1, IDH2, TET2, KRAS and BRAF mutation have been implicated in 
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CIMP formation in other cancers (such as glioma, AML and colorectal 
cancer) but, based on our profiling, do not show evidence of being 
CIMP causal mutations in esophageal adenocarcinoma. 
8.3  Findings in context and future aspects 
Since the commencement of my thesis, the first study using HM450 
technology applied to esophageal adenocarcinoma tissues was only recently 
published by Krause et al49 in February 2016. The group kindly agreed to 
share their data for use as my external validation data set prior to publication. 
Their study examines methylation profiles of normal, BE and EAC samples, 
but does not address intermediate dysplastic stages of carcinogenic 
development. To date, my study is the first to perform whole genome 
methylation profiling using comprehensive HM450 arrays on both low and 
high-grade dysplastic Barrett’s tissue. 
 
Current endoscopic diagnosis methods for EAC and its precursor disease, 
BE, are not viable for population screening, contributing to late stage EAC 
detection and poor prognosis. Considerable difficulties exist with current 
endoscopic/histologic diagnosis methods, especially surrounding correct 
diagnoses for intermediate disease development stages. A number of issues 
such as tissue heterogeneity, pathologist interpretation, sampling error and 
histology processing artifacts contribute to variation in diagnosis. We worked 
around this problem by exclusion of data pertaining to LGD samples for 
biomarker identification, but checking performance of selected biomarkers in 
these important samples indicative of early stage carcinogenic 
transformation. An alternative, assumption-free approach would be to use 
molecular signature (methylation, expression, mutational profile) to group 
patients, blinded to patient/sample diagnosis as defined by 
endoscopy/histology. We considered this alternative approach, however it 
quickly became complicated due to the molecularly disparate forms of EAC 
and the resultant large numbers of molecularly distinct groups; however this 
approach may be useful in cancer types with more uniform molecular 
disease profiles. 
Chapter 8:  General Discussion and Concluding Remarks 
 255 
 
Targeted amplicon sequencing (used for validation of methylation profiling in 
this study) has been used successfully monitor TP53 mutation in ovarian 
cancer patients with sensitivity and specificity >97%71. The BSP assays for 
targeted amplicon sequencing used as part of this study were designed with 
application as a blood test in mind: a shorter amplicon length than usually 
used for amplicon sequencing is appropriate for amplification of cell-free 
circulating (cfc)-DNA extracted from blood. 
 
Using (i) comprehensive methylation HM450 profiling, (ii) high-grade 
dysplasia included with EAC for all analyses, (iii) validation of selected 
regions in low-grade dysplasia, (iv) non-dysplastic BE as baseline and 
intervention-requiring disease (HGD-EAC) as the comparison group and (v) 
comprehensive controls including normal squamous epithelia, proximal 
stomach / duodenal tissues (columnar mucosal structure similar to that found 
in BE), and peripheral blood from normal healthy patients, enriched results 
for disease-associated methylation change indicative of early phase EAC 
development and enabled identification of novel biomarkers with potential 
application as a screening blood test. Biomarkers for esophageal 
adenocarcinoma to date have been limited in their clinical application, 
however my rigorous approach to biomarker identification, combined with 
new technology may help turn this around. 
 
The identification of novel aberrant DNA methylation in EAC carcinogenesis 
has far-reaching implications not only as biomarkers for early identification, 
but also for cancer treatment, as recently shown in a landmark paper by 
Rivenbark et al240, epigenetically reprogramming breast cancer cells by 
targeting DNA methylation.  
 
The focus for this study is identification of potentially clinically useful 
methylation biomarkers for identification of early phase esophageal 
adenocarcinoma. The study was designed with a view to blood investigation 
(all target regions are essentially unmethylated in peripheral blood from 
healthy patients and amplification assays for targeted sequencing are 
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suitable for degraded, shorter fragments of cell-free circulating DNA in 
blood), which, if successful, would be applicable for screening of high-risk 
populations: middle-aged Caucasian males or individuals with a family 
history. A blood test would allow for easily implemented, cost-effective 
screening of the high-risk population, enabling detection of EAC and HGD at 
a curable stage, and ultimately providing an opportunity to improve EAC 
incidence, prognosis and mortality. 
 
In the case of cancer patients, isolated cfc-DNA is known to reflect epigenetic 
characteristics of tumor occurring elsewhere in the body. In a 2014 study, 
Bettegowda et al were able to detect cfc-DNA with tumor origin from the 
blood of >75% of patients with advanced pancreatic, ovarian, colorectal, 
bladder, gastroesophageal, breast, melanoma, hepatocellular, and head and 
neck cancers241. The huge potential of ‘liquid biopsy’ (advantageous as it is 
widely accepted, readily repeated, convenient, non-invasive and low cost, 
also overcoming heterogeneity issues associated with tissue sampling) has 
been the focus for Dawson et al, analysing cfc-DNA in blood to assess 
tumour burden and treatment response in real time breast cancer 
management242. In a single-case study of serial plasma samples from a 
metastatic ER-positive and HER2-positive breast cancer patient, receiving 
two lines of targeted therapy over three years, Murtaza et al showed 
mutation levels in plasma reflect clonal hierarchy inferred from sequencing of 
tissue tumour biopsies, and plasma level of mutations specific to certain 
metastases correlate with treatment responses at these sites72. These 
studies highlight how cfc-DNA from plasma is a valuable, easily-accessible 
way to monitor or screen for cancerous changes occurring in tissues.  
 
Additionally, this study has formed the foundation for further work (and 
subsequent funding applications) into the investigation of disease 
progression and regression. Further analysis of subsequent samples taken 
from patients analysed here that have progressed (or regressed) in their 
disease classification is currently underway to confirm hypotheses from this 
this and to further investigate clinical utility of these biomarkers. 
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8.4  Concluding remarks 
The aims of this thesis were (i) to perform genome-wide methylation and 
expression profiling at all stages of the metaplasia-dysplasia-
adenocarcinoma sequence to uncover novel disease-associated aberrant 
methylation with potential clinical application, (ii) comprehensively validate a 
subset of potential methylation biomarkers, (iii) evaluate performance of 
validated biomarkers with regard to diagnostic utility and other clinical 
application and (iv) examine cancer-associated mutational load in the same 
samples used for expression and methylation profiling to gain a more 
complete understanding of molecular change occurring in the development of 
esophageal adenocarcinoma. 
 
By using well-classified patient data and stringent, quality controlled 
biospecimen selection for training and validation cohorts, I uncovered regions 
of disease-associated aberrant methylation novel for esophageal 
carcinogenesis. Utilizing comprehensive technical and independent 
validation by targeted amplicon sequencing and whole genome methylation 
profiling of a large external validation cohort, I demonstrated potential utility 
of these target regions for identification of intervention requiring disease. I 
propose a panel of three methylation biomarkers (TUBA3FP, VANGL2, 
ARL10) for identification of intervention requiring disease, reporting 100% 
sensitivity and 84.6% specificity and demonstrated biomarker application for 
prediction of disease progression as well as utility for monitoring disease 
status with treatment and predicting the necessity of treatment for low-grade 
dysplasia. By performing genome-wide methylation and expression profiling, 
as well as cancer-associated mutation screening on single tissue biopsies 
from all stages of the metaplasia-dysplasia-adenocarcinoma sequence, I was 
able to gain a more complete understanding of molecular change occurring 
in esophageal carcinogenesis.  
 
Overall, the aims of this thesis have been met and I have been able to 
propose potentially clinically valuable methylation biomarkers for the 
detection of intervention-requiring disease, with potential application for non-
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invasive, high-risk population screening for identification of esophageal 
adenocarcinoma at an early, treatable stage. The applicability of these novel 
epigenetic biomarkers to detect circulating tumor cells in blood to aid in 
clinical management will only be realized with further investigations 
conducted by our laboratory and clinical collaborators. 
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Appendix 1: Website links to software, genome browsers and online 
tools used in this study 
Software / Genome Browser / Online Tool and website link         
Affymetrix® Expression ConsoleTM 
http://www.affymetrix.com/support/learning/training_tutorials/tac_ec/index.affx 
Bioconductor minfi package 3.2 
http://bioconductor.org/packages/release/bioc/html/minfi.html 
Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 
https://david.ncifcrf.gov 
GenomeStudio v2011.1 with Methylation module 1.9.0 
http://www.illumina.com/techniques/microarrays/array-data-analysis-experimental-
design/genomestudio.html 
HaplotypeCaller (Genome Analysis Toolkit (GATK) variant discovery tools) 
https://www.broadinstitute.org/gatk/guide/tooldocs/org_broadinstitute_gatk_tools_walkers_h
aplotypecaller_HaplotypeCaller.php 
Illumina Experiment Manager (IEM) v1.9 
https://support.illumina.com/downloads/illumina-experiment-manager.html 
Integrative Genomics Viewer (IGV) 
https://www.broadinstitute.org/igv/ 
KAPA Library Quantification Data Analysis Template 
https://www.kapabiosystems.com/document/kapa-library-quantification-data-analysis-
template/ 
Linear Models for Microarray Analysis (LIMMA) package 
https://bioconductor.org/packages/release/bioc/html/limma.html 
MethPrimer: designing primer pairs for methylation PCRs 
http://www.urogene.org/methprimer/ 
Multiple Primer Analyzer 
https://www.thermofisher.com/au/en/home/brands/thermo-scientific/molecular-
biology/molecular-biology-learning-center/molecular-biology-resource-library/thermo-
scientific-web-tools/multiple-primer-analyzer.html 
Transcriptome Analysis Console (TAC) software 
http://www.affymetrix.com/support/learning/training_tutorials/tac_ec/index.affx 
UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) assembly 
https://genome.ucsc.edu/cgi-bin/hgGateway 
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Appendix 3: Yield, purity, correlation and bias in RNA isolation from 
esophageal tissue 
Yield, purity, correlation and biases in RNA isolation from esophageal tissue 
were examined following extraction from 154 tissue samples. Data includes 
samples extracted using trial kits (Bioline’s Isolate II RNA Mini Kit, with extra 
column desalt, Mo Bio’s UltraClean® Tissue & Cells RNA Isolation Kit and 
Zymo’s Quick-RNATM MiniPrep kit) as well as the selected Qiagen RNeasy 
Mini Kit (including protocol variations); chosen on the basis of superior 
absorbance ratios and RNA integrity number (RIN). 
Appendix 3.1  RNA yields 
(A) An average total RNA yield of 1.813 ± 1.632µg was obtained (median 
1.315µg, maximum 7.480µg). (B) Average concentration of 80.36 ± 
74.12ng/µL (median 54.05ng/µL, maximum 340.10ng/µL).  
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Appendix 3.2  Absorbance ratios 
(A) Absorbance ratio A260/280 provides an indication of protein 
contamination. Pure RNA will have A260/280 ~2.0. An average A260/280 
2.135 ± 0.4400 (median 2.130) was observed. Mo Bio’s UltraClean® Tissue 
& Cells RNA Isolation Kit did not perform as well as the other kits in this 
regard. The cause for increased variation in the small group of Qiagen 
RNeasy Mini Kit samples (processed together in a single batch) was unable 
to be determined. (B) Average A260/230 of 1.416 ± 0.5626 (median 1.540) 
indicates some contamination, hypothesized due to high salt concentration 
from RNAlater.  Acceptable A260/230 range for downstream expression and 
methylation profiling was assigned 1.50 - 2.20.   
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Appendix 3.3  Bioanalyzer RNA Integrity Number (RIN) 
Bioanalyzer RIN (0 – 10) is used to estimate the integrity of total RNA using 
electrophoretic trace and takes into account the presence or absence of 
degradation products. We applied a cut-off of ≥7.5 for inclusion of the sample 
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for genome-wide expression profiling. An average RIN of 8.029 ± 2.843 was 
obtained (median 8.90, maximum 10.00). Zymo’s Quick-RNATM MiniPrep kit 
was dismissed on this basis. 
 
 
Appendix 3.4  Yield correlation with tissue input (input-output correlation) 
(A) Average tissue biopsy input weight was 2.499 ± 1.560mg (median 
2.050mg, maximum 8.200mg). (B) Correlation between tissue input and total 
RNA yield (input-output correlation). Linear regression line of best fit is 
plotted with 95% confidence band. Person correlation coefficient r2 = 0.2189 
(assumes Gaussian distribution). 
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(B) 
 
Appendix 3.5  Purity correlation (tissue input and yield) 
(A) Correlation between purity (A260/230) and tissue input: investigating if a 
smaller initial biopsy results in poorer quality RNA. Linear regression line of 
best fit is plotted with 95% confidence band. Person correlation coefficient r2 
= 0.2346 (assumes Gaussian distribution). (B) Correlation between purity 
(A260/230) and total RNA yield (µg): investigating if a poor yield is 
synonymous with poor quality RNA. Linear regression line of best fit is 
plotted with 95% confidence band. Person correlation coefficient r2 = 0.3085 
(assumes Gaussian distribution). 
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Appendix 3.6  Gender bias 
Patient gender does not significantly affect yield or purity. (A) Total RNA yield 
(µg) separated by gender, Mann-Whitney test, p = 0.5870; (B) Purity (based 
on absorbance ratio 260nm/230nm), separated by gender, Mann-Whitney 
test, p = 0.5654. 
 
(A)      (B) 
 
Appendix 3.7  Sample type bias 
Sample type does not significantly affect yield or purity. (A) Total RNA yield 
(µg), separated by pathology confirmed sample type, Kruskal-Wallis test, p = 
0.5870; (B) Purity (based on absorbance ratio 260nm/230nm), separated by 
pathology confirmed sample type, Kruskal-Wallis test, p = 0.5654. 
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Appendix 3.8  Patient age bias 
Patient age (at the time the sample was taken) does not significantly affect 
yield or purity. (A) Total RNA yield (µg), separated by patient age, Kruskal-
Wallis test, p = 0.6571; (B) Purity (based on absorbance ratio 
260nm/230nm), separated by patient age, Kruskal-Wallis test, p = 0.5375. 
 
(A)      (B) 
  
Appendix 3.9  Sample distance from oral margin bias 
Sample distance from the oral margin (normal samples typically taken at 
25cm; diseased samples distally, dependent on esophageal length) does not 
significantly affect purity. Sample distance from the oral margin is 
significantly associated with total RNA yield, however when one-way ANOVA 
(multiple comparisons) were performed there is no significant difference 
between the groups when analyzed sequentially. (A) Total RNA yield (µg), 
separated by sample distance from oral margin, Kruskal-Wallis test, p = 
0.0265; (B) Purity (based on absorbance ratio 260nm/230nm), separated by 
sample distance from oral margin, Kruskal-Wallis test, p = 0.2460. 
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(A)      (B) 
  
Appendix 3.10  Collection hospital bias 
Collection hospital (standardized protocols) does not significantly affect yield 
or purity. (A) Total RNA yield (µg) separated by collection hospital, Mann-
Whitney test, p = 0.3795; (B) Purity (based on absorbance ratio 
260nm/230nm), separated by collection hospital, Mann-Whitney test, p = 
0.3265. 
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Appendix 4: Top differentially methylated sites identified by genome-wide methylation profiling 
For all results tabulated below, selection criteria pertaining to control tissue (duodenal and proximal stomach) as well as normal peripheral 
blood were NOT applied. Methylation averages for these specimens are shown for interest only. Additionally, no cut-off for baseline methylation 
has been applied and as such, may vary. Appendix 4 lists purely the top differentially methylated regions. Chapter 6 (and Appendix 7) pertain to 
data once biomarker specific selection criteria and cut-offs have been applied. 
 
Table 1: Top 100 hyper- and hypo-methylated probes for differentiating intervention-requiring disease from normal squamous 
epithelium 
55,424 hypermethylated and 20,876 hypomethylated CpG sites were identified as differentially methylated between normal squamous 
epithelium and intervention requiring disease (N v HGD-EAC, FDR < 0.01 and Δβ ≥ 0.20). Gencode v19 was used for annotation204, gene name 
protein-coding when not specified. logfc: log fold change, tstat: t-statistic, pval: p-value, adj_pval: adjusted p-value, βbase: average methylation in 
baseline samples, here, normal squamous epithelium, Δβ: difference in average methylation between comparison groups, here, between HGD-
EAC and N, βduo: average methylation in duodenal epithelium, βstom: average methylation in proximal stomach epithelium, βblood: average 
methylation in peripheral blood from disease-free patients. Top 100 hyper- and hypo-methylated sites based on greatest |Δβ|; listed in order of 
decreasing |Δβ|.  
 
gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
Top	100	hyper-methylated	sites	from	the	N	v	HGD-EAC	comparison	(differentiating	intervention	requiring	disease	from	normal	squamous	epithelium)	
AUTS2	 chr7	 69064092	 69064094	 cg17027195	 8.5872	 20.4221	 3.06E-15	 1.77E-12	 0.0110	 0.7995	 0.0215	 0.0101	 0.0110	
C8orf34		 chr8	 69244509	 69244511	 cg21479226	 8.0181	 21.2747	 1.36E-15	 9.92E-13	 0.0160	 0.7920	 0.3088	 0.0350	 0.0157	
N/A	 chr1	 24612044	 24612046	 cg10881071	 6.1419	 19.0719	 1.18E-14	 4.66E-12	 0.1138	 0.7869	 0.9353	 0.9328	 0.8912	
N/A	 chr5	 178781562	 178781564	 cg09068128	 6.0657	 9.0833	 1.10E-08	 2.26E-07	 0.1200	 0.7813	 0.9403	 0.9486	 0.9177	
EPHA6		 chr3	 96532042	 96532044	 cg11090352	 7.3684	 14.4170	 2.69E-12	 2.47E-10	 0.0242	 0.7795	 0.1033	 0.0426	 0.0111	
N/A	 chr10	 126314679	 126314681	 cg04426802	 6.4090	 17.5625	 5.98E-14	 1.47E-11	 0.1755	 0.7721	 0.9738	 0.9621	 0.9653	
EPB41L3	 chr18	 5543270	 5543272	 cg18543270	 7.2084	 17.9665	 3.83E-14	 1.07E-11	 0.0259	 0.7714	 0.1119	 0.0600	 0.0185	
N/A	 chr6	 41554528	 41554530	 cg15760474	 6.1398	 15.0013	 1.26E-12	 1.39E-10	 0.1823	 0.7579	 0.7390	 0.5747	 0.9176	
SCOC	 chr4	 141295028	 141295030	 cg21986225	 8.2781	 15.8192	 4.55E-13	 6.44E-11	 0.0104	 0.7550	 0.0275	 0.0130	 0.0100	
ADD2	 chr2	 70995458	 70995460	 cg15170605	 7.1315	 20.6494	 2.46E-15	 1.51E-12	 0.0246	 0.7550	 0.2279	 0.0560	 0.0191	
DOK5		 chr20	 53091928	 53091930	 cg19991022	 7.7318	 15.7062	 5.22E-13	 7.15E-11	 0.0154	 0.7536	 0.1233	 0.0190	 0.0100	
FOXI2		 chr10	 129535377	 129535379	 cg16642284	 5.9403	 14.8238	 1.58E-12	 1.65E-10	 0.0681	 0.7496	 0.4257	 0.1782	 0.1003	
DLGAP4		 chr20	 34894647	 34894649	 cg03414318	 6.8801	 19.4492	 8.05E-15	 3.55E-12	 0.0289	 0.7492	 0.2342	 0.0657	 0.0448	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
TBCD		 chr17	 80816850	 80816852	 cg07769421	 6.0985	 14.4443	 2.59E-12	 2.40E-10	 0.1992	 0.7454	 0.9454	 0.9180	 0.8687	
N/A	 chr17	 74696736	 74696738	 cg13387113	 5.5898	 10.0197	 2.06E-09	 5.40E-08	 0.1507	 0.7445	 0.7985	 0.8077	 0.9247	
MTRR	 chr5	 7850202	 7850204	 cg12539796	 8.1530	 17.7910	 4.64E-14	 1.22E-11	 0.0107	 0.7445	 0.0427	 0.0260	 0.0134	
N/A	 chr17	 80794273	 80794275	 cg18121066	 5.7747	 15.4522	 7.15E-13	 9.03E-11	 0.0767	 0.7431	 0.9454	 0.9095	 0.7214	
PIGG	 chr4	 512993	 512995	 cg18907098	 5.7269	 19.9362	 4.93E-15	 2.50E-12	 0.1766	 0.7425	 0.9431	 0.9259	 0.9057	
ZNF385B		 chr2	 180726327	 180726329	 cg06695611	 7.7510	 16.7092	 1.58E-13	 2.98E-11	 0.0141	 0.7412	 0.1514	 0.0123	 0.0115	
SLC2A9		 chr4	 10024411	 10024413	 cg11124021	 5.6511	 10.5456	 8.42E-10	 2.53E-08	 0.1755	 0.7390	 0.9539	 0.9484	 0.9480	
EPB41L3		 chr18	 5543547	 5543549	 cg07352438	 6.4517	 16.3496	 2.41E-13	 4.03E-11	 0.0380	 0.7376	 0.1180	 0.1145	 0.0348	
BCAT1	 chr12	 25055966	 25055968	 cg20399616	 6.5540	 13.9860	 4.78E-12	 3.85E-10	 0.0348	 0.7373	 0.5663	 0.0695	 0.0109	
HYDIN	 chr16	 71264578	 71264580	 cg09918510	 6.4279	 10.8229	 5.31E-10	 1.72E-08	 0.0384	 0.7364	 0.2870	 0.0850	 0.0128	
GSC	 chr14	 95235124	 95235126	 cg01163842	 7.1154	 17.0611	 1.05E-13	 2.20E-11	 0.0222	 0.7364	 0.1775	 0.0669	 0.0262	
DNAJC6		 chr1	 65731431	 65731433	 cg26615127	 6.1030	 15.3062	 8.58E-13	 1.03E-10	 0.0503	 0.7343	 0.0546	 0.0445	 0.0434	
ACAN	 chr15	 89346628	 89346630	 cg16968596	 7.6171	 17.5505	 6.06E-14	 1.48E-11	 0.0147	 0.7312	 0.1983	 0.0286	 0.0114	
FLI1		 chr11	 128564873	 128564875	 cg11017065	 7.7637	 23.7213	 1.54E-16	 2.13E-13	 0.0131	 0.7294	 0.2579	 0.0334	 0.0115	
N/A	 chr8	 119626988	 119626990	 cg05230834	 5.4692	 15.1480	 1.05E-12	 1.20E-10	 0.1744	 0.7290	 0.8398	 0.8575	 0.9124	
HMX3	 chr10	 124895447	 124895449	 cg18685408	 6.9471	 12.4102	 4.45E-11	 2.25E-09	 0.0241	 0.7290	 0.0402	 0.0119	 0.0108	
PRDM2	 chr1	 14026583	 14026585	 cg00922376	 8.0579	 24.6511	 7.09E-17	 1.28E-13	 0.0105	 0.7289	 0.0157	 0.0162	 0.0100	
N/A	 chr4	 1215111	 1215113	 cg12389346	 5.6259	 18.3971	 2.41E-14	 7.60E-12	 0.1948	 0.7279	 0.9564	 0.9447	 0.9617	
N/A	 chr13	 114797348	 114797350	 cg22906709	 5.6538	 13.6703	 7.34E-12	 5.39E-10	 0.1978	 0.7277	 0.8890	 0.8004	 0.9618	
DNM3	 chr1	 171810321	 171810323	 cg17154724	 8.0061	 11.0959	 3.41E-10	 1.19E-08	 0.0107	 0.7253	 0.3670	 0.0246	 0.0100	
GNAQP1	
pseudogene	 chr2	 132182670	 132182672	 cg20148575	 5.8178	 16.3811	 2.32E-13	 3.92E-11	 0.0609	 0.7244	 0.3326	 0.1720	 0.0135	
ST18		 chr8	 53322509	 53322511	 cg27649037	 6.0936	 14.7908	 1.65E-12	 1.70E-10	 0.2290	 0.7240	 0.9473	 0.9406	 0.9548	
ZNF790	 chr19	 37329089	 37329091	 cg10734240	 7.1385	 14.4022	 2.74E-12	 2.50E-10	 0.0201	 0.7231	 0.0260	 0.0496	 0.0258	
N/A	 chr19	 13112282	 13112284	 cg22824635	 6.6093	 18.5472	 2.05E-14	 6.85E-12	 0.2479	 0.7220	 0.9762	 0.9629	 0.9821	
N/A	 chr1	 76080726	 76080728	 cg07923233	 7.6957	 12.0282	 7.90E-11	 3.57E-09	 0.0132	 0.7218	 0.0697	 0.0283	 0.0129	
GSG1L		 chr16	 28074979	 28074981	 cg00843236	 7.5083	 23.7918	 1.45E-16	 2.06E-13	 0.0151	 0.7215	 0.1646	 0.0278	 0.0131	
NTNG1		 chr1	 107683774	 107683776	 cg07155336	 7.6575	 24.6729	 6.96E-17	 1.26E-13	 0.0135	 0.7214	 0.1629	 0.0296	 0.0109	
BRINP3	 chr1	 190447289	 190447291	 cg23010538	 5.6633	 12.1733	 6.34E-11	 2.98E-09	 0.0692	 0.7210	 0.2565	 0.1019	 0.0181	
RUNDC3B		 chr7	 87257537	 87257539	 cg18542829	 7.9486	 30.1483	 1.20E-18	 6.94E-15	 0.0109	 0.7207	 0.0203	 0.0148	 0.0105	
PTGDR		 chr14	 52734524	 52734526	 cg05302386	 7.4733	 12.0664	 7.45E-11	 3.40E-09	 0.0153	 0.7191	 0.2262	 0.0257	 0.0111	
N/A	 chr15	 28352097	 28352099	 cg03061682	 7.8673	 29.1240	 2.43E-18	 1.13E-14	 0.0114	 0.7183	 0.2481	 0.0151	 0.0100	
SYT9	 chr11	 7273147	 7273149	 cg18560328	 7.0229	 17.2739	 8.26E-14	 1.86E-11	 0.0214	 0.7182	 0.0781	 0.0428	 0.0123	
UNC80	 chr2	 210636349	 210636351	 cg12903638	 6.4373	 12.5148	 3.81E-11	 1.99E-09	 0.0337	 0.7177	 0.1709	 0.0465	 0.0198	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
TSHZ3		 chr19	 31841662	 31841664	 cg11199770	 7.2866	 17.1392	 9.63E-14	 2.06E-11	 0.0173	 0.7158	 0.1983	 0.0695	 0.0134	
N/A	 chr1	 9400774	 9400776	 cg24597774	 5.2908	 14.3981	 2.76E-12	 2.51E-10	 0.1803	 0.7157	 0.8990	 0.9162	 0.8934	
TUB	 chr11	 8040550	 8040552	 cg15344220	 7.5160	 18.8565	 1.48E-14	 5.38E-12	 0.0144	 0.7137	 0.1100	 0.0175	 0.0219	
SPOCK1	 chr5	 136834491	 136834493	 cg14650610	 6.4242	 20.5092	 2.81E-15	 1.67E-12	 0.0332	 0.7135	 0.2896	 0.0515	 0.0173	
N/A	 chr1	 9400738	 9400740	 cg04778236	 6.1980	 14.7910	 1.65E-12	 1.70E-10	 0.2469	 0.7132	 0.9662	 0.9599	 0.9370	
N/A	 chr17	 66292374	 66292376	 cg04173852	 5.9030	 16.2672	 2.65E-13	 4.32E-11	 0.2358	 0.7128	 0.9297	 0.9547	 0.9581	
FOXB2	 chr9	 79633736	 79633738	 cg14487131	 6.1901	 11.8285	 1.07E-10	 4.59E-09	 0.0399	 0.7122	 0.1931	 0.0912	 0.0184	
VWC2	 chr7	 49813087	 49813089	 cg01893212	 6.3335	 20.5484	 2.71E-15	 1.63E-12	 0.0354	 0.7121	 0.4188	 0.1283	 0.0140	
ZIK1	 chr19	 58095658	 58095660	 cg26246807	 6.1910	 11.3235	 2.36E-10	 8.77E-09	 0.0398	 0.7120	 0.3582	 0.0649	 0.0129	
N/A	 chr15	 69099677	 69099679	 cg16068038	 5.5744	 15.1584	 1.03E-12	 1.19E-10	 0.2186	 0.7116	 0.9181	 0.8627	 0.9019	
PTPRT	 chr20	 41818769	 41818771	 cg17859110	 7.3846	 22.1261	 6.20E-16	 5.59E-13	 0.0157	 0.7116	 0.1457	 0.0265	 0.0130	
	PRKAR1B		 chr7	 752291	 752293	 cg13895235	 5.8027	 20.2254	 3.71E-15	 2.02E-12	 0.0558	 0.7115	 0.2135	 0.0665	 0.0471	
	TFAP2B		 chr6	 50791201	 50791203	 cg27260772	 5.4339	 11.3418	 2.30E-10	 8.55E-09	 0.0811	 0.7112	 0.5176	 0.1912	 0.0563	
PTPN5		 chr11	 18813190	 18813192	 cg11334818	 5.6685	 17.1091	 9.96E-14	 2.11E-11	 0.0632	 0.7111	 0.3172	 0.1465	 0.0503	
N/A	 chr10	 556547	 556549	 cg26511507	 5.4479	 13.9426	 5.06E-12	 4.03E-10	 0.2101	 0.7106	 0.8678	 0.6674	 0.8797	
NKX2-2	 chr20	 21492913	 21492915	 cg22474464	 6.4319	 13.1029	 1.62E-11	 1.00E-09	 0.0324	 0.7105	 0.1869	 0.0796	 0.0211	
N/A	 chr1	 245524537	 245524539	 cg03130248	 5.5861	 16.8668	 1.32E-13	 2.59E-11	 0.2213	 0.7105	 0.9259	 0.9109	 0.9190	
ADHFE1	 chr8	 67344664	 67344666	 cg20295442	 6.3773	 15.0959	 1.12E-12	 1.27E-10	 0.0337	 0.7099	 0.1321	 0.0720	 0.0162	
ADHFE1	 chr8	 67344719	 67344721	 cg20912169	 6.9165	 14.8556	 1.52E-12	 1.59E-10	 0.0221	 0.7095	 0.1596	 0.0685	 0.0140	
GDF1	/	CERS1	 chr19	 19007310	 19007312	 cg03351460	 5.9629	 16.2050	 2.86E-13	 4.58E-11	 0.0476	 0.7094	 0.1881	 0.1565	 0.0601	
N/A	 chr10	 105510712	 105510714	 cg00730670	 5.7834	 17.4064	 7.12E-14	 1.66E-11	 0.2350	 0.7092	 0.9522	 0.9635	 0.9768	
	IGDCC3	 chr15	 65670303	 65670305	 cg01107006	 7.4118	 13.6773	 7.27E-12	 5.34E-10	 0.0152	 0.7090	 0.0340	 0.0172	 0.0100	
N/A	 chr1	 76081961	 76081963	 cg27547954	 7.8052	 17.1992	 8.99E-14	 1.97E-11	 0.0114	 0.7086	 0.0534	 0.0100	 0.0111	
VGLL3		 chr3	 87040285	 87040287	 cg12615137	 7.5480	 14.4402	 2.61E-12	 2.41E-10	 0.0137	 0.7086	 0.1509	 0.0168	 0.0101	
LMO1	 chr11	 8284745	 8284747	 cg21842523	 5.8796	 15.3362	 8.26E-13	 1.01E-10	 0.0507	 0.7080	 0.0649	 0.0613	 0.0180	
CTNND2	 chr5	 11904113	 11904115	 cg07195011	 6.8203	 18.7112	 1.73E-14	 6.03E-12	 0.0235	 0.7079	 0.2626	 0.0710	 0.0114	
N/A	 chr17	 78865086	 78865088	 cg10035831	 5.3191	 14.8846	 1.46E-12	 1.55E-10	 0.2029	 0.7075	 0.8951	 0.9007	 0.8697	
VAV3	 chr1	 108232420	 108232422	 cg09896211	 5.0877	 11.4982	 1.79E-10	 6.98E-09	 0.1530	 0.7070	 0.8691	 0.8668	 0.8836	
C11orf96	 chr11	 43963906	 43963908	 cg20062650	 7.2485	 12.0690	 7.42E-11	 3.39E-09	 0.0169	 0.7066	 0.0396	 0.0433	 0.0125	
N/A	 chr11	 20618229	 20618231	 cg02027945	 5.1649	 7.1032	 5.54E-07	 6.62E-06	 0.1111	 0.7065	 0.3202	 0.1272	 0.0176	
N/A	 chr13	 101194646	 101194648	 cg20198393	 5.6436	 17.4991	 6.42E-14	 1.54E-11	 0.2312	 0.7065	 0.9431	 0.9248	 0.9199	
GDF10	 chr10	 48438723	 48438725	 cg04110601	 7.4536	 18.3007	 2.67E-14	 8.16E-12	 0.0145	 0.7061	 0.0959	 0.0322	 0.0164	
CALML3	 chr10	 5567477	 5567479	 cg20691436	 6.4111	 13.6095	 7.98E-12	 5.77E-10	 0.2630	 0.7051	 0.9746	 0.9766	 0.9472	
IRX4	 chr5	 1883004	 1883006	 cg07882671	 6.5920	 13.2667	 1.29E-11	 8.41E-10	 0.0276	 0.7050	 0.3180	 0.1022	 0.0205	
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HMX3	 chr10	 124895473	 124895475	 cg00560482	 6.4198	 14.7924	 1.65E-12	 1.70E-10	 0.0316	 0.7049	 0.0529	 0.0374	 0.0181	
N/A	 chr13	 101194665	 101194667	 cg04832557	 5.1482	 17.5658	 5.96E-14	 1.46E-11	 0.1842	 0.7048	 0.9134	 0.8902	 0.8843	
RUNDC3B	 chr7	 87257672	 87257674	 cg17960051	 7.8504	 32.0346	 3.49E-19	 2.87E-15	 0.0107	 0.7041	 0.0110	 0.0229	 0.0100	
N/A	 chr7	 1850202	 1850204	 cg26202753	 5.1700	 15.8041	 4.64E-13	 6.52E-11	 0.1050	 0.7036	 0.8622	 0.6939	 0.8688	
N/A	 chr3	 184301729	 184301731	 cg24000814	 5.9076	 10.6415	 7.17E-10	 2.21E-08	 0.0477	 0.7028	 0.5302	 0.6924	 0.0364	
AEBP1	 chr7	 44143992	 44143994	 cg14249876	 7.3599	 22.6307	 3.95E-16	 4.10E-13	 0.0152	 0.7025	 0.1720	 0.0488	 0.0106	
N/A	 chr3	 197121409	 197121411	 cg05485379	 6.6472	 14.0083	 4.63E-12	 3.77E-10	 0.2723	 0.7018	 0.9299	 0.9498	 0.9707	
N/A	 chr9	 135465434	 135465436	 cg14192291	 5.8287	 12.7421	 2.73E-11	 1.52E-09	 0.0508	 0.7016	 0.2437	 0.1211	 0.0403	
RP11-834C11.7	
pseudogene	 chr12	 54473533	 54473535	 cg26407571	 5.3786	 12.2952	 5.28E-11	 2.58E-09	 0.2208	 0.7010	 0.9217	 0.3897	 0.9488	
GPR123	 chr10	 134901296	 134901298	 cg15825786	 6.4769	 17.0681	 1.04E-13	 2.19E-11	 0.0295	 0.7010	 0.2214	 0.0372	 0.0217	
	TMEM178B		 chr7	 140773904	 140773906	 cg07028821	 7.3338	 22.2452	 5.57E-16	 5.22E-13	 0.0154	 0.7009	 0.0884	 0.0460	 0.0126	
LAMA1	 chr18	 7116976	 7116978	 cg22455914	 6.5713	 15.3173	 8.46E-13	 1.02E-10	 0.0274	 0.7007	 0.1955	 0.0875	 0.0249	
PLXNA4	 chr7	 132262352	 132262354	 cg07258916	 7.2773	 17.7944	 4.63E-14	 1.22E-11	 0.0160	 0.7002	 0.0292	 0.0272	 0.0158	
N/A	 chr5	 510420	 510422	 cg17778888	 5.4888	 9.1154	 1.04E-08	 2.15E-07	 0.2306	 0.7002	 0.9613	 0.9541	 0.9667	
LRP1B	 chr2	 142887885	 142887887	 cg20443778	 6.1542	 10.4797	 9.40E-10	 2.78E-08	 0.0381	 0.7001	 0.1785	 0.0720	 0.0457	
HS3ST4		 chr16	 25703527	 25703529	 cg27014135	 7.6340	 25.9176	 2.58E-17	 6.02E-14	 0.0123	 0.7000	 0.0603	 0.0100	 0.0100	
CTD-2245F17.3	
lincRNA	 chr19	 53700526	 53700528	 cg23021477	 7.2922	 19.1884	 1.05E-14	 4.30E-12	 0.0158	 0.6997	 0.0142	 0.0530	 0.0149	
PURG	 chr8	 30890619	 30890621	 cg18324126	 7.5802	 16.6990	 1.60E-13	 3.00E-11	 0.0127	 0.6990	 0.0399	 0.0179	 0.0100	
DNM3	 chr1	 171810299	 171810301	 cg27429080	 7.3266	 12.1430	 6.64E-11	 3.10E-09	 0.0153	 0.6989	 0.4187	 0.0832	 0.0129	
N/A	 chr7	 20817529	 20817531	 cg08650910	 5.6553	 16.0507	 3.44E-13	 5.23E-11	 0.0582	 0.6986	 0.2162	 0.0689	 0.0400	
Top	100	hypo-methylated	sites	from	the	N	v	HGD-EAC	comparison	(differentiating	intervention	requiring	disease	from	normal	squamous	epithelium)	
SSBP3	 chr1	 54822030	 54822032	 cg00172603	 -5.6739	 -14.3153	 3.07E-12	 2.73E-10	 0.8606	 -0.7527	 0.2791	 0.2337	 0.0972	
N/A	 chr19	 2278617	 2278619	 cg27341866	 -5.7136	 -18.3377	 2.57E-14	 7.91E-12	 0.9259	 -0.7336	 0.2126	 0.8822	 0.8772	
N/A	 chr21	 36577538	 36577540	 cg09200260	 -5.0717	 -14.2823	 3.21E-12	 2.84E-10	 0.8186	 -0.7003	 0.5718	 0.1119	 0.0756	
N/A	 chr10	 70821370	 70821372	 cg07133930	 -5.0344	 -11.2392	 2.70E-10	 9.83E-09	 0.8136	 -0.6961	 0.3472	 0.6775	 0.3372	
N/A	 chr14	 107253272	 107253274	 cg19901523	 -4.8798	 -10.6762	 6.77E-10	 2.11E-08	 0.8391	 -0.6886	 0.6182	 0.7181	 0.0336	
RNF126P1	
pseudogene	 chr17	 55122827	 55122829	 cg02486253	 -4.8344	 -5.3735	 2.58E-05	 0.000179947	 0.8448	 -0.6846	 0.2897	 0.1549	 0.0830	
N/A	 chr4	 186434992	 186434994	 cg25581330	 -5.6293	 -15.4107	 7.53E-13	 9.38E-11	 0.7379	 -0.6841	 0.1176	 0.1204	 0.0613	
LAIR1	 chr19	 54876727	 54876729	 cg21878746	 -4.8264	 -6.7891	 1.08E-06	 1.18E-05	 0.8396	 -0.6838	 0.4442	 0.7485	 0.0554	
N/A	 chr13	 114880888	 114880890	 cg15972148	 -4.8456	 -15.3501	 8.12E-13	 9.92E-11	 0.8762	 -0.6787	 0.4216	 0.6814	 0.5137	
N/A	 chr3	 169384409	 169384411	 cg04120686	 -4.8181	 -18.1167	 3.26E-14	 9.46E-12	 0.8055	 -0.6775	 0.4131	 0.1603	 0.0521	
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LAIR1	 chr19	 54876748	 54876750	 cg01515802	 -4.8996	 -6.5208	 1.94E-06	 1.95E-05	 0.8897	 -0.6770	 0.5165	 0.7837	 0.0349	
N/A	 chr11	 69264656	 69264658	 cg26540315	 -4.9251	 -11.8641	 1.01E-10	 4.39E-09	 0.7691	 -0.6703	 0.3372	 0.1772	 0.1022	
CAPN2	 chr1	 223936798	 223936800	 cg06756211	 -5.0636	 -5.6882	 1.25E-05	 9.67E-05	 0.7513	 -0.6685	 0.0895	 0.1809	 0.0569	
ETS1	 chr11	 128391428	 128391430	 cg26503877	 -4.9611	 -7.0405	 6.33E-07	 7.43E-06	 0.7486	 -0.6613	 0.5437	 0.4361	 0.1129	
N/A	 chr7	 151442350	 151442352	 cg06436185	 -4.5894	 -6.5289	 1.90E-06	 1.92E-05	 0.8375	 -0.6612	 0.4179	 0.3406	 0.4143	
N/A	 chr1	 225942841	 225942843	 cg14520947	 -4.6784	 -20.4388	 3.01E-15	 1.76E-12	 0.8759	 -0.6598	 0.3817	 0.3076	 0.4668	
N/A	 chr5	 76034886	 76034888	 cg24722577	 -4.6761	 -14.3522	 2.93E-12	 2.63E-10	 0.7668	 -0.6528	 0.0993	 0.3956	 0.0785	
MSMB	 chr10	 51549504	 51549506	 cg10326726	 -4.6774	 -13.1745	 1.47E-11	 9.31E-10	 0.8908	 -0.6491	 0.2547	 0.2317	 0.8917	
N/A	 chr21	 36577637	 36577639	 cg21172011	 -4.9014	 -14.4596	 2.54E-12	 2.36E-10	 0.7325	 -0.6486	 0.2853	 0.0789	 0.1063	
SERPINA11	 chr14	 94917778	 94917780	 cg04368971	 -4.5131	 -7.2304	 4.24E-07	 5.25E-06	 0.7775	 -0.6448	 0.2661	 0.3842	 0.3291	
LPIN1	 chr2	 11917786	 11917788	 cg24011073	 -4.8677	 -7.4232	 2.84E-07	 3.71E-06	 0.9174	 -0.6419	 0.6594	 0.8887	 0.2334	
N/A	 chr1	 8143890	 8143892	 cg19274341	 -4.4702	 -11.7495	 1.21E-10	 5.07E-09	 0.7792	 -0.6418	 0.2164	 0.2048	 0.3203	
N/A	 chr20	 48998700	 48998702	 cg20430841	 -4.3960	 -18.9305	 1.37E-14	 5.13E-12	 0.8106	 -0.6417	 0.2717	 0.4300	 0.1799	
N/A	 chr2	 127955155	 127955157	 cg24923516	 -4.4270	 -14.5283	 2.32E-12	 2.21E-10	 0.8578	 -0.6388	 0.4572	 0.8108	 0.3561	
N/A	 chr3	 51104050	 51104052	 cg13302785	 -4.3935	 -11.7941	 1.13E-10	 4.79E-09	 0.7812	 -0.6360	 0.4936	 0.6309	 0.2261	
GDF15	 chr19	 18497142	 18497144	 cg12008047	 -5.4483	 -13.1243	 1.58E-11	 9.83E-10	 0.9535	 -0.6338	 0.3536	 0.3217	 0.9402	
N/A	 chr8	 108208343	 108208345	 cg21186098	 -4.4615	 -10.9903	 4.04E-10	 1.37E-08	 0.7510	 -0.6306	 0.1996	 0.4329	 0.2910	
N/A	 chr5	 123985367	 123985369	 cg21213593	 -4.4288	 -16.3170	 2.50E-13	 4.14E-11	 0.7521	 -0.6286	 0.2156	 0.2481	 0.0580	
RP11-443B7.2	
lincRNA	 chr1	 235091186	 235091188	 cg05926640	 -4.4112	 -17.6811	 5.24E-14	 1.34E-11	 0.7500	 -0.6264	 0.1799	 0.3767	 0.2003	
RP11-443B7.2	
lincRNA	 chr1	 235091105	 235091107	 cg20155035	 -4.2403	 -18.6750	 1.79E-14	 6.21E-12	 0.7972	 -0.6250	 0.1765	 0.3989	 0.2108	
IL18	 chr11	 112035944	 112035946	 cg05687149	 -4.2094	 -15.8409	 4.43E-13	 6.31E-11	 0.8364	 -0.6199	 0.4286	 0.2885	 0.2485	
KRT7	 chr12	 52627437	 52627439	 cg22958090	 -4.4639	 -6.0869	 5.06E-06	 4.46E-05	 0.8921	 -0.6196	 0.8111	 0.8005	 0.2288	
N/A	 chr1	 223936811	 223936813	 cg19598416	 -4.3328	 -5.0767	 5.14E-05	 0.000324477	 0.7408	 -0.6166	 0.1504	 0.2352	 0.0986	
SERPINA11	 chr14	 94917626	 94917628	 cg21007342	 -4.2892	 -16.8636	 1.32E-13	 2.60E-11	 0.7461	 -0.6154	 0.1383	 0.1462	 0.2459	
N/A	 chr3	 169384518	 169384520	 cg14580747	 -4.3049	 -14.5044	 2.40E-12	 2.26E-10	 0.7420	 -0.6150	 0.3788	 0.1520	 0.0663	
N/A	 chr16	 85981719	 85981721	 cg01574513	 -4.1659	 -7.0097	 6.76E-07	 7.86E-06	 0.7753	 -0.6141	 0.4753	 0.3828	 0.0759	
N/A	 chr7	 98311381	 98311383	 cg02928476	 -4.4793	 -10.0191	 2.07E-09	 5.41E-08	 0.7149	 -0.6139	 0.5553	 0.6538	 0.0290	
RP11-432J24.2	
lincRNA	 chr10	 134231548	 134231550	 cg23249922	 -4.2695	 -12.7922	 2.54E-11	 1.44E-09	 0.8710	 -0.6117	 0.5497	 0.3475	 0.4207	
N/A	 chr2	 208631683	 208631685	 cg15714846	 -4.0914	 -13.3042	 1.22E-11	 8.07E-10	 0.8193	 -0.6092	 0.2204	 0.2493	 0.1491	
N/A	 chr20	 22562477	 22562479	 cg20504791	 -4.1481	 -8.1457	 6.61E-08	 1.05E-06	 0.7611	 -0.6088	 0.5212	 0.0951	 0.1992	
N/A	 chr7	 116232818	 116232820	 cg10087556	 -4.2184	 -16.4325	 2.18E-13	 3.76E-11	 0.7388	 -0.6069	 0.1817	 0.2355	 0.0898	
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N/A	 chr8	 41176849	 41176851	 cg19656415	 -4.2337	 -15.3673	 7.95E-13	 9.79E-11	 0.7348	 -0.6064	 0.1796	 0.2020	 0.1455	
N/A	 chr8	 25059251	 25059253	 cg00157012	 -4.0847	 -16.2643	 2.66E-13	 4.34E-11	 0.8336	 -0.6057	 0.3308	 0.3344	 0.2122	
N/A	 chr16	 83869926	 83869928	 cg09683440	 -4.1157	 -9.4045	 6.14E-09	 1.36E-07	 0.7564	 -0.6045	 0.3438	 0.1502	 0.0694	
MX2	 chr21	 42734265	 42734267	 cg21130374	 -4.5215	 -13.7511	 6.57E-12	 4.93E-10	 0.6897	 -0.6014	 0.1585	 0.3620	 0.0460	
N/A	 chr4	 4397941	 4397943	 cg09852389	 -4.2394	 -13.0724	 1.70E-11	 1.04E-09	 0.7226	 -0.6014	 0.3718	 0.3827	 0.1824	
N/A	 chr2	 239403002	 239403004	 cg03217587	 -4.0096	 -12.7583	 2.67E-11	 1.49E-09	 0.8216	 -0.5992	 0.2144	 0.6836	 0.0663	
N/A	 chr3	 72870837	 72870839	 cg18720486	 -3.9874	 -17.0960	 1.01E-13	 2.13E-11	 0.8057	 -0.5984	 0.3567	 0.3511	 0.2215	
N/A	 chr11	 268949	 268951	 cg13185005	 -4.1682	 -15.3547	 8.07E-13	 9.89E-11	 0.7279	 -0.5984	 0.2285	 0.4909	 0.0524	
N/A	 chr4	 184949986	 184949988	 cg00331101	 -3.9687	 -10.1291	 1.71E-09	 4.60E-08	 0.8020	 -0.5965	 0.5905	 0.6668	 0.0826	
N/A	 chr22	 47082259	 47082261	 cg06766034	 -3.9807	 -12.5864	 3.43E-11	 1.82E-09	 0.8215	 -0.5958	 0.4129	 0.2894	 0.3885	
N/A	 chr19	 10715611	 10715613	 cg06943912	 -3.9608	 -10.4937	 9.18E-10	 2.72E-08	 0.7926	 -0.5955	 0.5468	 0.6639	 0.1094	
SEMA3C		 chr7	 80549170	 80549172	 cg09225287	 -3.9520	 -18.1146	 3.26E-14	 9.47E-12	 0.7952	 -0.5946	 0.3246	 0.6463	 0.3443	
N/A	 chr1	 15062528	 15062530	 cg19626253	 -3.9560	 -12.9783	 1.94E-11	 1.16E-09	 0.8135	 -0.5941	 0.2851	 0.4036	 0.1144	
N/A	 chr13	 114770147	 114770149	 cg21422164	 -5.0308	 -10.1190	 1.74E-09	 4.67E-08	 0.9469	 -0.5940	 0.9426	 0.9410	 0.8676	
N/A	 chr16	 81328088	 81328090	 cg00602295	 -3.9673	 -10.1694	 1.59E-09	 4.33E-08	 0.7645	 -0.5926	 0.1966	 0.1858	 0.3247	
N/A	 chr4	 184642693	 184642695	 cg22078781	 -3.9587	 -8.5828	 2.83E-08	 5.05E-07	 0.7664	 -0.5922	 0.2077	 0.1905	 0.1969	
N/A	 chr6	 1601508	 1601510	 cg16987638	 -3.9510	 -10.0682	 1.90E-09	 5.03E-08	 0.7639	 -0.5909	 0.1608	 0.1682	 0.2348	
N/A	 chr3	 124711100	 124711102	 cg19533443	 -4.5911	 -17.3034	 7.99E-14	 1.81E-11	 0.9237	 -0.5893	 0.3652	 0.5152	 0.8713	
N/A	 chr1	 111189870	 111189872	 cg03257417	 -4.1879	 -7.6364	 1.83E-07	 2.54E-06	 0.7055	 -0.5893	 0.3511	 0.1311	 0.3610	
N/A	 chr10	 115141826	 115141828	 cg01246622	 -4.3119	 -11.1481	 3.13E-10	 1.11E-08	 0.6879	 -0.5880	 0.4296	 0.4565	 0.0668	
N/A	 chr11	 655578	 655580	 cg17005319	 -5.2175	 -17.0047	 1.12E-13	 2.30E-11	 0.9559	 -0.5878	 0.4669	 0.3811	 0.9707	
SSBP3	 chr1	 54822502	 54822504	 cg08641990	 -3.9414	 -9.7606	 3.25E-09	 7.94E-08	 0.8351	 -0.5872	 0.4254	 0.3655	 0.2639	
CCDC141		 chr2	 179914863	 179914865	 cg24335070	 -4.0935	 -16.1103	 3.20E-13	 4.97E-11	 0.7153	 -0.5870	 0.1045	 0.0773	 0.0773	
NHLH2		 chr1	 116383237	 116383239	 cg23202177	 -3.8841	 -15.6275	 5.75E-13	 7.67E-11	 0.7912	 -0.5870	 0.2221	 0.1998	 0.2623	
N/A	 chr4	 124521390	 124521392	 cg03862787	 -4.3771	 -18.5209	 2.11E-14	 6.97E-12	 0.6778	 -0.5859	 0.1423	 0.1150	 0.0670	
N/A	 chr15	 70740428	 70740430	 cg19580937	 -3.8822	 -7.5942	 2.00E-07	 2.74E-06	 0.7702	 -0.5850	 0.2969	 0.4431	 0.1385	
N/A	 chr3	 193973395	 193973397	 cg21130113	 -3.9426	 -11.8567	 1.03E-10	 4.43E-09	 0.7411	 -0.5841	 0.2023	 0.2832	 0.0435	
EGFL7	 chr9	 139553209	 139553211	 cg14143326	 -3.8708	 -14.7132	 1.83E-12	 1.83E-10	 0.8117	 -0.5841	 0.3177	 0.5117	 0.1435	
N/A	 chr17	 63225019	 63225021	 cg04770088	 -3.9073	 -12.1449	 6.62E-11	 3.09E-09	 0.7470	 -0.5826	 0.2023	 0.2554	 0.0615	
N/A	 chr11	 269374	 269376	 cg11546385	 -3.9764	 -10.9091	 4.61E-10	 1.53E-08	 0.7277	 -0.5826	 0.4778	 0.6600	 0.0421	
N/A	 chr1	 204256845	 204256847	 cg25407979	 -4.1145	 -11.0370	 3.75E-10	 1.29E-08	 0.8802	 -0.5823	 0.5254	 0.2149	 0.1641	
PHACTR1	 chr6	 13274150	 13274152	 cg06879394	 -4.0535	 -6.2205	 3.76E-06	 3.45E-05	 0.7103	 -0.5816	 0.6272	 0.4093	 0.0188	
N/A	 chr6	 170532632	 170532634	 cg24454932	 -4.0455	 -6.6485	 1.47E-06	 1.53E-05	 0.7110	 -0.5813	 0.1161	 0.4979	 0.1287	
PRR26	 chr10	 696331	 696333	 cg14121234	 -6.2385	 -16.9982	 1.13E-13	 2.32E-11	 0.9806	 -0.5791	 0.4200	 0.3788	 0.9881	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
N/A	 chr9	 27379517	 27379519	 cg13648550	 -4.0224	 -17.9131	 4.06E-14	 1.11E-11	 0.7094	 -0.5788	 0.1821	 0.2131	 0.0903	
N/A	 chr3	 193587779	 193587781	 cg13323489	 -4.3353	 -6.3166	 3.04E-06	 2.87E-05	 0.6700	 -0.5786	 0.4743	 0.5284	 0.0323	
N/A	 chr6	 47468192	 47468194	 cg19989043	 -3.8567	 -15.1812	 1.00E-12	 1.17E-10	 0.8295	 -0.5781	 0.3706	 0.3302	 0.3069	
N/A	 chr5	 10485606	 10485608	 cg18430895	 -4.4727	 -13.1677	 1.48E-11	 9.37E-10	 0.6571	 -0.5776	 0.2582	 0.1692	 0.2016	
N/A	 chr13	 113584106	 113584108	 cg24028634	 -3.8155	 -4.6509	 0.000140331	 0.000764349	 0.8132	 -0.5770	 0.2847	 0.6844	 0.0678	
N/A	 chr17	 16200580	 16200582	 cg04592811	 -3.8622	 -19.2255	 1.01E-14	 4.18E-12	 0.8374	 -0.5759	 0.3949	 0.3322	 0.4376	
N/A	 chr5	 43039591	 43039593	 cg04122815	 -4.5932	 -11.6670	 1.38E-10	 5.63E-09	 0.6458	 -0.5755	 0.1972	 0.3784	 0.0495	
TBXAS1	 chr7	 139528854	 139528856	 cg05711445	 -4.0919	 -17.2591	 8.40E-14	 1.88E-11	 0.6911	 -0.5751	 0.2658	 0.2005	 0.1160	
N/A	 chr3	 112903053	 112903055	 cg00584840	 -3.8988	 -9.7576	 3.26E-09	 7.97E-08	 0.8495	 -0.5750	 0.2711	 0.1339	 0.9054	
N/A	 chr10	 30316431	 30316433	 cg12786570	 -3.9153	 -8.6504	 2.49E-08	 4.53E-07	 0.7191	 -0.5740	 0.5034	 0.5673	 0.0321	
N/A	 chr14	 78107676	 78107678	 cg18674234	 -3.8233	 -11.3111	 2.41E-10	 8.92E-09	 0.8299	 -0.5736	 0.5170	 0.7104	 0.4324	
DAPK1	 chr9	 90114754	 90114756	 cg13752933	 -4.0413	 -16.7465	 1.51E-13	 2.88E-11	 0.6945	 -0.5732	 0.1363	 0.1353	 0.1725	
N/A	 chr1	 3139866	 3139868	 cg15727188	 -4.0622	 -9.2256	 8.50E-09	 1.80E-07	 0.8821	 -0.5728	 0.2951	 0.2725	 0.8599	
GPSM3	 chr6	 32164800	 32164802	 cg06023661	 -3.9873	 -8.0012	 8.80E-08	 1.35E-06	 0.7021	 -0.5727	 0.1612	 0.1199	 0.3821	
N/A	 chr1	 203293432	 203293434	 cg06637812	 -3.8036	 -10.3499	 1.17E-09	 3.35E-08	 0.8249	 -0.5726	 0.1893	 0.3542	 0.0795	
N/A	 chr3	 169377817	 169377819	 cg00024967	 -3.7569	 -8.0374	 8.19E-08	 1.26E-06	 0.7726	 -0.5718	 0.3621	 0.2446	 0.0996	
N/A	 chr15	 78726575	 78726577	 cg20117256	 -3.7682	 -11.6184	 1.48E-10	 5.99E-09	 0.7573	 -0.5710	 0.2829	 0.4099	 0.2888	
SDE2	 chr1	 226187875	 226187877	 cg13556548	 -3.7316	 -10.1116	 1.76E-09	 4.72E-08	 0.7984	 -0.5687	 0.5740	 0.2162	 0.0802	
RP11-627G18.2	
antisense	 chr18	 19757467	 19757469	 cg15424989	 -3.7655	 -10.4575	 9.76E-10	 2.87E-08	 0.8219	 -0.5685	 0.3539	 0.2847	 0.8355	
RIN2	 chr20	 19870216	 19870218	 cg06856720	 -3.8881	 -6.8131	 1.03E-06	 1.13E-05	 0.7097	 -0.5680	 0.1839	 0.5960	 0.2525	
N/A	 chr10	 3466851	 3466853	 cg18692070	 -3.7497	 -11.0736	 3.53E-10	 1.23E-08	 0.7470	 -0.5670	 0.5438	 0.6523	 0.2476	
CCRL2		 chr3	 46448578	 46448580	 cg19850333	 -4.5527	 -18.0406	 3.54E-14	 1.01E-11	 0.6364	 -0.5670	 0.1085	 0.1340	 0.0762	
N/A	 chr7	 79964737	 79964739	 cg22110839	 -3.7217	 -13.6065	 8.02E-12	 5.78E-10	 0.7619	 -0.5667	 0.1472	 0.1527	 0.5017	
N/A	 chr2	 8849961	 8849963	 cg10900049	 -5.9226	 -20.6386	 2.48E-15	 1.53E-12	 0.9769	 -0.5665	 0.3620	 0.9587	 0.9695	
CACNA2D3		 chr3	 55040616	 55040618	 cg10791541	 -3.7253	 -13.3777	 1.10E-11	 7.44E-10	 0.8117	 -0.5659	 0.3341	 0.2476	 0.2095	
 
Table 2: Top 100 hyper- and hypo-methylated probes for differentiating Barrett’s esophagus from normal squamous epithelium 
44,201 hypermethylated and 26,985 hypomethylated CpG sites were identified as differentially methylated between normal squamous 
epithelium and Barrett’s esophagus (N v BE, FDR < 0.01 and Δβ ≥ 0.20). Gencode v19 was used for annotation204, gene name protein-coding 
when not specified. logfc: log fold change, tstat: t-statistic, pval: p-value, adj_pval: adjusted p-value, βbase: average methylation in baseline 
samples, here, normal squamous epithelium, Δβ: difference in average methylation between comparison groups, here, between BE and N, βduo: 
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average methylation in duodenal epithelium, βstom: average methylation in proximal stomach epithelium, βblood: average methylation in peripheral 
blood from disease-free patients. Top 100 hyper- and hypo-methylated sites based on greatest |Δβ|; listed in order of decreasing |Δβ|.  
 
gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
Top	100	hyper-methylated	sites	from	the	N	v	BE	comparison	(differentiating	Barrett’s	esophagus	from	normal	squamous	epithelium)	
N/A	 chr17	 80794273	 80794275	 cg18121066	 7.1119	 19.0306	 1.24E-14	 4.54E-12	 0.0767	 0.8432	 0.9454	 0.9095	 0.7214	
N/A	 chr5	 178781562	 178781564	 cg09068128	 6.9073	 10.3436	 1.18E-09	 3.37E-08	 0.1200	 0.8224	 0.9403	 0.9486	 0.9177	
C8orf34	 chr8	 69244509	 69244511	 cg21479226	 8.3115	 22.0532	 6.62E-16	 5.81E-13	 0.0160	 0.8216	 0.3088	 0.0350	 0.0157	
N/A	 chr1	 24612044	 24612046	 cg10881071	 6.6713	 20.7157	 2.30E-15	 1.44E-12	 0.1138	 0.8152	 0.9353	 0.9328	 0.8912	
N/A	 chr17	 40823929	 40823931	 cg19987356	 6.3464	 9.9307	 2.41E-09	 6.15E-08	 0.1166	 0.7982	 0.8963	 0.8786	 0.7327	
N/A	 chr10	 105517763	 105517765	 cg06888746	 6.6578	 12.2169	 5.94E-11	 2.83E-09	 0.0495	 0.7907	 0.8187	 0.8401	 0.0378	
SALL1	 chr16	 51185059	 51185061	 cg08439930	 6.4480	 15.4485	 7.18E-13	 8.83E-11	 0.0576	 0.7846	 0.2432	 0.0922	 0.0335	
TSHZ3	 chr19	 31841662	 31841664	 cg11199770	 7.8261	 18.4082	 2.38E-14	 7.21E-12	 0.0173	 0.7824	 0.1983	 0.0695	 0.0134	
WDR64	 chr1	 241912763	 241912765	 cg05940691	 6.3484	 10.5502	 8.35E-10	 2.52E-08	 0.1566	 0.7814	 0.8514	 0.9470	 0.9402	
SLC2A9	 chr4	 10024411	 10024413	 cg11124021	 6.6280	 12.3686	 4.73E-11	 2.35E-09	 0.1755	 0.7791	 0.9539	 0.9484	 0.9480	
EPB41L3		 chr18	 5543270	 5543272	 cg18543270	 7.2356	 18.0344	 3.56E-14	 9.72E-12	 0.0259	 0.7744	 0.1119	 0.0600	 0.0185	
N/A	 chr14	 91862863	 91862865	 cg10928544	 5.9615	 15.0008	 1.26E-12	 1.36E-10	 0.1301	 0.7730	 0.8658	 0.9018	 0.5149	
N/A	 chr10	 126314679	 126314681	 cg04426802	 6.3651	 17.4420	 6.84E-14	 1.55E-11	 0.1755	 0.7706	 0.9738	 0.9621	 0.9653	
TDRP	 chr8	 495816	 495818	 cg19019537	 6.7148	 15.5632	 6.23E-13	 7.95E-11	 0.0359	 0.7605	 0.2930	 0.0727	 0.0150	
FOXI2	 chr10	 129535377	 129535379	 cg16642284	 6.0130	 15.0051	 1.25E-12	 1.35E-10	 0.0681	 0.7570	 0.4257	 0.1782	 0.1003	
HOXD8	 chr2	 176994763	 176994765	 cg24416513	 6.0974	 15.1678	 1.02E-12	 1.16E-10	 0.0609	 0.7553	 0.3199	 0.2774	 0.0307	
FOXB2	 chr9	 79633736	 79633738	 cg14487131	 6.5333	 12.4844	 3.98E-11	 2.05E-09	 0.0399	 0.7538	 0.1931	 0.0912	 0.0184	
PIGG	 chr4	 512993	 512995	 cg18907098	 5.9529	 20.7228	 2.29E-15	 1.43E-12	 0.1766	 0.7534	 0.9431	 0.9259	 0.9057	
GNAQP1	pseudogene	 chr2	 132182670	 132182672	 cg20148575	 6.0756	 17.1069	 9.99E-14	 2.05E-11	 0.0609	 0.7530	 0.3326	 0.1720	 0.0135	
N/A	 chr7	 653308	 653310	 cg18367631	 5.9670	 14.7145	 1.82E-12	 1.80E-10	 0.1841	 0.7497	 0.8998	 0.9221	 0.5078	
TBCD	 chr17	 80816850	 80816852	 cg07769421	 6.0932	 14.4317	 2.64E-12	 2.38E-10	 0.1992	 0.7452	 0.9454	 0.9180	 0.8687	
N/A	 chr6	 41554528	 41554530	 cg15760474	 5.7845	 14.1333	 3.92E-12	 3.23E-10	 0.1823	 0.7424	 0.7390	 0.5747	 0.9176	
FLI1	 chr11	 128564873	 128564875	 cg11017065	 7.8597	 24.0145	 1.20E-16	 1.78E-13	 0.0131	 0.7419	 0.2579	 0.0334	 0.0115	
SLITRK5	 chr13	 88324569	 88324571	 cg15778745	 6.4861	 15.7254	 5.10E-13	 6.87E-11	 0.0379	 0.7416	 0.2914	 0.0811	 0.0176	
PIEZO2		 chr18	 11149434	 11149436	 cg03117976	 6.6372	 12.4613	 4.12E-11	 2.11E-09	 0.0334	 0.7413	 0.3945	 0.0994	 0.0160	
LAMA1	 chr18	 7116976	 7116978	 cg22455914	 6.8693	 16.0119	 3.60E-13	 5.32E-11	 0.0274	 0.7396	 0.1955	 0.0875	 0.0249	
N/A	 chr4	 1215111	 1215113	 cg12389346	 5.8660	 19.1821	 1.06E-14	 4.11E-12	 0.1948	 0.7390	 0.9564	 0.9447	 0.9617	
N/A	 chr4	 779479	 779481	 cg17128947	 5.7446	 15.5642	 6.22E-13	 7.94E-11	 0.0758	 0.7390	 0.3808	 0.6702	 0.0610	
VAV3	 chr1	 108232420	 108232422	 cg09896211	 5.5049	 12.4412	 4.25E-11	 2.16E-09	 0.1530	 0.7383	 0.8691	 0.8668	 0.8836	
TFAP2B		 chr6	 50791201	 50791203	 cg27260772	 5.6826	 11.8610	 1.02E-10	 4.39E-09	 0.0811	 0.7382	 0.5176	 0.1912	 0.0563	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
ZNF667	 chr19	 56989542	 56989544	 cg08063125	 7.2364	 17.9820	 3.77E-14	 1.01E-11	 0.0204	 0.7380	 0.3708	 0.0690	 0.0113	
EPB41L3	 chr18	 5543547	 5543549	 cg07352438	 6.4525	 16.3518	 2.40E-13	 3.93E-11	 0.0380	 0.7377	 0.1180	 0.1145	 0.0348	
N/A	 chr1	 2084518	 2084520	 cg04347414	 5.4229	 14.5112	 2.37E-12	 2.20E-10	 0.1335	 0.7351	 0.7488	 0.8300	 0.5873	
N/A	 chr8	 119626988	 119626990	 cg05230834	 5.5565	 15.3898	 7.73E-13	 9.36E-11	 0.1744	 0.7342	 0.8398	 0.8575	 0.9124	
VWC2	 chr7	 49813087	 49813089	 cg01893212	 6.4982	 21.0824	 1.63E-15	 1.13E-12	 0.0354	 0.7330	 0.4188	 0.1283	 0.0140	
PIEZO2		 chr18	 11149469	 11149471	 cg03686593	 5.6330	 16.0468	 3.45E-13	 5.17E-11	 0.0804	 0.7323	 0.4569	 0.1484	 0.0386	
N/A	 chr1	 245524537	 245524539	 cg03130248	 6.1507	 18.5717	 2.00E-14	 6.43E-12	 0.2213	 0.7315	 0.9259	 0.9109	 0.9190	
EPHA6	 chr3	 96533510	 96533512	 cg11410023	 5.7956	 17.5423	 6.12E-14	 1.43E-11	 0.0655	 0.7302	 0.3008	 0.1791	 0.0692	
RP11-388M20.9	
lincRNA	 chr16	 31238216	 31238218	 cg03016934	 6.1036	 14.3832	 2.81E-12	 2.51E-10	 0.2216	 0.7298	 0.9605	 0.9583	 0.8788	
CTNND2	 chr5	 11904113	 11904115	 cg07195011	 6.9846	 19.1621	 1.08E-14	 4.14E-12	 0.0235	 0.7297	 0.2626	 0.0710	 0.0114	
DLGAP4		 chr20	 34894647	 34894649	 cg03414318	 6.7104	 18.9695	 1.32E-14	 4.73E-12	 0.0289	 0.7282	 0.2342	 0.0657	 0.0448	
BRINP3		 chr1	 190447289	 190447291	 cg23010538	 5.7239	 12.3037	 5.21E-11	 2.55E-09	 0.0692	 0.7279	 0.2565	 0.1019	 0.0181	
SHISA9	 chr16	 12995295	 12995297	 cg04342955	 6.4946	 19.8316	 5.48E-15	 2.61E-12	 0.0343	 0.7279	 0.2794	 0.1079	 0.0675	
TDRP	 chr8	 494720	 494722	 cg03294066	 6.8126	 16.5778	 1.84E-13	 3.23E-11	 0.0265	 0.7271	 0.1823	 0.0509	 0.0180	
GNAO1		 chr16	 56228466	 56228468	 cg07700514	 7.8979	 32.0826	 3.38E-19	 2.64E-15	 0.0117	 0.7264	 0.1532	 0.0475	 0.0101	
LHX1	 chr17	 35294480	 35294482	 cg10043865	 7.1616	 20.7725	 2.18E-15	 1.38E-12	 0.0201	 0.7257	 0.1969	 0.0583	 0.0109	
N/A	 chr19	 13112282	 13112284	 cg22824635	 6.7797	 19.0252	 1.24E-14	 4.56E-12	 0.2479	 0.7253	 0.9762	 0.9629	 0.9821	
HS3ST4	 chr16	 25703527	 25703529	 cg27014135	 7.8061	 26.5019	 1.64E-17	 4.35E-14	 0.0123	 0.7238	 0.0603	 0.0100	 0.0100	
RIMS2		 chr8	 104512857	 104512859	 cg01566592	 6.7704	 17.9758	 3.79E-14	 1.01E-11	 0.0266	 0.7224	 0.1357	 0.0698	 0.0137	
LINC00404	lincRNA	 chr13	 112759892	 112759894	 cg25570913	 5.9567	 11.7827	 1.15E-10	 4.86E-09	 0.0523	 0.7218	 0.3602	 0.0814	 0.0752	
N/A	 chr17	 66292374	 66292376	 cg04173852	 6.1927	 17.0656	 1.05E-13	 2.13E-11	 0.2358	 0.7218	 0.9297	 0.9547	 0.9581	
N/A	 chr13	 101194665	 101194667	 cg04832557	 5.4139	 18.4726	 2.22E-14	 6.90E-12	 0.1842	 0.7217	 0.9134	 0.8902	 0.8843	
VWC2	 chr7	 49813032	 49813034	 cg04904331	 6.6846	 19.1678	 1.07E-14	 4.14E-12	 0.0283	 0.7214	 0.3670	 0.0832	 0.0139	
N/A	 chr10	 105510712	 105510714	 cg00730670	 6.1544	 18.5232	 2.11E-14	 6.69E-12	 0.2350	 0.7213	 0.9522	 0.9635	 0.9768	
N/A	 chr1	 9400774	 9400776	 cg24597774	 5.3676	 14.6072	 2.09E-12	 2.00E-10	 0.1803	 0.7205	 0.8990	 0.9162	 0.8934	
ST18	 chr8	 53322509	 53322511	 cg27649037	 5.9832	 14.5230	 2.34E-12	 2.17E-10	 0.2290	 0.7205	 0.9473	 0.9406	 0.9548	
ZNF471	 chr19	 57019068	 57019070	 cg00674365	 5.6520	 12.8609	 2.30E-11	 1.32E-09	 0.0696	 0.7203	 0.3719	 0.1561	 0.0312	
N/A	 chr15	 69099677	 69099679	 cg16068038	 5.7739	 15.7007	 5.26E-13	 7.03E-11	 0.2186	 0.7201	 0.9181	 0.8627	 0.9019	
N/A	 chr1	 15789861	 15789863	 cg04503318	 5.3179	 14.4895	 2.44E-12	 2.25E-10	 0.1754	 0.7192	 0.8649	 0.8397	 0.9246	
PTPRT	 chr20	 41818769	 41818771	 cg17859110	 7.4392	 22.2896	 5.35E-16	 4.93E-13	 0.0157	 0.7190	 0.1457	 0.0265	 0.0130	
N/A	 chr17	 80744832	 80744834	 cg11524039	 5.3585	 16.1036	 3.23E-13	 4.91E-11	 0.1837	 0.7186	 0.8990	 0.9007	 0.9108	
N/A	 chr11	 20618229	 20618231	 cg02027945	 5.2832	 7.2659	 3.94E-07	 4.94E-06	 0.1111	 0.7184	 0.3202	 0.1272	 0.0176	
C8orf34	 chr8	 69243485	 69243487	 cg22001496	 6.6837	 15.0652	 1.16E-12	 1.28E-10	 0.0278	 0.7183	 0.3725	 0.1192	 0.0202	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
POU3F3		 chr2	 105470560	 105470562	 cg19513834	 5.9548	 10.9242	 4.50E-10	 1.50E-08	 0.0509	 0.7178	 0.2020	 0.1018	 0.0115	
ZFP28	 chr19	 57050358	 57050360	 cg24152605	 6.8110	 23.1491	 2.51E-16	 2.91E-13	 0.0250	 0.7174	 0.2269	 0.0704	 0.0238	
ADCY4		 chr14	 24803872	 24803874	 cg23179456	 6.7146	 26.0050	 2.41E-17	 5.72E-14	 0.0269	 0.7168	 0.1412	 0.2256	 0.0147	
TBCD	 chr17	 80816701	 80816703	 cg23892310	 5.5093	 12.0764	 7.34E-11	 3.35E-09	 0.2051	 0.7165	 0.9434	 0.9207	 0.8632	
IRX4	 chr5	 1883004	 1883006	 cg07882671	 6.6770	 13.4378	 1.01E-11	 6.85E-10	 0.0276	 0.7164	 0.3180	 0.1022	 0.0205	
PAX9	 chr14	 37128585	 37128587	 cg04415798	 5.9812	 12.3324	 4.99E-11	 2.46E-09	 0.0489	 0.7157	 0.3165	 0.1758	 0.0629	
MTMR7	 chr8	 17271066	 17271068	 cg12296772	 5.4776	 11.2678	 2.58E-10	 9.51E-09	 0.0797	 0.7145	 0.3160	 0.2074	 0.0862	
SLC6A15	 chr12	 85306915	 85306917	 cg03064067	 5.5052	 15.3939	 7.69E-13	 9.31E-11	 0.0770	 0.7142	 0.3987	 0.2046	 0.2571	
BCAT1	 chr12	 25055966	 25055968	 cg20399616	 6.3647	 13.5819	 8.29E-12	 5.85E-10	 0.0348	 0.7134	 0.5663	 0.0695	 0.0109	
TRIM71	 chr3	 32860466	 32860468	 cg18249634	 5.8406	 9.9269	 2.43E-09	 6.19E-08	 0.0545	 0.7132	 0.2975	 0.0849	 0.1064	
N/A	 chr2	 468178	 468180	 cg13699355	 6.4120	 23.6609	 1.62E-16	 2.17E-13	 0.0333	 0.7125	 0.3016	 0.1055	 0.0175	
LHX1	 chr17	 35294475	 35294477	 cg05527869	 6.2955	 17.2772	 8.23E-14	 1.78E-11	 0.0363	 0.7111	 0.2070	 0.0662	 0.0118	
TRABD	 chr22	 50623691	 50623693	 cg11213574	 6.2140	 16.0442	 3.47E-13	 5.17E-11	 0.0385	 0.7098	 0.3554	 0.2732	 0.0196	
GMDS	 chr6	 1625573	 1625575	 cg04497116	 6.9296	 13.3038	 1.22E-11	 7.96E-10	 0.0218	 0.7092	 0.5299	 0.6931	 0.0308	
HOXD9	 chr2	 176987917	 176987919	 cg22674699	 5.6938	 11.8909	 9.74E-11	 4.23E-09	 0.0601	 0.7080	 0.4041	 0.3027	 0.0298	
N/A	 chr13	 101194646	 101194648	 cg20198393	 5.6770	 17.6026	 5.72E-14	 1.37E-11	 0.2312	 0.7078	 0.9431	 0.9248	 0.9199	
N/A	 chr7	 149917262	 149917264	 cg02864844	 7.1491	 20.0208	 4.54E-15	 2.29E-12	 0.0182	 0.7065	 0.1423	 0.0487	 0.0170	
N/A	 chr2	 105479053	 105479055	 cg11014373	 6.6435	 15.7198	 5.14E-13	 6.90E-11	 0.0267	 0.7063	 0.0925	 0.0612	 0.0100	
TSHZ3	 chr19	 31841951	 31841953	 cg15711268	 6.6028	 18.1317	 3.20E-14	 9.00E-12	 0.0275	 0.7057	 0.1291	 0.0713	 0.0139	
N/A	 chr3	 194018157	 194018159	 cg16924010	 5.0652	 10.9612	 4.24E-10	 1.43E-08	 0.1490	 0.7053	 0.8427	 0.4732	 0.1188	
VWC2	 chr7	 49813101	 49813103	 cg02467990	 6.5478	 17.6419	 5.48E-14	 1.32E-11	 0.0285	 0.7046	 0.4017	 0.1212	 0.0218	
VAT1L	 chr16	 77822418	 77822420	 cg07821427	 7.6074	 21.1462	 1.53E-15	 1.08E-12	 0.0128	 0.7043	 0.2112	 0.0341	 0.0117	
N/A	 chr13	 23733861	 23733863	 cg05494604	 6.9672	 19.4595	 7.96E-15	 3.38E-12	 0.0206	 0.7040	 0.2564	 0.0636	 0.0184	
CALML3	 chr10	 5567477	 5567479	 cg20691436	 6.3243	 13.4253	 1.03E-11	 6.95E-10	 0.2630	 0.7032	 0.9746	 0.9766	 0.9472	
ADD2	 chr2	 70995458	 70995460	 cg15170605	 6.7227	 19.4657	 7.91E-15	 3.37E-12	 0.0246	 0.7025	 0.2279	 0.0560	 0.0191	
GSG1L	 chr16	 28074461	 28074463	 cg10471437	 7.2613	 31.0663	 6.52E-19	 4.48E-15	 0.0164	 0.7023	 0.1960	 0.0309	 0.0135	
IRF4	 chr6	 393238	 393240	 cg21277995	 7.6165	 34.7276	 6.71E-20	 8.34E-16	 0.0126	 0.7018	 0.2845	 0.0391	 0.0100	
	FRMD4B		 chr3	 69591658	 69591660	 cg01360618	 5.5942	 20.4965	 2.85E-15	 1.69E-12	 0.0629	 0.7015	 0.4079	 0.1300	 0.0452	
N/A	 chr17	 78865086	 78865088	 cg10035831	 5.2140	 14.5906	 2.14E-12	 2.03E-10	 0.2029	 0.7014	 0.8951	 0.9007	 0.8697	
ADAMTS5	 chr21	 28339906	 28339908	 cg21646598	 6.2801	 13.0118	 1.85E-11	 1.11E-09	 0.0346	 0.7013	 0.2916	 0.1063	 0.0279	
N/A	 chr1	 9400738	 9400740	 cg04778236	 5.7995	 13.8400	 5.82E-12	 4.42E-10	 0.2469	 0.7012	 0.9662	 0.9599	 0.9370	
N/A	 chr1	 116371870	 116371872	 cg23952578	 6.2252	 9.7121	 3.54E-09	 8.51E-08	 0.2631	 0.7008	 0.9735	 0.9640	 0.9476	
RP11-567J20.2	
lincRNA	 chr8	 49468827	 49468829	 cg18991611	 7.7178	 36.8880	 1.95E-20	 4.40E-16	 0.0116	 0.7005	 0.2689	 0.0535	 0.0102	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
CTNND2	 chr5	 11904109	 11904111	 cg04996219	 7.3760	 22.3495	 5.07E-16	 4.73E-13	 0.0149	 0.7002	 0.2414	 0.0587	 0.0109	
NTRK3	 chr15	 88800566	 88800568	 cg05901579	 6.1253	 28.8734	 2.89E-18	 1.36E-14	 0.0388	 0.6991	 0.2658	 0.0787	 0.0135	
N/A	 chr6	 134378698	 134378700	 cg00583304	 5.3407	 13.8402	 5.82E-12	 4.42E-10	 0.2211	 0.6989	 0.9262	 0.9131	 0.9164	
N/A	 chr1	 246931895	 246931897	 cg06613253	 5.3201	 16.7414	 1.52E-13	 2.81E-11	 0.2199	 0.6986	 0.9323	 0.9191	 0.9064	
Top	100	hypo-methylated	sites	from	the	N	v	BE	comparison	(differentiating	Barrett’s	esophagus	from	normal	squamous	epithelium)	
XXYLT1-AS2	antisense	 chr3	 194868749	 194868751	 cg21937377	 -5.7252	 -9.1804	 9.23E-09	 1.93E-07	 0.9072	 -0.7513	 0.6947	 0.2261	 0.0840	
N/A	 chr13	 114812779	 114812781	 cg08707963	 -5.7178	 -9.8628	 2.71E-09	 6.81E-08	 0.9098	 -0.7490	 0.7258	 0.8046	 0.9250	
N/A	 chr19	 2278617	 2278619	 cg27341866	 -5.5779	 -17.9023	 4.11E-14	 1.07E-11	 0.9259	 -0.7186	 0.2126	 0.8822	 0.8772	
ARID5A	 chr2	 97204400	 97204402	 cg19954537	 -6.3760	 -8.1279	 6.85E-08	 1.08E-06	 0.7441	 -0.7103	 0.2891	 0.1339	 0.0235	
INPP5B		 chr1	 38412683	 38412685	 cg17949727	 -6.0032	 -8.5898	 2.79E-08	 5.00E-07	 0.7457	 -0.7020	 0.1169	 0.0530	 0.1055	
PRR26	 chr10	 695858	 695860	 cg01263942	 -5.0818	 -15.1879	 9.95E-13	 1.14E-10	 0.8894	 -0.6975	 0.2614	 0.1967	 0.8070	
N/A	 chr1	 3086486	 3086488	 cg01961086	 -5.7763	 -9.4810	 5.35E-09	 1.21E-07	 0.9505	 -0.6911	 0.4301	 0.2475	 0.9651	
N/A	 chr16	 54210495	 54210497	 cg00253658	 -4.8472	 -8.7281	 2.15E-08	 3.98E-07	 0.8427	 -0.6858	 0.2771	 0.1451	 0.3380	
N/A	 chr21	 36577538	 36577540	 cg09200260	 -4.7387	 -13.3447	 1.15E-11	 7.62E-10	 0.8186	 -0.6740	 0.5718	 0.1119	 0.0756	
N/A	 chr3	 169384409	 169384411	 cg04120686	 -4.7236	 -17.7613	 4.80E-14	 1.20E-11	 0.8055	 -0.6700	 0.4131	 0.1603	 0.0521	
GDF15	 chr19	 18497142	 18497144	 cg12008047	 -5.6913	 -13.7097	 6.96E-12	 5.10E-10	 0.9535	 -0.6693	 0.3536	 0.3217	 0.9402	
WNK2	 chr9	 95948058	 95948060	 cg13563298	 -4.7881	 -13.1358	 1.55E-11	 9.63E-10	 0.8873	 -0.6655	 0.3663	 0.8514	 0.9049	
N/A	 chr1	 8143890	 8143892	 cg19274341	 -4.7187	 -12.4025	 4.50E-11	 2.26E-09	 0.7792	 -0.6610	 0.2164	 0.2048	 0.3203	
INPP5D	 chr2	 233924929	 233924931	 cg00438740	 -4.5739	 -7.8323	 1.23E-07	 1.80E-06	 0.8176	 -0.6592	 0.4593	 0.6815	 0.0259	
N/A	 chr21	 36577637	 36577639	 cg21172011	 -5.0952	 -15.0315	 1.21E-12	 1.32E-10	 0.7325	 -0.6583	 0.2853	 0.0789	 0.1063	
N/A	 chr10	 134588039	 134588041	 cg09893465	 -5.3906	 -6.7894	 1.08E-06	 1.19E-05	 0.9453	 -0.6535	 0.3326	 0.2836	 0.9407	
N/A	 chr4	 186434992	 186434994	 cg25581330	 -4.9266	 -13.4871	 9.46E-12	 6.49E-10	 0.7379	 -0.6532	 0.1176	 0.1204	 0.0613	
N/A	 chr5	 171782206	 171782208	 cg10505610	 -5.2981	 -13.8526	 5.72E-12	 4.36E-10	 0.9412	 -0.6519	 0.4946	 0.2640	 0.9769	
N/A	 chr12	 68848993	 68848995	 cg15085883	 -4.5097	 -12.4477	 4.21E-11	 2.14E-09	 0.7950	 -0.6495	 0.4401	 0.1889	 0.5156	
N/A	 chr11	 69264656	 69264658	 cg26540315	 -4.6123	 -11.1106	 3.33E-10	 1.17E-08	 0.7691	 -0.6492	 0.3372	 0.1772	 0.1022	
LAIR1	 chr19	 54876727	 54876729	 cg21878746	 -4.4749	 -6.2946	 3.19E-06	 3.06E-05	 0.8396	 -0.6491	 0.4442	 0.7485	 0.0554	
RNF126P1	
pseudogene	 chr17	 55122827	 55122829	 cg02486253	 -4.4809	 -4.9806	 6.44E-05	 0.000424076	 0.8448	 -0.6488	 0.2897	 0.1549	 0.0830	
MSMB	 chr10	 51549504	 51549506	 cg10326726	 -4.6691	 -13.1513	 1.52E-11	 9.46E-10	 0.8908	 -0.6480	 0.2547	 0.2317	 0.8917	
LNX1	 chr4	 54374248	 54374250	 cg07080653	 -5.1022	 -17.6505	 5.42E-14	 1.32E-11	 0.9320	 -0.6467	 0.6127	 0.3824	 0.9549	
LAIR1	 chr19	 54876748	 54876750	 cg01515802	 -4.6504	 -6.1891	 4.03E-06	 3.76E-05	 0.8897	 -0.6466	 0.5165	 0.7837	 0.0349	
SSBP3	 chr1	 54822030	 54822032	 cg00172603	 -4.4707	 -11.2796	 2.54E-10	 9.36E-09	 0.8606	 -0.6428	 0.2791	 0.2337	 0.0972	
N/A	 chr2	 8849961	 8849963	 cg10900049	 -6.3796	 -22.2313	 5.64E-16	 5.15E-13	 0.9769	 -0.6404	 0.3620	 0.9587	 0.9695	
N/A	 chr20	 22562477	 22562479	 cg20504791	 -4.5325	 -8.9006	 1.55E-08	 3.01E-07	 0.7611	 -0.6401	 0.5212	 0.0951	 0.1992	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
N/A	 chr3	 124711100	 124711102	 cg19533443	 -4.9321	 -18.5886	 1.96E-14	 6.35E-12	 0.9237	 -0.6397	 0.3652	 0.5152	 0.8713	
N/A	 chr2	 238578490	 238578492	 cg22734058	 -4.5160	 -10.9431	 4.36E-10	 1.47E-08	 0.8786	 -0.6383	 0.3121	 0.4045	 0.9139	
N/A	 chr4	 186425696	 186425698	 cg25999637	 -5.2387	 -14.4591	 2.54E-12	 2.32E-10	 0.9432	 -0.6378	 0.4999	 0.8264	 0.9599	
N/A	 chr8	 108208343	 108208345	 cg21186098	 -4.5467	 -11.2001	 2.88E-10	 1.04E-08	 0.7510	 -0.6367	 0.1996	 0.4329	 0.2910	
N/A	 chr11	 111154825	 111154827	 cg21127079	 -5.0124	 -16.1774	 2.95E-13	 4.59E-11	 0.9324	 -0.6331	 0.7641	 0.4996	 0.9574	
N/A	 chr5	 76034886	 76034888	 cg24722577	 -4.4050	 -13.5203	 9.03E-12	 6.25E-10	 0.7668	 -0.6324	 0.0993	 0.3956	 0.0785	
N/A	 chr1	 3139866	 3139868	 cg15727188	 -4.4812	 -10.1772	 1.57E-09	 4.28E-08	 0.8821	 -0.6312	 0.2951	 0.2725	 0.8599	
SPG21	 chr15	 65277976	 65277978	 cg10207553	 -4.3205	 -8.7903	 1.91E-08	 3.59E-07	 0.7836	 -0.6302	 0.5324	 0.2044	 0.2336	
RASA3-IT1	
sense_intronic	 chr13	 114876209	 114876211	 cg21749794	 -4.2860	 -7.4421	 2.73E-07	 3.59E-06	 0.7979	 -0.6296	 0.6154	 0.6675	 0.0641	
MCM3AP	 chr21	 47704250	 47704252	 cg14211055	 -4.6064	 -12.0449	 7.70E-11	 3.49E-09	 0.9007	 -0.6294	 0.6194	 0.8415	 0.9456	
N/A	 chr1	 204256845	 204256847	 cg25407979	 -4.4511	 -11.9400	 9.03E-11	 3.98E-09	 0.8802	 -0.6287	 0.5254	 0.2149	 0.1641	
SERPINA11	 chr14	 94917626	 94917628	 cg21007342	 -4.4493	 -17.4933	 6.46E-14	 1.49E-11	 0.7461	 -0.6275	 0.1383	 0.1462	 0.2459	
N/A	 chr6	 112340332	 112340334	 cg02686793	 -4.4250	 -11.3301	 2.34E-10	 8.76E-09	 0.8780	 -0.6271	 0.4746	 0.2716	 0.9311	
GPSM3	/	NOTCH4	 chr6	 32164800	 32164802	 cg06023661	 -4.8365	 -9.7050	 3.58E-09	 8.60E-08	 0.7021	 -0.6259	 0.1612	 0.1199	 0.3821	
PDE7B	 chr6	 136174533	 136174535	 cg14623715	 -4.3247	 -14.5404	 2.29E-12	 2.14E-10	 0.8595	 -0.6256	 0.3714	 0.6836	 0.6437	
N/A	 chr3	 112903053	 112903055	 cg00584840	 -4.2726	 -10.6932	 6.58E-10	 2.06E-08	 0.8495	 -0.6235	 0.2711	 0.1339	 0.9054	
N/A	 chr10	 115141826	 115141828	 cg01246622	 -4.9840	 -12.8858	 2.22E-11	 1.28E-09	 0.6879	 -0.6228	 0.4296	 0.4565	 0.0668	
N/A	 chr4	 6324628	 6324630	 cg16616514	 -4.2692	 -6.0251	 5.81E-06	 5.18E-05	 0.8507	 -0.6226	 0.6921	 0.7551	 0.1038	
N/A	 chr1	 111189870	 111189872	 cg03257417	 -4.7277	 -8.6207	 2.63E-08	 4.75E-07	 0.7055	 -0.6226	 0.3511	 0.1311	 0.3610	
N/A	 chr10	 104556331	 104556333	 cg09671951	 -4.7575	 -7.7830	 1.36E-07	 1.96E-06	 0.6979	 -0.6192	 0.4162	 0.1185	 0.0809	
INPP5D	 chr2	 233924922	 233924924	 cg02788013	 -4.2367	 -5.3210	 2.91E-05	 0.000211719	 0.7692	 -0.6190	 0.4894	 0.6917	 0.0310	
N/A	 chr8	 2037873	 2037875	 cg17583158	 -4.3654	 -12.3708	 4.72E-11	 2.35E-09	 0.8797	 -0.6179	 0.4530	 0.5885	 0.7511	
N/A	 chr2	 16210107	 16210109	 cg03687070	 -4.4189	 -8.3566	 4.38E-08	 7.35E-07	 0.8880	 -0.6175	 0.4289	 0.2703	 0.9570	
RP11-498C9.17	
lincRNA	 chr17	 79924771	 79924773	 cg08574915	 -4.1685	 -15.3542	 8.08E-13	 9.68E-11	 0.8303	 -0.6164	 0.2972	 0.5579	 0.3073	
N/A	 chr16	 3211518	 3211520	 cg05982460	 -5.1233	 -14.3199	 3.06E-12	 2.67E-10	 0.9447	 -0.6157	 0.4497	 0.6811	 0.9578	
N/A	 chr8	 37218067	 37218069	 cg00576689	 -4.6455	 -12.9240	 2.10E-11	 1.23E-09	 0.9152	 -0.6139	 0.3617	 0.4693	 0.9411	
CLIC6	 chr21	 36041682	 36041684	 cg11528328	 -4.1263	 -5.4497	 2.16E-05	 0.000162929	 0.8033	 -0.6138	 0.5940	 0.5330	 0.0626	
SEMA3D	 chr7	 84671581	 84671583	 cg02607810	 -4.1188	 -16.8865	 1.29E-13	 2.48E-11	 0.8055	 -0.6130	 0.5737	 0.3838	 0.7743	
N/A	 chr16	 83869926	 83869928	 cg09683440	 -4.2132	 -9.6273	 4.11E-09	 9.67E-08	 0.7564	 -0.6130	 0.3438	 0.1502	 0.0694	
N/A	 chr10	 3160981	 3160983	 cg02579140	 -6.2766	 -16.5897	 1.81E-13	 3.19E-11	 0.9781	 -0.6129	 0.4978	 0.9574	 0.9823	
N/A	 chr7	 79964737	 79964739	 cg22110839	 -4.1895	 -15.3166	 8.47E-13	 1.00E-10	 0.7619	 -0.6127	 0.1472	 0.1527	 0.5017	
RP11-61F12.1	 chr16	 84628968	 84628970	 cg03738384	 -4.3636	 -11.4709	 1.87E-10	 7.28E-09	 0.8852	 -0.6127	 0.2475	 0.2505	 0.8560	
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antisense	
N/A	 chr6	 39176488	 39176490	 cg21619775	 -4.6300	 -12.9628	 1.98E-11	 1.17E-09	 0.9146	 -0.6126	 0.4134	 0.4665	 0.9043	
N/A	 chr11	 268949	 268951	 cg13185005	 -4.3436	 -16.0007	 3.65E-13	 5.36E-11	 0.7279	 -0.6115	 0.2285	 0.4909	 0.0524	
PIGB	 chr15	 55610623	 55610625	 cg19991916	 -4.5713	 -11.1186	 3.28E-10	 1.16E-08	 0.9107	 -0.6104	 0.7502	 0.8486	 0.9355	
N/A	 chr13	 114880888	 114880890	 cg15972148	 -4.2766	 -13.5477	 8.70E-12	 6.07E-10	 0.8762	 -0.6087	 0.4216	 0.6814	 0.5137	
N/A	 chr10	 3160925	 3160927	 cg05394294	 -4.7193	 -19.3696	 8.73E-15	 3.60E-12	 0.9241	 -0.6081	 0.4321	 0.8718	 0.9194	
RP11-443B7.2	
lincRNA	 chr1	 235091105	 235091107	 cg20155035	 -4.0721	 -17.9342	 3.97E-14	 1.05E-11	 0.7972	 -0.6078	 0.1765	 0.3989	 0.2108	
IRF8	 chr16	 85933162	 85933164	 cg04597312	 -4.1190	 -14.8322	 1.57E-12	 1.60E-10	 0.7646	 -0.6071	 0.1703	 0.1628	 0.7041	
N/A	 chr5	 78277491	 78277493	 cg08393937	 -4.0503	 -16.9875	 1.14E-13	 2.26E-11	 0.7969	 -0.6054	 0.2924	 0.2444	 0.7274	
N/A	 chr15	 78726575	 78726577	 cg20117256	 -4.1149	 -12.6873	 2.96E-11	 1.61E-09	 0.7573	 -0.6047	 0.2829	 0.4099	 0.2888	
N/A	 chr16	 81328088	 81328090	 cg00602295	 -4.0825	 -10.4646	 9.65E-10	 2.84E-08	 0.7645	 -0.6037	 0.1966	 0.1858	 0.3247	
LINC00261	lincRNA	 chr20	 22557517	 22557519	 cg08582485	 -4.0612	 -8.8072	 1.85E-08	 3.50E-07	 0.7734	 -0.6037	 0.4014	 0.1164	 0.1979	
SLC6A20	 chr3	 45837196	 45837198	 cg24940967	 -4.0671	 -9.3141	 7.23E-09	 1.57E-07	 0.8333	 -0.6036	 0.4712	 0.5924	 0.4450	
FLG2	 chr1	 152333422	 152333424	 cg03957898	 -4.0406	 -11.7463	 1.22E-10	 5.09E-09	 0.8244	 -0.6024	 0.4717	 0.3626	 0.8028	
N/A	 chr3	 169384033	 169384035	 cg09380805	 -4.0200	 -9.7771	 3.15E-09	 7.73E-08	 0.7870	 -0.6015	 0.4798	 0.1825	 0.0898	
N/A	 chr1	 12603853	 12603855	 cg20059492	 -4.5082	 -11.5663	 1.61E-10	 6.42E-09	 0.9113	 -0.6002	 0.4353	 0.3485	 0.9403	
CLIC6		 chr21	 36041604	 36041606	 cg19200589	 -3.9998	 -7.5517	 2.18E-07	 2.95E-06	 0.8065	 -0.5998	 0.5746	 0.4727	 0.0294	
N/A	 chr10	 123810031	 123810033	 cg05655953	 -5.7869	 -21.5344	 1.07E-15	 8.40E-13	 0.9702	 -0.5993	 0.3969	 0.4357	 0.9451	
INMT	 chr7	 30737555	 30737557	 cg13134297	 -4.0843	 -13.6018	 8.07E-12	 5.73E-10	 0.7485	 -0.5992	 0.2661	 0.4839	 0.2834	
IDO1	 chr8	 39782017	 39782019	 cg24188163	 -4.0122	 -17.9939	 3.72E-14	 1.00E-11	 0.7751	 -0.5991	 0.3325	 0.1948	 0.7816	
FLNB	 chr3	 58151254	 58151256	 cg05116002	 -4.3762	 -9.9915	 2.17E-09	 5.62E-08	 0.8992	 -0.5987	 0.6474	 0.2883	 0.9267	
N/A	 chr2	 239403002	 239403004	 cg03217587	 -4.0047	 -12.7428	 2.73E-11	 1.51E-09	 0.8216	 -0.5987	 0.2144	 0.6836	 0.0663	
PRR26	 chr10	 695876	 695878	 cg17198320	 -4.2225	 -16.3143	 2.51E-13	 4.07E-11	 0.8798	 -0.5982	 0.4039	 0.2511	 0.7990	
N/A	 chr3	 169377724	 169377726	 cg08004073	 -3.9818	 -9.7736	 3.17E-09	 7.77E-08	 0.7991	 -0.5980	 0.3229	 0.2549	 0.0760	
N/A	 chr6	 122253934	 122253936	 cg15010554	 -4.3981	 -23.1047	 2.61E-16	 3.00E-13	 0.6936	 -0.5967	 0.2625	 0.1152	 0.1863	
N/A	 chr8	 122823861	 122823863	 cg10131026	 -3.9745	 -9.5382	 4.82E-09	 1.11E-07	 0.8106	 -0.5966	 0.6546	 0.4002	 0.5814	
N/A	 chr14	 70160159	 70160161	 cg15935770	 -3.9882	 -11.7800	 1.16E-10	 4.88E-09	 0.7734	 -0.5964	 0.2505	 0.4254	 0.3750	
N/A	 chr7	 155592262	 155592264	 cg00802903	 -3.9842	 -4.7091	 0.000122277	 0.00074227	 0.8257	 -0.5953	 0.7369	 0.7637	 0.6551	
N/A	 chr15	 61044828	 61044830	 cg02010763	 -4.1813	 -9.6414	 4.01E-09	 9.47E-08	 0.8768	 -0.5950	 0.5388	 0.2084	 0.8698	
N/A	 chr11	 85453668	 85453670	 cg20943999	 -4.8256	 -9.1900	 9.07E-09	 1.90E-07	 0.9365	 -0.5942	 0.4244	 0.3910	 0.9285	
N/A	 chr2	 127955155	 127955157	 cg24923516	 -4.0708	 -13.3594	 1.13E-11	 7.49E-10	 0.8578	 -0.5936	 0.4572	 0.8108	 0.3561	
RP11-432J24.2	
lincRNA	 chr10	 134231548	 134231550	 cg23249922	 -4.1361	 -12.3925	 4.57E-11	 2.29E-09	 0.8710	 -0.5936	 0.5497	 0.3475	 0.4207	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
N/A	 chr19	 1547395	 1547397	 cg05649427	 -4.4526	 -14.6824	 1.90E-12	 1.86E-10	 0.9107	 -0.5929	 0.5714	 0.6729	 0.9368	
PRR26	 chr10	 696331	 696333	 cg14121234	 -6.3214	 -17.2241	 8.74E-14	 1.86E-11	 0.9806	 -0.5928	 0.4200	 0.3788	 0.9881	
ST14	 chr11	 130059790	 130059792	 cg23250795	 -4.2267	 -14.1700	 3.73E-12	 3.12E-10	 0.8859	 -0.5928	 0.3364	 0.6018	 0.8884	
N/A	 chr17	 70120540	 70120542	 cg06234051	 -5.4445	 -12.9736	 1.95E-11	 1.16E-09	 0.9624	 -0.5922	 0.4268	 0.3458	 0.9293	
RP11-797H7.5	
antisense	 chr7	 64349132	 64349134	 cg13990351	 -4.1741	 -7.0007	 6.89E-07	 8.03E-06	 0.7123	 -0.5917	 0.0393	 0.0239	 0.0176	
N/A	 chr4	 124521390	 124521392	 cg03862787	 -4.4524	 -18.8392	 1.51E-14	 5.23E-12	 0.6778	 -0.5901	 0.1423	 0.1150	 0.0670	
TNS3	 chr7	 47493387	 47493389	 cg07241084	 -3.9397	 -7.2895	 3.75E-07	 4.73E-06	 0.7616	 -0.5893	 0.3066	 0.1682	 0.1261	
C1orf132	
processed_transcript	 chr1	 207997019	 207997021	 cg10501210	 -3.9050	 -11.5966	 1.54E-10	 6.18E-09	 0.7892	 -0.5893	 0.2792	 0.2417	 0.8449	
ARHGAP44		 chr17	 12695724	 12695726	 cg24096540	 -5.1677	 -15.6439	 5.64E-13	 7.36E-11	 0.9537	 -0.5892	 0.4151	 0.7847	 0.9657	
 
Table 3: Top 100 hyper- and hypo-methylated probes for differentiating intervention requiring disease from Barrett’s esophagus 
1,648 hypermethylated and 153 hypomethylated CpG sites were identified as differentially methylated between Barrett’s esophagus and 
intervention requiring disease (BE v HGD-EAC, FDR < 0.01 and Δβ ≥ 0.20). Gencode v19 was used for annotation204, gene name protein-
coding when not specified. logfc: log fold change, tstat: t-statistic, pval: p-value, adj_pval: adjusted p-value, βbase: average methylation in 
baseline samples, here, Barrett’s esophagus, Δβ: difference in average methylation between comparison groups, here, between BE and HGD-
EAC, βduo: average methylation in duodenal epithelium, βstom: average methylation in proximal stomach epithelium, βblood: average methylation in 
peripheral blood from disease-free patients. Top 100 hyper- and hypo-methylated sites based on greatest |Δβ|; listed in order of decreasing 
|Δβ|.  
 
gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
Top	100	hyper-methylated	sites	from	the	BE	v	HGD-EAC	comparison	(differentiating	intervention	requiring	disease	from	Barrett’s	esophagus)	
N/A	 chr13	 114812779	 114812781	 cg08707963	 4.0335	 6.3513	 2.81E-06	 0.002321031	 0.1609	 0.5975	 0.7258	 0.8046	 0.9250	
DTX3	 chr12	 57998785	 57998787	 cg17730484	 4.0435	 7.4563	 2.65E-07	 0.000654129	 0.1189	 0.5710	 0.0488	 0.0563	 0.0465	
	DCBLD2		 chr3	 98620661	 98620663	 cg27352765	 5.4414	 6.6768	 1.38E-06	 0.001614185	 0.0318	 0.5564	 0.0144	 0.0168	 0.0194	
DCHS1	 chr11	 6677086	 6677088	 cg21012362	 4.6033	 7.3346	 3.41E-07	 0.000789165	 0.0621	 0.5546	 0.0133	 0.0227	 0.0192	
SNORD103B	snoRNA	 chr1	 31423070	 31423072	 cg04248332	 3.8322	 6.5539	 1.80E-06	 0.001813045	 0.3119	 0.5540	 0.7152	 0.4085	 0.9113	
GBGT1	 chr9	 136039124	 136039126	 cg14472025	 5.0940	 11.5566	 1.64E-10	 1.25E-05	 0.0392	 0.5428	 0.0246	 0.0384	 0.0237	
DTX3	 chr12	 57998761	 57998763	 cg11654179	 3.6754	 7.6312	 1.85E-07	 0.000565773	 0.1380	 0.5336	 0.0527	 0.0691	 0.0203	
ENOX1	 chr13	 44361211	 44361213	 cg24098938	 3.7498	 6.1753	 4.15E-06	 0.00281916	 0.1223	 0.5298	 0.0191	 0.0117	 0.0127	
GNG4	 chr1	 235812839	 235812841	 cg06714284	 4.2635	 7.5149	 2.35E-07	 0.000618223	 0.0727	 0.5283	 0.0100	 0.0123	 0.0100	
N/A	 chr5	 36690258	 36690260	 cg08407114	 3.5717	 7.5789	 2.06E-07	 0.000582086	 0.1420	 0.5211	 0.2623	 0.1483	 0.0296	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
ENOX1	 chr13	 44361219	 44361221	 cg01118451	 3.5284	 5.6312	 1.42E-05	 0.00501497	 0.1489	 0.5199	 0.0283	 0.0272	 0.0102	
N/A	 chr5	 36690456	 36690458	 cg18064852	 3.5381	 9.3310	 7.01E-09	 8.66E-05	 0.1377	 0.5120	 0.1742	 0.0781	 0.0567	
N/A	 chr5	 36690656	 36690658	 cg00132108	 3.9272	 10.8398	 5.17E-10	 2.00E-05	 0.0890	 0.5088	 0.1063	 0.0931	 0.0584	
FAM78B	 chr1	 166134281	 166134283	 cg21868774	 3.5507	 6.0964	 4.95E-06	 0.003050374	 0.1302	 0.5067	 0.0172	 0.0262	 0.0128	
EMILIN2	 chr18	 2847529	 2847531	 cg05102581	 3.8930	 6.0816	 5.12E-06	 0.003087359	 0.0907	 0.5064	 0.1153	 0.0171	 0.0103	
N/A	 chr5	 36690436	 36690438	 cg05542957	 5.6720	 13.8895	 5.44E-12	 2.50E-06	 0.0210	 0.5014	 0.0564	 0.0138	 0.0155	
KCNB2	 chr8	 73449523	 73449525	 cg15774465	 4.0321	 6.1592	 4.31E-06	 0.00287227	 0.0757	 0.4969	 0.0621	 0.0274	 0.0108	
QPCT	 chr2	 37571728	 37571730	 cg15162392	 4.3648	 5.2101	 3.77E-05	 0.008126585	 0.0565	 0.4960	 0.0465	 0.0637	 0.0373	
ADCY5	 chr3	 123167769	 123167771	 cg02978184	 3.3560	 5.2627	 3.33E-05	 0.007655235	 0.1523	 0.4956	 0.0367	 0.0305	 0.0125	
RARA	 chr17	 38506349	 38506351	 cg18125573	 3.4858	 5.5506	 1.71E-05	 0.005558375	 0.3758	 0.4951	 0.8638	 0.3560	 0.9426	
CLDN10	 chr13	 96204872	 96204874	 cg10305311	 3.8961	 6.7417	 1.20E-06	 0.001510758	 0.0844	 0.4941	 0.1449	 0.0236	 0.0114	
AC009236.2	lincRNA	 chr2	 45395869	 45395871	 cg20459525	 3.3935	 8.0388	 8.17E-08	 0.000351035	 0.1421	 0.4930	 0.0450	 0.0932	 0.0634	
RRAGD	 chr6	 90121669	 90121671	 cg22264975	 3.5273	 10.2153	 1.47E-09	 3.23E-05	 0.1204	 0.4917	 0.0447	 0.0780	 0.0304	
NMUR1	 chr2	 232395268	 232395270	 cg19187155	 3.4086	 5.3112	 2.98E-05	 0.007290931	 0.1367	 0.4903	 0.0668	 0.0704	 0.0208	
ENO4	 chr10	 118609166	 118609168	 cg15461105	 4.7516	 11.3811	 2.16E-10	 1.42E-05	 0.0397	 0.4870	 0.0233	 0.0445	 0.0259	
KCNQ3		 chr8	 133493433	 133493435	 cg04396550	 3.2384	 5.5880	 1.57E-05	 0.005319329	 0.1653	 0.4861	 0.0191	 0.0219	 0.0139	
ZBTB20		 chr3	 114103344	 114103346	 cg13792714	 3.1260	 5.4940	 1.95E-05	 0.00590825	 0.1969	 0.4846	 0.6993	 0.5548	 0.7404	
OBSL1	 chr2	 220417248	 220417250	 cg11531021	 3.1584	 5.3670	 2.61E-05	 0.006897738	 0.1846	 0.4844	 0.0239	 0.0271	 0.0133	
ENO4	 chr10	 118608697	 118608699	 cg01035689	 3.5355	 9.7828	 3.12E-09	 5.32E-05	 0.1105	 0.4798	 0.0698	 0.1111	 0.0834	
KCNMA1	 chr10	 79397454	 79397456	 cg09405661	 3.0217	 5.1978	 3.87E-05	 0.008231347	 0.2387	 0.4793	 0.0388	 0.0468	 0.0313	
GRASP	 chr12	 52400662	 52400664	 cg22196952	 5.1079	 9.1412	 9.92E-09	 0.000108173	 0.0291	 0.4788	 0.0124	 0.0121	 0.0100	
GPR25	 chr1	 200842281	 200842283	 cg19940077	 3.1130	 8.2719	 5.16E-08	 0.000264917	 0.3380	 0.4774	 0.6155	 0.2963	 0.8460	
N/A	 chr11	 130641100	 130641102	 cg16864819	 3.2846	 7.8211	 1.26E-07	 0.000456997	 0.3808	 0.4762	 0.7347	 0.6764	 0.8865	
PODN	 chr1	 53527664	 53527666	 cg01394819	 2.9963	 5.5760	 1.61E-05	 0.005401726	 0.2261	 0.4737	 0.0316	 0.0205	 0.0133	
KCNB2	 chr8	 73449518	 73449520	 cg18555069	 3.8960	 6.6330	 1.52E-06	 0.001696913	 0.0754	 0.4728	 0.0765	 0.0113	 0.0102	
USP32	 chr17	 58498976	 58498978	 cg09695735	 4.8985	 5.1528	 4.30E-05	 0.008596317	 0.0327	 0.4691	 0.0409	 0.0100	 0.0100	
QPCT	 chr2	 37571731	 37571733	 cg08786077	 3.6360	 5.6657	 1.31E-05	 0.004824456	 0.0938	 0.4690	 0.0873	 0.1146	 0.0563	
SH3RF3		 chr2	 109745613	 109745615	 cg22959667	 3.9233	 6.4746	 2.14E-06	 0.001987147	 0.0716	 0.4677	 0.0124	 0.0193	 0.0103	
INSC	 chr11	 15136455	 15136457	 cg02434443	 3.3785	 7.5072	 2.39E-07	 0.00062276	 0.1203	 0.4668	 0.1685	 0.0340	 0.0131	
SH3RF3		 chr2	 109745647	 109745649	 cg16117910	 3.6117	 5.4943	 1.95E-05	 0.00590825	 0.0947	 0.4664	 0.0211	 0.0380	 0.0162	
N/A	 chr17	 76993393	 76993395	 cg00902147	 3.3416	 7.4562	 2.65E-07	 0.000654129	 0.4100	 0.4657	 0.9205	 0.7199	 0.9834	
PRKG1	 chr10	 52833908	 52833910	 cg04884011	 3.1050	 5.4457	 2.18E-05	 0.006203342	 0.1659	 0.4653	 0.0803	 0.0332	 0.0275	
N/A	 chr1	 247611501	 247611503	 cg09226051	 3.3354	 5.8112	 9.43E-06	 0.00409674	 0.1218	 0.4615	 0.1542	 0.0717	 0.2766	
SCARF2	 chr22	 20792216	 20792218	 cg15243570	 3.1402	 7.6303	 1.86E-07	 0.000565773	 0.1532	 0.4615	 0.0386	 0.0322	 0.0100	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
PCLO	 chr7	 82792344	 82792346	 cg15478390	 3.7534	 7.2313	 4.24E-07	 0.000892687	 0.0805	 0.4610	 0.0307	 0.0144	 0.0194	
WWP2	 chr16	 69924615	 69924617	 cg27456203	 2.8969	 6.2708	 3.36E-06	 0.00248741	 0.2307	 0.4600	 0.5828	 0.1931	 0.8501	
CTD-3194G12.2	
lincRNA	 chr17	 35078658	 35078660	 cg21653132	 3.4578	 5.8886	 7.91E-06	 0.003761777	 0.1062	 0.4600	 0.0352	 0.0281	 0.0178	
N/A	 chr19	 36478288	 36478290	 cg13620744	 3.1270	 5.0557	 5.40E-05	 0.009586952	 0.1508	 0.4573	 0.0302	 0.0239	 0.0144	
DNM3	 chr1	 171810777	 171810779	 cg06211893	 3.0632	 5.9481	 6.92E-06	 0.003578714	 0.1632	 0.4566	 0.1392	 0.0372	 0.0169	
KRBA1		 chr7	 149412289	 149412291	 cg03788131	 3.4640	 5.5918	 1.56E-05	 0.005286613	 0.1029	 0.4557	 0.1176	 0.0322	 0.0270	
FADS1	 chr11	 61583570	 61583572	 cg13475388	 4.2667	 5.5058	 1.90E-05	 0.005854958	 0.0505	 0.4552	 0.0136	 0.0111	 0.0119	
N/A	 chr17	 31149876	 31149878	 cg01050010	 3.0708	 5.2913	 3.12E-05	 0.007422554	 0.1590	 0.4547	 0.3245	 0.3553	 0.2474	
FADS1	 chr11	 61583955	 61583957	 cg23992449	 3.8550	 5.8032	 9.60E-06	 0.004119001	 0.0710	 0.4541	 0.0109	 0.0143	 0.0103	
N/A	 chr19	 11784760	 11784762	 cg21771200	 3.4896	 6.6041	 1.62E-06	 0.001743736	 0.0993	 0.4540	 0.4908	 0.0540	 0.0555	
STOX2	 chr4	 184826298	 184826300	 cg10957242	 3.3215	 9.1851	 9.15E-09	 0.000107932	 0.1152	 0.4503	 0.0227	 0.0633	 0.0187	
EPHX3	 chr19	 15343344	 15343346	 cg17399362	 3.5499	 6.4958	 2.05E-06	 0.001926668	 0.0916	 0.4500	 0.0725	 0.0786	 0.0721	
ATP6V1B1		 chr2	 71192261	 71192263	 cg10598816	 2.8355	 5.3105	 2.98E-05	 0.007291554	 0.2260	 0.4498	 0.0538	 0.0642	 0.0510	
ENOX1	 chr13	 44361018	 44361020	 cg09320746	 3.0738	 6.2817	 3.28E-06	 0.002459659	 0.1522	 0.4496	 0.0533	 0.0538	 0.0513	
N/A	 chr22	 39784480	 39784482	 cg02038168	 3.2013	 5.0292	 5.75E-05	 0.009898916	 0.1307	 0.4496	 0.0921	 0.0340	 0.0264	
TTYH1	 chr19	 54926616	 54926618	 cg15723536	 2.9234	 5.5630	 1.66E-05	 0.005462332	 0.1876	 0.4490	 0.1494	 0.0631	 0.0193	
MOXD1	 chr6	 132722420	 132722422	 cg07570142	 3.5723	 9.8867	 2.60E-09	 4.99E-05	 0.0891	 0.4487	 0.1076	 0.0690	 0.0687	
RET	 chr10	 43572243	 43572245	 cg00540891	 2.8762	 5.8240	 9.16E-06	 0.004023324	 0.2008	 0.4477	 0.0518	 0.0922	 0.0293	
N/A	 chr5	 64103335	 64103337	 cg15663823	 2.8199	 6.5234	 1.93E-06	 0.00188473	 0.3319	 0.4463	 0.7027	 0.3887	 0.9056	
MEIS1	 chr2	 66667548	 66667550	 cg11433622	 3.0141	 5.3458	 2.75E-05	 0.00701948	 0.1600	 0.4461	 0.2529	 0.3408	 0.0282	
HLX	 chr1	 221053512	 221053514	 cg15356516	 3.8118	 5.9238	 7.30E-06	 0.003639877	 0.0703	 0.4448	 0.0344	 0.0512	 0.0214	
N/A	 chr1	 76081961	 76081963	 cg27547954	 2.7569	 5.5458	 1.73E-05	 0.005587535	 0.2756	 0.4444	 0.0534	 0.0100	 0.0111	
TTC9B	 chr19	 40724360	 40724362	 cg02724271	 3.1309	 5.6329	 1.42E-05	 0.005013328	 0.1363	 0.4440	 0.0340	 0.0214	 0.0145	
SCN5A		 chr3	 38691363	 38691365	 cg12926589	 2.9502	 6.3781	 2.65E-06	 0.002246071	 0.1704	 0.4432	 0.0630	 0.0825	 0.0895	
MOXD1	 chr6	 132722314	 132722316	 cg16478774	 4.9743	 11.6106	 1.50E-10	 1.25E-05	 0.0275	 0.4431	 0.0446	 0.0119	 0.0100	
PCP4L1		 chr1	 161228495	 161228497	 cg27223727	 3.7980	 6.0661	 5.30E-06	 0.003118637	 0.0702	 0.4421	 0.0139	 0.0180	 0.0119	
FADS1	 chr11	 61584111	 61584113	 cg27173322	 3.6321	 5.0862	 5.03E-05	 0.009246452	 0.0809	 0.4408	 0.0150	 0.0100	 0.0100	
EPHX3	 chr19	 15343394	 15343396	 cg19744936	 3.0748	 5.7771	 1.02E-05	 0.004231267	 0.1421	 0.4405	 0.1426	 0.1051	 0.0752	
DNM3	 chr1	 171810569	 171810571	 cg14376275	 2.9018	 7.0967	 5.62E-07	 0.001009502	 0.1777	 0.4399	 0.1308	 0.0703	 0.0244	
GRASP	 chr12	 52400666	 52400668	 cg09101796	 4.5903	 7.4387	 2.75E-07	 0.000669632	 0.0362	 0.4391	 0.0161	 0.0117	 0.0100	
RTN1	 chr14	 60337476	 60337478	 cg19556814	 4.3616	 5.2812	 3.19E-05	 0.007501944	 0.0430	 0.4372	 0.0218	 0.0362	 0.0107	
SCARF2	 chr22	 20792221	 20792223	 cg03952331	 3.0685	 7.9038	 1.07E-07	 0.000430591	 0.1383	 0.4355	 0.0158	 0.0145	 0.0100	
BOC	 chr3	 112930674	 112930676	 cg27085904	 4.1660	 5.6038	 1.51E-05	 0.005211485	 0.0499	 0.4353	 0.0550	 0.0544	 0.0339	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
N/A	 chr7	 127807499	 127807501	 cg25402610	 3.4832	 5.3360	 2.81E-05	 0.00710729	 0.0897	 0.4346	 0.0105	 0.0176	 0.0100	
N/A	 chr12	 121154736	 121154738	 cg23366404	 3.0373	 8.1111	 7.08E-08	 0.000320913	 0.4240	 0.4340	 0.8252	 0.9165	 0.9306	
MIR23B	miRNA	 chr9	 97846550	 97846552	 cg00351472	 2.7375	 7.7354	 1.50E-07	 0.000499938	 0.3430	 0.4339	 0.8012	 0.7944	 0.8788	
N/A	 chr20	 17595447	 17595449	 cg26161708	 2.6825	 6.6099	 1.60E-06	 0.001736403	 0.2720	 0.4338	 0.4220	 0.2588	 0.9597	
N/A	 chr10	 102587109	 102587111	 cg26439963	 3.9336	 12.6939	 2.93E-11	 6.73E-06	 0.0600	 0.4337	 0.0349	 0.0540	 0.0291	
DNM3	 chr1	 171811476	 171811478	 cg20800956	 3.7989	 6.0195	 5.89E-06	 0.00329238	 0.0672	 0.4333	 0.0618	 0.0197	 0.0102	
N/A	 chr13	 80233182	 80233184	 cg20271865	 2.7059	 9.3699	 6.53E-09	 8.66E-05	 0.2403	 0.4333	 0.2902	 0.5132	 0.8539	
COL19A1	 chr6	 70577477	 70577479	 cg17840061	 2.8147	 5.6117	 1.49E-05	 0.005165124	 0.1885	 0.4319	 0.0341	 0.0401	 0.0709	
SLC16A14		 chr2	 230933066	 230933068	 cg26338195	 4.0962	 6.2716	 3.35E-06	 0.00248741	 0.0519	 0.4317	 0.0266	 0.0348	 0.0196	
ZNF365	 chr10	 64133895	 64133897	 cg08984023	 3.7248	 10.2745	 1.33E-09	 3.06E-05	 0.0710	 0.4315	 0.0815	 0.0489	 0.0456	
DTX3	 chr12	 57998655	 57998657	 cg19217692	 3.7273	 10.8362	 5.20E-10	 2.00E-05	 0.0706	 0.4309	 0.0631	 0.0501	 0.0548	
SNORD103B	snoRNA	 chr1	 31423282	 31423284	 cg00581541	 2.8275	 6.4359	 2.33E-06	 0.002089962	 0.3869	 0.4306	 0.7399	 0.5569	 0.9039	
GRIN2A	 chr16	 10276798	 10276800	 cg16368442	 3.9156	 5.1558	 4.27E-05	 0.008564896	 0.0580	 0.4237	 0.1323	 0.0164	 0.0113	
GSC	 chr14	 95236122	 95236124	 cg10042799	 2.7612	 6.4693	 2.17E-06	 0.001994471	 0.1893	 0.4235	 0.0435	 0.0279	 0.0100	
N/A	 chr11	 16170022	 16170024	 cg21992400	 2.6436	 10.6847	 6.68E-10	 2.36E-05	 0.3400	 0.4230	 0.5923	 0.7226	 0.9092	
DNM3	 chr1	 171810375	 171810377	 cg04399751	 2.6045	 5.3669	 2.61E-05	 0.006897738	 0.2578	 0.4209	 0.3779	 0.1006	 0.0593	
DCBLD2		 chr3	 98620815	 98620817	 cg17198587	 3.5096	 6.3281	 2.96E-06	 0.002353487	 0.0814	 0.4208	 0.0489	 0.0523	 0.0447	
PIANP		 chr12	 6809511	 6809513	 cg12376068	 2.6622	 5.3429	 2.76E-05	 0.007044024	 0.2186	 0.4205	 0.0452	 0.0693	 0.0409	
DCBLD2		 chr3	 98620856	 98620858	 cg02464093	 4.3855	 5.1737	 4.10E-05	 0.008377138	 0.0391	 0.4205	 0.0103	 0.0207	 0.0118	
SEPW1	 chr19	 48285321	 48285323	 cg07953015	 2.5903	 6.9129	 8.30E-07	 0.001251874	 0.2705	 0.4202	 0.3720	 0.2460	 0.9075	
N/A	 chr12	 26963488	 26963490	 cg26381514	 2.6350	 6.6906	 1.34E-06	 0.001599275	 0.3505	 0.4197	 0.5625	 0.3171	 0.9099	
TRIM17	 chr1	 228604412	 228604414	 cg01907584	 2.7675	 5.4851	 1.99E-05	 0.005921511	 0.1806	 0.4195	 0.0906	 0.0921	 0.0474	
PIGR	 chr1	 207120021	 207120023	 cg20953047	 2.8184	 10.4408	 1.00E-09	 2.89E-05	 0.4144	 0.4187	 0.4803	 0.8615	 0.9021	
Top	100	hypo-methylated	sites	from	the	BE	v	HGD-EAC	comparison	(differentiating	intervention	requiring	disease	from	Barrett’s	esophagus)	
SOCS2	 chr12	 93967579	 93967581	 cg07687131	 -2.9815	 -5.2577	 3.37E-05	 0.007687167	 0.6585	 -0.4623	 0.2033	 0.7138	 0.1557	
EFCAB4A	 chr11	 830526	 830528	 cg06085985	 -3.0039	 -5.5809	 1.60E-05	 0.005365279	 0.5985	 -0.4418	 0.3232	 0.3162	 0.0976	
RP13-452N2.1	
processed_transcript	 chr7	 151505115	 151505117	 cg22528270	 -2.8620	 -5.4987	 1.93E-05	 0.005878605	 0.8559	 -0.4062	 0.8710	 0.9525	 0.3927	
N/A	 chr8	 10192942	 10192944	 cg06620390	 -3.6395	 -5.8878	 7.93E-06	 0.003761777	 0.9396	 -0.3844	 0.9419	 0.8852	 0.6912	
ZNF606	 chr19	 58513647	 58513649	 cg00664634	 -2.8363	 -5.8324	 8.98E-06	 0.00398856	 0.5072	 -0.3813	 0.1292	 0.0727	 0.0501	
FBLN2	 chr3	 13679573	 13679575	 cg17378193	 -2.2493	 -5.0307	 5.73E-05	 0.009882997	 0.7108	 -0.3700	 0.6037	 0.7389	 0.2557	
BST2	 chr19	 17516328	 17516330	 cg16363586	 -2.2076	 -5.1836	 4.01E-05	 0.00832743	 0.6629	 -0.3643	 0.6553	 0.7272	 0.1780	
N/A	 chr6	 33096302	 33096304	 cg15019001	 -2.1914	 -6.1093	 4.81E-06	 0.003012402	 0.6906	 -0.3623	 0.6531	 0.7279	 0.5065	
MMRN2	 chr10	 88730598	 88730600	 cg06744119	 -2.3580	 -5.5146	 1.86E-05	 0.005803324	 0.5525	 -0.3584	 0.2663	 0.1345	 0.0774	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
N/A	 chr7	 136575359	 136575361	 cg10276834	 -2.0960	 -6.0366	 5.67E-06	 0.003221268	 0.6445	 -0.3467	 0.6500	 0.6413	 0.2535	
N/A	 chr21	 43183465	 43183467	 cg03079733	 -2.0742	 -5.9823	 6.40E-06	 0.003440231	 0.6756	 -0.3447	 0.5998	 0.4209	 0.2149	
N/A	 chr3	 46139304	 46139306	 cg02352281	 -2.0508	 -5.1484	 4.35E-05	 0.008620947	 0.6759	 -0.3411	 0.5917	 0.6851	 0.2087	
N/A	 chr6	 167763757	 167763759	 cg10921277	 -2.7558	 -6.0132	 5.97E-06	 0.003298436	 0.4480	 -0.3407	 0.2345	 0.3670	 0.2004	
N/A	 chr16	 7354040	 7354042	 cg27199384	 -2.0786	 -5.6095	 1.49E-05	 0.005183593	 0.6152	 -0.3406	 0.1499	 0.0435	 0.0135	
N/A	 chr8	 10208256	 10208258	 cg26966828	 -2.4205	 -5.3256	 2.88E-05	 0.0071794	 0.8456	 -0.3399	 0.7218	 0.8193	 0.1752	
TRGJP1		 chr7	 38315970	 38315972	 cg04978343	 -1.9475	 -5.3354	 2.81E-05	 0.007110096	 0.7269	 -0.3186	 0.7779	 0.7195	 0.1297	
CDKN2A		 chr9	 21996206	 21996208	 cg14069088	 -1.9145	 -6.5382	 1.86E-06	 0.001837349	 0.6217	 -0.3181	 0.5965	 0.5697	 0.1930	
N/A	 chr10	 24160304	 24160306	 cg03844372	 -2.0402	 -5.8474	 8.69E-06	 0.003919528	 0.5233	 -0.3126	 0.6063	 0.6534	 0.0569	
RP11-968A15.2	
antisense	 chr12	 54655893	 54655895	 cg08269188	 -1.9130	 -6.7434	 1.19E-06	 0.001509272	 0.7308	 -0.3119	 0.6844	 0.6958	 0.2191	
DOK2	 chr8	 21771058	 21771060	 cg03732056	 -1.9379	 -6.5648	 1.76E-06	 0.001790566	 0.5458	 -0.3070	 0.5060	 0.4574	 0.0625	
N/A	 chr4	 109994038	 109994040	 cg08760493	 -1.7821	 -5.5404	 1.75E-05	 0.005617727	 0.6378	 -0.2992	 0.7423	 0.7365	 0.3963	
EFCAB4A		 chr11	 831169	 831171	 cg02261765	 -1.7738	 -5.6823	 1.26E-05	 0.004713968	 0.6315	 -0.2977	 0.4122	 0.4257	 0.2288	
RALBP1	 chr18	 9474142	 9474144	 cg21923525	 -1.8020	 -7.5537	 2.17E-07	 0.000594626	 0.7162	 -0.2963	 0.6979	 0.7455	 0.3495	
N/A	 chr2	 208014176	 208014178	 cg19361800	 -1.8214	 -5.4307	 2.26E-05	 0.006352666	 0.7366	 -0.2949	 0.7676	 0.6681	 0.4846	
UNKL	 chr16	 1428705	 1428707	 cg08063051	 -1.7670	 -5.3114	 2.97E-05	 0.007290931	 0.6891	 -0.2947	 0.6875	 0.7092	 0.7376	
N/A	 chr4	 24975753	 24975755	 cg17173896	 -1.7638	 -5.1841	 4.00E-05	 0.008320964	 0.6887	 -0.2942	 0.7476	 0.6892	 0.4569	
N/A	 chr6	 33096311	 33096313	 cg08506353	 -1.9134	 -5.2331	 3.57E-05	 0.007902748	 0.5025	 -0.2910	 0.5638	 0.6257	 0.3820	
N/A	 chr5	 42720520	 42720522	 cg18304305	 -1.9234	 -5.5939	 1.55E-05	 0.00527294	 0.7941	 -0.2899	 0.7305	 0.7650	 0.1234	
N/A	 chr18	 77586146	 77586148	 cg20450689	 -1.8025	 -6.5826	 1.69E-06	 0.001774645	 0.7522	 -0.2869	 0.7412	 0.8021	 0.3760	
ATP11A		 chr13	 113343375	 113343377	 cg03992114	 -1.7123	 -5.6844	 1.26E-05	 0.004703423	 0.6964	 -0.2846	 0.6347	 0.6519	 0.1961	
N/A	 chr7	 149562622	 149562624	 cg01077185	 -1.6712	 -7.0179	 6.64E-07	 0.001106374	 0.6346	 -0.2817	 0.6482	 0.6437	 0.1951	
N/A	 chr16	 6094219	 6094221	 cg08390979	 -1.6915	 -5.6660	 1.31E-05	 0.004824456	 0.7001	 -0.2806	 0.7431	 0.6695	 0.8026	
CEBPE		 chr14	 23589418	 23589420	 cg15691199	 -1.7098	 -6.9735	 7.30E-07	 0.001157145	 0.7247	 -0.2788	 0.6377	 0.7140	 0.1033	
COMMD3		 chr10	 22608857	 22608859	 cg10763374	 -1.6510	 -6.8516	 9.47E-07	 0.001335497	 0.6182	 -0.2780	 0.5913	 0.7222	 0.3231	
N/A	 chr21	 46388161	 46388163	 cg11327657	 -3.2905	 -5.2167	 3.71E-05	 0.008047264	 0.9540	 -0.2746	 0.9430	 0.9623	 0.3733	
N/A	 chr12	 124434451	 124434453	 cg02658319	 -1.8462	 -5.2218	 3.66E-05	 0.007994971	 0.7997	 -0.2735	 0.7566	 0.8013	 0.8503	
GPR85	 chr7	 112724673	 112724675	 cg14511782	 -1.6167	 -6.9915	 7.02E-07	 0.001133164	 0.6334	 -0.2730	 0.6358	 0.6334	 0.3905	
ZNF480	 chr19	 52801050	 52801052	 cg19866478	 -2.2008	 -7.3244	 3.49E-07	 0.000800043	 0.3989	 -0.2727	 0.2536	 0.1717	 0.0957	
IFLTD1		 chr12	 25707568	 25707570	 cg24850296	 -1.6128	 -5.7389	 1.11E-05	 0.004395291	 0.6202	 -0.2721	 0.6172	 0.6233	 0.3536	
ZNF239	 chr10	 44068713	 44068715	 cg07541020	 -1.7259	 -5.5121	 1.87E-05	 0.005820641	 0.7567	 -0.2721	 0.7974	 0.7932	 0.4747	
N/A	 chr16	 50743026	 50743028	 cg04172533	 -1.7023	 -5.1634	 4.20E-05	 0.008473117	 0.7503	 -0.2702	 0.6713	 0.7331	 0.3035	
N/A	 chr21	 46325852	 46325854	 cg04217515	 -2.1655	 -7.8767	 1.13E-07	 0.000432454	 0.8712	 -0.2699	 0.8293	 0.9046	 0.5474	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
N/A	 chr21	 27942802	 27942804	 cg14843731	 -1.5833	 -6.3025	 3.13E-06	 0.002395345	 0.6338	 -0.2677	 0.5774	 0.4675	 0.1825	
ICAM3	 chr19	 10450021	 10450023	 cg14145194	 -1.6572	 -6.1705	 4.20E-06	 0.002838124	 0.7336	 -0.2675	 0.6670	 0.7325	 0.1831	
N/A	 chr1	 42217076	 42217078	 cg23114964	 -1.5811	 -5.1711	 4.12E-05	 0.00841023	 0.6667	 -0.2660	 0.6012	 0.6452	 0.0281	
ACSF2	 chr17	 48502311	 48502313	 cg03919657	 -1.6214	 -6.5919	 1.66E-06	 0.001769908	 0.7150	 -0.2658	 0.5406	 0.7818	 0.4094	
N/A	 chr15	 80765903	 80765905	 cg27332878	 -1.6215	 -8.9275	 1.47E-08	 0.000138427	 0.7246	 -0.2637	 0.6451	 0.6889	 0.2540	
TBC1D13		 chr9	 131549074	 131549076	 cg27625732	 -1.7524	 -6.3823	 2.63E-06	 0.002236317	 0.7881	 -0.2634	 0.6811	 0.6735	 0.5530	
N/A	 chr16	 18039446	 18039448	 cg04749323	 -1.6611	 -5.4730	 2.05E-05	 0.006004868	 0.7529	 -0.2622	 0.8031	 0.7588	 0.8666	
S100B	 chr21	 48026042	 48026044	 cg00025591	 -1.5509	 -5.3601	 2.66E-05	 0.006948712	 0.6045	 -0.2617	 0.4809	 0.5174	 0.0771	
HERC2	 chr15	 28448837	 28448839	 cg07726456	 -1.7954	 -5.8478	 8.68E-06	 0.003919528	 0.8077	 -0.2602	 0.7490	 0.8200	 0.1755	
	AP006216.12	
antisense	 chr11	 116706152	 116706154	 cg03044513	 -1.6094	 -5.1906	 3.94E-05	 0.008274415	 0.7326	 -0.2595	 0.6561	 0.7199	 0.3136	
AP006216.12	
antisense	 chr11	 116706050	 116706052	 cg19299755	 -1.9385	 -6.2576	 3.46E-06	 0.002541402	 0.8451	 -0.2577	 0.7888	 0.8147	 0.4694	
RBFOX1		 chr16	 6533699	 6533701	 cg12310850	 -1.5468	 -5.6050	 1.51E-05	 0.00521066	 0.5617	 -0.2568	 0.1969	 0.1746	 0.1262	
RP11-109A6.3	
lincRNA	 chr10	 131568020	 131568022	 cg14308082	 -1.8815	 -5.4941	 1.95E-05	 0.00590825	 0.8345	 -0.2567	 0.8218	 0.8393	 0.4829	
N/A	 chr10	 131412578	 131412580	 cg19680672	 -1.6851	 -5.7270	 1.14E-05	 0.004452487	 0.7799	 -0.2556	 0.8167	 0.8127	 0.8731	
N/A	 chr3	 55693630	 55693632	 cg18243357	 -1.5252	 -6.5379	 1.87E-06	 0.001837349	 0.6988	 -0.2525	 0.5929	 0.6949	 0.6861	
N/A	 chr6	 33142005	 33142007	 cg15818109	 -1.6568	 -5.9454	 6.96E-06	 0.003578714	 0.7819	 -0.2499	 0.7583	 0.7658	 0.4720	
MSX1	 chr4	 4860589	 4860591	 cg22371591	 -1.6495	 -5.2851	 3.16E-05	 0.007464683	 0.7831	 -0.2481	 0.3349	 0.4055	 0.3070	
ZNF414	 chr19	 8580333	 8580335	 cg14574996	 -1.8293	 -5.2513	 3.42E-05	 0.007731177	 0.8364	 -0.2465	 0.7853	 0.7875	 0.2134	
N/A	 chr13	 107145932	 107145934	 cg24128998	 -1.5129	 -5.8502	 8.63E-06	 0.003910354	 0.7186	 -0.2464	 0.6109	 0.7596	 0.0775	
N/A	 chr5	 178776242	 178776244	 cg11303630	 -1.4621	 -5.7684	 1.04E-05	 0.004268686	 0.5798	 -0.2461	 0.6180	 0.6244	 0.2730	
N/A	 chr5	 92909433	 92909435	 cg15143788	 -1.4893	 -5.0305	 5.73E-05	 0.009882997	 0.7065	 -0.2449	 0.4218	 0.4242	 0.1078	
P2RY12	 chr3	 151057060	 151057062	 cg24630764	 -1.4907	 -6.1045	 4.87E-06	 0.003028742	 0.5337	 -0.2443	 0.5964	 0.4683	 0.5827	
N/A	 chr1	 216805706	 216805708	 cg13242895	 -1.6743	 -5.3321	 2.83E-05	 0.007140762	 0.8016	 -0.2429	 0.8370	 0.8101	 0.8497	
N/A	 chr15	 26044049	 26044051	 cg02334109	 -1.6484	 -6.2108	 3.84E-06	 0.002688417	 0.7950	 -0.2420	 0.7527	 0.7660	 0.2411	
NR4A2		 chr2	 157184879	 157184881	 cg00240195	 -1.9769	 -5.3095	 2.99E-05	 0.007299036	 0.8686	 -0.2419	 0.8187	 0.8679	 0.3595	
N/A	 chr7	 53393695	 53393697	 cg24859602	 -1.6679	 -6.4007	 2.52E-06	 0.002177049	 0.8020	 -0.2416	 0.7700	 0.7558	 0.8165	
IRF7	 chr11	 617139	 617141	 cg00645579	 -1.5273	 -6.2811	 3.28E-06	 0.002459659	 0.7498	 -0.2401	 0.7075	 0.7749	 0.3611	
N/A	 chr12	 56036795	 56036797	 cg23600372	 -1.7521	 -5.5139	 1.86E-05	 0.005804732	 0.8296	 -0.2385	 0.8167	 0.7947	 0.3956	
CAPN14	/	EHD3		 chr2	 31455442	 31455444	 cg13149833	 -1.4026	 -6.0776	 5.17E-06	 0.003094249	 0.6537	 -0.2371	 0.6828	 0.6542	 0.4075	
COMMD3	 chr10	 22608673	 22608675	 cg01077178	 -2.7482	 -7.2019	 4.50E-07	 0.000916574	 0.9414	 -0.2362	 0.8959	 0.9301	 0.8630	
FBLN2	 chr3	 13679635	 13679637	 cg17054708	 -1.6969	 -5.0329	 5.70E-05	 0.009850227	 0.8200	 -0.2358	 0.6742	 0.8244	 0.2287	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
WIPF1	 chr2	 175545837	 175545839	 cg00405190	 -1.4481	 -5.3363	 2.81E-05	 0.007105168	 0.7190	 -0.2351	 0.8438	 0.8103	 0.4334	
CUX1	 chr7	 101461822	 101461824	 cg12537379	 -1.7067	 -6.0426	 5.59E-06	 0.003193824	 0.8237	 -0.2350	 0.8758	 0.8485	 0.6744	
CBFA2T3		 chr16	 89024556	 89024558	 cg01534572	 -1.3830	 -6.2443	 3.56E-06	 0.00258875	 0.6004	 -0.2349	 0.6029	 0.6401	 0.0536	
TMC6	 chr17	 76117766	 76117768	 cg03297901	 -2.0061	 -5.1954	 3.90E-05	 0.00823586	 0.8793	 -0.2347	 0.7279	 0.8159	 0.0789	
N/A	 chr3	 154737056	 154737058	 cg06168950	 -1.7040	 -7.1226	 5.32E-07	 0.000995114	 0.8238	 -0.2345	 0.8006	 0.8677	 0.5395	
N/A	 chr3	 193629644	 193629646	 cg27203560	 -1.4038	 -6.1378	 4.52E-06	 0.002941399	 0.6817	 -0.2344	 0.6396	 0.6841	 0.2402	
N/A	 chr6	 1310484	 1310486	 cg17842822	 -1.3866	 -5.3205	 2.91E-05	 0.007215339	 0.5787	 -0.2343	 0.5991	 0.5746	 0.2330	
AL355531.2	 chr10	 131309401	 131309403	 cg00198994	 -1.4388	 -5.1523	 4.31E-05	 0.008601047	 0.7160	 -0.2341	 0.7482	 0.7339	 0.7471	
USP39	/	C2orf68		 chr2	 85839649	 85839651	 cg04738827	 -1.8310	 -5.8737	 8.18E-06	 0.003851778	 0.8520	 -0.2340	 0.8507	 0.7822	 0.8090	
HOXA9		 chr7	 27209196	 27209198	 cg15912800	 -2.3449	 -5.2015	 3.84E-05	 0.008195212	 0.3176	 -0.2337	 0.2929	 0.3142	 0.0548	
N/A	 chr4	 183795784	 183795786	 cg12835012	 -1.8386	 -6.2687	 3.38E-06	 0.002491702	 0.8540	 -0.2335	 0.7509	 0.8254	 0.2949	
CD93	 chr20	 23067155	 23067157	 cg20438277	 -1.3686	 -5.4027	 2.41E-05	 0.006608799	 0.6267	 -0.2327	 0.5078	 0.4557	 0.0553	
WRB	 chr21	 40756695	 40756697	 cg07777652	 -1.3735	 -6.1881	 4.04E-06	 0.002767446	 0.5810	 -0.2324	 0.5043	 0.6280	 0.2700	
N/A	 chr17	 10075024	 10075026	 cg12245236	 -1.7941	 -5.9524	 6.85E-06	 0.003567484	 0.3840	 -0.2316	 0.2973	 0.1756	 0.0880	
HK2	 chr2	 75059601	 75059603	 cg18638581	 -1.4100	 -5.2567	 3.38E-05	 0.007687167	 0.7071	 -0.2311	 0.6388	 0.7487	 0.3457	
CLCN7	 chr16	 1521616	 1521618	 cg09050670	 -2.4109	 -5.0532	 5.43E-05	 0.009609233	 0.9226	 -0.2310	 0.8976	 0.9207	 0.1894	
N/A	 chr5	 2537519	 2537521	 cg00055986	 -1.3616	 -6.6810	 1.37E-06	 0.001604759	 0.5691	 -0.2296	 0.3644	 0.4321	 0.3135	
N/A	 chr9	 101011717	 101011719	 cg13709496	 -1.5243	 -5.3483	 2.73E-05	 0.006987768	 0.7776	 -0.2289	 0.7882	 0.7707	 0.3856	
DOCK10	 chr2	 225813193	 225813195	 cg20992319	 -1.8133	 -5.2090	 3.77E-05	 0.008134651	 0.8545	 -0.2289	 0.8539	 0.8686	 0.8647	
IFNGR2		 chr21	 34774163	 34774165	 cg08173915	 -1.5958	 -5.0873	 5.02E-05	 0.009229273	 0.8036	 -0.2285	 0.8308	 0.8409	 0.3923	
N/A	 chr7	 157475736	 157475738	 cg03983213	 -1.4353	 -5.3536	 2.70E-05	 0.006986219	 0.7362	 -0.2283	 0.5509	 0.7117	 0.0967	
MIR143	miRNA	 chr5	 148808455	 148808457	 cg16684117	 -1.9963	 -5.4985	 1.93E-05	 0.005878605	 0.8842	 -0.2274	 0.8564	 0.9277	 0.3979	
QRFP	 chr9	 133768965	 133768967	 cg03924115	 -1.7808	 -5.7023	 1.21E-05	 0.004615908	 0.8503	 -0.2272	 0.8416	 0.8531	 0.4690	
N/A	 chr11	 970663	 970665	 cg06064525	 -2.0093	 -5.2608	 3.35E-05	 0.007670993	 0.8861	 -0.2271	 0.8517	 0.9021	 0.2674	
N/A	 chr11	 134254645	 134254647	 cg09447621	 -1.8041	 -6.0957	 4.96E-06	 0.003051182	 0.8551	 -0.2268	 0.7778	 0.8349	 0.2436	
N/A	 chr4	 174431729	 174431731	 cg09867290	 -1.5351	 -5.1147	 4.71E-05	 0.008950337	 0.7873	 -0.2264	 0.5910	 0.4572	 0.3391	
N/A	 chr8	 1106400	 1106402	 cg03907855	 -2.1418	 -6.1636	 4.26E-06	 0.002850094	 0.9020	 -0.2261	 0.9175	 0.8858	 0.9526	
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Appendix 5: Top differentially expressed transcript clusters identified by genome-wide expression profiling 
For all results tabulated below, selection criteria pertaining to control tissue (duodenal and proximal stomach) were NOT applied. Expression 
averages for these specimens are shown for interest only. Filtering of adjusted p-value < 0.05 and logfc > |log2(1.5)| was applied to tabulated 
results below. 
 
Table 1: Top 100 up- and down-regulated transcript clusters for differentiating intervention-requiring disease from normal squamous 
mucosa 
3,799 up-regulated and 2,998 down-regulated transcript clusters were identified as differentially expressed between normal squamous 
epithelium and intervention requiring disease (N v HGD-EAC, adjusted p-value < 0.05 and logfc > log2(1.5). Tx: transcript, logfc: log fold 
change, tstat: t-statistic, pval: p-value, adj_pval: adjusted p-value, Expbase: average expression in baseline samples, here, normal squamous 
epithelium, Expduo: average expression in duodenal epithelium, Expstom: average expression in proximal stomach epithelium, str: strand. Top 
100 up- and down-regulated transcript clusters based on greatest |logfc|; listed in order of decreasing |logfc|.  
 
Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
Top	100	up-regulated	transcript	clusters	from	the	N	v	HGD-EAC	comparison	(differentiating	intervention	requiring	disease	from	normal	squamous	epithelium)	
TC07001164.hg.1	 6.3114	 18.4387	 2.41E-14	 2.03E-10	 2.4452	 8.8125	 7.8018	 chr7	 16899029	 16921613	 -	 NM_176813	 AGR3	
TC03001719.hg.1	 6.2779	 33.0766	 1.95E-19	 1.32E-14	 4.2162	 10.9536	 8.2634	 chr3	 124624289	 124672663	 -	 NM_033049	 MUC13	
TC07002495.hg.1	 5.5034	 14.9081	 1.47E-12	 4.97E-09	 3.5054	 9.8782	 5.9416	 chr7	 100677704	 100680561	 +	 ---	 ---	
TC07002496.hg.1	 5.4451	 15.3308	 8.64E-13	 3.43E-09	 3.7525	 10.1808	 6.0229	 chr7	 100678736	 100679444	 +	 ---	 ---	
TC01003051.hg.1	 5.4311	 10.5644	 8.36E-10	 3.70E-07	 3.9260	 8.4103	 5.9298	 chr1	 120336641	 120354283	 -	 NM_001159352	 REG4	
TC05001911.hg.1	 5.2287	 13.0717	 1.75E-11	 2.75E-08	 4.3968	 10.3294	 10.7604	 chr5	 147204131	 147211349	 -	 NM_003122	 SPINK1	
TC04000836.hg.1	 5.1237	 5.9764	 6.55E-06	 1.55E-04	 3.0216	 8.2071	 10.5192	 chr4	 169013666	 169108893	 +	 NM_007193	 ANXA10	
TC19001505.hg.1	 5.1184	 20.1084	 4.37E-15	 7.32E-11	 5.8753	 11.3040	 10.3407	 chr19	 39292311	 39303740	 -	 NM_006149	 LGALS4	
TC0X001747.hg.1	 5.1092	 11.7019	 1.34E-10	 1.12E-07	 4.0778	 9.8024	 6.0420	 chrX	 65486697	 65487236	 +	 ---	 ---	
TC04002303.hg.1	 5.0681	 10.2300	 1.47E-09	 5.08E-07	 3.7880	 9.2823	 5.8750	 chr4	 165675283	 165724947	 +	 ---	 ---	
TC04001926.hg.1	 5.0109	 4.7156	 1.21E-04	 1.39E-03	 2.6228	 9.4718	 9.7421	 chr4	 15969851	 15970275	 +	 ---	 ---	
TC08001431.hg.1	 4.9964	 13.7593	 6.72E-12	 1.33E-08	 4.2965	 10.3560	 4.6983	 chr8	 95139394	 95229531	 -	 NM_001144663	 CDH17	
TC6_apd_hap1000067.hg.1	 4.9435	 13.6657	 7.64E-12	 1.47E-08	 3.6191	 8.0192	 6.7959	 chr6_apd
_hap1	 1318454	 1321112	 -	 NM_007028	 TRIM31	
TC19001042.hg.1	 4.8748	 13.1419	 1.59E-11	 2.55E-08	 4.3460	 11.1106	 10.1189	 chr19	 3474405	 3480540	 -	 NM_001136503	 C19orf77	
TC02004392.hg.1	 4.8563	 5.7701	 1.04E-05	 2.21E-04	 3.6442	 11.8566	 6.8967	 chr2	 88422556	 88427635	 -	 ---	 ---	
TC10001754.hg.1	 4.8432	 13.4147	 1.08E-11	 1.92E-08	 3.5286	 9.1097	 5.0902	 chr10	 129676105	 129691211	 -	 NM_152311	 CLRN3	
TC11002237.hg.1	 4.8177	 12.7749	 2.68E-11	 3.63E-08	 3.6472	 4.1360	 3.7047	 chr11	 102733464	 102745764	 -	 NM_002426	 MMP12	
TC12001723.hg.1	 4.7623	 29.0987	 2.64E-18	 8.90E-14	 3.3606	 8.0494	 8.1431	 chr12	 71518865	 71835678	 -	 NM_004616	 TSPAN8	
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Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
TC07003086.hg.1	 4.7237	 13.2845	 1.30E-11	 2.19E-08	 5.3527	 11.0530	 8.7097	 chr7	 100550661	 100551637	 -	 ---	 ---	
TC04000821.hg.1	 4.6434	 9.2612	 8.12E-09	 1.48E-06	 2.5396	 7.7616	 4.4132	 chr4	 165675216	 165724947	 +	 NR_038834	 LOC100505989	
TC0X001299.hg.1	 4.6139	 5.3967	 2.46E-05	 4.19E-04	 4.2781	 4.2814	 4.3001	 chrX	 115592849	 115594164	 -	 NM_001017978	 CXorf61	
TC03002462.hg.1	 4.5782	 10.9093	 4.73E-10	 2.50E-07	 3.3366	 8.8719	 8.1115	 chr3	 110917882	 110920289	 +	 ---	 ---	
TC01001720.hg.1	 4.5535	 6.7337	 1.23E-06	 4.52E-05	 5.4355	 10.8512	 11.4785	 chr1	 206317459	 206332104	 +	 NM_001910	 CTSE	
TC16000645.hg.1	 4.5416	 12.2887	 5.49E-11	 6.28E-08	 5.2593	 11.0469	 8.6785	 chr16	 82068858	 82132139	 +	 NM_002153	 HSD17B2	
TC03003109.hg.1	 4.5205	 5.6178	 1.48E-05	 2.88E-04	 2.9071	 4.1455	 9.6955	 chr3	 137749545	 137750672	 -	 ---	 ---	
TC13000228.hg.1	 4.4536	 6.8064	 1.06E-06	 4.07E-05	 4.5295	 10.8360	 5.5739	 chr13	 53602830	 53626196	 +	 NM_006418	 OLFM4	
TC07000640.hg.1	 4.4508	 11.2858	 2.58E-10	 1.72E-07	 4.2975	 9.4392	 5.6876	 chr7	 100663353	 100702140	 +	 NM_001040105	 MUC17	
TC03000545.hg.1	 4.4442	 13.0340	 1.85E-11	 2.79E-08	 3.2250	 8.7148	 6.4195	 chr3	 108015376	 108097132	 +	 NM_007072	 HHLA2	
TC11002234.hg.1	 4.3521	 10.4597	 9.96E-10	 4.09E-07	 3.3581	 5.8857	 5.4730	 chr11	 102660641	 102668966	 -	 NM_001145938	 MMP1	
TC05002798.hg.1	 4.3380	 8.4887	 3.45E-08	 3.84E-06	 5.0224	 8.8223	 9.0193	 chr5	 553527	 554002	 -	 ---	 ---	
TC07002497.hg.1	 4.3011	 10.5666	 8.33E-10	 3.70E-07	 4.3495	 9.3144	 5.5696	 chr7	 100701581	 100701790	 +	 ---	 ---	
TC02002835.hg.1	 4.2644	 7.9473	 9.95E-08	 7.66E-06	 3.0113	 9.6065	 3.5581	 chr2	 228226872	 228246711	 -	 NM_024795	 TM4SF20	
TC21000942.hg.1	 4.2271	 7.9856	 9.22E-08	 7.26E-06	 3.7456	 5.4679	 9.8031	 chr21	 36089937	 36090503	 -	 ---	 ---	
TC01000580.hg.1	 4.2243	 19.8898	 5.42E-15	 7.32E-11	 5.2139	 8.4753	 9.5359	 chr1	 46640745	 46651634	 +	 NM_005727	 TSPAN1	
TC07002629.hg.1	 4.2204	 17.8501	 4.55E-14	 2.89E-10	 3.3188	 8.6340	 3.7731	 chr7	 141870970	 141923474	 +	 ---	 ---	
TC11000788.hg.1	 4.2014	 9.9769	 2.27E-09	 6.67E-07	 4.6610	 8.3474	 7.1957	 chr11	 74166393	 74167870	 +	 ---	 ---	
TC11003279.hg.1	 4.1560	 10.5107	 9.14E-10	 3.89E-07	 5.3354	 8.7481	 10.2169	 chr11	 85416009	 85420543	 -	 ---	 ---	
TC07001163.hg.1	 4.1324	 14.9666	 1.37E-12	 4.86E-09	 3.5359	 7.4353	 7.7732	 chr7	 16831435	 16873057	 -	 NM_006408	 AGR2	
TC02002478.hg.1	 3.8579	 11.9361	 9.35E-11	 9.28E-08	 4.1374	 9.1093	 6.1959	 chr2	 162848751	 162931052	 -	 NM_001935	 DPP4	
TC12001163.hg.1	 3.8540	 6.6704	 1.41E-06	 5.00E-05	 3.3781	 9.4316	 5.6822	 chr12	 7801996	 7818502	 -	 NM_001644	 APOBEC1	
TC05002656.hg.1	 3.8370	 12.9948	 1.96E-11	 2.79E-08	 6.6027	 10.6394	 11.7181	 chr5	 139554736	 139623371	 +	 ---	 ---	
TC06001495.hg.1	 3.8286	 11.2445	 2.75E-10	 1.74E-07	 3.9586	 7.3347	 6.2694	 chr6	 30070674	 30080883	 -	 NM_007028	 TRIM31	
TC07000104.hg.1	 3.8114	 8.6952	 2.33E-08	 2.98E-06	 2.6294	 6.4699	 3.1402	 chr7	 15707572	 15721605	 +	 OTTHUMT000003
26059	
OTTHUMG0000
0152391	
TC07002158.hg.1	 3.8077	 7.9978	 9.00E-08	 7.17E-06	 2.3500	 6.1103	 2.8304	 chr7	 15707572	 15721605	 +	 ---	 ---	
TC05002612.hg.1	 3.7994	 14.7924	 1.71E-12	 5.24E-09	 4.9517	 8.7382	 9.3989	 chr5	 127522490	 127522778	 +	 ---	 ---	
TC15002310.hg.1	 3.7584	 7.1813	 4.76E-07	 2.25E-05	 4.6755	 6.7997	 5.5247	 chr15	 80253413	 80263461	 +	 ---	 ---	
TC01003498.hg.1	 3.7502	 9.5341	 4.96E-09	 1.09E-06	 3.7164	 5.2532	 4.9231	 chr1	 169481192	 169555826	 -	 NM_000130	 F5	
TC03001692.hg.1	 3.7480	 8.2863	 5.10E-08	 5.05E-06	 3.6063	 8.1441	 8.1161	 chr3	 120347015	 120401418	 -	 NM_000187	 HGD	
TC07000726.hg.1	 3.7347	 8.0810	 7.63E-08	 6.51E-06	 3.9643	 9.0968	 4.8152	 chr7	 117105838	 117308719	 +	 NM_000492	 CFTR	
TC12001909.hg.1	 3.7328	 14.1809	 3.81E-12	 8.86E-09	 4.0970	 8.6060	 8.9983	 chr12	 105196331	 105352522	 -	 NM_032148	 SLC41A2	
TC07002911.hg.1	 3.6990	 8.4343	 3.83E-08	 4.10E-06	 3.6934	 5.5731	 4.3933	 chr7	 41724713	 41726643	 -	 ---	 ---	
TC03001966.hg.1	 3.6905	 5.5899	 1.58E-05	 3.03E-04	 2.7781	 10.9035	 4.2462	 chr3	 164696686	 164796283	 -	 NM_001041	 SI	
TC07001607.hg.1	 3.6884	 6.7566	 1.17E-06	 4.38E-05	 2.9887	 7.4057	 5.9401	 chr7	 92817899	 92855837	 -	 NM_001039372	 HEPACAM2	
TC06000779.hg.1	 3.6845	 11.9156	 9.65E-11	 9.31E-08	 4.4808	 8.5530	 6.8147	 chr6	 86159302	 86205509	 +	 NM_001204813	 NT5E	
TC02000663.hg.1	 3.6792	 6.0664	 5.35E-06	 1.33E-04	 4.0127	 7.3808	 9.3863	 chr2	 108905095	 108926371	 +	 NM_001056	 SULT1C2	
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Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
TC01000939.hg.1	 3.6702	 11.9581	 9.04E-11	 9.11E-08	 4.7383	 8.5278	 9.1496	 chr1	 109656585	 109749403	 +	 NM_020775	 KIAA1324	
TC11000835.hg.1	 3.6645	 9.1497	 9.96E-09	 1.68E-06	 4.5680	 6.9778	 8.3597	 chr11	 77726761	 77727541	 +	 ---	 ---	
TC6_qbl_hap6000121.hg.1	 3.6590	 10.9808	 4.21E-10	 2.40E-07	 4.3113	 7.5305	 6.4799	 chr6_qbl
_hap6	 1363640	 1373843	 -	 NM_007028	 TRIM31	
TC04000408.hg.1	 3.6558	 6.4473	 2.30E-06	 7.12E-05	 3.4989	 3.5081	 3.2133	 chr4	 74606223	 74609433	 +	 NM_000584	 IL8	
TC6_mann_hap4000109.hg.
1	 3.6241	 10.8830	 4.94E-10	 2.58E-07	 4.3768	 7.5584	 6.4977	
chr6_ma
nn_hap4	 1369234	 1379436	 -	 NM_007028	 TRIM31	
TC06003087.hg.1	 3.6236	 14.2657	 3.40E-12	 8.83E-09	 2.8769	 6.0188	 7.3205	 chr6	 138661322	 138665748	 +	 ---	 ---	
TC11002235.hg.1	 3.5996	 6.8195	 1.03E-06	 3.99E-05	 3.2416	 4.3371	 3.9633	 chr11	 102706528	 102714534	 -	 NM_002422	 MMP3	
TC6_ssto_hap7000112.hg.1	 3.5946	 10.9546	 4.39E-10	 2.42E-07	 4.3653	 7.4995	 6.4556	 chr6_ssto_hap7	 1401127	 1411327	 -	 NM_007028	 TRIM31	
TC6_mcf_hap5000111.hg.1	 3.5681	 10.8564	 5.16E-10	 2.63E-07	 4.3540	 7.4624	 6.4218	 chr6_mcf_hap5	 1452557	 1462764	 -	 NM_007028	 TRIM31	
TC02004744.hg.1	 3.5678	 8.9452	 1.45E-08	 2.19E-06	 4.4454	 8.6138	 6.0504	 chr2	 188328960	 188330769	 -	 ---	 ---	
TC17001473.hg.1	 3.5675	 4.1583	 4.55E-04	 3.75E-03	 4.0590	 10.7581	 8.9311	 chr17	 39030852	 39041495	 -	 NM_019010	 KRT20	
TC07000902.hg.1	 3.5670	 16.0853	 3.43E-13	 1.82E-09	 3.3879	 7.9542	 3.5929	 chr7	 141811549	 141921088	 +	 NR_003715	 LOC93432	
TC02000488.hg.1	 3.5611	 8.5415	 3.12E-08	 3.57E-06	 4.0763	 8.8376	 7.7078	 chr2	 79347488	 79350545	 +	 NM_002909	 REG1A	
TC12001803.hg.1	 3.5578	 9.0718	 1.15E-08	 1.84E-06	 4.4349	 8.5463	 7.7317	 chr12	 91496406	 91505608	 -	 NM_002345	 LUM	
TC6_apd_hap1000090.hg.1	 3.5271	 11.7823	 1.18E-10	 1.04E-07	 5.5961	 9.0822	 9.0774	 chr6_apd
_hap1	 3145724	 3161577	 -	 NM_001178044	 SLC44A4	
TC6_ssto_hap7000145.hg.1	 3.5271	 11.7823	 1.18E-10	 1.04E-07	 5.5961	 9.0822	 9.0774	 chr6_ssto_hap7	 3163717	 3179566	 -	 NM_001178044	 SLC44A4	
TC6_mcf_hap5000151.hg.1	 3.5269	 11.7713	 1.20E-10	 1.04E-07	 5.5958	 9.0829	 9.0767	 chr6_mcf
_hap5	 3210847	 3226696	 -	 NM_001178044	 SLC44A4	
TC21000486.hg.1	 3.4950	 5.1505	 4.36E-05	 6.39E-04	 6.7498	 10.4136	 12.1854	 chr21	 43782391	 43786703	 -	 NM_003225	 TFF1	
TC6_dbb_hap3000120.hg.1	 3.4793	 10.4666	 9.85E-10	 4.08E-07	 4.4217	 7.4503	 6.4023	 chr6_dbb_hap3	 1364399	 1374601	 -	 NM_007028	 TRIM31	
TC11002228.hg.1	 3.4767	 6.6162	 1.59E-06	 5.46E-05	 4.3612	 5.4140	 4.4952	 chr11	 102391239	 102401484	 -	 NM_002423	 MMP7	
TC6_qbl_hap6000166.hg.1	 3.4762	 11.7919	 1.17E-10	 1.04E-07	 5.6029	 9.0342	 9.0051	 chr6_qbl_hap6	 3124760	 3140615	 -	 NM_001178044	 SLC44A4	
TC04002588.hg.1	 3.4513	 5.1044	 4.85E-05	 6.91E-04	 2.7599	 3.0278	 2.8318	 chr4	 74861359	 74862455	 -	 ---	 ---	
TC08000499.hg.1	 3.4454	 13.2963	 1.28E-11	 2.19E-08	 3.8938	 8.6670	 6.3749	 chr8	 76320149	 76479078	 +	 NM_004133	 HNF4G	
TC6_dbb_hap3000165.hg.1	 3.4423	 11.5834	 1.61E-10	 1.25E-07	 5.6097	 9.0117	 8.9988	 chr6_dbb_hap3	 3116555	 3132405	 -	 NM_001178044	 SLC44A4	
TC06001549.hg.1	 3.4417	 11.5920	 1.59E-10	 1.25E-07	 5.6096	 9.0110	 8.9991	 chr6	 31830969	 31846823	 -	 NM_001178044	 SLC44A4	
TC6_cox_hap2000176.hg.1	 3.4417	 11.5920	 1.59E-10	 1.25E-07	 5.6096	 9.0110	 8.9991	 chr6_cox_hap2	 3340716	 3356577	 -	 NM_001178044	 SLC44A4	
TC03000806.hg.1	 3.4410	 5.4696	 2.08E-05	 3.71E-04	 4.4273	 10.3388	 8.0240	 chr3	 149191761	 149221181	 +	 NM_004617	 TM4SF4	
TC05001556.hg.1	 3.4168	 6.0179	 5.96E-06	 1.44E-04	 3.1773	 6.1503	 6.6863	 chr5	 82837296	 82877139	 -	 ENST0000051389 VCAN-AS1	
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TC0X001610.hg.1	 3.4159	 10.5927	 7.97E-10	 3.64E-07	 3.6586	 6.4117	 7.7453	 chrX	 17168618	 17171104	 +	 ---	 ---	
TC06002119.hg.1	 3.3936	 6.5879	 1.69E-06	 5.70E-05	 3.7363	 9.9695	 3.9040	 chr6	 133001997	 133035194	 -	 NM_004666	 VNN1	
TC15001539.hg.1	 3.3718	 5.7748	 1.03E-05	 2.19E-04	 4.6285	 8.5096	 8.2462	 chr15	 63362224	 63364110	 -	 ---	 ---	
TC07001227.hg.1	 3.3716	 9.7872	 3.17E-09	 8.10E-07	 3.1313	 3.2578	 2.9617	 chr7	 27233122	 27239725	 -	 NM_000522	 HOXA13	
TC11002162.hg.1	 3.3688	 10.3833	 1.13E-09	 4.40E-07	 4.7160	 7.6027	 9.1337	 chr11	 85405265	 85522184	 -	 NM_001162951	 SYTL2	
TC12002508.hg.1	 3.3559	 3.7646	 1.16E-03	 7.49E-03	 3.4514	 10.2113	 4.6968	 chr12	 92271167	 92274184	 +	 ---	 ---	
TC17000050.hg.1	 3.3429	 7.1245	 5.37E-07	 2.48E-05	 5.4769	 10.9838	 9.1509	 chr17	 4675187	 4686508	 +	 NM_003963	 TM4SF5	
TC6_cox_hap2000131.hg.1	 3.3404	 9.8494	 2.84E-09	 7.52E-07	 4.5392	 7.4426	 6.4162	 chr6_cox_hap2	 1582796	 1593011	 -	 NM_007028	 TRIM31	
TC10000890.hg.1	 3.3383	 6.3617	 2.78E-06	 8.17E-05	 5.2124	 10.3478	 5.2156	 chr10	 124320181	 124403252	 +	 NM_004406	 DMBT1	
TC06003855.hg.1	 3.3296	 6.4106	 2.49E-06	 7.55E-05	 3.4881	 5.2683	 3.8587	 chr6	 133065009	 133079033	 -	 ---	 ---	
TC16000214.hg.1	 3.3259	 7.1763	 4.82E-07	 2.27E-05	 5.0996	 8.3160	 7.3764	 chr16	 19421861	 19510435	 +	 NM_001105248	 TMC5	
TC04001092.hg.1	 3.3227	 15.7995	 4.85E-13	 2.18E-09	 4.9611	 8.3840	 8.2981	 chr4	 25749049	 25865382	 -	 NM_015187	 SEL1L3	
TC12002823.hg.1	 3.3160	 11.3361	 2.38E-10	 1.62E-07	 2.4148	 6.6428	 5.2070	 chr12	 31535160	 31537109	 -	 ---	 ---	
TC03000878.hg.1	 3.3148	 5.3448	 2.77E-05	 4.59E-04	 3.6472	 8.3997	 8.0774	 chr3	 160394947	 160396240	 +	 NM_025047	 ARL14	
TC09000138.hg.1	 3.3099	 6.1175	 4.77E-06	 1.21E-04	 6.2672	 9.2864	 6.1852	 chr9	 33218363	 33248565	 +	 NM_014471	 SPINK4	
TC07002628.hg.1	 3.3024	 14.2896	 3.29E-12	 8.83E-09	 3.4898	 7.7724	 3.3495	 chr7	 141811549	 141843783	 +	 ---	 ---	
TC11003311.hg.1	 3.2907	 7.9369	 1.02E-07	 7.76E-06	 4.8586	 6.3095	 5.9152	 chr11	 102667775	 102668070	 -	 ---	 ---	
Top	100	down-regulated	transcript	clusters	from	the	N	v	HGD-EAC	comparison	(differentiating	intervention	requiring	disease	from	normal	squamous	epithelium)	
TC04001258.hg.1	 -6.3568	 -6.0146	 6.01E-06	 1.45E-04	 10.7669	 2.6350	 2.6667	 chr4	 69092371	 69111438	 -	 NM_182502	 TMPRSS11B	
TC04000369.hg.1	 -6.3452	 -6.5538	 1.82E-06	 6.01E-05	 11.0680	 3.4914	 3.4121	 chr4	 69313167	 69363322	 +	 NM_014058	 TMPRSS11E	
TC06001785.hg.1	 -6.3423	 -6.5305	 1.92E-06	 6.23E-05	 11.0703	 3.4573	 3.2183	 chr6	 49695092	 49712168	 -	 NM_001190986	 CRISP3	
TC4_ctg9_hap1000001.hg.1	 -6.3325	 -6.5117	 2.00E-06	 6.43E-05	 11.0813	 3.4932	 3.3825	 chr4_ctg9_hap1	 143089	 193241	 +	 NM_014058	 TMPRSS11E	
TC04002642.hg.1	 -6.2743	 -11.9266	 9.49E-11	 9.28E-08	 11.4194	 4.0165	 8.4066	 chr4	 100340208	 100341836	 -	 ---	 ---	
TC01000821.hg.1	 -6.2403	 -6.7377	 1.22E-06	 4.49E-05	 10.2816	 3.3565	 2.9857	 chr1	 86889769	 86922241	 +	 NM_006536	 CLCA2	
TC04001253.hg.1	 -6.1784	 -7.0108	 6.83E-07	 2.96E-05	 9.5993	 2.8341	 2.7737	 chr4	 68775103	 68829858	 -	 NM_001114387	 TMPRSS11A	
TC01000835.hg.1	 -6.1105	 -7.0146	 6.77E-07	 2.95E-05	 10.5098	 3.6973	 3.8221	 chr1	 89829436	 89853719	 +	 NM_198460	 GBP6	
TC02000716.hg.1	 -6.0653	 -7.0829	 5.86E-07	 2.65E-05	 11.5806	 4.5013	 4.5807	 chr2	 113763038	 113766126	 +	 BC107043	 IL36A	
TC18000228.hg.1	 -5.9244	 -6.8624	 9.36E-07	 3.72E-05	 10.1920	 3.3984	 3.4266	 chr18	 61254223	 61271873	 +	 NM_012397	 SERPINB13	
TC12000136.hg.1	 -5.8960	 -6.5996	 1.65E-06	 5.61E-05	 10.9389	 3.8276	 3.8357	 chr12	 8975068	 9039597	 +	 NM_144670	 A2ML1	
TC16000456.hg.1	 -5.8725	 -7.5739	 2.11E-07	 1.26E-05	 10.0465	 3.7904	 3.6352	 chr16	 55600584	 55601599	 +	 NM_032330	 CAPNS2	
TC01004511.hg.1	 -5.8452	 -5.8617	 8.48E-06	 1.89E-04	 11.5816	 3.6352	 2.8749	 chr1	 87012759	 87046432	 +	 ---	 ---	
TC18000124.hg.1	 -5.8178	 -5.6277	 1.44E-05	 2.84E-04	 10.2571	 2.9679	 2.7953	 chr18	 28898052	 28937393	 +	 NM_001942	 DSG1	
TC18000188.hg.1	 -5.8122	 -7.1980	 4.60E-07	 2.20E-05	 8.8368	 2.8528	 2.7814	 chr18	 52258390	 52266724	 +	 NM_173629	 DYNAP	
TC04001412.hg.1	 -5.7854	 -11.8940	 9.97E-11	 9.48E-08	 9.6438	 3.4076	 6.6783	 chr4	 100333418	 100356894	 -	 NM_000673	 ADH7	
TC04000413.hg.1	 -5.6799	 -7.0198	 6.70E-07	 2.93E-05	 8.2143	 2.3131	 2.2276	 chr4	 75174190	 75181024	 +	 NM_001013442	 EPGN	
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TC01000823.hg.1	 -5.6718	 -5.9555	 6.86E-06	 1.61E-04	 11.0913	 3.5421	 2.8544	 chr1	 87012759	 87046437	 +	 NM_012128	 CLCA4	
TC11001505.hg.1	 -5.6479	 -8.2075	 5.95E-08	 5.60E-06	 8.8387	 3.0188	 2.9702	 chr11	 26580579	 26593815	 -	 NM_001135091	 MUC15	
TC01005829.hg.1	 -5.6146	 -5.5926	 1.57E-05	 3.02E-04	 9.5017	 3.4639	 3.4949	 chr1	 152286184	 152286725	 -	 ---	 ---	
TC6_mcf_hap5000038.hg.1	 -5.5672	 -6.5773	 1.73E-06	 5.80E-05	 11.4233	 4.8206	 4.8134	 chr6_mcf_hap5	 2333431	 2339631	 +	 NM_001010909	 MUC21	
TC6_apd_hap1000031.hg.1	 -5.5497	 -6.5418	 1.87E-06	 6.12E-05	 11.4397	 4.8544	 4.8559	 chr6_apd_hap1	 2263124	 2269314	 +	 NM_001010909	 MUC21	
TC6_dbb_hap3000044.hg.1	 -5.5497	 -6.5418	 1.87E-06	 6.12E-05	 11.4397	 4.8544	 4.8559	 chr6_dbb_hap3	 2245596	 2251786	 +	 NM_001010909	 MUC21	
TC04001255.hg.1	 -5.4948	 -7.6800	 1.70E-07	 1.10E-05	 8.0668	 2.4031	 2.4842	 chr4	 68918916	 68995598	 -	 NM_207407	 TMPRSS11F	
TC18000435.hg.1	 -5.4481	 -6.1788	 4.16E-06	 1.10E-04	 10.1880	 3.4078	 3.0548	 chr18	 28570052	 28622781	 -	 NM_001941	 DSC3	
TC01003247.hg.1	 -5.4446	 -6.2256	 3.75E-06	 1.02E-04	 11.7091	 5.0342	 5.0450	 chr1	 152381719	 152386750	 -	 NM_016190	 CRNN	
TC20000023.hg.1	 -5.4441	 -6.0622	 5.40E-06	 1.34E-04	 11.6566	 4.9902	 4.8450	 chr20	 2276613	 2321725	 +	 NM_003245	 TGM3	
TC04002578.hg.1	 -5.4294	 -7.4071	 2.98E-07	 1.61E-05	 7.2778	 1.7763	 1.7791	 chr4	 69049896	 69051921	 -	 ---	 ---	
TC04001257.hg.1	 -5.3799	 -7.7687	 1.42E-07	 9.58E-06	 7.4605	 1.8600	 2.0223	 chr4	 69054242	 69083798	 -	 NM_001129907	 TMPRSS11BNL	
TC13000295.hg.1	 -5.2383	 -5.8960	 7.85E-06	 1.78E-04	 10.3551	 2.7336	 3.3748	 chr13	 78049967	 78219398	 +	 NM_001160706	 SCEL	
TC19001572.hg.1	 -5.2273	 -6.9726	 7.40E-07	 3.13E-05	 12.0359	 6.1708	 5.9529	 chr19	 42891171	 42894444	 -	 NM_032488	 CNFN	
TC01001244.hg.1	 -5.2004	 -7.6408	 1.84E-07	 1.15E-05	 9.4470	 3.8030	 3.9397	 chr1	 152881021	 152884362	 +	 NM_005547	 IVL	
TC6_cox_hap2000051.hg.1	 -5.1827	 -6.2706	 3.39E-06	 9.49E-05	 11.7406	 5.2996	 5.5784	 chr6_cox
_hap2	 2463385	 2469590	 +	 NM_001010909	 MUC21	
TC18001005.hg.1	 -5.1361	 -5.4747	 2.05E-05	 3.68E-04	 10.3935	 3.4489	 3.5458	 chr18	 61322431	 61329197	 -	 NM_006919	 SERPINB3	
TC01001488.hg.1	 -5.1269	 -6.8412	 9.80E-07	 3.86E-05	 9.8172	 4.2112	 4.4631	 chr1	 171154347	 171181822	 +	 NM_001460	 FMO2	
TC18001004.hg.1	 -5.1073	 -5.4743	 2.06E-05	 3.68E-04	 9.7904	 3.3744	 3.3226	 chr18	 61304493	 61311532	 -	 NM_002974	 SERPINB4	
TC04001252.hg.1	 -5.0828	 -5.6459	 1.39E-05	 2.75E-04	 10.3312	 3.9104	 3.7742	 chr4	 68686594	 68749750	 -	 NM_004262	 TMPRSS11D	
TC01005830.hg.1	 -5.0365	 -5.2383	 3.55E-05	 5.50E-04	 7.3810	 2.0343	 2.2763	 chr1	 152287087	 152287969	 -	 ---	 ---	
TC17001468.hg.1	 -5.0223	 -5.1302	 4.57E-05	 6.60E-04	 9.2495	 3.7841	 3.5375	 chr17	 38854243	 38860002	 -	 NM_019016	 KRT24	
TC6_mann_hap4000046.hg.
1	 -5.0000	 -6.2110	 3.87E-06	 1.04E-04	 11.7601	 5.4994	 5.7704	
chr6_ma
nn_hap4	 2299571	 2305861	 +	 NM_001010909	 MUC21	
TC05000810.hg.1	 -4.9901	 -7.2258	 4.34E-07	 2.10E-05	 9.3987	 3.6424	 4.7522	 chr5	 147691982	 147695485	 +	 NM_032566	 SPINK7	
TC15001829.hg.1	 -4.9868	 -7.3270	 3.52E-07	 1.81E-05	 10.6656	 5.1489	 5.1443	 chr15	 89998680	 90039844	 -	 NM_016321	 RHCG	
TC01006366.hg.1	 -4.9742	 -8.7526	 2.09E-08	 2.77E-06	 9.0579	 4.3205	 4.4973	 chr1	 115125469	 115213043	 -	 NM_001256404	 DENND2C	
TC19001446.hg.1	 -4.9579	 -6.1356	 4.58E-06	 1.18E-04	 11.0953	 4.9862	 4.8912	 chr19	 36014269	 36019253	 -	 NM_198538	 SBSN	
TC13001343.hg.1	 -4.9389	 -7.4007	 3.02E-07	 1.62E-05	 9.5388	 4.1725	 4.2259	 chr13	 20797502	 20806372	 -	 ---	 ---	
TC6_qbl_hap6000044.hg.1	 -4.8630	 -6.0500	 5.55E-06	 1.37E-04	 11.7903	 5.4797	 5.9121	 chr6_qbl_hap6	 2244470	 2250865	 +	 NM_001010909	 MUC21	
TC12001538.hg.1	 -4.8538	 -8.2918	 5.05E-08	 5.01E-06	 10.7002	 5.5556	 5.4813	 chr12	 53231588	 53242778	 -	 NM_173352	 KRT78	
TC02001715.hg.1	 -4.8068	 -9.9149	 2.53E-09	 7.09E-07	 8.9278	 3.9288	 3.8544	 chr2	 31395922	 31456724	 -	 NM_001145122	 CAPN14	
TC12001536.hg.1	 -4.7999	 -5.2816	 3.21E-05	 5.14E-04	 11.9955	 5.1747	 5.0701	 chr12	 53200327	 53208335	 -	 NM_002272	 KRT4	
TC06000353.hg.1	 -4.7494	 -6.3924	 2.59E-06	 7.75E-05	 11.8250	 6.0283	 6.1762	 chr6	 30951485	 30957680	 +	 NM_001010909	 MUC21	
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TC12002789.hg.1	 -4.7243	 -6.2908	 3.25E-06	 9.19E-05	 7.5141	 2.8223	 2.7429	 chr12	 21689123	 21757554	 -	 ---	 ---	
TC06003208.hg.1	 -4.6975	 -7.4081	 2.97E-07	 1.61E-05	 7.6543	 2.7852	 2.7239	 chr6	 168084231	 168088891	 +	 ---	 ---	
TC03001905.hg.1	 -4.6411	 -8.3434	 4.57E-08	 4.64E-06	 8.2332	 3.5838	 3.3951	 chr3	 151011876	 151034740	 -	 NM_023915	 GPR87	
TC04002094.hg.1	 -4.6041	 -8.0889	 7.52E-08	 6.43E-06	 9.6699	 5.2431	 6.6181	 chr4	 87515885	 87736302	 +	 ---	 ---	
TC10002963.hg.1	 -4.5910	 -8.3065	 4.91E-08	 4.90E-06	 10.0795	 5.1799	 5.0563	 chr10	 47157983	 47174122	 -	 NM_001098845	 ANXA8L1	
TC04000282.hg.1	 -4.5826	 -8.0363	 8.34E-08	 6.90E-06	 8.5796	 4.4648	 6.5740	 chr4	 48988264	 49064098	 +	 NM_025087	 CWH43	
TC14000971.hg.1	 -4.5679	 -7.4266	 2.86E-07	 1.56E-05	 9.9252	 5.0235	 4.9707	 chr14	 24718320	 24732416	 -	 NM_000359	 TGM1	
TC19000538.hg.1	 -4.5642	 -8.1952	 6.10E-08	 5.68E-06	 10.0305	 5.6299	 5.2216	 chr19	 39687601	 39692524	 +	 NM_001001414	 NCCRP1	
TC18000127.hg.1	 -4.5535	 -6.7730	 1.13E-06	 4.27E-05	 11.2379	 6.7588	 3.1241	 chr18	 29027732	 29058665	 +	 NM_001944	 DSG3	
TC01005834.hg.1	 -4.5038	 -4.0986	 5.24E-04	 4.16E-03	 11.2587	 3.5787	 3.0263	 chr1	 153012201	 153013594	 -	 ---	 ---	
TC11002740.hg.1	 -4.5006	 -7.8738	 1.15E-07	 8.45E-06	 10.8745	 6.3786	 5.9918	 chr11	 67429963	 67430223	 +	 ---	 ---	
TC17000513.hg.1	 -4.5006	 -5.8977	 7.82E-06	 1.78E-04	 11.1606	 5.1270	 4.9398	 chr17	 39657235	 39658661	 +	 OTTHUMT000002
57901	
OTTHUMG0000
0133684	
TC12001297.hg.1	 -4.4970	 -6.0998	 4.96E-06	 1.25E-04	 7.0979	 2.6419	 2.5754	 chr12	 21689123	 21757781	 -	 NM_021957	 GYS2	
TC01006378.hg.1	 -4.4970	 -4.8689	 8.43E-05	 1.06E-03	 9.3667	 3.3687	 3.4908	 chr1	 153112594	 153113969	 -	 NR_003062	 SPRR2C	
TC04000469.hg.1	 -4.4889	 -8.0617	 7.93E-08	 6.65E-06	 9.2999	 4.9455	 6.2504	 chr4	 87515468	 87736328	 +	 NM_006264	 PTPN13	
TC14000080.hg.1	 -4.4693	 -6.2460	 3.58E-06	 9.88E-05	 9.1969	 4.5054	 4.4745	 chr14	 21510385	 21512393	 +	 NM_032572	 RNASE7	
TC01005836.hg.1	 -4.4523	 -4.8884	 8.05E-05	 1.02E-03	 9.2679	 3.4210	 3.6068	 chr1	 153112594	 153113969	 -	 ---	 ---	
TC0X001579.hg.1	 -4.4012	 -7.5003	 2.46E-07	 1.40E-05	 8.9929	 3.9831	 3.7414	 chrX	 2670337	 2693037	 +	 ---	 ---	
TC10000314.hg.1	 -4.3983	 -8.0296	 8.45E-08	 6.93E-06	 9.6810	 4.9928	 4.7928	 chr10	 48255225	 48279199	 +	 NM_001098845	 ANXA8L1	
TC03002609.hg.1	 -4.3949	 -9.0807	 1.13E-08	 1.83E-06	 8.7266	 6.4090	 5.0587	 chr3	 152557179	 152559228	 +	 ---	 ---	
TC05000805.hg.1	 -4.3779	 -5.3968	 2.46E-05	 4.19E-04	 11.1755	 4.3385	 5.7582	 chr5	 147405246	 147516925	 +	 NM_001127699	 SPINK5	
TC01001254.hg.1	 -4.3469	 -6.5664	 1.77E-06	 5.89E-05	 10.9544	 5.9423	 5.8387	 chr1	 153330330	 153333503	 +	 NM_002965	 S100A9	
TC12001526.hg.1	 -4.3334	 -5.8414	 8.88E-06	 1.96E-04	 11.5277	 5.4670	 5.3992	 chr12	 52908359	 52914471	 -	 NM_000424	 KRT5	
TC01005828.hg.1	 -4.3324	 -5.2619	 3.36E-05	 5.28E-04	 9.6127	 4.8973	 4.6607	 chr1	 152274640	 152281460	 -	 ---	 ---	
TC10000309.hg.1	 -4.3293	 -8.0914	 7.48E-08	 6.43E-06	 9.6987	 5.1796	 4.9404	 chr10	 47742393	 47770871	 +	 NM_001630	 ANXA8L2	
TC01004997.hg.1	 -4.3018	 -7.0731	 5.98E-07	 2.69E-05	 8.7065	 4.2472	 4.1867	 chr1	 209602165	 209606183	 +	 ---	 ---	
TC06001902.hg.1	 -4.2689	 -7.4680	 2.63E-07	 1.47E-05	 8.4768	 4.4059	 4.6807	 chr6	 80624529	 80657315	 -	 NM_022726	 ELOVL4	
TC01001199.hg.1	 -4.2679	 -8.5456	 3.09E-08	 3.55E-06	 8.4876	 4.1976	 4.1870	 chr1	 151009029	 151020076	 +	 NM_001159642	 BNIPL	
TC03001042.hg.1	 -4.2646	 -7.5996	 2.01E-07	 1.22E-05	 8.7630	 4.3226	 4.2599	 chr3	 189349205	 189615068	 +	 NM_003722	 TP63	
TC06004001.hg.1	 -4.2645	 -7.3546	 3.32E-07	 1.74E-05	 8.4543	 3.8965	 3.6994	 chr6	 168080306	 168096970	 -	 ---	 ---	
TC12002888.hg.1	 -4.2634	 -5.2968	 3.10E-05	 5.01E-04	 12.1279	 6.0879	 6.1057	 chr12	 52912731	 52912944	 -	 ---	 ---	
TC04001254.hg.1	 -4.2328	 -5.9372	 7.15E-06	 1.66E-04	 6.8616	 2.6571	 2.4297	 chr4	 68857530	 68863205	 -	 NR_033737	 TMPRSS11GP	
TC03000836.hg.1	 -4.2097	 -9.3658	 6.72E-09	 1.31E-06	 8.8243	 6.4595	 5.1308	 chr3	 152557179	 152559228	 +	 OTTHUMT000003
56944	
OTTHUMG0000
0159695	
TC10001522.hg.1	 -4.1915	 -8.8850	 1.63E-08	 2.35E-06	 9.3831	 5.4160	 6.8116	 chr10	 93388197	 93392858	 -	 NM_005398	 PPP1R3C	
TC12001436.hg.1	 -4.1846	 -8.3825	 4.23E-08	 4.40E-06	 8.0995	 3.9126	 3.8091	 chr12	 48103517	 48119355	 -	 NM_001172439	 ENDOU	
TC06002317.hg.1	 -4.1651	 -7.3481	 3.37E-07	 1.76E-05	 7.8980	 3.4924	 3.2863	 chr6	 168080306	 168096970	 -	 BC093745	 LOC441178	
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Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
TC08001637.hg.1	 -4.1503	 -6.8333	 9.96E-07	 3.91E-05	 8.1732	 3.4877	 3.4292	 chr8	 130760442	 130799134	 -	 NM_031415	 GSDMC	
TC6_mann_hap4000176.hg.
1	 -4.1104	 -6.3103	 3.11E-06	 8.95E-05	 6.8706	 3.0106	 2.5619	
chr6_ma
nn_hap4	 2370339	 2376003	 +	 ---	 ---	
TC01003245.hg.1	 -4.1052	 -5.2983	 3.09E-05	 5.00E-04	 8.5067	 4.1574	 4.1342	 chr1	 152274651	 152297679	 -	 NM_002016	 FLG	
TC21000361.hg.1	 -4.0956	 -5.3705	 2.61E-05	 4.39E-04	 6.9501	 2.6219	 2.7697	 chr21	 31537882	 31539074	 -	 ENST00000286808	 CLDN17	
TC01001747.hg.1	 -4.0924	 -6.9911	 7.12E-07	 3.04E-05	 8.5964	 4.3827	 4.3584	 chr1	 209602165	 209606183	 +	 NR_029622	 MIR205	
TC19001152.hg.1	 -4.0530	 -8.7028	 2.29E-08	 2.95E-06	 8.1629	 3.9707	 4.0935	 chr19	 9800600	 9811493	 -	 NM_001199814	 ZNF812	
TC18000227.hg.1	 -4.0394	 -6.2900	 3.25E-06	 9.20E-05	 6.8332	 2.8412	 2.7312	 chr18	 61223393	 61234244	 +	 NM_080474	 SERPINB12	
TC6_mcf_hap5000187.hg.1	 -4.0372	 -6.0127	 6.03E-06	 1.45E-04	 6.9908	 3.0713	 2.7608	 chr6_mcf_hap5	 2403917	 2409577	 +	 ---	 ---	
TC04002559.hg.1	 -4.0226	 -8.4004	 4.09E-08	 4.28E-06	 10.5837	 6.8799	 7.1823	 chr4	 57514710	 57522067	 -	 ---	 ---	
TC15001996.hg.1	 -4.0045	 -8.5064	 3.33E-08	 3.76E-06	 7.8457	 3.7938	 3.6918	 chr15	 100940600	 101084925	 -	 NM_178842	 CERS3	
TC12001524.hg.1	 -4.0034	 -5.0441	 5.59E-05	 7.72E-04	 11.7605	 6.2612	 6.0276	 chr12	 52862300	 52867569	 -	 NM_173086	 KRT6C	
TC21000282.hg.1	 -3.9703	 -6.9460	 7.83E-07	 3.27E-05	 7.5708	 4.4694	 3.9218	 chr21	 15340810	 15340916	 -	 ---	 ---	
TC06003648.hg.1	 -3.9599	 -7.5036	 2.44E-07	 1.40E-05	 8.8855	 4.4670	 5.8041	 chr6	 42059976	 42061997	 -	 ---	 ---	
TC06003638.hg.1	 -3.9568	 -8.0087	 8.81E-08	 7.05E-06	 6.5756	 2.3900	 2.4994	 chr6	 40825508	 40827706	 -	 ---	 ---	
 
Table 2: Top 100 up- and down-regulated transcript clusters for differentiating non-dysplastic Barrett’s esophagus from normal 
mucosa 
2,512 up-regulated and 1,984 down-regulated transcript clusters were identified as differentially expressed between normal squamous 
epithelium and non-dysplastic Barrett’s epithelium (N v BE, adjusted p-value < 0.05 and logfc > log2(1.5). Tx: transcript, logfc: log fold change, 
tstat: t-statistic, pval: p-value, adj_pval: adjusted p-value, Expbase: average expression in baseline samples, here, normal squamous epithelium, 
Expduo: average expression in duodenal epithelium, Expstom: average expression in proximal stomach epithelium, str: strand. Top 100 up- and 
down-regulated transcript clusters based on greatest |logfc|; listed in order of decreasing |logfc|.  
 
Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
Top	100	up-regulated	transcript	clusters	from	the	N	v	BE	comparison	(differentiating	Barrett’s	mucosa	from	normal	squamous	epithelium)	
TC02004392.hg.1	 7.6692	 9.1123	 1.07E-08	 4.84E-06	 3.6442	 11.8566	 6.8967	 chr2	 88422556	 88427635	 -	 ---	 ---	
TC04001926.hg.1	 7.3129	 6.8820	 8.98E-07	 1.07E-04	 2.6228	 9.4718	 9.7421	 chr4	 15969851	 15970275	 +	 ---	 ---	
TC04000836.hg.1	 6.9995	 8.1643	 6.48E-08	 1.81E-05	 3.0216	 8.2071	 10.5192	 chr4	 169013666	 169108893	 +	 NM_007193	 ANXA10	
TC03001966.hg.1	 6.8452	 10.3680	 1.16E-09	 9.02E-07	 2.7781	 10.9035	 4.2462	 chr3	 164696686	 164796283	 -	 NM_001041	 SI	
TC17001473.hg.1	 6.8321	 7.9637	 9.63E-08	 2.37E-05	 4.0590	 10.7581	 8.9311	 chr17	 39030852	 39041495	 -	 NM_019010	 KRT20	
TC01003051.hg.1	 6.8151	 13.2566	 1.35E-11	 2.47E-08	 3.9260	 8.4103	 5.9298	 chr1	 120336641	 120354283	 -	 NM_001159352	 REG4	
TC03001719.hg.1	 6.6770	 35.1794	 5.54E-20	 3.74E-15	 4.2162	 10.9536	 8.2634	 chr3	 124624289	 124672663	 -	 NM_033049	 MUC13	
TC07001746.hg.1	 6.5292	 15.7106	 5.40E-13	 2.15E-09	 3.2495	 11.3912	 5.1625	 chr7	 107405912	 107443678	 -	 NM_000111	 SLC26A3	
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Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
TC07001164.hg.1	 6.3814	 18.6433	 1.94E-14	 1.87E-10	 2.4452	 8.8125	 7.8018	 chr7	 16899029	 16921613	 -	 NM_176813	 AGR3	
TC07002496.hg.1	 6.1978	 17.4501	 7.08E-14	 5.31E-10	 3.7525	 10.1808	 6.0229	 chr7	 100678736	 100679444	 +	 ---	 ---	
TC07002495.hg.1	 6.1425	 16.6395	 1.78E-13	 1.00E-09	 3.5054	 9.8782	 5.9416	 chr7	 100677704	 100680561	 +	 ---	 ---	
TC13000228.hg.1	 6.1392	 9.3826	 6.52E-09	 3.52E-06	 4.5295	 10.8360	 5.5739	 chr13	 53602830	 53626196	 +	 NM_006418	 OLFM4	
TC02002835.hg.1	 5.8781	 10.9545	 4.39E-10	 4.43E-07	 3.0113	 9.6065	 3.5581	 chr2	 228226872	 228246711	 -	 NM_024795	 TM4SF20	
TC08001431.hg.1	 5.8277	 16.0487	 3.59E-13	 1.61E-09	 4.2965	 10.3560	 4.6983	 chr8	 95139394	 95229531	 -	 NM_001144663	 CDH17	
TC01001720.hg.1	 5.7680	 8.5297	 3.19E-08	 1.09E-05	 5.4355	 10.8512	 11.4785	 chr1	 206317459	 206332104	 +	 NM_001910	 CTSE	
TC02000663.hg.1	 5.5000	 9.0686	 1.16E-08	 5.04E-06	 4.0127	 7.3808	 9.3863	 chr2	 108905095	 108926371	 +	 NM_001056	 SULT1C2	
TC12002508.hg.1	 5.4797	 6.1470	 4.47E-06	 3.01E-04	 3.4514	 10.2113	 4.6968	 chr12	 92271167	 92274184	 +	 ---	 ---	
TC12000709.hg.1	 5.4769	 6.0731	 5.27E-06	 3.33E-04	 3.4963	 10.2307	 4.4731	 chr12	 92271167	 92274184	 +	 ---	 ---	
TC0Y000083.hg.1	 5.4480	 5.6504	 1.37E-05	 6.11E-04	 2.7882	 2.7436	 6.0001	 chrY	 25365581	 25437503	 +	 NM_001005785	 DAZ2	
TC04001500.hg.1	 5.4478	 9.0957	 1.10E-08	 4.95E-06	 2.3328	 9.5233	 2.8036	 chr4	 120238405	 120243545	 -	 NM_000134	 FABP2	
TC03000806.hg.1	 5.4187	 8.6131	 2.72E-08	 9.46E-06	 4.4273	 10.3388	 8.0240	 chr3	 149191761	 149221181	 +	 NM_004617	 TM4SF4	
TC03003109.hg.1	 5.4013	 6.7124	 1.29E-06	 1.33E-04	 2.9071	 4.1455	 9.6955	 chr3	 137749545	 137750672	 -	 ---	 ---	
TC19001505.hg.1	 5.3819	 21.1434	 1.61E-15	 2.18E-11	 5.8753	 11.3040	 10.3407	 chr19	 39292311	 39303740	 -	 NM_006149	 LGALS4	
TC0X000177.hg.1	 5.3282	 11.6424	 1.47E-10	 1.65E-07	 2.9150	 9.6800	 4.6208	 chrX	 38211736	 38280703	 +	 NM_000531	 OTC	
TC21000486.hg.1	 5.3163	 7.8344	 1.25E-07	 2.80E-05	 6.7498	 10.4136	 12.1854	 chr21	 43782391	 43786703	 -	 NM_003225	 TFF1	
TC0X001747.hg.1	 5.3010	 12.1413	 6.85E-11	 8.26E-08	 4.0778	 9.8024	 6.0420	 chrX	 65486697	 65487236	 +	 ---	 ---	
TC06000631.hg.1	 5.2950	 10.1277	 1.75E-09	 1.24E-06	 3.3383	 9.3989	 3.7220	 chr6	 46761094	 46807519	 +	 NM_005588	 MEP1A	
TC0X000529.hg.1	 5.2920	 7.6756	 1.72E-07	 3.50E-05	 4.2925	 6.1041	 10.3953	 chrX	 107288200	 107322414	 +	 NM_001170553	 VSIG1	
TC15001837.hg.1	 5.2196	 16.3525	 2.50E-13	 1.20E-09	 5.3104	 11.3706	 5.8109	 chr15	 90328120	 90358094	 -	 NM_001150	 ANPEP	
TC04002303.hg.1	 5.2165	 10.5296	 8.86E-10	 7.29E-07	 3.7880	 9.2823	 5.8750	 chr4	 165675283	 165724947	 +	 ---	 ---	
TC01000822.hg.1	 5.1943	 9.2976	 7.60E-09	 3.83E-06	 3.1142	 10.1797	 3.4495	 chr1	 86934051	 86965974	 +	 NM_001285	 CLCA1	
TC05001911.hg.1	 5.1628	 12.9069	 2.22E-11	 3.57E-08	 4.3968	 10.3294	 10.7604	 chr5	 147204131	 147211349	 -	 NM_003122	 SPINK1	
TC07000640.hg.1	 5.1472	 13.0518	 1.80E-11	 3.12E-08	 4.2975	 9.4392	 5.6876	 chr7	 100663353	 100702140	 +	 NM_001040105	 MUC17	
TC07003086.hg.1	 5.1434	 14.4651	 2.61E-12	 7.68E-09	 5.3527	 11.0530	 8.7097	 chr7	 100550661	 100551637	 -	 ---	 ---	
TC0Y000093.hg.1	 5.1163	 5.6385	 1.41E-05	 6.21E-04	 2.9781	 2.8803	 5.2257	 chrY	 26979967	 27053187	 +	 NM_001005375	 DAZ4	
TC03001985.hg.1	 5.1142	 12.3569	 4.96E-11	 6.20E-08	 3.0163	 6.8658	 6.5837	 chr3	 169556967	 169587718	 -	 NM_024727	 LRRC31	
TC19001042.hg.1	 5.0942	 13.7335	 6.96E-12	 1.67E-08	 4.3460	 11.1106	 10.1189	 chr19	 3474405	 3480540	 -	 NM_001136503	 C19orf77	
TC16000645.hg.1	 5.0671	 13.7107	 7.18E-12	 1.67E-08	 5.2593	 11.0469	 8.6785	 chr16	 82068858	 82132139	 +	 NM_002153	 HSD17B2	
TC6_apd_hap1000067.hg.1	 5.0321	 13.9107	 5.47E-12	 1.37E-08	 3.6191	 8.0192	 6.7959	 chr6_apd_hap1	 1318454	 1321112	 -	 NM_007028	 TRIM31	
TC09001421.hg.1	 5.0198	 8.8234	 1.83E-08	 7.01E-06	 4.7877	 11.7273	 8.7092	 chr9	 104182842	 104198105	 -	 NM_000035	 ALDOB	
TC10000627.hg.1	 4.9838	 5.5424	 1.76E-05	 7.21E-04	 3.6520	 8.1987	 10.4879	 chr10	 90424146	 90438572	 +	 NM_001198828	 LIPF	
TC01003768.hg.1	 4.9506	 10.2001	 1.55E-09	 1.15E-06	 5.2061	 10.7348	 7.9139	 chr1	 207101863	 207119811	 -	 NM_002644	 PIGR	
TC01000580.hg.1	 4.9159	 23.1459	 2.66E-16	 4.48E-12	 5.2139	 8.4753	 9.5359	 chr1	 46640745	 46651634	 +	 NM_005727	 TSPAN1	
TC11003279.hg.1	 4.8994	 12.3909	 4.71E-11	 6.01E-08	 5.3354	 8.7481	 10.2169	 chr11	 85416009	 85420543	 -	 ---	 ---	
TC0Y000210.hg.1	 4.8712	 5.5490	 1.73E-05	 7.14E-04	 3.0026	 2.9094	 5.2087	 chrY	 26909216	 26959639	 -	 NM_020364	 DAZ3	
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Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
TC01003409.hg.1	 4.8424	 7.6855	 1.68E-07	 3.46E-05	 4.3600	 9.7169	 6.2701	 chr1	 160846329	 160854960	 -	 NM_017625	 ITLN1	
TC07002497.hg.1	 4.8171	 11.8341	 1.09E-10	 1.27E-07	 4.3495	 9.3144	 5.5696	 chr7	 100701581	 100701790	 +	 ---	 ---	
TC18000135.hg.1	 4.8005	 10.2362	 1.45E-09	 1.09E-06	 3.1120	 10.7710	 3.6477	 chr18	 29769987	 29800366	 +	 NM_005925	 MEP1B	
TC04000821.hg.1	 4.7844	 9.5425	 4.89E-09	 2.77E-06	 2.5396	 7.7616	 4.4132	 chr4	 165675216	 165724947	 +	 NR_038834	 LOC100505989	
TC03002462.hg.1	 4.7791	 11.3878	 2.19E-10	 2.28E-07	 3.3366	 8.8719	 8.1115	 chr3	 110917882	 110920289	 +	 ---	 ---	
TC10001754.hg.1	 4.7720	 13.2174	 1.43E-11	 2.53E-08	 3.5286	 9.1097	 5.0902	 chr10	 129676105	 129691211	 -	 NM_152311	 CLRN3	
TC06002119.hg.1	 4.7505	 9.2220	 8.72E-09	 4.24E-06	 3.7363	 9.9695	 3.9040	 chr6	 133001997	 133035194	 -	 NM_004666	 VNN1	
TC12001723.hg.1	 4.7238	 28.8638	 3.11E-18	 1.05E-13	 3.3606	 8.0494	 8.1431	 chr12	 71518865	 71835678	 -	 NM_004616	 TSPAN8	
TC0Y000196.hg.1	 4.5882	 5.5904	 1.57E-05	 6.67E-04	 3.1479	 3.0561	 4.4589	 chrY	 25275502	 25345254	 -	 NM_001005375	 DAZ4	
TC03000545.hg.1	 4.5199	 13.2559	 1.35E-11	 2.47E-08	 3.2250	 8.7148	 6.4195	 chr3	 108015376	 108097132	 +	 NM_007072	 HHLA2	
TC02003394.hg.1	 4.4886	 5.6237	 1.46E-05	 6.35E-04	 4.7806	 10.7495	 9.5061	 chr2	 89185097	 89185706	 +	 ---	 ---	
TC12001163.hg.1	 4.4101	 7.6328	 1.88E-07	 3.74E-05	 3.3781	 9.4316	 5.6822	 chr12	 7801996	 7818502	 -	 NM_001644	 APOBEC1	
TC03000510.hg.1	 4.4048	 8.3294	 4.69E-08	 1.44E-05	 2.8646	 8.7313	 3.0343	 chr3	 100328433	 100414323	 +	 NM_032787	 GPR128	
TC02002478.hg.1	 4.3996	 13.6121	 8.22E-12	 1.80E-08	 4.1374	 9.1093	 6.1959	 chr2	 162848751	 162931052	 -	 NM_001935	 DPP4	
TC02002069.hg.1	 4.3689	 8.2764	 5.20E-08	 1.54E-05	 4.2701	 9.2833	 5.0923	 chr2	 88422508	 88427650	 -	 NM_001443	 FABP1	
TC07000104.hg.1	 4.3684	 9.9659	 2.32E-09	 1.58E-06	 2.6294	 6.4699	 3.1402	 chr7	 15707572	 15721605	 +	 OTTHUMT000003
26059	
OTTHUMG0000
0152391	
TC03001692.hg.1	 4.3654	 9.6511	 4.03E-09	 2.39E-06	 3.6063	 8.1441	 8.1161	 chr3	 120347015	 120401418	 -	 NM_000187	 HGD	
TC04001406.hg.1	 4.3406	 8.0685	 7.82E-08	 2.06E-05	 3.6357	 9.5860	 3.7062	 chr4	 100044808	 100078949	 -	 NM_000670	 ADH4	
TC07002629.hg.1	 4.3321	 18.3222	 2.73E-14	 2.30E-10	 3.3188	 8.6340	 3.7731	 chr7	 141870970	 141923474	 +	 ---	 ---	
TC07000726.hg.1	 4.3270	 9.3626	 6.76E-09	 3.59E-06	 3.9643	 9.0968	 4.8152	 chr7	 117105838	 117308719	 +	 NM_000492	 CFTR	
TC07001163.hg.1	 4.3246	 15.6626	 5.73E-13	 2.15E-09	 3.5359	 7.4353	 7.7732	 chr7	 16831435	 16873057	 -	 NM_006408	 AGR2	
TC07002158.hg.1	 4.3189	 9.0715	 1.15E-08	 5.04E-06	 2.3500	 6.1103	 2.8304	 chr7	 15707572	 15721605	 +	 ---	 ---	
TC08000907.hg.1	 4.3169	 5.2201	 3.70E-05	 1.18E-03	 2.6901	 11.1934	 3.6942	 chr8	 6782215	 6783598	 -	 NM_001926	 DEFA6	
TC02004093.hg.1	 4.3083	 7.4999	 2.46E-07	 4.44E-05	 2.3753	 10.9422	 4.8379	 chr2	 21225293	 21225747	 -	 ---	 ---	
TC01001831.hg.1	 4.2953	 7.7115	 1.60E-07	 3.32E-05	 3.5952	 7.0827	 8.4796	 chr1	 222910549	 222924147	 +	 NM_207468	 FAM177B	
TC04001261.hg.1	 4.2692	 6.1914	 4.05E-06	 2.83E-04	 3.2448	 8.6020	 8.1218	 chr4	 69512315	 69536494	 -	 NM_001076	 UGT2B15	
TC0Y000279.hg.1	 4.2582	 5.6256	 1.45E-05	 6.34E-04	 3.4712	 3.3489	 4.2141	 chrY	 26980079	 26999579	 +	 ---	 ---	
TC10002643.hg.1	 4.2408	 7.4980	 2.47E-07	 4.45E-05	 2.5628	 8.0562	 4.5686	 chr10	 52559793	 52565728	 -	 ---	 ---	
TC4_ctg9_hap1000004.hg.1	 4.2237	 6.1691	 4.25E-06	 2.92E-04	 3.6915	 9.5171	 8.5147	 chr4_ctg9_hap1	 224704	 249081	 -	 NM_001076	 UGT2B15	
TC11002492.hg.1	 4.1910	 9.0824	 1.13E-08	 5.01E-06	 7.0391	 11.3513	 11.6740	 chr11	 1017314	 1018174	 +	 ---	 ---	
TC11002162.hg.1	 4.1660	 12.8406	 2.44E-11	 3.74E-08	 4.7160	 7.6027	 9.1337	 chr11	 85405265	 85522184	 -	 NM_001162951	 SYTL2	
TC05002656.hg.1	 4.1130	 13.9296	 5.33E-12	 1.37E-08	 6.6027	 10.6394	 11.7181	 chr5	 139554736	 139623371	 +	 ---	 ---	
TC21000942.hg.1	 4.1034	 7.7519	 1.47E-07	 3.14E-05	 3.7456	 5.4679	 9.8031	 chr21	 36089937	 36090503	 -	 ---	 ---	
TC04001270.hg.1	 4.0581	 4.8162	 9.55E-05	 2.22E-03	 6.1255	 10.7143	 10.5084	 chr4	 71521258	 71547534	 -	 NM_144646	 IGJ	
TC12003252.hg.1	 4.0283	 9.9172	 2.52E-09	 1.66E-06	 3.6433	 8.6170	 4.7328	 chr12	 70219084	 70352503	 +	 BC143553	 MYRFL	
TC04002595.hg.1	 4.0012	 6.3404	 2.91E-06	 2.30E-04	 2.9016	 6.9788	 4.8625	 chr4	 76103904	 76105665	 -	 ---	 ---	
Appendix 5: Top differentially expressed transcript clusters identified by genome-wide expression profiling 
 321 
Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
TC08000721.hg.1	 3.9930	 6.1669	 4.27E-06	 2.93E-04	 4.5042	 5.6046	 8.5598	 chr8	 124864227	 125132302	 +	 NM_001039112	 FER1L6	
TC06000970.hg.1	 3.9707	 6.5406	 1.88E-06	 1.70E-04	 3.4092	 8.2051	 6.1367	 chr6	 127840600	 127912962	 +	 NM_001010905	 C6orf58	
TC13000576.hg.1	 3.9688	 7.0120	 6.81E-07	 8.76E-05	 3.9294	 4.5442	 8.6068	 chr13	 38136719	 38183563	 -	 NM_001135934	 POSTN	
TC04001193.hg.1	 3.9674	 12.7089	 2.95E-11	 4.07E-08	 2.7636	 6.9652	 5.7111	 chr4	 52859866	 52883786	 -	 NM_001024611	 LRRC66	
TC01003125.hg.1	 3.9519	 10.1579	 1.66E-09	 1.21E-06	 3.7925	 7.7597	 7.3715	 chr1	 146655884	 146697230	 -	 NM_001461	 FMO5	
TC01000939.hg.1	 3.9465	 12.8585	 2.38E-11	 3.74E-08	 4.7383	 8.5278	 9.1496	 chr1	 109656585	 109749403	 +	 NM_020775	 KIAA1324	
TC07003085.hg.1	 3.9250	 8.7804	 1.98E-08	 7.43E-06	 5.3184	 10.3073	 6.5764	 chr7	 100547228	 100550424	 -	 ---	 ---	
TC12002772.hg.1	 3.9199	 9.3072	 7.47E-09	 3.79E-06	 4.6866	 9.3261	 4.3949	 chr12	 14765566	 14849497	 -	 ---	 ---	
TC06001495.hg.1	 3.9128	 11.4917	 1.86E-10	 2.03E-07	 3.9586	 7.3347	 6.2694	 chr6	 30070674	 30080883	 -	 NM_007028	 TRIM31	
TC05001963.hg.1	 3.9119	 6.1538	 4.40E-06	 2.98E-04	 4.2769	 4.4892	 4.6522	 chr5	 151771093	 151812929	 -	 NM_020167	 NMUR2	
TC11002989.hg.1	 3.9044	 7.0843	 5.84E-07	 7.85E-05	 8.0050	 8.7442	 12.1725	 chr11	 1212782	 1213779	 -	 ---	 ---	
TC12000268.hg.1	 3.8945	 7.8480	 1.21E-07	 2.73E-05	 3.7509	 6.4194	 8.6899	 chr12	 27849428	 27850566	 +	 NM_001029874	 REP15	
TC02004978.hg.1	 3.8910	 4.8217	 9.42E-05	 2.19E-03	 5.8691	 11.4305	 10.1621	 chr2	 89998789	 89999564	 +	 ENST00000453166	 IGKV2D-28	
TC12001271.hg.1	 3.8808	 9.2365	 8.50E-09	 4.16E-06	 4.5943	 9.1396	 4.3426	 chr12	 14765568	 14849519	 -	 NM_004963	 GUCY2C	
TC06003665.hg.1	 3.8797	 6.6313	 1.54E-06	 1.50E-04	 2.8288	 8.2129	 5.0389	 chr6	 45866380	 45866814	 -	 ---	 ---	
TC12001909.hg.1	 3.8787	 14.7349	 1.84E-12	 5.98E-09	 4.0970	 8.6060	 8.9983	 chr12	 105196331	 105352522	 -	 NM_032148	 SLC41A2	
TC04002940.hg.1	 3.8734	 6.8853	 8.91E-07	 1.07E-04	 4.1950	 7.1497	 7.2337	 chr4	 15969849	 16086001	 -	 NM_006017	 PROM1	
TC11000788.hg.1	 3.8730	 9.1970	 9.13E-09	 4.34E-06	 4.6610	 8.3474	 7.1957	 chr11	 74166393	 74167870	 +	 ---	 ---	
TC02004946.hg.1	 3.8704	 4.7651	 1.08E-04	 2.39E-03	 6.1313	 11.6365	 10.5231	 chr2	 89521179	 89521942	 -	 ENST0000048276
9	 IGKV2-28	
Top	100	down-regulated	transcript	clusters	from	the	N	v	BE	comparison	(differentiating	Barrett’s	mucosa	from	normal	squamous	epithelium)	
TC4_ctg9_hap1000001.hg.1	 -5.0713	 -5.2148	 3.75E-05	 1.19E-03	 11.0813	 3.4932	 3.3825	 chr4_ctg9_hap1	 143089	 193241	 +	 NM_014058	 TMPRSS11E	
TC04000369.hg.1	 -5.0586	 -5.2249	 3.66E-05	 1.17E-03	 11.0680	 3.4914	 3.4121	 chr4	 69313167	 69363322	 +	 NM_014058	 TMPRSS11E	
TC04001258.hg.1	 -5.0294	 -4.7587	 1.09E-04	 2.42E-03	 10.7669	 2.6350	 2.6667	 chr4	 69092371	 69111438	 -	 NM_182502	 TMPRSS11B	
TC18000124.hg.1	 -4.7607	 -4.6051	 1.57E-04	 3.09E-03	 10.2571	 2.9679	 2.7953	 chr18	 28898052	 28937393	 +	 NM_001942	 DSG1	
TC01005834.hg.1	 -4.7172	 -4.2928	 3.30E-04	 5.11E-03	 11.2587	 3.5787	 3.0263	 chr1	 153012201	 153013594	 -	 ---	 ---	
TC01000821.hg.1	 -4.7092	 -5.0845	 5.08E-05	 1.44E-03	 10.2816	 3.3565	 2.9857	 chr1	 86889769	 86922241	 +	 NM_006536	 CLCA2	
TC01004511.hg.1	 -4.7089	 -4.7222	 1.19E-04	 2.57E-03	 11.5816	 3.6352	 2.8749	 chr1	 87012759	 87046432	 +	 ---	 ---	
TC18000435.hg.1	 -4.6733	 -5.3001	 3.08E-05	 1.05E-03	 10.1880	 3.4078	 3.0548	 chr18	 28570052	 28622781	 -	 NM_001941	 DSC3	
TC04001253.hg.1	 -4.6299	 -5.2538	 3.42E-05	 1.13E-03	 9.5993	 2.8341	 2.7737	 chr4	 68775103	 68829858	 -	 NM_001114387	 TMPRSS11A	
TC01000835.hg.1	 -4.5937	 -5.2733	 3.27E-05	 1.09E-03	 10.5098	 3.6973	 3.8221	 chr1	 89829436	 89853719	 +	 NM_198460	 GBP6	
TC02000716.hg.1	 -4.5936	 -5.3643	 2.65E-05	 9.49E-04	 11.5806	 4.5013	 4.5807	 chr2	 113763038	 113766126	 +	 BC107043	 IL36A	
TC12000136.hg.1	 -4.5715	 -5.1171	 4.71E-05	 1.38E-03	 10.9389	 3.8276	 3.8357	 chr12	 8975068	 9039597	 +	 NM_144670	 A2ML1	
TC01000823.hg.1	 -4.5600	 -4.7881	 1.02E-04	 2.31E-03	 11.0913	 3.5421	 2.8544	 chr1	 87012759	 87046437	 +	 NM_012128	 CLCA4	
TC01006377.hg.1	 -4.5249	 -4.1584	 4.54E-04	 6.34E-03	 11.6230	 3.7703	 4.1079	 chr1	 153028589	 153030013	 -	 NM_005988	 SPRR2A	
TC18000228.hg.1	 -4.4808	 -5.1902	 3.97E-05	 1.23E-03	 10.1920	 3.3984	 3.4266	 chr18	 61254223	 61271873	 +	 NM_012397	 SERPINB13	
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TC04001252.hg.1	 -4.4576	 -4.9514	 6.94E-05	 1.78E-03	 10.3312	 3.9104	 3.7742	 chr4	 68686594	 68749750	 -	 NM_004262	 TMPRSS11D	
TC13000295.hg.1	 -4.3241	 -4.8670	 8.47E-05	 2.04E-03	 10.3551	 2.7336	 3.3748	 chr13	 78049967	 78219398	 +	 NM_001160706	 SCEL	
TC01003247.hg.1	 -4.2956	 -4.9118	 7.62E-05	 1.90E-03	 11.7091	 5.0342	 5.0450	 chr1	 152381719	 152386750	 -	 NM_016190	 CRNN	
TC20000023.hg.1	 -4.2841	 -4.7705	 1.06E-04	 2.37E-03	 11.6566	 4.9902	 4.8450	 chr20	 2276613	 2321725	 +	 NM_003245	 TGM3	
TC18001005.hg.1	 -4.2761	 -4.5580	 1.76E-04	 3.33E-03	 10.3935	 3.4489	 3.5458	 chr18	 61322431	 61329197	 -	 NM_006919	 SERPINB3	
TC6_mcf_hap5000038.hg.1	 -4.1744	 -4.9318	 7.27E-05	 1.84E-03	 11.4233	 4.8206	 4.8134	 chr6_mcf_hap5	 2333431	 2339631	 +	 NM_001010909	 MUC21	
TC16000456.hg.1	 -4.1692	 -5.3772	 2.57E-05	 9.28E-04	 10.0465	 3.7904	 3.6352	 chr16	 55600584	 55601599	 +	 NM_032330	 CAPNS2	
TC6_apd_hap1000031.hg.1	 -4.1663	 -4.9111	 7.63E-05	 1.90E-03	 11.4397	 4.8544	 4.8559	 chr6_apd_hap1	 2263124	 2269314	 +	 NM_001010909	 MUC21	
TC6_dbb_hap3000044.hg.1	 -4.1663	 -4.9111	 7.63E-05	 1.90E-03	 11.4397	 4.8544	 4.8559	 chr6_dbb
_hap3	 2245596	 2251786	 +	 NM_001010909	 MUC21	
TC01003260.hg.1	 -4.1316	 -5.1570	 4.29E-05	 1.29E-03	 9.8320	 3.9570	 3.8919	 chr1	 153346181	 153348125	 -	 NM_005621	 S100A12	
TC17001468.hg.1	 -4.1182	 -4.2067	 4.05E-04	 5.88E-03	 9.2495	 3.7841	 3.5375	 chr17	 38854243	 38860002	 -	 NM_019016	 KRT24	
TC18000188.hg.1	 -4.0953	 -5.0717	 5.24E-05	 1.47E-03	 8.8368	 2.8528	 2.7814	 chr18	 52258390	 52266724	 +	 NM_173629	 DYNAP	
TC18001004.hg.1	 -4.0845	 -4.3780	 2.70E-04	 4.45E-03	 9.7904	 3.3744	 3.3226	 chr18	 61304493	 61311532	 -	 NM_002974	 SERPINB4	
TC06001785.hg.1	 -4.0489	 -4.1690	 4.43E-04	 6.25E-03	 11.0703	 3.4573	 3.2183	 chr6	 49695092	 49712168	 -	 NM_001190986	 CRISP3	
TC04001255.hg.1	 -4.0078	 -5.6016	 1.53E-05	 6.54E-04	 8.0668	 2.4031	 2.4842	 chr4	 68918916	 68995598	 -	 NM_207407	 TMPRSS11F	
TC01004752.hg.1	 -3.9937	 -3.8459	 9.55E-04	 1.06E-02	 12.1839	 3.7808	 6.1204	 chr1	 152957973	 152958289	 +	 ---	 ---	
TC6_cox_hap2000051.hg.1	 -3.9710	 -4.8046	 9.81E-05	 2.25E-03	 11.7406	 5.2996	 5.5784	 chr6_cox
_hap2	 2463385	 2469590	 +	 NM_001010909	 MUC21	
TC12001523.hg.1	 -3.9690	 -4.4580	 2.23E-04	 3.89E-03	 11.6105	 5.0357	 4.9967	 chr12	 52840435	 52845971	 -	 NM_005555	 KRT6B	
TC12001536.hg.1	 -3.9300	 -4.3245	 3.06E-04	 4.86E-03	 11.9955	 5.1747	 5.0701	 chr12	 53200327	 53208335	 -	 NM_002272	 KRT4	
TC02001715.hg.1	 -3.9147	 -8.0748	 7.73E-08	 2.04E-05	 8.9278	 3.9288	 3.8544	 chr2	 31395922	 31456724	 -	 NM_001145122	 CAPN14	
TC04000413.hg.1	 -3.9141	 -4.8374	 9.08E-05	 2.14E-03	 8.2143	 2.3131	 2.2276	 chr4	 75174190	 75181024	 +	 NM_001013442	 EPGN	
TC19001446.hg.1	 -3.9071	 -4.8353	 9.13E-05	 2.15E-03	 11.0953	 4.9862	 4.8912	 chr19	 36014269	 36019253	 -	 NM_198538	 SBSN	
TC11001505.hg.1	 -3.8991	 -5.6662	 1.32E-05	 5.95E-04	 8.8387	 3.0188	 2.9702	 chr11	 26580579	 26593815	 -	 NM_001135091	 MUC15	
TC19001572.hg.1	 -3.8938	 -5.1939	 3.94E-05	 1.23E-03	 12.0359	 6.1708	 5.9529	 chr19	 42891171	 42894444	 -	 NM_032488	 CNFN	
TC01001244.hg.1	 -3.8731	 -5.6906	 1.25E-05	 5.72E-04	 9.4470	 3.8030	 3.9397	 chr1	 152881021	 152884362	 +	 NM_005547	 IVL	
TC12001525.hg.1	 -3.8673	 -4.5220	 1.92E-04	 3.52E-03	 11.9040	 5.6935	 5.6717	 chr12	 52880958	 52887181	 -	 NM_005554	 KRT6A	
TC01005829.hg.1	 -3.8562	 -3.8410	 9.66E-04	 1.07E-02	 9.5017	 3.4639	 3.4949	 chr1	 152286184	 152286725	 -	 ---	 ---	
TC12002888.hg.1	 -3.8372	 -4.7673	 1.07E-04	 2.38E-03	 12.1279	 6.0879	 6.1057	 chr12	 52912731	 52912944	 -	 ---	 ---	
TC6_mann_hap4000046.hg.
1	 -3.8331	 -4.7615	 1.09E-04	 2.41E-03	 11.7601	 5.4994	 5.7704	
chr6_ma
nn_hap4	 2299571	 2305861	 +	 NM_001010909	 MUC21	
TC6_qbl_hap6000044.hg.1	 -3.7804	 -4.7032	 1.25E-04	 2.64E-03	 11.7903	 5.4797	 5.9121	 chr6_qbl_hap6	 2244470	 2250865	 +	 NM_001010909	 MUC21	
TC05000805.hg.1	 -3.7629	 -4.6387	 1.45E-04	 2.92E-03	 11.1755	 4.3385	 5.7582	 chr5	 147405246	 147516925	 +	 NM_001127699	 SPINK5	
TC01006375.hg.1	 -3.7361	 -4.2882	 3.34E-04	 5.15E-03	 10.1894	 3.8505	 4.2319	 chr1	 153042704	 153044111	 -	 NM_001017418	 SPRR2B	
TC17000513.hg.1	 -3.7118	 -4.8641	 8.53E-05	 2.05E-03	 11.1606	 5.1270	 4.9398	 chr17	 39657235	 39658661	 +	 OTTHUMT000002 OTTHUMG0000
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57901	 0133684	
TC04001257.hg.1	 -3.7040	 -5.3486	 2.75E-05	 9.71E-04	 7.4605	 1.8600	 2.0223	 chr4	 69054242	 69083798	 -	 NM_001129907	 TMPRSS11BNL	
TC17001508.hg.1	 -3.6987	 -4.3286	 3.03E-04	 4.83E-03	 12.0644	 5.4486	 5.5278	 chr17	 39657233	 39661865	 -	 NM_002274	 KRT13	
TC04002578.hg.1	 -3.6828	 -5.0243	 5.85E-05	 1.59E-03	 7.2778	 1.7763	 1.7791	 chr4	 69049896	 69051921	 -	 ---	 ---	
TC15001829.hg.1	 -3.6700	 -5.3922	 2.48E-05	 9.06E-04	 10.6656	 5.1489	 5.1443	 chr15	 89998680	 90039844	 -	 NM_016321	 RHCG	
TC12001526.hg.1	 -3.6606	 -4.9345	 7.23E-05	 1.83E-03	 11.5277	 5.4670	 5.3992	 chr12	 52908359	 52914471	 -	 NM_000424	 KRT5	
TC01001488.hg.1	 -3.6170	 -4.8264	 9.32E-05	 2.18E-03	 9.8172	 4.2112	 4.4631	 chr1	 171154347	 171181822	 +	 NM_001460	 FMO2	
TC12001538.hg.1	 -3.5802	 -6.1160	 4.79E-06	 3.12E-04	 10.7002	 5.5556	 5.4813	 chr12	 53231588	 53242778	 -	 NM_173352	 KRT78	
TC01005830.hg.1	 -3.5797	 -3.7231	 1.28E-03	 1.30E-02	 7.3810	 2.0343	 2.2763	 chr1	 152287087	 152287969	 -	 ---	 ---	
TC01006378.hg.1	 -3.5579	 -3.8522	 9.41E-04	 1.05E-02	 9.3667	 3.3687	 3.4908	 chr1	 153112594	 153113969	 -	 NR_003062	 SPRR2C	
TC06000353.hg.1	 -3.5562	 -4.7864	 1.02E-04	 2.31E-03	 11.8250	 6.0283	 6.1762	 chr6	 30951485	 30957680	 +	 NM_001010909	 MUC21	
TC01001246.hg.1	 -3.5268	 -4.1143	 5.05E-04	 6.84E-03	 12.0565	 5.5651	 6.4198	 chr1	 152956557	 152958290	 +	 NM_001199828	 SPRR1A	
TC05000810.hg.1	 -3.5150	 -5.0899	 5.02E-05	 1.43E-03	 9.3987	 3.6424	 4.7522	 chr5	 147691982	 147695485	 +	 NM_032566	 SPINK7	
TC01005836.hg.1	 -3.5147	 -3.8589	 9.26E-04	 1.04E-02	 9.2679	 3.4210	 3.6068	 chr1	 153112594	 153113969	 -	 ---	 ---	
TC01001254.hg.1	 -3.5096	 -5.3015	 3.06E-05	 1.04E-03	 10.9544	 5.9423	 5.8387	 chr1	 153330330	 153333503	 +	 NM_002965	 S100A9	
TC01006366.hg.1	 -3.5071	 -6.1712	 4.23E-06	 2.91E-04	 9.0579	 4.3205	 4.4973	 chr1	 115125469	 115213043	 -	 NM_001256404	 DENND2C	
TC12001524.hg.1	 -3.5012	 -4.4113	 2.49E-04	 4.20E-03	 11.7605	 6.2612	 6.0276	 chr12	 52862300	 52867569	 -	 NM_173086	 KRT6C	
TC01006374.hg.1	 -3.4836	 -4.2407	 3.74E-04	 5.57E-03	 9.8343	 4.0621	 4.0546	 chr1	 153012201	 153014407	 -	 NM_006945	 SPRR2D	
TC0X001579.hg.1	 -3.4744	 -5.9209	 7.42E-06	 4.10E-04	 8.9929	 3.9831	 3.7414	 chrX	 2670337	 2693037	 +	 ---	 ---	
TC10002963.hg.1	 -3.4630	 -6.2656	 3.43E-06	 2.55E-04	 10.0795	 5.1799	 5.0563	 chr10	 47157983	 47174122	 -	 NM_001098845	 ANXA8L1	
TC10000314.hg.1	 -3.4342	 -6.2694	 3.40E-06	 2.54E-04	 9.6810	 4.9928	 4.7928	 chr10	 48255225	 48279199	 +	 NM_001098845	 ANXA8L1	
TC13001343.hg.1	 -3.4336	 -5.1450	 4.41E-05	 1.32E-03	 9.5388	 4.1725	 4.2259	 chr13	 20797502	 20806372	 -	 ---	 ---	
TC01003255.hg.1	 -3.4272	 -3.8276	 9.97E-04	 1.09E-02	 10.3695	 4.7888	 4.6191	 chr1	 153065611	 153078660	 -	 NM_001024209	 SPRR2E	
TC03001905.hg.1	 -3.4075	 -6.1257	 4.69E-06	 3.09E-04	 8.2332	 3.5838	 3.3951	 chr3	 151011876	 151034740	 -	 NM_023915	 GPR87	
TC01001247.hg.1	 -3.4056	 -4.2733	 3.46E-04	 5.29E-03	 11.4350	 5.0623	 5.1009	 chr1	 152974223	 152976332	 +	 NM_001097589	 SPRR3	
TC10000309.hg.1	 -3.3714	 -6.3011	 3.17E-06	 2.43E-04	 9.6987	 5.1796	 4.9404	 chr10	 47742393	 47770871	 +	 NM_001630	 ANXA8L2	
TC14000971.hg.1	 -3.3575	 -5.4588	 2.13E-05	 8.17E-04	 9.9252	 5.0235	 4.9707	 chr14	 24718320	 24732416	 -	 NM_000359	 TGM1	
TC19000538.hg.1	 -3.3296	 -5.9784	 6.52E-06	 3.77E-04	 10.0305	 5.6299	 5.2216	 chr19	 39687601	 39692524	 +	 NM_001001414	 NCCRP1	
TC06003208.hg.1	 -3.3166	 -5.2305	 3.62E-05	 1.16E-03	 7.6543	 2.7852	 2.7239	 chr6	 168084231	 168088891	 +	 ---	 ---	
TC01001248.hg.1	 -3.2934	 -4.3953	 2.59E-04	 4.32E-03	 11.9041	 6.4651	 6.5435	 chr1	 153003678	 153005376	 +	 NM_003125	 SPRR1B	
TC01006376.hg.1	 -3.2793	 -3.2693	 3.70E-03	 2.64E-02	 9.3937	 3.6838	 3.8991	 chr1	 153084590	 153085991	 -	 NM_001014450	 SPRR2F	
TC02002218.hg.1	 -3.2732	 -4.9750	 6.57E-05	 1.72E-03	 7.3787	 2.8417	 2.7842	 chr2	 113531492	 113542971	 -	 NM_000575	 IL1A	
TC02003832.hg.1	 -3.2487	 -4.9517	 6.94E-05	 1.78E-03	 9.5578	 4.9481	 5.2620	 chr2	 218999678	 219000012	 +	 ---	 ---	
TC06003648.hg.1	 -3.2371	 -6.1339	 4.60E-06	 3.06E-04	 8.8855	 4.4670	 5.8041	 chr6	 42059976	 42061997	 -	 ---	 ---	
TC08001637.hg.1	 -3.2269	 -5.3131	 2.98E-05	 1.02E-03	 8.1732	 3.4877	 3.4292	 chr8	 130760442	 130799134	 -	 NM_031415	 GSDMC	
TC11002740.hg.1	 -3.2267	 -5.6451	 1.39E-05	 6.14E-04	 10.8745	 6.3786	 5.9918	 chr11	 67429963	 67430223	 +	 ---	 ---	
TC12002789.hg.1	 -3.1721	 -4.2239	 3.89E-04	 5.72E-03	 7.5141	 2.8223	 2.7429	 chr12	 21689123	 21757554	 -	 ---	 ---	
TC01004997.hg.1	 -3.1476	 -5.1754	 4.11E-05	 1.26E-03	 8.7065	 4.2472	 4.1867	 chr1	 209602165	 209606183	 +	 ---	 ---	
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Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
TC01005828.hg.1	 -3.1353	 -3.8080	 1.04E-03	 1.13E-02	 9.6127	 4.8973	 4.6607	 chr1	 152274640	 152281460	 -	 ---	 ---	
TC01001199.hg.1	 -3.1038	 -6.2147	 3.84E-06	 2.73E-04	 8.4876	 4.1976	 4.1870	 chr1	 151009029	 151020076	 +	 NM_001159642	 BNIPL	
TC12001436.hg.1	 -3.0994	 -6.2087	 3.89E-06	 2.75E-04	 8.0995	 3.9126	 3.8091	 chr12	 48103517	 48119355	 -	 NM_001172439	 ENDOU	
TC18000127.hg.1	 -3.0992	 -4.6099	 1.55E-04	 3.06E-03	 11.2379	 6.7588	 3.1241	 chr18	 29027732	 29058665	 +	 NM_001944	 DSG3	
TC03001042.hg.1	 -3.0927	 -5.5112	 1.89E-05	 7.52E-04	 8.7630	 4.3226	 4.2599	 chr3	 189349205	 189615068	 +	 NM_003722	 TP63	
TC04000282.hg.1	 -3.0808	 -5.4026	 2.42E-05	 8.91E-04	 8.5796	 4.4648	 6.5740	 chr4	 48988264	 49064098	 +	 NM_025087	 CWH43	
TC12002078.hg.1	 -3.0776	 -4.8061	 9.78E-05	 2.24E-03	 8.2826	 4.1435	 4.1012	 chr12	 123185840	 123187904	 -	 NM_177551	 HCAR2	
TC06004001.hg.1	 -3.0511	 -5.2619	 3.36E-05	 1.11E-03	 8.4543	 3.8965	 3.6994	 chr6	 168080306	 168096970	 -	 ---	 ---	
TC12001297.hg.1	 -3.0497	 -4.1367	 4.78E-04	 6.59E-03	 7.0979	 2.6419	 2.5754	 chr12	 21689123	 21757781	 -	 NM_021957	 GYS2	
TC06003638.hg.1	 -3.0310	 -6.1348	 4.59E-06	 3.06E-04	 6.5756	 2.3900	 2.4994	 chr6	 40825508	 40827706	 -	 ---	 ---	
TC02000963.hg.1	 -3.0084	 -4.9519	 6.94E-05	 1.78E-03	 9.5383	 5.3231	 5.1732	 chr2	 159651829	 159719293	 +	 NM_001017920	 DAPL1	
TC15001996.hg.1	 -3.0011	 -6.3750	 2.70E-06	 2.19E-04	 7.8457	 3.7938	 3.6918	 chr15	 100940600	 101084925	 -	 NM_178842	 CERS3	
TC12000189.hg.1	 -2.9943	 -5.3439	 2.78E-05	 9.77E-04	 10.7819	 6.5816	 5.7443	 chr12	 13349602	 13369708	 +	 NM_001423	 EMP1	
TC04002094.hg.1	 -2.9936	 -5.2595	 3.38E-05	 1.11E-03	 9.6699	 5.2431	 6.6181	 chr4	 87515885	 87736302	 +	 ---	 ---	
TC6_mann_hap4000176.hg.
1	 -2.9905	 -4.5911	 1.63E-04	 3.16E-03	 6.8706	 3.0106	 2.5619	
chr6_ma
nn_hap4	 2370339	 2376003	 +	 ---	 ---	
 
Table 3: Top 100 up- and down-regulated transcript clusters for differentiating intervention-requiring disease from non-dysplastic 
Barrett’s 
553 up-regulated and 297 down-regulated transcript clusters were identified as differentially expressed between non-dysplastic Barrett’s 
mucosa and intervention requiring disease (BE v HGD-EAC, adjusted p-value < 0.05 and logfc > log2(1.5). Tx: transcript, logfc: log fold change, 
tstat: t-statistic, pval: p-value, adj_pval: adjusted p-value, Expbase: average expression in baseline samples, here, non-dysplastic Barrett’s 
mucosa, Expduo: average expression in duodenal epithelium, Expstom: average expression in proximal stomach epithelium, str: strand. Top 100 
up- and down-regulated transcript clusters based on greatest |logfc|; listed in order of decreasing |logfc|.  
 
Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
Top	100	up-regulated	transcript	clusters	from	the	BE	v	HGD-EAC	comparison	(differentiating	intervention	requiring	disease	from	non-dysplastic	Barrett’s	mucosa)	
TC10000008.hg.1	 0.9875	 9.1616	 9.75E-09	 9.40E-05	 6.7622	 6.4083	 6.8725	 chr10	 1034338	 1065876	 +	 NM_012341	 GTPBP4	
TC11002233.hg.1	 3.1433	 8.6302	 2.63E-08	 1.78E-04	 3.2374	 3.7780	 4.7078	 chr11	 102641233	 102651359	 -	 NM_002425	 MMP10	
TC20001062.hg.1	 0.8791	 8.5569	 3.03E-08	 1.86E-04	 7.7647	 7.4875	 7.6931	 chr20	 2633178	 2639039	 +	 ---	 ---	
TC11002234.hg.1	 3.8424	 8.4301	 3.86E-08	 1.86E-04	 3.8678	 5.8857	 5.4730	 chr11	 102660641	 102668966	 -	 NM_001145938	 MMP1	
TC09000691.hg.1	 0.6903	 8.4675	 3.59E-08	 1.86E-04	 6.4568	 6.2320	 6.4354	 chr9	 131217434	 131263571	 +	 NM_001242352	 ODF2	
TC07001654.hg.1	 0.8182	 8.3177	 4.80E-08	 2.03E-04	 6.3423	 6.3634	 6.2829	 chr7	 99690351	 99699563	 -	 NM_182776	 MCM7	
TC02001579.hg.1	 0.8089	 8.3384	 4.61E-08	 2.03E-04	 4.2422	 4.2419	 4.4507	 chr2	 11584501	 11606297	 -	 NM_198256	 E2F6	
TC20000637.hg.1	 0.7846	 7.7811	 1.39E-07	 3.52E-04	 7.8419	 7.8910	 7.9649	 chr20	 13694969	 13765565	 -	 NM_016649	 ESF1	
TC03003098.hg.1	 0.7644	 7.7738	 1.41E-07	 3.52E-04	 7.4047	 7.2070	 7.3635	 chr3	 133319450	 133380690	 -	 ---	 ---	
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Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
TC03001796.hg.1	 0.6654	 7.8514	 1.21E-07	 3.52E-04	 6.8308	 6.6603	 6.7833	 chr3	 133317019	 133380737	 -	 NM_007027	 TOPBP1	
TC20000026.hg.1	 0.6631	 7.8418	 1.23E-07	 3.52E-04	 6.3135	 6.2026	 6.2336	 chr20	 2632791	 2639039	 +	 ENST00000413522	 SNORD56	
TC01003200.hg.1	 0.7385	 7.7480	 1.48E-07	 3.58E-04	 8.3374	 8.1723	 8.0951	 chr1	 150190717	 150208504	 -	 NM_030920	 ANP32E	
TC03001632.hg.1	 1.3822	 7.7119	 1.60E-07	 3.72E-04	 4.6369	 4.2227	 4.4731	 chr3	 108268718	 108308491	 -	 NM_020890	 KIAA1524	
TC03000930.hg.1	 1.2695	 7.4383	 2.79E-07	 5.42E-04	 6.8198	 5.8232	 6.3298	 chr3	 172468472	 172539264	 +	 NM_018098	 ECT2	
TC20000063.hg.1	 1.0923	 7.4438	 2.76E-07	 5.42E-04	 5.5652	 5.7772	 5.7838	 chr20	 5931298	 5975852	 +	 NM_032485	 MCM8	
TC07002911.hg.1	 3.5651	 7.4207	 2.90E-07	 5.43E-04	 3.8273	 5.5731	 4.3933	 chr7	 41724713	 41726643	 -	 ---	 ---	
TC19001301.hg.1	 0.6634	 7.3541	 3.32E-07	 5.91E-04	 6.2860	 6.2293	 6.5576	 chr19	 19312224	 19314238	 -	 NM_176880	 NR2C2AP	
TC09002753.hg.1	 0.7617	 7.1391	 5.21E-07	 8.58E-04	 5.9991	 6.0231	 5.9738	 chr9	 116169518	 116172955	 -	 ---	 ---	
TC02001139.hg.1	 0.9127	 7.0213	 6.68E-07	 1.02E-03	 5.8863	 5.7925	 5.5752	 chr2	 196440701	 196602426	 +	 NM_020342	 SLC39A10	
TC16000634.hg.1	 0.9658	 6.9882	 7.16E-07	 1.07E-03	 6.5930	 6.2274	 6.5186	 chr16	 81040103	 81066719	 +	 NM_001100624	 CENPN	
TC01002529.hg.1	 0.6280	 6.8853	 8.91E-07	 1.28E-03	 6.7942	 6.6781	 6.8074	 chr1	 38422647	 38456593	 -	 NM_006802	 SF3A3	
TC11002237.hg.1	 2.8166	 6.8179	 1.03E-06	 1.42E-03	 5.6483	 4.1360	 3.7047	 chr11	 102733464	 102745764	 -	 NM_002426	 MMP12	
TC08001507.hg.1	 0.7486	 6.8041	 1.06E-06	 1.43E-03	 6.0614	 6.1313	 6.1001	 chr8	 104410863	 104427468	 -	 NM_030780	 SLC25A32	
TC11003311.hg.1	 3.0850	 6.7924	 1.09E-06	 1.44E-03	 5.0643	 6.3095	 5.9152	 chr11	 102667775	 102668070	 -	 ---	 ---	
TC08001584.hg.1	 1.3620	 6.7240	 1.26E-06	 1.64E-03	 6.0454	 5.7622	 6.3661	 chr8	 124332090	 124428590	 -	 NM_014109	 ATAD2	
TC06003842.hg.1	 1.2737	 6.7106	 1.30E-06	 1.65E-03	 2.8942	 4.0897	 3.3473	 chr6	 126497759	 126498481	 -	 ---	 ---	
TC01003679.hg.1	 1.4503	 6.6842	 1.37E-06	 1.72E-03	 4.8733	 4.2871	 4.3622	 chr1	 200520625	 200589862	 -	 NM_014875	 KIF14	
TC09001632.hg.1	 0.6940	 6.6691	 1.42E-06	 1.74E-03	 6.9215	 6.8208	 6.9426	 chr9	 131231236	 131235291	 -	 OTTHUMT000000
54431	
OTTHUMG0000
0020745	
TC01003416.hg.1	 0.7756	 6.6586	 1.45E-06	 1.75E-03	 7.8658	 7.7989	 7.9958	 chr1	 161070346	 161087901	 -	 NM_012394	 PFDN2	
TC09000573.hg.1	 0.8191	 6.6427	 1.50E-06	 1.78E-03	 6.5976	 6.3365	 6.4034	 chr9	 116037623	 116055466	 +	 NM_001244926	 PRPF4	
TC11003312.hg.1	 3.0525	 6.5873	 1.69E-06	 1.85E-03	 3.5618	 4.9599	 4.7804	 chr11	 102668128	 102668877	 -	 ---	 ---	
TC01002500.hg.1	 1.2475	 6.5860	 1.70E-06	 1.85E-03	 5.6019	 5.3196	 5.0381	 chr1	 36185819	 36235568	 -	 NM_001190481	 CLSPN	
TC08000701.hg.1	 1.1968	 6.6028	 1.64E-06	 1.85E-03	 4.3672	 4.2573	 4.6509	 chr8	 121457640	 121554373	 +	 NM_022045	 MTBP	
TC10000729.hg.1	 0.6551	 6.5887	 1.69E-06	 1.85E-03	 5.2822	 5.3109	 5.3055	 chr10	 102747124	 102754158	 +	 NM_001163812	 C10orf2	
TC03000503.hg.1	 0.7602	 6.5738	 1.74E-06	 1.87E-03	 4.9040	 4.8526	 5.2280	 chr3	 99536678	 99897476	 +	 NM_001167924	 CMSS1	
TC12001106.hg.1	 1.1225	 6.5353	 1.90E-06	 1.97E-03	 6.0030	 5.7554	 5.6722	 chr12	 2966847	 2986321	 -	 NM_001243088	 FOXM1	
TC0X000921.hg.1	 0.9784	 6.4914	 2.09E-06	 2.14E-03	 5.4755	 5.8402	 6.1915	 chrX	 23720370	 23784592	 -	 NM_001033583	 ACOT9	
TC03001751.hg.1	 0.6980	 6.4765	 2.16E-06	 2.17E-03	 5.9481	 5.5719	 5.7402	 chr3	 127783625	 127872757	 -	 NM_003707	 RUVBL1	
TC02002445.hg.1	 0.8094	 6.4485	 2.29E-06	 2.23E-03	 5.3803	 5.3321	 5.4994	 chr2	 157180944	 157198860	 -	 NM_006186	 NR4A2	
TC12002747.hg.1	 0.7529	 6.4366	 2.35E-06	 2.24E-03	 4.0666	 4.2865	 3.9532	 chr12	 9546891	 9566384	 -	 ---	 ---	
TC17001291.hg.1	 1.1905	 6.3996	 2.55E-06	 2.25E-03	 3.5389	 3.7734	 3.1448	 chr17	 26598641	 26598673	 -	 ---	 ---	
TC20000357.hg.1	 0.8815	 6.4182	 2.45E-06	 2.25E-03	 6.3500	 6.3416	 6.1610	 chr20	 44441215	 44445596	 +	 NM_007019	 UBE2C	
TC12001142.hg.1	 0.7720	 6.4056	 2.52E-06	 2.25E-03	 6.1129	 5.8878	 5.9953	 chr12	 6666029	 6677857	 -	 NM_001033714	 NOP2	
TC20000385.hg.1	 0.6363	 6.4276	 2.40E-06	 2.25E-03	 6.6297	 6.6035	 6.5681	 chr20	 47835832	 47860614	 +	 NM_017895	 DDX27	
TC19002224.hg.1	 0.8162	 6.3685	 2.73E-06	 2.33E-03	 6.6218	 6.7176	 7.1703	 chr19	 53935227	 53947925	 +	 ---	 ---	
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Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
TC10000900.hg.1	 0.6798	 6.3650	 2.76E-06	 2.33E-03	 7.2043	 6.9398	 7.0861	 chr10	 124913760	 124924886	 +	 NM_001007793	 BUB3	
TC20000198.hg.1	 1.3386	 6.3085	 3.12E-06	 2.49E-03	 7.1837	 6.4453	 6.2455	 chr20	 30326904	 30389608	 +	 NM_012112	 TPX2	
TC08001528.hg.1	 1.1368	 6.2984	 3.19E-06	 2.49E-03	 5.5913	 5.5809	 5.9407	 chr8	 110253148	 110346614	 -	 NM_001128211	 NUDCD1	
TC09002191.hg.1	 0.8368	 6.2955	 3.21E-06	 2.49E-03	 8.0579	 7.8427	 8.0115	 chr9	 116170093	 116170786	 +	 ---	 ---	
TC07001177.hg.1	 0.8028	 6.3257	 3.01E-06	 2.49E-03	 5.4768	 5.3166	 5.6015	 chr7	 19735085	 19748710	 -	 NM_001002926	 TWISTNB	
TC08002008.hg.1	 0.7956	 6.2507	 3.55E-06	 2.63E-03	 7.8715	 7.2982	 7.6158	 chr8	 90770370	 90782052	 +	 ---	 ---	
TC12002211.hg.1	 0.7756	 6.2576	 3.49E-06	 2.63E-03	 4.6182	 5.0041	 5.0178	 chr12	 7087683	 7089096	 +	 ---	 ---	
TC02004051.hg.1	 0.6975	 6.2550	 3.51E-06	 2.63E-03	 5.1491	 5.2019	 5.3123	 chr2	 11584501	 11606297	 -	 ---	 ---	
TC19000443.hg.1	 0.6860	 6.2049	 3.93E-06	 2.85E-03	 6.3569	 6.0960	 6.5430	 chr19	 34895303	 34917072	 +	 NM_032346	 PDCD2L	
TC15001350.hg.1	 0.6352	 6.1983	 3.99E-06	 2.86E-03	 6.5864	 6.5122	 6.6898	 chr15	 50569389	 50647605	 -	 NM_016654	 GABPB1	
TC07002137.hg.1	 1.4656	 6.1740	 4.21E-06	 2.99E-03	 3.6406	 3.5168	 3.4445	 chr7	 8301863	 8384146	 +	 ---	 ---	
TC03000518.hg.1	 0.6228	 6.1261	 4.68E-06	 3.26E-03	 6.5662	 6.6896	 6.8116	 chr3	 101280706	 101285290	 +	 NM_017819	 TRMT10C	
TC01001430.hg.1	 1.4352	 6.1116	 4.84E-06	 3.33E-03	 5.7653	 5.1832	 5.1570	 chr1	 163291690	 163325554	 +	 NM_031423	 NUF2	
TC07001259.hg.1	 0.8257	 6.0861	 5.12E-06	 3.47E-03	 5.3532	 5.3228	 5.4833	 chr7	 32620553	 32758780	 -	 NR_036680	 DPY19L1P1	
TC17001346.hg.1	 0.6022	 6.0849	 5.13E-06	 3.47E-03	 6.2284	 6.1506	 6.2170	 chr17	 30187923	 30228731	 -	 NM_018428	 UTP6	
TC05000154.hg.1	 0.6040	 6.0772	 5.22E-06	 3.49E-03	 6.9486	 6.7317	 6.9989	 chr5	 34915481	 34926101	 +	 NM_018321	 BRIX1	
TC03000114.hg.1	 1.0977	 6.0570	 5.46E-06	 3.58E-03	 6.0911	 6.0151	 5.9534	 chr3	 20215736	 20227919	 +	 ENST0000044144
2	 SGOL1-AS1	
TC11002235.hg.1	 3.4700	 6.0013	 6.19E-06	 3.77E-03	 3.3712	 4.3371	 3.9633	 chr11	 102706528	 102714534	 -	 NM_002422	 MMP3	
TC08001560.hg.1	 1.1185	 6.0205	 5.93E-06	 3.77E-03	 3.8235	 3.6226	 4.0013	 chr8	 120846181	 120868250	 -	 NM_024094	 DSCC1	
TC20001440.hg.1	 0.9493	 6.0044	 6.15E-06	 3.77E-03	 6.5798	 6.9932	 6.7147	 chr20	 13763456	 13765569	 -	 ---	 ---	
TC03000242.hg.1	 1.1619	 5.9463	 7.01E-06	 3.99E-03	 5.4515	 5.0005	 4.9262	 chr3	 44803209	 44914868	 +	 NM_020242	 KIF15	
TC05001352.hg.1	 0.9225	 5.9475	 6.99E-06	 3.99E-03	 2.7944	 2.9962	 3.1393	 chr5	 54273692	 54281491	 -	 NM_001135604	 ESM1	
TC01003798.hg.1	 1.3213	 5.9368	 7.16E-06	 4.00E-03	 5.2409	 5.0854	 4.9558	 chr1	 211831599	 211848972	 -	 NM_001204182	 NEK2	
TC07000384.hg.1	 0.9517	 5.9121	 7.57E-06	 4.02E-03	 5.6995	 6.0298	 5.9177	 chr7	 64126501	 64171404	 +	 NM_001013746	 ZNF107	
TC06001799.hg.1	 0.7835	 5.9106	 7.60E-06	 4.02E-03	 6.6114	 6.4119	 6.5477	 chr6	 52128807	 52149582	 -	 NM_002388	 MCM3	
TC15000875.hg.1	 0.7109	 5.9099	 7.61E-06	 4.02E-03	 5.5139	 5.5235	 5.4312	 chr15	 91509575	 91531854	 +	 ENST00000554388	 PRC1-AS1	
TC12001361.hg.1	 1.2737	 5.8587	 8.54E-06	 4.12E-03	 7.3470	 7.0351	 6.8868	 chr12	 31433518	 31479306	 -	 NM_001135811	 FAM60A	
TC01000563.hg.1	 0.8931	 5.8444	 8.82E-06	 4.22E-03	 4.7675	 4.5683	 4.6364	 chr1	 45205490	 45233439	 +	 NM_006845	 KIF2C	
TC04000411.hg.1	 2.0652	 5.8194	 9.34E-06	 4.32E-03	 5.7771	 5.7266	 5.0013	 chr4	 74735109	 74737019	 +	 NM_001511	 CXCL1	
TC01006326.hg.1	 0.6552	 5.8207	 9.31E-06	 4.32E-03	 6.7922	 6.8511	 7.0289	 chr1	 149858490	 149858961	 +	 NM_003517	 HIST2H2AC	
TC05001319.hg.1	 1.1994	 5.8063	 9.62E-06	 4.36E-03	 3.4597	 3.1126	 3.4485	 chr5	 43486803	 43515273	 -	 NM_198566	 C5orf34	
TC09001377.hg.1	 1.0513	 5.8113	 9.51E-06	 4.36E-03	 5.3577	 5.5816	 5.7663	 chr9	 99401859	 99417599	 -	 NM_153698	 AAED1	
TC07000159.hg.1	 1.1480	 5.7813	 1.02E-05	 4.52E-03	 6.7238	 6.7284	 6.8919	 chr7	 26191847	 26226756	 +	 NM_004289	 NFE2L3	
TC13000493.hg.1	 0.8181	 5.7688	 1.05E-05	 4.56E-03	 5.6762	 6.2843	 5.5456	 chr13	 25456412	 25497085	 -	 NM_018451	 CENPJ	
TC13000119.hg.1	 1.1800	 5.7610	 1.07E-05	 4.59E-03	 6.0656	 6.1441	 5.9873	 chr13	 34392186	 34540695	 +	 NM_181558	 RFC3	
TC04000408.hg.1	 3.5757	 5.7567	 1.08E-05	 4.59E-03	 3.5790	 3.5081	 3.2133	 chr4	 74606223	 74609433	 +	 NM_000584	 IL8	
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Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
TC05003257.hg.1	 1.4744	 5.7478	 1.10E-05	 4.62E-03	 4.1786	 4.5060	 3.9078	 chr5	 137627772	 137666776	 -	 ---	 ---	
TC03002088.hg.1	 0.9307	 5.7343	 1.13E-05	 4.66E-03	 5.7318	 5.9236	 6.0598	 chr3	 186507669	 186524847	 -	 NM_002916	 RFC4	
TC02000669.hg.1	 0.8840	 5.7230	 1.16E-05	 4.73E-03	 3.8468	 3.7762	 3.9905	 chr2	 109403213	 109493034	 +	 NM_144978	 CCDC138	
TC19001804.hg.1	 0.7853	 5.7229	 1.16E-05	 4.73E-03	 6.6097	 7.0707	 7.0332	 chr19	 53268747	 53290034	 -	 NM_198457	 ZNF600	
TC01001976.hg.1	 1.2822	 5.6891	 1.26E-05	 4.79E-03	 5.0936	 4.9226	 4.5555	 chr1	 242011269	 242058450	 +	 NM_003686	 EXO1	
TC01000461.hg.1	 1.1655	 5.6597	 1.34E-05	 4.79E-03	 4.7042	 4.7057	 4.1676	 chr1	 36204990	 36209177	 +	 OTTHUMT00000023222	
OTTHUMG0000
0008426	
TC20000871.hg.1	 1.0661	 5.6878	 1.26E-05	 4.79E-03	 6.6591	 6.2196	 6.7346	 chr20	 43570771	 43589127	 -	 NM_006809	 TOMM34	
TC01001476.hg.1	 0.9914	 5.6860	 1.26E-05	 4.79E-03	 4.9703	 4.9438	 5.0705	 chr1	 169631245	 169823221	 +	 NM_018186	 C1orf112	
TC10000664.hg.1	 0.9893	 5.6911	 1.25E-05	 4.79E-03	 5.3032	 4.6644	 4.7940	 chr10	 95256369	 95288849	 +	 NM_018131	 CEP55	
TC08000546.hg.1	 0.9340	 5.6675	 1.32E-05	 4.79E-03	 5.9138	 6.0435	 6.0320	 chr8	 90914087	 90940116	 +	 NM_001126111	 OSGIN2	
TC13001100.hg.1	 0.8788	 5.6584	 1.35E-05	 4.79E-03	 7.5982	 7.0408	 6.5181	 chr13	 53029617	 53035443	 +	 ---	 ---	
TC14001561.hg.1	 0.8735	 5.6717	 1.31E-05	 4.79E-03	 6.0422	 7.1370	 6.5288	 chr14	 105324129	 105325618	 -	 ---	 ---	
TC10000413.hg.1	 0.8727	 5.6702	 1.31E-05	 4.79E-03	 8.0091	 7.4114	 7.8545	 chr10	 70715884	 70744829	 +	 NM_004728	 DDX21	
TC07000771.hg.1	 0.8587	 5.6557	 1.36E-05	 4.79E-03	 5.6978	 6.0956	 6.9274	 chr7	 128032601	 128032635	 +	 ---	 ---	
TC0X000185.hg.1	 0.8587	 5.6557	 1.36E-05	 4.79E-03	 5.6978	 6.0956	 6.9274	 chrX	 40217980	 40218014	 +	 ---	 ---	
TC10000534.hg.1	 0.8587	 5.6557	 1.36E-05	 4.79E-03	 5.6978	 6.0956	 6.9274	 chr10	 79539622	 79539656	 +	 ---	 ---	
TC16000856.hg.1	 0.8587	 5.6557	 1.36E-05	 4.79E-03	 5.6978	 6.0956	 6.9274	 chr16	 10207165	 10207199	 -	 ---	 ---	
TC13000223.hg.1	 0.8249	 5.7019	 1.22E-05	 4.79E-03	 7.0093	 6.5832	 5.9840	 chr13	 53029495	 53050763	 +	 NM_001098525	 CKAP2	
TC01005857.hg.1	 0.6864	 5.6521	 1.37E-05	 4.80E-03	 8.9411	 8.7448	 8.8511	 chr1	 156278752	 156308206	 -	 ---	 ---	
Top	100	down-regulated	transcript	clusters	from	the	BE	v	HGD-EAC	comparison	(differentiating	intervention	requiring	disease	from	non-dysplastic	Barrett’s	mucosa)	
TC05002693.hg.1	 -2.8627	 -13.2203	 1.42E-11	 9.59E-07	 8.3185	 7.0106	 7.2005	 chr5	 150400124	 150408543	 +	 ---	 ---	
TC05000837.hg.1	 -1.6592	 -12.0845	 7.46E-11	 2.52E-06	 6.8565	 5.9994	 6.1108	 chr5	 150399999	 150408554	 +	 NM_002084	 GPX3	
TC07001746.hg.1	 -5.1100	 -11.2244	 2.84E-10	 4.80E-06	 9.7787	 11.3912	 5.1625	 chr7	 107405912	 107443678	 -	 NM_000111	 SLC26A3	
TC03000208.hg.1	 -1.6600	 -9.7721	 3.25E-09	 4.39E-05	 6.8234	 5.8305	 5.9881	 chr3	 40428647	 40470110	 +	 NM_001248	 ENTPD3	
TC14000908.hg.1	 -0.9062	 -9.4068	 6.24E-09	 7.02E-05	 7.4939	 7.0233	 7.1822	 chr14	 21484922	 21539031	 -	 NM_201535	 NDRG2	
TC21000305.hg.1	 -3.4770	 -8.9969	 1.32E-08	 1.11E-04	 6.3180	 10.5951	 3.6926	 chr21	 19641433	 19858197	 -	 NM_002772	 TMPRSS15	
TC02000571.hg.1	 -0.6011	 -8.5024	 3.36E-08	 1.86E-04	 6.8137	 6.1809	 6.5520	 chr2	 95940201	 95957056	 +	 NM_001165977	 PROM2	
TC05003085.hg.1	 -1.5308	 -8.2195	 5.81E-08	 2.15E-04	 4.8530	 6.1163	 6.3207	 chr5	 74337140	 74341142	 -	 ---	 ---	
TC06001229.hg.1	 -0.6272	 -8.1994	 6.05E-08	 2.15E-04	 6.7756	 6.5017	 6.5614	 chr6	 3269196	 3457256	 -	 NM_015482	 SLC22A23	
TC14000076.hg.1	 -1.0892	 -8.1275	 6.96E-08	 2.35E-04	 7.9139	 7.4242	 7.6918	 chr14	 21484931	 21485921	 +	 ---	 ---	
TC06003372.hg.1	 -1.0659	 -8.0610	 7.94E-08	 2.55E-04	 7.7696	 7.4614	 7.4056	 chr6	 3269986	 3274708	 -	 ---	 ---	
TC15001837.hg.1	 -2.7297	 -7.8068	 1.32E-07	 3.52E-04	 10.5301	 11.3706	 5.8109	 chr15	 90328120	 90358094	 -	 NM_001150	 ANPEP	
TC02002365.hg.1	 -1.1825	 -7.4688	 2.62E-07	 5.42E-04	 5.5617	 5.4934	 5.1223	 chr2	 133429372	 134326034	 -	 NM_207363	 NCKAP5	
TC0X000177.hg.1	 -3.7021	 -7.3845	 3.12E-07	 5.70E-04	 8.2432	 9.6800	 4.6208	 chrX	 38211736	 38280703	 +	 NM_000531	 OTC	
TC03001820.hg.1	 -2.1758	 -7.2173	 4.42E-07	 7.65E-04	 5.3846	 6.2051	 6.1396	 chr3	 137842560	 137851229	 -	 NM_016161	 A4GNT	
TC15001318.hg.1	 -1.2592	 -7.1555	 5.03E-07	 8.49E-04	 7.1036	 7.3251	 6.1126	 chr15	 45771809	 45815005	 -	 NM_013309	 SLC30A4	
TC18000135.hg.1	 -3.6422	 -7.0897	 5.78E-07	 9.07E-04	 7.9125	 10.7710	 3.6477	 chr18	 29769987	 29800366	 +	 NM_005925	 MEP1B	
Appendix 5: Top differentially expressed transcript clusters identified by genome-wide expression profiling 
 328 
Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
TC18000557.hg.1	 -0.7296	 -6.6256	 1.56E-06	 1.81E-03	 10.0556	 9.4675	 9.4529	 chr18	 61056423	 61089752	 -	 NM_004869	 VPS4B	
TC15000354.hg.1	 -2.8312	 -6.4667	 2.20E-06	 2.19E-03	 8.0859	 9.0364	 6.5693	 chr15	 45544428	 45568149	 +	 NM_004212	 SLC28A2	
TC05002527.hg.1	 -0.7051	 -6.3978	 2.56E-06	 2.25E-03	 10.6606	 10.1333	 9.9384	 chr5	 96079244	 96109116	 +	 ---	 ---	
TC17000834.hg.1	 -0.5875	 -6.4028	 2.54E-06	 2.25E-03	 7.9664	 7.8964	 7.6920	 chr17	 72744752	 72765499	 +	 NM_004252	 SLC9A3R1	
TC01000822.hg.1	 -3.8973	 -6.3683	 2.74E-06	 2.33E-03	 8.3085	 10.1797	 3.4495	 chr1	 86934051	 86965974	 +	 NM_001285	 CLCA1	
TC06001825.hg.1	 -2.8403	 -6.3126	 3.09E-06	 2.49E-03	 6.4383	 7.7389	 5.6694	 chr6	 55618443	 55740375	 -	 NM_021073	 BMP5	
TC04002642.hg.1	 -3.5757	 -6.2047	 3.93E-06	 2.85E-03	 8.7208	 4.0165	 8.4066	 chr4	 100340208	 100341836	 -	 ---	 ---	
TC14000951.hg.1	 -1.2205	 -6.0119	 6.04E-06	 3.77E-03	 8.1053	 8.4408	 8.7194	 chr14	 23594504	 23652850	 -	 NM_012244	 SLC7A8	
TC15001730.hg.1	 -0.7402	 -6.0254	 5.87E-06	 3.77E-03	 6.6622	 6.3791	 5.8327	 chr15	 81601394	 81616524	 -	 NM_181900	 STARD5	
TC14001302.hg.1	 -1.6045	 -5.9950	 6.28E-06	 3.79E-03	 8.2383	 8.1536	 7.6704	 chr14	 74424713	 74486102	 -	 NM_001249	 ENTPD5	
TC08000508.hg.1	 -1.7874	 -5.9843	 6.43E-06	 3.84E-03	 6.4689	 7.8497	 6.3283	 chr8	 80523049	 80578410	 +	 NM_001199214	 STMN2	
TC02004093.hg.1	 -3.7632	 -5.9802	 6.49E-06	 3.85E-03	 6.6836	 10.9422	 4.8379	 chr2	 21225293	 21225747	 -	 ---	 ---	
TC21001061.hg.1	 -0.7517	 -5.9670	 6.69E-06	 3.93E-03	 6.2901	 5.7960	 6.2397	 chr21	 37529080	 37666572	 +	 NM_005128	 DOPEY2	
TC04001412.hg.1	 -3.1675	 -5.9447	 7.03E-06	 3.99E-03	 7.0260	 3.4076	 6.6783	 chr4	 100333418	 100356894	 -	 NM_000673	 ADH7	
TC10001637.hg.1	 -0.8103	 -5.9525	 6.91E-06	 3.99E-03	 6.5511	 5.7781	 5.8481	 chr10	 105791044	 105845760	 -	 NR_030760	 MIR936	
TC04001406.hg.1	 -3.4899	 -5.9220	 7.40E-06	 4.02E-03	 7.9762	 9.5860	 3.7062	 chr4	 100044808	 100078949	 -	 NM_000670	 ADH4	
TC04002840.hg.1	 -2.4671	 -5.9088	 7.63E-06	 4.02E-03	 10.5312	 9.7103	 9.9395	 chr4	 175411328	 175444044	 -	 ---	 ---	
TC01000999.hg.1	 -0.7786	 -5.9109	 7.59E-06	 4.02E-03	 7.2323	 6.7148	 7.4365	 chr1	 113933371	 114228545	 +	 NM_001142782	 MAGI3	
TC05002526.hg.1	 -1.0382	 -5.8884	 7.99E-06	 4.06E-03	 9.0568	 8.2406	 8.0493	 chr5	 96071868	 96077284	 +	 ---	 ---	
TC17001830.hg.1	 -1.3366	 -5.8706	 8.31E-06	 4.07E-03	 6.7722	 7.1157	 6.9622	 chr17	 67240576	 67323323	 -	 NM_018672	 ABCA5	
TC14002346.hg.1	 -0.6422	 -5.8716	 8.29E-06	 4.07E-03	 5.6582	 5.3406	 5.4958	 chr14	 74399213	 74417117	 -	 NM_152445	 FAM161B	
TC12000495.hg.1	 -0.9646	 -5.8607	 8.50E-06	 4.12E-03	 7.6113	 7.5522	 6.0394	 chr12	 56324756	 56347811	 +	 NM_001345	 DGKA	
TC04001409.hg.1	 -2.5474	 -5.8421	 8.87E-06	 4.22E-03	 6.7199	 7.0291	 5.5124	 chr4	 100197523	 100212185	 -	 NM_000667	 ADH1A	
TC11002370.hg.1	 -0.9567	 -5.8194	 9.34E-06	 4.32E-03	 5.9010	 7.2855	 5.1221	 chr11	 119225925	 119252436	 -	 NM_001243759	 USP2	
TC01003216.hg.1	 -0.5971	 -5.8245	 9.23E-06	 4.32E-03	 6.7503	 6.3920	 6.8309	 chr1	 150965682	 150980854	 -	 NM_001040217	 FAM63A	
TC02001628.hg.1	 -1.6405	 -5.8066	 9.61E-06	 4.36E-03	 5.2961	 10.2699	 4.1713	 chr2	 21224301	 21266945	 -	 NM_000384	 APOB	
TC15002157.hg.1	 -0.6898	 -5.7929	 9.91E-06	 4.43E-03	 3.6160	 3.5079	 3.5149	 chr15	 40666600	 40668192	 +	 ---	 ---	
TC15001312.hg.1	 -0.9327	 -5.7747	 1.03E-05	 4.56E-03	 3.9874	 4.6933	 3.8862	 chr15	 45543884	 45571449	 -	 ---	 ---	
TC07001825.hg.1	 -0.9444	 -5.7701	 1.04E-05	 4.56E-03	 5.8357	 6.0240	 5.5991	 chr7	 123670970	 123673523	 -	 NM_001136002	 TMEM229A	
TC02001115.hg.1	 -0.5906	 -5.7438	 1.11E-05	 4.62E-03	 6.0381	 6.2863	 5.5535	 chr2	 190744335	 191068210	 +	 NM_001042519	 C2orf88	
TC17001017.hg.1	 -0.6682	 -5.7350	 1.13E-05	 4.66E-03	 6.7733	 6.7112	 6.3865	 chr17	 3907739	 4046314	 -	 NM_015113	 ZZEF1	
TC06000970.hg.1	 -3.7826	 -5.6878	 1.26E-05	 4.79E-03	 7.3800	 8.2051	 6.1367	 chr6	 127840600	 127912962	 +	 NM_001010905	 C6orf58	
TC04001753.hg.1	 -2.1907	 -5.6597	 1.34E-05	 4.79E-03	 7.5396	 6.9543	 7.1422	 chr4	 175411328	 175444305	 -	 NM_000860	 HPGD	
TC04001193.hg.1	 -1.9474	 -5.6945	 1.24E-05	 4.79E-03	 6.7310	 6.9652	 5.7111	 chr4	 52859866	 52883786	 -	 NM_001024611	 LRRC66	
TC10000986.hg.1	 -1.6933	 -5.6566	 1.35E-05	 4.79E-03	 7.5633	 6.9335	 7.6024	 chr10	 5029967	 5060225	 -	 NM_001135241	 AKR1C2	
TC17000061.hg.1	 -1.1910	 -5.6810	 1.28E-05	 4.79E-03	 5.8012	 6.5332	 6.2881	 chr17	 4981754	 4999669	 +	 NM_153018	 ZFP3	
TC05000498.hg.1	 -0.9089	 -5.6505	 1.37E-05	 4.80E-03	 7.4607	 6.7025	 7.0093	 chr5	 102455853	 102538937	 +	 NM_015216	 PPIP5K2	
TC10001315.hg.1	 -1.7222	 -5.6362	 1.42E-05	 4.91E-03	 7.0503	 5.1631	 5.4130	 chr10	 61410522	 61495760	 -	 NM_194298	 SLC16A9	
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Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
TC10000370.hg.1	 -1.4374	 -5.6304	 1.44E-05	 4.95E-03	 6.7611	 6.9069	 5.7868	 chr10	 61815632	 61820501	 +	 OTTHUMT00000048179	
OTTHUMG0000
0018286	
TC11002446.hg.1	 -0.8382	 -5.6103	 1.50E-05	 5.10E-03	 7.4657	 7.0380	 6.4637	 chr11	 128834955	 129062093	 -	 NM_001142685	 ARHGAP32	
TC05000469.hg.1	 -0.6460	 -5.5774	 1.62E-05	 5.26E-03	 8.7009	 8.2945	 8.0797	 chr5	 95865525	 96115299	 +	 NM_001042440	 CAST	
TC05001487.hg.1	 -2.5488	 -5.5520	 1.72E-05	 5.45E-03	 8.0888	 9.4578	 9.3542	 chr5	 74321171	 74326724	 -	 NM_016591	 GCNT4	
TC11002988.hg.1	 -1.8063	 -5.5362	 1.78E-05	 5.50E-03	 8.0619	 7.2306	 5.2448	 chr11	 1093317	 1094883	 -	 ---	 ---	
TC19002693.hg.1	 -1.4130	 -5.5275	 1.82E-05	 5.51E-03	 7.3304	 8.3278	 6.3001	 chr19	 19254774	 19384074	 -	 NM_001001524	 TM6SF2	
TC0X001696.hg.1	 -0.8470	 -5.5016	 1.93E-05	 5.77E-03	 6.4186	 7.7685	 6.0413	 chrX	 48306415	 48307284	 +	 ---	 ---	
TC05001002.hg.1	 -1.2953	 -5.4716	 2.07E-05	 5.94E-03	 7.7134	 8.7046	 6.1478	 chr5	 175969512	 176022975	 +	 NM_001171976	 CDHR2	
TC12000807.hg.1	 -0.7025	 -5.4613	 2.12E-05	 6.03E-03	 7.4189	 7.2975	 7.5518	 chr12	 104458235	 104500304	 +	 NM_013320	 HCFC2	
TC06002965.hg.1	 -1.0848	 -5.4506	 2.17E-05	 6.09E-03	 6.5874	 6.2996	 5.3019	 chr6	 106808683	 106969074	 +	 ---	 ---	
TC04001807.hg.1	 -0.6537	 -5.4495	 2.18E-05	 6.09E-03	 8.6750	 8.3440	 7.7171	 chr4	 185548850	 185570663	 -	 NM_004346	 CASP3	
TC08001462.hg.1	 -0.8186	 -5.4374	 2.24E-05	 6.17E-03	 7.4714	 6.3916	 7.1347	 chr8	 99202061	 99306621	 -	 NM_024759	 NIPAL2	
TC15002529.hg.1	 -0.7137	 -5.4216	 2.32E-05	 6.29E-03	 8.1774	 7.6382	 8.5358	 chr15	 49280967	 49338630	 -	 ---	 ---	
TC19000404.hg.1	 -0.8036	 -5.4144	 2.36E-05	 6.34E-03	 6.6670	 6.3440	 7.2068	 chr19	 23945746	 24014998	 +	 NR_003662	 RPSAP58	
TC10001319.hg.1	 -0.8431	 -5.4056	 2.41E-05	 6.38E-03	 6.8769	 7.0892	 6.2729	 chr10	 61786056	 62493284	 -	 NM_001149	 ANK3	
TC02001977.hg.1	 -0.9373	 -5.3896	 2.50E-05	 6.50E-03	 6.7224	 6.2162	 6.3029	 chr2	 72403113	 73053177	 -	 NM_015189	 EXOC6B	
TC17001890.hg.1	 -0.7272	 -5.3825	 2.54E-05	 6.50E-03	 8.9104	 9.4410	 8.7395	 chr17	 73937589	 73975515	 -	 NM_001185039	 ACOX1	
TC15001339.hg.1	 -0.6384	 -5.3885	 2.51E-05	 6.50E-03	 8.0660	 7.5612	 8.4501	 chr15	 49280835	 49338760	 -	 NM_001193489	 SECISBP2L	
TC02002194.hg.1	 -1.4166	 -5.3592	 2.68E-05	 6.51E-03	 10.1642	 9.8855	 7.1844	 chr2	 110841447	 110874143	 -	 NM_005434	 MALL	
TC06003373.hg.1	 -0.6944	 -5.3565	 2.70E-05	 6.51E-03	 4.9371	 4.8688	 5.0064	 chr6	 3308907	 3313510	 -	 ---	 ---	
TC02002487.hg.1	 -0.6035	 -5.3279	 2.88E-05	 6.75E-03	 6.0139	 5.7755	 6.7461	 chr2	 165510134	 165700189	 -	 NM_014900	 COBLL1	
TC21000730.hg.1	 -2.2084	 -5.3233	 2.91E-05	 6.79E-03	 8.0516	 8.0492	 5.1748	 chr21	 41014313	 41031839	 +	 ---	 ---	
TC02001000.hg.1	 -1.9922	 -5.3209	 2.93E-05	 6.80E-03	 6.5570	 3.4053	 3.9284	 chr2	 169921299	 169952677	 +	 NM_005771	 DHRS9	
TC01003477.hg.1	 -1.5565	 -5.2872	 3.17E-05	 7.04E-03	 7.7319	 8.2822	 5.1185	 chr1	 167022073	 167059868	 -	 NM_005814	 GPA33	
TC05001379.hg.1	 -0.6035	 -5.2596	 3.38E-05	 7.26E-03	 6.3610	 6.6917	 5.6896	 chr5	 56215429	 56267502	 -	 NM_152622	 MIER3	
TC14002093.hg.1	 -1.3424	 -5.2449	 3.50E-05	 7.40E-03	 5.6459	 6.7498	 4.0190	 chr14	 76041231	 76045931	 -	 ---	 ---	
TC16000525.hg.1	 -0.8291	 -5.2259	 3.65E-05	 7.61E-03	 6.1977	 6.3862	 5.0128	 chr16	 66995132	 67009052	 +	 NM_001185176	 CES3	
TC04001500.hg.1	 -3.4233	 -5.2175	 3.73E-05	 7.67E-03	 7.7806	 9.5233	 2.8036	 chr4	 120238405	 120243545	 -	 NM_000134	 FABP2	
TC11002494.hg.1	 -2.6855	 -5.2165	 3.74E-05	 7.67E-03	 8.3252	 7.2058	 4.6150	 chr11	 1096364	 1097364	 +	 ---	 ---	
TC05000563.hg.1	 -0.6195	 -5.1840	 4.03E-05	 8.00E-03	 6.8616	 6.8888	 6.9354	 chr5	 118373467	 118584833	 +	 NM_005509	 DMXL1	
TC06003507.hg.1	 -1.0646	 -5.1723	 4.14E-05	 8.08E-03	 4.6590	 3.8771	 3.8943	 chr6	 19802395	 19804981	 -	 ---	 ---	
TC10002844.hg.1	 -0.9398	 -5.1737	 4.13E-05	 8.08E-03	 4.8172	 4.8039	 5.1429	 chr10	 118587736	 118609222	 -	 ---	 ---	
TC19001261.hg.1	 -0.9606	 -5.1443	 4.42E-05	 8.48E-03	 7.1867	 8.4599	 5.8052	 chr19	 15988834	 16008884	 -	 NM_001082	 CYP4F2	
TC11000811.hg.1	 -0.9353	 -5.1153	 4.73E-05	 8.87E-03	 5.2651	 6.8059	 4.1689	 chr11	 75428864	 75444003	 +	 BC103877	 MOGAT2	
TC02002858.hg.1	 -0.9908	 -5.1045	 4.85E-05	 8.97E-03	 6.1596	 5.4424	 5.0610	 chr2	 231972944	 231989832	 -	 NM_000867	 HTR2B	
TC15000409.hg.1	 -0.7208	 -5.0748	 5.20E-05	 9.34E-03	 3.6359	 5.2556	 6.5888	 chr15	 51973550	 52013228	 +	 NM_013243	 SCG3	
TC04000806.hg.1	 -1.0362	 -5.0733	 5.22E-05	 9.34E-03	 7.4766	 7.7458	 7.3705	 chr4	 159593277	 159630775	 +	 NM_004453	 ETFDH	
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Tx	cluster	ID	 logfc	 tstat	 pval	 adj_pval	 Exprbase	 Exprduo	 Exprstom	 chr	 start	 end	 str	 Tx	ID	 Tx	gene	
TC08002619.hg.1	 -0.6118	 -5.0619	 5.36E-05	 9.43E-03	 7.5931	 7.4534	 7.2223	 chr8	 124260690	 124287781	 -	 NM_001017926	 ZHX1	
TC05003086.hg.1	 -0.7437	 -5.0586	 5.40E-05	 9.45E-03	 5.7928	 6.5715	 6.5307	 chr5	 74343544	 74348668	 -	 ---	 ---	
TC21000177.hg.1	 -0.9679	 -5.0475	 5.54E-05	 9.60E-03	 5.6970	 5.5768	 4.4822	 chr21	 40928369	 41098012	 +	 NM_006057	 B3GALT5	
TC05000684.hg.1	 -0.8459	 -5.0434	 5.60E-05	 9.66E-03	 5.8032	 6.1334	 4.8542	 chr5	 135549736	 135557847	 +	 ENST00000514459	 TRPC7-AS1	
TC15001473.hg.1	 -0.5868	 -5.0414	 5.62E-05	 9.66E-03	 6.6968	 6.4598	 6.4836	 chr15	 56297911	 56299359	 -	 ENST00000393358	 CNOT6LP1	
TC04001408.hg.1	 -2.6324	 -5.0369	 5.68E-05	 9.74E-03	 7.5542	 8.3771	 3.8637	 chr4	 100123795	 100140694	 -	 NM_000672	 ADH6	
TC10001555.hg.1	 -1.3092	 -5.0211	 5.90E-05	 9.98E-03	 8.9081	 8.9212	 8.3005	 chr10	 97951455	 98031333	 -	 NM_001114094	 BLNK	
TC07002319.hg.1	 -0.7644	 -5.0189	 5.93E-05	 9.98E-03	 2.7389	 2.3025	 2.7664	 chr7	 54624663	 54639419	 +	 ---	 ---	
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Appendix 6: Illumina TruSeq Adapter Sequences 
Sequences of Illumina oligonucleotides (proprietary to Illumina, see copyright 
notice below) used for conjugation with amplified template for targeted 
sequencing. Index sequences are 6 bases as underlined. Index numbers 17, 
24 and 26 are reserved and are not available for sample indexing. 
 
 
TruSeq Adapter, Index 1 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 2 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACCGATGTATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 3 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACTTAGGCATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 4 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACTGACCAATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 5 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACACAGTGATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 6 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACGCCAATATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 7 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACCAGATCATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 8 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACACTTGAATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 9 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACGATCAGATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 10 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACTAGCTTATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 11 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACGGCTACATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 12 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACCTTGTAATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 13 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACAGTCAACAATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 14 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACAGTTCCGTATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 15 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACATGTCAGAATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 16 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACCCGTCCCGATCTCGTATGCCGTCTTCTGCTTG 
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TruSeq Adapter, Index 18 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACGTCCGCACATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 19 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACGTGAAACGATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 20 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACGTGGCCTTATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 21 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACGTTTCGGAATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 22 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACCGTACGTAATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 23 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACGAGTGGATATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 25 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACACTGATATATCTCGTATGCCGTCTTCTGCTTG 
 
TruSeq Adapter, Index 27 
5’ GATCGGAAGAGCACACGTCTGAACTCCAGTCACATTCCTTTATCTCGTATGCCGTCTTCTGCTTG 
 
 
Oligonucleotide sequences © 2015 Illumina, Inc. All rights reserved. 
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Appendix 7: Hypermethylation biomarker probes for BE and EAC 
Hypermethylated probes for identification of intervention requiring disease with respect to normal squamous epithelium 
799 probes (top 200, greatest Δβ shown), hypermethylated in HGD and EAC in comparison to N were identified using stringent cut-
off criteria (minimal methylation in control tissues and normal peripheral blood). Gencode v19 was used for annotation204, gene 
name protein-coding when not specified. logfc: log fold change, tstat: t-statistic, pval: p-value, adj_pval: adjusted p-value, βbase: 
average methylation in baseline samples, here, normal squamous epithelium, Δβ: difference in average methylation between 
comparison groups, here, between HGD-EAC and N, βduo: average methylation in duodenal epithelium, βstom: average methylation 
in proximal stomach epithelium, βblood: average methylation in peripheral blood from disease-free patients. Listed in order of 
decreasing Δβ. Entries in grey correspond to target region genes validated by targeted amplicon sequencing (from N v Any disease 
(intersection between N v BE and N v HGD-EAC) as well as N v HGD-EAC comparison groups). Note that region selection for 
validation included criteria pertaining to identification of aberrant methylation across groups of probes (within 300bp, at least 2 
differentially methylated probes required) as well as region suitability for BSP assay design. Hence some of the top aberrantly 
hypermethylated individual probes listed here were not part of regions selected for validation.  
 
gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
AUTS2	 chr7	 69064092	 69064094	 cg17027195	 8.5872	 20.4221	 3.06E-15	 1.77E-12	 0.0110	 0.7995	 0.0215	 0.0101	 0.0110	
SCOC	 chr4	 141295028	 141295030	 cg21986225	 8.2781	 15.8192	 4.55E-13	 6.44E-11	 0.0104	 0.7550	 0.0275	 0.0130	 0.0100	
MTRR	 chr5	 7850202	 7850204	 cg12539796	 8.1530	 17.7910	 4.64E-14	 1.22E-11	 0.0107	 0.7445	 0.0427	 0.0260	 0.0134	
DNAJC6	 chr1	 65731431	 65731433	 cg26615127	 6.1030	 15.3062	 8.58E-13	 1.03E-10	 0.0503	 0.7343	 0.0546	 0.0445	 0.0434	
HMX3	 chr10	 124895447	 124895449	 cg18685408	 6.9471	 12.4102	 4.45E-11	 2.25E-09	 0.0241	 0.7290	 0.0402	 0.0119	 0.0108	
PRDM2	 chr1	 14026583	 14026585	 cg00922376	 8.0579	 24.6511	 7.09E-17	 1.28E-13	 0.0105	 0.7289	 0.0157	 0.0162	 0.0100	
ZNF790	 chr19	 37329089	 37329091	 cg10734240	 7.1385	 14.4022	 2.74E-12	 2.50E-10	 0.0201	 0.7231	 0.0260	 0.0496	 0.0258	
N/A	 chr1	 76080726	 76080728	 cg07923233	 7.6957	 12.0282	 7.90E-11	 3.57E-09	 0.0132	 0.7218	 0.0697	 0.0283	 0.0129	
RUNDC3B	 chr7	 87257537	 87257539	 cg18542829	 7.9486	 30.1483	 1.20E-18	 6.94E-15	 0.0109	 0.7207	 0.0203	 0.0148	 0.0105	
SYT9	 chr11	 7273147	 7273149	 cg18560328	 7.0229	 17.2739	 8.26E-14	 1.86E-11	 0.0214	 0.7182	 0.0781	 0.0428	 0.0123	
IGDCC3	 chr15	 65670303	 65670305	 cg01107006	 7.4118	 13.6773	 7.27E-12	 5.34E-10	 0.0152	 0.7090	 0.0340	 0.0172	 0.0100	
N/A	 chr1	 76081961	 76081963	 cg27547954	 7.8052	 17.1992	 8.99E-14	 1.97E-11	 0.0114	 0.7086	 0.0534	 0.0100	 0.0111	
LMO1	 chr11	 8284745	 8284747	 cg21842523	 5.8796	 15.3362	 8.26E-13	 1.01E-10	 0.0507	 0.7080	 0.0649	 0.0613	 0.0180	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
C11orf96	 chr11	 43963906	 43963908	 cg20062650	 7.2485	 12.0690	 7.42E-11	 3.39E-09	 0.0169	 0.7066	 0.0396	 0.0433	 0.0125	
GDF10	 chr10	 48438723	 48438725	 cg04110601	 7.4536	 18.3007	 2.67E-14	 8.16E-12	 0.0145	 0.7061	 0.0959	 0.0322	 0.0164	
HMX3	 chr10	 124895473	 124895475	 cg00560482	 6.4198	 14.7924	 1.65E-12	 1.70E-10	 0.0316	 0.7049	 0.0529	 0.0374	 0.0181	
RUNDC3B	 chr7	 87257672	 87257674	 cg17960051	 7.8504	 32.0346	 3.49E-19	 2.87E-15	 0.0107	 0.7041	 0.0110	 0.0229	 0.0100	
TMEM178B	 chr7	 140773904	 140773906	 cg07028821	 7.3338	 22.2452	 5.57E-16	 5.22E-13	 0.0154	 0.7009	 0.0884	 0.0460	 0.0126	
PLXNA4	 chr7	 132262352	 132262354	 cg07258916	 7.2773	 17.7944	 4.63E-14	 1.22E-11	 0.0160	 0.7002	 0.0292	 0.0272	 0.0158	
HS3ST4	 chr16	 25703527	 25703529	 cg27014135	 7.6340	 25.9176	 2.58E-17	 6.02E-14	 0.0123	 0.7000	 0.0603	 0.0100	 0.0100	
CTD-2245F17.3	
lincRNA	 chr19	 53700526	 53700528	 cg23021477	 7.2922	 19.1884	 1.05E-14	 4.30E-12	 0.0158	 0.6997	 0.0142	 0.0530	 0.0149	
PURG	 chr8	 30890619	 30890621	 cg18324126	 7.5802	 16.6990	 1.60E-13	 3.00E-11	 0.0127	 0.6990	 0.0399	 0.0179	 0.0100	
T	protein_coding	 chr6	 166582309	 166582311	 cg06073449	 7.1279	 13.4022	 1.07E-11	 7.22E-10	 0.0177	 0.6981	 0.0537	 0.0161	 0.0100	
ZNF662	 chr3	 42947689	 42947691	 cg24384244	 7.2728	 13.1744	 1.47E-11	 9.31E-10	 0.0156	 0.6946	 0.0631	 0.0468	 0.0131	
ZNF829	 chr19	 37407215	 37407217	 cg20680720	 7.7261	 33.5780	 1.33E-19	 1.36E-15	 0.0111	 0.6935	 0.0972	 0.0133	 0.0119	
KCNMA1	 chr10	 79397454	 79397456	 cg09405661	 6.4890	 12.2274	 5.84E-11	 2.80E-09	 0.0276	 0.6904	 0.0388	 0.0468	 0.0313	
PURG	 chr8	 30890616	 30890618	 cg01755467	 7.7055	 15.7107	 5.20E-13	 7.12E-11	 0.0110	 0.6887	 0.0229	 0.0108	 0.0100	
RUNDC3B	 chr7	 87257073	 87257075	 cg04710402	 7.1399	 21.0156	 1.73E-15	 1.17E-12	 0.0166	 0.6876	 0.0688	 0.0354	 0.0116	
CLSTN2	 chr3	 139654263	 139654265	 cg22610211	 7.6646	 9.9617	 2.28E-09	 5.89E-08	 0.0113	 0.6872	 0.0332	 0.0116	 0.0100	
NDRG4	 chr16	 58497814	 58497816	 cg02040433	 7.7941	 28.7004	 3.27E-18	 1.42E-14	 0.0102	 0.6856	 0.0909	 0.0103	 0.0105	
PODN	 chr1	 53527664	 53527666	 cg01394819	 7.2886	 14.8584	 1.51E-12	 1.59E-10	 0.0147	 0.6851	 0.0316	 0.0205	 0.0133	
EPHA7	 chr6	 94129626	 94129628	 cg06740629	 6.0442	 7.7775	 1.38E-07	 1.98E-06	 0.0377	 0.6834	 0.0787	 0.0637	 0.0273	
KIRREL	 chr1	 157963810	 157963812	 cg12612104	 6.6430	 13.6640	 7.41E-12	 5.43E-10	 0.0233	 0.6811	 0.0407	 0.0477	 0.0200	
KCNQ3	 chr8	 133493423	 133493425	 cg22308501	 6.9964	 9.5663	 4.59E-09	 1.06E-07	 0.0178	 0.6808	 0.0143	 0.0265	 0.0136	
SDC2	 chr8	 97507560	 97507562	 cg10292139	 5.8141	 12.5914	 3.40E-11	 1.81E-09	 0.0439	 0.6771	 0.0413	 0.0514	 0.0471	
HMX3	 chr10	 124895460	 124895462	 cg14663510	 5.8692	 13.5466	 8.71E-12	 6.18E-10	 0.0416	 0.6756	 0.0800	 0.0441	 0.0275	
WIPF1	 chr2	 175546915	 175546917	 cg26831241	 6.8703	 16.9994	 1.13E-13	 2.31E-11	 0.0188	 0.6725	 0.0150	 0.0320	 0.0233	
CELF2	 chr10	 11059726	 11059728	 cg12356890	 6.3607	 9.3509	 6.76E-09	 1.48E-07	 0.0276	 0.6725	 0.0313	 0.0604	 0.0266	
NTNG1	 chr1	 107683714	 107683716	 cg11396157	 6.8935	 19.2390	 9.97E-15	 4.15E-12	 0.0183	 0.6707	 0.0924	 0.0149	 0.0112	
RP4-555D20.4	
lincRNA	 chr3	 44040810	 44040812	 cg27606567	 6.6427	 22.5873	 4.10E-16	 4.22E-13	 0.0220	 0.6701	 0.0981	 0.0477	 0.0164	
BMP3	 chr4	 81952023	 81952025	 cg26917673	 6.5372	 22.0933	 6.39E-16	 5.68E-13	 0.0238	 0.6699	 0.0141	 0.0373	 0.0121	
N/A	 chr2	 105479053	 105479055	 cg11014373	 6.3844	 15.1067	 1.10E-12	 1.26E-10	 0.0267	 0.6697	 0.0925	 0.0612	 0.0100	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
PRDM2	 chr1	 14026604	 14026606	 cg09765994	 6.5614	 18.6329	 1.87E-14	 6.40E-12	 0.0233	 0.6696	 0.0246	 0.0293	 0.0144	
RET	 chr10	 43572064	 43572066	 cg05621401	 6.8539	 11.6842	 1.34E-10	 5.51E-09	 0.0187	 0.6689	 0.0343	 0.0309	 0.0100	
ADHFE1	 chr8	 67344587	 67344589	 cg18065361	 7.5235	 19.0847	 1.17E-14	 4.62E-12	 0.0113	 0.6664	 0.0618	 0.0139	 0.0100	
WHAMMP2	
pseudogene	 chr15	 28983116	 28983118	 cg11794877	 7.3934	 29.8372	 1.48E-18	 8.22E-15	 0.0124	 0.6663	 0.0177	 0.0105	 0.0100	
TNFSF11	 chr13	 43148934	 43148936	 cg26224671	 6.6724	 13.8532	 5.72E-12	 4.43E-10	 0.0208	 0.6633	 0.0520	 0.0379	 0.0235	
RP11-1055B8.7	 chr17	 79373380	 79373382	 cg16560774	 7.0204	 14.3365	 2.99E-12	 2.68E-10	 0.0161	 0.6632	 0.0837	 0.0404	 0.0100	
CPLX2	 chr5	 175223981	 175223983	 cg07295964	 6.8016	 13.4048	 1.06E-11	 7.20E-10	 0.0188	 0.6621	 0.0987	 0.0529	 0.0145	
KCNMA1	 chr10	 79398054	 79398056	 cg24113782	 6.6829	 8.7793	 1.95E-08	 3.67E-07	 0.0205	 0.6620	 0.0144	 0.0185	 0.0199	
PURG	 chr8	 30890631	 30890633	 cg23139473	 6.9123	 12.6829	 2.98E-11	 1.63E-09	 0.0172	 0.6605	 0.0216	 0.0190	 0.0121	
CELF2	 chr10	 11059732	 11059734	 cg11472279	 6.3952	 9.2650	 7.91E-09	 1.69E-07	 0.0252	 0.6597	 0.0335	 0.0552	 0.0145	
BVES	 chr6	 105584550	 105584552	 cg14159026	 6.3043	 19.9856	 4.70E-15	 2.41E-12	 0.0270	 0.6596	 0.0835	 0.0445	 0.0184	
H2AFY2	 chr10	 71813352	 71813354	 cg19726179	 6.7892	 17.4173	 7.03E-14	 1.65E-11	 0.0187	 0.6591	 0.0607	 0.0322	 0.0134	
SNCA	 chr4	 90758796	 90758798	 cg20776829	 7.2147	 11.1523	 3.11E-10	 1.10E-08	 0.0136	 0.6589	 0.0843	 0.0824	 0.0111	
GATA5	 chr20	 61051340	 61051342	 cg16714055	 5.9028	 13.1064	 1.62E-11	 1.00E-09	 0.0367	 0.6581	 0.0780	 0.0354	 0.0332	
AC079776.1	
lincRNA	 chr2	 130635165	 130635167	 cg06480249	 7.6369	 17.1478	 9.53E-14	 2.05E-11	 0.0100	 0.6578	 0.0100	 0.0114	 0.0103	
T	protein_coding	 chr6	 166582205	 166582207	 cg19675288	 5.7797	 15.9228	 4.01E-13	 5.85E-11	 0.0403	 0.6574	 0.0837	 0.0580	 0.0219	
CELF2	 chr10	 11060651	 11060653	 cg13950829	 5.4920	 9.9944	 2.16E-09	 5.61E-08	 0.0511	 0.6568	 0.0686	 0.0940	 0.0259	
RP11-139I14.2	
lincRNA	 chr1	 156358230	 156358232	 cg12062819	 7.4740	 14.0662	 4.29E-12	 3.55E-10	 0.0111	 0.6551	 0.0813	 0.0116	 0.0103	
KIF5C	 chr2	 149632704	 149632706	 cg14986699	 7.5956	 10.8637	 4.97E-10	 1.63E-08	 0.0102	 0.6551	 0.0397	 0.0243	 0.0123	
NDRG4	 chr16	 58497800	 58497802	 cg08791131	 7.5531	 24.6331	 7.19E-17	 1.29E-13	 0.0105	 0.6551	 0.0446	 0.0100	 0.0100	
EFCC1/KIAA1257	 chr3	 128720432	 128720434	 cg20506715	 5.4470	 12.9964	 1.89E-11	 1.13E-09	 0.0524	 0.6546	 0.0912	 0.0655	 0.0314	
GATA5	 chr20	 61051431	 61051433	 cg08568720	 6.3908	 11.6262	 1.47E-10	 5.93E-09	 0.0246	 0.6545	 0.0786	 0.0195	 0.0155	
ENOX1	 chr13	 44361219	 44361221	 cg01118451	 7.0402	 12.3084	 5.18E-11	 2.53E-09	 0.0151	 0.6537	 0.0283	 0.0272	 0.0102	
SCOC	 chr4	 141294680	 141294682	 cg20366601	 7.4083	 10.6187	 7.45E-10	 2.28E-08	 0.0115	 0.6534	 0.0135	 0.0106	 0.0114	
NA	 chr19	 40314926	 40314928	 cg06936564	 5.0145	 7.5515	 2.18E-07	 2.95E-06	 0.0774	 0.6532	 0.0971	 0.0854	 0.0334	
PCBP3	 chr21	 47063284	 47063286	 cg01145054	 7.2598	 7.5567	 2.16E-07	 2.93E-06	 0.0128	 0.6522	 0.0190	 0.0144	 0.0100	
ANKLE1	 chr19	 17392769	 17392771	 cg27101125	 5.9897	 14.9595	 1.33E-12	 1.45E-10	 0.0329	 0.6509	 0.0711	 0.0451	 0.0207	
SHD	 chr19	 4279440	 4279442	 cg26646370	 4.9837	 13.7830	 6.29E-12	 4.77E-10	 0.0777	 0.6495	 0.0629	 0.0835	 0.0692	
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TRBJ2-1	 chr7	 142494913	 142494915	 cg21621906	 7.3948	 22.0045	 6.92E-16	 6.09E-13	 0.0114	 0.6479	 0.0846	 0.0111	 0.0104	
KIAA0226L	 chr13	 46961582	 46961584	 cg23833588	 6.4562	 13.2700	 1.28E-11	 8.38E-10	 0.0225	 0.6462	 0.0126	 0.0281	 0.0100	
DRD4	 chr11	 637174	 637176	 cg12928379	 5.5851	 18.8822	 1.44E-14	 5.30E-12	 0.0444	 0.6459	 0.0492	 0.0361	 0.0221	
ZNF461	 chr19	 37157994	 37157996	 cg27545919	 5.8829	 12.7045	 2.88E-11	 1.59E-09	 0.0349	 0.6459	 0.0625	 0.0437	 0.0204	
OBSL1	 chr2	 220417248	 220417250	 cg11531021	 6.4123	 11.9363	 9.08E-11	 4.01E-09	 0.0232	 0.6458	 0.0239	 0.0271	 0.0133	
KCNQ3	 chr8	 133493170	 133493172	 cg13070215	 7.4738	 8.7276	 2.15E-08	 3.99E-07	 0.0106	 0.6457	 0.0110	 0.0142	 0.0115	
ZNF790	 chr19	 37329380	 37329382	 cg18876786	 7.3732	 20.8873	 1.96E-15	 1.28E-12	 0.0114	 0.6452	 0.0185	 0.0190	 0.0116	
TRPC4	 chr13	 38443949	 38443951	 cg19275632	 6.1212	 10.0497	 1.96E-09	 5.17E-08	 0.0288	 0.6447	 0.0710	 0.0368	 0.0286	
N/A	 chr8	 25909325	 25909327	 cg00829961	 6.3733	 10.0520	 1.95E-09	 5.15E-08	 0.0237	 0.6445	 0.0914	 0.0175	 0.0177	
SAMD3/TMEM200A	 chr6	 130686696	 130686698	 cg20334627	 6.6517	 9.9826	 2.20E-09	 5.71E-08	 0.0192	 0.6440	 0.0248	 0.0528	 0.0121	
KCNQ3	 chr8	 133492475	 133492477	 cg27016990	 7.4037	 40.2134	 3.31E-21	 1.90E-16	 0.0111	 0.6435	 0.0639	 0.0271	 0.0113	
GALNT14	 chr2	 31360692	 31360694	 cg21583226	 6.3703	 19.6874	 6.33E-15	 2.99E-12	 0.0236	 0.6432	 0.0544	 0.0469	 0.0135	
TRBJ2-1	 chr7	 142494952	 142494954	 cg08430489	 6.1580	 17.9820	 3.77E-14	 1.05E-11	 0.0276	 0.6422	 0.1000	 0.0409	 0.0217	
GATA5	 chr20	 61051347	 61051349	 cg11982072	 5.5588	 13.4094	 1.05E-11	 7.17E-10	 0.0440	 0.6406	 0.0789	 0.0315	 0.0347	
DTX3	 chr12	 57998785	 57998787	 cg17730484	 5.3911	 10.8902	 4.76E-10	 1.57E-08	 0.0503	 0.6395	 0.0488	 0.0563	 0.0465	
CNTFR	 chr9	 34589710	 34589712	 cg13518298	 5.8620	 18.4328	 2.32E-14	 7.38E-12	 0.0342	 0.6391	 0.0343	 0.0417	 0.0117	
EPB41L3	 chr18	 5629682	 5629684	 cg03718824	 5.9428	 15.8703	 4.28E-13	 6.14E-11	 0.0320	 0.6384	 0.0433	 0.0883	 0.0371	
ENOX1	 chr13	 44361211	 44361213	 cg24098938	 7.0579	 12.7327	 2.77E-11	 1.54E-09	 0.0139	 0.6383	 0.0191	 0.0117	 0.0127	
EHD3	 chr2	 31456774	 31456776	 cg18444347	 6.2639	 15.2463	 9.25E-13	 1.10E-10	 0.0250	 0.6381	 0.0623	 0.0306	 0.0207	
TMEM178B	 chr7	 140773735	 140773737	 cg16633901	 5.7002	 19.6729	 6.42E-15	 3.02E-12	 0.0387	 0.6380	 0.0804	 0.0766	 0.0398	
MED12L	 chr3	 150803668	 150803670	 cg21401219	 5.4639	 12.7528	 2.69E-11	 1.50E-09	 0.0466	 0.6365	 0.0643	 0.0711	 0.0238	
EOMES	 chr3	 27763101	 27763103	 cg24434959	 6.1404	 20.5374	 2.74E-15	 1.64E-12	 0.0272	 0.6365	 0.0278	 0.0403	 0.0228	
CAMK2B	 chr7	 44364924	 44364926	 cg17035091	 7.1596	 28.6349	 3.42E-18	 1.47E-14	 0.0127	 0.6354	 0.0132	 0.0193	 0.0128	
SGCE	 chr7	 94284431	 94284433	 cg19734015	 5.6063	 7.4622	 2.62E-07	 3.46E-06	 0.0411	 0.6351	 0.0857	 0.0335	 0.0133	
GRID2	 chr4	 93226379	 93226381	 cg02468050	 6.1239	 13.6981	 7.07E-12	 5.22E-10	 0.0274	 0.6351	 0.0751	 0.0386	 0.0211	
TLL1	 chr4	 166794785	 166794787	 cg24521633	 6.5363	 15.1003	 1.11E-12	 1.27E-10	 0.0200	 0.6349	 0.0420	 0.0286	 0.0146	
RUNDC3B	 chr7	 87257766	 87257768	 cg15414833	 5.5316	 18.2767	 2.74E-14	 8.34E-12	 0.0435	 0.6344	 0.0433	 0.0521	 0.0376	
PRDM2	 chr1	 14026589	 14026591	 cg05346841	 7.1979	 22.6269	 3.96E-16	 4.10E-13	 0.0123	 0.6341	 0.0208	 0.0277	 0.0100	
OSTM1/NR2E1	 chr6	 108487159	 108487161	 cg18918349	 5.9064	 9.2492	 8.14E-09	 1.74E-07	 0.0322	 0.6339	 0.0850	 0.0433	 0.0290	
N/A	 chr7	 1709949	 1709951	 cg10669265	 6.3108	 16.2049	 2.86E-13	 4.58E-11	 0.0236	 0.6335	 0.0870	 0.0384	 0.0144	
MPPED2	 chr11	 30607067	 30607069	 cg11855526	 6.2535	 25.9300	 2.56E-17	 6.00E-14	 0.0245	 0.6324	 0.0494	 0.0373	 0.0153	
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FOXI3	 chr2	 88752321	 88752323	 cg23511613	 7.4235	 32.2323	 3.08E-19	 2.57E-15	 0.0104	 0.6322	 0.0989	 0.0125	 0.0105	
PRKCQ	 chr10	 6622554	 6622556	 cg19910780	 6.3292	 15.7237	 5.11E-13	 7.02E-11	 0.0230	 0.6314	 0.0259	 0.0255	 0.0227	
STAC2	 chr17	 37382172	 37382174	 cg07280482	 6.2057	 14.7219	 1.80E-12	 1.82E-10	 0.0252	 0.6309	 0.0982	 0.0424	 0.0187	
PRR5	 chr22	 45064470	 45064472	 cg04480903	 6.5405	 13.1934	 1.43E-11	 9.13E-10	 0.0196	 0.6308	 0.0697	 0.0224	 0.0161	
L3MBTL4	 chr18	 6414973	 6414975	 cg18556788	 6.3332	 13.5215	 9.02E-12	 6.35E-10	 0.0229	 0.6307	 0.0513	 0.0426	 0.0172	
N/A	 chr7	 1704583	 1704585	 cg06700935	 6.2979	 15.9453	 3.90E-13	 5.74E-11	 0.0233	 0.6295	 0.0421	 0.0310	 0.0106	
GAMT	 chr19	 1401309	 1401311	 cg24102241	 7.2337	 17.6728	 5.29E-14	 1.34E-11	 0.0117	 0.6294	 0.0432	 0.0169	 0.0104	
EVL	 chr14	 100438736	 100438738	 cg21164440	 6.0070	 17.7565	 4.82E-14	 1.26E-11	 0.0291	 0.6294	 0.0312	 0.0287	 0.0197	
ZNF665	 chr19	 53696648	 53696650	 cg01620580	 6.7938	 15.9956	 3.67E-13	 5.50E-11	 0.0161	 0.6291	 0.0731	 0.0154	 0.0161	
SIX2	 chr2	 45237688	 45237690	 cg02711647	 5.5078	 9.7187	 3.50E-09	 8.45E-08	 0.0431	 0.6288	 0.0893	 0.0186	 0.0228	
SH3RF3	 chr2	 109745827	 109745829	 cg09392940	 6.7878	 18.8365	 1.51E-14	 5.45E-12	 0.0162	 0.6285	 0.0167	 0.0215	 0.0142	
AUTS2	 chr7	 69063474	 69063476	 cg21591173	 6.0799	 10.2520	 1.38E-09	 3.86E-08	 0.0274	 0.6282	 0.0216	 0.0285	 0.0229	
PRDM2	 chr1	 14026617	 14026619	 cg07596209	 7.0365	 19.9890	 4.68E-15	 2.41E-12	 0.0135	 0.6282	 0.0171	 0.0151	 0.0106	
FOXL2	 chr3	 138666117	 138666119	 cg06186698	 6.3491	 14.3611	 2.89E-12	 2.61E-10	 0.0222	 0.6274	 0.0860	 0.0347	 0.0218	
NRG1	 chr8	 32406927	 32406929	 cg06926782	 6.4958	 13.7397	 6.68E-12	 4.99E-10	 0.0199	 0.6274	 0.0891	 0.0341	 0.0164	
MED12L	 chr3	 150804062	 150804064	 cg24255728	 5.6107	 19.4389	 8.13E-15	 3.56E-12	 0.0393	 0.6274	 0.0256	 0.0466	 0.0223	
TBX21	 chr17	 45810864	 45810866	 cg09775582	 7.2370	 30.7668	 7.95E-19	 5.30E-15	 0.0116	 0.6266	 0.0874	 0.0100	 0.0100	
ADCY5	 chr3	 123167769	 123167771	 cg02978184	 6.3752	 10.9513	 4.31E-10	 1.45E-08	 0.0217	 0.6262	 0.0367	 0.0305	 0.0125	
ELOVL5	 chr6	 53213870	 53213872	 cg21195414	 7.2580	 20.5902	 2.60E-15	 1.57E-12	 0.0114	 0.6261	 0.0103	 0.0820	 0.0101	
N/A	 chr7	 1705348	 1705350	 cg06134410	 5.9519	 19.0129	 1.26E-14	 4.86E-12	 0.0298	 0.6256	 0.0489	 0.0346	 0.0328	
ST8SIA1	 chr12	 22488228	 22488230	 cg24239882	 5.2033	 8.6129	 2.67E-08	 4.81E-07	 0.0543	 0.6246	 0.0999	 0.0641	 0.0769	
CALY	 chr10	 135139099	 135139101	 cg26583481	 6.7123	 15.6892	 5.33E-13	 7.25E-11	 0.0167	 0.6236	 0.0408	 0.0359	 0.0180	
ZNF790/ZNF345	 chr19	 37341733	 37341735	 cg12033943	 5.5624	 16.3561	 2.39E-13	 4.01E-11	 0.0401	 0.6235	 0.0227	 0.0355	 0.0389	
POU3F2	 chr6	 99283200	 99283202	 cg16202970	 6.4171	 15.0950	 1.12E-12	 1.27E-10	 0.0207	 0.6227	 0.0662	 0.0159	 0.0106	
FAM78B	 chr1	 166134281	 166134283	 cg21868774	 6.9192	 13.0140	 1.84E-11	 1.11E-09	 0.0143	 0.6226	 0.0172	 0.0262	 0.0128	
DTX3	 chr12	 57998761	 57998763	 cg11654179	 5.2805	 12.0104	 8.11E-11	 3.65E-09	 0.0500	 0.6216	 0.0527	 0.0691	 0.0203	
NEUROG1	 chr5	 134871965	 134871967	 cg07035503	 6.8408	 16.8405	 1.36E-13	 2.65E-11	 0.0150	 0.6215	 0.0892	 0.0438	 0.0102	
KIF6	 chr6	 39692937	 39692939	 cg26867890	 5.5147	 13.5583	 8.57E-12	 6.10E-10	 0.0411	 0.6212	 0.0929	 0.0490	 0.0138	
PROKR1	 chr2	 68870811	 68870813	 cg13451280	 7.2977	 9.6473	 3.97E-09	 9.42E-08	 0.0108	 0.6208	 0.0316	 0.0130	 0.0101	
ELOVL5	 chr6	 53213158	 53213160	 cg13529912	 7.2005	 9.3349	 6.96E-09	 1.52E-07	 0.0115	 0.6202	 0.0100	 0.0121	 0.0100	
ARMC4	 chr10	 28288002	 28288004	 cg13397820	 5.7467	 11.3542	 2.25E-10	 8.42E-09	 0.0339	 0.6196	 0.0778	 0.0594	 0.0122	
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GRIN3A	 chr9	 104501029	 104501031	 cg18794577	 6.0871	 15.9796	 3.75E-13	 5.58E-11	 0.0261	 0.6195	 0.0599	 0.0447	 0.0320	
PRDM2	 chr1	 14026816	 14026818	 cg09826587	 7.2065	 20.6811	 2.38E-15	 1.48E-12	 0.0114	 0.6191	 0.0116	 0.0182	 0.0100	
ADARB2	 chr10	 1779834	 1779836	 cg02899206	 5.6091	 17.8687	 4.26E-14	 1.15E-11	 0.0377	 0.6191	 0.0275	 0.0456	 0.0377	
SNX32	 chr11	 65601331	 65601333	 cg11198128	 7.3460	 32.3319	 2.89E-19	 2.52E-15	 0.0103	 0.6191	 0.0677	 0.0100	 0.0100	
ELOVL5	 chr6	 53213027	 53213029	 cg27599958	 6.7477	 11.2512	 2.65E-10	 9.67E-09	 0.0159	 0.6190	 0.0142	 0.0301	 0.0151	
BEND5	 chr1	 49242518	 49242520	 cg16573178	 6.3514	 26.3634	 1.83E-17	 4.72E-14	 0.0213	 0.6188	 0.0199	 0.0295	 0.0128	
CTD-2319I12.5	
lincRNA	 chr17	 58217356	 58217358	 cg14689219	 5.2668	 8.4718	 3.50E-08	 6.07E-07	 0.0497	 0.6185	 0.0591	 0.0328	 0.0100	
HMX3	 chr10	 124895637	 124895639	 cg11628754	 6.0534	 16.4579	 2.12E-13	 3.69E-11	 0.0266	 0.6184	 0.0735	 0.0308	 0.0165	
FGF14-AS2	lincRNA	 chr13	 103047052	 103047054	 cg16398329	 7.2364	 35.2351	 4.98E-20	 6.74E-16	 0.0111	 0.6182	 0.0942	 0.0141	 0.0100	
N/A	 chr10	 131769580	 131769582	 cg15344419	 5.2108	 20.9298	 1.88E-15	 1.25E-12	 0.0519	 0.6178	 0.0818	 0.0333	 0.0230	
CLSTN2	 chr3	 139654244	 139654246	 cg08853659	 6.2904	 18.3889	 2.43E-14	 7.62E-12	 0.0222	 0.6174	 0.0623	 0.0257	 0.0169	
OBSL1	 chr2	 220417029	 220417031	 cg02527669	 5.5641	 16.4478	 2.14E-13	 3.73E-11	 0.0388	 0.6173	 0.0794	 0.0595	 0.0323	
SAMD3/TMEM200A	 chr6	 130686707	 130686709	 cg26483578	 6.4653	 8.9200	 1.50E-08	 2.94E-07	 0.0194	 0.6171	 0.0249	 0.0439	 0.0180	
MAD2L2	 chr1	 11752161	 11752163	 cg02397176	 6.8389	 12.4094	 4.45E-11	 2.25E-09	 0.0148	 0.6170	 0.0896	 0.0257	 0.0164	
N/A	 chr5	 1667642	 1667644	 cg15658945	 5.0091	 12.0373	 7.79E-11	 3.53E-09	 0.0615	 0.6169	 0.0476	 0.0507	 0.0408	
VENTX	 chr10	 135050778	 135050780	 cg18002909	 5.4405	 12.4759	 4.03E-11	 2.08E-09	 0.0424	 0.6154	 0.0991	 0.0752	 0.0427	
EIF4E3	 chr3	 71803557	 71803559	 cg10172415	 6.5836	 17.4694	 6.63E-14	 1.58E-11	 0.0177	 0.6152	 0.0481	 0.0264	 0.0118	
EPDR1	 chr7	 37960901	 37960903	 cg08608193	 5.6183	 10.1348	 1.69E-09	 4.56E-08	 0.0366	 0.6147	 0.0186	 0.0399	 0.0180	
CNTFR	 chr9	 34589386	 34589388	 cg13578447	 6.4554	 16.6664	 1.66E-13	 3.09E-11	 0.0194	 0.6147	 0.0303	 0.0299	 0.0261	
N/A	 chr1	 111098149	 111098151	 cg02585459	 5.0450	 11.5918	 1.55E-10	 6.19E-09	 0.0587	 0.6145	 0.0499	 0.0747	 0.0470	
KIF6	 chr6	 39693359	 39693361	 cg01138981	 6.9366	 12.5875	 3.42E-11	 1.82E-09	 0.0136	 0.6144	 0.0204	 0.0152	 0.0103	
SH3RF3	 chr2	 109745811	 109745813	 cg12518410	 7.1217	 18.8779	 1.45E-14	 5.30E-12	 0.0119	 0.6142	 0.0100	 0.0146	 0.0113	
CLDN11	 chr3	 170136498	 170136500	 cg21389743	 6.2786	 14.0673	 4.28E-12	 3.55E-10	 0.0220	 0.6139	 0.0270	 0.0352	 0.0174	
H2AFY2	 chr10	 71812611	 71812613	 cg26166804	 5.5202	 17.9283	 4.00E-14	 1.10E-11	 0.0394	 0.6135	 0.0627	 0.0514	 0.0466	
TUB	 chr11	 8103016	 8103018	 cg09498146	 6.3395	 15.5852	 6.06E-13	 7.98E-11	 0.0210	 0.6132	 0.0919	 0.0227	 0.0162	
B3GAT2	 chr6	 71666681	 71666683	 cg16556906	 6.7127	 23.1880	 2.43E-16	 2.87E-13	 0.0158	 0.6121	 0.0858	 0.0185	 0.0156	
H2AFY2	 chr10	 71812595	 71812597	 cg17163751	 5.4222	 18.2084	 2.95E-14	 8.82E-12	 0.0422	 0.6117	 0.0622	 0.0565	 0.0502	
MED12L	 chr3	 150804057	 150804059	 cg12217936	 7.0489	 27.6807	 6.81E-18	 2.40E-14	 0.0124	 0.6113	 0.0100	 0.0100	 0.0100	
BMP3	 chr4	 81951955	 81951957	 cg22403273	 6.0836	 13.4772	 9.59E-12	 6.65E-10	 0.0251	 0.6111	 0.0170	 0.0442	 0.0184	
SLIT2	 chr4	 20253513	 20253515	 cg13755796	 5.5292	 11.7199	 1.27E-10	 5.27E-09	 0.0386	 0.6109	 0.0376	 0.0390	 0.0126	
Appendix 7: Hypermethylation biomarker probes for BE and EAC 
 339 
gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
ALX4	 chr11	 44330902	 44330904	 cg26365854	 6.7108	 20.8148	 2.10E-15	 1.34E-12	 0.0158	 0.6107	 0.0915	 0.0128	 0.0100	
NEUROG1	 chr5	 134871806	 134871808	 cg22630755	 6.9868	 18.2025	 2.97E-14	 8.84E-12	 0.0129	 0.6105	 0.0726	 0.0205	 0.0111	
PRKCB	 chr16	 23847239	 23847241	 cg00735962	 6.0049	 17.8395	 4.40E-14	 1.17E-11	 0.0266	 0.6105	 0.0183	 0.0194	 0.0144	
GNG4	 chr1	 235813443	 235813445	 cg20285514	 6.5341	 10.7241	 6.25E-10	 1.98E-08	 0.0179	 0.6103	 0.0193	 0.0318	 0.0177	
CD1D	 chr1	 158150648	 158150650	 cg12124922	 5.7274	 17.0940	 1.01E-13	 2.14E-11	 0.0328	 0.6099	 0.0273	 0.0600	 0.0211	
ATP6V1B1	 chr2	 71192261	 71192263	 cg10598816	 4.8767	 10.0052	 2.12E-09	 5.52E-08	 0.0663	 0.6095	 0.0538	 0.0642	 0.0510	
ZNF790/ZNF345	 chr19	 37341869	 37341871	 cg03100040	 5.1806	 12.4490	 4.20E-11	 2.14E-09	 0.0507	 0.6087	 0.0394	 0.0585	 0.0357	
KCNQ3	 chr8	 133493433	 133493435	 cg04396550	 5.3879	 10.1843	 1.55E-09	 4.24E-08	 0.0427	 0.6087	 0.0191	 0.0219	 0.0139	
CELF2	 chr10	 11059576	 11059578	 cg23858040	 7.2090	 12.0365	 7.80E-11	 3.54E-09	 0.0109	 0.6080	 0.0245	 0.0257	 0.0100	
FGFR1	 chr8	 38325949	 38325951	 cg27063138	 5.5583	 9.5182	 5.00E-09	 1.14E-07	 0.0371	 0.6080	 0.0231	 0.0304	 0.0254	
KIAA1211L	 chr2	 99553441	 99553443	 cg04787024	 5.6110	 14.8013	 1.63E-12	 1.68E-10	 0.0356	 0.6077	 0.0948	 0.0607	 0.0328	
ZNF569/ZNF570	 chr19	 37957994	 37957996	 cg14142713	 5.2517	 23.4589	 1.92E-16	 2.47E-13	 0.0475	 0.6076	 0.0559	 0.0363	 0.0506	
EPDR1	 chr7	 37960872	 37960874	 cg10876076	 4.8110	 10.3249	 1.22E-09	 3.47E-08	 0.0694	 0.6074	 0.0519	 0.0749	 0.0246	
PPP1R14A	 chr19	 38747200	 38747202	 cg13564825	 5.9802	 12.6420	 3.16E-11	 1.71E-09	 0.0267	 0.6072	 0.0655	 0.0423	 0.0197	
CWH43	 chr4	 48988252	 48988254	 cg22930650	 5.5056	 12.3030	 5.22E-11	 2.55E-09	 0.0384	 0.6064	 0.0590	 0.0489	 0.0226	
MME	 chr3	 154797916	 154797918	 cg23209255	 6.2001	 9.6999	 3.62E-09	 8.69E-08	 0.0225	 0.6064	 0.0199	 0.0175	 0.0106	
RP11-1055B8.7	 chr17	 79373672	 79373674	 cg07219667	 5.6287	 11.1415	 3.16E-10	 1.12E-08	 0.0349	 0.6064	 0.0657	 0.0377	 0.0269	
CD38	 chr4	 15780305	 15780307	 cg15994026	 6.1665	 10.3768	 1.12E-09	 3.22E-08	 0.0228	 0.6034	 0.0438	 0.0444	 0.0103	
EPHA6	 chr3	 96533289	 96533291	 cg15093079	 6.7418	 21.4263	 1.18E-15	 9.09E-13	 0.0149	 0.6034	 0.0918	 0.0439	 0.0157	
ZNF71	 chr19	 57106537	 57106539	 cg22995684	 6.0414	 21.7878	 8.43E-16	 7.16E-13	 0.0250	 0.6030	 0.0632	 0.0298	 0.0258	
ISM1	 chr20	 13201455	 13201457	 cg18993918	 6.3228	 15.0757	 1.15E-12	 1.29E-10	 0.0202	 0.6022	 0.0862	 0.0655	 0.0149	
NTNG1	 chr1	 107683186	 107683188	 cg07005523	 5.9594	 11.9949	 8.31E-11	 3.72E-09	 0.0265	 0.6022	 0.0731	 0.0364	 0.0297	
WIPF1	 chr2	 175547398	 175547400	 cg25075147	 6.4759	 22.0444	 6.68E-16	 5.92E-13	 0.0180	 0.6019	 0.0148	 0.0271	 0.0100	
GATA5	 chr20	 61051422	 61051424	 cg24500900	 6.6628	 13.4728	 9.65E-12	 6.68E-10	 0.0157	 0.6014	 0.0336	 0.0216	 0.0114	
TSLP	 chr5	 110408996	 110408998	 cg24994173	 6.9507	 19.5733	 7.10E-15	 3.26E-12	 0.0127	 0.6013	 0.0515	 0.0312	 0.0115	
PRKG1	 chr10	 52833908	 52833910	 cg04884011	 5.7674	 11.0806	 3.49E-10	 1.21E-08	 0.0305	 0.6007	 0.0803	 0.0332	 0.0275	
FADS2/FADS1	 chr11	 61595484	 61595486	 cg23760165	 7.0829	 30.4147	 1.00E-18	 6.36E-15	 0.0115	 0.6007	 0.0107	 0.0141	 0.0107	
KCTD8	 chr4	 44450880	 44450882	 cg11258164	 5.8484	 11.9653	 8.69E-11	 3.86E-09	 0.0285	 0.6001	 0.0438	 0.0260	 0.0315	
CNTNAP2	 chr7	 145813007	 145813009	 cg09571420	 6.2109	 19.4319	 8.19E-15	 3.58E-12	 0.0217	 0.6001	 0.0950	 0.0307	 0.0107	
PTHLH	 chr12	 28122370	 28122372	 cg19083459	 6.8207	 11.1136	 3.31E-10	 1.16E-08	 0.0139	 0.6000	 0.0475	 0.0156	 0.0122	
L3MBTL4	 chr18	 6414957	 6414959	 cg22058122	 6.1714	 19.7903	 5.71E-15	 2.76E-12	 0.0223	 0.5999	 0.0411	 0.0381	 0.0213	
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ADCY5	 chr3	 123167506	 123167508	 cg15993383	 5.7653	 12.3511	 4.86E-11	 2.41E-09	 0.0304	 0.5999	 0.0412	 0.0540	 0.0210	
DCHS1	 chr11	 6677086	 6677088	 cg21012362	 6.5492	 11.4311	 1.99E-10	 7.61E-09	 0.0169	 0.5998	 0.0133	 0.0227	 0.0192	
GSC	 chr14	 95236122	 95236124	 cg10042799	 6.8953	 17.6975	 5.15E-14	 1.32E-11	 0.0131	 0.5997	 0.0435	 0.0279	 0.0100	
ZNF569/ZNF570	 chr19	 37957996	 37957998	 cg03884783	 5.0340	 23.7619	 1.48E-16	 2.08E-13	 0.0546	 0.5996	 0.0610	 0.0474	 0.0596	
NAV2	 chr11	 19735700	 19735702	 cg20686479	 6.2210	 10.7094	 6.41E-10	 2.01E-08	 0.0215	 0.5994	 0.0751	 0.0331	 0.0126	
CXCL12	 chr10	 44880561	 44880563	 cg26267854	 6.0079	 14.7073	 1.84E-12	 1.84E-10	 0.0252	 0.5990	 0.0977	 0.0440	 0.0141	
MPPED1	 chr11	 30607359	 30607361	 cg24185576	 4.6608	 20.9207	 1.89E-15	 1.25E-12	 0.0756	 0.5985	 0.0853	 0.0656	 0.0592	
 
 
Hypermethylated probes for identification of Barrett’s esophagus mucosa with respect to normal squamous epithelium 
235 probes (all shown), hypermethylated in non-dysplastic BE in comparison to N were identified using stringent cut-off criteria 
(minimal methylation in control tissues and normal peripheral blood). Gencode v19 used for annotation204, gene name protein-
coding when not specified. logfc: log fold change, tstat: t-statistic, pval: p-value, adj_pval: adjusted p-value, βbase: average 
methylation in baseline samples, here, normal squamous epithelium, Δβ: difference in average methylation between comparison 
groups, here, between non-dysplastic BE and N, βduo: average methylation in duodenal epithelium, βstom: average methylation in 
proximal stomach epithelium, βblood: average methylation in peripheral blood from disease-free patients. Listed in order of 
decreasing Δβ. Entries in grey correspond to target region genes validated by targeted amplicon sequencing (from N v Any disease 
(intersection between N v BE and N v HGD-EAC) as well as N v HGD-EAC comparison groups). Note that region selection for 
validation included criteria pertaining to identification of aberrant methylation across groups of probes (within 300bp, at least 2 
differentially methylated probes required) as well as region suitability for BSP assay design. Hence some of the top aberrantly 
hypermethylated individual probes listed here were not part of regions selected for validation.  
 
gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
AUTS2	 chr7	 69064092	 69064094	 cg17027195	 8.5872	 20.4221	 3.06E-15	 1.77E-12	 0.0110	 0.7995	 0.0215	 0.0101	 0.0110	
SCOC	 chr4	 141295028	 141295030	 cg21986225	 8.2781	 15.8192	 4.55E-13	 6.44E-11	 0.0104	 0.7550	 0.0275	 0.0130	 0.0100	
MTRR	 chr5	 7850202	 7850204	 cg12539796	 8.1530	 17.7910	 4.64E-14	 1.22E-11	 0.0107	 0.7445	 0.0427	 0.0260	 0.0134	
DNAJC6	 chr1	 65731431	 65731433	 cg26615127	 6.1030	 15.3062	 8.58E-13	 1.03E-10	 0.0503	 0.7343	 0.0546	 0.0445	 0.0434	
PRDM2	 chr1	 14026583	 14026585	 cg00922376	 8.0579	 24.6511	 7.09E-17	 1.28E-13	 0.0105	 0.7289	 0.0157	 0.0162	 0.0100	
ZNF790	 chr19	 37329089	 37329091	 cg10734240	 7.1385	 14.4022	 2.74E-12	 2.50E-10	 0.0201	 0.7231	 0.0260	 0.0496	 0.0258	
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RUNDC3B	 chr7	 87257537	 87257539	 cg18542829	 7.9486	 30.1483	 1.20E-18	 6.94E-15	 0.0109	 0.7207	 0.0203	 0.0148	 0.0105	
SYT9	 chr11	 7273147	 7273149	 cg18560328	 7.0229	 17.2739	 8.26E-14	 1.86E-11	 0.0214	 0.7182	 0.0781	 0.0428	 0.0123	
GDF10	 chr10	 48438723	 48438725	 cg04110601	 7.4536	 18.3007	 2.67E-14	 8.16E-12	 0.0145	 0.7061	 0.0959	 0.0322	 0.0164	
RUNDC3B	 chr7	 87257672	 87257674	 cg17960051	 7.8504	 32.0346	 3.49E-19	 2.87E-15	 0.0107	 0.7041	 0.0110	 0.0229	 0.0100	
TMEM178B	 chr7	 140773904	 140773906	 cg07028821	 7.3338	 22.2452	 5.57E-16	 5.22E-13	 0.0154	 0.7009	 0.0884	 0.0460	 0.0126	
PLXNA4	 chr7	 132262352	 132262354	 cg07258916	 7.2773	 17.7944	 4.63E-14	 1.22E-11	 0.0160	 0.7002	 0.0292	 0.0272	 0.0158	
HS3ST4	 chr16	 25703527	 25703529	 cg27014135	 7.6340	 25.9176	 2.58E-17	 6.02E-14	 0.0123	 0.7000	 0.0603	 0.0100	 0.0100	
CTD-2245F17.3	
lincRNA	 chr19	 53700526	 53700528	 cg23021477	 7.2922	 19.1884	 1.05E-14	 4.30E-12	 0.0158	 0.6997	 0.0142	 0.0530	 0.0149	
T	protein_coding	 chr6	 166582309	 166582311	 cg06073449	 7.1279	 13.4022	 1.07E-11	 7.22E-10	 0.0177	 0.6981	 0.0537	 0.0161	 0.0100	
ZNF568	 chr19	 37407215	 37407217	 cg20680720	 7.7261	 33.5780	 1.33E-19	 1.36E-15	 0.0111	 0.6935	 0.0972	 0.0133	 0.0119	
RUNDC3B	 chr7	 87257073	 87257075	 cg04710402	 7.1399	 21.0156	 1.73E-15	 1.17E-12	 0.0166	 0.6876	 0.0688	 0.0354	 0.0116	
NDRG4	 chr16	 58497814	 58497816	 cg02040433	 7.7941	 28.7004	 3.27E-18	 1.42E-14	 0.0102	 0.6856	 0.0909	 0.0103	 0.0105	
KIRREL	 chr1	 157963810	 157963812	 cg12612104	 6.6430	 13.6640	 7.41E-12	 5.43E-10	 0.0233	 0.6811	 0.0407	 0.0477	 0.0200	
RP4-555D20.4	
lincRNA	 chr3	 44040810	 44040812	 cg27606567	 6.6427	 22.5873	 4.10E-16	 4.22E-13	 0.0220	 0.6701	 0.0981	 0.0477	 0.0164	
BMP3	 chr4	 81952023	 81952025	 cg26917673	 6.5372	 22.0933	 6.39E-16	 5.68E-13	 0.0238	 0.6699	 0.0141	 0.0373	 0.0121	
N/A	 chr2	 105479053	 105479055	 cg11014373	 6.3844	 15.1067	 1.10E-12	 1.26E-10	 0.0267	 0.6697	 0.0925	 0.0612	 0.0100	
PRDM2	 chr1	 14026604	 14026606	 cg09765994	 6.5614	 18.6329	 1.87E-14	 6.40E-12	 0.0233	 0.6696	 0.0246	 0.0293	 0.0144	
ADHFE1	 chr8	 67344587	 67344589	 cg18065361	 7.5235	 19.0847	 1.17E-14	 4.62E-12	 0.0113	 0.6664	 0.0618	 0.0139	 0.0100	
WHAMMP2	
pseudogene	 chr15	 28983116	 28983118	 cg11794877	 7.3934	 29.8372	 1.48E-18	 8.22E-15	 0.0124	 0.6663	 0.0177	 0.0105	 0.0100	
TNFSF11	 chr13	 43148934	 43148936	 cg26224671	 6.6724	 13.8532	 5.72E-12	 4.43E-10	 0.0208	 0.6633	 0.0520	 0.0379	 0.0235	
CPLX2	 chr5	 175223981	 175223983	 cg07295964	 6.8016	 13.4048	 1.06E-11	 7.20E-10	 0.0188	 0.6621	 0.0987	 0.0529	 0.0145	
BVES	 chr6	 105584550	 105584552	 cg14159026	 6.3043	 19.9856	 4.70E-15	 2.41E-12	 0.0270	 0.6596	 0.0835	 0.0445	 0.0184	
H2AFY2	 chr10	 71813352	 71813354	 cg19726179	 6.7892	 17.4173	 7.03E-14	 1.65E-11	 0.0187	 0.6591	 0.0607	 0.0322	 0.0134	
T	protein_coding	 chr6	 166582205	 166582207	 cg19675288	 5.7797	 15.9228	 4.01E-13	 5.85E-11	 0.0403	 0.6574	 0.0837	 0.0580	 0.0219	
SHD	 chr19	 4279440	 4279442	 cg26646370	 4.9837	 13.7830	 6.29E-12	 4.77E-10	 0.0777	 0.6495	 0.0629	 0.0835	 0.0692	
TRBJ2-1	 chr7	 142494913	 142494915	 cg21621906	 7.3948	 22.0045	 6.92E-16	 6.09E-13	 0.0114	 0.6479	 0.0846	 0.0111	 0.0104	
DRD4	 chr11	 637174	 637176	 cg12928379	 5.5851	 18.8822	 1.44E-14	 5.30E-12	 0.0444	 0.6459	 0.0492	 0.0361	 0.0221	
ZNF790	 chr19	 37329380	 37329382	 cg18876786	 7.3732	 20.8873	 1.96E-15	 1.28E-12	 0.0114	 0.6452	 0.0185	 0.0190	 0.0116	
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TRPC4	 chr13	 38443949	 38443951	 cg19275632	 6.1212	 10.0497	 1.96E-09	 5.17E-08	 0.0288	 0.6447	 0.0710	 0.0368	 0.0286	
KCNQ3	 chr8	 133492475	 133492477	 cg27016990	 7.4037	 40.2134	 3.31E-21	 1.90E-16	 0.0111	 0.6435	 0.0639	 0.0271	 0.0113	
GALNT14	 chr2	 31360692	 31360694	 cg21583226	 6.3703	 19.6874	 6.33E-15	 2.99E-12	 0.0236	 0.6432	 0.0544	 0.0469	 0.0135	
TRBJ2-1	 chr7	 142494952	 142494954	 cg08430489	 6.1580	 17.9820	 3.77E-14	 1.05E-11	 0.0276	 0.6422	 0.1000	 0.0409	 0.0217	
EPB41L3	 chr18	 5629682	 5629684	 cg03718824	 5.9428	 15.8703	 4.28E-13	 6.14E-11	 0.0320	 0.6384	 0.0433	 0.0883	 0.0371	
TMEM178B	 chr7	 140773735	 140773737	 cg16633901	 5.7002	 19.6729	 6.42E-15	 3.02E-12	 0.0387	 0.6380	 0.0804	 0.0766	 0.0398	
EOMES	 chr3	 27763101	 27763103	 cg24434959	 6.1404	 20.5374	 2.74E-15	 1.64E-12	 0.0272	 0.6365	 0.0278	 0.0403	 0.0228	
CAMK2B	 chr7	 44364924	 44364926	 cg17035091	 7.1596	 28.6349	 3.42E-18	 1.47E-14	 0.0127	 0.6354	 0.0132	 0.0193	 0.0128	
GRID2	 chr4	 93226379	 93226381	 cg02468050	 6.1239	 13.6981	 7.07E-12	 5.22E-10	 0.0274	 0.6351	 0.0751	 0.0386	 0.0211	
TLL1	 chr4	 166794785	 166794787	 cg24521633	 6.5363	 15.1003	 1.11E-12	 1.27E-10	 0.0200	 0.6349	 0.0420	 0.0286	 0.0146	
RUNDC3B	 chr7	 87257766	 87257768	 cg15414833	 5.5316	 18.2767	 2.74E-14	 8.34E-12	 0.0435	 0.6344	 0.0433	 0.0521	 0.0376	
PRDM2	 chr1	 14026589	 14026591	 cg05346841	 7.1979	 22.6269	 3.96E-16	 4.10E-13	 0.0123	 0.6341	 0.0208	 0.0277	 0.0100	
N/A	 chr7	 1709949	 1709951	 cg10669265	 6.3108	 16.2049	 2.86E-13	 4.58E-11	 0.0236	 0.6335	 0.0870	 0.0384	 0.0144	
MPPED2	 chr11	 30607067	 30607069	 cg11855526	 6.2535	 25.9300	 2.56E-17	 6.00E-14	 0.0245	 0.6324	 0.0494	 0.0373	 0.0153	
FOXI3	 chr2	 88752321	 88752323	 cg23511613	 7.4235	 32.2323	 3.08E-19	 2.57E-15	 0.0104	 0.6322	 0.0989	 0.0125	 0.0105	
L3MBTL4	 chr18	 6414973	 6414975	 cg18556788	 6.3332	 13.5215	 9.02E-12	 6.35E-10	 0.0229	 0.6307	 0.0513	 0.0426	 0.0172	
ZNF665	 chr19	 53696648	 53696650	 cg01620580	 6.7938	 15.9956	 3.67E-13	 5.50E-11	 0.0161	 0.6291	 0.0731	 0.0154	 0.0161	
SIX2	 chr2	 45237688	 45237690	 cg02711647	 5.5078	 9.7187	 3.50E-09	 8.45E-08	 0.0431	 0.6288	 0.0893	 0.0186	 0.0228	
ZNF790	 chr19	 37341733	 37341735	 cg12033943	 5.5624	 16.3561	 2.39E-13	 4.01E-11	 0.0401	 0.6235	 0.0227	 0.0355	 0.0389	
GRIN3A	 chr9	 104501029	 104501031	 cg18794577	 6.0871	 15.9796	 3.75E-13	 5.58E-11	 0.0261	 0.6195	 0.0599	 0.0447	 0.0320	
ADARB2	 chr10	 1779834	 1779836	 cg02899206	 5.6091	 17.8687	 4.26E-14	 1.15E-11	 0.0377	 0.6191	 0.0275	 0.0456	 0.0377	
SNX32	 chr11	 65601331	 65601333	 cg11198128	 7.3460	 32.3319	 2.89E-19	 2.52E-15	 0.0103	 0.6191	 0.0677	 0.0100	 0.0100	
BEND5	 chr1	 49242518	 49242520	 cg16573178	 6.3514	 26.3634	 1.83E-17	 4.72E-14	 0.0213	 0.6188	 0.0199	 0.0295	 0.0128	
FGF14-IT1	
lincRNA	 chr13	 103047052	 103047054	 cg16398329	 7.2364	 35.2351	 4.98E-20	 6.74E-16	 0.0111	 0.6182	 0.0942	 0.0141	 0.0100	
N/A	 chr10	 131769580	 131769582	 cg15344419	 5.2108	 20.9298	 1.88E-15	 1.25E-12	 0.0519	 0.6178	 0.0818	 0.0333	 0.0230	
B3GAT2	 chr6	 71666681	 71666683	 cg16556906	 6.7127	 23.1880	 2.43E-16	 2.87E-13	 0.0158	 0.6121	 0.0858	 0.0185	 0.0156	
BMP3	 chr4	 81951955	 81951957	 cg22403273	 6.0836	 13.4772	 9.59E-12	 6.65E-10	 0.0251	 0.6111	 0.0170	 0.0442	 0.0184	
ALX4	 chr11	 44330902	 44330904	 cg26365854	 6.7108	 20.8148	 2.10E-15	 1.34E-12	 0.0158	 0.6107	 0.0915	 0.0128	 0.0100	
CD1D	 chr1	 158150648	 158150650	 cg12124922	 5.7274	 17.0940	 1.01E-13	 2.14E-11	 0.0328	 0.6099	 0.0273	 0.0600	 0.0211	
ZNF790	 chr19	 37341869	 37341871	 cg03100040	 5.1806	 12.4490	 4.20E-11	 2.14E-09	 0.0507	 0.6087	 0.0394	 0.0585	 0.0357	
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ZNF569	 chr19	 37957994	 37957996	 cg14142713	 5.2517	 23.4589	 1.92E-16	 2.47E-13	 0.0475	 0.6076	 0.0559	 0.0363	 0.0506	
EPDR1	 chr7	 37960872	 37960874	 cg10876076	 4.8110	 10.3249	 1.22E-09	 3.47E-08	 0.0694	 0.6074	 0.0519	 0.0749	 0.0246	
EPHA6	 chr3	 96533289	 96533291	 cg15093079	 6.7418	 21.4263	 1.18E-15	 9.09E-13	 0.0149	 0.6034	 0.0918	 0.0439	 0.0157	
ZNF71	 chr19	 57106537	 57106539	 cg22995684	 6.0414	 21.7878	 8.43E-16	 7.16E-13	 0.0250	 0.6030	 0.0632	 0.0298	 0.0258	
TSLP	 chr5	 110408996	 110408998	 cg24994173	 6.9507	 19.5733	 7.10E-15	 3.26E-12	 0.0127	 0.6013	 0.0515	 0.0312	 0.0115	
CNTNAP2	 chr7	 145813007	 145813009	 cg09571420	 6.2109	 19.4319	 8.19E-15	 3.58E-12	 0.0217	 0.6001	 0.0950	 0.0307	 0.0107	
L3MBTL4	 chr18	 6414957	 6414959	 cg22058122	 6.1714	 19.7903	 5.71E-15	 2.76E-12	 0.0223	 0.5999	 0.0411	 0.0381	 0.0213	
ZNF569	 chr19	 37957996	 37957998	 cg03884783	 5.0340	 23.7619	 1.48E-16	 2.08E-13	 0.0546	 0.5996	 0.0610	 0.0474	 0.0596	
AP000783.1	 chr11	 123301170	 123301172	 cg03401096	 6.3640	 29.2060	 2.29E-18	 1.08E-14	 0.0192	 0.5980	 0.0116	 0.0365	 0.0100	
ADARB2	 chr10	 1778843	 1778845	 cg07025949	 5.8016	 19.3253	 9.13E-15	 3.89E-12	 0.0293	 0.5978	 0.0567	 0.0527	 0.0316	
EPB41L3	 chr18	 5629179	 5629181	 cg07003920	 5.2372	 20.3938	 3.15E-15	 1.80E-12	 0.0455	 0.5970	 0.0484	 0.0633	 0.0390	
ZNF536	 chr19	 30718423	 30718425	 cg00382463	 5.8127	 15.5748	 6.14E-13	 8.05E-11	 0.0288	 0.5959	 0.0350	 0.0445	 0.0204	
BCL2	 chr18	 60985731	 60985733	 cg24740531	 7.1697	 20.1051	 4.17E-15	 2.23E-12	 0.0105	 0.5944	 0.0106	 0.0283	 0.0107	
ALX4	 chr11	 44331107	 44331109	 cg24335138	 6.0367	 16.3539	 2.39E-13	 4.01E-11	 0.0241	 0.5940	 0.0832	 0.0215	 0.0196	
EMX1	 chr2	 73151594	 73151596	 cg16781647	 5.5478	 18.5085	 2.14E-14	 7.04E-12	 0.0349	 0.5936	 0.0600	 0.0651	 0.0146	
RNF217	 chr6	 125284358	 125284360	 cg06993703	 5.0805	 16.5282	 1.95E-13	 3.48E-11	 0.0496	 0.5888	 0.0923	 0.0553	 0.0379	
LRRFIP1	 chr2	 238535909	 238535911	 cg15674193	 5.6697	 16.7889	 1.44E-13	 2.78E-11	 0.0310	 0.5886	 0.0831	 0.0320	 0.0273	
BEND5	 chr1	 49242512	 49242514	 cg11666087	 6.1358	 25.9571	 2.50E-17	 5.93E-14	 0.0218	 0.5883	 0.0157	 0.0155	 0.0146	
N/A	 chr1	 158119672	 158119674	 cg18873957	 5.1725	 11.3588	 2.23E-10	 8.36E-09	 0.0455	 0.5869	 0.0575	 0.0642	 0.0786	
ZNF736	 chr7	 63767840	 63767842	 cg23849078	 7.0027	 39.9533	 3.79E-21	 1.93E-16	 0.0114	 0.5855	 0.0794	 0.0126	 0.0111	
POU4F1	 chr13	 79177194	 79177196	 cg02279670	 6.4530	 23.5191	 1.82E-16	 2.38E-13	 0.0169	 0.5835	 0.0875	 0.0359	 0.0113	
EPB41L3	 chr18	 5544230	 5544232	 cg16924702	 6.8475	 20.3432	 3.30E-15	 1.87E-12	 0.0126	 0.5816	 0.0320	 0.0487	 0.0119	
RP4-555D20.4	
lincRNA	 chr3	 44041024	 44041026	 cg07451080	 6.1961	 16.4152	 2.23E-13	 3.81E-11	 0.0202	 0.5816	 0.0748	 0.0420	 0.0122	
METTL24	 chr6	 110679106	 110679108	 cg10259748	 4.8461	 17.4090	 7.10E-14	 1.66E-11	 0.0581	 0.5815	 0.0723	 0.0545	 0.0372	
ZNF568	 chr19	 37407461	 37407463	 cg03443751	 6.2568	 16.0396	 3.48E-13	 5.28E-11	 0.0192	 0.5808	 0.0546	 0.0183	 0.0159	
N/A	 chr1	 164290544	 164290546	 cg24862510	 6.1779	 12.6454	 3.14E-11	 1.70E-09	 0.0201	 0.5776	 0.0615	 0.0407	 0.0109	
RUNDC3B	 chr7	 87258093	 87258095	 cg10600178	 4.8995	 14.0011	 4.68E-12	 3.79E-10	 0.0543	 0.5773	 0.0284	 0.0692	 0.0243	
MEGF8	 chr19	 42828155	 42828157	 cg11957331	 5.7002	 16.4698	 2.09E-13	 3.66E-11	 0.0287	 0.5769	 0.0948	 0.0558	 0.0145	
CALCA	 chr11	 14995200	 14995202	 cg22863523	 6.6162	 15.0898	 1.13E-12	 1.28E-10	 0.0144	 0.5754	 0.0768	 0.0238	 0.0139	
EGR2	 chr10	 64575441	 64575443	 cg07852757	 5.1116	 18.7759	 1.61E-14	 5.72E-12	 0.0451	 0.5753	 0.0746	 0.0863	 0.0562	
Appendix 7: Hypermethylation biomarker probes for BE and EAC 
 344 
gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
N/A	 chr10	 131770222	 131770224	 cg25446309	 5.8829	 17.1955	 9.03E-14	 1.97E-11	 0.0247	 0.5741	 0.0456	 0.0302	 0.0262	
EPB41L3	 chr18	 5544098	 5544100	 cg16622495	 6.8115	 24.3432	 9.13E-17	 1.52E-13	 0.0124	 0.5732	 0.0355	 0.0387	 0.0103	
RCSD1	 chr1	 167599718	 167599720	 cg18800085	 7.0311	 33.3011	 1.58E-19	 1.51E-15	 0.0106	 0.5727	 0.0725	 0.0222	 0.0100	
GABRA4	 chr4	 46995820	 46995822	 cg16976370	 5.8633	 15.3667	 7.95E-13	 9.79E-11	 0.0247	 0.5708	 0.0409	 0.0306	 0.0215	
BMP3	 chr4	 81951950	 81951952	 cg20642710	 6.3442	 15.1842	 1.00E-12	 1.16E-10	 0.0171	 0.5690	 0.0175	 0.0249	 0.0171	
ZNF582	 chr19	 56905093	 56905095	 cg25267765	 6.6918	 18.0420	 3.53E-14	 1.01E-11	 0.0133	 0.5688	 0.0424	 0.0224	 0.0100	
N/A	 chr4	 180979630	 180979632	 cg12950911	 5.1801	 18.8264	 1.53E-14	 5.50E-12	 0.0413	 0.5684	 0.0640	 0.0561	 0.0251	
FBN1	 chr15	 48938346	 48938348	 cg10480343	 6.0087	 20.3711	 3.22E-15	 1.83E-12	 0.0218	 0.5680	 0.0986	 0.0321	 0.0189	
PDE3A	 chr12	 20521462	 20521464	 cg17535647	 4.9003	 16.4560	 2.12E-13	 3.70E-11	 0.0517	 0.5677	 0.0707	 0.0927	 0.0207	
CD1D	 chr1	 158150796	 158150798	 cg04360049	 5.1061	 16.8909	 1.28E-13	 2.54E-11	 0.0434	 0.5666	 0.0692	 0.0636	 0.0423	
ZNF470	 chr19	 57078441	 57078443	 cg03153658	 6.1502	 18.4341	 2.31E-14	 7.37E-12	 0.0195	 0.5657	 0.0328	 0.0212	 0.0112	
WNT5A	 chr3	 55521350	 55521352	 cg22615158	 6.9736	 21.3848	 1.22E-15	 9.37E-13	 0.0107	 0.5652	 0.0803	 0.0100	 0.0105	
ATRNL1	 chr10	 116854027	 116854029	 cg24252925	 5.5557	 18.6848	 1.77E-14	 6.16E-12	 0.0303	 0.5648	 0.0800	 0.0784	 0.0229	
ZNF470	 chr19	 57078764	 57078766	 cg09265529	 6.6193	 39.0290	 6.12E-21	 2.35E-16	 0.0137	 0.5630	 0.0792	 0.0283	 0.0143	
ZNF665	 chr19	 53696641	 53696643	 cg07686635	 4.9633	 16.5287	 1.95E-13	 3.48E-11	 0.0478	 0.5624	 0.0796	 0.0509	 0.0350	
KCNN2	 chr5	 113697329	 113697331	 cg26063563	 6.4189	 25.1290	 4.81E-17	 9.42E-14	 0.0157	 0.5618	 0.0984	 0.0151	 0.0116	
DYDC1	 chr10	 82117088	 82117090	 cg03701427	 5.8448	 14.5511	 2.25E-12	 2.16E-10	 0.0240	 0.5617	 0.0892	 0.0509	 0.0169	
ZNF470	 chr19	 57078779	 57078781	 cg24334111	 6.2114	 32.7921	 2.17E-19	 2.03E-15	 0.0183	 0.5612	 0.0618	 0.0337	 0.0104	
COL4A4	 chr2	 228029516	 228029518	 cg22388982	 4.9251	 16.9820	 1.15E-13	 2.35E-11	 0.0489	 0.5610	 0.0956	 0.0603	 0.0550	
ZNF528	 chr19	 52900973	 52900975	 cg27258025	 5.3675	 20.0356	 4.47E-15	 2.34E-12	 0.0338	 0.5569	 0.0891	 0.0568	 0.0235	
FAM181B	 chr11	 82444797	 82444799	 cg09617579	 4.9178	 25.0101	 5.30E-17	 1.01E-13	 0.0482	 0.5568	 0.0997	 0.0802	 0.0223	
TMEM178B	 chr2	 39893077	 39893079	 cg19935171	 6.4207	 17.2647	 8.35E-14	 1.87E-11	 0.0153	 0.5560	 0.0661	 0.0540	 0.0163	
SLC8A1	 chr2	 40679518	 40679520	 cg03307465	 5.2186	 18.1299	 3.21E-14	 9.37E-12	 0.0375	 0.5546	 0.0576	 0.0468	 0.0153	
ZNF569	/	ZNF570	 chr19	 37958345	 37958347	 cg08630279	 5.7623	 37.9997	 1.06E-20	 2.87E-16	 0.0246	 0.5531	 0.0259	 0.0251	 0.0244	
PLXNA4	 chr7	 132261417	 132261419	 cg05950570	 6.3815	 17.4361	 6.89E-14	 1.63E-11	 0.0154	 0.5508	 0.0374	 0.0361	 0.0127	
CPE	 chr4	 166300251	 166300253	 cg16534103	 5.1693	 18.3062	 2.65E-14	 8.14E-12	 0.0383	 0.5508	 0.0400	 0.0338	 0.0284	
ZNF790	 chr19	 37329273	 37329275	 cg22379207	 6.4450	 19.9861	 4.70E-15	 2.41E-12	 0.0146	 0.5496	 0.0200	 0.0129	 0.0208	
NAT16	 chr7	 100823376	 100823378	 cg14562712	 4.6498	 19.6985	 6.26E-15	 2.97E-12	 0.0577	 0.5483	 0.0884	 0.0738	 0.0402	
TLL1	 chr4	 166794970	 166794972	 cg19898128	 6.4722	 22.5648	 4.19E-16	 4.28E-13	 0.0143	 0.5480	 0.0293	 0.0358	 0.0106	
RP11-433J8.1	
lincRNA	 chr14	 97059191	 97059193	 cg24034005	 6.2511	 21.2393	 1.40E-15	 1.02E-12	 0.0167	 0.5479	 0.0549	 0.0352	 0.0160	
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ZNF331	 chr19	 54024322	 54024324	 cg15205507	 5.9858	 19.9968	 4.65E-15	 2.40E-12	 0.0202	 0.5467	 0.0470	 0.0217	 0.0166	
BMP3	 chr4	 81951952	 81951954	 cg26105156	 5.5803	 18.0396	 3.54E-14	 1.01E-11	 0.0274	 0.5465	 0.0200	 0.0496	 0.0100	
HS3ST4	 chr16	 25703829	 25703831	 cg26734696	 6.1888	 16.3548	 2.39E-13	 4.01E-11	 0.0174	 0.5465	 0.0296	 0.0187	 0.0136	
ZNF790	 chr19	 37329447	 37329449	 cg06466031	 5.0846	 14.3001	 3.14E-12	 2.78E-10	 0.0398	 0.5445	 0.0768	 0.0472	 0.0420	
TLL1	 chr4	 166795523	 166795525	 cg10756127	 5.3673	 15.6897	 5.33E-13	 7.25E-11	 0.0319	 0.5444	 0.0584	 0.0647	 0.0338	
N/A	 chr11	 132934553	 132934555	 cg02224864	 4.8669	 15.7233	 5.12E-13	 7.03E-11	 0.0472	 0.5441	 0.0979	 0.0570	 0.0287	
ZNF71	 chr19	 57106851	 57106853	 cg04181321	 5.8695	 15.7170	 5.16E-13	 7.07E-11	 0.0218	 0.5441	 0.0494	 0.0211	 0.0137	
AP000783.1	 chr11	 123300866	 123300868	 cg19419279	 5.3960	 18.4616	 2.25E-14	 7.25E-12	 0.0309	 0.5425	 0.0319	 0.0576	 0.0297	
SLC30A2	 chr1	 26372894	 26372896	 cg00703260	 5.6972	 18.0195	 3.62E-14	 1.02E-11	 0.0246	 0.5423	 0.0582	 0.0483	 0.0179	
NPAS3	 chr14	 33403109	 33403111	 cg18945335	 5.9024	 13.6155	 7.92E-12	 5.73E-10	 0.0211	 0.5422	 0.0982	 0.0395	 0.0191	
N/A	 chr11	 123229179	 123229181	 cg10096161	 4.9694	 21.8788	 7.76E-16	 6.68E-13	 0.0429	 0.5411	 0.0597	 0.0703	 0.0302	
RFTN1	 chr3	 16554465	 16554467	 cg04066019	 6.2008	 15.9765	 3.76E-13	 5.60E-11	 0.0168	 0.5408	 0.0678	 0.0242	 0.0119	
ADARB2	 chr10	 1780002	 1780004	 cg23684973	 4.4698	 21.3153	 1.31E-15	 9.70E-13	 0.0648	 0.5407	 0.0898	 0.0955	 0.0784	
CD1D	 chr1	 158151362	 158151364	 cg05338433	 6.0783	 19.1650	 1.08E-14	 4.36E-12	 0.0183	 0.5389	 0.0801	 0.0433	 0.0165	
N/A	 chr5	 159399505	 159399507	 cg03825010	 5.5197	 15.7795	 4.78E-13	 6.67E-11	 0.0277	 0.5385	 0.0997	 0.0265	 0.0220	
ZNF569	/	ZNF570	 chr19	 37960106	 37960108	 cg17778441	 5.0898	 24.0350	 1.18E-16	 1.79E-13	 0.0383	 0.5371	 0.0352	 0.0301	 0.0337	
ZNF141	 chr4	 330693	 330695	 cg11510060	 5.8515	 20.3210	 3.38E-15	 1.89E-12	 0.0214	 0.5369	 0.0573	 0.0387	 0.0243	
ZNF570	 chr19	 37960413	 37960415	 cg11595155	 6.1399	 13.6933	 7.11E-12	 5.25E-10	 0.0173	 0.5369	 0.0129	 0.0100	 0.0145	
PLXNC1	 chr12	 94543448	 94543450	 cg13565656	 4.5538	 18.2670	 2.77E-14	 8.40E-12	 0.0582	 0.5338	 0.0663	 0.0604	 0.0128	
NDRG4	 chr16	 58498150	 58498152	 cg00984694	 5.7637	 22.4872	 4.48E-16	 4.51E-13	 0.0224	 0.5324	 0.0476	 0.0310	 0.0136	
UBE2QL1	 chr5	 6449089	 6449091	 cg06997381	 6.8403	 33.4199	 1.47E-19	 1.47E-15	 0.0101	 0.5301	 0.0670	 0.0100	 0.0100	
CTD-2162K18.5	
antisense	 chr19	 37288704	 37288706	 cg00578154	 6.7525	 19.0238	 1.25E-14	 4.81E-12	 0.0108	 0.5297	 0.0639	 0.0171	 0.0108	
GCM2	 chr6	 10882239	 10882241	 cg14250833	 5.2099	 10.7123	 6.38E-10	 2.01E-08	 0.0337	 0.5295	 0.0974	 0.0585	 0.0270	
EPB41L3	 chr18	 5629370	 5629372	 cg24496223	 5.9115	 23.1556	 2.49E-16	 2.93E-13	 0.0198	 0.5289	 0.0496	 0.0565	 0.0232	
L3MBTL4	 chr18	 6414975	 6414977	 cg14352983	 5.3618	 11.1962	 2.90E-10	 1.04E-08	 0.0295	 0.5261	 0.0687	 0.0623	 0.0232	
ZNF528	 chr19	 52901123	 52901125	 cg03091337	 5.2010	 27.9030	 5.79E-18	 2.17E-14	 0.0331	 0.5244	 0.0993	 0.0396	 0.0327	
ASIC2	 chr17	 31618408	 31618410	 cg02984614	 4.2779	 13.1360	 1.55E-11	 9.71E-10	 0.0697	 0.5227	 0.0584	 0.0779	 0.0134	
LRRC10B	 chr11	 61277016	 61277018	 cg06341513	 6.6246	 19.4110	 8.37E-15	 3.64E-12	 0.0113	 0.5183	 0.0485	 0.0343	 0.0100	
N/A	 chr1	 158083474	 158083476	 cg13930105	 6.6645	 35.5015	 4.27E-20	 6.63E-16	 0.0110	 0.5183	 0.0115	 0.0151	 0.0106	
FER1L4	 chr20	 34189410	 34189412	 cg13544006	 4.8011	 17.2086	 8.90E-14	 1.96E-11	 0.0439	 0.5175	 0.0447	 0.0878	 0.0480	
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pseudogene	
BICC1	 chr10	 60272753	 60272755	 cg07857251	 6.2585	 27.1340	 1.02E-17	 3.13E-14	 0.0146	 0.5175	 0.0772	 0.0232	 0.0140	
ZNF793	 chr19	 37997293	 37997295	 cg11623861	 6.5465	 27.1097	 1.04E-17	 3.14E-14	 0.0119	 0.5173	 0.0852	 0.0224	 0.0100	
SLC22A31	 chr16	 89267825	 89267827	 cg00588720	 5.5521	 19.0896	 1.16E-14	 4.61E-12	 0.0245	 0.5166	 0.0537	 0.0368	 0.0229	
BEND5	 chr1	 49242756	 49242758	 cg03603214	 6.1778	 33.6681	 1.26E-19	 1.32E-15	 0.0154	 0.5152	 0.0102	 0.0116	 0.0100	
N/A	 chr1	 180204220	 180204222	 cg05719164	 5.1254	 11.3222	 2.37E-10	 8.79E-09	 0.0335	 0.5143	 0.0787	 0.0689	 0.0229	
DYDC1/DYDC2	 chr10	 82116364	 82116366	 cg11854806	 6.2211	 23.9412	 1.28E-16	 1.88E-13	 0.0148	 0.5139	 0.0731	 0.0228	 0.0109	
AJAP1	 chr1	 4716536	 4716538	 cg02483484	 6.2899	 28.0591	 5.17E-18	 2.02E-14	 0.0139	 0.5099	 0.0766	 0.0273	 0.0120	
FJX1	 chr11	 35641504	 35641506	 cg02370395	 4.2562	 16.5442	 1.91E-13	 3.44E-11	 0.0657	 0.5078	 0.0843	 0.0580	 0.0651	
EPB41L3	 chr18	 5544236	 5544238	 cg22335490	 6.2575	 17.7290	 4.97E-14	 1.28E-11	 0.0140	 0.5065	 0.0190	 0.0304	 0.0111	
N/A	 chr11	 132934138	 132934140	 cg00232735	 5.5297	 17.6758	 5.27E-14	 1.34E-11	 0.0238	 0.5054	 0.0947	 0.0702	 0.0155	
GALNT14	 chr2	 31360816	 31360818	 cg03279535	 4.7489	 20.1652	 3.93E-15	 2.12E-12	 0.0431	 0.5047	 0.0880	 0.0640	 0.0415	
N/A	 chr17	 47301740	 47301742	 cg15262242	 4.7881	 18.0917	 3.34E-14	 9.65E-12	 0.0414	 0.5026	 0.0334	 0.0370	 0.0268	
WSCD1	 chr17	 5974077	 5974079	 cg27112897	 5.8788	 21.0772	 1.63E-15	 1.13E-12	 0.0181	 0.5025	 0.0702	 0.0276	 0.0109	
BMP3	 chr4	 81951471	 81951473	 cg02621694	 4.4591	 12.8704	 2.27E-11	 1.31E-09	 0.0537	 0.5016	 0.0454	 0.0918	 0.0662	
BMP3	 chr4	 81952329	 81952331	 cg20276585	 5.9374	 28.1406	 4.88E-18	 1.93E-14	 0.0171	 0.4983	 0.0163	 0.0326	 0.0109	
CLSTN2	 chr3	 139653544	 139653546	 cg01755562	 4.7459	 9.0599	 1.15E-08	 2.35E-07	 0.0419	 0.4978	 0.0865	 0.0314	 0.0124	
UNC5A	 chr5	 176237220	 176237222	 cg13928709	 4.5310	 12.5583	 3.57E-11	 1.89E-09	 0.0497	 0.4978	 0.0716	 0.0906	 0.0151	
CPE	 chr4	 166300016	 166300018	 cg03465206	 6.4812	 20.0086	 4.59E-15	 2.38E-12	 0.0114	 0.4966	 0.0222	 0.0146	 0.0108	
HOPX	 chr4	 57522144	 57522146	 cg09853371	 4.4606	 19.9234	 5.00E-15	 2.52E-12	 0.0524	 0.4965	 0.0426	 0.0980	 0.0453	
ZNF569	/	ZNF570	 chr19	 37958452	 37958454	 cg18244915	 5.2442	 25.1673	 4.67E-17	 9.26E-14	 0.0283	 0.4963	 0.0217	 0.0230	 0.0285	
ST8SIA1	 chr12	 22487667	 22487669	 cg12253830	 5.6819	 14.7149	 1.82E-12	 1.83E-10	 0.0201	 0.4929	 0.0846	 0.0348	 0.0122	
WSCD1	 chr17	 5974065	 5974067	 cg25578609	 6.0146	 32.3166	 2.92E-19	 2.52E-15	 0.0156	 0.4908	 0.0618	 0.0246	 0.0144	
C12orf39	 chr12	 21680507	 21680509	 cg10437806	 5.0995	 23.2249	 2.35E-16	 2.81E-13	 0.0305	 0.4886	 0.0998	 0.0435	 0.0181	
PRKG2	 chr4	 82136838	 82136840	 cg13798300	 4.9784	 10.1719	 1.59E-09	 4.32E-08	 0.0332	 0.4864	 0.0313	 0.0326	 0.0100	
N/A	 chr8	 143591595	 143591597	 cg07139330	 6.1852	 14.1885	 3.64E-12	 3.12E-10	 0.0135	 0.4849	 0.0868	 0.0134	 0.0141	
ZNF569	/	ZNF570	 chr19	 37958443	 37958445	 cg25451874	 4.9866	 22.7739	 3.48E-16	 3.75E-13	 0.0326	 0.4842	 0.0345	 0.0351	 0.0362	
AP000783.1	 chr11	 123301673	 123301675	 cg05289253	 4.9930	 28.6174	 3.47E-18	 1.48E-14	 0.0324	 0.4839	 0.0236	 0.0733	 0.0243	
ALK	 chr2	 30144578	 30144580	 cg14163665	 5.1610	 10.6445	 7.14E-10	 2.20E-08	 0.0285	 0.4832	 0.0787	 0.0361	 0.0136	
AP000783.1	 chr11	 123301489	 123301491	 cg10904699	 4.3111	 25.3078	 4.17E-17	 8.61E-14	 0.0555	 0.4829	 0.0417	 0.0700	 0.0264	
TCF24	 chr8	 67874205	 67874207	 cg26618965	 5.2840	 17.8850	 4.19E-14	 1.14E-11	 0.0257	 0.4811	 0.0933	 0.0284	 0.0129	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
ZNF569	/	ZNF570	 chr19	 37960541	 37960543	 cg02385791	 4.7901	 14.4822	 2.47E-12	 2.31E-10	 0.0371	 0.4789	 0.0338	 0.0346	 0.0396	
AC114730.5	
antisense	 chr2	 242743213	 242743215	 cg03462699	 5.0963	 16.7562	 1.49E-13	 2.85E-11	 0.0293	 0.4788	 0.0273	 0.0990	 0.0194	
N/A	 chr4	 4867101	 4867103	 cg12378888	 5.2164	 10.6356	 7.24E-10	 2.23E-08	 0.0267	 0.4784	 0.0797	 0.0500	 0.0106	
MATK	 chr19	 3786124	 3786126	 cg13535593	 4.6430	 13.0909	 1.65E-11	 1.02E-09	 0.0410	 0.4754	 0.0982	 0.0505	 0.0247	
ZEB2	 chr2	 145274974	 145274976	 cg11540007	 6.4930	 33.8973	 1.10E-19	 1.23E-15	 0.0104	 0.4753	 0.0944	 0.0283	 0.0100	
EBF2	 chr8	 25901421	 25901423	 cg16749235	 4.7995	 11.4351	 1.98E-10	 7.57E-09	 0.0359	 0.4734	 0.0876	 0.0465	 0.0103	
ZNF43	 chr19	 22018952	 22018954	 cg13604887	 4.7725	 23.2484	 2.30E-16	 2.79E-13	 0.0360	 0.4690	 0.0851	 0.0456	 0.0502	
DMRT1	 chr9	 841558	 841560	 cg13762060	 5.9164	 18.1889	 3.01E-14	 8.96E-12	 0.0153	 0.4690	 0.0964	 0.0201	 0.0173	
CALY	 chr10	 135150427	 135150429	 cg14614314	 5.5752	 15.8077	 4.61E-13	 6.49E-11	 0.0195	 0.4677	 0.0193	 0.0591	 0.0174	
TMEM200C	 chr18	 5896266	 5896268	 cg23841467	 3.8430	 10.8061	 5.46E-10	 1.77E-08	 0.0745	 0.4616	 0.0926	 0.0878	 0.0698	
ST8SIA1	 chr12	 22487657	 22487659	 cg16970851	 5.6456	 15.4951	 6.78E-13	 8.67E-11	 0.0178	 0.4585	 0.0897	 0.0287	 0.0100	
ANKRD24	 chr19	 4198057	 4198059	 cg14339043	 5.1927	 15.5132	 6.63E-13	 8.52E-11	 0.0248	 0.4568	 0.0428	 0.0433	 0.0169	
N/A	 chr18	 77558845	 77558847	 cg13135595	 5.0720	 15.0915	 1.12E-12	 1.28E-10	 0.0271	 0.4567	 0.0877	 0.0456	 0.0108	
GPR156	 chr3	 120004185	 120004187	 cg15602740	 5.0729	 6.1461	 4.43E-06	 3.98E-05	 0.0270	 0.4556	 0.0723	 0.0428	 0.0168	
ZNF610	 chr19	 52839935	 52839937	 cg09383947	 4.1594	 18.5761	 1.99E-14	 6.69E-12	 0.0532	 0.4479	 0.0910	 0.0474	 0.0302	
ZNF536	 chr19	 30719148	 30719150	 cg00757082	 4.6704	 13.8622	 5.65E-12	 4.39E-10	 0.0351	 0.4457	 0.0736	 0.0537	 0.0420	
PRKG2	 chr4	 82136115	 82136117	 cg01508023	 4.2530	 14.5317	 2.31E-12	 2.20E-10	 0.0487	 0.4450	 0.0649	 0.0827	 0.0258	
LRRC10B	 chr11	 61276446	 61276448	 cg25923577	 5.4033	 8.6520	 2.48E-08	 4.51E-07	 0.0201	 0.4448	 0.0796	 0.0402	 0.0143	
NELL1	 chr11	 20691428	 20691430	 cg01563031	 6.0000	 18.6232	 1.89E-14	 6.44E-12	 0.0128	 0.4416	 0.0827	 0.0164	 0.0107	
HAND1	 chr5	 153858821	 153858823	 cg15376615	 5.3663	 12.7541	 2.68E-11	 1.50E-09	 0.0203	 0.4409	 0.0774	 0.0178	 0.0100	
HCN1	 chr5	 45696464	 45696466	 cg19697475	 5.1665	 13.9734	 4.86E-12	 3.90E-10	 0.0231	 0.4362	 0.0564	 0.0562	 0.0112	
CBLN1	 chr16	 49316882	 49316884	 cg07571509	 5.1657	 10.2443	 1.40E-09	 3.90E-08	 0.0229	 0.4335	 0.0512	 0.0475	 0.0391	
GREB1L	 chr18	 18821912	 18821914	 cg06711831	 3.6164	 5.3134	 2.96E-05	 0.000202799	 0.0787	 0.4330	 0.0884	 0.0908	 0.0287	
TRHDE	 chr12	 72666263	 72666265	 cg02511156	 5.3378	 15.5085	 6.67E-13	 8.56E-11	 0.0199	 0.4309	 0.0984	 0.0341	 0.0123	
EMX2	 chr10	 119304582	 119304584	 cg03339065	 4.3591	 6.0540	 5.45E-06	 4.76E-05	 0.0409	 0.4256	 0.0855	 0.0539	 0.0387	
TLL1	 chr4	 166795259	 166795261	 cg12836011	 4.4886	 15.7833	 4.75E-13	 6.65E-11	 0.0368	 0.4249	 0.0591	 0.0726	 0.0302	
CTNNA2	 chr2	 79739939	 79739941	 cg08047376	 4.4171	 8.3993	 4.03E-08	 6.84E-07	 0.0381	 0.4203	 0.0464	 0.0351	 0.0135	
ZNF528	 chr19	 52900926	 52900928	 cg20725941	 5.0897	 11.1858	 2.95E-10	 1.06E-08	 0.0225	 0.4170	 0.0715	 0.0329	 0.0204	
N/A	 chr11	 132864164	 132864166	 cg27312388	 3.8247	 5.8726	 8.20E-06	 6.75E-05	 0.0603	 0.4159	 0.0810	 0.0512	 0.0268	
GPM6A	 chr4	 176922778	 176922780	 cg08576864	 3.9045	 7.9689	 9.38E-08	 1.42E-06	 0.0553	 0.4120	 0.0666	 0.0690	 0.0445	
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gencode	 chr	 start	 end	 probe	 logfc	 tstat	 pval	 adj_pval	 βbase	 Δβ	 βduo	 βstom	 βblood	
CTNNA2	 chr2	 79740321	 79740323	 cg01546568	 3.4034	 6.3201	 3.01E-06	 2.85E-05	 0.0855	 0.4119	 0.0691	 0.0460	 0.0521	
TMEM200C	 chr18	 5895538	 5895540	 cg20523393	 6.0882	 17.3377	 7.69E-14	 1.75E-11	 0.0106	 0.4101	 0.0812	 0.0117	 0.0122	
N/A	 chr13	 112712474	 112712476	 cg03276408	 3.4408	 12.2201	 5.91E-11	 2.82E-09	 0.0817	 0.4097	 0.0861	 0.0565	 0.0137	
ZNF331	 chr19	 54023998	 54024000	 cg11332363	 3.8060	 9.6065	 4.27E-09	 1.00E-07	 0.0590	 0.4081	 0.0434	 0.0904	 0.0452	
N/A	 chr6	 137819266	 137819268	 cg19003797	 4.8572	 10.8726	 4.90E-10	 1.61E-08	 0.0257	 0.4080	 0.0453	 0.0437	 0.0100	
ZNF829	 chr19	 37407059	 37407061	 cg02370417	 5.8801	 24.4497	 8.36E-17	 1.43E-13	 0.0120	 0.4052	 0.0848	 0.0204	 0.0140	
NXPH3	 chr17	 47653305	 47653307	 cg15167646	 4.0576	 5.5329	 1.78E-05	 0.00013133	 0.0469	 0.4034	 0.0370	 0.0568	 0.0259	
RBM11	 chr21	 15588607	 15588609	 cg16492707	 5.7822	 11.1165	 3.29E-10	 1.16E-08	 0.0127	 0.4024	 0.0218	 0.0100	 0.0119	
GALNTL6	 chr4	 172734506	 172734508	 cg14307443	 5.1480	 11.8680	 1.01E-10	 4.36E-09	 0.0196	 0.3953	 0.0947	 0.0220	 0.0114	
ALX1	 chr12	 85674693	 85674695	 cg00765312	 3.5604	 4.2547	 0.000359866	 0.001702469	 0.0682	 0.3952	 0.0588	 0.0931	 0.0152	
N/A	 chr19	 48918115	 48918117	 cg15779837	 4.7671	 9.2429	 8.23E-09	 1.75E-07	 0.0258	 0.3935	 0.0981	 0.0294	 0.0147	
CELF4	 chr18	 35147078	 35147080	 cg15179725	 5.7606	 17.1063	 9.99E-14	 2.12E-11	 0.0117	 0.3799	 0.0930	 0.0118	 0.0126	
FOXB1	 chr15	 60298042	 60298044	 cg04861263	 5.7211	 14.5027	 2.40E-12	 2.26E-10	 0.0121	 0.3796	 0.0523	 0.0163	 0.0142	
TENM3	 chr4	 183066336	 183066338	 cg10603183	 4.5886	 8.1505	 6.55E-08	 1.04E-06	 0.0274	 0.3768	 0.0467	 0.0420	 0.0342	
SPATA32	 chr17	 43339588	 43339590	 cg24542751	 3.6793	 9.7360	 3.39E-09	 8.23E-08	 0.0551	 0.3724	 0.0548	 0.0549	 0.0157	
HRH2	 chr5	 175084742	 175084744	 cg17483297	 4.0517	 9.3242	 7.10E-09	 1.55E-07	 0.0398	 0.3676	 0.0541	 0.0462	 0.0440	
EMX2	 chr10	 119304585	 119304587	 cg24188415	 4.9120	 6.8287	 9.94E-07	 1.10E-05	 0.0198	 0.3582	 0.0590	 0.0445	 0.0180	
SYT6	 chr1	 114696461	 114696463	 cg09177131	 5.0757	 14.7079	 1.84E-12	 1.84E-10	 0.0173	 0.3555	 0.0982	 0.0263	 0.0104	
HOXC8	 chr12	 54403177	 54403179	 cg02344911	 3.9058	 7.2538	 4.04E-07	 5.03E-06	 0.0395	 0.3416	 0.0775	 0.0700	 0.0434	
EDARADD	 chr1	 236558873	 236558875	 cg23020486	 5.6803	 7.7715	 1.39E-07	 2.00E-06	 0.0101	 0.3344	 0.0163	 0.0105	 0.0100	
RP4-555D20.3	
lincRNA	 chr3	 44038249	 44038251	 cg14560001	 3.6444	 6.8465	 9.57E-07	 1.06E-05	 0.0441	 0.3218	 0.0614	 0.0488	 0.0186	
 
Hypermethylated probes for differentiation of intervention requiring disease from normal and non-dysplastic disease 
165 probes (all shown), hypermethylated in HGD and EAC in comparison to non-dysplastic BE were identified using stringent cut-
off criteria (minimal methylation in normal and control tissues, as well as normal peripheral blood). This is the most clinically 
relevant comparison, differentiating intervention-requiring disease from normal and non-dysplastic disease. Gencode v19 used for 
annotation204, gene name protein-coding when not specified. logfc: log fold change, tstat: t-statistic, pval: p-value, adj_pval: 
adjusted p-value, βnorm: average methylation in normal squamous epitheilium, βbase: average methylation in baseline samples, here, 
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non-dysplastic BE epithelium, Δβ: difference in average methylation between comparison groups, here, between HGD-EAC and 
BE, βduo: average methylation in duodenal epithelium, βstom: average methylation in proximal stomach epithelium, βblood: average 
methylation in peripheral blood from disease-free patients. Listed in order of decreasing Δβ. Entries in grey correspond to target 
region genes validated by targeted amplicon sequencing. Note that region selection for validation included criteria pertaining to 
identification of aberrant methylation across groups of probes (within 300bp, at least 2 differentially methylated probes required) as 
well as region suitability for BSP assay design. Hence some of the top aberrantly hypermethylated individual probes listed here 
were not part of regions selected for validation. 
 
gencode chr start end probe logfc tstat pval adj_pval βnorm βbase Δβ βduo βstom βblood 
DCHS1 chr11 6677086 6677088 cg21012362 6.5492 11.4311 1.99E-10 7.61E-09 0.0197 0.0169 0.5998 0.0133 0.0227 0.0192 
GNG4 chr1 235812839 235812841 cg06714284 7.1102 13.7287 6.78E-12 5.05E-10 0.0108 0.0108 0.5902 0.0100 0.0123 0.0100 
DCBLD2 chr3 98620661 98620663 cg27352765 6.2823 8.4444 3.69E-08 6.35E-07 0.0194 0.0180 0.5702 0.0144 0.0168 0.0194 
KCNB2 chr8 73449523 73449525 cg15774465 6.3478 10.6222 7.41E-10 2.27E-08 0.0176 0.0162 0.5564 0.0621 0.0274 0.0108 
GBGT1 chr9 136039124 136039126 cg14472025 5.2494 13.0458 1.76E-11 1.07E-09 0.0359 0.0353 0.5466 0.0246 0.0384 0.0237 
KCNB2 chr8 73449518 73449520 cg18555069 6.8205 12.7203 2.82E-11 1.56E-09 0.0108 0.0106 0.5376 0.0765 0.0113 0.0102 
SH3RF3 chr2 109745647 109745649 cg16117910 5.5862 9.3091 7.30E-09 1.58E-07 0.0268 0.0259 0.5351 0.0211 0.0380 0.0162 
PCLO chr7 82792344 82792346 cg15478390 6.0999 12.8736 2.26E-11 1.31E-09 0.0185 0.0169 0.5247 0.0307 0.0144 0.0194 
SH3RF3 chr2 109745613 109745615 cg22959667 6.1606 11.1374 3.18E-10 1.13E-08 0.0167 0.0161 0.5232 0.0124 0.0193 0.0103 
FADS1 chr11 61583955 61583957 cg23992449 6.4606 10.6539 7.03E-10 2.18E-08 0.0128 0.0124 0.5127 0.0109 0.0143 0.0103 
QPCT chr2 37571728 37571730 cg15162392 4.8835 6.3856 2.61E-06 2.52E-05 0.0471 0.0401 0.5124 0.0465 0.0637 0.0373 
N/A chr5 36690436 36690438 cg05542957 6.6452 17.8258 4.47E-14 1.19E-11 0.0109 0.0108 0.5116 0.0564 0.0138 0.0155 
N/A chr7 127807499 127807501 cg25402610 6.3224 10.6097 7.56E-10 2.31E-08 0.0157 0.0136 0.5108 0.0105 0.0176 0.0100 
FADS1 chr11 61584111 61584113 cg27173322 6.5875 10.1053 1.78E-09 4.76E-08 0.0114 0.0112 0.5105 0.0150 0.0100 0.0100 
PCP4L1 chr1 161228495 161228497 cg27223727 6.1377 10.7388 6.10E-10 1.93E-08 0.0157 0.0147 0.4976 0.0139 0.0180 0.0119 
GRASP chr12 52400662 52400664 cg22196952 6.5829 12.9052 2.16E-11 1.26E-09 0.0108 0.0106 0.4972 0.0124 0.0121 0.0100 
ENO4 chr10 118609166 118609168 cg15461105 5.0526 13.2572 1.31E-11 8.49E-10 0.0330 0.0324 0.4943 0.0233 0.0445 0.0259 
FADS1 chr11 61583570 61583572 cg13475388 6.0038 8.4868 3.40E-08 5.92E-07 0.0168 0.0157 0.4900 0.0136 0.0111 0.0119 
DNM3 chr1 171811476 171811478 cg20800956 5.9419 10.3139 1.24E-09 3.53E-08 0.0175 0.0160 0.4845 0.0618 0.0197 0.0102 
HLX chr1 221053512 221053514 cg15356516 4.5176 7.6909 1.64E-07 2.31E-06 0.0472 0.0443 0.4708 0.0344 0.0512 0.0214 
C17orf64 chr17 58498976 58498978 cg09695735 4.7841 5.5127 1.87E-05 0.000136659 0.0423 0.0353 0.4665 0.0409 0.0100 0.0100 
GRASP chr12 52400666 52400668 cg09101796 6.1815 10.9734 4.15E-10 1.40E-08 0.0132 0.0123 0.4630 0.0161 0.0117 0.0100 
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gencode chr start end probe logfc tstat pval adj_pval βnorm βbase Δβ βduo βstom βblood 
EPHX3 chr19 15343344 15343346 cg17399362 3.7437 7.5042 2.40E-07 3.21E-06 0.0851 0.0811 0.4606 0.0725 0.0786 0.0721 
ARHGAP22 chr10 49732002 49732004 cg11790857 4.9357 9.5057 5.11E-09 1.17E-07 0.0325 0.0303 0.4587 0.0314 0.0435 0.0233 
MOXD1 chr6 132722314 132722316 cg16478774 6.1534 15.7335 5.05E-13 6.96E-11 0.0133 0.0123 0.4582 0.0446 0.0119 0.0100 
RTN1 chr14 60337476 60337478 cg19556814 5.2710 6.9915 7.02E-07 8.13E-06 0.0241 0.0234 0.4568 0.0218 0.0362 0.0107 
N/A chr11 123947156 123947158 cg11633126 5.7072 10.9566 4.27E-10 1.44E-08 0.0186 0.0168 0.4545 0.0437 0.0291 0.0198 
SLC16A14 chr2 230933066 230933068 cg26338195 4.8369 8.1124 7.06E-08 1.11E-06 0.0334 0.0317 0.4519 0.0266 0.0348 0.0196 
DCBLD2 chr3 98620815 98620817 cg17198587 4.1042 8.1065 7.14E-08 1.12E-06 0.0569 0.0554 0.4467 0.0489 0.0523 0.0447 
ZNF365 chr10 64133895 64133897 cg08984023 4.0808 12.3306 5.01E-11 2.47E-09 0.0587 0.0563 0.4462 0.0815 0.0489 0.0456 
DCBLD2 chr3 98620856 98620858 cg02464093 5.8339 7.5392 2.24E-07 3.02E-06 0.0156 0.0147 0.4449 0.0103 0.0207 0.0118 
BOC chr3 112930674 112930676 cg27085904 4.4421 6.5456 1.84E-06 1.86E-05 0.0434 0.0416 0.4436 0.0550 0.0544 0.0339 
N/A chr10 102587109 102587111 cg26439963 4.1981 14.8407 1.55E-12 1.62E-10 0.0513 0.0504 0.4433 0.0349 0.0540 0.0291 
EPHX3 chr19 15342748 15342750 cg03562044 5.4184 10.8754 4.87E-10 1.60E-08 0.0211 0.0194 0.4394 0.0521 0.0242 0.0119 
ELOVL5 chr6 53212617 53212619 cg14378848 5.3004 10.0967 1.81E-09 4.82E-08 0.0218 0.0211 0.4383 0.0186 0.0264 0.0259 
N/A chr17 45867660 45867662 cg16624787 4.9431 10.5956 7.74E-10 2.36E-08 0.0282 0.0274 0.4367 0.0303 0.0195 0.0248 
DTX3 chr12 57998655 57998657 cg19217692 3.8377 12.2221 5.89E-11 2.81E-09 0.0665 0.0657 0.4358 0.0631 0.0501 0.0548 
RTN1 chr14 60337473 60337475 cg04510871 4.1255 6.9102 8.35E-07 9.44E-06 0.0515 0.0507 0.4316 0.0413 0.0495 0.0189 
DTX3 chr12 57998580 57998582 cg06596054 3.7651 10.7294 6.20E-10 1.96E-08 0.0681 0.0665 0.4256 0.0529 0.0731 0.0889 
RRAGD chr6 90121835 90121837 cg11571263 4.0899 13.3066 1.22E-11 8.05E-10 0.0516 0.0506 0.4251 0.0451 0.0523 0.0469 
NEUROG2 chr4 113437229 113437231 cg26708817 4.9705 10.1637 1.61E-09 4.36E-08 0.0259 0.0252 0.4228 0.0257 0.0281 0.0194 
GBGT1 chr9 136039280 136039282 cg21244880 5.8679 14.1114 4.03E-12 3.39E-10 0.0134 0.0130 0.4220 0.0113 0.0165 0.0101 
N/A chr5 36690601 36690603 cg18711394 4.2676 14.5817 2.17E-12 2.10E-10 0.0435 0.0431 0.4214 0.0758 0.0313 0.0305 
RP11-266L9.5	
lincRNA chr16 25078094 25078096 cg04153495 4.3415 7.1323 5.21E-07 6.27E-06 0.0403 0.0396 0.4160 0.0289 0.0445 0.0368 
QPCT chr2 37572288 37572290 cg17304496 3.6358 5.9972 6.19E-06 5.31E-05 0.0706 0.0701 0.4138 0.0576 0.0684 0.0622 
N/A chr10 102586998 102587000 cg25531836 3.8943 14.5757 2.18E-12 2.11E-10 0.0567 0.0560 0.4128 0.0600 0.0564 0.0658 
TNFRSF9 chr1 8002527 8002529 cg18859763 4.7807 14.4678 2.51E-12 2.34E-10 0.0289 0.0273 0.4084 0.0534 0.0381 0.0249 
RRAGD chr6 90121832 90121834 cg21051989 3.5041 10.6344 7.26E-10 2.24E-08 0.0799 0.0763 0.4075 0.0352 0.0838 0.0465 
ZNF365 chr10 64133887 64133889 cg01137532 4.2486 14.4466 2.58E-12 2.40E-10 0.0423 0.0407 0.4059 0.0884 0.0409 0.0477 
CLDN10 chr13 96204859 96204861 cg16275739 4.4569 10.1397 1.68E-09 4.53E-08 0.0362 0.0345 0.4052 0.0770 0.0328 0.0256 
NPAS3 chr14 33408947 33408949 cg04900565 4.0206 7.4394 2.75E-07 3.61E-06 0.0502 0.0484 0.4038 0.0432 0.0673 0.0282 
SPOCK1 chr5 136835106 136835108 cg12420858 6.1255 12.2557 5.60E-11 2.70E-09 0.0100 0.0100 0.4036 0.0269 0.0100 0.0100 
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RLTPR chr16 67678845 67678847 cg00846114 5.1760 7.9173 1.04E-07 1.55E-06 0.0223 0.0198 0.4028 0.0103 0.0258 0.0102 
N/A chr7 6566323 6566325 cg02266348 4.2644 10.7254 6.24E-10 1.97E-08 0.0396 0.0392 0.4005 0.0856 0.0431 0.0306 
RRAGD chr6 90121825 90121827 cg04879577 4.2246 10.0364 2.00E-09 5.27E-08 0.0416 0.0396 0.3958 0.0210 0.0250 0.0308 
TBX2 chr17 59477018 59477020 cg22163056 5.1185 11.3161 2.39E-10 8.86E-09 0.0204 0.0197 0.3916 0.0466 0.0227 0.0117 
SLC47A1 chr17 19437790 19437792 cg17332016 4.6368 10.1756 1.58E-09 4.29E-08 0.0302 0.0279 0.3890 0.0348 0.0339 0.0341 
TEPP chr16 58018879 58018881 cg07844931 5.5384 11.4297 2.00E-10 7.62E-09 0.0159 0.0143 0.3885 0.0133 0.0201 0.0114 
DCBLD2 chr3 98620634 98620636 cg07906351 5.9518 7.5830 2.05E-07 2.79E-06 0.0105 0.0105 0.3858 0.0100 0.0131 0.0100 
SCUBE2 chr11 9113166 9113168 cg10782380 4.7702 8.2696 5.18E-08 8.51E-07 0.0261 0.0241 0.3783 0.0280 0.0312 0.0113 
SMOC1 chr14 70346220 70346222 cg15996043 3.3892 6.6998 1.31E-06 1.39E-05 0.0752 0.0722 0.3771 0.0551 0.0580 0.0263 
ENO4 chr10 118609144 118609146 cg02909379 3.6950 12.3620 4.78E-11 2.38E-09 0.0566 0.0550 0.3750 0.0532 0.0638 0.0646 
ZNF365 chr10 64133882 64133884 cg09906751 4.3542 16.3624 2.37E-13 3.99E-11 0.0335 0.0324 0.3740 0.0896 0.0400 0.0473 
DNER chr2 230578916 230578918 cg16365799 4.8184 9.2968 7.46E-09 1.61E-07 0.0248 0.0227 0.3727 0.0117 0.0265 0.0144 
SCARF2 chr22 20792142 20792144 cg03143742 4.6360 12.4185 4.39E-11 2.22E-09 0.0266 0.0258 0.3710 0.0183 0.0374 0.0137 
SH3RF3 chr2 109745515 109745517 cg22725460 4.0024 8.5825 2.83E-08 5.06E-07 0.0427 0.0420 0.3705 0.0383 0.0372 0.0412 
PPAP2B chr1 57110721 57110723 cg09763175 4.5006 8.1441 6.63E-08 1.05E-06 0.0316 0.0284 0.3697 0.0475 0.0369 0.0129 
GRIN2A chr16 10276579 10276581 cg09239744 4.4023 7.2563 4.02E-07 5.01E-06 0.0307 0.0295 0.3619 0.0789 0.0320 0.0187 
RLTPR chr16 67678825 67678827 cg03314195 3.6049 7.8308 1.24E-07 1.81E-06 0.0561 0.0543 0.3571 0.0318 0.0486 0.0187 
CKB chr14 103989335 103989337 cg13714067 4.4320 12.8808 2.23E-11 1.29E-09 0.0290 0.0279 0.3550 0.0574 0.0302 0.0252 
CHRM1 chr11 62691250 62691252 cg04557452 5.4764 9.6967 3.64E-09 8.73E-08 0.0133 0.0127 0.3520 0.0478 0.0105 0.0100 
N/A chr17 35014411 35014413 cg08967106 5.1016 12.3247 5.05E-11 2.49E-09 0.0173 0.0167 0.3512 0.0165 0.0247 0.0100 
BOC chr3 112930781 112930783 cg05953927 5.7288 6.8758 8.99E-07 1.01E-05 0.0107 0.0106 0.3512 0.0214 0.0100 0.0100 
N/A chr1 76081271 76081273 cg03662422 4.0379 11.1032 3.37E-10 1.18E-08 0.0379 0.0371 0.3507 0.0432 0.0507 0.0537 
N/A chr16 22173764 22173766 cg01869826 5.4560 10.7594 5.90E-10 1.88E-08 0.0131 0.0126 0.3465 0.0162 0.0190 0.0100 
N/A chr13 100547248 100547250 cg14684709 4.5799 11.0244 3.82E-10 1.31E-08 0.0253 0.0240 0.3462 0.0279 0.0372 0.0150 
AMZ1 chr7 2728343 2728345 cg17081778 5.6184 10.2632 1.36E-09 3.79E-08 0.0110 0.0109 0.3395 0.0156 0.0132 0.0115 
ADAM22 chr7 87563907 87563909 cg05351302 3.9549 7.9076 1.06E-07 1.58E-06 0.0383 0.0375 0.3390 0.0382 0.0375 0.0493 
N/A chr17 35014437 35014439 cg00371418 3.5126 9.2527 8.09E-09 1.73E-07 0.0567 0.0534 0.3383 0.0610 0.0654 0.0555 
CKB chr14 103989314 103989316 cg14294629 5.5605 14.8260 1.58E-12 1.64E-10 0.0115 0.0112 0.3376 0.0368 0.0149 0.0101 
IGSF22 chr11 18727773 18727775 cg12670477 3.8993 8.7403 2.10E-08 3.91E-07 0.0456 0.0388 0.3370 0.0473 0.0439 0.0274 
RTN1 chr14 60337153 60337155 cg07544748 3.9460 8.4161 3.90E-08 6.65E-07 0.0385 0.0369 0.3345 0.0307 0.0352 0.0155 
PPAP2B chr1 57111498 57111500 cg05494069 3.7885 9.4733 5.42E-09 1.23E-07 0.0455 0.0416 0.3334 0.0832 0.0569 0.0481 
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RRAGD chr6 90122496 90122498 cg19187185 3.3849 9.3540 6.72E-09 1.48E-07 0.0586 0.0561 0.3269 0.0512 0.0781 0.0573 
GRASP chr12 52400649 52400651 cg09889291 5.2518 9.8050 3.00E-09 7.43E-08 0.0144 0.0133 0.3266 0.0100 0.0111 0.0116 
TUBA3FP	
pseudogene chr22 21368602 21368604 cg06912515 5.6109 9.3912 6.29E-09 1.39E-07 0.0102 0.0102 0.3245 0.0144 0.0100 0.0100 
TSPAN9 chr12 3309494 3309496 cg07987843 4.8133 12.7495 2.70E-11 1.51E-09 0.0187 0.0179 0.3211 0.0114 0.0158 0.0132 
MDGA1 chr6 37663981 37663983 cg08494905 3.5289 8.1665 6.35E-08 1.01E-06 0.0490 0.0482 0.3208 0.0492 0.0608 0.0526 
FEV chr2 219849188 219849190 cg01157126 3.9585 10.9820 4.10E-10 1.39E-08 0.0355 0.0339 0.3193 0.0927 0.0453 0.0130 
GRASP chr12 52400529 52400531 cg08102256 5.0152 13.1377 1.55E-11 9.70E-10 0.0153 0.0149 0.3130 0.0191 0.0267 0.0128 
SULF1 chr8 70405203 70405205 cg20169702 3.6043 9.7537 3.29E-09 8.02E-08 0.0439 0.0430 0.3101 0.0500 0.0601 0.0322 
CTSF chr11 66336124 66336126 cg17381565 5.5295 11.1987 2.89E-10 1.04E-08 0.0100 0.0100 0.3081 0.0144 0.0118 0.0100 
N/A chr3 46940346 46940348 cg21792155 3.0056 5.9016 7.68E-06 6.39E-05 0.0732 0.0693 0.3049 0.0780 0.0681 0.0504 
CKB chr14 103989207 103989209 cg02248320 4.5138 10.8238 5.31E-10 1.72E-08 0.0226 0.0207 0.3046 0.0303 0.0238 0.0117 
RHBDL3 chr17 30592656 30592658 cg04493025 5.0470 6.0487 5.51E-06 4.81E-05 0.0142 0.0138 0.3030 0.0114 0.0148 0.0100 
QPCT chr2 37572395 37572397 cg12040278 3.0675 6.0440 5.57E-06 4.85E-05 0.0656 0.0643 0.3013 0.0509 0.0658 0.0575 
MGA chr15 41913565 41913567 cg15924985 3.5711 11.7538 1.20E-10 5.04E-09 0.0427 0.0422 0.3013 0.0404 0.0426 0.0516 
SLC16A14 chr2 230931792 230931794 cg02821501 4.3285 7.0212 6.59E-07 7.70E-06 0.0236 0.0233 0.3003 0.0145 0.0189 0.0261 
STOX2 chr4 184826313 184826315 cg07089892 3.5119 8.4247 3.83E-08 6.56E-07 0.0454 0.0440 0.3002 0.0253 0.0371 0.0276 
STK33 chr11 8615750 8615752 cg15247111 3.0251 5.4308 2.26E-05 0.000160683 0.0690 0.0661 0.2994 0.0236 0.0419 0.0319 
TUBA3FP	
psuedogene chr22 21368764 21368766 cg01038149 3.4432 10.2741 1.33E-09 3.73E-08 0.0463 0.0460 0.2980 0.0440 0.0459 0.0469 
FAM132A chr1 1182423 1182425 cg06443533 3.7782 9.5952 4.36E-09 1.02E-07 0.0370 0.0348 0.2963 0.0580 0.0571 0.0847 
RTN1 chr14 60337616 60337618 cg04147372 3.5535 5.7194 1.16E-05 9.09E-05 0.0443 0.0416 0.2959 0.0209 0.0279 0.0268 
ENO4 chr10 118608472 118608474 cg09763162 3.6571 8.6997 2.26E-08 4.18E-07 0.0422 0.0381 0.2950 0.0340 0.0355 0.0418 
TRANK1 chr3 36986153 36986155 cg06163735 3.0070 6.0535 5.46E-06 4.76E-05 0.0664 0.0654 0.2945 0.0591 0.0624 0.0589 
ENOX1 chr13 44361063 44361065 cg13319488 3.4003 8.4919 3.37E-08 5.88E-07 0.0478 0.0467 0.2942 0.0315 0.0449 0.0360 
FEV chr2 219849134 219849136 cg15138883 5.1554 8.2396 5.50E-08 8.95E-07 0.0124 0.0122 0.2930 0.0207 0.0100 0.0153 
RP11-266L9.5	
lincRNA chr16 25078438 25078440 cg00611485 3.7876 7.4336 2.78E-07 3.64E-06 0.0341 0.0332 0.2887 0.0248 0.0295 0.0261 
C17orf64 chr17 58498870 58498872 cg10179315 2.5745 5.5150 1.86E-05 0.000136029 0.0962 0.0927 0.2857 0.0561 0.0765 0.0794 
ALPL chr1 21835619 21835621 cg17015803 3.1905 8.6740 2.38E-08 4.36E-07 0.0535 0.0531 0.2856 0.0818 0.0587 0.0413 
C1orf51 chr1 150254476 150254478 cg11207983 4.1445 9.3304 7.02E-09 1.53E-07 0.0253 0.0246 0.2842 0.0432 0.0300 0.0255 
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TTYH1 chr19 54926733 54926735 cg23695687 4.3693 11.2096 2.84E-10 1.02E-08 0.0231 0.0207 0.2831 0.0688 0.0336 0.0187 
SLC16A14 chr2 230931921 230931923 cg00455164 5.2150 8.3194 4.70E-08 7.82E-07 0.0113 0.0111 0.2830 0.0114 0.0135 0.0230 
EID3 chr12 104697192 104697194 cg01857475 2.6514 6.0529 5.46E-06 4.77E-05 0.0883 0.0841 0.2818 0.0342 0.0394 0.0622 
ASB8 chr12 48576855 48576857 cg12396999 3.2355 13.3319 1.18E-11 7.82E-10 0.0508 0.0499 0.2809 0.0630 0.0876 0.0489 
HCP5	
sense_overlapping chr6 31431069 31431071 cg12034086 4.1806 10.4123 1.05E-09 3.06E-08 0.0242 0.0235 0.2807 0.0269 0.0285 0.0186 
GBGT1 chr9 136039282 136039284 cg24340029 2.6461 8.2933 4.95E-08 8.18E-07 0.0848 0.0838 0.2804 0.0712 0.0829 0.0955 
RRAGD chr6 90122151 90122153 cg10651618 3.5217 6.9866 7.10E-07 8.20E-06 0.0440 0.0390 0.2788 0.0166 0.0639 0.0118 
SYT5 chr19 55685291 55685293 cg07721458 4.0892 10.4624 9.68E-10 2.85E-08 0.0256 0.0244 0.2744 0.0338 0.0495 0.0274 
CDK14 chr7 90226449 90226451 cg02759151 3.6159 10.9176 4.55E-10 1.51E-08 0.0357 0.0350 0.2727 0.0400 0.0327 0.0345 
VANGL2 chr1 160370362 160370364 cg18398058 3.3587 6.6893 1.34E-06 1.42E-05 0.0430 0.0422 0.2691 0.0402 0.0430 0.0393 
ISM2 chr14 77965283 77965285 cg16049707 5.0457 10.5625 8.18E-10 2.47E-08 0.0120 0.0117 0.2686 0.0100 0.0119 0.0109 
TUBA3FP	
pseudogene chr22 21368706 21368708 cg21014483 4.6553 7.9397 9.95E-08 1.50E-06 0.0162 0.0154 0.2668 0.0202 0.0177 0.0191 
PNPLA3 chr22 44319578 44319580 cg04692420 4.4558 9.8897 2.59E-09 6.54E-08 0.0190 0.0177 0.2655 0.0176 0.0160 0.0119 
CACNA1G chr17 48636899 48636901 cg24280645 5.1749 14.2419 3.39E-12 2.96E-10 0.0104 0.0103 0.2632 0.0100 0.0136 0.0100 
RRAGD chr6 90122153 90122155 cg09700990 2.7536 6.6853 1.35E-06 1.43E-05 0.0698 0.0683 0.2626 0.0398 0.0813 0.0374 
N/A chr4 24473412 24473414 cg14910061 3.2357 9.6013 4.31E-09 1.01E-07 0.0455 0.0449 0.2621 0.0556 0.0590 0.0561 
STK33 chr11 8615574 8615576 cg02541031 3.5111 6.2467 3.54E-06 3.28E-05 0.0371 0.0359 0.2620 0.0213 0.0359 0.0188 
STK33 chr11 8615693 8615695 cg00393798 3.4487 5.0336 5.69E-05 0.000353999 0.0379 0.0368 0.2575 0.0163 0.0217 0.0204 
TUBA3FP	
pseudogene chr22 21368673 21368675 cg23000550 4.6830 8.0497 7.99E-08 1.24E-06 0.0172 0.0143 0.2573 0.0142 0.0179 0.0100 
CCDC85A chr2 56410779 56410781 cg11572305 2.6956 7.9680 9.40E-08 1.43E-06 0.0713 0.0698 0.2573 0.0588 0.0790 0.0554 
CACNA2D2 chr3 50541010 50541012 cg20220436 3.3138 7.0507 6.19E-07 7.28E-06 0.0419 0.0409 0.2568 0.0293 0.0581 0.0141 
GALNT16 chr14 69727351 69727353 cg05157120 2.9376 7.3828 3.09E-07 3.99E-06 0.0568 0.0559 0.2561 0.0490 0.0610 0.0699 
NKX1-2 chr10 126138878 126138880 cg25531679 2.9972 9.6593 3.89E-09 9.24E-08 0.0531 0.0522 0.2533 0.0363 0.0563 0.0464 
TEPP chr16 58018971 58018973 cg05869503 5.1431 9.8084 2.98E-09 7.39E-08 0.0100 0.0100 0.2530 0.0165 0.0100 0.0108 
BOC chr3 112931125 112931127 cg06189303 4.3543 7.0673 5.98E-07 7.06E-06 0.0182 0.0178 0.2527 0.0217 0.0175 0.0132 
B4GALNT1 chr12 58026475 58026477 cg21818749 4.9934 10.6400 7.19E-10 2.22E-08 0.0111 0.0111 0.2517 0.0342 0.0107 0.0100 
SCUBE2 chr11 9113369 9113371 cg02783889 4.0217 9.7544 3.28E-09 8.01E-08 0.0229 0.0222 0.2474 0.0300 0.0265 0.0151 
ZNF599 chr19 35263966 35263968 cg00259785 3.4955 6.6676 1.41E-06 1.48E-05 0.0334 0.0331 0.2455 0.0360 0.0474 0.0324 
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LRRC43 chr12 122667626 122667628 cg21176475 3.6331 6.1937 3.99E-06 3.64E-05 0.0304 0.0296 0.2451 0.0275 0.0241 0.0308 
SMAD9 chr13 37494041 37494043 cg03754180 2.8654 6.0744 5.21E-06 4.57E-05 0.0566 0.0548 0.2424 0.0540 0.0561 0.0437 
RPL7P44	
pseudogene chr13 77554506 77554508 cg25163979 3.4808 8.4202 3.87E-08 6.61E-07 0.0335 0.0326 0.2408 0.0535 0.0514 0.0260 
PLXND1 chr3 129324500 129324502 cg01060026 4.8684 8.6660 2.41E-08 4.41E-07 0.0115 0.0113 0.2388 0.0208 0.0100 0.0111 
MAST4 chr5 65893335 65893337 cg26172694 5.0263 8.8942 1.57E-08 3.06E-07 0.0100 0.0100 0.2377 0.0109 0.0103 0.0100 
PCLO chr7 82792410 82792412 cg06129054 3.9476 9.2851 7.62E-09 1.64E-07 0.0224 0.0217 0.2336 0.0373 0.0285 0.0252 
TOX2 chr20 42543406 42543408 cg23872756 4.3602 8.6709 2.39E-08 4.38E-07 0.0169 0.0159 0.2336 0.0144 0.0240 0.0113 
AKT3 chr1 244014034 244014036 cg16546309 3.0670 6.1218 4.68E-06 4.17E-05 0.0444 0.0435 0.2325 0.0210 0.0403 0.0192 
ABR chr17 1082704 1082706 cg07464092 3.6904 5.8202 9.24E-06 7.48E-05 0.0278 0.0262 0.2316 0.0170 0.0249 0.0254 
MYH10 chr17 8534125 8534127 cg01044722 4.8301 7.0756 5.88E-07 6.96E-06 0.0111 0.0110 0.2295 0.0100 0.0114 0.0107 
CR2 chr1 207627580 207627582 cg09936645 4.6799 7.0231 6.57E-07 7.67E-06 0.0140 0.0122 0.2285 0.0100 0.0104 0.0100 
ENO4 chr10 118608840 118608842 cg03871675 2.7984 11.7732 1.17E-10 4.92E-09 0.0534 0.0529 0.2268 0.0426 0.0462 0.0555 
N/A chr7 127807620 127807622 cg16511994 3.2933 7.0918 5.68E-07 6.76E-06 0.0370 0.0345 0.2248 0.0186 0.0316 0.0465 
LRRC43 chr12 122667955 122667957 cg26953749 3.0535 6.9742 7.29E-07 8.39E-06 0.0426 0.0419 0.2243 0.0403 0.0345 0.0442 
MKX chr10 28031329 28031331 cg04923620 2.3721 7.0465 6.25E-07 7.34E-06 0.0779 0.0765 0.2237 0.0610 0.0676 0.0728 
C9orf171 chr9 135285408 135285410 cg08987373 2.4646 7.2610 3.98E-07 4.97E-06 0.0710 0.0700 0.2235 0.0751 0.0696 0.0779 
DRD2 chr11 113346206 113346208 cg20007462 2.4898 12.3338 4.98E-11 2.46E-09 0.0682 0.0675 0.2215 0.0554 0.0716 0.0561 
MKX chr10 28031090 28031092 cg01424281 3.1190 6.0132 5.97E-06 5.15E-05 0.0412 0.0389 0.2211 0.0222 0.0195 0.0279 
NTRK1 chr1 156830079 156830081 cg03055346 3.3025 8.3070 4.82E-08 7.99E-07 0.0333 0.0328 0.2180 0.0261 0.0334 0.0213 
STK33 chr11 8615578 8615580 cg12675870 2.5914 5.0911 4.97E-05 0.000315326 0.0603 0.0588 0.2148 0.0294 0.0490 0.0455 
LMO2 chr11 33891204 33891206 cg03476291 2.2343 5.6539 1.35E-05 0.000103395 0.0825 0.0818 0.2136 0.0712 0.0786 0.0734 
PDE2A chr11 72353586 72353588 cg23186104 2.4587 6.0314 5.73E-06 4.97E-05 0.0678 0.0655 0.2125 0.0618 0.0802 0.0329 
STK33 chr11 8615505 8615507 cg08788717 4.8219 6.6270 1.54E-06 1.60E-05 0.0100 0.0100 0.2122 0.0100 0.0100 0.0100 
LRRC43 chr12 122667648 122667650 cg26211360 3.0302 7.0123 6.72E-07 7.82E-06 0.0416 0.0389 0.2094 0.0340 0.0443 0.0511 
STEAP1 chr7 89783611 89783613 cg05797929 4.2563 8.8284 1.78E-08 3.39E-07 0.0151 0.0147 0.2070 0.0134 0.0124 0.0118 
KLHL14 chr18 30351341 30351343 cg03513246 2.3861 5.5843 1.58E-05 0.000118681 0.0690 0.0673 0.2066 0.0567 0.0583 0.0689 
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Pan-cancer panel for mutational profiling. Samples were profiled across two 
separate runs, the first profiling 300 targets, the second including an 
additional 13 targets (total n=313, v2) as the panel was developed. ENST: 
Ensembl spliced transcript. 
  
Gene	 Ensembl	Reference	 Gene	
Ensembl	
Reference	
Cancer	genes	(full	length)	from	other	sources	including	Foundation	Medicine,	Illumina’s	TruSight				
			Tumor	Panel	and	TruSeq	Amplicon	
LRP2	 ENST00000263816	 CCND1	 ENST00000227507	
CDKN2A	(P16)	 ENST00000579755	 CCND2	 ENST00000261254	
RPA1	 ENST00000254719	 CCND3	 ENST00000372991	
BRCA1	 ENST00000357654	 CCNE1	 ENST00000262643	
BRCA2	 ENST00000544455	 CD79A	 ENST00000221972	
ATM	 ENST00000278616	 CD79B	 ENST00000392795	
PALB2	 ENST00000261584	 CDC73	 ENST00000367435	
DAXX	 ENST00000374542	 CDK12	 ENST00000447079	
ATRX	 ENST00000373344	 CDK4	 ENST00000257904	
NF1	 ENST00000358273	 CDK6	 ENST00000424848	
Ikaros/IKZF1	 ENST00000331340	 CDK8	 ENST00000381527	
WIF1	 ENST00000286574	 CDKN2B	 ENST00000276925	
SNIP1	 ENST00000296215	 CDKN2C	 ENST00000371761	
SMAD4	 ENST00000342988	 CEBPA	 ENST00000498907	
p53	 ENST00000269305	 CHEK1	 ENST00000534070	
MGMT	 ENST00000306010	 CHEK2	 ENST00000382580	
PTTG	 ENST00000393964	 CIC	 ENST00000575354	
EGF	 ENST00000265171	 CRKL	 ENST00000411769	
EGFR	 ENST00000275493	 CRLF2	 ENST00000381567	
BRAF	 ENST00000288602	 CTCF	 ENST00000264010	
HIF1	alpha	 ENST00000539097	 CTNNA1	 ENST00000302763	
bFGF/FGF2	 ENST00000264498	 DNMT3A	 ENST00000264709	
Ptd-FGFR4	 ENST00000292408	 DOT1L	 ENST00000398665	
E-cadherin/CDH1	 ENST00000261769	 EMSY/C11orf30	 ENST00000334736	
pNCAM	 NCAM1	 EMSY/C11orf30	 ENST00000263253	
MMP2	 ENST00000219070	 ERBB3	 ENST00000267101	
MMP9	 ENST00000372330	 ERG	 ENST00000417133	
NM23/NME2	 ENST00000393193	 ESR1	 ENST00000440973	
Hst/FGF4	 ENST00000168712	 EZH2	 ENST00000320356	
Topo	II	alpha/TOP2A	 ENST00000423485	 FAM123B	(WTX)/AMER1	 ENST00000330258	
Galectin	3/LGALS3	 ENST00000254301	 FAM46C	 ENST00000369448	
VEGF	 ENST00000372067	 FANCA	 ENST00000389301	
COX2/PTGS2	 ENST00000367468	 FANCC	 ENST00000289081	
AKT1	 ENST00000554581	 FANCD2	 ENST00000287647	
PTEN	 ENST00000371953	 FANCE	 ENST00000229769	
HER-2/ERBB2	 ENST00000406381	 FANCF	 ENST00000327470	
KRAS	 ENST00000256078	 FANCG	 ENST00000378643	
NRAS	 ENST00000369535	 FANCL	 ENST00000402135	
BCL2	 ENST00000398117	 FGF10	 ENST00000264664	
adamts6	 ENST00000381055	 FGF14	 ENST00000376131	
crmp1	 ENST00000324989	 FGF19	 ENST00000294312	
dcamkl3	 ENST00000416516	 FGF23	 ENST00000237837	
ask	 ENST00000265728	 FGF3	 ENST00000334134	
CCNB1	 ENST00000256442	 FGF6	 ENST00000228837	
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Gene	 Ensembl	Reference	 Gene	
Ensembl	
Reference	
AURKB	 ENST00000316199	 FLT1	 ENST00000282397	
CENPE	 ENST00000265148	 FLT4	 ENST00000261937	
HMGA1	 ENST00000447654	 GID4	(C17orf39)	 ENST00000268719	
HMGA2	 ENST00000403681	 GNA13	 ENST00000439174	
WNT4	 ENST00000290167	 GPR124	 ENST00000412232	
WNT9a	 ENST00000272164	 GRIN2A	 ENST00000396573	
ALK	 ENST00000389048	 GSK3B	 ENST00000316626	
APC	 ENST00000457016	 HGF	 ENST00000222390	
FBXW7	 ENST00000281708	 IDH2	 ENST00000330062	
FGFR2	 ENST00000358487	 IGF1R	 ENST00000268035	
FOXL2	 ENST00000330315	 IKBKE	 ENST00000367120	
GNAQ	 ENST00000286548	 IL7R	 ENST00000303115	
GNAS	 ENST00000371100	 INHBA	 ENST00000242208	
KIT	 ENST00000288135	 IRF4	 ENST00000380956	
MAPK2	 ENST00000215832	 IRS2	 ENST00000375856	
MET	 ENST00000318493	 JAK1	 ENST00000342505	
MSH6	 ENST00000234420	 KAT6A	 ENST00000396930	
PDGFRA	 ENST00000257290	 KDM5A	 ENST00000399788	
PIK3CA	 ENST00000263967	 KDM5C	 ENST00000375401	
SRC	 ENST00000373578	 KEAP1	 ENST00000171111	
STK11	 ENST00000326873	 KLHL6	 ENST00000341319	
ABL1	 ENST00000372348	 LRP1B	 ENST00000389484	
MLH1	 ENST00000231790	 MAP2K1	 ENST00000307102	
RET	(MEN2)	 ENST00000355710	 MAP2K2	 ENST00000262948	
ERBB4	 ENST00000342788	 MAP2K4	 ENST00000353533	
HNF1A	 ENST00000257555	 MAP3K1	 ENST00000399503	
MPL	 ENST00000372470	 MCL1	 ENST00000369026	
NOTCH1	 ENST00000277541	 MED12	 ENST00000374080	
SMARCB1	 ENST00000263121	 MEF2B	 ENST00000424583	
IDH1	 ENST00000415913	 MITF	 ENST00000352241	
NPM1	 ENST00000296930	 MLL2	 ENST00000301067	
SMO	 ENST00000249373	 MRE11A	 ENST00000323929	
JAK2	 ENST00000381652	 MSH2	 ENST00000233146	
JAK3	 ENST00000458235	 MUTYH	 ENST00000372098	
KDR	 ENST00000263923	 MYC	 ENST00000377970	
FLT3	 ENST00000241453	 MYCL1	 ENST00000397332	
VHL	 ENST00000256474	 MYCN	 ENST00000281043	
CSF1R	 ENST00000286301	 MYD88	 ENST00000417037	
GNA11	 ENST00000078429	 NF2	 ENST00000338641	
PTPN11	 ENST00000351677	 NFE2L2	 ENST00000397062	
RB1	 ENST00000267163	 NFKBIA	 ENST00000216797	
SMARCA4	 ENST00000429416	 NKX2-1	 ENST00000354822	
FOXA1	 ENST00000250448	 NOTCH2	 NOTCH2	
ASXL1	 ENST00000375687	 NTRK1	 ENST00000524377	
CYP2D6	 ENST00000360608	 NTRK2	 ENST00000376214	
DDR2	 ENST00000367922	 NTRK3	 ENST00000360948	
KDM6A	 ENST00000377967	 NUP93	 ENST00000308159	
NKX3-1	 ENST00000380871	 PAK3	 ENST00000360648	
ZFHX3	 ENST00000268489	 PBRM1	 ENST00000394830	
JUN	 ENST00000371222	 PDGFRB	 ENST00000261799	
MTOR	 ENST00000361445	 PDK1	 ENST00000410055	
RAF1	 ENST00000251849	 PIK3CG	 ENST00000359195	
GATA1	 ENST00000376670	 PIK3R1	 ENST00000521381	
EPHA3	 ENST00000336596	 PIK3R2	 PIK3R2	
CREBBP	 ENST00000262367	 PPP2R1A	 ENST00000322088	
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Gene	 Ensembl	Reference	 Gene	
Ensembl	
Reference	
ARID1A	 ENST00000324856	 PRDM1	 ENST00000369096	
SPOP	 ENST00000393331	 PRKDC	 ENST00000314191	
AR	 ENST00000374690	 PTCH1	 ENST00000331920	
MDM2	 ENST00000462284	 RAD50	 ENST00000265335	
UGT1A1	 ENST00000305208	 RAD51	 ENST00000382643	
EPHB1	 ENST00000398015	 RARA	 ENST00000254066	
MLL1	 ENST00000534358	 RICTOR	 ENST00000357387	
FGFR3	 ENST00000340107	 RNF43	 ENST00000584437	
CHD1	 ENST00000284049	 RPTOR	 ENST00000306801	
MDM4	 ENST00000367182	 RUNX1	 ENST00000300305	
EPHA5	 ENST00000273854	 SETD2	 ENST00000409792	
MLL3	 ENST00000262189	 SF3B1	 ENST00000335508	
GATA2	 ENST00000341105	 SMAD2	 ENST00000262160	
GATA3	 ENST00000379328	 SOCS1	 ENST00000332029	
HRAS	 ENST00000451590	 SOX10	 ENST00000396884	
AKT2	 ENST00000424901	 SPEN	 ENST00000375759	
AKT3	 ENST00000263826	 STAG2	 ENST00000218089	
ARAF	 ENST00000377045	 STAT4	 ENST00000392320	
ARFRP1	 ENST00000359715	 SUFU	 ENST00000369902	
ARID2	 ENST00000334344	 TET2	 ENST00000540549	
ATR	 ENST00000350721	 TGFBR2	 ENST00000359013	
AURKA	 ENST00000395909	 TNFAIP3	 ENST00000237289	
AXL	 ENST00000301178	 TNFRSF14	 ENST00000355716	
BAP1	 ENST00000460680	 TOP1	 ENST00000361337	
BARD1	 ENST00000260947	 TSC1	 ENST00000298552	
BCL2L2	 ENST00000250405	 TSC2	 ENST00000219476	
BCL6	 ENST00000406870	 TSHR	 ENST00000541158	
BCOR	 ENST00000342274	 WISP3	 WISP3	
BCORL1	 ENST00000540052	 WT1	 ENST00000332351	
BLM	 ENST00000355112	 XPO1	 ENST00000406957	
BRIP1	 ENST00000259008	 ZNF217	 ENST00000371471	
BTK	 ENST00000308731	 ZNF703	 ENST00000331569	
CARD11	 ENST00000396946	 FBX4	 ENST00000281623	
CBFB	 ENST00000412916	 SOS1	 ENST00000402219	
CBL	 ENST00000264033	 	 	
Familial	pituitary	genes	
AIP	 ENST00000279146	 SDHA	 ENST00000264932	
MEN1	 ENST00000337652	 SDHB	 ENST00000375499	
p27	(KIP1)/CDKN1B	 ENST00000228872	 SDHC	 ENST00000367975	
PRKAR1A	(Carney	
Complex)	 ENST00000536854	 SDHD	 ENST00000375549	
Pituitary	development	(embryonic)	genes	
PIT1	 ENST00000350375	 PAX7	 ENST00000420770	
LHX2	 ENST00000373615	 FGF8	 ENST00000320185	
LHX3	 ENST00000371746	 FGFR1	 ENST00000447712	
LHX4	 ENST00000263726	 BMP4	 ENST00000245451	
SOX2	 ENST00000325404	 BMP8	 ENST00000372827	
SOX3	 ENST00000370536	 SHH	 ENST00000297261	
SOX9	 ENST00000245479	 GLI2	 ENST00000452319	
β-catenin/CTNNB1	 ENST00000349496	 TCF7L1	 ENST00000282111	
HESX1	 ENST00000295934	 SIX6	 ENST00000327720	
OTX2	 ENST00000339475	 SIX3	 ENST00000260653	
PROP1	 ENST00000308304	 KAL1	 ENST00000262648	
PAX5	 ENST00000358127	 CHD7	 ENST00000423902	
PAX6	 ENST00000419022	 	 	
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Gene	 Ensembl	Reference	 Gene	
Ensembl	
Reference	
Additional	genes	to	screen	in	Pan-cancer	panel	v2	
MCC		 ENST00000408903	 RYR1	 ENST00000359596	
JRK		 ENST00000507178	 CACNA1S	 ENST00000362061	
CCAR2		 ENST00000308511	 CDKN2A	(P14ARF	isoform)	 ENST00000361570	
SIRT1		 ENST00000212015	 DDX3X	 ENST00000399959	
BCL9		 ENST00000234739	 RAC1	 ENST00000356142	
PMS2		 ENST00000265849	 TERT	incl.	promoter	region	 ENST00000310581	
EPCAM		 ENST00000263735	 	 	
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Original Article
Changes in gene expression of neo-squamous
mucosa after endoscopic treatment for
dysplastic Barrett’s esophagus and
intramucosal adenocarcinoma
Angelique Levert-Mignon1, Michael J Bourke2, Sarah J Lord1,3,
Andrew C Taylor4, Antony R Wettstein5, Melanie Edwards3,6,
Natalia K Botelho1, Rebecca Sonson2, Chatura Jayasekera4, Oliver M Fisher1,
Melissa L Thomas1,3, Finlay Macrae7,8, Damian J Hussey9,10, David I Watson9,10
and Reginald V Lord1,3,5
Abstract
Background: Endoscopic therapy, including by radiofrequency ablation (RFA) or endoscopic mucosal resection (EMR), is first
line treatment for Barrett’s esophagus (BE) with high-grade dysplasia (HGD) or intramucosal cancer (IMC) and may be
appropriate for some patients with low-grade dysplasia (LGD).
Objective: The purpose of this study was to investigate the molecular effects of endotherapy.
Methods: mRNA expression of 16 genes significantly associated with different BE stages was measured in paired pre-
treatment BE tissues and post-treatment neo-squamous biopsies from 36 patients treated by RFA (19 patients, 3 IMC, 4 HGD,
12 LGD) or EMR (17 patients, 4 IMC, 13 HGD). EMR was performed prior to RFA in eight patients. Normal squamous
esophageal tissues were from 20 control individuals.
Results: Endoscopic therapy resulted in significant change towards the normal squamous expression profile for all genes.
The neo-squamous expression profile was significantly different to the normal control profile for 11 of 16 genes.
Conclusion: Endotherapy results in marked changes in mRNA expression, with replacement of the disordered BE dysplasia
or IMC profile with a more ‘‘normal’’ profile. The neo-squamous mucosa was significantly different to the normal control
squamous mucosa for most genes. The significance of this finding is uncertain but it may support continued endoscopic
surveillance after successful endotherapy.
Keywords
Barrett’s esophagus, high-grade dysplasia, esophageal adenocarcinoma, esophageal neoplasms, radiofrequency ablation,
endoscopic mucosal resection
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Introduction
Barrett’s esophagus (BE) is a premalignant condition in
which the normal squamous lining of the lower
esophagus is replaced by an intestinal metaplastic
(IM) columnar epithelium in response to prolonged
severe gastro-esophageal reﬂux. BE is the major
risk factor for esophageal adenocarcinoma (EAC),
a cancer with a high case fatality ratio and a rapidly
rising incidence.1 The progression from normal
esophagus to BE and adenocarcinoma is thought
to involve a complex, multistep process, from
IM to low-grade dysplasia (LGD), high-grade dyspla-
sia (HGD), early intramucosal cancer (IMC), to inva-
sive EAC.
Intervention is recommended for patients with HGD
or IMC, based on the estimated 7–19% yearly risk of
EAC developing in patients with HGD.1 Endoscopic
therapy has replaced esophagectomy as the preferred
ﬁrst-line treatment for most patients with HGD/IMC,
as it avoids the morbidity and mortality associated with
esophagectomy, preserves the esophagus, and has
equivalent survival outcomes.2,3 Guidelines1,4,5 have
recommended endoscopic mucosal resection (EMR)
for visible lesions and radiofrequency ablation (RFA)
of ﬂat mucosae, including after EMR. Complete
Barrett’s excision (CBE) endoscopic resection is an
alternative for shorter Barrett’s segments.2 More
recently, endoscopic therapy has been recommended
for patients with persistent and conﬁrmed (by two
expert gastrointestinal pathologists, in two or more
endoscopies) multifocal LGD.6,7
Eradication of cancer, dysplasia, and all BE is
reported in up to 94% of patients treated with RFA
or EMR,3,8–10 The risk of EAC development is also
signiﬁcantly reduced.11 The rate of progression to
EAC was one per 181 patient-years (0.55%/patient-
years) in a multicenter US study, at three years after
RFA or RFA and EMR combined treatment for dys-
plastic BE.8 In another study, the cancer-related mor-
tality rate was 0.2% in EMR treated patients with IMC
after ﬁve years.3
Although RFA and EMR have proven to be safe
and eﬀective in at least the medium term,9,12,13 there
are reports of recurrence.13 The durability over dec-
ades, which is relevant for this disease, and underlying
molecular eﬀect, remains unknown. It has previously
been shown that the altered mRNA expression of cer-
tain genes is associated with diﬀerent stages of the
Barrett’s to adenocarcinoma sequence.14 By comparing
gene expression in the tissue biopsies of dysplastic
Barrett’s or IMC mucosa before endoscopic therapy
and in the normal-appearing neo-squamous mucosa
post-treatment, we evaluated the molecular eﬀect of
endoscopic treatment.
Methods
Patients
Patients in the treatment group undergoing RFA,
EMR, or combination of RFA plus EMR for the treat-
ment of histopathologically conﬁrmed BE with dyspla-
sia or IMC were invited to participate in this
prospective multi-center study. The treatment selected
was at the discretion of the endoscopist. BE length was
recorded using the Prague classiﬁcation. Post-treatment
biopsies were taken from the macroscopically normal
appearing neo-squamous mucosa from the same area as
the pre-treatment BE, as measured by distance from the
incisors.
A control group consisted of individuals with the
typical reﬂux symptoms of heartburn or regurgitation
but without a history of current or past macroscopic
reﬂux esophagitis (RE) or BE (non RE/BE). Inclusion
criteria for both groups were age 18 years and ability
to give informed consent. Approval for the study was
obtained from the Human Research Ethics Committee
at each center and participants provided written
informed consent.
Endoscopic treatment
Radiofrequency ablation. After removal of visible lesions
where present by EMR, the abnormal mucosa was
ablated by RFA using either a circumferential balloon
catheter or a ﬂat plate device (BARRx Medical/
Covidien, Inc., Sunnyvale California, USA). The radio-
frequency energy was delivered to the Barrett’s mucosa
(12 J/cm2, 40W/cm2) twice in sequence. The device was
removed and cleaned between applications, and the
ablated epithelium was cleaned by irrigation or
scrapped oﬀ with the edge of the device.
Endoscopic mucosal resection. The irregular mucosa was
resected using the Duette multiband mucosectomy
system (Cook Medical, Bloomington, Indiana, USA).
The mucosa is lifted by aspiration, ligated to form a
pseudopolyp, and resected by electrocautery, as
described previously.10 Both RFA and EMR were per-
formed in single or multiple sessions, depending on the
extent of BE.
Tissue specimens
From review of the histopathological reports of routine
hematoxylin and eosin-stained (H&E) tissue sections,
archival formalin-ﬁxed, paraﬃn-embedded (FFPE)
esophageal tissue samples were obtained from the
study centers. The worst histopathological grade of
BE/IMC was selected for the pre-treatment dysplastic
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BE or IMC study tissues. The post-treatment samples
were matched neo-squamous mucosa collected from the
same area as the previous BE mucosa.
RNA isolation
Two 7 mm unstained sections cut from each FFPE
sample block were used for RNA extraction. At least
55 ng total RNA was isolated by a column-based puri-
ﬁcation method using the Ambion RecoverAll Total
Nucleic Acid Isolation kit for FFPE, Cat # AM1975
(Life Technologies, Carlsbad, California, USA) or the
QIAGEN RNeasy FFPE kit, Cat # 744404 (Qiagen,
Valencia, California, USA), according to the manufac-
turer’s protocol. RNA purity and concentration was
measured using a NanoPhotometer (Implen, Westlake
Village, California, USA).
mRNA quantification by multiplex tandem
polymerase chain reaction (MT-PCR)
Sixteen genes signiﬁcantly diﬀerentially expressed at the
mRNA level in BE and EAC compared to normal
squamous esophagus were selected from previous stu-
dies.14,15 Full details of the MT-PCR methods were
reported previously.14 In brief, mRNA expression
levels of the genes of interest and the internal reference
gene, NONO (‘‘non-POU domain containing, octamer-
binding’’; NM_007363), were measured in duplicate
with pre- and post-treatment tissues assessed simultan-
eously. MT-PCR was performed using a real-time
quantitative PCR system (Rotor-Gene RG6000,
Qiagen, Valencia, California, USA). Primers for study
genes and NONO were designed using Primer 3 soft-
ware; the size of the ‘‘inner’’ amplicon was restricted to
70–90 bp and the ‘‘outer’’ amplicon to <150 bp. All
primer pairs spanned an intron-exon boundary and
the products were evaluated on a Bioanalyser DNA
separation chip for the correct size (Agilent, Santa
Clara, California, USA).
MT-PCR was performed in two steps. In the ﬁrst
step the RNA was converted into cDNA and ampliﬁed
using multiplexed gene speciﬁc primers (‘‘outer’’ pri-
mers). In the second step the product from step one
was used as a template for PCRs in a 72-well disc con-
taining lyophilized single-gene primers (‘‘inner’’ pri-
mers) in each well. ‘‘Outer’’ primer mix was prepared
by adding to one single tube 1 ml of each primer (for-
ward and reverse) of all genes to 53 ml RNAse free
diethylpyrocarbonate (DEPC) water to a total 125 ml,
and they were lyophilized in 0.2ml tubes. ‘‘Inner’’
primer mixes were prepared in diﬀerent tubes (for
each gene) by adding 4 ml of each primer (forward
and reverse) into 424 ml of DEPC water.
Statistical analysis
The mRNA relative expression values were measured
as the ratio of the absolute expression values of each
target gene to the expression of the reference gene
NONO, set to a ﬁxed level (10,000). Gene expression
values were not normally distributed, and therefore are
summarized as medians with the 25th–75th interquar-
tile range (IQR).
To identify genes diﬀerentially expressed post-
treatment compared to pre-treatment values, unpaired
(all subjects) and paired (subset of subjects with pre-
and post-treatment samples) analyses were performed
using the Wilcoxon rank-sum and signed rank test
respectively. The Wilcoxon rank-sum test was also
used to compare gene expression in normal squamous
control versus post-treatment neo-squamous. Fold
change was calculated to describe the magnitude of
the change in gene expression levels pre- and post-treat-
ment. All data analyses were performed using the SAS
software (version 9.3).
Results
As shown in Table 1, 36 endotherapy patients (19 RFA,
17 EMR) and 20 control individuals were enrolled in
the study. Most patients in both groups were male. In
the RFA group, eight patients (42%) underwent focal
EMR before RFA to remove nodular lesions contain-
ing IMC (three patients), HGD (four patients) or LGD
(one patient). The remaining 11 patients were treated
by RFA alone. In the EMR treatment group, ﬁve
patients had CBE with complete eradication of BE in
a single session; the remaining patients had stepwise
EMR over more than one treatment session. Table 1
shows that EMR was performed for HGD or IMC,
whereas the patients treated by RFA mostly (63%)
had LGD in the untreated or post-EMR BE.
Maximal BE length was 6 cm pre-RFA and 9 cm pre-
EMR, with a median of 2 cm for both treatment
groups, and RFA or EMR was performed in up to
three sessions at 2–3 month intervals. The median inter-
val between the last treatment session and the post-
treatment neo-squamous biopsy was three months for
RFA and six months for EMR.
At the time of neo-squamous biopsy for this study,
17 of 19 (89%) RFA treated patients and 14 of 17
(82%) EMR patients had complete eradication of dys-
plasia; with complete eradication of IM in 6/19 (32%)
RFA and 10/17 (59%) EMR patients. Subsequent to
the post-treatment study biopsy, dysplasia was eradi-
cated in all patients apart from one EMR patient who
chose not to have further treatment because of
advanced age, and IM has been eradicated in 58%
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and 88% of RFA and EMR patients, respectively.
There was no sub-squamous BE in any of the neo-
squamous or normal squamous tissues.
Twenty individuals were enrolled in the control
group. Normal esophagus biopsies were obtained
from the distal esophagus in 11 individuals and from
the proximal (25 cm from incisors) esophagus in nine
individuals.
Table 2 shows unpaired relative mRNA expression
values for the 16 study genes in dysplastic Barrett’s or
Table 2. Difference in gene expression, pre- versus post-endoscopic treatment
Gene
Pre-treatment BE Post-treatment neo-squamous
p-valuea Fold changen Median expression (IQR) n Median expression (IQR)
Downregulated
TSPAN8 34 236.5 (8.9–2075.2) 25 3.8 (0.3–16.3) <0.0001 –62
TSPAN1 36 13,219.4 (19.8–32,268.7) 33 226.6 (1.5–574.8) 0.003 –58
CTSE 36 15,185.0 (8383.0–23,798.0) 18 402.9 (66.9–5434.8) 0.0001 –38
MMP7 31 355.2 (127.2–556.7) 25 17.4 (4.5–73.7) <0.0001 –20
MMP1 34 21.1 (9.2–92.3) 26 3.1 (1.1–5.7) <0.0001 –7
COX-2 36 219.9 (92.7–559.3) 34 49.0 (19.8–159.2) 0.0005 –5
ODC1 36 4780.1 (3005.0–5798.1) 36 1434.9 (1044.2–2109.0) <0.0001 –3
CD151 36 1657.6 (1241.8–2212.7) 33 574.8 (391.1–872.4) <0.0001 –3
SPARC 36 15,177.1 (13,566.4–36,100.0) 36 5180.1 (4206.4–11,393.2) <0.0001 –3
RARA 30 223.1 (131.3–283.7) 24 95.4 (69.1–154.5) 0.0004 –2
Upregulated
ADH7 36 43.5 (11.3–172.6) 36 556.7 (294.4–902.8) <0.0001 13
KRT4 36 32,854.0 (12,736.1–109,360.5) 36 251,647.6 (134,571.2–434,243.6) <0.0001 8
RARG 33 108.3 (55.2–212.6) 33 674.9 (430.1–930.3) <0.0001 6
SERPINB2 33 53.5 (6.2–98.4) 36 261.9 (110.2–1349.9) <0.0001 5
PITX1 36 3252.2 (901.4–11,746.6) 36 10,505.4 (6280.0–80,569.9) <0.0001 3
TP73L 33 8.1 (4.2–27.3) 35 23.0 (8.1–58.9) 0.02 3
IQR: interquartile range, aWilcoxon test.
Table 1. Patients, pathology and treatment data
RFA
(n¼ 19)
EMR
(n¼ 17)
No BE normal controls
(n¼ 20)
Sex, n (%)
Males 17 (90%) 15 (88%) 17 (85%)
Females 2 (10%) 2 (12%) 3 (15%)
Age, years, median (range) 69 (52–84) 62 (31–82) 55 (33–77)
Length of BE (Prague Classification), cm, median (range)
Circumferential (C) 0 (0–3)a 0 (0–5)
Maximal (M) 2 (0.5–6)a 2 (0.5–9)
Histological grade pre-treatment, n (%)
Low-grade dysplasia 12 (63%)a 0 (0%)
High-grade dysplasia 4 (21%)a 14 (76%)
Intramucosal cancer 3 (16%)a 4 (24%)
Median time, last treatment session to post-treatment
biopsy (range), months
3 (1–15) 6 (1–57)
No. of treatment sessions, median (range) 2 (1–3) 2 (1–3)
BE: Barrett’s esophagus; EMR: endoscopic mucosal resection; RFA: radiofrequency ablation.
aPre-RFA, post-EMR wherever applicable.
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IMC pre-endoscopic treatment tissues and matched
neo-squamous tissue samples post-treatment in the 36
patients. Endoscopic therapy resulted in a highly sig-
niﬁcant change in median values for all 16 genes
(Table 2). This was veriﬁed by paired analysis for
patients with acceptable PCR results pre- and post
endotherapy and the changes remained signiﬁcant for
all genes (data not shown). Ten genes were down-regu-
lated and six genes were up-regulated in the normal
neo-squamous mucosa after endoscopic treatment; all
changes were from a Barrett’s-associated proﬁle
towards a normal squamous epithelium proﬁle.
Table 3 shows the relative gene expression levels in
the neo-squamous epithelium compared to true normal
squamous tissue from the 20 control individuals with
gastro-esophageal reﬂux disease symptoms, but no RE/
BE. The neo-squamous mucosa was signiﬁcantly diﬀer-
ent to true normal squamous mucosa for 11/16 (69%)
genes. This diﬀerence was most marked for CD151,
SPARC and TP73L (p< 0.0001, shown graphically in
Figure 1). Figure 1 also shows data for three genes
with no signiﬁcant diﬀerence between neo-squamous
esophagus and true normal esophagus.
Comparing neo-squamous biopsies taken less than
three months post-treatment versus more than three
months post-treatment, there was no signiﬁcant dif-
ference found except that SPARC mRNA expression
was signiﬁcantly lower in the greater than three
months follow-up tissue cohort (p¼ 0.0159; data no
shown)
Discussion
This study shows that there are marked changes in the
relative mRNA expression levels of selected genes after
RFA or EMR for the treatment of dysplastic BE or
IMC. These changes are, as expected, towards a more
‘‘normal’’ squamous esophagus proﬁle from non-BE
patients. The mRNA expression in the neo-squamous
mucosa post-treatment is not the same as found in the
normal squamous mucosa, however, despite the neo-
squamous mucosa being histopathologically indistin-
guishable from normal squamous epithelia.
Our ﬁndings indicate molecular as well as macro-
and microscopic reversal of BE by endoscopic therapy.
The expression of genes which have previously shown
to be increased in a stepwise fashion from normal
squamous esophagus to BE to EAC are signiﬁcantly
down-regulated by endotherapy, whereas those genes
underexpressed in BE and EAC compared to normal
mucosa are increased in expression after endotherapy.
Although our study is the ﬁrst to report mRNA expres-
sion changes, previous studies using diﬀerent labora-
tory approaches have been reported.16 Pouw et al.
found no abnormal immunohistochemical (IHC)
expression for Ki-67 and p53, and no numerical
chromosomal abnormalities in the neo-squamous
epithelia of 22 patients successfully treated with RFA
for HGD or IMC.17 Most of the patients (73%) in that
study were treated with EMR before RFA for visible
lesions, and salvage EMR was used on 18% of the
Table 3. Difference in gene expression: normal squamous versus neo-squamous
Gene
Normal squamous Neo-squamous
p-valuean Median expression (IQR) n Median expression (IQR)
CD151 20 40.0 (12.4–141.3) 33 574.8 (391.1–872.4) <0.0001
SPARC 20 1345.7 (259.7–3051.6) 36 5180.1 (4206.4–11393.2) <0.0001
TP73L 20 246.6 (206.8–356.9) 35 23.0 (8.1–58.9) <0.0001
PITX1 20 4458.0 (2770.1–8831.0) 36 10,505.4 (6280.0–80,569.9) 0.0002
ADH7 20 1370.1 (598.7–2572.7) 36 556.7 (294.4–902.8) 0.001
RARA 20 40.1 (14.3–90.9) 24 95.4 (69.1–154.5) 0.009
MMP7 20 100.3 (33.7–199.2) 25 17.4 (4.5–73.7) 0.0095
CTSE 12 37.8 (8.0–132.2) 18 402.9 (66.9–5434.8) 0.01
SERPINB2 20 1395.4 (996.0–2953.7) 36 261.9 (110.2–1349.9) 0.01
RARG 20 238.8 (153.5–598.5) 33 674.9 (430.6–930.3) 0.02
MMP1 17 8.6 (2.7–34.1) 26 3.1 (1.1–5.7) 0.02
TSPAN1 16 29.3 (5.2–60.1) 33 226.6 (1.5–574.8) 0.25
TSPAN8 10 8.8 (5.4–15.4) 25 3.8 (0.3–16.3) 0.32
ODC1 20 1370.1 (310.0–2147.3) 36 1434.9 (1044.2–2109.0) 0.33
KRT4 19 281,526 (9455–737,308) 36 251,647.6 (134,571.2–434,243.5) 0.41
COX-2 20 51.9 (21.1–87.0) 34 49.0 (19.8–159.2) 0.73
IQR: interquartile range, aWilcoxon test.
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patients after ﬁve RFA sessions to achieve complete
eradication of BE. Krishnan et al., using IHC and
Western blot methods, showed similar b-catenin
expression in the neo-squamous and normal squamous
mucosa at 12 months after successful RFA.18 Other
studies have shown persistent genetic abnormalities in
remnant BE after photodynamic therapy (PDT) or
argon plasma coagulation (APC).19–21
Comparing the gene expression proﬁle of the neo-
squamous mucosa with the normal squamous mucosa
from individuals with typical reﬂux symptoms but no
history of RE or BE, we found a signiﬁcant diﬀerence
for most genes. The relevance of this ﬁnding is unclear;
we discuss three possible interpretations here. One
interpretation is that this reﬂects ongoing wound heal-
ing, although only a minority of our selected genes
(such as COX-2, matrix metallopeptidases 1 and 7) is
clearly involved in wound healing. There was also no
important change in the ﬁndings when we compared
early post-treatment results (<3 months after endother-
apy) with later post-treatment results (>3 months), sug-
gesting that wound healing does not explain our results.
A second interpretation is that the diﬀerences in gene
expression between the neosquamous and the normal
squamous mucosa reﬂects a degree of molecular abnor-
mality that is found even in the squamous mucosa in
patients with BE. Brabender et al., for example, found
a widespread carcinogenic ﬁeld eﬀect, measured in RNA
quantiﬁcation as in our study, in the normal squamous
esophageal epithelia in patients with either BE or
Barrett’s adenocarcinoma.22 In this respect the ideal
design for our study would have included normal pre-
treatment squamous esophagus tissues from the patients
with BE, but we lacked the biopsy samples to do this.
A third interpretation is that patients with dysplastic
BE/IMC retain some risk of disease persistence or
recurrence, even after successful endoscopic therapy.
This further suggests that ongoing surveillance after
successful endotherapy is warranted, especially in
younger patients. In keeping with this, Lewis et al.
found raised cell proliferation (Ki-67) and COX-2 pro-
tein expression by IHC in buried subsquamous glands
after APC. They interpreted this ﬁnding as making it
unclear whether the risk of cancer is adequately reduced
by ablation, with potential implications for patient
follow up.23 Similarly, Dijckmeester et al. found signiﬁ-
cantly higher expression of the microRNA-143 in neo-
squamous after APC compared to normal squamous
from control subjects, although expression of CK-8,
CK-14, and microRNA-205 was similar.24
Clinical studies also suggest the need for ongoing sur-
veillance and optimal reﬂux control after endoscopic
therapy. Disease recurrence has been reported after com-
plete eradication of Barrett’s at variable rates. In a
Netherlands cohort study, IM was present in 10% of
patients treated with RFA after EMR for visible nodules
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Figure 1. Endoscopic therapy resulted in significant changes in relative mRNA expression levels pre- and post-treatment for Barrett’s
esophagus (BE) with dysplasia or intramucosal cancer, compared to true normal squamous mucosa from control individuals with reflux
symptoms but no BE. (a) Neo-squamous mucosa is significantly different to normal (p< 0.0001). (b) Neo-squamous mucosa difference is
not significant (ns) compared to normal. Box plots show median (heavily longitudinal bar) and interquartile range (box).
EndoRx: Endotherapy; NSE: Neo-squamous epithelium.
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at ﬁve years after treatment.25 Others report worse out-
comes, including 33% BE recurrence rates at two-year
follow-up after EMR and RFA,12 5% recurrence of IM
per year after RFA,26 and 14.5% recurrence of neoplasia
(HGD or EAC) after approximately two years for
EMR.3 Cancer can recur even ﬁve or more years after
successful endotherapy.3 There are several clinical fac-
tors associated with worse response to endotherapy,
including ongoing acid reﬂux exposure (which is usual
in BE patients treated by PPIs), longer Barrett’s seg-
ment, and a longer history of dysplastic BE.27–29
Genetic biomarkers could play a role in predicting
response to endoscopic treatment.16 A lower response
to endoscopic treatment has been reported in patients
with multiple chromosomal gains (gain of two or more
locus-speciﬁc probes to MYC, p16, HER-2/neu and
ZNF217, evaluated by ﬂuorescence in situ hybridiza-
tion (FISH)) in the dysplastic Barrett’s epithelium.30
After PDT, p16 allelic loss, also detected by FISH,
was found to predict loss of dysplasia.31
Our study was prospective, used biopsies evaluated
by H&E (rather than an adjacent biopsy with unknown
pathology), and by simultaneously running pre- and
post- treatment biopsies we limited the possibility of a
‘‘batch eﬀect’’. Despite these methodological advan-
tages, we acknowledge some limitations. Some neo-
squamous biopsies were obtained pre-complete BE
eradication. Consequently, it is possible (but unknown)
if the remnant BE may eﬀect the gene expression of the
neo-squamous mucosa. Our normal squamous samples
also include biopsies at various levels above the gastro-
esophageal junction, which has been reported to inﬂu-
ence gene expression,32 although there was no
signiﬁcant diﬀerence in expression in distal compared
to proximal esophagus biopsies in our study (data not
shown). We did not compare the mRNA expression
changes after EMR compared to RFA because of the
small number of patients in each group and the diﬀer-
ence in severity of Barrett’s disease: most of the patients
undergoing EMR had IMC or HGD whereas patients
undergoing RFA had mostly LGD (after EMR treat-
ment of IMC or HGD in some cases).
Our study found that the abnormal gene expression
present at baseline in patients with dysplastic Barrett’s
or IMC is altered after endotherapy towards a normal
esophagus expression proﬁle. This alteration was highly
signiﬁcant for all genes, indicating that the neo-
squamous mucosa harbors a very greatly reduced
malignant risk compared to untreated Barrett’s disease.
This is consistent with the normal histopathological
appearance of the neo-squamous mucosa and the reas-
suring results of clinical studies regarding the long-term
cancer risk after endoscopic therapy. The neo-
squamous mucosa was signiﬁcantly diﬀerent to the
normal control squamous mucosa for most genes but
the signiﬁcance of this ﬁnding is uncertain. One inter-
pretation is that it suggests that attention should be
given to careful inspection of the neo-squamous
mucosa as well as, of course, any persistent BE areas
after endotherapy. This could include taking random
biopsies from a normal appearing neo-squamous
mucosa; although the beneﬁt of this is disputed it can
rarely uncover buried (sub-squamous) BE or even
adenocarcinoma.17,33–35 Altogether, we interpret our
results as providing some support for long-term endo-
scopic surveillance after endoscopic treatment of BE/
IMC, even if the BE has been completely eradicated, we
acknowledge that more extensive studies with longer
follow-up periods are needed to more thoroughly
evaluate the neo-squamous mucosa.
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ABSTRACT
Background. Cathepsin E (CTSE), an aspartic proteinase,
is differentially expressed in the metaplasia–dysplasia–
neoplasia sequence of gastric and colon cancer. We eval-
uated CTSE in Barrett’s esophagus (BE) and cancer
because increased CTSE levels are linked to improved
survival in several cancers, and other cathepsins are up-
regulated in BE and esophageal adenocarcinoma (EAC).
Methods. A total of 273 pretreatment tissues from 199
patients were analyzed [31 normal squamous esophagus (NE),
29 BE intestinal metaplasia, 31 BE with dysplasia (BE/D), 108
EAC]. CTSE relative mRNA expression was measured by
real-time polymerase chain reaction, and protein expression
was measured by immunohistochemistry. CTSE serum levels
were determined by enzyme-linked immunosorbent assay.
Results. Median CTSE mRNA expression levels were
C1,000-fold higher in BE/intestinal metaplasia and BE/D
compared to NE. CTSE levels were significantly lower in
EAC compared to BE/intestinal metaplasia and BE/D, but
significantly higher than NE levels. A similar expression
pattern was present in immunohistochemistry, with absent
staining in NE, intense staining in intestinal metaplasia and
dysplasia, and less intense EAC staining. CTSE serum
analysis did not discriminate patient groups. In a uni- and
multivariable Cox proportional hazards model, CTSE
expression was not significantly associated with survival in
patients with EAC, although CTSE expression above the
25th percentile was associated with a 41 % relative risk
reduction for death (hazard ratio 0.59, 95 % confidence
interval 0.27–1.26, p = 0.17).
Conclusions. CTSE mRNA expression is up-regulated
more than any known gene in Barrett intestinal metaplasia
and dysplasia tissues. Protein expression is similarly highly
intense in intestinal metaplasia and dysplasia tissues.
Barrett’s esophagus (BE) is the condition in which the
normal distal squamous lining of the esophagus is replaced
by specialized metaplastic columnar epithelium.1 BE is the
strongest recognized risk factor for esophageal adenocar-
cinoma (EAC), a highly malignant cancer with an
unparalleled 6-fold increase in incidence over the past three
decades.2 Less than 5 % of patients presenting with EAC
have a previous diagnosis of BE because they have not
undergone endoscopy, but even for patients under surveil-
lance, there are significant problems, including sampling
error and difficulties with the histopathologic interpretation
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of degree of dysplasia, and EAC may develop between
endoscopies.3–5
These problems have stimulated the search for clinically
relevant biological markers, but so far, no biomarkers have
proven sufficient for routine clinical practice.6,7 Because of
the problems with endoscopic diagnosis and surveillance, it
is worth exploring non endoscopic, cheaper, and less-
invasive diagnostic and monitoring options, such as blood,
saliva, and brush cytology tests.
Cathepsin E (CTSE) is an intracellular aspartic protease
that is normally expressed in a wide range of immune cells
but also is present in osteoclasts and gastric epithelial cells;
secreted forms have been described.8–10 A differential
expression pattern has been demonstrated for CTSE in
normal, metaplastic, dysplastic, and neoplastic gastric
epithelium as well as in the intestinal dysplasia–neoplasia
sequence in APCmin/? mice.11–15 Furthermore, CTSE has
also been suggested as both a diagnostic and a prognostic
biomarker for some cancers.16
Other members of the cathepsin family (cathepsin B, C,
D, K, and S) have been found to be up-regulated in BE and
EAC, but analysis of CTSE in BE and EAC has not been
reported.17–20
This study aimed to evaluate the potential prognostic value
of CTSE to predict progression to more advanced disease in
patients with Barrett metaplasia–dysplasia–adenocarcinoma
spectrum, and to predict survival for patients with EAC.
MATERIALS AND METHODS
Study Design, Study Population, and Specimen
Collection
A diagnostic case control analysis was performed to
examine the associations among the following: (1) CTSE
tissue mRNA expression and normal squamous esophagus
(NE), BE, BE with dysplasia (BE/D) and EAC; (2) CTSE
serum protein levels and NE, BE, BE/D and EAC; and (3)
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FIG. 1 CTSE mRNA expression analysis (a). CTSE is increased in
BE and BE/D in comparison to NE. CTSE mRNA expression of
CTSE in EAC is significantly lower than BE and dysplastic BE, but is
significantly higher compared to NE. Immunohistochemical staining
for CTSE (d–f). Marked, intense staining in BE and EAC with
decreased staining intensity and shift in staining pattern with
neoplastic progression of Barrett epithelium. Quantification of these
findings could be statistically confirmed (b, c)
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the association between CTSE and overall EAC patient
survival (Supplementary Fig. 1).
The NE, BE, and BE/D tissues as well as blood samples
were collected at endoscopies performed at St. Vincent’s
Hospital, Sydney, from patients prospectively enrolled onto
a research collaboration entitled PROBE-NET (Progression
of Barrett’s Esophagus to Esophageal Adenocarcinoma
Network). The EAC specimens were obtained either from
patients at St. Vincent’s Hospital or from patients who had
been enrolled onto the population-based case-control
Australian Cancer Study.21 All tissues were fixed in for-
malin and embedded in paraffin. The pathology diagnosis
was established by pathologists at the respective host
institutions. Before mRNA extraction, a section of each
tissue sample was also sent for hematoxylin and eosin
staining and reviewed to confirm the pathology in the
research specimen. BE was defined as intestinal metaplasia
with the presence of goblet cells. Patient serum samples
were collected at study recruitment, centrifuged at
14,0009 g, and then stored at -80 C until further use.
For the analysis of CTSE as a prognostic marker for EAC
survival, we used tissue samples from an independent cohort
of 75 patients with early stage EAC (I–IIB) from the Aus-
tralian Cancer Study.21 All subjects had undergone treatment
with potentially curative surgery alone and received no
chemo- or radiotherapy. Patients who died within 30 days of
surgery or who had cancer-involved operative resection
margins (R1/R2 resection) were excluded.
Institutional review board approval for this study was
obtained at all collaborating institutions, and all patients
provided written informed consent.
RNA Isolation
From each paraffin-embedded tissue block, two 7 lm
sections were cut and used for RNA extraction using the
Qiagen FFPE RNeasy Kit (Cat. #74404; Qiagen, Valencia,
CA) following the manufacturer’s protocol. RNA yield and
quality was measured using a Biospec Nano spectrophotom-
eter (Shimadzu Scientific Instruments, Sydney, Australia).
Multiplexed Tandem Polymerase Chain Reaction
Multiplexed tandem polymerase chain reaction (MT-PCR)
was used to quantitate the mRNA expression level of CTSE
and a reference gene, NONO (non-POU domain containing,
octamer-binding (NONO), transcript variant 2; NM_007363),
using the Rotor-Gene 6000 real-time quantitative PCR system
(Corbett Life Sciences/Qiagen, Sydney, Australia), as
described previously.22,23 Primers were designed with the
help of Primer 3 software modified by AusDiagnostics Pty.
Ltd. (AusDiagnostics, Alexandria, New South Wales, Aus-
tralia), leading to a CTSE ‘‘inner’’ amplicon of 73 bp and an
‘‘outer’’ amplicon of 120 bp. Outer primer sequences for
CTSE were 50-CTCAATGGACCAGAGTGCCAAG-30 (for-
ward) and 50-GAGGAGCCAGTGTCGAAGATG-30 (reverse).
Inner primer sequences were 50-GAGTGCCAAGGAACCC
CTCATC-30 (forward) and 50-TGGTGGGGAGCCAATGG
AGATA-30 (reverse). All primer pairs spanned an intron–
exon boundary, and all samples were run in duplicate. The
correct size and integrity of the products was verified on a
Bioanalyzer DNA separation chip (Agilent Technologies,
Forest Hill, Victoria, Australia).
CTSE Enzyme-Linked Immunosorbent Assay
A CTSE enzyme-linked immunosorbent assay (ELISA)
kit (Biomatik Corp, Cambridge, Ontario, Canada) was used
to measure CTSE protein levels in serum. Briefly, after
reconstitution of all reagents, serum samples were incu-
bated on precoated plates at 37 C and 70 % humidity for
2 h. After addition of the primary antibody and incubation
for another hour at 37 C, plates were washed three times
with wash buffer. Addition of the secondary antibody was
followed by a further incubation for 30 min at 37 C, and
plates were then washed another five times before the
addition of the reaction substrate. For antibody binding
detection, the supplier’s detection reagent was added for
15 min and the reaction halted by addition of the provided
stopping solution. Plate readouts occurred in a 96-well
multiplate reader (Multiskan Microplate Reader; Thermo
Labsystems/Thermo Scientific, Waltham, MA) at an
absorbance of 450 nm. All samples were assayed in trip-
licate and run without dilution. All plate readings had an
intra-assay coefficient of variation\15 %.
Immunohistochemistry
Tissue specimens were processed in a standard fashion
with regular formalin fixation and paraffin embedding.
CTSE was identified in 5 lm tissue sections using a rabbit
polyclonal anti-CTSE antibody (Cat. #ab36996; Abcam,
Waterloo, NSW, Australia) in a standard alkaline phos-
phatase anti-alkaline phosphatase technique, as described
previously.24
Immunohistochemistry Scoring
The sections were scored using a four-step scale: (0) no
staining or equal to background, (1) weak diffuse cyto-
plasmic staining, (2) moderate cytoplasmic staining in at
least 10 % of cells, and (3) strong immunostaining in a
majority of cells.25 Immunohistochemistry sections were
scored by two experienced investigators who were blinded
to clinical information. In cases of disagreement, consensus
was reached after reanalysis on a multiheaded microscope.
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Statistical Analysis
The mRNA raw expression values were obtained on the
Rotor-Gene MT-PCR system, and then relative expression
values were calculated as the ratio of the mRNA level of
CTSE to the control gene NONO, with the expression of
NONO set to a fixed level (1000). Where necessary, log2
transformation of relative expression values and/or serum
values was performed to achieve normal distribution. Dif-
ferences between two groups were measured by Student’s
t test or the Wilcoxon rank-sum test. One-way analysis of
variance was used to compare differential gene and protein
expression between patient groups. The Kaplan–Meier
method was used for survival estimates, and differences in
survival were analyzed using the log-rank test. Cox propor-
tional hazards models were used for uni- and multivariable
analysis. All p values of B0.05 were regarded as statistically
significant. All analyses were performed by the SAS Statis-
tical Package, version 9.2 (SAS Institute, Cary, NC). Prism
(GraphPad Prism version 6.0c for Mac OS X; GraphPad
Software, San Diego, CA) was used for graphs.
RESULTS
Patients and Tissues
As shown in Table 1, a total of 273 tissue specimens from
199 patients were included. Ninety-one patients were studied
to evaluate CTSE as a marker for the progression of BE to
EAC, 33 patients provided serum samples to evaluate CTSE
as a biomarker in blood, and 75 early-stage EAC patients were
included in the evaluation of CTSE as a prognostic biomarker.
TABLE 1 Clinical and pathologic characteristics of included patients
Characteristic All (n = 199) BE progression study
(n = 91)
Serum analysis
(n = 33)
Prognostic biomarker in EAC
(n = 75)
n % n % n % n %
Sex
Male 164 82.4 67 73.6 29 87.9 68 90.7
Female 35 18.6 24 26.4 4 12.1 7 9.3
Age, year, median (IQR) 63 (55–71) 62 (53–69) 63 (54–70) 67 (59–74)
Diagnosis
Healthy controls/normal squamous 31 15.6 22 24.2 9 27.3 – –
BE intestinal metaplasia 29 14.6 21 23.1 8 24.2 – –
BE with dysplasia 31 15.6 22 24.2 9 27.3 – –
Esophageal adenocarcinoma 108 54.2 26 28.5 7 21.2 75 100
TNM (AJCC, 7th edition)
Tis 2 1.9 2 7.7 – – – –
T1–2 88 81.5 8 30.7 5 71.4 75 100
T3–4 8 7.4 6 23.1 2 28.6 – –
N1–3 34 31.5 7 26.9 3 42.9 24 32.0
M? 3 2.8 3 11.5 – – – –
Unknown T, N or M 10a 9.3 10a 38.5 – – – –
Tumor stage (AJCC, 7th edition)
0 (Tis) 2 1.9 2 7.7 – – – –
IA–B 33 30.6 2 7.7 3 42.9 28 37.3
IIA 26 24.1 2 7.7 1 14.3 23 30.7
IIB 29 26.9 4 15.4 1 14.3 24 32.0
IIIA–C 7 6.5 5 19.2 2 28.6 – –
IV 3 2.8 3 11.5 – – – –
Unknown stage 8a 7.4 8a 30.8 – – – –
Survival, d, median (range) 1,182 (630–1,685) 1,305 (195–1,780) 1,277 (766–1,342) 1,161 (724–1,663)
Totals may not equal 100 % due to rounding
BE Barrett’s esophagus, EAC esophageal adenocarcinoma, IQR interquartile range, TNM tumor, node, metastasis classification system, AJCC
American Joint Committee on Cancer
a Two patients included had no clinical data on T and N status but were found to be M? at assessment. Regardless of this, primary tissue
samples were used for analysis in the respective study. These patients were excluded from survival analysis
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Each part of the study included an independent cohort of
patients, thus allowing for intrastudy validation of CTSE as a
marker for the respective pathologies. Despite chart review,
the correct tumor stage could not be assessed in 8 patients
(7.4 %) as a result of incomplete clinical data.
Expression Analysis As shown in Fig. 1a, median CTSE
mRNA relative expression was more than 1,000-fold
higher in BE compared to NE (18.41 vs. 23,221;
p\ 0.001). Median CTSE mRNA expression in EAC
was lower than in BE and dysplastic BE (p\ 0.001) but
higher than in NE (875.14 vs. 18.41; p = 0.0024).
Immunohistochemistry All BE specimens and all EAC
specimens stained strongly for CTSE, with high specificity
to the glandular structures and almost absent staining of the
stromal fraction of the esophageal specimens. Figure 1d–f
provides representative immunostaining patterns of the
respective histopathology tissue types.
CTSE staining was completely absent within the squa-
mous epithelium, whereas in BE/D median staining scores
were 2.25 (p\0.001, Fig. 1b). Staining intensities in EAC
were similar to BE (median staining score 2.0), but the
location shifted more apically and the staining pattern
showed more granular features in EAC. Staining in EAC
was significantly lower than in BE/D (2.0 vs. 2.25;
p = 0.016, Fig. 1b).
CTSE immunostaining was also assessed in cardiac and
gastric fundus mucosa because CTSE is known to be present
in gastric glands.13 CTSE staining was significantly higher
in both proximal gastric mucosae compared to BE (2.0 vs.
2.5 and 3.0; p = 0.0067 and\0.001, respectively; Fig. 1c).
CTSE Serum ELISA As shown in Fig. 2, there were no
significant differences between patient groups.
Analysis of CTSE as a Prognostic Biomarker in Early-
Stage EAC
Patient Survival Overall median survival of the patients in
the independent EAC cohort was 3.2 years (38.7 months),
and overall 5-year survival was 66 %.
T1a and T1b patients showed a significantly increased sur-
vival (58.7 and 46.0 months, respectively) compared to T2
patients (25.2 months;p\0.001). Stage I (IA?B) patients had
a median survival of 41.2 months (3.4 years), whereas stage II
(IIA?IIB) survived 31.4 months (2.61 years, p = 0.0027).
CTSE mRNA Expression and Tumor Stage
No significant difference was found in CTSE expression
levels between T stages, American Joint Committee on
Cancer (AJCC) stage I versus II cancers, lymph node
negative versus positive disease, or male versus female sex
(data not shown).
CTSE EAC Tissue mRNA Expression and Survival For
survival analysis, CTSE expression values were
dichotomized at the 25th percentile, median, and 75th
percentile to determine the influence of CTSE expression
on overall patient survival. Kaplan–Meier survival curves
showed that patients with a CTSE expression above the
25th percentile had a non-significant trend toward
improved overall survival (log-rank p = 0.14, Fig. 3). In
uni- and multivariable analysis, elevated CTSE expression
levels were not significantly associated with survival
[hazard ratio (HR) 0.65; 95 % confidence interval (CI)
0.73–3.24, p = 0.25). CTSE expression above the 25th
percentile was associated with a non-significant 41 %
relative risk reduction for death (HR 0.59, 95 % CI
0.27–1.26, p = 0.17). In a backward stepwise regression
model including sex, age, overall tumor stage, and CTSE
expression below the 25th percentile, only age (HR 1.04,
95 % CI 1.00–1.08; p = 0.04) and AJCC stage II (HR
4.93, 95 % CI 1.88–12.88; p = 0.001) were independent
prognostic markers for decreased survival (Table 2).
DISCUSSION
This novel study shows that CTSE is highly overexpressed
in BE and BE/D compared to normal esophageal tissue. CTSE
mRNA expression was 1,000-fold higher in BE compared to
normal esophageal tissue, which we believe to be the highest
gene expression change reported for this disease. Lower levels
of CTSE mRNA were observed in EAC compared to BE. A
similar expression pattern has been demonstrated for CTSE in
NE
0
5
10
ANOVA p = 0.68
BE
Diagnosis
CTSE Serum Values
ng
/m
l
BE-LGD EAC
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normal, metaplastic, dysplastic, and neoplastic gastric epi-
thelium as well as in the intestinal dysplasia–neoplasia
sequence in APCmin/? mice.11–15 One explanation for our
observed CTSE overexpression is that exposure to gastric
refluxate induces expression of gastric proteases; consistent
with this we found that despite the remarkable induction in BE
tissues, CTSE levels are still lower than those found in either
gastric fundus or cardiac mucosa.
Alternatively, the remarkably high CTSE expression
levels may indicate a functional role in this disease.
Unfortunately, the exact function of CTSE remains to be
defined because the specific substrate for this protease is
not known.10,26 A role in host defense has been suggested
because of the high CTSE expression in immune and
antigen presenting cells, but CTSE was solely expressed in
glandular BE cells and not in stromal cells in the present
study, similar to the distribution observed in a mouse
intestinal neoplasia study.14
Interestingly, the other cathepsin family members
cathepsin B, C, K, and S are also up-regulated in BE and
EAC, and cathepsin D (CTSD) mRNA expression shows a
significant stepwise increase in erosive esophagitis, intes-
tinal metaplasia and EAC.17–20 Further functional
hypotheses for CTSE in Barrett disease involve the con-
tents of the gastro-esophageal refluxate. Intracellular and
secreted CTSD requires a low pH to exert its proteolytic
activity, leading to the speculation that CTSD activity may
be especially enhanced in the acidic environment of gas-
troesophageal reflux associated disease.20,27 CTSD is also
involved in the resistance to the bile salt deoxycholate–
induced apoptosis in colon cancer cell lines.28 Because
CTSE is highly homologous to CTSD, there may be a
similar acid and bile-associated function for CTSE in the
context of BE development.9,26
A conclusive explanation for the significantly lower
CTSE expression levels in EAC compared to BE is not
available. In particular, it is not clear if CTSE expression is
down-regulated in EAC and thus CTSE more a marker of
BE than of EAC. In other cancers, CTSE has been shown
to exert an antitumorigenic effect in prostate cancer cells—
for example, by acting as the cleavage enzyme for tumor
necrosis factor-related apoptosis ligand (TRAIL), which
has also been implicated in the pathogenesis of EAC.29,30
Injection of purified CTSE into human tumor xenografts
results in a dose-dependent induction of apoptosis and
inhibition of tumor growth.29 It can therefore be speculated
that the increased levels of CTSE in BE and BE/D may
serve a protective mechanism. In this hypothesis, the
down-regulation of CTSE marks an enhanced susceptibility
to neoplasia formation, as suggested by a mouse melanoma
study.29 Further, loss of CTSE expression has also been
shown to induce mammary gland neoplasia.31
High levels of CTSE have been shown to be associated
with improved survival in various cancers, but in EAC we
found only a non-significant trend in which expression of
CTSE above the 25th percentile resulted in a 41 % risk
reduction for death.31–33A larger study including patients
with worse disease stage could be undertaken, as limited
power and small survival differences due to the inclusion
of only early stage, chemoradiotherapy-naive patients may
have reduced our ability to detect a statistically significant
association.
Finally, although highly desirable from a clinical per-
spective, this study indicates a lack of value in measuring
CTSE protein levels in serum. Although there was a non-
significant trend to higher CTSE protein levels in patients
with EAC, our exploratory study was not powered to detect
small differences in CTSE expression between patient
groups. Alternatively, however, CTSE activity levels could
be studied according to a recent report, which showed that
CTSE activity levels but not protein levels were associated
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FIG. 3 CTSE mRNA expression and survival. Dichotomization at
log2-transformed 25th percentile. Patients with CTSE over the 25th
percentile show a 41 % reduction in risk for death (HR 0.59, 95 % CI
0.27–1.26; p = 0.17)
TABLE 2 Uni- and multivariable analysis for factors contributing to
mortality according to the Cox proportional hazards model
Variable Univariable analysis Multivariable analysis
HR 95 % CI p HR 95 % CI p
Age 1.04 1.00–1.08 0.04 1.04 1.00–1.08 0.04
Sex (male) 1.71 0.41–7.15 0.464 1.49 0.35–6.38 0.59
AJCC stage II 4.68 1.80–12.14 0.002 4.93 1.88–12.88 0.001
Log CTSE\25th
percentile
1.54 0.73–3.24 0.25 1.71 0.79–3.65 0.17
Log CTSE[25th
percentile
0.65 0.31–1.36 0.25 0.59 0.27–1.26 0.17
HR hazard ratio, CI 95 % confidence interval, AJCC American Joint
Committee on Cancer, CTSE cathepsin E
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with more advanced disease, recurrence, and prognosis in
patients with breast cancer.31
CONCLUSIONS
The remarkable induction of CTSE expression in BE
intestinal metaplasia and dysplasia, together with the sig-
nificant down-regulation in EAC tissues, suggests a
possible role for CTSE in the Barrett disease spectrum. The
intense CTSE protein expression in BE and lower levels of
expression in EAC could be evaluated by pathologists as a
method to simplify the evaluation of esophageal tissues,
although we acknowledge that further studies are required
to substantiate this potential benefit.
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Abstract
Barrett’s esophagus (BE), a common condition, is the only known precursor to esophageal
adenocarcinoma (EAC). There is uncertainty about the best way to manage BE as most
people with BE never develop EAC and most patients diagnosed with EAC have no
preceding diagnosis of BE. Moreover, there have been recent advances in knowledge and
practice about the management of BE and early EAC. To aid clinical decision making in
this rapidly moving field, Cancer Council Australia convened an expert working party to
identify pertinent clinical questions. The questions covered a wide range of topics includ-
ing endoscopic and histological definitions of BE and early EAC; prevalence, incidence,
natural history, and risk factors for BE; and methods for managing BE and early EAC. The
latter considered modification of lifestyle factors; screening and surveillance strategies;
and medical, endoscopic, and surgical interventions. To answer each question, the working
party systematically reviewed the literature and developed a set of recommendations
through consensus. Evidence underpinning each recommendation was rated according to
quality and applicability.
Author contributions: Davic C Whiteman, Mark Appleyard, Farzan Fahrtash Bahin, Yuri V
Bobryshev, Michael J Bourke, Ian Brown, Adrian Chung, Andrew Clouston, John Emery, Guy D
Eslick, Louisa G Gordon, Florian Grimpen, Geoff Hebbard, Luke Hourigan, Bradley J Kendall,
Eric Y T Lee, Angelique Levert, Reginald V Lord, Sarah J Lord, Alan Moss, Ian Norton, Darren
Pavey, Spiro Raftopoulos, Shan Rajendra, Mark Schoeman, Rajvinder Singh, Freddy Sitas, Mark
Smithers, Andrew Taylor, Melissa L Thomas, Iain Thomson, Henry To, David I Watson, and Ian
F Yusoff reviewed the literature and compiled the evidence summaries. Emma Dickins and
Laura Holliday conducted systematic literature searches, screened the primary literature, and
collated the evidence summaries. Jutta von Dincklage and Christine Vuletich managed the
guideline development process and provided project governance. Ian Olver provided oversight
and funding and Derek Maule provided consumer input. All authors were involved in drafting
and critical revision of the manuscript.
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Introduction
Barrett’s esophagus (BE) is the only known precursor to esopha-
geal adenocarcinoma (EAC), a cancer with a rapidly rising inci-
dence. Most people with BE never develop EAC however, and
most patients diagnosed with EAC have no preceding diagnosis of
BE. Thus, there is uncertainty about the best way to manage this
condition.
These guidelines about BE and early EAC are aimed at gastro-
enterologists, pathologists, surgeons and physicians, and other
members of multidisciplinary teams to which patients with BE and
EAC are referred. The guidelines will also be relevant to primary
care practitioners and patients diagnosed with this condition. The
need to develop Australian guidelines for the management of BE
and early EAC was identified as a priority by a strategic partner-
ship of clinicians, researchers, patients, and policy makers initiated
by Cancer Council NSW in 2011.
Information covered by the guidelines includes:
1 Endoscopic and histological definitions of BE and early EAC
2 Prevalence, incidence, natural history, and risk factors for BE
3 Management of BE and early EAC, including modification of
lifestyle factors, screening, surveillance, and medical, endo-
scopic, and surgical interventions.
The evidence summaries and recommendations are provided
separately for BE without dysplasia and BE with dysplasia and/or
early cancer, but do not extend to the management of invasive
EAC. The recommendations contained herein should not override
good clinical judgment. However, they do represent consensus
views of expert practitioners and accord with international prac-
tices. This publication represents a summary of more extensive
material hosted on the Cancer Council Australia Wiki platform1
that explores the reasons underlying the recommendations in more
detail.
Methods
Guideline development was facilitated by Cancer Council Austra-
lia, which managed the project and provided in-kind support. No
external funding was received for guideline development.
The guidelines were developed by a multidisciplinary working
group and used standard methodology.2 A series of clinical ques-
tions were developed to be answered based on systematic reviews.
In consultation with the working group, systematic search strate-
gies were developed by project officers using the PICO framework
and limits and exclusion criteria were pre-defined to complete the
systematic review protocol. Databases searched included the
Cochrane Library, PubMed, Embase, Trip Database, Econlit,
National Health Service (UK) Economic Evaluation Database, the
National Guideline Clearinghouse, the National Comprehensive
Cancer Network and the National Institute for Health and Clinical
Excellence, Scottish Intercollegiate Guidelines Network, and
Canadian Medical Association. Search results were screened by
project officers and relevant articles were sent to topic authors for
critical appraisal with respect to level and quality of evidence,
effect size, and clinical importance and relevance. The level of
evidence for each article was assigned according to the National
Health and Medical Research Council of Australia Evidence Hier-
archy (Table 1).
Each topic author summarized the relevant body of literature
and then developed recommendations. Each recommendation was
assigned a grade by the working group taking into account the
volume, consistency, generalizability, applicability, and clinical
impact of the supporting evidence (Table 2). When there was
insufficient evidence to make a specific recommendation but con-
sensus among experts about the advisability of making a clinically
relevant statement, the working group formulated “practice
points” to guide clinical practice. The working group also
reviewed comparable international guidelines to calibrate the
recommendations.
The draft guidelines underwent public consultation in June and
July 2014. Feedback was reviewed by topic authors and the
working group. Subsequent changes to the draft were agreed by
consensus of the working group and the final guidelines were
released on August 2014. The Wiki guidelines will be reviewed
annually and updated as required.
Guidelines for BE without dysplasia
What is the definition of BE and how is it
described? BE is a premalignant condition of the esophagus
defined as the presence of metaplastic columnar epithelium,3
Table 1 Hierarchy of evidence recommendation†
Level Description
I A systematic review of level II studies
II A randomized controlled trial (intervention) or a
prospective cohort study (etiology)
III-1 A pseudo-randomized controlled trial (intervention) or
all or none design (etiology)
III-2 A comparative study with concurrent controls
(intervention) or a retrospective cohort study
(etiology)
III-3 A comparative study without concurrent controls
(intervention) or a case–control study (etiology)
IV Case series with either post-test or pre-test/post-test
outcomes or a cross-sectional study
†Adapted from the National Health and Medical Research Council of
Australia.
Table 2 Body of evidence recommendation†
Grade Description
A Body of evidence can be trusted to guide practice
B Body of evidence can be trusted to guide practice in
most situations
C Body of evidence provides some support for
recommendation(s) but care should be taken in its
application
D Body of evidence is weak and recommendation
must be applied with caution
Practice point Where no good-quality evidence is available but
there is consensus among expert working group
members, so-called Practice points are given
†Adapted from the National Health and Medical Research Council of
Australia.
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which appears endoscopically as salmon pink mucosa extending
above the gastro-esophageal junction (GEJ) and into the tubular
esophagus, thereby replacing the normal stratified squamous epi-
thelium.3,4 An accurate diagnosis of BE depends on the endoscopic
recognition of the anatomic landmarks at the GEJ and squamoco-
lumnar junction.5 Using the Prague C&M (circumferential and
maximal) criteria proposed by the International Working Group
for the Classification of Esophagitis,6 the landmark for the GEJ is
the proximal end of the gastric folds.
The metaplastic columnar mucosa can be one of three types:
gastric-fundic type, cardiac type, and intestinal type.7 There
remains disagreement as to the histological features of the colum-
nar mucosa necessary to define BE as reflected in the differing
definitions given in European and American guidelines.8–11 For the
Australian guidelines, however, the presence of intestinal metapla-
sia with morphologically typical goblet cells was considered nec-
essary for the diagnosis of BE.
Biopsies from the tubular esophagus containing columnar
mucosa without intestinal metaplasia should be given a descriptive
diagnosis (e.g. columnar mucosa without intestinal metaplasia),
but it is currently recommended that these are not diagnosed as BE
until the biological significance of this entity is clarified.
Intestinal metaplasia occurring in isolation at the GEJ or cardia
without metaplasia in the tubular esophagus is not considered BE.
It may be a precursor to carcinoma, but the risk is low and sur-
veillance is not warranted.12,13 However, goblet cells noted in a
GEJ biopsy can be confirmed to be intestinal metaplasia in
columnar-lined esophagus (CLE) if the particular biopsy fragment
shows native esophageal structures such as submucosal glands
and/or ducts.
Practice points. To identify patients at increased risk of
neoplastic progression, BE is defined as metaplastic columnar
mucosa in the tubular esophagus, with intestinal metaplasia proven
histologically.
Biopsies to confirm intestinal metaplasia should be performed
when any length of possible BE is seen extending above the GEJ.
The extent of BE should be described using the Prague C&M
criteria.
What is the optimal tissue sampling at endoscopy
for diagnosis of BE? Intestinal metaplasia can be patchy
and may not be consistently sampled with endoscopic biopsies14
(level of evidence IV). Advancements in chromoendoscopy
(methylene blue, indigo carmine, and acetic acid), endoscope
digital enhancements (narrow-band imaging, i-SCAN, Fujinon
intelligent chromo endoscopy), and enhanced magnification have
not been shown to be superior to the currently accepted practice of
random four-quadrant biopsies at 2-cm intervals15–17 (levels of
evidence I, II, IV, respectively); however, the diagnostic yield may
be higher with increasing number of biopsies (level of evidence
IV).18 Jumbo biopsy forceps have not been shown to be superior to
standard capacity forceps in obtaining adequate biopsy samples
(level of evidence II).19 Office-based unsedated transnasal endos-
copy using pediatric biopsy forceps is well tolerated and may
emerge as a cost-effective strategy (level of evidence II).20–22
Recommendation. Random four-quadrant biopsies at 2-cm
intervals are the mainstay for tissue sampling (recommendation
grade B).
Practice points. Focal abnormalities such as ulcerated or
nodular lesions should be targeted with biopsies and labeled before
random biopsies from the rest of the mucosa as minor biopsy-
related bleeding is common and may impair endoscopic views.
Technological advancements in chromoendoscopy, digital
enhancements, and enhanced magnification complement rather
than replace random four-quadrant biopsies at 2-cm intervals.
Biopsies obtained every 2 cm should be placed into separate jars
that are labeled according to the distance from the incisors, while
biopsies from the GEJ and cardia can also be specifically labeled
as such.
Are there biomarkers for the diagnosis of
BE? Numerous biomarkers have been proposed to aid the diag-
nosis of BE. Estimates of diagnostic accuracy have been reported
for tissue biomarkers, including cytokeratin profiling,23–29 immu-
nohistochemical biomarkers to detect goblet cells such as mucin
immunostaining,30,31 and stress response protein AG2;32 a serum
biomarker (G1733); and a non-endoscopic capsule sponge device to
collect cytology samples for Trefoil factor 3 immunohistochemis-
try (TFF3)34,35 (diagnostic accuracy level of evidence II–III-3).
These studies provide insufficient evidence to recommend any
biomarkers to supplement or replace standard practice use of
endoscopy and histopathology due to study designs with a high
risk of bias, wide variation in accuracy estimates across studies,
and no comparison with current standard practice.
Recommendation. There is insufficient evidence to recom-
mend cytokeratins, MUC, G17, or AG2 to aid BE diagnosis
(grade D).
There is insufficient evidence to recommend the non-
endoscopic capsule sponge device with TFF3 for BE screening
(grade C).
What is the prevalence of BE in the Australian
population in comparison with other popula-
tions? Globally, the prevalence of BE is low (<5%) but is higher
in selected groups such as those with gastro-esophageal reflux
disease (>15%). There are no studies describing the prevalence of
BE in an asymptomatic, unselected Australian population. One
small study suggests a high prevalence in high-risk patient popu-
lations.36 A data linkage study conducted in one Australian health-
care region reported prevalence rates at each of three time points as
0.42% (1990), 2.3% (1998), and 4.2% (2002).37 International
studies suggest prevalence varies significantly by ethnicity (e.g.
Asians <1% prevalence) and gender (more common in males).
Which factors best predict the risk of developing
BE? Risk factors for BE have been assessed in more than 50
studies. All studies have been observational, and most have been
case–control studies of variable quality. From these studies, the
major risk factors identified include age,38 male sex,39 history of
frequent gastro-esophageal acid reflux,40 central obesity,41
smoking,42 and family history43 (level of evidence III-3, IV). A few
studies have conducted serological assays comparing the preva-
lence of anti-Helicobacter pylori antibodies between BE cases and
controls, reporting risk reductions of about 50% for persons with
Australian clinical practice guidelines for BE and EAC DC Whiteman et al.
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past infection with H. pylori.44,45 There is no evidence that alcohol
consumption or dietary or nutritional factors influence risk.46,47
Recommendation. Clinical assessment of a person’s future
risk of BE should consider their age, sex, history of gastro-
esophageal acid reflux, waist–hip ratio, or other measures of
central adiposity, smoking history, and family history of EAC
and/or BE (grade B).
What is the incidence of neoplasia in patients
with BE? Five population-based, prospective studies with large
sample sizes and complete follow up of patients with uncompli-
cated BE with no dysplasia have reported progression rates to
high-grade dysplasia (HGD) or adenocarcinoma of 2.2–2.6/1000
person-years (py) in Northern Ireland,48,49 3.3/1000 py in the Neth-
erlands,50 1.2/1000 py in Denmark,51 and 3/1000 py in the United
Kingdom.52 Meta-analyses of high-quality studies derived similar
estimates of progression risks.53,54
What are the risk factors for progression from
non-dysplastic BE to HGD or adenocarcinoma?
Increased rates of progression from non-dysplastic BE to HGD or
adenocarcinoma have been associated with patient factors (age,
sex, smoking), endoscopic appearance (greater segment length),
and aneuploidy48,55–58 (level of evidence III-2). There is observa-
tional evidence that regular users of proton pump inhibitors (PPIs),
non-steroidal anti-inflammatory drugs, and statins may have lower
rates of progression from BE to cancer59–64 (level of evidence: II,
III-2, III-3).
Recommendation. Clinical assessment of future risk of
HGD or adenocarcinoma in the setting of non-dysplastic BE
should consider age, sex, smoking history, and endoscopic find-
ings (grade C).
For which populations is screening for BE cost-
effective? In line with accepted epidemiologic practice, these
guidelines reserve “screening” to describe the process of identify-
ing new cases of disease in an unselected population, whereas
“surveillance” describes the systematic follow up of patients with
known disease at periodic intervals as part of an early detection
strategy to prevent progression to cancer.
There is no evidence to support population screening for BE.
However, health economic studies generally suggest that one-off
screening of 50-year-old men with gastro-esophageal reflux
disease might be cost-effective. Both the cytosponge65 and ultra-
thin endoscopy66 may be more cost-effective compared with stan-
dard endoscopic screening. General population screening, even if
conducted coincident with colonoscopy screening, is not cost-
effective.
What is appropriate medical systemic therapy for
symptoms associated with BE? Medical systemic
therapy for patients with BE aims to control symptoms and reduce
the risk of complications. Uncomplicated BE is not a cause of
symptoms (indeed patients with BE may have reduced sensitivity
to esophageal acidification); rather these are due to the symptoms
of gastro-esophageal reflux.67 Acid suppression with PPI is the
most effective systemic therapy for reflux symptoms in patients
with BE and will control symptoms in most patients with a durable
effect over years (level of evidence II, IV)68–78 Higher than stan-
dard doses of PPI may be required to control symptoms in a
proportion of patients (level of evidence IV).79–81
Recommendation. Symptomatic patients with BE should be
treated with PPI therapy, with the dose titrated to control symp-
toms (grade C).
Are there any medical or surgical interventions
that cause regression of BE? Regression of BE is defined
by a reduction in the length or area of metaplastic columnar epi-
thelium; however, the significance of regression in BE is unclear.
There are insufficient data to indicate that regression leads to
reduced incidence of EAC. The degree of Barrett’s regression
appears largest among patients undergoing anti-reflux surgery
although a randomized trial comparing surgical and medical
therapy found no significant differences.76
Combined analysis of randomized trials has not demonstrated
BE regression with medical therapy82 (level of evidence I).
Recommendation. There is insufficient evidence to recom-
mend the use of acid suppressive therapy for the regression of BE
(grade B).
There is insufficient evidence to recommend anti-reflux surgery
for the regression of BE (grade C).
Practice point. Acid suppressive therapy and anti-reflux surgery
can be used to control symptoms and heal reflux esophagitis in
patients with BE. There is insufficient evidence to recommend
high-dose (twice daily) acid suppressive therapy when symptom
control or mucosal healing is achieved with standard dosing.
Is there a role for ablative therapy to treat BE?
Various endoscopic techniques have been investigated for eradi-
cating BE epithelium, including those that deliver focal ablation
(argon plasma coagulation [APC], laser heater probe, and endo-
scopic mucosal resection [EMR]) and those that ablate broad fields
(photodynamic therapy [PDT] and radiofrequency ablation
[RFA]).
APC is a widely available monopolar electrocautery method.
Randomized trials show that medically treated patients and
patients with prior fundoplication can be cleared of Barrett’s
mucosa whereas control patients do not show significant
regression.83–85
PDT involves administration of a photosensitizer drug (typically
oral aminolevulinic acid, or IV photofrin) and subsequent expo-
sure of the Barrett’s mucosa to a laser light. Because of potentially
severe skin sensitivity, the subject must remain in a darkened
environment, restricting use of this technology to cooler climate
countries.
RFA involves placement of a balloon catheter in the esophagus,
through which radiofrequency energy is delivered allowing
treatment of a 3-cm circumferential segment of the esophagus.
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Side effects include chest pain, dysphagia, and stricture formation.
Rare complications such as bleeding and perforation have been
noted. Randomized sham-controlled studies have shown high
levels of eradication of both non-dysplastic (> 90%) and dysplastic
(> 90%) Barrett’s mucosa.82 Long-term follow up studies show the
response is durable with the majority of patients (> 85%) main-
taining complete eradication at 5 years.
Recommendation. Long-term outcome studies do not yet
support ablation in patients without dysplasia (grade B).
Are there any treatments that prevent progres-
sion of BE to cancer? There is limited evidence to support
preventive strategies. The choice of anti-reflux therapy (i.e. PPIs vs
anti-reflux surgery) has not been shown to influence progression to
cancer. There is interest in the use of COX inhibitors, but to date
only small trials have been conducted with no clear evidence of
benefit. A large randomized controlled trial is being conducted to
evaluate the efficacy of aspirin to prevent the onset of cancer in
patients with BE.86 This trial is due to report in 2019.
Ablation therapies have shown benefit in randomized trials, but
only in those who have already developed dysplasia. In these
individuals, the risk of cancer progression appears to be reduced
by approximately 50% by both PDT87 and RFA,88–90 but cancer risk
is not eliminated. The only randomized trial91 to evaluate ablation
(APC) in non-dysplastic BE failed to show benefit for ablation.
Recommendation. Ablation of BE should remain limited to
individuals with HGD in BE who are at imminent risk of devel-
oping EAC (grade B).
Practice points. The treatment of gastro-esophageal reflux with
either PPIs or anti-reflux surgery has not been shown to influence
progression to EAC.
There is currently no high-quality evidence supporting the use
of COX inhibitors for prevention of EAC.
How frequently should patients with BE undergo
endoscopy? The aim of surveillance is to detect dysplasia and
early cancer for early treatment. Endoscopic surveillance in
patients with BE is the current standard of practice,8,9 although
there is no evidence from randomized controlled trials for its
effectiveness. There is, however, indirect evidence based on earlier
stage and improved survival in EAC patients detected at surveil-
lance, although these retrospective studies are subject to potential
lead and length time bias.92,93
Both the British Society of Gastroenterology (BSG) and Ameri-
can Gastroenterological Association (AGA) have published guide-
lines for endoscopic surveillance of BE.8,9 The guidelines differ in
the criteria for the diagnosis of BE with both requiring a CLE but
the AGA also requiring intestinal metaplasia to be present in biop-
sies from the CLE. This Australian guideline uses the AGA criteria
for a diagnosis of BE. British and American guidelines also use the
grade of dysplasia found at endoscopy to determine the timing of
the subsequent surveillance endoscopy. These recommendations
are based on the evidence of an increased risk of EAC with
increasing degrees of dysplasia. In those with no dysplasia, the
BSG guidelines also take into account the absence of intestinal
metaplasia and short-segment (< 3 cm) length, both of which
appear to be associated with a decreased risk of malignant pro-
gression. Both guidelines recommend biopsies of any visible
lesion or mucosal irregularity and quadrantic biopsies. The BSG
guidelines recommend quadrantic biopsies every 2 cm in all sur-
veillance endoscopies. The AGA guidelines recommend Seattle
protocol biopsies with quadrantic biopsies every 2 cm unless there
is suspected or known dysplasia where every 1 cm is recom-
mended. These biopsy protocols have been shown to increase the
detection of advanced (high grade and early adenocarcinoma)
lesions.94,95 However, there is low adherence to the protocols96
resulting in lower detection rates of dysplasia.97
The recommendations of the Australian working group for fre-
quency of surveillance are shown in Table 3 and Figure 1. The
diagnosis of BE requires intestinal metaplasia in biopsies from the
CLE. Recommendations for CLE without intestinal metaplasia are
discussed below.
Uncertainty regarding risk of low-grade dysplasia (LGD)
progression. The optimum management of patients diagnosed
with LGD is uncertain. There is considerable debate about the
risks of progression to HGD or cancer in this group. Population-
based studies report cancer progression rates of ∼0.5% p.a.51 In
contrast, studies undertaken in academic centers in which diagno-
ses of LGD are made only after review by expert gastrointestinal
pathologists report progression rates up to 13% p.a.98 Importantly,
in those studies, about 85% of patients diagnosed originally with
LGD were down-staged to non-dysplastic BE upon expert review.
Among down-staged patients, the progression rate was ∼0.5% p.a.
Endoscopic surveillance in patients with CLE without
intestinal metaplasia. In patients with no intestinal metaplasia
or dysplasia detected in biopsies from long-segment (≥ 3 cm)
CLE, endoscopic surveillance as per the protocol for long-segment
BE is recommended (i.e. every 2–3 years). If there is 1 to < 3 cm
of CLE without intestinal metaplasia or dysplasia, a repeat endos-
copy in 3–5 years is suggested with consideration for discharge
from surveillance if the repeat endoscopy with Seattle protocol
biopsies again shows no intestinal metaplasia or dysplasia. In
patients with CLE less than 1 cm without intestinal metaplasia or
dysplasia on biopsies from the CLE, no endoscopic surveillance is
suggested. If dysplasia is found in any biopsies from a CLE
without intestinal metaplasia, then recommendations are as per the
protocols for BE with dysplasia.
Practice points. In the absence of randomized trial evidence,
the frequency of surveillance endoscopy in BE can be guided by
current practice guidelines.
It is advisable to undertake endoscopic surveillance in suitable
patients with BE. The frequency of surveillance is based on the
presence or absence of dysplasia on previous Seattle protocol
biopsies and length of BE.
A diagnosis of dysplasia (indefinite, low, and high grade) should
be confirmed by a second pathologist, ideally an expert gastroin-
testinal pathologist.
Esophageal biopsies should be taken according to the Seattle
protocol.
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Is surveillance cost-effective for follow up of
patients with BE? A recent systematic review99 of seven
studies100–106 found inconsistent assessments of the value of sur-
veillance, ranging from being cost-effective to highly cost-
ineffective. Hence, surveillance of all patients with non-dysplastic
BE may not be cost-effective, but this may change with identifi-
cation of patients at high risk of progression to EAC.
Are there groups of patients with non-dysplastic
BE that require more frequent surveillance? Sur-
veillance protocols for patients with BE are based on observational
studies.54,107 However, groups of patients may be identified with
high rates of progression, and thus who may benefit from more
frequent surveillance. Such groups include patients with longer
segments of BE (≥ 3 cm) (level of evidence III-2),53,54,56,107–110 as
well as older patients, males, and smokers (level of evidence II,
III-2).48,55,57,111,112
Recommendation. Patients with BE length equal to or greater
than 3 cm may have intensive surveillance, possibly every 2–3
years following the Seattle protocol (grade C).
Are there groups of patients with BE that can be
discharged from surveillance? There is limited high-
quality evidence to address this question with certainty, although
studies are in progress which may yield risk reducing modifiers (II,
III-2, III-3).
Recommendation. For patients with < 1 cm of CLE that do
not have evidence of intestinal metaplasia or dysplasia on Seattle
protocol biopsy of the segment, endoscopic surveillance is not
recommended (grade C).
Practice point. Patients with evidence of “regression” of BE
(i.e. reduced CLE length or absence of intestinal metaplasia) can
still continue surveillance.
Patients with significant comorbidities, or those unable to tol-
erate procedural intervention for dysplasia/EAC, may be consid-
ered for discharge from surveillance.
Guidelines for BE with dysplasia or
early cancer
What are the endoscopic features of neoplasia
(dysplasia and early cancer) within a BE
segment? Because random sampling of quadrantic biopsies
every 2 cm suffers from sampling error and, at times, limited
adherence,97,113 newer modalities have been proposed including
chromoendoscopy, electronic image enhancement technologies,
and high magnification platforms. There is limited information
whether these methods can ultimately change patient manage-
ment. Presently, high-resolution white light endoscopy (HR-WLE)
remains the gold standard in evaluating patients with BE although
the newer modalities may be used in addition to HR-WLE to
Table 3 Recommended frequency of endoscopic surveillance of patients with Barrett’s esophagus
No dysplasia† on endoscopic assessment and Seattle protocol biopsy‡
Short (< 3 cm) segment Repeat endoscopy in 3–5
years
Long (≥ 3 cm) segment Repeat endoscopy in 2–3
years
†If there has been previous low-grade dysplasia, see low-grade dysplasia protocol.
‡Seattle protocol—biopsy of any mucosal irregularity and quadrantic biopsies every 2 cm unless known or suspected dysplasia then quadrantic
biopsies every 1 cm.
Indefinite for dysplasia on biopsy
The changes of indefinite for dysplasia on biopsy should be confirmed by a second pathologist, ideally an expert gastrointestinal pathologist. If
indefinite for dysplasia is confirmed, then the following endoscopic surveillance is recommended:
1. Repeat endoscopy in 6 months with Seattle protocol biopsies for suspected dysplasia (biopsy of any mucosal irregularity and quadrantic
biopsies every 1 cm) on maximal acid suppression.
2. If repeat shows no dysplasia, then follow as per non-dysplastic protocol.
3. If repeat shows low-grade or high-grade dysplasia or adenocarcinoma, then follow protocols for these respective conditions.
4. If repeat again shows confirmed indefinite for dysplasia, then repeat endoscopy in 6 months with Seattle protocol biopsies for suspected
dysplasia.
Low-grade dysplasia on biopsy
The changes of low-grade dysplasia on biopsy should be confirmed by a second pathologist, ideally an expert gastrointestinal pathologist. If
low-grade dysplasia is confirmed, then the following endoscopic surveillance is recommended (or refer to an expert center for assessment):
1. Repeat endoscopy every 6 months with Seattle protocol biopsies for dysplasia (biopsy of any mucosal irregularity and quadrantic biopsies
every 1 cm).
2. If two consecutive 6 monthly endoscopies with Seattle dysplasia biopsy protocol show no dysplasia, then consider reverting to a less frequent
follow up schedule.
High-grade dysplasia or adenocarcinoma on biopsy
Referral to a center that has integrated expertise in endoscopy, imaging, surgery, and histopathology.
DC Whiteman et al. Australian clinical practice guidelines for BE and EAC
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improve characterization of lesions.114 Thus, it is important to
understand the gross morphological features of dysplasia and early
cancer and if available, apply some of the more advanced imaging
methods.
Given the inconspicuous nature of dysplasia in BE,115 meticu-
lous inspection and attention to subtle endoscopic anomalies using
the best available imaging equipment and endoscopes are war-
ranted. Debris and mucus should be washed off. If there is exten-
sive peristalsis, antispasmodic agents can be used. There is some
evidence that cancer preferentially occurs in the distal Barrett’s
segment116 and in the 2–5 o’clock position in patients with shorter
segments of BE (< 5 cm).117
All ulcers in BE should be monitored closely for carcinoma.
Biopsies should always be taken in depressed regions and if nega-
tive, repeated after a course of PPI therapy. Visible lumps or
nodules consisting of HGD suggest a more advanced lesion where
more sinister pathology may be present. Suspicious lesions visu-
alized on “white light overview” can be interrogated further with
any of the enhanced imaging techniques described earlier. It is not
yet clear, however, whether these modalities can replace biopsies
(Fig. 2).
What is the histological definition and grading of
dysplasia in patients with BE? Dysplasia is an unequivo-
cal neoplastic transformation of the epithelial cells that is confined
within the basement membrane of the metaplastic glandular tissue
within which it arises. Histological features that characterize dys-
plasia are best identified on standard H&E-stained sections and
comprise cytological changes and/or architectural changes.118,119
Cytological features involve nuclear changes (such as increase
in size, irregular shape, increased nuclear:cytoplasmic ratio,
nuclear crowding, hyperchromasia, and the presence of nucleoli)
and cytoplasmic changes such as mucin depletion. Dysplastic cells
exhibit increased mitotic activity, including atypical forms and
surface mitoses. There is typically failure of cellular maturation
toward the surface of the mucosa, although this is not always the
case.120 Goblet cell numbers are reduced and dysplastic cells may
lose their normal vertical polarity.
Architectural features are irregular gland outline, variability in
glandular size, gland crowding with “back-to-back” pattern,
and villiform surface contour. None of these cytological or
architectural features are sufficient to diagnose dysplasia in iso-
lation. Ancillary tests (e.g. p53, AMACR and Ki67 stains) have
been advocated to aid the diagnosis of dysplasia; however at
present, conventional H&E examination remains the gold
standard.
Grading of BE dysplasia is best performed on the H&E stain.
Pathologists should report BE biopsies as fitting into one of four
categories.118,119,121–123 The rationale for this tiered approach is to
stratify patients into categories of increasing risk for development
of or concurrent presence of EAC. Many papers have shown an
increasing risk ranging from small (negative for dysplasia) to
significant (HGD).124
1 Negative for dysplasia
2 Indefinite for dysplasia—when the pathologist believes that the
biopsy is displaying some features of true dysplasia but is
unable to exclude a non-neoplastic process as the cause of the
abnormality. In general, the consideration is whether the histo-
logical features are sufficient to diagnose LGD. However, in
some situations the pathologist is concerned that the features
may represent HGD. The concept of indefinite for HGD/
adenocarcinoma has not been studied specifically; however,
pathologists recognize a subgroup of indefinite for dysplasia
where the cytological and/or architectural abnormality is
marked but a confident diagnosis of HGD cannot be made. In
some of these situations, the concern is that invasive adenocar-
cinoma may exist.
3 LGD—displays mild-to-moderate cytological atypia and, at
a b
c d
Figure 2 (a) C0M3 Barrett’s esophagus con-
taining a 2 × 1 cm (Paris 0–Is) lesion at 6
o’clock in white light and in (b) as seen with
narrow-band imaging. (c) Flat C2M4 Barrett’s
esophagus. (d) Closer examination using
narrow-band imaging reveals a focal area with
irregular capillary and mucosal pattern at 12
o’clock.
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most, mild disturbance of gland architecture. The neoplastic
epithelial cells are crowded, elongated, and hyperchromatic.
The cells generally retain their vertical polarity.
4 HGD—typically displays both architectural abnormality and
severe cytological atypia. Aberrant architectural features
include glandular crowding, branching or budding glands, vil-
liform, cribriform, micropapillary, or cystically dilated crypt
patterns. Cytological features include complete loss of cell
polarity, rounded enlarged nuclei with irregular-thickened
nuclear membranes, and conspicuous nucleoli. Typical and
atypical mitotic figures are readily identified at all levels within
the glands, as well as on the luminal surface.
Grading of dysplasia is subject to significant interobserver
variability,125–127 especially LGD. Interobserver agreement among
general histopathologists ranges from kappa values of 0.14 to 0.32.
Specialist gastrointestinal histopathologists have better agreement
(kappa 0.48–0.69).128 When a diagnosis of LGD made by a general
histopathologist is reviewed by an expert panel, the diagnosis is
most often down-graded to “negative for dysplasia.”
These data support the notion that all cases of BE diagnosed as
dysplasia (indefinite, low, or high grade) should be reviewed by at
least one expert GI pathologist.
What are the histological features of early adeno-
carcinoma of the esophagus? Early adenocarcinoma
refers to invasion into mucosa or superficial submucosa, but not
deeper (T1 in the current TNM system). Adenocarcinoma exists
when there is invasion beyond the basement membrane of the
epithelium. The histological features identifying that invasion has
occurred include:129,130
1 Single neoplastic cells or small clusters of neoplastic cells in the
lamina propria.
2 Complex architectural patterns characterized by solid growth
patterns, tight cribriform growth pattern, glands with acute
angulation in at least one part of their outline, and a pattern of
anastomosing fusion of small glands.
3 Neoplastic cells invading overlying squamous epithelium.
4 Desmoplastic stromal reaction.
Significant interobserver variability exists between pathologists
in the separation of HGD from early invasive adenocarcinoma in
biopsy specimens.131 Recent studies have identified a variety of
histological patterns that predict invasive adenocarcinoma includ-
ing solid or cribriform growth patterns, ulceration of dysplastic
epithelium, abundant neutrophils within dysplastic epithelium,
dilated neoplastic glands containing necrotic debris, and dysplastic
glandular epithelium being incorporated into squamous epithe-
lium. The risk of adenocarcinoma is increased with number of
features present.132
The histological report of EMRs should include data that are
important for clinical management, particularly the identification
of patients who should be considered for esophagectomy. These
are discussed in greater detail in the guidelines for reporting
esophageal and gastro-esophageal carcinomas provided by the
Royal College of Pathologists of Australasia.133
What are the best modalities for accurately
staging early EAC? Early EACs are those defined as intra-
mucosal adenocarcinoma (T1a) or superficial submucosal adeno-
carcinoma (T1b).114 A more comprehensive subclassification of
early esophageal cancers has been proposed with mucosal disease
and submucosal disease divided into three categories, respectively
(m1-3/4 and sm1-3) based on depth of invasion.
Options for staging of early EAC include:
1 Endoscopic biopsy
2 Endoscopic resection (ER) (also known as EMR)
3 Endoscopic ultrasound (EUS) with or without fine-needle aspi-
rate (FNA)
4 Positron emission tomography-computerized tomography
(PET-CT), once the diagnosis of cancer has been confirmed
Endoscopic biopsy is useful but is subject to sampling error. ER
is superior to biopsy and results in a change in diagnosis in up to
50% of patients with dysplasia or adenocarcinoma (level of evi-
dence IV).134–137 Moreover, ER allows improved pathological
staging of HGD and T1m and T1sm adenocarcinoma as compared
with biopsy and EUS (level of evidence IV)136,138 (Fig. 3). Rates of
adverse events following ER, such as perforation, bleeding, and
stricturing, are low when performed at expert centers (level of
evidence IV).138–140 EUS is not accurate for determining the stage
of early EAC, especially distinguishing T1m from T1sm tumors. It
is useful for differentiating T1 and >T1 stages (level of evidence
IV).141,142 EUS and EUS guided FNA (EUS-FNA) are superior to
CT for locoregional lymph node staging (level of evidence
IV).143,144
Recommendations. ER is the most accurate staging modality
for early EAC for suitable lesions and where appropriate expertise
is available (grade D).
EUS can be used prior to ER when deeper invasion is consid-
ered likely, particularly for lesions with ulcerated or depressed
morphology (grade D).
FDG-PET or PET/CT is not routinely indicated in staging early
EAC. It is best used for the staging of distant metastases or in cases
of suspected more advanced local disease (grade D).
What is the appropriate management of LGD in
patients with BE? Recent studies suggest that when the
diagnosis of LGD is agreed on by two or more expert pathologists,
the risk of progression to neoplasia is higher than previously
reported (level of evidence III-2).88,98,145 British and American
guidelines recommend increased frequency of surveillance.8,9
Endoscopic ablation with a range of methods is associated with
lower rates of progression to cancer (level of evidence IV).146 In
particular, an RCT reported that RFA in patients with confirmed
LGD have significantly lower rates of progression to cancer or
HGD, although as yet there is no evidence of an overall survival
benefit (level of evidence II).88
Recommendations. The diagnosis of LGD should be con-
firmed by a second pathologist, ideally an expert gastrointestinal
pathologist (grade C).
In patients with confirmed LGD, it is advised to perform rigor-
ous high-definition endoscopy or refer to an expert centre for
assessment (grade C).
In patients with confirmed LGD, intensified endoscopic surveil-
lance is required. Endoscopic ablation may be considered
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especially where LGD is definite, multifocal, and present on
more than one occasion. This decision needs to be individualized
based on discussion of risk and benefits with the patient
(grade B).
What are the goals of treatment of HGD in
patients with BE? There is no high-level evidence that
directly answers this question, and so the guidelines are based on
expert opinion. As HGD is prone to both over- and under-staging,
the first goal of management is to confirm the diagnosis.
Once HGD has been confirmed, the goal of treatment is to
prevent the progression to malignancy through the removal of
dysplastic tissue. More specifically, the goals of treatment are:
1 The removal of all dysplastic tissue114
2 The removal of all Barrett’s metaplasia if possible114
3 Preservation of normal swallowing/nutrition
4 Minimization of morbidity due to the eradication technique
5 Confirmation of the diagnosis of HGD (i.e. exclusion of malig-
nancy) through examination of resected tissue (endoscopically
or surgically), where possible
6 Continued follow up in patients who have had endoscopic
therapy114
There is no management strategy that perfectly fulfils all these
criteria. Current practice favors endotherapy (ER or ablation) over
surveillance or esophagectomy for HGD/T1a cancer, although no
randomized control trials have compared the two modalities
directly. All patients should be discussed at a multidisciplinary
meeting.
Practice point. The confirmation of HGD should act as a trigger
for definitive treatment.
What is the best endoscopic treatment for HGD in
patients with BE? ER alters histological grade or local T
stage in 48% of patients and reduces esophagectomy rates by
providing an effective local therapy. ER has a high success rate
(94%) for complete Barrett’s excision in short-segment BE (level
of evidence IV).139 RFA has been shown to completely eradicate
HGD in 81% of patients at 1 year of follow up versus 19%
complete eradication in patients undergoing endoscopic surveil-
lance alone. Similar outcomes are reported following RFA at 2 and
3 years of follow up with 95% and 96% complete eradication,
respectively (level of evidence II)89,90 (Fig. 4).
Recommendations. ER should be considered for patients with
intramucosal adenocarcinoma or HGD and visible/nodular lesions
(grade D).
RFA should be considered for patients with HGD within flat
segments of BE. RFA is not appropriate in patients with visible
abnormalities; these should be treated by ER. RFA may be the
preferred treatment strategy over ER for patients with long-
segment BE or circumferential Barrett’s due to a lower rate of
stricture formation (grade B).
Practice point. It is advisable to refer patients with BE and
dysplasia or early EAC to tertiary referral centers for management.
What is the best endoscopic management of early
EAC? Early EAC comprises the histological tumor classification
of T1a (invasion into the mucosa) and T1b (invasion into submu-
cosa but not muscularis propria). The depth of invasion can be
further stratified based on mucosal (m1–m3/m1–m4) or submuco-
sal (sm1–sm3) involvement.123,147 ER is the most accurate T
staging modality for early EAC (level of evidence IV)137,139
a b
c d
Figure 3 (a) C3M4 Barrett’s esophagus. After
careful inspection, a focal abnormality was
noted at 2 o’clock. (b) Focal endoscopic
mucosal resection was performed for staging
confirming high-grade dysplasia. (c) C7M8 Bar-
rett’s esophagus. Using a distal attachment
cap for improved visualization, nodular lesion
with slight depression (Paris 0–IIa+IIc) noted at
12–2 o’clock. (d) This area is completely
excised by endoscopic mucosal resection. His-
tology confirmed Barrett’s esophagus with
high-grade dysplasia and focal area of
intramucosal adenocarcinoma (M1-T1a).
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(Fig. 5). The risk of lymph node involvement with T1a and T1b
early EAC is 1.3–2.5% and 12–31%, respectively.148–151 Unlike
locally advanced or node-involving disease, early EAC can often
be cured with surgical or endoscopic approaches. Endoscopic
treatment is less morbid and expensive than esophagectomy, and is
organ preserving.152 ER is effective for T1a early EAC when per-
formed in experienced centers. Selected patients with T1b early
EAC may benefit from ER if esophagectomy is not indicated
(levels of evidence II, III-2, IV).153–157
Recommendations. All lesions and visible abnormalities
should be staged by focal ER (grade D).
If ER of early EAC is planned, ER is appropriate in most cases.
Ablative therapies should not be used as primary endoscopic
therapy for early EAC (grade C).
Patients with T1a adenocarcinoma on endoscopic work-up
should be offered ER in preference to esophagectomy (grade D).
Selected patients with T1b early EAC may also be offered ER but
only if esophagectomy is not indicated (grade D).
Following resection of early EAC the remaining Barrett’s
mucosa should be eradicated. Barrett’s eradication options include
complete ER, RFA, cryotherapy, and APC (grade C).
Following resection of early EAC, the patient should undergo
regular and careful surveillance examinations (grade C).
Practice point. ER of early EAC should be performed in referral
centers that have integrated expertise in endoscopy, imaging,
surgery, and histopathology.
Careful and dedicated endoscopic interrogation of all Barrett’s
mucosa is advised.
After successful endoscopic treatment for BE
neoplasia, how frequently should patients
undergo endoscopy? There is no high-level evidence that
directly answers this question, and so the guidelines are based on
expert opinion. Following endoscopic treatment for BE with neo-
plasia, patients should be considered for three monthly surveil-
lance endoscopies with Seattle protocol to confirm clearance of
disease. Once clearance has been achieved, consider six monthly
endoscopic surveillance for 1 year, then annually. Higher risk
patients may require closer surveillance endoscopy after clearance
of BE neoplasia is achieved (i.e. initially six monthly for a year).
ER of mucosal irregularities (nodules, depressed areas) in the
squamous epithelium should be considered to clarify possible
recurrent or metachronous intramucosal adenocarcinoma from
subsquamous glands.
Practice point. Consider three monthly surveillance endoscopy
with Seattle protocol during the endoscopic treatment phase to
confirm clearance of intramucosal adenocarcinoma and residual
BE. Once clearance has been achieved, consider six monthly endo-
scopic surveillance for 1 year, then annually.
Higher risk patients may require closer surveillance endoscopy
after clearance of BE neoplasia is achieved (i.e. initially three
monthly for a year). ER of any nodularity in the squamous epithe-
lium should be considered to clarify possible recurrent or
metachronous cancer from subsquamous glands.
What endoscopic surveillance protocol should be
followed for patients with HGD? Surveillance is gen-
erally not indicated for patients with HGD and therapeutic inter-
vention must be considered instead.
a b
c d
Figure 4 (a) C5M7 Barrett’s esophagus with
high-grade dysplasia previously treated by
endoscopic mucosal resection and
radiofrequency ablation—residual disease
remaining at 7 o’clock proximally and 12–4
o’clock distally. (b) Focal radiofrequency abla-
tion to sites of residual Barrett’s mucosa. (c)
C2M4 Barrett’s esophagus previously treated
by radiofrequency ablation for flat high-grade
dysplasia. (d) Residual Barrett’s mucosa is
treated by focal radiofrequency ablation.
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How effective is endoscopic management com-
pared with surgical management for HGD in
patients with BE? There are no randomized controlled trials
comparing surgery with endoscopic treatments for HGD. Evi-
dence therefore comes largely from non-randomized retrospective
studies. These studies report that endoscopic treatment of HGD
provides similar outcomes to surgery with regard to overall sur-
vival and cancer-related mortality (level of evidence III-2).153,158–162
In addition, the studies tend to report that compared with surgery,
endoscopic treatments result in less morbidity but higher rates of
local recurrence (level of evidence III-2).153,158–162
Recommendation. Patients with HGD in BE should be
managed in centers with high-volume experience of the condition.
The treatment and follow up should occur in those specialist
centers (grade C).
Practice points. Patients with HGD in BE can be discussed at a
multidisciplinary team meeting at a specialist centre.
Endoscopic treatment will be the first-line treatment option for
the majority of patients with HGD in BE. There will be a group of
patients for whom endoscopic treatment is not appropriate or suc-
cessful and they will be best treated with surgery in a specialist
centre.
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MIC-1/GDF15 in Barrett’s oesophagus and
oesophageal adenocarcinoma
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Background: Biomarkers are needed to improve current diagnosis and surveillance strategies for patients with Barrett’s
oesophagus (BO) and oesophageal adenocarcinoma (OAC). Macrophage inhibitory cytokine 1/growth differentiation factor 15
(MIC-1/GDF15) tissue and plasma levels have been shown to predict disease progression in other cancer types and was therefore
evaluated in BO/OAC.
Methods: One hundred thirty-eight patients were studied: 45 normal oesophagus (NE), 37 BO, 16 BO with low-grade dysplasia
(LGD) and 40 OAC.
Results: Median tissue expression of MIC-1/GDF15 mRNA wasX25-fold higher in BO and LGD compared to NE (Po0.001); two-
fold higher in OAC vs BO (P¼ 0.039); and 47-fold higher in OAC vs NE (Po0.001). Relative MIC-1/GDF15 tissue expression4720
discriminated between the presence of either OAC or LGD vs NE with 94% sensitivity and 71% specificity (ROC AUC 0.86, 95% CI
0.73–0.96; Po0.001). Macrophage inhibitory cytokine 1/growth differentiation factor 15 plasma values were also elevated in
patients with OAC vs NE (Po0.001) or BO (P¼ 0.015). High MIC-1/GDF15 plasma levels (X1140pgml 1) were an independent
predictor of poor survival for patients with OAC (HR 3.87, 95% CI 1.01–14.75; P¼ 0.047).
Conclusions: Plasma and tissue levels of MIC-1/GDF15 are significantly elevated in patients with BO, LGD and OAC. Plasma
MIC-1/GDF15 may have value in diagnosis and monitoring of Barrett’s disease.
Barrett’s oesophagus (BO) is an acquired condition in which the
normal squamous lining of the distal oesophagus is replaced by a
specialised intestinal metaplastic (IM) columnar epithelium
(Phillips et al, 2011). Barrett’s oesophagus is found in B6–12%
of all upper gastrointestinal endoscopies (Ford et al, 2005) and in
an estimated 1.6% of individuals in Western populations. Known
risk factors for BO include gastroesophageal reflux disease
(GERD), male sex, age over 50 years, Caucasian ethnicity, obesity
(especially with a central/visceral fat distribution) and smoking
(Cook et al, 2012; Fitzgerald et al, 2014).
Barrett’s oesophagus is a multistage disease in which a
minority of patients progress from IM through the stages of
low-grade dysplasia (LGD) to high-grade dysplasia (HGD) and
to oesophageal adenocarcinoma (OAC; Clemons et al, 2013).
Recent population-based data indicate that patients with BO
without dysplasia have an B0.5% annual risk of progression
from BO to OAC (Hvid-Jensen et al, 2011; Desai et al, 2012).
This risk is higher for patients with HGD, who may have a 6% or
higher annual risk of progressing to cancer (Spechler, 2013).
Oesophageal adenocarcinoma is a highly fatal cancer, which has
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increased six-fold in incidence over the past three decades
(Eheman et al, 2012).
Recent data indicate that endoscopic surveillance may correlate
with earlier stage diagnosis and improved survival from cancer
(Bhat et al, 2014). For this reason, guidelines on the management
of BO (Spechler et al, 2011; Fitzgerald et al, 2014) generally
recommend endoscopic surveillance with histopathological assess-
ment of dysplasia in four-quadrant random biopsies taken every
2 cm, in addition to targeted biopsies taken from macroscopically
visible lesions (so-called Seattle protocol).
There are significant problems with the endoscopic surveillance
of patients with BO, including sampling error and variation in
the histopathological interpretation of the degree of dysplasia
(Reid et al, 1988; Lao-Sirieix and Fitzgerald, 2012). In addition,
OAC can also develop in the interval between surveillance
endoscopies (Spechler, 2007). Further, only 5–7% of patients
presenting with OAC have a previous diagnosis of BO (Dulai et al,
2002; Bhat et al, 2014).
These deficiencies in current management have stimulated a
search for biomarkers to improve both the early detection of OAC
and the identification of patients with BO who are at high risk of
progressing OAC. So far no biomarkers have proven adequate for
routine clinical practice (Varghese et al, 2012; Fitzgerald et al,
2014). A blood biomarker would have several advantages over the
current subjective histologic interpretation of endoscopic tissue
biopsies, including being less invasive and safer, less expensive and
potentially applicable for at-risk population screening.
Macrophage inhibitory cytokine 1 (MIC-1, also known as
growth differentiation factor 15, GDF15), is a divergent member of
the transforming growth factor-b (TGF-b) superfamily, which is
not highly expressed under normal conditions, other than in the
placenta (Bootcov et al, 1997; Fairlie et al, 1999). Its expression is
increased by injury, inflammation or malignancy and it is involved
in the pathogenesis of a number of disease including cancer and
cardiovascular diseases (Breit et al, 2011).
Macrophage inhibitory cytokine 1/growth differentiation factor
15 expression is increased in most cancers including those of the
prostate, colon, ovary and breast (Welsh et al, 2003; de Wit et al,
2005), and various cancer cell lines are known to secrete large
amounts of MIC-1/GDF15 (Bauskin et al, 2006; Unsicker et al,
2013). In many cancers, MIC-1/GDF15 serum levels are associated
with histopathological cancer grade, stage and extent of disease,
and have been reported as predictors of disease progression in
prostate, ovary and colorectal cancer (Bauskin et al, 2006).
Macrophage inhibitory cytokine 1/growth differentiation factor
15 may also have a role as a clinical biomarker in multiple
myeloma, oral squamous cancer and bladder cancer (Brown et al,
2003, 2006; Costa et al, 2010; Wallin et al, 2011; Brown et al, 2012;
Corre et al, 2012). Serum levels of MIC-1/GDF15 are reported to
increase during the progression of colorectal cancer (Brown et al,
2003) and serum MIC-1/GDF15 measurement is a validated
prospective biomarker of the presence of colorectal polyps and
cancer, indicating that it has potential as a screening tool in these
diseases (Brown et al, 2012).
The above data suggest that MIC-1/GDF15 may be useful in the
management of BO and OAC. We investigated MIC-1/GDF15
plasma and tissue levels in patients with different stages of BO to
assess the potential of MIC-1/GDF15 quantification as a biomarker
for diagnosis, for prediction of progression in patients with BO, as
well as for diagnosis and prognosis in patients with OAC.
MATERIALS AND METHODS
Study design, study population and specimen collection. We
performed a retrospective diagnostic case–control analysis to
examine the associations between (a) MIC-1/GDF15 tissue mRNA
expression and normal oesophagus (NE), BO, LGD and OAC;
(b) MIC-1/GDF15 plasma protein levels and NE, BO, LGD and
OAC; and (c) to test the association between MIC-1/GDF15 plasma
levels and overall survival in patients with OAC. An analysis of the
performance of MIC-1/GDF15 tissue and plasma levels to distinguish
between NE, BO, LGD and OAC was also conducted.
The NE, BO and LGD tissues and blood samples were collected
at endoscopies performed at St Vincent’s Hospital, Sydney,
Australia. These were obtained from patients prospectively enroled
in an Australia-wide research collaboration entitled PROBE-NET:
Progression of Barrett’s Esophagus to Esophageal Adenocarcinoma
Network. The OAC specimens were either obtained from patients
at St Vincent’s Hospital or from patients who had been enroled in
the population-based case–control Australian Cancer Study
through the QIMR Berghofer Medical Research Institute (QIMRB;
Whiteman et al, 2008). All tissues were formalin fixed and paraffin
embedded. The pathological diagnoses were established by
pathologists at the respective host institutions. Sections from tissue
blocks for mRNA extraction were chosen after reviewing the
histopathologic reports and haematoxylin and eosin (H&E) stained
slides to confirm the presence of the correct diagnoses. Barrett’s
oesophagus was diagnosed when there was any length of columnar
mucosa in the tubular oesophagus, with IM containing goblet cells
on histopathological examination.
Patient plasma samples were collected at study recruitment,
centrifuged at 1800 g, and the resultant plasma stored at  80 1C
until further use. For the analysis of plasma MIC-1/GDF15 levels
as a prognostic marker for OAC survival, we used pretreatment
samples from an independent cohort of 23 patients with OAC
from the Australian Cancer Study (Whiteman et al, 2008) and 7
patients treated at St Vincent’s Hospital, Sydney. All subjects were
treated by oesophagectomy with curative intent and received no
preoperative chemotherapy or radiotherapy. Only patients with
complete clinicopathological and follow-up data (n¼ 27) were
included in the survival analysis.
Institutional review board approval for this study was obtained
at all collaborating institutions and all patients provided written
informed consent.
RNA isolation. All tissues processed were cut from formalin-
fixed, paraffin-embedded tissue blocks. Two 7-mm sections were
cut for RNA extraction, which was performed using the Qiagen
FFPE RNeasy kit, (cat # 74404, Qiagen, Valencia, CA, USA)
following the manufacturer’s protocol. Satisfactory RNA yield and
quality were confirmed using the BioSpec-nano spectrophotometer
(Shimadzu Scientific Instruments, Sydney, Australia).
Multiplexed tandem PCR. Multiplexed tandem PCR (MT-PCR)
was used to quantitate the mRNA expression levels of MIC-1/
GDF15 and a reference gene, NONO (‘non-POU domain-
containing, octamer-binding (NONO), transcript variant 2’;
NM_007363), using the Rotor-Gene 6000 real-time quantitative
PCR system (Corbett Life Sciences/Qiagen, Sydney, Australia), as
previously described (Stanley and Szewczuk, 2005; Botelho et al,
2010). Briefly, MT-PCR is performed in two stages. In the first
stage, isolated RNA is converted into cDNA and amplified using
gene-specific primers (‘outer’ primers). In the second step, the
product from stage one is used as a template for PCRs run in a 72-
well disc-containing single-gene primers (‘inner’ primers) in each
well. Primers were designed using Primer 3 software modified by
AusDiagnostics Pty. Ltd. (AusDiagnostics, Alexandria, New South
Wales, Australia). All primer pairs spanned an intron–exon
boundary and all samples were run in duplicate. Correct product
size and integrity was verified on a Bioanalyzer DNA separation
chip (Agilent Technologies, Forest Hill, Victoria, Australia). The
relative mRNA expression values were calculated as the ratio of the
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raw MIC-1/GDF15 mRNA values to the control gene NONO, with
the expression of NONO set to a fixed level (1000).
MIC-1/GDF15 enzyme-linked immunosorbent assay. Plasma
MIC-1/GDF15 levels were measured using a validated sandwich
enzyme immunoassay, as described previously (Moore et al, 2000;
Fairlie et al, 2001; Brown et al, 2002). Briefly, mouse mAb 26G6H6
was used for antigen capture and sheep PAb 233-P was used for
detection. The human MIC-1/GDF15 (hMIC-1/GDF15) plasma
concentration was determined by reference to a standard curve,
which was constructed using recombinant hMIC-1/GDF15. All
samples were run in duplicate. To ensure reproducibility, the
coefficient of variation for all readings was below 10%. Assay
performance was further monitored using standard diagnostic
laboratory quality control procedures.
Statistical analysis. Continuous variables were compared using
t-test statistics, Wilcoxon rank-sum test, one-way analysis of
variance and the Kruskal–Wallis test where appropriate. Where
necessary, log2 transformation of mRNA relative expression and
plasma ELISA values was performed to achieve normal distribution
for these analyses. Differences between proportions derived from
categorical data were analysed using Pearson’s chi-squared test or
Fisher’s exact test.
The area under the curve (AUC) of the receiver operator
characteristic (ROC) curve and 95% confidence interval (CI) was
calculated to explore the performance of MIC-1/GDF15 tissue and
plasma levels to discriminate between patient pathology groups for
three distinct potential clinical uses as follows: (i) to explore the
potential of MIC-1/GDF15 tissue and/or plasma measurement as a
screening test for OAC, we assessed discrimination between OAC
vs non-OAC patients (NE, BO and LGD); (ii) to assess the
potential of MIC-1/GDF15 measurement as a triage test to rule out
low-risk patients who do not require further intervention or
endoscopy surveillance, we assessed discrimination between NE
and BO vs LGD and OAC; and (iii) to assess the performance of
tissue MIC-1/GDF15 gene expression and plasma levels as a
diagnostic test to identify patients at high risk of developing OAC,
we assessed discrimination between OAC and its respective ‘high’-
risk population (BO IMþ LGD). For each of these potential
biomarker purposes, the optimal cut point for MIC-1/GDF15 was
selected by the Youden’s index (Youden, 1950) to inform future
validation studies and the sensitivity, specificity at this cut point
was reported with 95% CI.
As MIC-1/GDF15 plasma values are known to correlate with
nutritional status and BMI (Johnen et al, 2007; Breit et al, 2011),
BMI was recorded for all patients providing plasma samples, and
we performed a separate analysis for patients who were non-obese
and not underweight (BMI 18.5–29.9 kgm 2) as defined by the
WHO (WHO, 2014).
The Kaplan–Meier method was used to compare survival times
for patients classified by MIC-1/GDF15 cutoff levels and
differences in survival times were compared using the log-rank
test. A Cox proportional hazards model was used to identify
independent factors associated with mortality. Only patients with
complete clinicopathological and survival data were included for
survival analysis (n¼ 27). Data are presented as mean (s.d.),
median (interquartile range (IQR)) and OR/HR (95% CI), where
applicable. All P-values o0.05 were regarded as statistically
significant. For ROC curve AUC analysis, the P-value indicates
the probability that an observed sample AUC is found when the
true AUC is 0.5 (no difference between groups). If the P-value is
o0.05, it can be concluded that the AUC is statistically
significantly different from 0.5 providing statistical evidence that
the biomarker has the ability to distinguish between the two groups
(Youden, 1950; Obuchowski, 2003).
All statistical analyses were performed using R Statistical
Packages (R Core Team, 2013) and graphing/plotting was
performed in Prism (GraphPad Prism version 6.0c for Mac OS
X, GraphPad Software, San Diego, California, USA).
RESULTS
Patients and tissues. Demographic data for the 138 patients
included in this study are shown in Table 1. Briefly, 45 patients
(33%) who underwent clinically indicated upper endoscopy
showing no BO and who had no history of GERD were included
as healthy controls and provided normal squamous oesophageal
tissue and baseline blood samples. Thirty-seven patients (27%) had
histologically confirmed BO with IM but no dysplasia, and 16
patients (12%) had BO with LGD. Of the 40 patients with OAC,
most had AJCC stage I–IIB disease (73%), whereas 8 patients were
stage III (20%) and 1 was stage IV (3%). Despite chart review the
correct tumour stage could not be assessed in two patients (5%)
due to incomplete clinical data.
MIC-1/GDF15 tissue mRNA expression analysis. MIC-1/GDF15
was significantly overexpressed in BO, LGD and OAC when
compared to normal squamous oesophagus (Figure 1A). Median
relative mRNA expression of MIC-1/GDF15 increased 25-fold
from NE to BO (44.2 to 1092.0; Po0.001), with median expression
levels higher in BO–LGD compared to BO, although this difference
was not statistically significant (1092.0 vs 1185; P¼ 0.43).
Macrophage inhibitory cytokine 1/growth differentiation factor
15 expression was 47 times higher in OAC compared to NE
(2249.0 vs 44.2; Po0.001), and was also significantly higher in
OAC compared to BO IM (2249 vs 1092; P¼ 0.039).
The AUC for the discriminative performance of MIC-1/GDF15
gene expression to distinguish between OAC and non-OAC (NE,
BO and LGD) was 0.82 (95% CI 0.70–0.93; Po0.001). For this
analysis, the optimal cut point for relative MIC-1/GDF15 mRNA
expression was 961, which yielded a sensitivity of 88% (95% CI 68–
97%) and specificity of 64% (95% CI 44–81%) for the detection of
OAC (Table 2).
The AUC for the discriminative performance of MIC-1/GDF15
to rule out LGD or OAC was 0.86 (95% CI 0.73–0.96; Po0.001).
For this analysis, the optimal cut point for relative MIC-1/GDF15
mRNA expression was 720, which yielded a sensitivity of 94%
(95% CI 79–99%) and specificity of 71% (95% CI 48–89%;
Table 2). This result indicates that if MIC-1/GDF15 mRNA
expression values are low, the presence of OAC and/or dysplastic
Barrett’s disease can be ruled out with a 6% false-negative rate
(95% CI 1–21%).
The diagnostic performance of tissue MIC-1/GDF15 gene
expression to distinguish between OAC and the at-risk population
(BO IM, LGD) was AUC 0.70 (95% CI 0.51–0.88; Figure 1B) with a
sensitivity of 63% (95% CI 41–81%) and specificity of 77% (95% CI
50–93%) at the optimal cut point of 1768 (Table 2).
MIC-1/GDF15 plasma analysis. Median MIC-1/GDF15 plasma
values were significantly higher in patients with OAC compared to
healthy controls (1018 vs 606 pgml 1; Po0.001), patients with BO
(1018 vs 783 pgml 1; P¼ 0.015) and patients with BO with LGD
(735 pgml 1, P¼ 0.027; Figure 2A).
The discriminative performance of plasma MIC-1/GDF15 levels
to distinguish between NE, BO, LGD and OAC is shown in
Figure 2B and Table 2. For example, for use as a screening test, the
AUC of plasma MIC-1/GDF15 levels for the detection of OAC vs
non-malignant oesophageal findings (NE, BO and LGD) was 0.75
(95% CI 0.65–0.85; Po0.001) with MIC-1/GDF15 plasma levels
above an optimal cut point of 811 pgml 1 yielding a sensitivity of
83% (95% CI 65–94%) and specificity of 62% (95% CI 50–74%) for
the detection of OAC. However, the AUC for MIC-1/GDF15
plasma measurements as a triage test to rule out LGD or OAC did
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not indicate potential for discriminating between patient groups
(data not shown).
In patients who were non-obese and not underweight (BMI
18.5–29.9 kgm 2) as defined by the WHO (WHO, 2014), median
MIC-1/GDF15 plasma levels were slightly lower for all patient
groups except for those patients with OAC, where median plasma
levels were in a similar range (1040.5 pgml 1; P¼ 0.85). Figure 2C
summarises the findings of the plasma analysis when corrected
for BMI.
The discriminative performance of plasma MIC-1/GDF15 levels
corrected for BMI to distinguish between NE, BO, LGD and OAC
is shown in Figure 2D and Table 2. Briefly, non-obese patients with
a MIC-1/GDF15 plasma value above the optimal cut point of
811 pgml 1 were approximately four times more likely to have a
malignant oesophageal finding than those with lower MIC-1/
GDF15 plasma levels (AUC 0.85 (95% CI 0.76–0.95), sensitivity
84% (95% CI 64–95%) and specificity 80% (95% CI 65–90%)).
MIC-1/GDF15 plasma levels and overall survival in OAC. Two
patients were excluded from the survival analysis due to
incomplete clinicopathological data. Patients were grouped into
AJCC stages 1 and 2 in one group and stages 3 and 4 in another
group.
There were no significant associations between MIC-1/GDF15
plasma levels and any of the following known prognostic factors:
histopathological grade, T-stage, positive nodal status, higher
tumour stage (data not shown).
There was a non-significant trend towards worse overall survival
in patients with OAC and elevated levels of MIC-1/GDF15
(X1140 pgml 1 (optimal cut point determined by ROC curve
analysis); 47.5 vs 33.0 months, P¼ 0.063; Figure 3). However, in a
multivariable Cox proportional hazards model including the
independent variables age, BMI, overall tumour stage and plasma
MIC-1/GDF15 values X1140 pgml 1, both elevated plasma
MIC-1/GDF15 levels (HR 3.87, 95% CI 1.01–14.75; P¼ 0.048)
and worse tumour stages (HR 13.85, 95% CI 2.31–83.23, P¼ 0.004)
were significant independent prognostic markers for mortality
(Table 3).
DISCUSSION
In this novel study, we found evidence for an association between
MIC-1/GDF15 tissue and plasma levels in patients with BO and
OAC. This suggests that MIC-1/GDF15 could be evaluated further
for its potential as a biomarker in this disease, with our results
indicating a greater biomarker potential for measuring MIC-1/
GDF15 in blood rather than tissues. A non-tissue, non-endoscopic
biomarker or biomarker panel detectable in blood would offer a
Table 1. Clinical and pathologic characteristics of included patients
All (n¼138) mRNA analysis (n¼53) Plasma analysis (n¼99)
Number % Number % Number %
Gender
Males 102 74 42 79 73 74
Females 36 26 11 21 26 26
Median age, years (range) 60 51–68 63 55–74 61 51–68
Diagnosis
Normal oesophagus 45 33 12 23 33 33
Barrett’s oesophagus IM 37 27 10 19 27 27
Barrett’s oesophagus with dysplasia 16 12 7 13 9 9
Oesophageal adenocarcinoma 40 29 24 45 30 30
TNM (7th edition)
T1–2 31 78 22 92 23 77
T3–4 7 18 — — 7 23
N1–3 11 8 3 13 10 33
Mþ 1 3 — — 1 3
Unknown T, N or M 2 5 2 8 0 —
Tumour stage (AJCC 7th edition)
IA–B 14 35 9 38 11 37
IIA 13 33 10 42 9 30
IIB 2 5 2 8 1 3
IIIA–C 8 20 1 4 8 27
IV 1 3 — — 1 3
Unknown stage 2 5 2 8 0 —
Median survival, months (range) 38 18–51 34 18–48 43 23–56
Abbreviations: AJCC¼American Joint Committee on Cancer; IM¼ intestinal metaplasia; TNM¼ tumour, node and metastasis.
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Figure 1. Boxplot of tissue MIC-1/GDF15 mRNA expression analysis
by pathology diagnosis. Raw relative mRNA expression values are
presented. Differences in relative gene expression values were
calculated using Student’s t-test following log2 transformation. Bold
values indicates that these are statistically significant. Dot indicates
outlier as is convention for presenting boxplot data.
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major advantage if it could replace the need for pathology
classification of dysplasia. Although the presence of dysplasia in
BO detected by histopathological examination of tissue specimens
is the most informative current predictor of risk of progression to
OAC, it is not a reliable tests as shown by the disturbing lack of
agreement between pathologists and their interpretation of
presence or severity of dysplasia (Reid et al, 1988; Spechler,
2007). Histopathological examination of the primary tumour and
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Figure 2. Boxplots of MIC-1/GDF15 plasma levels by pathology diagnosis and corresponding receiver operator characteristic (ROC) curves for
performance analysis of tissue MIC-1/GDF15 plasma levels to discriminate patient groups. (A and B) Show the analysis of the whole study cohort,
whereas (C and D) depict the findings in the non-obese, non-underweight (as categorised by the WHO) patient population. Differences in plasma
values were calculated using Student’s t-test following log2 transformation. Data are presented untransformed as pgml 1. Bold values indicates
that these are statistically significant. Dot indicates outlier as is convention for presenting boxplot data. **Po0.01; ***Po0.001.
Table 2. Discriminative performance of plasma MIC-1/GDF15 in predicting the presence of oesophageal pathologies
Youden indexa Cutoff pointa AUC (95% CI) Sensitivity (95% CI) Specificity (95% CI) P-valueb
Tissue mRNA (n¼54)
Non-malignant vs OAC 0.52 961 0.82 (0.70–0.93) 0.88 (0.68–0.97) 0.64 (0.44–0.81) 0.001
NEþBO vs LGDþOAC 0.65 720 0.86 (0.73–0.96) 0.94 (0.79–0.99) 0.71 (0.48–0.89) o0.001
BOþ LGD vs OAC 0.39 1768 0.70 (0.51–0.88) 0.63 (0.41–0.81) 0.77 (0.50–0.93) 0.03
Plasma ELISA for all patients (n¼99)
Non-malignant vs OAC 0.46 811 0.75 (0.65–0.85) 0.83 (0.65–0.94) 0.62 (0.50–0.74) o0.001
NE vs BOþ LGDþOAC 0.35 705 0.70 (0.58–0.82) 0.74 (0.62–0.84) 0.61 (0.42–0.77) 0.001
BOþ LGD vs OAC 0.39 811 0.72 (0.56–0.84) 0.83 (0.65–0.94) 0.56 (0.38–0.72) 0.003
Plasma ELISA for patients with a BMI of 18.5–29.9 kgm2 (n¼69)
Non-malignant vs OAC 0.63 811 0.85 (0.76–0.95) 0.84 (0.64–0.95) 0.80 (0.65–0.90) o0.001
NE vs BOþ LGDþOAC 0.44 705 0.77 (0.65–0.90) 0.69 (0.55–0.82) 0.75 (0.51–0.91) o0.001
BOþ LGD vs OAC 0.59 836 0.83 (0.71–0.95) 0.76 (0.55–0.91) 0.83 (0.63–0.95) o0.001
Abbreviations: AUC¼ area under the curve; BO¼Barrett’s oesophagus; BMI¼body mass index; CI¼ confidence interval; OAC¼oesophageal adenocarcinoma; ELISA¼ enzyme-linked
immunosorbent assay; LGD¼BO with low-grade dysplasia; MIC-1/GDF15¼macrophage inhibitory cytokine 1/growth differentiation factor 15; NE¼normal oesophagus/healthy controls;
ROC¼ receiver operator characteristic.
aGrouped as more vs less than the cutoff point generated by the ROC and Youden index; for relative gene expression no units apply for plasma measurements (pgml 1).
bP-value o0.05 indicates that observed AUC is significantly different from 0.5 providing statistical evidence that the biomarker has the ability to distinguish between the two groups.
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resected lymph nodes along with radiologic tests is also the current
basis of staging patients with OAC and determining prognosis, but
similarly has limited accuracy. For example, B50% of patients
assessed as having no lymph node involvement at diagnosis, and
thus a good prognosis, will still die of their disease by 10 years
(Rice et al, 2003). Identifying predictive and prognostic biomarkers
for BO and OAC is thus crucial to improve clinical care.
Our evaluation of MIC-1/GDF15 plasma quantification as a
diagnostic test for OAC found that patients with high MIC-1/
GDF15 plasma levels who were neither underweight nor obese
were more than four times more likely to have OAC. This
likelihood decreased by two-fold if obese or underweight patients
were included in the analysis. This reduction may be explained by
the confounding effect of the known relationship of MIC-1/GDF15
blood levels and BMI (Johnen et al, 2007; Breit et al, 2011). This
finding addresses a potential limitation of the clinical applicability
of plasma MIC-1/GDF15 analysis for the diagnosis and monitoring
of patients with Barrett’s disease, as patients with BO usually have
higher BMI and increased waist circumference (Kubo et al, 2013).
Conversely, however, as elevated MIC-1/GDF15 serum levels are
known to be associated with tumour-induced weight loss
(Wakchoure et al, 2009; Tsai et al, 2012), patients with noted
weight loss (despite the lack of dysphagia/reduced food intake) and
elevated plasma MIC-1 levels may identify those at highest risk of
bearing an oesophageal malignancy.
Others have shown the potential clinical use for MIC-1/GDF15
in blood for the diagnosis and/or monitoring of pancreatic,
prostate, colon and thyroid cancers, especially when MIC-1/
GDF15 is combined with other markers, as we anticipate would
also be the case with OAC (Koopmann et al, 2004; Brown et al,
2006). In pancreatic cancer, for example, combining MIC-1/
GDF15 serum levels with CA19-9 significantly improved the
diagnosis of pancreatic cancer leading to a sensitivity of 70% and
specificity of 85% (Koopmann et al, 2004). In prostate cancer, the
combination of serum MIC-1/GDF15 levels with prostate-specific
antigen significantly improved the overall diagnostic specificity and
shows great potential for monitoring of disease progression (Brown
et al, 2006).
In this study, we also found that elevated MIC-1/GDF15 plasma
levels were an independent prognostic marker for reduced overall
survival in patients, although the reliability of this finding is
diminished by the small number of patients in this section
(n¼ 27). This finding was significant when MIC-1/GDF15 was
included in a multivariable Cox proportional hazards model, which
was adjusted for age, tumour stage and BMI. The patients in this
study were treated by oesophagectomy alone in all but one case.
Because no patient received neoadjuvant chemotherapy or radio-
therapy, our findings are unlikely to be explained by variations in
treatment or the effect of treatment on tumour biology.
Studies of patients with other malignancies have suggested that
MIC-1/GDF15 is a marker of adverse prognosis as its blood levels
increased with increasing histopathological grade, invasiveness and
metastasis (Mimeault and Batra, 2010; Breit et al, 2011). However,
in this study, we did not find a significant difference in plasma
MIC-1/GDF15 levels between patients with lower vs higher stages
of OAC. We believe this is most likely due to the limited number of
patients with more advanced stages of the disease. Further studies
are required to help resolve whether blood levels of MIC-1/GDF15
can help in OAC staging. A blood marker that can identify patients
with locally limited but perhaps occult disseminated disease would
potentially allow early allocation to more aggressive treatment
strategies.
Our finding that elevated plasma MIC-1/GDF15 provides
independent prognostic information contrasts with the only other
report on MIC-1/GDF15 blood levels that included patients with
OAC (Skipworth et al, 2010). In this study, patients with elevated
MIC-1/GDF15 levels showed reduced survival compared to those
with lower MIC-1/GDF15 levels, but MIC-1/GDF15 was not an
independent prognostic indicator. However, this study also
included patients with oesophageal squamous, undifferentiated
and neuroendocrine carcinoma, and 52% of the included cancers
were not of oesophageal origin (oesophageal junction with
undefined localisation or gastric cancer) leading to a more
heterogeneous study population. In contrast to Skipworth et al,
2010 however, we did not have data on systemic inflammatory
markers and were therefore not able to adjust for this in our Cox
regression model.
In oesophageal tissue biopsies, we found that MIC-1/GDF15
mRNA levels were associated with the presence of BO as well as the
stage of the disease (IM, LGD and OAC). These findings indicate it
may have potential to aid in conventional histopathology methods.
This could be explored in future studies by comparing MIC-1/
GDF15 results with conventional methods to determine its clinical
value for patient management. In particular, given the high clinical
need to identify patients at risk of progression to OAC, our results
suggest that it may be useful to explore tissue MIC-1/GDF15 levels
Table 3. Univariable and multivariable Cox proportional hazards model for survival (n¼27)
Univariable analysis Multivariable analysis
Variable HR 95% CI P-value HR 95% CI P-value
Age 0.99 0.95–1.04 0.82 1.04 0.98–1.11 0.23
Body mass index 0.96 0.84–1.10 0.59 0.99 0.85–1.15 0.88
High tumour stage (III/IV) 5.85 1.92–17.85 0.0019 13.86 2.31–83.23 0.004
MIC-1/GDF15 plasma levels X1140pgml 1 2.91 0.89–9.48 0.076 3.87 1.01–14.75 0.048
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; MIC-1/GDF15¼macrophage inhibitory cytokine 1/growth differentiation factor 15.
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Figure 3. Survival of OAC patients stratified by MIC-1/GDF15 plasma
levels X1140pgml1 (as determined by ROC curve analysis).
MIC-1/GDF15 analysis in Barrett’s disease BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.100 1389
in prospective studies of BO patients, in contrast to the cross-
sectional design of the present study. It would also be useful to
investigate through in vivo studies (which we have not performed),
the correlation between MIC-1/GDF15 tissue and plasma levels in
this disease, as in other malignancies the intracellular processing of
MIC-1/GDF15 ultimately determines the relative amount of MIC-
1/GDF that remains in the tumour microenvironment vs the
amount diffusing into the systemic circulation. This additive
predictive value has been demonstrated in prostate cancer stromal
staining, where detection of proMIC-1/GDF15 was an important
independent predictor of disease relapse (Bauskin et al, 2005,
2006).
There are two possible explanations for our findings in tissues.
First, the increased MIC-1/GDF15 levels in BO IM, BO–LGD and
OAC may be linked to the inflammatory response of the
oesophagus to severe GERD, as MIC-1/GDF15 is increased in
response to multiple cellular stressors and following acute injury
and/or inflammatory tissue changes (Fairlie et al, 1999; Welsh et al,
2003; Unsicker et al, 2013). Alternatively (or in addition) MIC-1/
GDF15 levels may also signal neoplastic progression of BO to
OAC, which is consistent with data in colon cancer, in which MIC-
1/GDF15 levels increase with disease progression from normal to
adenoma, carcinoma and metastatic disease (Brown et al, 2003).
There are clear limitations to our findings. First, due to the
relatively small sample size of the present study, the results
presented must be interpreted with caution and require confirma-
tion in future, larger well-described Barrett’s/OAC patient cohorts.
Second, tissue specimen sampling error may occur, a general
problem in all studies using endoscopic biopsy specimens from
patients with Barrett’s disease (Lao-Sirieix and Fitzgerald, 2012).
By reviewing the histology of all specimens used prior to RNA
extraction, we attempted to minimise non-uniformity in the tissue
specimens used. Third, our estimates of sensitivity and specificity
are drawn from a selective sample of patients presenting for
endoscopy and therefore need to be interpreted with caution due to
the potential for spectrum bias, which is associated with over-
estimates of test accuracy (Pepe et al, 2008). Lastly, MIC-1/GDF15
plasma levels are known to be influenced by the use of non-
steroidal anti-inflammatory drugs (NSAIDs; Brown et al, 2012),
which in turn have been shown to influence oesophageal
adenocarcinogenesis and the prognosis of patients affected by this
cancer (Buskens et al, 2002). We did not have complete data on
patients’ NSAID use and thus were not able to correct for this
possible confounding factor.
In conclusion, however, this study provides evidence to suggest
that blood MIC-1/GDF15 measurements may have a clinical role
for diagnosis and monitoring of Barrett’s disease spectrum. These
findings need to be confirmed in larger prospective studies, in
particular studies including serial MIC-1/GDF15 blood measure-
ments in patients with different stages of BO to determine how
dynamic changes in MIC-1/GDF15 levels may be used to inform
patient management. Further, for patients already affected by
OAC, blood levels of MIC-1/GDF15 may help provide additional
prognostic information.
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